<SEC-DOCUMENT>0001299130-25-000168.txt : 20251106
<SEC-HEADER>0001299130-25-000168.hdr.sgml : 20251106
<ACCEPTANCE-DATETIME>20251106160420
ACCESSION NUMBER:		0001299130-25-000168
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		81
CONFORMED PERIOD OF REPORT:	20250930
FILED AS OF DATE:		20251106
DATE AS OF CHANGE:		20251106

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
		CENTRAL INDEX KEY:			0001299130
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				161590339
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34899
		FILM NUMBER:		251458141

	BUSINESS ADDRESS:	
		STREET 1:		1305 O'BRIEN DRIVE
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		650-521-8000

	MAIL ADDRESS:	
		STREET 1:		1305 O'BRIEN DRIVE
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PACIFIC BIOSCIENCES OF CALIFORNIA INC
		DATE OF NAME CHANGE:	20050829

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NANOFLUIDICS INC
		DATE OF NAME CHANGE:	20040729
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>pacb-20250930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:541066b6-d2f9-469d-bf86-6042e3dcfaa4,g:e6194c68-cd08-4fb8-9cf2-74de760e8618,d:eb0962265ffb4e35ba6bd2d2c7eff64b-->
<html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2025" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:pacb="http://www.pacificbiosciences.com/20250930" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>pacb-20250930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-25">0001299130</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="f-26">12-31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-27">2025</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-28">Q3</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-29">false</ix:nonNumeric><ix:nonNumeric contextRef="c-91" name="pacb:StockIssuedDuringPeriodAverageTradingPeriodAcquisition" id="f-465">P20D</ix:nonNumeric><ix:nonNumeric contextRef="c-107" name="us-gaap:ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-559">http://fasb.org/us-gaap/2025#GoodwillAndIntangibleAssetImpairment</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-128" decimals="8" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="f-739">0.20451570</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-143" decimals="7" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="f-740">0.0465116</ix:nonFraction><ix:nonNumeric contextRef="c-171" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-747">http://fasb.org/us-gaap/2025#CostOfRevenue</ix:nonNumeric><ix:nonNumeric contextRef="c-182" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-777">http://fasb.org/us-gaap/2025#CostOfRevenue</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="pacb-20250930.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="d"><xbrli:measure>utr:D</xbrli:measure></xbrli:unit><xbrli:unit id="customer"><xbrli:measure>pacb:customer</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ServiceAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ServiceAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ServiceAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ServiceAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">pacb:AchievementOfMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-02</xbrli:startDate><xbrli:endDate>2023-08-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-02</xbrli:startDate><xbrli:endDate>2023-08-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2025RestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2025RestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">pacb:DevelopedTechnologyAndIntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-07</xbrli:startDate><xbrli:endDate>2025-03-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">pacb:DevelopedTechnologyAndIntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2025-10-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2026-10-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-21</xbrli:startDate><xbrli:endDate>2024-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-21</xbrli:startDate><xbrli:endDate>2024-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-21</xbrli:startDate><xbrli:endDate>2024-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pacb:DebtInstrumentConvertibleTermsOfConversionAxis">pacb:DebtConversionTermsOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-21</xbrli:startDate><xbrli:endDate>2024-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pacb:DebtInstrumentConvertibleTermsOfConversionAxis">pacb:DebtConversionTermsTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-21</xbrli:startDate><xbrli:endDate>2024-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pacb:DebtInstrumentConvertibleTermsOfConversionAxis">pacb:DebtConversionTermsTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-21</xbrli:startDate><xbrli:endDate>2024-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pacb:DebtInstrumentConvertibleTermsOfConversionAxis">pacb:DebtConversionTermsTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-21</xbrli:startDate><xbrli:endDate>2024-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ExchangeTransactionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-21</xbrli:startDate><xbrli:endDate>2024-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-30</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pacb:DebtInstrumentConvertibleTermsOfConversionAxis">pacb:DebtConversionTermsOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-30</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-30</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-30</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pacb:DebtInstrumentConvertibleTermsOfConversionAxis">pacb:DebtConversionTermsTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-30</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ExchangeTransactionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ExchangeTransactionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-30</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-16</xbrli:startDate><xbrli:endDate>2021-02-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pacb:EmployeeSeparationCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2025RestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2025RestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2025RestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pacb:EmployeeSeparationCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2025RestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pacb:EmployeeSeparationCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2025RestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pacb:InProcessResearchAndDevelopmentIndefiniteLivedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2025RestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pacb:EmployeeSeparationCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2025RestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2025RestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pacb:EmployeeSeparationCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2025RestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2025RestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2025RestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pacb:EmployeeSeparationCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2024RestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2024RestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2024RestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2024RestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2024RestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2024RestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2024RestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:SanDiegoOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:SanDiegoOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2024RestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2024RestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2024RestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2024RestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2024RestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:SanDiegoOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pacb:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pacb:A2020PlanInducementPlanAndTheOmniomePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsPSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:StockBasedCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:StockBasedCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pacb:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pacb:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pacb:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pacb:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AmericasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AmericasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AmericasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AmericasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:InstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:InstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:InstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:InstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ConsumableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ConsumableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ConsumableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001299130</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ConsumableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ieb0962265ffb4e35ba6bd2d2c7eff64b_1"></div><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">_____________________________________________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Form <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">_____________________________________________________________________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">x</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">September 30, 2025</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Or</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-34899</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">_____________________________________________________________________________________________</span></div><div style="margin-top:3pt;text-align:center"><img src="pacb-20250930_g1.jpg" alt="Logo 1.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:260px" id="i-1"/></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">Pacific Biosciences of California, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">_____________________________________________________________________________________________</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">16-1590339</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">1305 O&#8217;Brien Drive</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-10">Menlo Park</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-11">CA</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-12">94025</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Zip Code)</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-13">650</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-14">521-8000</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">_____________________________________________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:37.291%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.510%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.899%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-15">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-16">PACB</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-17">The NASDAQ Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-18">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-19">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-20">Accelerated filer</ix:nonNumeric> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-21">o</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Emerging growth company </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-22">o</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-23">x</ix:nonNumeric></span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Number of shares outstanding of the issuer&#8217;s common stock as of October&#160;31, 2025: <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-24">301,907,431</ix:nonFraction>. </span></div><div style="margin-bottom:1pt;margin-top:2pt;text-indent:25.2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="ieb0962265ffb4e35ba6bd2d2c7eff64b_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:16pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Page</span></td></tr><tr><td colspan="3" style="background-color:#df1995;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_10">PART I. FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="background-color:#df1995;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_13">Item 1. Financial Statements (unaudited):</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_16">Condensed Consolidated Balance Sheets as of </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_16">September</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_16"> 30, 2025 and December 31, 2024</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_16">3</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_19">Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_19">Nine</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_19"> Months Ended </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_19">September</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_19"> 30, 2025 and 2024</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_19">4</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_22">Condensed Consolidated Statements of Stockholders&#8217; Equity for the Three and </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_22">Nine</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_22"> Months Ended </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_22">September</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_22"> 30, 2025 and 2024</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_22">5</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_25">Condensed Consolidated Statements of Cash Flows for the </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_25">Nine</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_25"> Months Ended </a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_25">September</a><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_25"> 30, 2025 and 2024</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_25">6</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_28">Notes to Condensed Consolidated Financial Statements </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_28">7</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_61">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_61">27</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_82">Item 3. Quantitative and Qualitative Disclosures About Market Risk</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_82">39</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_85">Item 4. Controls and Procedures</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_85">39</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#df1995;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_88">PART II. OTHER INFORMATION</a></span></div></td><td colspan="3" style="background-color:#df1995;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_91">Item 1. Legal Proceedings</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_91">40</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_94">Item 1A. Risk Factors </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_94">41</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_97">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_97">82</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_100">Item 3. Defaults Upon Senior Securities </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_100">82</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_103">Item 4. Mine Safety Disclosures </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_103">82</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_106">Item 5. Other Information</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_106">83</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_109">Item 6. Exhibits</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_109">84</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_112">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_112">85</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-2"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></td></tr></table></div></div></div><div id="ieb0962265ffb4e35ba6bd2d2c7eff64b_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="ieb0962265ffb4e35ba6bd2d2c7eff64b_13"></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #df1995;border-top:1pt solid #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 1.  FINANCIAL STATEMENTS</span></td></tr></table></div><div id="ieb0962265ffb4e35ba6bd2d2c7eff64b_16"></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PACIFIC BIOSCIENCES OF CALIFORNIA, INC.</span></div><div style="padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(Unaudited)</span></div></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except par value)</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current assets </span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents </span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-30">56,467</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-31">55,370</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Investments </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-32">242,187</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-33">334,561</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-34">30,616</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-35">27,524</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory, net</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-36">53,153</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-37">58,755</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-38">11,513</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-39">18,781</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Short-term restricted cash</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="f-40">300</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="f-41">690</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total current assets </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-42">394,236</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-43">495,681</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Property and equipment, net </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-44">22,127</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-45">30,505</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease right-of-use assets, net </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-46">42,583</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-47">16,091</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-term restricted cash</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-48">1,532</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-49">1,532</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Intangible assets, net</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-50">16,143</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-51">389,572</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-52">317,761</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-53">317,761</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other long-term assets </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-54">8,776</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-55">9,305</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total assets </span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-56">803,158</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-57">1,260,447</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Liabilities and Stockholders&#8217; Equity </span></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current liabilities</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts payable </span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-58">16,362</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-59">16,590</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accrued expenses </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-60">29,172</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-61">22,595</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred revenue, current </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-62">16,049</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-63">13,864</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease liabilities, current</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-64">621</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-65">10,026</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other liabilities, current </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-66">1,005</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-67">3,224</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 46pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total current liabilities </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-68">63,209</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-69">66,299</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred revenue, non-current </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-70">4,400</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-71">5,900</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contingent consideration liability, non-current</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="f-72">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-73">18,700</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease liabilities, non-current </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-74">54,300</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-75">14,914</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Convertible senior notes, net, non-current</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ConvertibleLongTermNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-76">645,159</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ConvertibleLongTermNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-77">647,494</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other liabilities, non-current </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="3" id="f-78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="f-79">546</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total liabilities </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-80">767,068</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-81">753,853</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commitments and contingencies </span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-3" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-82"></ix:nonFraction></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-83"></ix:nonFraction></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-84"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-85">0.001</ix:nonFraction></ix:nonFraction> par value:</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Authorized <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-86"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-87">50,000</ix:nonFraction></ix:nonFraction> shares; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-88"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-89"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-90"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-91">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding </span></div></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-93">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-94"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-95">0.001</ix:nonFraction></ix:nonFraction> par value:</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Authorized <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-96"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-97">1,000,000</ix:nonFraction></ix:nonFraction> shares; issued and outstanding <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-98"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-99">301,853</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-100"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-101">294,418</ix:nonFraction></ix:nonFraction> shares at September&#160;30, 2025 and December&#160;31, 2024, respectively </span></div></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-102">302</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-103">294</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additional paid-in capital </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-104">2,690,304</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-105">2,654,804</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated other comprehensive income</span></div></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-106">415</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-107">422</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated deficit </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-108">2,654,931</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-109">2,148,926</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total stockholders&#8217; equity </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-110">36,090</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-111">506,594</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total liabilities and stockholders&#8217; equity </span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-112">803,158</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-113">1,260,447</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_28">notes</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-3"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></td></tr></table></div></div></div><div id="ieb0962265ffb4e35ba6bd2d2c7eff64b_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PACIFIC BIOSCIENCES OF CALIFORNIA, INC.</span></div><div style="padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(Unaudited)</span></div></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.235%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except per share amounts)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenue:</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Product revenue </span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-114">32,597</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-115">35,296</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-116">96,793</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-117">102,051</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Service and other revenue </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-118">5,844</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-119">4,671</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-120">18,567</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-121">12,739</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 46pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total revenue </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-122">38,441</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-123">39,967</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-124">115,360</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-125">114,790</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of Revenue:</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of product revenue </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-126">19,204</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-127">23,278</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-128">65,559</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-129">68,808</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of service and other revenue </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-130">3,078</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-131">3,484</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-132">11,709</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-133">10,588</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of acquired intangible assets</span></div></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" scale="3" id="f-134">183</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" format="ixt:num-dot-decimal" scale="3" id="f-135">3,201</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" format="ixt:num-dot-decimal" scale="3" id="f-136">4,711</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" format="ixt:num-dot-decimal" scale="3" id="f-137">7,172</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Loss on purchase commitment</span></div></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="pacb:LossOnPurchaseCommitment" scale="3" id="f-138">75</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="pacb:LossOnPurchaseCommitment" format="ixt:fixed-zero" scale="3" id="f-139">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="pacb:LossOnPurchaseCommitment" format="ixt:num-dot-decimal" scale="3" id="f-140">4,167</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="pacb:LossOnPurchaseCommitment" scale="3" id="f-141">998</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 46pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total cost of revenue </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-142">22,540</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-143">29,963</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-144">86,146</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-145">87,566</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 73pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross profit</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-146">15,901</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-147">10,004</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-148">29,214</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-149">27,224</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating Expense:</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-150">22,846</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-151">25,516</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-152">74,428</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-153">107,456</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales, general and administrative </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-154">31,099</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-155">43,746</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-156">107,442</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-157">133,376</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Impairment charges</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:fixed-zero" scale="3" id="f-158">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:fixed-zero" scale="3" id="f-159">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:num-dot-decimal" scale="3" id="f-160">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:num-dot-decimal" scale="3" id="f-161">93,200</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of acquired intangible assets</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="pacb:AmortizationOfAcquiredIntangibleAssets" scale="3" id="f-162">833</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="pacb:AmortizationOfAcquiredIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-163">3,649</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="pacb:AmortizationOfAcquiredIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-164">363,708</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="pacb:AmortizationOfAcquiredIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-165">13,377</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:fixed-zero" scale="3" id="f-166">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="f-167">1,170</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="f-168">18,700</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="f-169">1,100</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 46pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total operating expense </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-170">54,778</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-171">74,081</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-172">541,878</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-173">348,509</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating loss </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-174">38,877</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-175">64,077</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-176">512,664</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-177">321,285</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest expense </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-178">1,739</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-179">3,538</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-180">5,214</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-181">10,655</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other income, net </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-182">2,999</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-183">6,890</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-184">11,989</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-185">19,718</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Loss before income taxes</span></div></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-186">37,617</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-187">60,725</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-188">505,889</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-189">312,222</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income tax provision</span></div></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-190">383</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-191">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-192">116</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-193">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-194">38,000</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-195">60,725</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-196">506,005</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-197">312,222</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other comprehensive income:</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unrealized gain (loss) on investments </span></div></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-198">148</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-199">2,076</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-200">7</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-201">1,334</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Comprehensive loss</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-202">37,852</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-203">58,649</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-204">506,012</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-205">310,888</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss per share:</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic </span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-206">0.13</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-207">0.22</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-208">1.69</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-209">1.15</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Diluted </span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-210">0.13</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-211">0.22</ix:nonFraction>)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-212">1.69</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-213">1.15</ix:nonFraction>)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average shares outstanding used in calculating net loss per share:</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic </span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-214">300,844</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-215">272,915</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-216">299,303</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-217">271,631</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Diluted </span></td><td colspan="3" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-218">300,844</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-219">272,915</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-220">299,303</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-221">271,631</ix:nonFraction></span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_28">notes</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the condensed consolidated financial statements. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-4"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></td></tr></table></div></div></div><div id="ieb0962265ffb4e35ba6bd2d2c7eff64b_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PACIFIC BIOSCIENCES OF CALIFORNIA, INC.</span></div><div style="padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</span></div><div style="padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(Unaudited)</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.769%"><tr><td style="width:1.0%"/><td style="width:26.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.546%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.546%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.546%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.546%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.546%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.552%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Three Months Ended September 30, 2025</span></td></tr><tr style="height:25pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Additional <br/>Paid-in<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Comprehensive Income</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Accumulated <br/>Deficit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance at June 30, 2025</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-222">300,350</ix:nonFraction></span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-223">300</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-224">2,677,853</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-225">267</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-226">2,616,931</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-227">61,489</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-228">38,000</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-229">38,000</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other comprehensive income</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-230">148</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-231">148</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of common stock in conjunction with equity plans</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-23" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-232">1,503</ix:nonFraction></span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-233">2</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-234">1,467</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-235">1,469</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-236">10,984</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-237">10,984</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance at September 30, 2025</span></td><td colspan="3" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-238">301,853</ix:nonFraction></span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-239">302</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-240">2,690,304</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-241">415</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-242">2,654,931</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-243">36,090</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.769%"><tr><td style="width:1.0%"/><td style="width:26.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.546%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.546%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.546%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.546%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.546%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.552%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2025</span></td></tr><tr style="height:25pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Additional <br/>Paid-in<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Accumulated <br/>Deficit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance at December 31, 2024</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-29" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-244">294,418</ix:nonFraction></span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-245">294</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-246">2,654,804</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-247">422</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-248">2,148,926</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-249">506,594</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-250">506,005</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-251">506,005</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other comprehensive loss</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-252">7</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-253">7</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of common stock in conjunction with equity plans</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-35" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-254">7,435</ix:nonFraction></span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-255">8</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-256">3,420</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-257">3,428</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-258">32,080</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-259">32,080</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance at September 30, 2025</span></td><td colspan="3" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-260">301,853</ix:nonFraction></span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-261">302</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-262">2,690,304</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-263">415</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-264">2,654,931</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-265">36,090</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.769%"><tr><td style="width:1.0%"/><td style="width:26.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.546%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.546%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.546%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.546%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.546%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.552%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Three Months Ended September 30, 2024</span></td></tr><tr style="height:25pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Additional <br/>Paid-in<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Comprehensive</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(Loss) Income</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Accumulated <br/>Deficit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance at June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-37" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-266">272,491</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-267">272</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-268">2,583,523</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-269">523</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-270">2,090,572</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-271">492,700</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-272">60,725</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-273">60,725</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other comprehensive income</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-274">2,076</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-275">2,076</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of common stock in conjunction with equity plans</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-44" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-276">1,321</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-277">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-278">810</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-279">812</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Share-based compensation expense</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-280">18,259</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-281">18,259</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance at September 30, 2024</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-46" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-282">273,812</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-283">274</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-284">2,602,592</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-285">1,553</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-286">2,151,297</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-287">453,122</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.769%"><tr><td style="width:1.0%"/><td style="width:26.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.546%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.546%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.546%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.546%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.546%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.335%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.552%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Nine Months Ended September 30, 2024</span></td></tr><tr style="height:25pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Additional <br/>Paid-in<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Comprehensive Income</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Accumulated <br/>Deficit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance at December 31, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-51" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-288">267,744</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-289">268</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-290">2,539,892</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-291">219</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-292">1,839,075</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-293">701,304</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-294">312,222</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-295">312,222</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other comprehensive income</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-296">1,334</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-297">1,334</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of common stock in conjunction with equity plans</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-58" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-298">6,068</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-299">6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-300">7,697</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-301">7,703</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Share-based compensation expense</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-302">55,003</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-303">55,003</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance at September 30, 2024</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-46" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-304">273,812</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-305">274</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-306">2,602,592</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-307">1,553</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-308">2,151,297</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-309">453,122</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_28">notes</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.461%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.820%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-5"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></td></tr></table></div></div></div><div id="ieb0962265ffb4e35ba6bd2d2c7eff64b_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:72pt;padding-right:72pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.846%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PACIFIC BIOSCIENCES OF CALIFORNIA, INC.</span></div><div style="padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(Unaudited)</span></div></td></tr></table><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.846%"><tr><td style="width:1.0%"/><td style="width:73.216%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.468%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.346%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.470%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span id="i7b4062ded7164095bdcd67e11ea94a23_3-1-1-1-187453"></span><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-310">506,005</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-311">312,222</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Adjustments to reconcile net loss to net cash used in operating activities</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Depreciation </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="f-312">10,251</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="f-313">10,932</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-314">368,429</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-315">20,558</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amortization of right-of-use assets</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="f-316">3,083</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="f-317">10,912</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-318">32,080</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-319">55,003</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Impairment charges</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:num-dot-decimal" scale="3" id="f-320">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:num-dot-decimal" scale="3" id="f-321">93,200</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accretion of discount and amortization of premium on marketable securities, net</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" format="ixt:num-dot-decimal" scale="3" id="f-322">3,905</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" format="ixt:num-dot-decimal" scale="3" id="f-323">10,663</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Change in the estimated fair value of contingent consideration</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="f-324">18,700</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="f-325">1,100</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Inventory provision</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="3" id="f-326">9,768</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="3" id="f-327">3,715</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Deferred income taxes</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="3" id="f-328">546</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" format="ixt:fixed-zero" scale="3" id="f-329">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-330">1,456</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-331">1,002</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Changes in assets and liabilities </span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-332">3,092</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-333">7,232</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Inventory, net</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-334">4,926</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-335">15,394</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Prepaid expenses and other assets </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-336">7,797</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-337">3,534</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accounts payable </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="f-338">761</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-339">2,222</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accrued expenses </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-340">1,396</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-341">26,665</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Deferred revenue </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="f-342">685</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="f-343">875</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-344">661</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-345">9,252</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other liabilities </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-346">2,219</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-347">7,053</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 50.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net cash used in operating activities </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-348">92,140</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-349">175,408</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Purchases of property and equipment </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-350">1,853</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-351">4,571</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Purchases of intangible assets</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-352">5,000</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:fixed-zero" scale="3" id="f-353">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Purchases of investments </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="f-354">183,817</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="f-355">418,164</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sales of investments </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="f-356">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-357">8,061</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Maturities of investments </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-358">280,089</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-359">480,440</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 50.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net cash provided by investing activities </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-360">89,419</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-361">65,766</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Proceeds from issuance of common stock from equity plans</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="f-362">3,428</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="f-363">7,703</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Notes payable principal payoff</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:fixed-zero" scale="3" id="f-364">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:RepaymentsOfNotesPayable" scale="3" id="f-365">490</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 50.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net cash provided by financing activities </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-366">3,428</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-367">7,213</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net increase (decrease) in cash, cash equivalents, and restricted cash</span></div></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="f-368">707</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-369">102,429</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash, cash equivalents, and restricted cash at beginning of period </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-370">57,592</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-371">182,633</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash, cash equivalents, and restricted cash at end of period </span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-372">58,299</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-373">80,204</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash and cash equivalents at end of period </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-374">56,467</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-375">77,982</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Restricted cash at end of period </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-376">1,832</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-377">2,222</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash, cash equivalents, and restricted cash at end of period </span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-378">58,299</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-379">80,204</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Supplemental disclosure of non-cash investing and financing activities</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Right-of-use asset and lease liability recognized due to lease extension</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-380">29,575</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-381">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See accompanying </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_28">notes</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> to the condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.461%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.820%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-6"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></td></tr></table></div></div></div><div id="ieb0962265ffb4e35ba6bd2d2c7eff64b_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PACIFIC BIOSCIENCES OF CALIFORNIA, INC.</span></div><div style="padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(Unaudited)</span></div></td></tr></table></div><div id="ieb0962265ffb4e35ba6bd2d2c7eff64b_31"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="f-382" continuedAt="f-382-1" escape="true"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 1.  ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Business Overview</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a life science technology company that designs, develops, and manufactures advanced sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products and technology, which include our HiFi long-read sequencing technology, address solutions across a broad set of applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our focus is on creating some of the world's most advanced sequencing systems to provide our customers with the most complete and accurate view of genomes, transcriptomes, and epigenomes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations ("CROs"), pharmaceutical companies, and agricultural companies.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References in this report to &#8220;PacBio,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; the &#8220;Company,&#8221; and &#8220;our&#8221; refer to Pacific Biosciences of California, Inc. and its consolidated subsidiaries.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-383" escape="true"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Basis of Presentation and Consolidation</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States, or U.S. GAAP, as set forth in the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC. The unaudited condensed consolidated financial statements include the accounts of Pacific Biosciences and our wholly owned subsidiaries. Certain information and footnote disclosures typically included in our audited financial statements have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements have been prepared on a consistent basis with the December&#160;31, 2024 audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state our financial position, results of operations, comprehensive loss, and cash flows for the period, but are not necessarily indicative of the results to be expected for the entire year or any future periods. All intercompany transactions and balances have been eliminated.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2024 (the "2024 Annual Report").</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-384" escape="true"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Use of Estimates</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes to the financial statements. On an ongoing basis, we evaluate our significant estimates, including those relating to the valuation of inventory, fair value of contingent consideration, valuation of acquired intangible assets, useful lives assigned to finite-lived assets, asset impairment assessments, computation of provisions for income taxes, and valuations related to our convertible senior notes. While the extent of the potential impact of current macroeconomic conditions on our business is highly uncertain, we considered information available related to assumptions and estimates used to determine the results reported and asset valuations as of September&#160;30, 2025. Actual results could differ materially from these estimates.</span></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-7"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><ix:continuation id="f-382-1" continuedAt="f-382-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-385" escape="true"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash, and Investments</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments purchased with an original maturity of 90 days or less to be cash equivalents. Cash equivalents may be comprised of money market funds, certificates of deposit, commercial paper, corporate bonds and notes, and government agencies&#8217; securities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify our investments in debt securities as available-for-sale and report the investments at fair value in current assets. We evaluate our available-for-sale investments in unrealized loss positions and assess whether the unrealized loss is credit-related. Unrealized gains and losses that are not credit-related are recognized in accumulated other comprehensive income (loss) in stockholders&#8217; equity. Realized gains and losses, expected credit losses, as well as interest income, on available-for-sale securities are reported in other income, net. The cost used in the determination of gains and losses of securities sold is based on the specific identification method. The cost of marketable securities is adjusted for the amortization of premiums and discounts to expected maturity. Premium and discount amortization is recorded in other income, net. We have the ability to hold, and do not intend to sell investments in unrealized loss positions before the recovery of their amortized cost bases.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment portfolio at any point in time contains investments in cash deposits, money market funds, commercial paper, corporate debt securities and U.S. government and agency securities with high credit ratings. We have established guidelines regarding diversification and maturities of investments with the objectives of maintaining safety and liquidity, while maximizing yield. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash includes cash that is not readily available for use in the Company&#8217;s operating activities. Restricted cash is primarily comprised of cash pledged under letters of credit.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-386" escape="true"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Pronouncements Pending Adoption</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This new standard requires a company to expand its existing income tax disclosures, specifically related to the rate reconciliation and income taxes paid. The standard is effective for annual periods beginning in 2025 and is expected to be applied retrospectively. We expect that the adoption of this new standard will result in incremental income tax related disclosures to the notes to the consolidated financial statements but will not have a material impact on the consolidated financial statements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-04, </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt With Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This new standard clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion or extinguishment of convertible debt. The standard will be effective for us beginning in the first quarter of 2026, with early adoption permitted. The new standard is expected to be applied prospectively, but retrospective application is permitted. We do not expect the adoption of this new standard to have a material impact on the consolidated financial statements and related disclosures.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This new standard requires a company to provide disaggregated disclosures, within the notes to the financial statements, of specified categories of expenses that are included in line items on the face of the income statement. The standard will be effective for us beginning in 2027, and interim periods within 2028, with early adoption permitted. The new standard is expected to be applied prospectively, but retrospective application is permitted. We are currently evaluating the impact of ASU 2024-03 on the consolidated financial statements and related disclosures.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2025, the FASB issued ASU 2025-06, </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This new standard clarifies and modernizes the recognition and disclosure framework for capitalized internal-use software costs by removing all references to project stages and introduces a more judgment-based approach. The standard also clarifies the threshold to be applied to begin capitalizing. The standard will be effective for us beginning in the first quarter of 2028, with early adoption permitted, and can be applied using a prospective, retrospective, or modified transition approach. We are currently evaluating the impact of ASU 2025-06 on the consolidated financial statements and related disclosures.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-8"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><ix:continuation id="f-382-2"><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes to our significant accounting policies as disclosed in our 2024 Annual Report.</span></div></ix:continuation><div id="ieb0962265ffb4e35ba6bd2d2c7eff64b_34"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="f-387" continuedAt="f-387-1" escape="true"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 2.  FINANCIAL INSTRUMENTS</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy established under U.S. GAAP requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs that may be used to measure fair value are as follows: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Level 1: quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="f-388" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider an active market as one in which transactions for the asset or liability occurs with sufficient frequency and volume to provide pricing information on an ongoing basis. Conversely, we view an inactive market as one in which there are few transactions for the asset or liability, the prices are not current, or price quotations vary substantially either over time or among market makers. Where appropriate, our non-performance risk, or that of our counterparty, is considered in determining the fair values of liabilities and assets, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify our cash deposits and money market funds within Level 1 of the fair value hierarchy because they are valued using bank balances or quoted market prices. We classify our investments as Level 2 instruments based on market pricing and other observable inputs. We did not classify any of our investments within Level 3 of the fair value hierarchy.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the entire fair value measurement requires management to make judgments and consider factors specific to the asset or liability. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of our accounts receivable, prepaid expenses, other current assets, accounts payable, accrued expenses and other liabilities, current, approximate fair value due to their short maturities.</span></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-9"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><ix:continuation id="f-387-1" continuedAt="f-387-2"><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="f-389" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the fair value of our financial assets and liabilities that were measured on a recurring basis:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.933%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash and cash equivalents </span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-390">52,483</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-391">3,984</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-392">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-393">56,467</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-394">55,370</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-395">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-396">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-397">55,370</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Corporate debt securities </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-398">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-399">23,420</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-400">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-401">23,420</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-402">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-403">46,905</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-404">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-405">46,905</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">U.S. government &amp; agency securities</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-406">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-407">218,767</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-408">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-409">218,767</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-410">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-411">287,656</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-412">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-413">287,656</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total investments </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-414">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-415">242,187</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-416">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-417">242,187</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-418">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-419">334,561</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-420">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-421">334,561</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Short-term restricted cash</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="pacb:ShortTermRestrictedCashFairValueDisclosure" scale="3" id="f-422">300</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="pacb:ShortTermRestrictedCashFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-423">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="pacb:ShortTermRestrictedCashFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-424">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="pacb:ShortTermRestrictedCashFairValueDisclosure" scale="3" id="f-425">300</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="pacb:ShortTermRestrictedCashFairValueDisclosure" scale="3" id="f-426">690</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="pacb:ShortTermRestrictedCashFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-427">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="pacb:ShortTermRestrictedCashFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-428">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="pacb:ShortTermRestrictedCashFairValueDisclosure" scale="3" id="f-429">690</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Long-term restricted cash</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="pacb:LongTermRestrictedCashFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-430">1,532</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="pacb:LongTermRestrictedCashFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-431">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="pacb:LongTermRestrictedCashFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-432">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="pacb:LongTermRestrictedCashFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-433">1,532</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="pacb:LongTermRestrictedCashFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-434">1,532</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="pacb:LongTermRestrictedCashFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-435">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="pacb:LongTermRestrictedCashFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-436">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="pacb:LongTermRestrictedCashFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-437">1,532</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total assets measured at fair value </span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-438">54,315</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-439">246,171</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-440">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-441">300,486</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-442">57,592</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-443">334,561</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-444">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-445">392,153</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-446">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-447">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-448">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-449">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-450">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-451">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-452">18,700</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-453">18,700</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total liabilities measured at fair value </span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-454">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-455">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-456">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-457">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-458">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-459">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-460">18,700</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-461">18,700</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2025, there were no transfers between Level 1, Level 2, or Level 3 assets or liabilities reported at fair value on a recurring basis, and our valuation techniques did not change compared to the prior year.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Contingent Consideration</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the August 2023 </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apton Biosystems, Inc. (&#8220;Apton&#8221;)</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> acquisition, contingent consideration of $<ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-462">25.0</ix:nonFraction>&#160;million, which we may elect to pay in cash, shares of our common stock or a combination of cash and shares of our common stock, is due upon the achievement of a milestone, defined as the achievement of $<ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" name="pacb:BusinessCombinationConsiderationTransferredRevenueAchievementMilestone" format="ixt:num-dot-decimal" scale="6" id="f-463">50.0</ix:nonFraction>&#160;million in revenue associated with Apton's technology, provided that the milestone event occurs prior to the <ix:nonNumeric contextRef="c-92" name="pacb:BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod" format="ixt-sec:durwordsen" id="f-464">five-year</ix:nonNumeric> anniversary of the closing date of the acquisition. The number of shares, if any, to be issued in connection with the achievement of the specified milestone is not known and will be calculated based on the daily volume-weighted average price of our common stock for the <span style="-sec-ix-hidden:f-465">twenty</span> trading days ending on and including the fifth trading day immediately prior to the occurrence of the specified milestone. Upon achievement of the milestone, we may pay cash in lieu of our common stock to ensure that the issuance of our common stock does not exceed <ix:nonFraction unitRef="number" contextRef="c-93" decimals="3" name="pacb:PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger" scale="-2" id="f-466">19.9</ix:nonFraction>% of our outstanding shares of common stock then outstanding.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration is accounted for as a liability at fair value, with changes during each reporting period recognized in our condensed consolidated statements of operations and comprehensive loss. The fair value of the contingent consideration liability was calculated using a Monte Carlo Simulation to estimate the volatility and systematic relative risk of revenues subject to sales milestone payments and discounting the associated cash payment amounts to their present values using a credit-risk-adjusted interest rate.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify contingent consideration within Level 3, as factors used to develop the estimate of fair value include unobservable inputs that are not supported by market activity and are significant to the fair value. Estimates and assumptions used in the Monte Carlo simulation include risk-adjusted forecasted revenues for products and services leveraging Apton's technology and an estimated credit spread.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of the contingent consideration liability based on the simulated revenue of the Company through the <ix:nonNumeric contextRef="c-94" name="pacb:BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod" format="ixt-sec:durwordsen" id="f-467">five-year</ix:nonNumeric> anniversary of the closing date of the acquisition. The key input used in the determination of the fair value included projected revenues of the high-throughput short-read products and services leveraging Apton's technology. Primarily due to management's decision to cease development of the high-throughput short-read system, and the resulting changes in the expected future revenues, among other factors, and as the milestone event must occur prior to the <ix:nonNumeric contextRef="c-94" name="pacb:BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod" format="ixt-sec:durwordsen" id="f-468">five-year</ix:nonNumeric> anniversary of the closing date of the acquisition, the estimated fair value of the contingent consideration liability is $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="0" id="f-469">0</ix:nonFraction>. An increase in the fair value of the liability may result from an acceleration in the timing of or increase in projected revenues and from a </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-10"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><ix:continuation id="f-387-2" continuedAt="f-387-3"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decrease in discount rates, including the risk-free rate and estimated subordinated credit spread for a CCC credit rating.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="f-470" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the estimated fair value of the contingent consideration liability during the nine months ended September&#160;30, 2025 were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Beginning balance as of December 31, 2024</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-471">18,700</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Change in estimated fair value</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="f-472">18,700</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Ending balance as of September 30, 2025</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-473">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to the fair value are recorded as change in fair value of contingent consideration in the condensed consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash, and Investments</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="f-474" continuedAt="f-474-1" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize our cash, cash equivalents, restricted cash, and investments:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="21" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of September 30, 2025</span></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortized<br/>Cost </span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-475">56,467</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-476">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-477">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-478">56,467</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-479">23,298</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-480">123</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-481">1</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-482">23,420</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. government &amp; agency securities</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-483">218,475</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-484">309</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-485">17</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-486">218,767</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total investments </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-487">241,773</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-488">432</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-489">18</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-490">242,187</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total cash, cash equivalents and investments </span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-491">298,240</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-492">432</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-493">18</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-494">298,654</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Short-term restricted cash</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="f-495">300</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="f-496">300</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-term restricted cash</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-497">1,532</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-498">1,532</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-499">55,370</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-500">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-501">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-502">55,370</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-503">46,746</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-504">184</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-505">25</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-506">46,905</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. government &amp; agency securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-507">287,393</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-508">418</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-509">155</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-510">287,656</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total investments</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-511">334,139</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-512">602</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-513">180</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-514">334,561</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total cash, cash equivalents and investments</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-515">389,509</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-516">602</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-517">180</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="3" id="f-518">389,931</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Short-term restricted cash</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="f-519">690</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="f-520">690</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-term restricted cash</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-521">1,532</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-522">1,532</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-11"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><ix:continuation id="f-387-3"><ix:continuation id="f-474-1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the contractual maturities of our cash equivalents and available-for-sale investments, excluding money market funds, as of September&#160;30, 2025:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due in one year or less </span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" format="ixt:num-dot-decimal" scale="3" id="f-523">181,705</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due after one year through five years </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" format="ixt:num-dot-decimal" scale="3" id="f-524">64,466</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" format="ixt:num-dot-decimal" scale="3" id="f-525">246,171</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual maturities may differ from contractual maturities because issuers may have the right to call or prepay obligations without call or prepayment penalties.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment income included in other income, net </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the condensed consolidated statements of operations and comprehensive loss </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:InvestmentIncomeNet" scale="6" id="f-526">3.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InvestmentIncomeNet" scale="6" id="f-527">10.4</ix:nonFraction> million for the three and nine months ended September&#160;30, 2025, respectively, and $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:InvestmentIncomeNet" scale="6" id="f-528">6.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:InvestmentIncomeNet" scale="6" id="f-529">19.8</ix:nonFraction> million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the three and nine months ended September&#160;30, 2024, respectively.</span></div></ix:continuation><div id="ieb0962265ffb4e35ba6bd2d2c7eff64b_37"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="f-530" continuedAt="f-530-1" escape="true"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#1383c6;border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 3.  BALANCE SHEET COMPONENTS </span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Inventory, Net</span></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="f-531" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inventory, net, consisted of the following components:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Purchased materials</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="f-532">41,788</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="f-533">45,270</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Work in process</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="f-534">25,189</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="f-535">22,172</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="f-536">16,435</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="f-537">14,081</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 8.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory, gross</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="f-538">83,412</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="f-539">81,523</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 2.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory reserve</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryValuationReserves" format="ixt:num-dot-decimal" scale="3" id="f-540">30,259</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryValuationReserves" format="ixt:num-dot-decimal" scale="3" id="f-541">22,768</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 8.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory, net</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-542">53,153</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-543">58,755</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Goodwill and Intangible Assets</span></div></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is reviewed for impairment at least annually during the second quarter, or more frequently if an event occurs indicating the potential for impairment. Based on quantitative interim impairment tests performed in 2024, we recorded impairment charges of $<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-544">93.2</ix:nonFraction>&#160;million in the second quarter of 2024 and $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-545">51.3</ix:nonFraction>&#160;million in the fourth quarter of 2024.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted a quantitative interim impairment test as of March 31, 2025, based on a decline in stock price and market capitalization during the first quarter of 2025, macroeconomic uncertainties, and revised strategic plans emphasizing HiFi sequencing and discontinuing short-read platform development, and concluded there was <ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="f-546">no</ix:nonFraction> impairment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We completed our annual goodwill impairment assessment on April 1, 2025 and noted <ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="f-547">no</ix:nonFraction> impairment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in our future operating results, cash flows, share price, market capitalization or discount rates used when conducting future goodwill impairment tests could affect the implied fair value of goodwill and may result in additional impairment charges in the future.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets include developed technology, customer relationships, and acquired in-process research and development ("IPR&amp;D"). In connection with the Apton acquisition in August 2023, we allocated $<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" scale="6" id="f-548">55.0</ix:nonFraction> million of the purchase price to IPR&amp;D. This asset is considered indefinite-lived until the associated research and development activities are either completed or abandoned, and it is tested for impairment annually and more </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-12"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><ix:continuation id="f-530-1" continuedAt="f-530-2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized a $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-549">40.0</ix:nonFraction>&#160;million impairment charge in the fourth quarter of 2024 as a result of a quantitative interim impairment test.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our decision to cease development of the high-throughput short-read sequencing platform, which would utilize the IPR&amp;D, and the resulting changes to the expected future cash flows, among other factors, we concluded that it was more likely than not that the fair value of the IPR&amp;D was less than its carrying amount, requiring an interim impairment assessment. Using a discounted cash flow model under the income approach, we determined the fair value was below carrying value and recorded a $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:num-dot-decimal" scale="6" id="f-550">15.0</ix:nonFraction>&#160;million impairment charge. The decline in the fair value of the IPR&amp;D below its carrying amount as of March 31, 2025 resulted primarily from changes in the timing of expected future cash flows as compared to the fair value as of December 31, 2024, driven by the restructuring initiatives that prioritize the adoption of HiFi sequencing. The impairment charge is included in our consolidated statements of operations and comprehensive loss for the nine months ended September 30, 2025. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant estimates and assumptions used in the income approach include timing of future cash flows, revenue growth assumptions, a selected discount rate of <ix:nonFraction unitRef="number" contextRef="c-3" decimals="3" name="pacb:IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate" scale="-2" id="f-551">14.0</ix:nonFraction>%, and a selected obsolescence factor of <ix:nonNumeric contextRef="c-3" name="pacb:IntangibleAssetImpairmentDiscountedCashFlowModelTerm" format="ixt-sec:duryear" id="f-552">11</ix:nonNumeric> years. The discount rate was based primarily on the weighted average cost of capital, determined using market, peer company, industry data, and related risk factors. The assessment is a level 3 measurement due to its reliance on certain unobservable inputs and significant management judgment. The assumptions used were inherently subject to uncertainty and small changes in these assumptions could have had a significant impact on the concluded value. A decrease of <ix:nonFraction unitRef="number" contextRef="c-3" decimals="4" name="pacb:IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate" scale="0" id="f-553">200</ix:nonFraction> basis points to the discount rate used in our analysis would have resulted in an increase in the estimated fair value of the IPR&amp;D of approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="pacb:AdditionalIntangibleAssetImpairmentChangeInDiscountRate" format="ixt:num-dot-decimal" scale="6" id="f-554">3</ix:nonFraction>&#160;million, and an increase of <ix:nonNumeric contextRef="c-3" name="pacb:IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm" format="ixt-sec:durwordsen" id="f-555">one year</ix:nonNumeric> to the obsolescence factor used in our analysis would have resulted in an increase in the estimated fair value of the IPR&amp;D of approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="pacb:AdditionalIntangibleAssetImpairmentChangeInTerm" format="ixt:num-dot-decimal" scale="6" id="f-556">3</ix:nonFraction>&#160;million. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock" id="f-557" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to IPR&amp;D during the nine months ended September&#160;30, 2025 were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance as of December&#160;31, 2024</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-558">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-559">Impairment charge</span></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-560">15,000</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance as of September&#160;30, 2025</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:fixed-zero" scale="3" id="f-561">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_46">Note 5. Restructuring</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information on costs incurred in connection with our current year restructuring activities.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="f-562" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to IPR&amp;D, we had the following acquired finite-lived intangible assets:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.163%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.056%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except years)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>Useful Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Developed technology</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-109" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-563">3</ix:nonNumeric> &#8212; <ix:nonNumeric contextRef="c-110" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-564">15</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-565">421,179</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-566">405,036</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-567">16,143</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-568">411,179</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-569">36,607</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-570">374,572</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Customer relationships</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-113" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-571">2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="f-572">360</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="f-573">360</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="3" id="f-574">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="f-575">360</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="f-576">360</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="3" id="f-577">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-578">421,539</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-579">405,396</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-580">16,143</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-581">411,539</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-582">36,967</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-583">374,572</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-13"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><ix:continuation id="f-530-2" continuedAt="f-530-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="f-584" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization expense of intangible assets with finite lives is as follows:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Remainder of 2025</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="f-585">1,020</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-586">4,078</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-587">4,078</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="f-588">1,301</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2029</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="3" id="f-589">745</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2030 and thereafter</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="pacb:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="f-590">4,921</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-591">16,143</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of acquired intangible assets is included within our cost of revenue if the costs and expenses related to the intangible assets are attributable to revenue generating activities. Amortization expense for intangible assets that are not directly related to sales generating activities are amortized to operating expenses. For developed technology intangible assets that are utilized in both revenue generating activities and in research and development activities, we allocate the amortization expense between cost of revenue and operating expenses. The finite-lived intangible assets are amortized using the straight-line method over their estimated useful lives.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2025, we revised the estimated useful life of the developed technology acquired in the 2021 Omniome, Inc. ("Omniome") acquisition. This change reflects updated strategic plans and restructuring initiatives focused on accelerating HiFi sequencing adoption, leading to ceased development of our high-throughput short-read platform and revised expectations for the timing and amount of future cash flows from short-read sequencing products and services. As a result of the change in estimate, during the three months ended March 31, 2025, we recognized accelerated amortization of $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5" name="pacb:RestructuringAndRelatedCostAcceleratedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-592">359.3</ix:nonFraction>&#160;million within amortization of acquired intangible assets in operating expenses, reflecting our revised estimate that the asset will no longer generate economic benefit beyond March 31, 2025. This expense had a negative impact on basic and diluted net loss per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-116" decimals="2" name="pacb:ChangeInEarningsPerShare" scale="0" id="f-593">1.20</ix:nonFraction> for the nine months ended September 30, 2025.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review finite-lived intangible assets for impairment when indication of potential impairment exists, such as a significant reduction in cash flows associated with the assets. In the first quarter of 2025, as part of our interim goodwill impairment test, we also performed a recoverability test for the definite-lived asset group and noted <ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="f-594">no</ix:nonFraction> impairment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;7, 2025, the Company entered into an agreement to acquire certain developed technology and related intellectual property from The Chinese University of Hong Kong for total consideration of $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:AssetAcquisitionConsiderationTransferred" format="ixt:num-dot-decimal" scale="6" id="f-595">9.7</ix:nonFraction>&#160;million. In addition, the Company entered into a license agreement for complementary developed technology during the three months ended March 31, 2025. Both the acquired technology and license are classified as intangible assets and are being amortized over an estimated useful life of <ix:nonNumeric contextRef="c-118" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="f-596"><ix:nonNumeric contextRef="c-119" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="f-597">three years</ix:nonNumeric></ix:nonNumeric>. As of September&#160;30, 2025, $<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-5" name="us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-598">5.0</ix:nonFraction>&#160;million of these intangible assets remained unpaid. This amount is included in accrued liabilities on the condensed consolidated balance sheets and is expected to be paid in 2026.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_46">Note 5. Restructuring</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information on costs incurred in connection with our current year restructuring activities.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Deferred Revenue</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2025, we had a total of $<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="f-599">20.4</ix:nonFraction>&#160;million of deferred revenue, $<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-600">16.0</ix:nonFraction>&#160;million of which was recorded as deferred revenue, current, and $<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-601">4.4</ix:nonFraction>&#160;million of which was recorded as deferred revenue, non-current, which primarily relates to deferred service contract revenues and is scheduled to be recognized in the next <ix:nonNumeric contextRef="c-122" name="pacb:ContractWithCustomerLiabilityNoncurrentRecognitionPeriod" format="ixt-sec:durwordsen" id="f-602">four years</ix:nonNumeric>. Revenue recorded in the three and nine months ended September&#160;30, 2025 includes $<ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="f-603">2.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="f-604">10.5</ix:nonFraction>&#160;million, respectively, that was included in deferred revenue as of December&#160;31, 2024.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-14"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><ix:continuation id="f-530-3"><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Obligations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly enter into contracts with multiple performance obligations. These contracts are believed to be firm as of the balance sheet date. However, we may allow customers to make product substitutions or certain modifications at our discretion. The timing of shipments depends on several factors, including agreed upon shipping schedules, which may span multiple quarters. Most performance obligations are generally satisfied within a year of the contract execution date. As of September&#160;30, 2025, the aggregate amount of the transaction price allocated to remaining performance obligations was $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="f-605">48.7</ix:nonFraction>&#160;million, of which approximately <ix:nonFraction unitRef="number" contextRef="c-124" decimals="2" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" id="f-606">72</ix:nonFraction>% is expected to be converted to revenue over the next <ix:nonNumeric contextRef="c-124" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durwordsen" id="f-607">twelve months</ix:nonNumeric>, approximately <ix:nonFraction unitRef="number" contextRef="c-125" decimals="2" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" id="f-608">23</ix:nonFraction>% in the following <ix:nonNumeric contextRef="c-125" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durwordsen" id="f-609">twelve months</ix:nonNumeric>, and the remainder thereafter.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Product Warranties</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally provide a <ix:nonNumeric contextRef="c-1" name="pacb:StandardProductWarrantyPeriod" format="ixt-sec:durwordsen" id="f-610">one-year</ix:nonNumeric> warranty on instruments. In addition, we provide a limited warranty on consumables. At the time revenue is recognized, an accrual is established for estimated warranty costs based on historical experience as well as anticipated product performance. We periodically review the warranty reserve for adequacy and adjust the warranty accrual, if necessary, based on actual experience and estimated costs to be incurred. Warranties are recorded as part of accrued expenses on the condensed consolidated balance sheets and warranty expense is recorded as a component of cost of product revenue in the condensed consolidated statements of operations and comprehensive loss. There were no material changes in estimates for the periods presented below. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock" id="f-611" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the reserve for product warranties were as follows for the periods indicated:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.778%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.782%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance at beginning of period</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:ProductWarrantyAccrual" format="ixt:num-dot-decimal" scale="3" id="f-612">2,688</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:ProductWarrantyAccrual" format="ixt:num-dot-decimal" scale="3" id="f-613">3,462</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ProductWarrantyAccrual" format="ixt:num-dot-decimal" scale="3" id="f-614">3,100</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:ProductWarrantyAccrual" format="ixt:num-dot-decimal" scale="3" id="f-615">4,681</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additions charged to cost of product revenue</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ProductWarrantyAccrualWarrantiesIssued" format="ixt:num-dot-decimal" scale="3" id="f-616">1,252</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ProductWarrantyAccrualWarrantiesIssued" format="ixt:num-dot-decimal" scale="3" id="f-617">1,414</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProductWarrantyAccrualWarrantiesIssued" format="ixt:num-dot-decimal" scale="3" id="f-618">3,809</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ProductWarrantyAccrualWarrantiesIssued" format="ixt:num-dot-decimal" scale="3" id="f-619">4,787</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repairs and replacements</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ProductWarrantyAccrualPayments" format="ixt:num-dot-decimal" scale="3" id="f-620">1,384</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ProductWarrantyAccrualPayments" format="ixt:num-dot-decimal" scale="3" id="f-621">1,610</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProductWarrantyAccrualPayments" format="ixt:num-dot-decimal" scale="3" id="f-622">4,353</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ProductWarrantyAccrualPayments" format="ixt:num-dot-decimal" scale="3" id="f-623">6,202</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance at end of period</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ProductWarrantyAccrual" format="ixt:num-dot-decimal" scale="3" id="f-624">2,556</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:ProductWarrantyAccrual" format="ixt:num-dot-decimal" scale="3" id="f-625">3,266</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ProductWarrantyAccrual" format="ixt:num-dot-decimal" scale="3" id="f-626">2,556</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:ProductWarrantyAccrual" format="ixt:num-dot-decimal" scale="3" id="f-627">3,266</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="ieb0962265ffb4e35ba6bd2d2c7eff64b_40"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-628" continuedAt="f-628-1" escape="true"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 4.  CONVERTIBLE SENIOR NOTES</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2029 Convertible Senior Notes</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 7, 2024, we entered into an exchange agreement with SB Northstar LP (&#8220;SBN&#8221;), a subsidiary of SoftBank Group Corp., pursuant to which we agreed to exchange the remaining approximately $<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-629">459.0</ix:nonFraction>&#160;million in aggregate principal amount of our previously held <ix:nonFraction unitRef="number" contextRef="c-126" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-630">1.50</ix:nonFraction>% Convertible Senior Notes due 2028 (the &#8220;2028 Notes&#8221;) outstanding for (i) $<ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-631">200.0</ix:nonFraction>&#160;million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="c-127" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-632">1.50</ix:nonFraction>% Convertible Senior Notes due 2029 (the &#8220;2029 Notes&#8221;), (ii) <ix:nonFraction unitRef="shares" contextRef="c-128" decimals="0" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="f-633">20,451,570</ix:nonFraction> shares of common stock (the &#8220;Exchange Shares&#8221;) and (iii) $<ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-5" name="pacb:PaymentsInConjunctionWithNotesExchange" format="ixt:num-dot-decimal" scale="6" id="f-634">50.0</ix:nonFraction>&#160;million of cash (the &#8220;2024 Exchange Transaction&#8221;). The Exchange Shares were issued on November 21, 2024 (the &#8220;Closing Date&#8221;). The 2029 Notes, the Exchange Shares, and shares of common stock issuable upon conversion of the 2029 Notes were subject to certain lock-up restrictions for a <ix:nonNumeric contextRef="c-130" name="pacb:HoldingPeriodForTransferAssignmentOrSaleOfFounderShares" format="ixt-sec:durwordsen" id="f-635">six-month</ix:nonNumeric> period (the &#8220;Lock-Up Period&#8221;) beginning on the Closing Date of the 2024 Exchange Transaction.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon any conversion of the 2029 Notes, SBN will not be entitled to be issued a number of shares of the Company&#8217;s common stock which would cause SBN's beneficial ownership of common stock to exceed either <ix:nonFraction unitRef="number" contextRef="c-129" decimals="4" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="f-636">9.9</ix:nonFraction>% of the total number of issued and outstanding shares of common stock or <ix:nonFraction unitRef="number" contextRef="c-129" decimals="4" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="f-637">9.9</ix:nonFraction>% of the combined voting power of all of the securities of the Company, in each case, following such conversion.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2029 Notes are governed by an indenture (the &#8220;2029 Indenture&#8221;) between the Company and U.S. Bank Trust Company, National Association, as trustee. The 2029 Notes bear interest at a rate of <ix:nonFraction unitRef="number" contextRef="c-127" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-638">1.50</ix:nonFraction>% per annum. Interest on the 2029 Notes is payable semi-annually in arrears on February 15 and August 15, commencing on February 15, 2025. The 2029 Notes will mature on August 15, 2029, subject to earlier conversion, redemption or repurchase.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-15"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><ix:continuation id="f-628-1" continuedAt="f-628-2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2029 Notes are convertible at the option of the holder at any time from the expiration of the Lock-Up Period until the second scheduled trading day prior to the maturity date, including in connection with a redemption by the Company. The 2029 Notes are convertible into shares of our common stock based on an initial conversion rate of 204.5157 shares of common stock per $1,000 principal amount of the 2029 Notes (which is equal to an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="c-127" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-639">4.89</ix:nonFraction> per share of common stock), in each case subject to customary anti-dilution and other adjustments as a result of certain extraordinary transactions. Upon conversion of the 2029 Notes, we may elect to settle such conversion obligation in cash, shares of our common stock, or a combination of cash and shares of our common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after August 20, 2027, and prior to the 31st scheduled trading day immediately preceding the maturity date, the 2029 Notes will be redeemable by the Company in the event that the closing sale price of our common stock has been at least <ix:nonFraction unitRef="number" contextRef="c-128" decimals="2" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="f-640">150</ix:nonFraction>% of the conversion price then in effect for at least <ix:nonFraction unitRef="d" contextRef="c-128" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="f-641">20</ix:nonFraction> trading days (whether or not consecutive) during any <ix:nonFraction unitRef="d" contextRef="c-128" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="f-642">30</ix:nonFraction> consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide the redemption notice at a redemption price of <ix:nonFraction unitRef="number" contextRef="c-128" decimals="2" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="f-643">100</ix:nonFraction>% of the principal amount of such 2029 Notes, plus accrued and unpaid interest up to, but excluding, the redemption date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a Fundamental Change (as defined in the 2029 Indenture), the holders of the 2029 Notes may require that we repurchase all or part of the principal amount of the 2029 Notes at a purchase price of par plus unpaid interest up to, but excluding, the maturity date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2029 Notes are subject to certain debt and lien covenants as well as springing guarantees, in each case, the terms of which are set forth in a second letter agreement between the Company and SBN entered into in connection with the Indenture.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2029 Indenture includes customary &#8220;events of default,&#8221; which may result in the acceleration of the maturity of the 2029 Notes under the 2029 Indenture. The 2029 Indenture also includes customary covenants for convertible notes of this type.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent we elect, the sole remedy for an event of default relating to our failure to comply with certain of our reporting obligations shall, for the first <ix:nonNumeric contextRef="c-128" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-644">360</ix:nonNumeric> calendar days after the occurrence of such an event of default, consist exclusively of the right to receive additional interest on the 2029 Notes at a rate equal to (i) <ix:nonFraction unitRef="number" contextRef="c-131" decimals="4" name="pacb:DebtInstrumentInterestInTheEventOfDefault" scale="-2" id="f-645">0.25</ix:nonFraction>% per annum of the principal amount of the 2029 Notes outstanding for each day during the first <ix:nonNumeric contextRef="c-131" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-646">180</ix:nonNumeric> calendar days of the <ix:nonNumeric contextRef="c-128" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-647">360</ix:nonNumeric>-day period after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived) and (ii) <ix:nonFraction unitRef="number" contextRef="c-132" decimals="4" name="pacb:DebtInstrumentAdditionalInterestInEventOfDefault" scale="-2" id="f-648">0.50</ix:nonFraction>% per annum of the principal amount of the 2029 Notes outstanding for each day from, and including, the <ix:nonNumeric contextRef="c-133" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-649">181</ix:nonNumeric></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> calendar day to, and including, the <ix:nonNumeric contextRef="c-134" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-650">360</ix:nonNumeric></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> calendar day after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived as provided for in the 2029 Indenture). On the <ix:nonNumeric contextRef="c-132" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-651">361</ix:nonNumeric></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> day after such event of default (if the event of default relating to our failure to comply with its obligations is not cured or waived prior to such <ix:nonNumeric contextRef="c-132" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-652">361</ix:nonNumeric></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> day), the 2029 Notes shall be subject to acceleration as provided for in the 2029 Indenture.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2029 Notes are accounted for in accordance with the authoritative guidance for convertible debt instruments that may be settled in cash upon conversion. Under ASU 2020-06, the guidance requires that debt with an embedded conversion feature is accounted for in its entirety as a liability and no portion of the proceeds from the issuance of the convertible debt instrument is accounted for as attributable to the conversion feature unless the conversion feature is required to be accounted for separately as an embedded derivative or the conversion feature results in a substantial premium. The conversion feature of the 2029 Notes is not accounted for as an embedded derivative because it is considered to be indexed to our common stock, and the 2029 Notes were not issued at a substantial premium; therefore, the 2029 Notes are accounted for in their entirety as a liability. Because we may elect to settle any conversions entirely in shares, and because settlement in shares is the default settlement method, the liability is classified as non-current.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The requirement to repurchase the 2029 Notes, including unpaid interest to the maturity date in the event of a Fundamental Change, is considered a put option for certain periods requiring bifurcation under ASC 815 &#8211; </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> However, given the low probability of such a Fundamental Change occurring during the applicable periods, the value of the embedded derivative is immaterial.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The additional interest feature in the event of our failure to comply with certain reporting obligations is also considered an embedded derivative requiring bifurcation under ASC 815. However, due to the nature and terms of the reporting obligations, the value of the embedded derivative is immaterial.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-16"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><ix:continuation id="f-628-2" continuedAt="f-628-3"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exchange qualified as a troubled debt restructuring under ASC 470-60 &#8211; </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Troubled Debt Restructurings by Debtors</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Since the undiscounted cash flows of the 2029 Notes were less than the carrying amount of the exchanged 2028 Notes, the carrying value of the 2029 Notes was determined based on the total undiscounted cash flows. As a result, no interest expense will be recognized for the 2029 Notes. The Company recorded a gain on debt restructuring of $<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-5" name="us-gaap:GainsLossesOnRestructuringOfDebt" format="ixt:num-dot-decimal" scale="6" id="f-653">154.4</ix:nonFraction>&#160;million, which resulted in a decrease of basic net loss per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-135" decimals="2" name="pacb:RestructuringOfDebtPricePerShare" scale="0" id="f-654">0.56</ix:nonFraction>, during the year ended December 31, 2024 in our consolidated statements of operations and comprehensive loss. The gain was calculated as the difference between the carrying amount of the old debt and the carrying amount of the new debt, adjusted for debt issuance costs. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred issuance costs related to the 2029 Notes of approximately $<ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-5" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="6" id="f-655">3.1</ix:nonFraction>&#160;million, including $<ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-5" name="pacb:DebtIssuanceCostLenderFees" format="ixt:num-dot-decimal" scale="6" id="f-656">0.2</ix:nonFraction>&#160;million of lender fees, which were recorded as a reduction to the gain on debt restructuring in our consolidated statements of operations and comprehensive loss. We also paid accrued but unpaid interest of $<ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-5" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" format="ixt:num-dot-decimal" scale="6" id="f-657">1.8</ix:nonFraction>&#160;million on the 2028 Notes in connection with the 2024 Exchange Transaction.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not receive any cash proceeds from the 2024 Exchange Transaction. In exchange for issuing the 2029 Notes, Exchange Shares and paying $<ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-5" name="pacb:PaymentsInConjunctionWithNotesExchange" format="ixt:num-dot-decimal" scale="6" id="f-658">50.0</ix:nonFraction>&#160;million of cash pursuant to the 2024 Exchange Transaction, we received and cancelled the exchanged 2028 Notes. Following the closing of the 2024 Exchange Transaction, <ix:nonFraction unitRef="usd" contextRef="c-126" decimals="0" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="0" id="f-659">no</ix:nonFraction> amounts were outstanding on the 2028 Notes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of the liability for the 2029 Notes as of September&#160;30, 2025 is $<ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-5" name="us-gaap:ConvertibleNotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-660">212.0</ix:nonFraction>&#160;million, of which $<ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-5" name="us-gaap:ConvertibleLongTermNotesPayable" scale="6" id="f-661">209.0</ix:nonFraction> million is included as convertible senior notes, net, non-current, and $<ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="f-662">3.0</ix:nonFraction> million is included as accrued expenses on our consolidated balance sheets.</span></div><ix:nonNumeric contextRef="c-1" name="pacb:ScheduleOfInterestExpenseTableTextBlock" id="f-663" continuedAt="f-663-1" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to the 2029 Notes during the nine months ended September 30, 2025 were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.082%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Carrying amount as of December&#160;31, 2024</span></div></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:ConvertibleNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-664">214,200</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contractual interest expense</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="f-665">2,200</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Carrying amount as of September&#160;30, 2025</span></div></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:ConvertibleNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-666">212,000</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2025, the estimated fair value (Level 2) of the 2029 Notes was $<ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-5" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:num-dot-decimal" scale="6" id="f-667">169.4</ix:nonFraction>&#160;million. The fair value of the 2029 Notes is estimated using a binomial lattice model that is primarily affected by the trading price of our common stock, market interest rates and volatility.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2030 Convertible Senior Notes</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, we entered into a privately negotiated exchange agreement with a holder of our outstanding 2028 Notes, pursuant to which we issued $<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-668">441.0</ix:nonFraction>&#160;million in aggregate principal amount of our <ix:nonFraction unitRef="number" contextRef="c-142" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-669">1.375</ix:nonFraction>% Convertible Senior Notes due 2030 (the &#8220;2030 Notes&#8221; and together with the 2029 Notes, the &#8220;Notes&#8221;) in exchange for $<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-670">441.0</ix:nonFraction>&#160;million principal amount of the 2028 Notes (the &#8220;2023 Exchange Transaction&#8221;), pursuant to exemptions from registration under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and the rules and regulations thereunder. The 2030 Notes were issued on June 30, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2030 Notes are governed by an indenture (the &#8220;2030 Indenture&#8221;) between the Company and U.S. Bank Trust Company, National Association, as trustee. The 2030 Notes bear interest at a rate of <ix:nonFraction unitRef="number" contextRef="c-142" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-671">1.375</ix:nonFraction>% per annum. Interest on the 2030 Notes is payable semi-annually in arrears on June 15 and December 15, commencing on December 15, 2023. The 2030 Notes will mature on December 15, 2030, subject to earlier conversion, redemption or repurchase.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2030 Notes are convertible at the option of the holder at any time until the second scheduled trading day prior to the maturity date, including in connection with a redemption by the Company. The 2030 Notes are convertible into shares of our common stock based on an initial conversion rate of 46.5116 shares of common stock per $1,000 principal amount of the 2030 Notes (which is equal to an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="c-142" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-672">21.50</ix:nonFraction> per share of common stock), in each case subject to customary anti-dilution and other adjustments as a result of certain extraordinary transactions. Upon conversion of the 2030 Notes, we may elect to settle such conversion obligation in cash, shares of our common stock, or a combination of cash and shares of our common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after June 20, 2028, and prior to the 31st scheduled trading day immediately preceding the maturity date, the 2030 Notes will be redeemable by the Company in the event that the closing sale price of our common stock has been at least <ix:nonFraction unitRef="number" contextRef="c-143" decimals="2" name="pacb:DebtInstrumentRedemptionPricePercentageOfConversionPrice" scale="-2" id="f-673">150</ix:nonFraction>% of the conversion price then in effect for at least <ix:nonNumeric contextRef="c-143" name="pacb:DebtInstrumentRedemptionPriceTradingDays" format="ixt-sec:durday" id="f-674">20</ix:nonNumeric> trading days (whether or not </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-17"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><ix:continuation id="f-628-3" continuedAt="f-628-4"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consecutive) during any <ix:nonNumeric contextRef="c-143" name="pacb:DebtInstrumentRedemptionPriceConsecutiveTradingDays" format="ixt-sec:durday" id="f-675">30</ix:nonNumeric> consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide the redemption notice at a redemption price of <ix:nonFraction unitRef="number" contextRef="c-143" decimals="2" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="f-676">100</ix:nonFraction>% of the principal amount of such 2030 Notes, plus accrued and unpaid interest up to, but excluding, the redemption date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a Fundamental Change (as defined in the 2030 Indenture), the holders of the 2030 Notes may require that we repurchase all or part of the principal amount of the 2030 Notes at a purchase price equal to <ix:nonFraction unitRef="number" contextRef="c-143" decimals="2" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="f-677">100</ix:nonFraction>% of the principal amount of the notes to be repurchased, plus any accrued and unpaid interest up to, but excluding, the fundamental change repurchase date, and all unpaid interest from the fundamental change repurchase date thereon, but excluding, the maturity date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2030 Indenture includes customary &#8220;events of default,&#8221; which may result in the acceleration of the maturity of the 2030 Notes under the 2030 Indenture. The 2030 Indenture also includes customary covenants for convertible notes of this type.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent we elect, the sole remedy for an event of default relating to our failure to comply with certain of our reporting obligations shall, for the first <ix:nonNumeric contextRef="c-143" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-678">360</ix:nonNumeric> calendar days after the occurrence of such an event of default, consist exclusively of the right to receive additional interest on the 2030 Notes at a rate equal to (i) <ix:nonFraction unitRef="number" contextRef="c-143" decimals="4" name="pacb:DebtInstrumentInterestInTheEventOfDefault" scale="-2" id="f-679">0.25</ix:nonFraction>% per annum of the principal amount of the 2030 Notes outstanding for each day during the first <ix:nonNumeric contextRef="c-144" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-680">180</ix:nonNumeric> calendar days of the <ix:nonNumeric contextRef="c-143" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-681">360</ix:nonNumeric>-day period after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived) and (ii) <ix:nonFraction unitRef="number" contextRef="c-143" decimals="4" name="pacb:DebtInstrumentAdditionalInterestInEventOfDefault" scale="-2" id="f-682">0.50</ix:nonFraction>% per annum of the principal amount of the 2030 Notes outstanding for each day from, and including, the <ix:nonNumeric contextRef="c-145" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-683">181</ix:nonNumeric></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> calendar day to, and including, the <ix:nonNumeric contextRef="c-146" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-684">360</ix:nonNumeric></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> calendar day after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived as provided for in the 2030 Indenture). On the <ix:nonNumeric contextRef="c-147" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-685">361</ix:nonNumeric></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> day after such event of default (if the event of default relating to our failure to comply with its obligations is not cured or waived prior to such <ix:nonNumeric contextRef="c-147" name="pacb:DebtInstrumentDebtDefaultCalendarDays" format="ixt-sec:durday" id="f-686">361</ix:nonNumeric></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> day), the 2030 Notes shall be subject to acceleration as provided for in the 2030 Indenture.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2030 Notes are accounted for in accordance with the authoritative guidance for convertible debt instruments that may be settled in cash upon conversion. Under ASU 2020-06, the guidance requires that debt with an embedded conversion feature is accounted for in its entirety as a liability and no portion of the proceeds from the issuance of the convertible debt instrument is accounted for as attributable to the conversion feature unless the conversion feature is required to be accounted for separately as an embedded derivative or the conversion feature results in a substantial premium. The conversion feature of the 2030 Notes is not accounted for as an embedded derivative because it is considered to be indexed to our common stock, and the 2030 Notes were not issued at a substantial premium; therefore, the 2030 Notes are accounted for in their entirety as a liability. Because we may elect to settle any conversions entirely in shares, and because settlement in shares is the default settlement method, the liability is classified as non-current.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The requirement to repurchase the 2030 Notes, including unpaid interest to the maturity date in the event of a Fundamental Change, is considered a put option for certain periods requiring bifurcation under ASC 815 &#8211; </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> However, given the low probability of such a Fundamental Change occurring during the applicable periods, the value of the embedded derivative is immaterial.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The additional interest feature in the event of our failure to comply with certain reporting obligations is also considered an embedded derivative requiring bifurcation under ASC 815. However, due to the nature and terms of the reporting obligations, the value of the embedded derivative is immaterial.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2023 Exchange Transaction was accounted for as an extinguishment driven by the change in fair value of the embedded conversion option. We recorded a loss on extinguishment of debt of approximately $<ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="f-687">2.0</ix:nonFraction>&#160;million in connection with the 2023 Exchange Transaction during the year ended December 31, 2023, which represents the difference between the fair value and the principal amount of the 2030 Notes of the debt at the modification date, plus unamortized debt issuance costs of $<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-5" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="6" id="f-688">1.5</ix:nonFraction>&#160;million related to the respective portion of the 2028 Notes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred issuance costs related to the 2030 Notes of approximately $<ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-5" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="6" id="f-689">7.3</ix:nonFraction>&#160;million, which were recorded as debt issuance costs and are presented as a reduction to the 2030 Notes on our condensed consolidated balance sheets. The debt issuance costs are amortized to interest expense using the effective interest method over the term of the 2030 Notes, resulting in an effective interest rate of <ix:nonFraction unitRef="number" contextRef="c-142" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-690">1.6</ix:nonFraction>%. We also paid accrued but unpaid interest of $<ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-5" name="us-gaap:DebtInstrumentPeriodicPaymentInterest" format="ixt:num-dot-decimal" scale="6" id="f-691">2.5</ix:nonFraction>&#160;million on the 2028 Notes in connection with the 2023 Exchange Transaction on June 30, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not receive any cash proceeds from the 2023 Exchange Transaction. In exchange for issuing the 2030 Notes pursuant to the 2023 Exchange Transaction, we received and cancelled the exchanged 2028 Notes. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-18"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><ix:continuation id="f-628-4"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the closing of the 2023 Exchange Transaction, $<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-692">459.0</ix:nonFraction>&#160;million in aggregate principal amount of 2028 Notes remained outstanding with terms unchanged.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="f-693" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net carrying amount of the liability for the 2030 Notes is included as convertible senior notes, net, non-current in the condensed consolidated balance sheets as follows:</span></div><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Principal amount</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-694">441,000</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-695">441,000</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unamortized debt premium</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedPremium" scale="3" id="f-696">398</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedPremium" scale="3" id="f-697">453</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="us-gaap:UnamortizedDebtIssuanceExpense" format="ixt:num-dot-decimal" scale="3" id="f-698">5,239</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-3" name="us-gaap:UnamortizedDebtIssuanceExpense" format="ixt:num-dot-decimal" scale="3" id="f-699">5,959</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net carrying amount</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-700">436,159</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-701">435,494</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:continuation id="f-663-1" continuedAt="f-663-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the 2030 Notes was as follows:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.778%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.782%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contractual interest expense</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="f-702">1,516</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="f-703">1,516</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="f-704">4,548</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="f-705">4,565</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-706">241</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-707">237</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-708">720</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-709">712</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total interest expense</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-710">1,757</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-711">1,753</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-712">5,268</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-713">5,277</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2025, the estimated fair value (Level 2) of the 2030 Notes was $<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-5" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="6" id="f-714">314.5</ix:nonFraction> million. The fair value of the 2030 Notes is estimated using a binomial lattice model that is primarily affected by the trading price of our common stock, market interest rates and volatility.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2028 Convertible Senior Notes</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 9, 2021, we entered into an investment agreement with SBN relating to the issuance and sale to SBN of $<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-715">900.0</ix:nonFraction>&#160;million in aggregate principal amount of the 2028 Notes. The 2028 Notes were issued on February 16, 2021 and bore interest at a rate of <ix:nonFraction unitRef="number" contextRef="c-160" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-716">1.50</ix:nonFraction>% per annum. As discussed above, in June 2023 we completed an exchange of $<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-717">441.0</ix:nonFraction>&#160;million in aggregate principal amount of our 2028 Notes for $<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-718">441.0</ix:nonFraction>&#160;million aggregate principal amount of the 2030 Notes, leaving approximately $<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-719">459.0</ix:nonFraction>&#160;million in aggregate principal amount of 2028 Notes outstanding. Also as discussed above, in November 2024 we completed an exchange of the remaining $<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-720">459.0</ix:nonFraction>&#160;million in aggregate principal amount of the 2028 Notes outstanding for (i) $<ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-721">200.0</ix:nonFraction>&#160;million aggregate principal amount of the 2029 Notes, (ii) the Exchange Shares and (iii) $<ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-5" name="pacb:PaymentsInConjunctionWithNotesExchange" format="ixt:num-dot-decimal" scale="6" id="f-722">50.0</ix:nonFraction>&#160;million of cash. As of December 31, 2024 <ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="0" id="f-723">no</ix:nonFraction> amounts were outstanding on the 2028 Notes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred issuance costs related to the 2028 Notes of approximately $<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-5" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="6" id="f-724">4.5</ix:nonFraction>&#160;million, which were recorded as debt issuance costs and are presented as a reduction to the 2028 Notes on our consolidated balance sheets. The debt issuance costs were amortized to interest expense using the effective interest method over the term of the 2028 Notes, resulting in an effective interest rate of <ix:nonFraction unitRef="number" contextRef="c-160" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-725">1.6</ix:nonFraction>%. In connection with the 2024 Exchange Transaction, the remaining unamortized debt issuance costs related to the 2028 Notes of $<ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="6" id="f-726">1.1</ix:nonFraction>&#160;million were extinguished by offsetting the carrying amount of the convertible senior notes. </span></div><ix:continuation id="f-663-2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the 2028 Notes was as follows:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.778%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.778%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.778%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.782%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contractual interest expense</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:fixed-zero" scale="3" id="f-727">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="f-728">1,721</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:fixed-zero" scale="3" id="f-729">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="f-730">5,163</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:fixed-zero" scale="3" id="f-731">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-732">81</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:fixed-zero" scale="3" id="f-733">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-734">243</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total interest expense</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:fixed-zero" scale="3" id="f-735">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-736">1,802</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:fixed-zero" scale="3" id="f-737">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-738">5,406</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-19"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></td></tr></table></div></div></div><div id="ieb0962265ffb4e35ba6bd2d2c7eff64b_46"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="f-741" continuedAt="f-741-1" escape="true"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 5.  RESTRUCTURING</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2025 Restructuring</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2025, we implemented an expense reduction initiative aimed at lowering our annualized run-rate operating expenses. These actions, which included workforce reductions and other cost-saving measures, were part of a broader strategic shift to prioritize the adoption of HiFi sequencing.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="f-742" continuedAt="f-742-1" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the pre-tax restructuring charges are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.687%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.175%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cumulative amount incurred to date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Employee separation costs</span></div></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="3" id="f-743">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-3" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="3" id="f-744">4,787</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other costs</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-3" name="us-gaap:RestructuringCharges" scale="3" id="f-745">66</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-3" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="3" id="f-746">629</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="-sec-ix-hidden:f-747"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total restructuring charges </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></span></div></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-3" name="us-gaap:RestructuringCharges" scale="3" id="f-748">66</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-3" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="3" id="f-749">5,416</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Cumulative charges incurred to date include $<ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-5" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="f-750">3.3</ix:nonFraction>&#160;million in sales, general and administrative expense and $<ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-5" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="f-751">2.1</ix:nonFraction>&#160;million in research and development expense.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Charges included employee separation costs comprised of approximately $<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="pacb:RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits" format="ixt:num-dot-decimal" scale="6" id="f-752">2.5</ix:nonFraction>&#160;million related to salaries, wages and other employee benefits paid to terminated employees pursuant to the Worker Adjustment and Retraining Notification (WARN) Act and approximately $<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="6" id="f-753">2.3</ix:nonFraction>&#160;million of severance costs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Charges included in other costs are primarily related to legal expenses incurred in connection with employee separation matters.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the restructuring and strategic shift, we incurred an additional $<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="pacb:RestructuringChargesAdditionalCostsIncurred" format="ixt:num-dot-decimal" scale="6" id="f-754">388.6</ix:nonFraction>&#160;million in costs. These include $<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="pacb:RestructuringAndRelatedCostAcceleratedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-755">359.3</ix:nonFraction>&#160;million of accelerated amortization of certain intangible assets, $<ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-756">15.0</ix:nonFraction>&#160;million of IPR&amp;D impairment charges, $<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="f-757">8.0</ix:nonFraction>&#160;million related to excess inventory due to decreased external demand and $<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="pacb:GainLossOnPurchaseCommitments" format="ixt:num-dot-decimal" scale="6" id="f-758">3.9</ix:nonFraction>&#160;million for estimated losses on purchase commitments tied to anticipated future excess inventory included in cost of revenue, and $<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="us-gaap:RestructuringReserveAcceleratedDepreciation" format="ixt:num-dot-decimal" scale="6" id="f-759">2.4</ix:nonFraction>&#160;million of accelerated depreciation of fixed assets. See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_37">Note 3. Balance Sheet Components</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information on the IPR&amp;D impairment assessment and the change in estimated useful life of the intangible asset and accelerated amortization.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="f-760" continuedAt="f-760-1" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the liabilities related to the restructuring is as follows:</span></div><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.115%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, excluding non-cash activities)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Employee Separation Costs</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expense recorded in YTD 2025</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="f-761">4,787</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-3" name="us-gaap:RestructuringCharges" scale="3" id="f-762">629</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="f-763">5,416</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash paid during YTD 2025</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="3" id="f-764">4,787</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-3" name="us-gaap:PaymentsForRestructuring" scale="3" id="f-765">528</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="3" id="f-766">5,315</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amount recorded in current liabilities<br/>as of September 30, 2025</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="3" id="f-767">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-3" name="us-gaap:RestructuringReserve" scale="3" id="f-768">101</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-3" name="us-gaap:RestructuringReserve" scale="3" id="f-769">101</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Estimated total restructuring costs to still be incurred</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-3" name="us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1" format="ixt:fixed-zero" scale="3" id="f-770">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-3" name="us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1" format="ixt:fixed-zero" scale="3" id="f-771">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-3" name="us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1" format="ixt:fixed-zero" scale="3" id="f-772">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-20"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><ix:continuation id="f-741-1"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2024 Restructuring</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2024, we implemented an expense reduction initiative that included workforce reductions, the closing of our San Diego office, and other actions to reduce annualized run-rate operating expenses.</span></div><ix:continuation id="f-742-1"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the pre-tax restructuring charges are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.687%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.175%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cumulative amount incurred to date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Employee separation costs</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="3" id="f-773">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-3" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="3" id="f-774">10,008</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other costs</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="3" id="f-775">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-3" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="3" id="f-776">16,102</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="-sec-ix-hidden:f-777"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total restructuring charges</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></span></div></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="3" id="f-778">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-3" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="3" id="f-779">26,110</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:40.5pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Cumulative charges incurred to date include $<ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-5" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="f-780">15.8</ix:nonFraction> million in sales, general and administrative expense; $<ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-5" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="f-781">5.9</ix:nonFraction> million in research and development expense; and $<ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-5" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="f-782">4.4</ix:nonFraction> million in cost of revenue.</span></div></ix:continuation><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumulative charges incurred to date include employee separation costs comprised of approximately $<ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-5" name="pacb:RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits" format="ixt:num-dot-decimal" scale="6" id="f-783">5.5</ix:nonFraction>&#160;million related to salaries, wages and other employee benefits paid to terminated employees pursuant to the Worker Adjustment and Retraining Notification (WARN) Act and approximately $<ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="6" id="f-784">4.5</ix:nonFraction>&#160;million of severance costs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other costs in cumulative charges incurred to date are primarily related to accelerated amortization and depreciation of $<ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-5" name="us-gaap:RestructuringReserveAcceleratedDepreciation" format="ixt:num-dot-decimal" scale="6" id="f-785">8.1</ix:nonFraction>&#160;million for the right-of-use asset, leasehold improvements, and furniture and fixtures relating to the abandonment of the San Diego office. We also incurred cumulative charges to date for excess inventory of $<ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="f-786">3.6</ix:nonFraction>&#160;million primarily relating to a decrease in internal demand resulting from the expense reduction initiatives which were recognized in cost of product revenues. The accelerated amortization and depreciation, which was recognized in sales, general and administrative expense, was determined as a result of the Company's change in estimate pertaining to its remaining useful life of the San Diego office utilizing the estimated date on which it planned to abandon the San Diego office. The lease liability pertaining to the San Diego office was also remeasured during the three months ended June 30, 2024 resulting in a reduction in the operating lease liability balance of $<ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="f-787">4.4</ix:nonFraction>&#160;million, which was offset against the right-of-use asset on the condensed consolidated balance sheets. We fully exited our San Diego office in September 2024.</span></div><ix:continuation id="f-760-1"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the liabilities related to the restructuring is as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.114%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amount recorded in current liabilities as of December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="us-gaap:RestructuringReserve" scale="3" id="f-788">170</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:RestructuringReserve" scale="3" id="f-789">170</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional expense recorded</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:RestructuringCharges" scale="3" id="f-790">888</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" name="us-gaap:RestructuringCharges" scale="3" id="f-791">888</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="3" id="f-792">1,058</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="3" id="f-793">1,058</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amount recorded in current liabilities as of September&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="3" id="f-794">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="3" id="f-795">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated total restructuring costs to still be incurred</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1" format="ixt:fixed-zero" scale="3" id="f-796">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1" format="ixt:fixed-zero" scale="3" id="f-797">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table above excludes noncash activities and amounts incurred relating to the San Diego office lease liability. The ending balance of the San Diego office lease liability was $<ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="f-798">0</ix:nonFraction> at the end of the second quarter of 2025.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-21"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></td></tr></table></div></div></div><div id="ieb0962265ffb4e35ba6bd2d2c7eff64b_49"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LossContingencyDisclosures" id="f-799" escape="true"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 6.  COMMITMENTS AND CONTINGENCIES</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Leases</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into various operating lease agreements, primarily relating to our corporate offices. On March 7, 2025, we amended our existing lease covering our corporate headquarters, as well as our research and development, manufacturing, and distribution facilities in Menlo Park, California. The lease amendment extends the term to April 30, 2034. See </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6 &#8211; Commitments and Contingencies</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, subsection titled &#8220;Leases&#8221;, in Part I, Item 1 of the Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 for information regarding the Company&#8217;s maturity of lease liabilities under its lease agreements.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Contingencies</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may become involved in legal proceedings, claims and assessments from time to time in the ordinary course of business. We accrue liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe that the ultimate outcome of any such pending matters is probable or reasonably estimable, or that these matters will have a material adverse effect on our business; however, the results of litigation and claims are inherently unpredictable. Regardless of the outcome, litigation can have an adverse impact on us because of litigation and settlement costs, diversion of management resources, and other factors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see subsection titled </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_91">Legal Proceedings, in Part II, Item 1</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Indemnification</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Delaware law and agreements entered into with each of our directors and officers, we may have obligations, under certain circumstances, to hold harmless and indemnify each of our directors and officers against losses suffered or incurred by the indemnified party in connection with their service to us, and judgements, fines, settlements and expenses related to claims arising against such directors and officers to the fullest extent permitted under Delaware law, our bylaws and our certificate of incorporation. We also enter and have entered into indemnification agreements with our directors and officers that may require us to indemnify them against liabilities that arise by reason of their status or service as directors or officers, except as prohibited by applicable law. In addition, we may have obligations to hold harmless and indemnify third parties involved with our fundraising efforts and their respective affiliates, directors, officers, employees, agents or other representatives against any and all losses, claims, damages and liabilities related to claims arising against such parties pursuant to the terms of agreements entered into between such third parties and us in connection with such fundraising efforts. To the extent that any such indemnification obligations apply to the lawsuits described above, any associated expenses incurred are included within the related accrued litigation expense amounts. <ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="pacb:AdditionalLiabilityAssociatedWithIndemnificationObligations" format="ixt:fixed-zero" scale="0" id="f-800"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="pacb:AdditionalLiabilityAssociatedWithIndemnificationObligations" format="ixt:fixed-zero" scale="0" id="f-801">No</ix:nonFraction></ix:nonFraction> additional liability associated with such indemnification obligations has been recorded as of September&#160;30, 2025 and December&#160;31, 2024.</span></div></ix:nonNumeric><div id="ieb0962265ffb4e35ba6bd2d2c7eff64b_52"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-802" continuedAt="f-802-1" escape="true"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 7.  EQUITY PLANS AND SHARE-BASED COMPENSATION</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Equity Plans</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2025, the Company had share-based compensation awards outstanding under the 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;), the 2020 Inducement Equity Incentive Plan (the &#8220;Inducement Plan&#8221;), the 2021 adopted Omniome Equity Incentive Plan of Pacific Biosciences of California, Inc. (the &#8220;Omniome Plan&#8221;) and the 2010 Employee Stock Purchase Plan, from which we issued equity awards and employee stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 4, 2025, our stockholders approved an amendment to the 2020 Plan to reserve an additional <ix:nonFraction unitRef="shares" contextRef="c-195" decimals="-6" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="f-803">23</ix:nonFraction>&#160;million shares of our common stock for issuance pursuant to equity awards granted under the 2020 Plan.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2025, we had <ix:nonFraction unitRef="shares" contextRef="c-196" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="f-804">37.8</ix:nonFraction>&#160;million shares remaining and available for future issuance under the 2020 Plan, Inducement Plan, and the Omniome Plan. Shares remaining and available for future issuance reflect shares that may become eligible to vest upon the achievement of maximum targets for certain equity awards.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-22"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><ix:continuation id="f-802-1" continuedAt="f-802-2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9 &#8211; Stockholders' Equity</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in Part II, Item 8 of our 2024 Annual Report for more information on the Company's equity plans</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Stock Options</span></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-805" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for time-based awards:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(shares in thousands)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Number<br/>of shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Weighted<br/>average<br/>exercise price</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at December 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-197" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-806">10,509</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-197" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-807">11.09</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Granted </span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-198" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="f-808">8,290</ix:nonFraction></span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-198" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-809">1.22</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Canceled</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-198" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="3" id="f-810">2,501</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-198" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-811">7.89</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expired</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-198" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="3" id="f-812">376</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-198" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-813">6.44</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at September 30, 2025</span></td><td colspan="3" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-199" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-814">15,922</ix:nonFraction></span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-199" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-815">6.57</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Restricted Stock Units ("RSU") and Performance Stock Units ("PSU")</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant RSUs for which the respective shares vest when the requisite service period is achieved.&#160;We granted PSUs during the first quarter of 2023 for which the number of shares issuable is based on performance relative to specified revenue targets and continued employment through the vesting period. The PSUs are issuable following the third year of the performance period. Maximum achievement of the revenue goal under the PSUs will result in up to <ix:nonFraction unitRef="number" contextRef="c-200" decimals="2" name="pacb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal" scale="-2" id="f-816">200</ix:nonFraction>% of the target number of shares subject to the PSUs to become eligible to vest, while not meeting the minimum achievement of the revenue goal under the PSUs will result in no shares subject to the PSUs becoming eligible to vest. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="f-817" continuedAt="f-817-1" escape="true">The following table summarizes the time-based RSUs and PSUs activity: </ix:nonNumeric></span></div><ix:continuation id="f-817-1"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Restricted Stock Units (RSU)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Performance Stock Units (PSU)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Weighted average grant date<br/>fair value</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(shares in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">RSU</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PSU</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at December 31, 2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-201" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="f-818">14,211</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-202" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="f-819">392</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-201" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-820">7.41</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-202" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-821">9.43</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-203" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="f-822">11,895</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-204" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="3" id="f-823">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-203" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-824">1.25</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-204" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-825">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-203" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="3" id="f-826">4,331</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-204" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:fixed-zero" scale="3" id="f-827">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-203" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-828">9.47</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-204" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-829">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-203" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="3" id="f-830">3,652</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-204" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:fixed-zero" scale="3" id="f-831">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-203" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-832">4.08</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-204" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-833">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at September 30, 2025</span></td><td colspan="2" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-205" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="f-834">18,123</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-206" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="f-835">392</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-205" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-836">3.55</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-206" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-837">9.43</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Employee Stock Purchase Plan ("ESPP")</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares issued under our ESPP wer</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" format="ixt:num-dot-decimal" scale="0" id="f-838">3,102,930</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-15" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" format="ixt:num-dot-decimal" scale="0" id="f-839">1,906,529</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> durin</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g the nine months ended September&#160;30, 2025 and 2024, respectively. In the first quarter of 2025, an additional <ix:nonFraction unitRef="shares" contextRef="c-207" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="6" id="f-840">4.0</ix:nonFraction>&#160;million shares were reserved under the ESPP. As of September&#160;30, 2025, <ix:nonFraction unitRef="shares" contextRef="c-208" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="f-841">15.2</ix:nonFraction>&#160;million shares of our common stock remain avai</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lable for issuance under our ESPP.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Share-based Compensation</span></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-842" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.627%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.630%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of revenue</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-843">892</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-844">1,229</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-845">2,982</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-846">4,466</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-847">3,050</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-848">4,740</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-849">8,964</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-850">15,119</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales, general and administrative</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-851">7,042</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-852">12,290</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-853">20,134</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-854">35,418</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total share-based compensation expense</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-855">10,984</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-856">18,259</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-857">32,080</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-858">55,003</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-23"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><ix:continuation id="f-802-2"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Determining Fair Value</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of stock options granted using the Black-Scholes valuation method and a single option award approach. When determining the current share prices underlying the stock options for calculating the grant-date fair value, we reference the observable market prices of our stock. This fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. The fair market value of RSUs and PSUs granted is the closing price of our shares on the date of grant and is generally recognized as compensation expense on a straight-line basis over the respective vesting period. For shares purchased under our ESPP, we estimate the grant-date fair value, and the resulting share-based compensation expense, using the Black-Scholes option-pricing model. We estimate forfeitures of stock options, RSUs and shares purchased under our ESPP which is utilized to determine the compensation expense to be recorded over the requisite service period.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Expected Term - The expected term used in the Black-Scholes valuation method represents the period that the stock options are expected to be outstanding and is determined based on historical experience of similar awards, considering the contractual terms of the stock options and vesting schedules.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Expected Volatility - The expected volatility used in the Black-Scholes valuation method is derived from the implied volatility related to our share price over the expected term.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Expected Dividend - We have never paid dividends on our shares and, accordingly, the dividend yield percentage is <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-859"><ix:nonFraction unitRef="number" contextRef="c-15" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-860">zero</ix:nonFraction></ix:nonFraction> for all periods.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Risk-Free Interest Rate - The risk-free interest rate used in the Black-Scholes valuation method is the implied yield currently available on U.S. Treasury constant maturities issued with a term equivalent to the expected terms.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-861" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of employee stock options was estimated using the following assumptions:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected term in years</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-223" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-862">4.9</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-224" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-863">4.9</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected volatility </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;<ix:nonFraction unitRef="number" contextRef="c-223" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-864">95</ix:nonFraction>% &#8212; <ix:nonFraction unitRef="number" contextRef="c-223" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-865">96</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-224" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-866">81</ix:nonFraction>% &#8212; <ix:nonFraction unitRef="number" contextRef="c-224" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-867">93</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk-free interest rate </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;<ix:nonFraction unitRef="number" contextRef="c-223" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-868">3.89</ix:nonFraction>% &#8212; <ix:nonFraction unitRef="number" contextRef="c-223" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-869">4.29</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-224" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-870">3.48</ix:nonFraction>% &#8212; <ix:nonFraction unitRef="number" contextRef="c-224" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-871">4.32</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Dividend yield </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-223" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-872">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-224" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-873">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average grant date fair value per share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-223" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-874">0.90</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-224" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-875">1.40</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="f-876" escape="true"><div style="margin-top:15pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of shares to be issued under the ESPP was estimated using the following assumptions:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected term in years</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-225" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-877">0.5</ix:nonNumeric> &#8212; <ix:nonNumeric contextRef="c-226" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-878">2.0</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-227" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-879">0.5</ix:nonNumeric> &#8212; <ix:nonNumeric contextRef="c-228" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-880">2.0</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected volatility </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-229" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-881">101</ix:nonFraction>% &#8212; <ix:nonFraction unitRef="number" contextRef="c-229" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-882">113</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-230" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-883">81</ix:nonFraction>% &#8212; <ix:nonFraction unitRef="number" contextRef="c-230" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-884">118</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk-free interest rate </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-229" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-885">3.66</ix:nonFraction>% &#8212; <ix:nonFraction unitRef="number" contextRef="c-229" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-886">4.31</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-230" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-887">3.88</ix:nonFraction>% &#8212; <ix:nonFraction unitRef="number" contextRef="c-230" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-888">5.27</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Dividend yield </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-229" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-889">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-230" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-890">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average grant date fair value per share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-229" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-891">0.89</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-230" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-892">1.53</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ieb0962265ffb4e35ba6bd2d2c7eff64b_55"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-893" continuedAt="f-893-1" escape="true"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 8.  NET LOSS PER SHARE</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding and potential shares assuming the dilutive effect of the Notes, using the if-converted method, and outstanding equity awards using the treasury stock method.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-24"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><ix:continuation id="f-893-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-894" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of the basic and diluted net loss per share amounts presented in the condensed consolidated statements of operations and comprehensive loss:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.235%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except per share amounts)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Numerator:</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-895">38,000</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-896">60,725</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-897">506,005</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-898">312,222</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Denominator:</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average shares used in computing<br/>basic net loss per share</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-899">300,844</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-900">272,915</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-901">299,303</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-902">271,631</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic net loss per share</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-903">0.13</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-904">0.22</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-905">1.69</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-906">1.15</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Diluted</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average shares used in computing<br/>diluted net loss per share</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-907">300,844</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-908">272,915</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-909">299,303</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-910">271,631</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Diluted net loss per share</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-911">0.13</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-912">0.22</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-913">1.69</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-914">1.15</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-915" escape="true"><div style="margin-top:15pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following shares issuable upon conversion of the Notes and outstanding equity awards were excluded from the computation of diluted net loss per share for the periods presented because the effect of including such shares would have been antidilutive:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.235%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Shares issuable upon conversion of<br/>convertible senior notes</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-916">61,415</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-232" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-917">31,063</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-233" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-918">61,415</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-234" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-919">31,063</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity awards</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-235" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-920">42,599</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-236" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-921">36,496</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-237" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-922">42,599</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-238" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-923">36,496</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_52">Note 7. Equity Plans and Share-Based Compensation</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for detailed information on equity awards.</span></div></ix:continuation><div id="ieb0962265ffb4e35ba6bd2d2c7eff64b_58"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-924" continuedAt="f-924-1" escape="true"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 9.  SEGMENT AND GEOGRAPHIC INFORMATION</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are organized as, and operate in, <ix:nonFraction unitRef="customer" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-925">one</ix:nonFraction> reportable segment: the development, manufacturing, and marketing of integrated platforms for genetic analysis. Our chief operating decision-maker ("CODM") is our Chief Executive Officer. Our CODM reviews financial information presented on a consolidated basis for the purposes of evaluating financial performance and allocating resources.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a regular basis, our CODM reviews:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">total revenues by category</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">total expenses and expenses by function, including sales and marketing and general and administrative, which include depreciation and share-based compensation</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">net loss per share</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our assets are primarily located in the United States of America and not allocated to any specific region, and we do not measure the performance of geographic regions based upon asset-based metrics. Therefore, geographic information is presented only for revenue.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-25"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><ix:continuation id="f-924-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="f-926" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the segment profit or loss, including significant segment expenses is as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.235%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total revenue</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-927">38,441</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-928">39,967</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-929">115,360</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-930">114,790</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less:</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of revenue</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-931">22,540</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-932">29,963</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-933">86,146</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="f-934">87,566</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-935">22,846</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-936">25,516</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-937">74,428</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-938">107,456</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales and marketing</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="f-939">15,465</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="f-940">18,435</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="f-941">55,057</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="f-942">64,779</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-943">15,634</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-944">25,311</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-945">52,385</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-946">68,597</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Impairment charges</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:fixed-zero" scale="3" id="f-947">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:fixed-zero" scale="3" id="f-948">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:num-dot-decimal" scale="3" id="f-949">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:num-dot-decimal" scale="3" id="f-950">93,200</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:fixed-zero" scale="3" id="f-951">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="f-952">1,170</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="f-953">18,700</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="f-954">1,100</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of acquired intangible assets</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="f-955">833</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-956">3,649</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-957">363,708</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-958">13,377</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other income, net</span></div></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-959">1,260</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-960">3,352</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-961">6,775</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-962">9,063</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income tax provision</span></div></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-963">383</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-964">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-965">116</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-966">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Consolidated net loss</span></td><td colspan="2" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-967">38,000</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-968">60,725</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-969">506,005</ix:nonFraction>)</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-970">312,222</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="f-971" escape="true"><div style="margin-top:15pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our revenue by geographic location is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.235%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Americas</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-972">18,097</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-973">20,107</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-974">52,087</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-975">58,542</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-976">10,752</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-977">9,119</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-978">29,459</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-979">24,497</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Asia-Pacific</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-980">9,592</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-981">10,741</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-982">33,814</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-983">31,751</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-984">38,441</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-985">39,967</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-986">115,360</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-987">114,790</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="f-988" escape="true"><div style="margin-top:15pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our revenue by category is as follows: </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.235%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Instrument revenue</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-989">11,318</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-990">16,788</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-991">36,484</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-992">50,491</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Consumable revenue</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-993">21,279</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-994">18,508</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-995">60,309</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-996">51,560</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Product revenue</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-997">32,597</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-998">35,296</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-999">96,793</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1000">102,051</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Service and other revenue</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1001">5,844</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1002">4,671</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1003">18,567</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1004">12,739</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1005">38,441</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1006">39,967</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1007">115,360</ix:nonFraction>&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1008">114,790</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-26"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></td></tr></table></div></div></div><div id="ieb0962265ffb4e35ba6bd2d2c7eff64b_61"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #df1995;border-top:1pt solid #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 2.  MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations together with (i) our unaudited condensed consolidated financial statements and related notes that are included elsewhere in this Quarterly Report on Form 10-Q and (ii) our 2024 Annual Report filed with the U.S. Securities and Exchange Commission, or the SEC, on March 17, 2025. This discussion contains forward-looking statements based upon current plans, expectations and beliefs that involve risks and uncertainties. The words &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;predicts,&#8221; &#8220;projects,&#8221; &#8220;seeks,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including, but not limited to, those discussed in the section entitled &#8220;Risk Factors&#8221; and elsewhere in this Quarterly Report on Form 10-Q, and you should not place undue reliance on our forward-looking statements. We do not assume any obligation to update any forward-looking statements. In preparing this Management's Discussion and Analysis ("MD&amp;A"), we presume that readers have access to and have read the MD&amp;A in our 2024 Annual Report on Form 10-K, pursuant to Instruction 2 to paragraph (b) of Item 303 of Regulation S-K.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our MD&amp;A is organized into the following sections:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Overview and Outlook </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Results of Operations </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Liquidity and Capital Resources </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Critical Accounting Policies and Estimates</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Recent Accounting Pronouncements</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Off Balance Sheet Arrangements</span></div><div id="ieb0962265ffb4e35ba6bd2d2c7eff64b_64"></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">OVERVIEW AND OUTLOOK</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About PacBio</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products and technology, which include our HiFi long-read sequencing technology, address solutions across a broad set of applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. Long-read sequencing was recognized by the journal Nature Methods as its &#8220;method of the year&#8221; for 2022 for its contributions to biological understanding and future potential. </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-read sequencing</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has been applied to produce telomere-to-telomere genomes of humans, pangenome references, and has been recognized for its ability to provide more complete views of human variation</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We focus on creating some of the world&#8217;s most advanced sequencing systems to provide our customers with the most complete and accurate view of genomes, transcriptomes, and epigenomes. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations ("CROs"), pharmaceutical companies, and agricultural companies.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-27"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Strategic Objectives</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2025 strategic objectives are to grow revenue and expand gross margins through the following four activities: </span></div><div style="margin-top:9pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.41pt">Enabling the full-scale release of the Vega benchtop platform to broaden our market reach.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We believe this platform broadens the long-read market opportunity.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.41pt">Accelerating samples onto the Revio platform via SPRQ chemistry and application kits.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SPRQ chemistry enables the sub-$500 HiFi genome, improves methylation detection capabilities, and achieves a 75% reduction in DNA input requirements for human whole genome sequencing.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These features can drive more samples onto HiFi sequencing than ever before. </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.41pt">Investing in future product launches to diversify our offerings.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We continue to develop sequencing systems designed to increase throughput and lower the cost to sequence a genome, which we believe will allow us to address an even larger part of the market. Additionally, we continue to develop kitted-solutions, like our Kinnex Full-length RNA kits and PureTarget, and enhance our on-market sequencers with products like SPRQ chemistry to drive more sequencing volume. </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.41pt">Progressing our clinical strategy to improve outcomes and create durability.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Revio is increasingly being used in laboratory developed tests ("LDT") and clinical research settings to consolidate multiple tests and address complex genetic challenges. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to believe that with the capabilities of our HiFi chemistry and SMRT</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology, we can be a market leader in whole-genome clinical sequencing. Leading institutions have adopted our products to study rare and inherited disease. We believe the market opportunity for clinical sequencing is significant and could drive substantial revenue growth for the Company. We plan to continue to pursue partner collaborations where the technologies being developed or applications being considered extend beyond whole-genome clinical sequencing. Collaborative arrangements add to the awareness of our products and service offerings and may drive new applications for use of our technology.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Financial Overview</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key highlights of the nine months ended September 30, 2025 consolidated financial results include the following:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.636%"><tr><td style="width:1.0%"/><td style="width:22.863%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.182%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.863%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.182%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.863%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.182%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.865%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#009ca2;border-left:1pt solid #009ca2;border-top:1pt solid #009ca2;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue of</span></td><td colspan="3" style="border-left:1pt solid #009ca2;padding:0 1pt"/><td colspan="3" style="background-color:#009ca2;border-left:1pt solid #009ca2;border-top:1pt solid #009ca2;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit of</span></div></td><td colspan="3" style="border-left:1pt solid #009ca2;padding:0 1pt"/><td colspan="3" style="background-color:#009ca2;border-left:1pt solid #009ca2;border-top:1pt solid #009ca2;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating loss of</span></div></td><td colspan="3" style="border-left:1pt solid #009ca2;padding:0 1pt"/><td colspan="3" style="background-color:#009ca2;border-left:1pt solid #009ca2;border-right:1pt solid #009ca2;border-top:1pt solid #009ca2;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and investments of</span></div></td></tr><tr><td colspan="3" style="background-color:#009ca2;border-left:1pt solid #009ca2;border-top:1pt solid #009ca2;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:18pt;font-weight:700;line-height:120%">$115.4 M</span></td><td colspan="3" style="border-left:1pt solid #009ca2;padding:0 1pt"/><td colspan="3" style="background-color:#009ca2;border-left:1pt solid #009ca2;border-top:1pt solid #009ca2;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:18pt;font-weight:700;line-height:120%">$29.2 M</span></td><td colspan="3" style="border-left:1pt solid #009ca2;padding:0 1pt"/><td colspan="3" style="background-color:#009ca2;border-left:1pt solid #009ca2;border-top:1pt solid #009ca2;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:18pt;font-weight:700;line-height:120%">$512.7 M</span></div></td><td colspan="3" style="border-left:1pt solid #009ca2;padding:0 1pt"/><td colspan="3" style="background-color:#009ca2;border-left:1pt solid #009ca2;border-right:1pt solid #009ca2;border-top:1pt solid #009ca2;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:18pt;font-weight:700;line-height:120%">$298.7 M</span></div></td></tr><tr><td colspan="3" style="background-color:#009ca2;border-bottom:1pt solid #009ca2;border-left:1pt solid #009ca2;border-top:1pt solid #009ca2;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compared to $114.8 M during the same period of 2024</span></div></td><td colspan="3" style="border-left:1pt solid #009ca2;padding:0 1pt"/><td colspan="3" style="background-color:#009ca2;border-bottom:1pt solid #009ca2;border-left:1pt solid #009ca2;border-top:1pt solid #009ca2;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compared to $27.2 M during the same period of 2024</span></div></td><td colspan="3" style="border-left:1pt solid #009ca2;padding:0 1pt"/><td colspan="3" style="background-color:#009ca2;border-bottom:1pt solid #009ca2;border-left:1pt solid #009ca2;border-top:1pt solid #009ca2;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compared to $321.3 M during the same period of 2024</span></div></td><td colspan="3" style="border-left:1pt solid #009ca2;padding:0 1pt"/><td colspan="3" style="background-color:#009ca2;border-bottom:1pt solid #009ca2;border-left:1pt solid #009ca2;border-right:1pt solid #009ca2;border-top:1pt solid #009ca2;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compared to $389.9 M at December&#160;31, 2024</span></div></td></tr></table></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.91pt">Revenue was comprised of $36.5 million in instrument revenue, $60.3 million in consumables revenue and $18.6 million in service and other revenue during the nine months ended September 30, 2025. Revenue was comprised of $50.5 million in instrument revenue, $51.6 million in consumables revenue and $12.7 million in service and other revenue during the nine months ended September 30, 2024. The increase was primarily due to higher consumable sales, Vega unit sales, and service and other revenue, partially offset by lower Revio unit sales.</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.91pt">Gross profit increased during the nine months ended September 30, 2025 compared to the same period of 2024. The increase was primarily driven by growth in consumable revenue and lower cost of product revenue, partially offset by restructuring-related charges of $12.4&#160;million during the nine months ended September 30, 2025 compared to $4.4 million for the same period of 2024. See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_46">Note 5. Restructuring</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Part I, Item 1 of this Quarterly Report on Form 10-Q for additional information. Gross margins may be affected by product mix, manufacturing efficiencies, changes in warranty costs, average selling price fluctuations, future product launches, changes to inventory reserves, costs of raw materials, and tariffs.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-28"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.14pt">Loss from operations increased $191.4 million during the nine months ended September 30, 2025, compared with the same period of 2024, primarily due to a $193.4 million increase in operating expenses. This increase included $382.4&#160;million of restructuring-related costs, comprised primarily of $359.3 million in accelerated amortization of acquired intangibles, $15.0 million of impairment charges, and $4.8 million of employee separation costs. By contrast, restructuring-related charges totaled $20.3 million in the prior-year period. These increases in restructuring-related costs were partially offset by a $78.2 million decrease in impairment charges, a $19.8 million change in fair value of contingent consideration, and reductions in research and development and sales, general and administrative expenses due to headcount and related cost savings from the restructuring.</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.91pt">Cash, cash equivalents, and short-term investments were $298.7 million at September&#160;30, 2025, which represents a 23% decrease compared to the balance at December&#160;31, 2024.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sales cycle for Revio instrument purchases continues to be elongated. We believe this has been caused by, among other reasons, the uncertainty surrounding the funding for new capital equipment, in particular, uncertainty in the United States related to the National Institutes of Health ("NIH") and academic funding; procurement delays; small-to-mid-size existing customers yet to increase their sample volumes to drive an upgrade to Revio; new customers, which have shown they have longer sales cycles compared to existing PacBio customers; and sample volumes materializing slower than expected for some potential Revio customers.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Macroeconomic dynamics impacting the Company in the future may include rising inflation, geopolitical tensions, volatile capital markets, tariffs, uncertainty in the United States related to NIH and academic funding, and fluctuating exchange rates. These factors could continue to impact our revenues and results of operations in future periods; however, the magnitude and duration of these impacts is highly uncertain and inherently unpredictable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, we evaluate our significant estimates, including those related to the valuation of goodwill and finite-lived assets. However, these estimates could change in future periods based on events or changes in circumstances, which could result in material future impairment charges. We recorded $15.0 million of impairment charges during the nine months ended September 30, 2025. See additional discussion below in Results of Operations, as well as </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_37">Note 3. Balance Sheet Components</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in Part I, Item 1 of this Quarterly Report on Form 10-Q for further information. Additionally, refer to the Critical Accounting Policies and Estimates section of our 2024 Annual Report for further discussion on the Company's asset impairment assessments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_94">Risk Factors</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section for further discussion.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-29"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></td></tr></table></div></div></div><div id="ieb0962265ffb4e35ba6bd2d2c7eff64b_67"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Comparison of the Three Months Ended September 30, 2025 and 2024</span></div></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.235%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except percentages)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$ Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenue:</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Product revenue </span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">32,597&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">35,296&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,699)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(8</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Service and other revenue </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,844&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,671&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,173&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total revenue </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,441&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">39,967&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,526)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of Revenue:</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of product revenue </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19,204&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23,278&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,074)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(18</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of service and other revenue </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,078&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,484&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(406)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(12</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of acquired intangible assets</span></div></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">183&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,201&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,018)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(94</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Loss on purchase commitment</span></div></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">75&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total cost of revenue </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,540&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29,963&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7,423)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(25</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 68.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross profit</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,901&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,004&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,897&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">59</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating Expense:</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,846&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25,516&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,670)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(10)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales, general and administrative </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,099&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">43,746&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(12,647)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(29)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of acquired intangible assets</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">833&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,649&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,816)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(77)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,170&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,170)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(100)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total operating expense </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">54,778&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">74,081&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(19,303)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(26</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating loss </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(38,877)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(64,077)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25,200&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(39)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest expense </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,739)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,538)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,799&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(51)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other income, net </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,999&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,890&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,891)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(56</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Loss before income taxes</span></div></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(37,617)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(60,725)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23,108&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(38</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income tax provision</span></div></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">383&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">383&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(38,000)</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(60,725)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,725&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(37</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%)</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-30"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Revenue</span></div></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:6pt;text-align:justify"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Total Revenue</span></div></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:31.563%"><div style="margin-top:6pt;text-align:justify"><img src="pacb-20250930_g3.jpg" alt="15" style="height:153px;margin-bottom:5pt;vertical-align:text-bottom;width:172px" id="i-31"/></div></div><div style="display:inline-block;max-width:0.072%;min-width:0.000%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:68.365%"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue decreased $1.6 million, or 4%, for the third quarter of 2025 compared with the same quarter of 2024.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue decreased $2.7 million, or 8%, primarily due to a decrease of $5.5 million, or 33%, in instrument revenue, partially offset by an increase of $2.8 million, or 15%, in consumable revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service and other revenue increased $1.1 million, or 25%, primarily driven by an increase in Revio service contracts.</span></div></div></div><div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:6pt;text-align:justify"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Instrument Revenue</span></div></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:31.563%"><div style="margin-top:6pt;text-align:justify"><img src="pacb-20250930_g4.jpg" alt="387" style="height:153px;margin-bottom:5pt;vertical-align:text-bottom;width:172px" id="i-32"/></div></div><div style="display:inline-block;max-width:0.072%;min-width:0.000%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:68.365%"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Instrument revenue decreased for the third quarter of 2025, primarily due to a lower number of Revio systems sold&#8212;13 units compared to 22 units in the same quarter of 2024. This decline primarily reflects variability in customer purchasing behavior resulting from uncertainty surrounding the funding for new capital equipment, particularly among academic and research institutions. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease was partially offset by sales of the Vega system, with 32 units sold during the third quarter of 2025 following its commercial launch in the fourth quarter of 2024.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that instrument revenue may fluctuate quarter-to-quarter based on timing of customer purchasing decisions, sales mix, and funding dynamics.</span></div></div></div><div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:6pt;text-align:justify"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consumables Revenue</span></div></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:31.563%"><div style="margin-top:12pt;text-align:justify"><img src="pacb-20250930_g5.jpg" alt="1074" style="height:163px;margin-bottom:5pt;vertical-align:text-bottom;width:172px" id="i-33"/></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:0.072%;min-width:0.000%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:68.365%"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in consumables revenue for the third quarter of 2025 was primarily driven by higher Revio consumables sales, reflecting the continued expansion of the Revio instrument installed base.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shipments of Vega consumables also contributed modestly during the period, and we anticipate increased contributions as customers begin ramping usage of the Vega platform and the installed base expands.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Looking ahead, we expect continued growth in consumables revenue as adoption of the Revio and Vega platforms expands. This anticipated growth reflects increasing instrument placements, improving consumable utilization, and broadening addressable application for our platforms.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-34"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:21pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cost of Revenue and Gross Profit</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cost of revenue decreased $7.4 million, or 25%, in the third quarter of 2025 compared to the same quarter of 2024 primarily due to a decrease in cost of product revenue and a decrease of $3.0 million in amortization attributable to acquired intangible assets that are related to sales generating activities. Total cost of revenue included share-based compensation expense of $0.9 million and $1.2 million during the third quarter of 2025 and 2024, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product revenue decreased $4.1 million, or 18%, in the third quarter of 2025 compared to the same quarter of 2024 primarily due to a shift in product mix to lower cost instruments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit increased $5.9 million, or 59%, in the third quarter of 2025 compared to the same quarter of 2024 driven primarily by lower cost of revenue and higher consumables sales. Gross margins may be affected by product mix, manufacturing efficiencies, changes in warranty costs, average selling price fluctuations, future product launches, changes to inventory reserves, costs of raw materials and tariffs.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Research and Development Expense</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense decreased by $2.7 million, or 10%, for the third quarter of 2025, compared to the same quarter of 2024. The decrease was primarily driven by decreases in personnel and related expenses, including share-based compensation. Research and development expense included share-based compensation expense of $3.1 million and $4.7 million during the third quarter of 2025 and 2024, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Sales, General, and Administrative Expense</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales, general and administrative expense decreased by $12.6 million, or 29%, for the third quarter of 2025, compared to the same quarter of 2024. The decrease was primarily due to $6.9 million of restructuring charges recorded in the third quarter of 2024 and a decrease in share-based compensation expense. Sales, general, and administrative expense included share-based compensation expense of $7.0 million and $12.3 million during the third quarter of 2025 and 2024, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Amortization of Acquired Intangible Assets</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of acquired intangible assets included in operating expenses for the third quarter of 2025 and 2024 consists of amortization expense attributable to acquired intangible assets that are not directly related to sales generating activities.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Change in Fair Value of Contingent Consideration</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value of contingent consideration during the third quarter of 2024 represents the remeasurement impact of contingent consideration due upon the achievement of a milestone.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Interest Expense</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the third quarter of 2025 and 2024 was primarily comprised of interest on the convertible senior notes. The decrease was due to lower convertible notes balances as a result of the notes exchange transaction in November 2024. See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_40">Note 4. Convertible Senior Notes</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Part I, Item 1 of this Quarterly Report on Form 10-Q for additional information.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Income, Net</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net for the third quarter of 2025 decreased compared to the same quarter of 2024 primarily driven by lower investment income due to lower cash and investment balances.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-35"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></td></tr></table></div></div></div><div id="ieb0962265ffb4e35ba6bd2d2c7eff64b_70"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Comparison of the Nine Months Ended September 30, 2025 and 2024</span></div></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.235%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except percentages)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$ Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenue:</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Product revenue </span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">96,793&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">102,051&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,258)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Service and other revenue </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,567&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,739&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,828&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">46</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total revenue </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">115,360&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">114,790&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">570&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of Revenue:</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of product revenue </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">65,559&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">68,808&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,249)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of service and other revenue </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,709&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,588&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,121&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of acquired intangible assets</span></div></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,711&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,172&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,461)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(34</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Loss on purchase commitment</span></div></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,167&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">998&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,169&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">318</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total cost of revenue </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">86,146&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">87,566&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,420)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 68.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross profit</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29,214&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27,224&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,990&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating Expense:</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">74,428&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">107,456&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(33,028)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(31</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales, general and administrative </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">107,442&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">133,376&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(25,934)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(19</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Impairment charges</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,000&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">93,200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(78,200)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(84</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of acquired intangible assets</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">363,708&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,377&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">350,331&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2619</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(18,700)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(19,800)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1800</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total operating expense </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">541,878&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">348,509&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">193,369&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">55</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating loss </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(512,664)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(321,285)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(191,379)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">60</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest expense </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,214)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(10,655)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,441&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(51</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other income, net </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,989&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19,718&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7,729)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(39</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Loss before income taxes</span></div></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(505,889)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(312,222)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(193,667)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">62</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income tax provision</span></div></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">116&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">116&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(506,005)</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(312,222)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(193,783)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">62</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-36"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Revenue</span></div></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:6pt;text-align:justify"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Total Revenue</span></div></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:31.563%"><div style="margin-top:6pt;text-align:justify"><img src="pacb-20250930_g6.jpg" alt="15" style="height:153px;margin-bottom:5pt;vertical-align:text-bottom;width:172px" id="i-37"/></div></div><div style="display:inline-block;max-width:0.072%;min-width:0.000%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:68.365%"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue increased $0.6 million during the nine months ended September 30, 2025 compared with the same period of 2024.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue decreased $5.3 million, or 5%, primarily due to a decrease of $14.0 million, or 28%, in instrument revenue, partially offset by an increase of $8.7 million, or 17%, in consumable revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service and other revenue increased $5.9 million, or 46%, primarily driven by an increase in Revio service contracts.</span></div></div></div><div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:6pt;text-align:justify"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Instrument Revenue</span></div></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:31.563%"><div style="margin-top:6pt;text-align:justify"><img src="pacb-20250930_g7.jpg" alt="383" style="height:153px;margin-bottom:5pt;vertical-align:text-bottom;width:172px" id="i-38"/></div></div><div style="display:inline-block;max-width:0.072%;min-width:0.000%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:68.365%"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Instrument revenue decreased during the nine months ended September 30, 2025, primarily due a lower number of Revio systems sold&#8212;40 units compared to 74 units in the same period of 2024. This decline primarily reflects variability in customer purchasing behavior resulting from uncertainty surrounding the funding for new capital equipment, particularly among academic and research institutions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease was partially offset by sales of the Vega system, with 98 units sold during the nine months ended September 30, 2025 following its commercial launch in the fourth quarter of 2024.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that instrument revenue may fluctuate quarter-to-quarter based on timing of customer purchasing decisions, sales mix, and funding dynamics.</span></div></div></div><div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:6pt;text-align:justify"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consumables Revenue</span></div></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:31.563%"><div style="margin-top:12pt;text-align:justify"><img src="pacb-20250930_g8.jpg" alt="1056" style="height:163px;margin-bottom:5pt;vertical-align:text-bottom;width:172px" id="i-39"/></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:0.072%;min-width:0.000%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:68.365%"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in consumables revenue during the nine months ended September 30, 2025 was primarily driven by higher Revio consumables sales, reflecting the continued expansion of the Revio instrument installed base.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shipments of Vega consumables also contributed modestly during the period, and we anticipate increased contributions as customers begin ramping usage of the Vega platform and the installed base expands.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Looking ahead, we expect continued growth in consumables revenue as adoption of the Revio and Vega platforms expands. This anticipated growth reflects increasing instrument placements, improving consumable utilization, and broadening addressable application for our platforms.</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div></div></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-40"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:21pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cost of Revenue and Gross Profit</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cost of revenue decreased $1.4 million, or 2%, during the nine months ended September 30, 2025, compared to the same period of 2024 primarily due to decreases in cost of product revenue, amortization of acquired intangible assets, and share-based compensation expense. These decreases were partially offset by an increase in restructuring-related charges. We recorded $12.4 million during the nine months ended September 30, 2025, which included $3.9 million relating to loss on purchase commitments which is based on an estimate of future excess inventory related to supply agreements for which we do not expect to have related sales. Restructuring-related charges were $4.4 million for the same period of 2024. Total cost of revenue included share-based compensation expense of $3.0 million and $4.5 million during the nine months ended September 30, 2025 and 2024, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product revenue decreased $3.2 million, or 5%, during the nine months ended September 30, 2025, compared to the same period of 2024 primarily due to a shift in product mix to lower cost instruments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit increased $2.0 million, or 7%, during the nine months ended September 30, 2025, compared to the same period of 2024 driven primarily by growth in consumable revenue which was partially offset by an increase in restructuring-related charges. See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_46">Note 5. Restructuring</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Part I, Item 1 of this Quarterly Report on Form 10-Q for additional information about restructuring activities. Gross margins may be affected by product mix, manufacturing efficiencies, changes in warranty costs, average selling price fluctuations, future product launches, changes to inventory reserves, costs of raw materials and tariffs.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Research and Development Expense</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense decreased by $33.0 million, or 31%, during the nine months ended September 30, 2025, compared to the same period of 2024. The decrease was primarily driven by a decrease in personnel and related expenses, including share-based compensation expense, lower product development costs due to the transition of launched products from development to commercialization, and lower restructuring-related charges. We recorded $2.7 million of restructuring-related charges during the nine months ended September 30, 2025 compared to $5.9 million for the same period of 2024. Research and development expense included share-based compensation expense of $9.0 million and $15.1 million during the nine months ended September 30, 2025 and 2024, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Sales, General, and Administrative Expense</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales, general and administrative expense decreased by $25.9 million, or 19%, during the nine months ended September 30, 2025, compared to the same period of 2024. The decrease was primarily due to a decrease in personnel and related expenses, including share-based compensation expense, and lower restructuring-related charges. We recorded $5.5 million of restructuring-related charges during the nine months ended September 30, 2025 compared to $14.4 million for the same period of 2024. Sales, general, and administrative expense included share-based compensation expense of $20.1 million and $35.4 million during the nine months ended September 30, 2025 and 2024, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Impairment Charges</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded impairment charges of $15.0 million during the nine months ended September 30, 2025, related to in-process research and development (&#8220;IPR&amp;D&#8221;). These charges resulted from an interim impairment assessment performed in response to identified indicators of impairment during the period. The impairment test concluded that the carrying amount of our IPR&amp;D assets exceeded their estimated fair value. See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_37">Note 3. Balance Sheet Components</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Part I, Item 1 of this Quarterly Report on Form 10-Q for additional information.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized a goodwill impairment charge of $93.2 million during the nine months ended September 30, 2024. This charge was primarily driven by a sustained decrease in our stock price and changes in the timing of expected future cash flows under our long-term plan, reflecting the ongoing impact of longer-than-anticipated median sales cycles and other contributing factors. These conditions indicated that the fair value of the reporting unit may have been less than its carrying amount, prompting the performance of an interim goodwill impairment test. The results of the test confirmed that the reporting unit&#8217;s carrying amount exceeded its estimated fair value.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-41"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Amortization of Acquired Intangible Assets</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of acquired intangible assets during the nine months ended September 30, 2025 included $359.3 million of accelerated amortization related to developed technology from the 2021 Omniome acquisition, reflecting our revised estimate that the asset will no longer generate economic benefit beyond March 31, 2025. We expect significantly lower amortization expense in future periods.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Change in Fair Value of Contingent Consideration</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value of contingent consideration during the nine months ended September 30, 2024 represents the remeasurement impact of contingent consideration due upon the achievement of a milestone.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized a change in fair value of contingent consideration of $18.7 million during the nine months ended September 30, 2025, resulting in a contingent consideration liability of $0. This was primarily due to management's decision to cease development of the high-throughput short-read system, the associated changes in expected future revenues, and the requirement that the milestone event occur prior to the five-year anniversary of the acquisition closing date.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Interest Expense</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense during the nine months ended September 30, 2025 and 2024 was primarily comprised of interest on the convertible senior notes. The decrease was due to lower convertible notes balances as a result of the notes exchange transaction in November 2024. See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_40">Note 4. Convertible Senior Notes</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Part I, Item 1 of this Quarterly Report on Form 10-Q for additional information.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Income, Net</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net during the nine months ended September 30, 2025 decreased compared to the same period of 2024 primarily driven by lower investment income due to lower cash and investment balances.</span></div><div id="ieb0962265ffb4e35ba6bd2d2c7eff64b_73"></div><div style="margin-top:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2025, we had cash, cash equivalents and investments of $298.7 million compared to $389.9 million as of December&#160;31, 2024. We believe that our existing cash, cash equivalents and investments will be sufficient to fund our projected operating requirements beyond the next 12 months from the date of filing of this Quarterly Report on Form 10-Q for the quarter ended September&#160;30, 2025.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary sources of liquidity, other than our holdings of cash, cash equivalents, and investments, have primarily been through the issuance of debt or equity securities, together with cash flow from operating activities. We have historically incurred, and expect to continue to incur, operating losses and generate negative cash flows from operations on an annual basis, and as a result, we may require additional capital resources to execute our strategic initiatives to grow our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We began implementing expense reduction initiatives in the second quarter of 2024, including workforce reductions, facility downsizing, and a streamlined development pipeline, with the goal of lowering annualized run-rate operating expenses by year-end. In the first quarter of 2025, we implemented additional actions, including further workforce reductions, to support continued cost savings.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that may affect our capital needs include, but are not limited to, the pace of adoption of our products, which affects the sales of our products and services; our ability to efficiently manage our operations; the effectiveness of our expense reduction initiatives; our ability to attract and retain customers and collaborators; the progress of our research and development programs; initiation, expansion, or funding of research programs and collaborations; the purchase of patent licenses; the impact of product quality; litigation costs, including the costs involved in preparing, filing, prosecuting, defending and enforcing intellectual property rights; costs of developing new and enhanced products; acquisitions of complementary businesses, technologies or assets; achievement of milestones in connection with acquisitions; and other factors. There can be no assurance that funds will be available on favorable terms, or at all.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-42"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Contingent Consideration</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our 2023 acquisition of Apton, we agreed to pay $25.0 million to former Apton equity holders if a high-throughput sequencer incorporating Apton&#8217;s technology generates $50.0 million in revenue within five years of the closing. Payment may be made in cash, stock, or a combination of cash and stock. As of September&#160;30, 2025, due primarily to the decision to discontinue development of the system and revised revenue expectations, the fair value of the contingent consideration liability was estimated at $0.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash Flow Summary</span></div></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net cash used in operating activities </span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(92,140)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(175,408)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net cash provided by investing activities </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">89,419&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">65,766&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net cash provided by financing activities </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,428&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,213&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net increase (decrease) in cash, cash equivalents, and restricted cash</span></div></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">707&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(102,429)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Activities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary uses of cash in operating activities include the development of future products and product enhancements, manufacturing, and support functions related to our sales, general and administrative activities. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in operating activities during the nine months ended September 30, 2025 of $92.1 million was due primarily to a $506.0 million net loss that included non-cash items such as amortization of acquired intangible assets of $368.4&#160;million, an impairment charge of $15.0 million, share-based compensation of $32.1&#160;million, $9.8&#160;million of inventory adjustments, and depreciation expense of $10.3&#160;million, partially offset by an $18.7 million decrease in the change in the fair value of the contingent consideration and $3.1&#160;million in net changes to operating assets and liabilities. Cash flow impact from changes in net operating assets and liabilities was primarily driven by increases in accounts receivable and inventory, as well as decreases in accrued expenses and other liabilities. These uses of cash were partially offset by a decrease in prepaid expenses and other assets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in operating activities for the nine months ended September 30, 2024 of $175.4 million was due primarily to a $312.2 million net loss that included non-cash items such as a goodwill impairment charge of $93.2 million, share-based compensation of $55.0&#160;million, amortization of acquired intangible assets of $20.6&#160;million, depreciation expense of $10.9&#160;million and amortization of right-of-use assets of $10.9&#160;million. This was offset by the accretion of discount and amortization of premium on marketable securities, net of $10.7&#160;million and $48.9&#160;million in net changes to operating assets and liabilities. Cash flow impact from changes in net operating assets and liabilities was primarily driven by an increase in inventory, as well as decreases in accrued expenses and operating lease liabilities. These uses of cash were partially offset by a decrease in accounts receivable.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing Activities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investing activities consist primarily of capital expenditures and investment purchases, sales, and maturities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by investing activities during the nine months ended September 30, 2025, was primarily from $280.1&#160;million of maturities of investments partially offset by $183.8&#160;million of purchases of investments and $5.0&#160;million in purchases of intangible assets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by investing activities for the nine months ended September 30, 2024, was primarily from $488.5&#160;million of maturities and sales of investments partially offset by $418.2&#160;million in purchases of investments and $4.6&#160;million in purchases of property and equipment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by financing activities during the nine months ended September 30, 2025 resulted from $3.4&#160;million of proceeds from the issuance of common stock through our equity compensation plans.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-43"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by financing activities during the nine months ended September 30, 2024 resulted primarily from $7.7&#160;million of proceeds from the issuance of common stock through our equity compensation plans.</span></div><div id="ieb0962265ffb4e35ba6bd2d2c7eff64b_76"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We presented our contractual obligations at December&#160;31, 2024 in our 2024 Annual Report. There were no material changes outside the ordinary course of business to our contractual obligations during the nine months ended September 30, 2025.</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING POLICIES AND ESTIMATES</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion and analysis of our financial condition and results of operations are based upon our unaudited condensed consolidated financial statements, which have been prepared in accordance with the rules and regulations of the SEC. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. We evaluate our critical accounting policies and estimates on an ongoing basis. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes to our significant accounting policies as disclosed in our 2024 Annual Report.</span></div><div id="ieb0962265ffb4e35ba6bd2d2c7eff64b_79"></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RECENT ACCOUNTING PRONOUNCEMENTS</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_31">Note 1. Organization and Significant Accounting Policies</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, subsection titled &#8220;Recent Accounting Pronouncements&#8221;, in Part I, Item 1 of this Quarterly Report on Form 10-Q for information regarding applicable recent accounting pronouncements. </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">OFF-BALANCE SHEET ARRANGEMENTS</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2025, we did not have any off-balance sheet arrangements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we enter into standard indemnification arrangements. Pursuant to these arrangements, we indemnify, hold harmless, and agree to reimburse the indemnified parties for losses suffered or incurred by the indemnified party in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third party with respect to its technology, or from claims relating to our performance or non-performance under a contract, any defective products supplied by us, or any acts or omissions, or willful misconduct, committed by us or any of our employees, agents or representatives. The term of these indemnification agreements is generally perpetual after the execution of the agreement. The maximum potential amount of future payments we could be required to make under these agreements is not determinable because it involves claims that may be made against us in future periods but have not yet been made. To date, we have not incurred costs to defend lawsuits or settle claims related to these indemnification agreements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also enter and have entered into indemnification agreements with our directors and officers that may require us to indemnify them against liabilities that arise by reason of their status or service as directors or officers, except as prohibited by applicable law. In addition, we may have obligations to hold harmless and indemnify third parties involved with our fundraising efforts and their respective affiliates, directors, officers, employees, agents or other representatives against any and all losses, claims, damages and liabilities related to claims arising against such parties pursuant to the terms of agreements entered into between us and such third parties in connection with such fundraising efforts. To the extent that such indemnification obligations apply to the lawsuits described in </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_49">Note 6. Commitments and Contingencies</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Part I, Item 1 of this Quarterly Report on Form 10-Q, any associated expenses incurred are included within the related accrued litigation expense amounts. No additional liability associated with such indemnification agreements has been recorded as of September&#160;30, 2025.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-44"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></td></tr></table></div></div></div><div id="ieb0962265ffb4e35ba6bd2d2c7eff64b_82"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:15pt;padding-left:55.44pt;text-align:justify;text-indent:-55.44pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #df1995;border-top:1pt solid #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 3.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </span></div></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Interest Rate and Market Risk</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2030 Notes and 2029 Notes have fixed annual interest rates of 1.375% and 1.50%, respectively, and accordingly we do not have any economic interest rate exposure or financial statement risk associated with changes in interest rates. The fair value of the notes, however, may fluctuate when interest rates and the market price of our stock changes. See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_40">Note 4. Convertible Senior Notes</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Part I, Item 1 of this Quarterly Report on Form 10-Q for additional information.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2025, we invested in cash equivalents, U.S. government and agency securities, and corporate debt securities which were designated as cash equivalents and available-for-sale investments. Our cash equivalents and available-for-sale securities as of September&#160;30, 2025 was $298.7 million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our exposure to market risk for changes in interest rates relates primarily to our investment portfolio comprised of marketable securities. We invest in a number of securities including U.S. government and agency securities, U.S. Treasury securities, and corporate debt securities and money market funds. We attempt to ensure the safety and preservation of our invested principal funds by limiting default risk, market risk and reinvestment risk. We mitigate default risk by investing in high grade investment securities. The fair market value of our fixed rate securities may be adversely impacted by increases in interest rates while income earned may decline as a result of decreases in interest rates. A hypothetical 100 basis-point (one percentage point) increase or decrease in interest rates compared to rates at September&#160;30, 2025 would have affected the fair value of our investment portfolio by approximately $1.6&#160;million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no other material changes in market risk from the information provided in our 2024 Annual Report.</span></div><div id="ieb0962265ffb4e35ba6bd2d2c7eff64b_85"></div><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #df1995;border-top:1pt solid #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 4.  CONTROLS AND PROCEDURES</span></div></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer, our Chief Financial Officer and our Chief Accounting Officer evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our chief executive officer and our chief financial officer concluded that our disclosure controls and procedures are designed at a reasonable assurance level and are effective to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms and that such information is accumulated and communicated to our management, including our chief executive officer and our chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An evaluation was performed under the supervision and with the participation of our management, including our Chief Executive Officer, Chief Financial Officer and Chief Accounting Officer to determine whether any change in our internal control over financial reporting occurred during the quarter ended September 30, 2025 that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. There were no material changes in our internal control over financial reporting during the quarter ended September 30, 2025, that have materially affected, or were reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-45"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></td></tr></table></div></div></div><div id="ieb0962265ffb4e35ba6bd2d2c7eff64b_88"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="ieb0962265ffb4e35ba6bd2d2c7eff64b_91"></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #df1995;border-top:1pt solid #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 1.  LEGAL PROCEEDINGS</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">U.S. District Court Proceedings</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 26, 2019, Personal Genomics of Taiwan, Inc. (&#8220;PGI&#8221;) filed a complaint in the U.S. District Court for the District of Delaware against us for patent infringement (C.A. No. 19-cv-1810) (the &#8220;PGI District Court matter&#8221;). The matter from this complaint is based on PGI&#8217;s U.S. Patent No. 7,767,441 (the &#8220;&#8216;441 Patent&#8221;). The complaint alleges that our Sequel systems and Sequel II systems infringe the &#8216;441 Patent. The complaint seeks unspecified monetary damages and an order enjoining us from infringing the &#8217;441 Patent. On November 20, 2019, we filed our answer to the complaint, denying infringement and seeking declaratory judgments of non-infringement and invalidity of the &#8216;441 Patent.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 22, 2020, we filed a petition requesting institution of an inter-partes review ("IPR") to the Patent Trial and Appeals Board (the &#8220;Board&#8221;) at the United States Patent Office (IPR2020-01163) requesting the Board to find a set of claims in the &#8216;441 Patent invalid. On June 27, 2020, we filed a second petition (IPR2020-01200) requesting institution of an IPR requesting the Board to find another set of claims in the &#8216;441 Patent invalid. The two petitions (the &#8220;PacBio IPR Petitions&#8221;) together asserted that all of the claims relevant to the PGI complaint are invalid. On January 19, 2021, the Board ordered that both PacBio IPR Petitions be instituted on all grounds presented. On January 18, 2022, the Board issued decisions on the two IPRs. In one IPR, all challenged claims were found unpatentable, including PGI&#8217;s core device claims. In the second IPR, the Board did not find the disputed claims unpatentable. PGI and PacBio each appealed to the U.S. Court of Appeals for the Federal Circuit, which affirmed both IPR decisions on January 9, 2024.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 25, 2020, the court ordered a stay of the PGI District Court matter based on a joint stipulation by the parties pending a final written decision on the IPRs. Following the final written decisions on the IPRs described above, on February 2, 2022, the judge ordered that the PGI District Court matter be reopened. However, in a subsequent order dated September 15, 2022, the judge stayed the PGI District Court matter pending a final decision by the U.S. Court of Appeals for the Federal Circuit regarding the appeal described above. On February 26, 2024, we moved to transfer the case from the District of Delaware to the Northern District of California and that motion was granted on June 18, 2024. On March 18, 2024, the parties filed a joint status report in which PGI requested the Court set a revised scheduling order and we requested grant of our motion to transfer and proposed an alternate scheduling order. A case management conference was held on October 10, 2024 and the Court set a trial date of October 5, 2026. We plan to vigorously defend against the remaining claims.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Proceedings</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may also be involved in a variety of other claims, lawsuits, investigations, and proceedings relating to securities laws, product liability, patent infringement, contract disputes, employment, and other matters that arise in the normal course of our business. In addition, third parties may, from time to time, assert claims against us in the form of letters and other communications.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record a provision for contingent losses when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. We currently do not believe that the ultimate outcome of any of the matters described above is probable or reasonably estimable, or that these matters will have a material adverse effect on our business; however, the results of litigation and claims are inherently unpredictable. Regardless of the outcome, litigation can have an adverse impact on us because of litigation and settlement costs, diversion of management resources, and other factors.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-46"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></td></tr></table></div></div></div><div id="ieb0962265ffb4e35ba6bd2d2c7eff64b_94"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #df1995;border-top:1pt solid #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 1A.  RISK FACTORS</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should carefully consider the risks and uncertainties described below, together with all of the other information in our public filings with the SEC, which could materially affect our business, financial condition, results of operations and prospects. The risks described below are not the only risks facing us. Risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially affect our business, financial condition, results of operations and prospects. In addition, any worsening of the economic environment may exacerbate the risks described below, any of which could have a material impact on us. This situation is changing rapidly, and additional impacts may arise that we are not aware of currently.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Summary Risk Factors</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the principal risks that could adversely affect our business, operations, and financial results. Such risks are discussed more fully below and include, but are not limited to, risks related to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our ability to successfully market, commercialize, and sell current and future products and related maintenance services;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our ability to achieve profitability for our business;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our ability to implement required expense reduction initiatives;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our ability to repay our debt and fund our long-term operations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our ability to successfully leverage and integrate our acquisitions and future acquisitions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our ability to successfully research, develop and timely manufacture our current and future products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">management of new product introductions and transitions, resultant costs, and ability of new products to generate promised performance;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">recent significant changes to our leadership team and resultant disruptions to our business;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">retention, recruitment, and training of senior management, key personnel, scientists and engineers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our ability to further penetrate nucleic acid sequencing applications, as well as grow product demand;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our reliance on outsourcing to other companies for manufacturing certain of our products, components and sub-assemblies, some of which are sole-sourced;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the impact of tariffs recently imposed by the U.S. government and its trading partners in response, other possible tariffs or trade protection measures, import or export licensing requirements, new or different customs duties, trade embargoes and sanctions and other trade barriers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our ability to consistently manufacture our instruments and consumables to meet customers&#8217; specifications, quantity, cost, or performance requirements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the high amount of competition we face in our industry;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our ability to attract customers and increase sales of current and future products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our reliance on a limited number of customers for a significant portion of our revenues, including academic, research and government institutions, which may be impacted by reductions in funding or targeted cancellations of certain grants or contracts by the U.S. federal government;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the complexity of our products giving rise to defects or errors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our unpredictable and lengthy sales cycles;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the possibility that our goodwill or intangible assets could become impaired;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">adverse effects resulting from political and economic tensions between the United States and other countries, including China and Russia, and other geopolitical uncertainties;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">securing and maintaining patent or other intellectual property protection for our products and related improvements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">current and future legal proceedings filed against us claiming intellectual property infringement;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-47"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the potential adverse impact of health epidemics;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">potential cybersecurity incidents and security breaches;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">governmental regulations that burden operations or narrow the market for our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">adverse effects resulting from new, increased, or enhanced trade tariffs, import restrictions, export restrictions, or other trade barriers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">evolving ethical, legal, privacy, social, and regulatory concerns regarding genetic testing;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">volatility of the price of our common stock; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our stock price falling as a result of future offerings or sales of securities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our risk factors are not guarantees that no such conditions exist as of the date hereof and should not be interpreted as an affirmative statement that such risks or conditions have not materialized, in whole or in part.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Risks Related to Our Business</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span id="i443ff6acf0ff4b5dba4ef72478faf9d8_195437"></span><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The commercialization and sales of our current or future products may be unsuccessful or less successful than anticipated. While we plan to continue pursuing new products and expanding into adjacent markets, we have limited experience in managing and selling multiple products and, as a result, may face challenges selling in new markets and fail to successfully carry out these initiatives, which may adversely impact our business, financial condition or results of operation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made and expect to continue making substantial investments to develop new products and enhance our existing products through our acquisitions and research and development efforts. For example, we commenced commercial shipments of Revio, our long-read sequencing system, and of Onso, our SBB short-read platform, in 2023. We also began taking orders and shipping our new Vega benchtop long-read sequencing system in the fourth quarter of 2024. Our future success is substantially dependent on our ability to successfully develop and commercialize our products, including in particular the Revio and Vega systems, as well as acquired technologies, which are anticipated to be used in demanding scientific research that requires substantial levels of accuracy and precision. In addition, we may not be successful in transitioning the customers of our prior generation products to our Revio and Vega products, or transitioning users of other third-party sequencing platforms to our portfolio of products, and have incurred and could continue to incur related obsolete inventory charges and losses on firm purchase commitments. Customers may also be slower than we anticipate in making new capital equipment acquisitions, especially in the current economic environment. Due to challenges we may experience in developing and marketing our existing products and launching new products, we may not be able to effectively:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">manage the timeliness of our new product introductions and the rate at which sales of our new products may cannibalize sales of our existing products or manage sales and marketing of multiple sequencing platforms;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">drive adoption of our current and future products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">maintain our competitive position by continuing to attract and retain customers for our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">provide appropriate levels of customer training and support for our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">implement an effective marketing strategy to promote awareness of our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">develop and implement an effective sales and distribution strategy for our current and future products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">develop, manufacture and commercialize new products or achieve an acceptable return on our manufacturing or research and development efforts and expenses;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">comply with regulatory requirements applicable to our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">anticipate and adapt to changes in our market;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">accommodate customer expectations and demands with respect to our products, increase product adoption by our existing customers or develop new customer relationships;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">deliver our early access systems to our external early access testing sites or complete our external early access testing program on our currently expected timelines;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-48"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">overcome unexpected challenges discovered during early access testing;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">complete the scientific and technical validation of new products on our currently expected timeline or at all;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">deliver our future products in a timely manner to our customers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">grow our market share by marketing and selling our products for new and additional applications;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">manage the significant burdens that expanding our existing or future products into current and new markets may impose on marketing, compliance, and other administrative and managerial resources;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">maintain and develop strategic relationships with vendors, manufacturers, and other industry partners to acquire necessary materials for the production of, and to develop, manufacture and commercialize, our existing or future products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">adapt or scale our manufacturing activities to meet performance specifications and potential demand at a reasonable cost;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">avoid infringement and misappropriation of third-party intellectual property;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">obtain and maintain any necessary licenses to third-party intellectual property on commercially reasonable terms;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">obtain valid and enforceable patents that give us a competitive advantage or enforce existing patents;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">protect our proprietary technology; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">attract, retain, and motivate qualified personnel.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risks noted above, especially with respect to the marketing, sales, and commercialization of our products, may be heightened by the impact of current uncertain market and other conditions. In addition, a high percentage of our expenses is and will continue to be fixed. Accordingly, if we do not generate revenue as and when anticipated, we could suffer a material adverse effect on our business, financial conditions, results of operations and prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate goodwill and other intangible assets with indefinite useful lives for impairment annually and whenever events or changes in circumstances indicate that the fair value of such assets may be less than the carrying value. We also perform regular reviews to determine if any event has occurred that may indicate that the carrying values of our intangible assets with finite lives and other finite-lived assets are impaired. Events that would indicate impairment and trigger an interim impairment test include, but are not limited to, unexpected adverse business conditions, weak demand for a specific product line or business, economic factors, shifting focus to certain lines of business, unanticipated technological changes or competitive activities, loss of key personnel, changes in business strategy, and acts by governments or courts. The occurrence of any of these events, may require us to record future impairment charges. For example, we recorded $184.5 million of impairment charges during the year ended December 31, 2024 as described in additional detail in </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 4.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Balance Sheet Components</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Part II, Item 8 of our 2024 Annual Report, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$15.0 million of impairment charges during the nine months ended September 30, 2025, as described in additional detail in </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_37">Note 3. Balance Sheet Components</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Part I, Item 1 of this Quarterly Report on Form 10-Q. Additionally, amortization of acquired intangible assets during the nine months ended September 30, 2025 included $359.3 million of accelerated amortization pertaining to the Company's change in estimate of its remaining useful life of the developed technology acquired in connection with the 2021 Omniome acquisition as described in additional detail in </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_46">Note 5. Restructuring</a></span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_46"> </a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in Part I, Item 1 of this Quarterly Report on Form 10-Q. Any such charges may adversely affect our results of operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred losses to date, and we expect to continue to incur significant losses as we develop our business and we may never achieve profitability.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have generally incurred net losses each quarter since inception, and we cannot be certain if or when we will produce sufficient revenue from our operations to support our costs. Even if profitability is achieved in the future, we may not be able to sustain profitability on a consistent basis. We expect to continue to incur substantial losses and negative cash flow from operations for the foreseeable future. Although we initiated expense reduction plans during the second quarter of 2024, and further expense reduction plans during the first quarter of 2025, we do not expect to be profitable in 2025, and there can be no assurance that these expense reduction initiatives will be successful in helping us achieve profitability.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-49"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net losses since inception and our expectation of incurring substantial losses and negative cash flow for the foreseeable future could:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">make it more difficult for us to satisfy our obligations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">increase our vulnerability to general adverse economic and industry conditions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">limit our ability to fund future working capital, capital expenditures, research and development and other business opportunities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">increase the volatility of the price of our common stock;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">limit our flexibility to react to changes in our business and the industry in which we operate;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">place us at a disadvantage to other companies that offer nucleic acid sequencing equipment or consumables; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">limit our ability to borrow additional funds.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, inflationary pressure, including as a result of supply shortages, has adversely impacted and could continue to adversely impact our financial results, and our operating costs may increase. We may not fully offset these cost increases by raising prices for our products and services, which could result in downward pressure on our margins. Further, our customers may choose to reduce their business with us if we increase our pricing.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any or all of the foregoing may have a material adverse effect on our business, operations, financial condition, and prospects. </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An impairment in value of our tangible or intangible assets could also be recorded as a result of weaker economic conditions. </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more information on impairment considerations, see &#8220;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i443ff6acf0ff4b5dba4ef72478faf9d8_195437">The commercialization and sales of our current or future products may be unsuccessful or less successful than anticipated. While we plan to continue pursuing new products and expanding into adjacent markets, we have limited experience in managing and selling multiple products and, as a result, may face challenges selling in new markets and fail to successfully carry out these initiatives, which may adversely impact our business, financial condition or results of operation.</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; above.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Expense reduction initiatives could be disruptive to our operations and adversely affect our results of operations and financial condition, and we may not realize some or all of the anticipated benefits of these initiatives, whether in the time frame anticipated or at all.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our expense reduction initiatives comprise, among other things, workforce reductions, facilities downsizing and a refined pipeline of development activities. For example, during the second quarter of 2024 we initiated plans to reduce certain of our annualized run-rate operating expenses by the end of the year, with the intent of better aligning our organizational structure and resources with our strategic initiatives, and during the first quarter of 2025 we initiated further plans to reduce certain of our annualized run-rate operating expenses by the end of the year, given persistent uncertainty surrounding academic and NIH funding, along with the introduction and impact of new or changing tariffs. The implementation of these expense reduction initiatives, including the impact of workforce reductions, could impair our ability to invest in developing, marketing and selling new and existing products, be disruptive to our operations, make it difficult to attract or retain employees, result in higher than anticipated charges, divert the attention of management, result in a loss of accumulated knowledge, impact our customer and supplier relationships, and otherwise adversely affect our results of operations and financial condition. In addition, our ability to complete our expense reduction initiatives and achieve the anticipated benefits within the expected time frame is subject to estimates and assumptions and may vary materially from our expectations, including as a result of factors that are beyond our control. Furthermore, our efforts to stabilize our business may not be successful.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-50"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are not cash flow positive and may not have sufficient cash to make required payments under the terms of our debt or fund our long-term planned operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations have consumed substantial amounts of cash since inception, and we expect to continue to incur substantial losses and negative cash flow from operations for the foreseeable future. Additional funds may not be available on terms acceptable to us or at all. We have incurred significant debt, and we may incur additional debt in the future. As of December 31, 2024, we had outstanding approximately $200.0&#160;million aggregate principal amount of our 1.50% Convertible Senior Notes due 2029 (the &#8220;2029 Notes&#8221;) and $441.0&#160;million aggregate principal amount of our 1.375% Convertible Senior Notes due 2030 (the &#8220;2030 Notes&#8221; and together with the 2029 Notes, the &#8220;Notes&#8221;). As discussed in </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_40">Note 4. Convertible Senior Notes</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in Part I, Item 1 of this Quarterly Report on Form 10-Q, we exchanged the remaining approximately $459.0&#160;million in aggregate principal amount of our 1.50% Convertible Senior Notes due 2028 (the &#8220;2028 Notes&#8221;) for (i) $200.0&#160;million aggregate principal amount of the 2029 Notes, (ii) 20,451,570 shares of common stock and (iii) $50.0&#160;million of cash (the &#8220;2024 Exchange Transaction&#8221;). The 2024 Exchange Transaction closed on November 21, 2024. We may not have sufficient cash to make required payments under the terms of this debt, and should this occur, debt holders have rights senior to common stockholders to make claims on our assets. In addition, if we do not have sufficient cash to make the required payments at maturity, we may need to raise additional capital, which could result in dilution of our existing investors, or refinance or restructure our debt, which will depend on, among other things, the condition of the capital markets and our financial condition at such time, and which may be at higher interest rates. We may not be able to issue equity securities due to unacceptable terms and conditions to us in the capital markets. To the extent that we intend to raise additional funds through the sale of our common stock, downward fluctuations in our stock price could adversely affect such fundraising efforts. Furthermore, equity financings normally involve shares sold at a discount to the current market price and fundraising through sales of additional shares of common stock or other equity securities will have a dilutive effect on our existing investors. We may be required to seek equity financing at a time when the market price for our common stock is low, which would further dilute ownership for existing common stockholders.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our growth will depend, in part, on our ability to fund our commercialization efforts and our efforts to develop new products and improve our existing products. To the extent our existing resources are not sufficient, it may require us to delay, or even not allow us to conduct any or all of these activities that we believe would be beneficial for our future growth. We may need to raise additional funds through public or private debt or equity financing or alternative financing arrangements, which may include collaborations or licensing arrangements. If we are unable to raise funds on favorable terms, or at all, we may have to reduce our cash burn rate and may not be able to support our commercialization efforts, launching of new products, or operations, or to increase or maintain the level of our research and development activities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to generate sufficient cash flows or to raise adequate funds to finance our forecasted expenditures, we may have to make significant changes to our operations, including delaying or reducing the scope of, or eliminating some or all of, our development programs. We also may have to reduce sales, marketing, engineering, customer support or other resources devoted to our existing or new products, or we may need to cease operations. Any of these actions could materially impede our ability to achieve our business objectives and could materially harm our operating results, and there can be no assurance that any of these actions would be successful. If our cash, cash equivalents and investments are insufficient to fund our projected operating requirements and we are unable to raise capital, it could have a material adverse effect on our business, financial condition and results of operations and prospects.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have made acquisitions and, in the future, may continue to acquire businesses, technologies or assets, form joint ventures or make other strategic investments with companies that could adversely affect our operating results, dilute our stockholders&#8217; ownership, or cause us to incur debt or significant expense.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our business strategy, we have acquired and expect to continue to pursue acquisitions of complementary businesses, technologies, or assets. We may also pursue technology license arrangements, strategic alliances or investments that complement our business. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisitions and strategic transactions involve numerous risks, any of which could harm our business and negatively affect our financial condition and results of operations, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">intense competition for suitable acquisition targets, which could increase prices and adversely affect our ability to consummate deals on favorable or acceptable terms;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">failure or material delay in closing a transaction;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-51"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">transaction-related lawsuits or claims;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">difficulties in integrating the technologies, operations, existing contracts, and personnel of an acquired company;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">difficulties in retaining key employees or business partners of an acquired company;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">difficulties in retaining suppliers, partners, or customers of an acquired company;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">challenges with integrating the brand identity of an acquired company with our own;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">diversion of financial and management resources from existing operations or alternative acquisition opportunities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">failure to realize the anticipated benefits or synergies of a transaction;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">difficulties in developing technology post-acquisition;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">failure to identify the problems, liabilities, or other shortcomings or challenges of an acquired company or technology, including issues related to intellectual property, regulatory compliance practices, litigation, revenue recognition or other accounting practices, or employee or user issues;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">risks that regulatory bodies may enact new laws or promulgate new regulations that are adverse to an acquired company or business;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">risks that regulatory bodies do not approve our acquisitions or business combinations or delay such approvals;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">theft of our trade secrets or confidential information that we share with potential acquisition candidates or other potential strategic partners;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">risk that an acquired company or investment in new services cannibalizes a portion of our existing business; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">adverse market reaction to an acquisition or other strategic transaction.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To finance any acquisitions or other strategic investments, we may raise additional funds, which could adversely affect our existing stockholders and our business. If the price of our common stock is low or volatile, we may not be able to acquire other companies for stock. In addition, our stockholders may experience substantial dilution as a result of additional securities we may issue for acquisitions. Open market sales of substantial amounts of our common stock issued to stockholders of companies we acquire could also depress our stock price. Additional funds may not be available on terms that are favorable to us, or at all.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to address the foregoing risks or other problems encountered in connection with past or future acquisitions of businesses, new technologies, services, and other assets and strategic investments, or if we fail to successfully integrate such acquisitions or investments, our business, financial condition, and results of operations could be adversely affected, including potential impairments of goodwill and intangible assets.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-52"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to successfully develop and timely manufacture our current and future products our business may be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Considering the highly complex technologies involved in our products, there can be no assurance that we will be able to manufacture and commercialize our current and future products on a timely basis or continue providing adequate support for our existing products. The commercial success of our products, including the Revio, Onso and Vega systems, and the products under development, including acquired technologies, depends on a number of factors, including performance and reliability of the systems, our anticipating and effectively addressing customer preferences and demands, the success of our sales and marketing efforts, effective forecasting and management of product demand, purchase commitments and inventory levels, effective management of manufacturing and supply costs, and the quality of our products, including consumables such as SMRT Cells and reagents. Should we face delays in or discover unexpected defects during the further development or manufacturing process of instruments or consumables related to our products, including any delays or defects in software development or product functionality, the timing and success of the continued rollout and scaling of our products may be significantly impacted, which may materially and negatively impact our revenue and gross margin. The ability of our customers to successfully utilize our products will also depend on our ability to deliver high quality SMRT Cells and reagents. We have designed SMRT Cells and other consumables specifically for the Sequel, Sequel II/IIe, Revio and Vega systems, and may need to develop in the future, other customized SMRT Cells and consumables for our future products. Our production of the SMRT Cells for the Sequel and Sequel II/IIe systems has been and may in the future, including with respect to the Revio system, be below desired levels and yields, and we have experienced and may experience in the future manufacturing delays, product or quality defects, SMRT Cell variability, and other issues. The performance of our consumables is critical to our customers&#8217; successful utilization of our products, and any defects or performance issues with our consumables would adversely affect our business. All of the foregoing could have a material adverse effect on our ability to sell our products or result in other material adverse effects on our business, operations, financial condition, operations and prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development of our products is complex and costly. Problems in the design or quality of our products may have a material and adverse effect on our brand, business, financial condition, and operating results, and could result in us losing our certifications from the International Organization for Standardization (&#8220;ISO&#8221;). If we were to lose ISO certification, then our customers might choose not to purchase products from us and this could adversely impact our ability to develop products approved for clinical uses. Unanticipated problems with our products could divert substantial resources, which may impair our ability to support our new and existing products and could substantially increase our costs. If we encounter development challenges or discover errors in our products late in our development cycle, including during external beta testing, we may be forced to undertake design and/or production changes, delay product shipments or the scaling of manufacturing or supply. The completion of the production and external testing of our beta systems may also take longer than currently planned, cost more than currently expected and the scientific and technical validation may not be completed on our currently expected timelines or at all. Such testing may also expose fundamental flaws in our products that may cause us to abandon the further development of such products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the continued rollout of our current and future products, including with respect to the SMRT Cell, the Revio, Onso and Vega systems, is delayed or is not successful or less successful than anticipated, then we may not be able to achieve an acceptable return, if any, on our substantial research and development efforts, and our business may be materially and adversely affected. The expenses or losses associated with delayed or unsuccessful product development or lack of market acceptance of our existing and new products, including the SMRT Cell and the Revio, Onso and Vega systems could materially and adversely affect our business, operations, financial condition, and prospects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-53"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our research and development efforts may not result in the benefits that we anticipate, and our failure to successfully market, sell, and commercialize our current and future products could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have dedicated significant resources to developing our current products. We are also engaged in substantial and complex research and development efforts, which, if successful, may result in the introduction of new products in the future, including in connection with the SMRT Cell and the Revio, Onso and Vega systems, in addition to other products currently under development, including acquired technologies. Our research and development efforts are complex and require us to incur substantial expenses and we may not be able to develop, manufacture and commercialize new products or obtain regulatory approval if necessary. We may divert significant resources to research and development initiatives that do not result in commercialized products, and even if these efforts do result in commercialized products, there can be no assurance that such products will compete successfully in the market or achieve an acceptable return, if any, on our research and development efforts and expenses. Moreover, our joint research and development efforts with partners require significant management attention and operational resources. If we are unable to successfully manage such joint research and development efforts, our future results may be adversely impacted. Furthermore, we will need to continue to expand our internal capabilities or seek new partnerships or collaborations, or both, in order to successfully develop, market, sell and commercialize our products for and in the markets we seek to reach. If we are unable to do so or are delayed, then this could materially and adversely affect our business, operations, financial condition, and prospects.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We must successfully manage new product introductions and transitions and the development of acquired technologies, for which we may incur significant costs during these transitions and development, and these efforts may not result in the benefits we anticipate.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our products and services fail to deliver the performance, scalability or results expected by our current and future customers, or are not delivered on a timely basis, our reputation and credibility may suffer, our current and future sales and revenue may be materially harmed and our business may not succeed. For instance, if we are not able to successfully execute on the commercialization plan for our Revio HiFi long-read sequencing system and the Vega benchtop long-read sequencing system, and each of their related consumables, and any future products that may be developed for research, medical and clinical uses, including acquired technologies, it could have a material adverse effect on our business, financial condition and results of operations. In addition, the introduction of future products, including with respect to future long-read products, and related consumables, has led and may in the future lead to our limiting or ceasing development of further enhancements to our existing products as we focus our resources on new products, and has resulted and could in the future result in reduced marketplace acceptance and loss of sales of our existing products, materially adversely affecting our revenue and operating results. The introduction of new products, including the recent commercialization of our Vega system, has had and may in the future also have a negative impact on our revenue in the near-term as our current and future customers have delayed or cancelled and may in the future delay or cancel orders of existing products in anticipation of new products and we may also be pressured to decrease prices for our existing products. Our experience in managing product transitions is limited, and we have experienced, and may in the future experience, difficulty in managing or forecasting customer reactions, purchasing decisions or transition requirements with respect to newly launched products. We have incurred and may continue to incur significant costs in completing these transitions, including costs of write-downs of our products, as current or future customers transition to new products. If we do not successfully manage these product transitions, including with respect to the Revio, Onso and Vega systems and each of their related consumables, and any future long-read products, our business, operations, financial condition, and prospects may be materially and adversely affected.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business may be adversely affected by epidemics or other public health emergencies.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business could be adversely impacted by the effects of epidemics or other public health emergencies. These impacts could include, but are not necessarily limited to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">shutdowns or business disruptions experienced by manufacturers, suppliers and other third parties with whom we conduct business;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">disruptions or interruptions to our supply chains;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">changes in applicable public health regulations that require us to modify our business practices and operations; and</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-54"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">disruption to customer demand for our products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which any epidemic or other public health emergency impacts our business and financial results inherently depends on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of a particular public health matter and the actions to contain it or treat its impact, among others. Even after an epidemic or public health emergency has subsided, </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we may continue to experience an adverse impact to our business as a result of economic aftershocks, including recessionary effects and inflationary pressures.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant changes to our leadership team and the resulting management transitions might harm our future operating results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have in recent years experienced significant changes to our leadership team, and although we believe these leadership transitions are in the best interest of our stakeholders, these transitions may result in the loss of personnel with deep institutional or technical knowledge. Further, the transition could potentially disrupt our operations and relationships with employees, suppliers, partners, and customers due to added costs, operational inefficiencies, decreased employee morale and productivity and increased turnover. We must successfully recruit and integrate our new leadership team members within our organization to achieve our operating objectives; as such, the leadership </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">transition</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> may temporarily affect our business performance and results of operations while the new members of our leadership team become familiar with our business. In addition, our competitors may seek to use this transition and the related potential disruptions to gain a competitive advantage over us. Furthermore, these changes may increase our dependency on the other members of our leadership team that remain with us, who are not contractually obligated to remain employed with us and may leave at any time. Any such departure could be particularly disruptive given that we are already experiencing leadership transitions and, to the extent we experience additional management turnover, competition for top management is high such that it may take some time to find a candidate that meets our requirements. Our future operating results depend substantially upon the continued service of our key personnel and in significant part upon our ability to attract and retain qualified management personnel. If we are unable to mitigate these or other similar risks, our business, results of operations and financial condition may be materially and adversely affected.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on the continuing efforts of our senior management team and other key personnel. If we lose members of our senior management team or other key personnel or are unable to successfully retain, recruit and train qualified scientists, engineers, sales personnel and other employees, our ability to maintain, develop and commercialize our products could be harmed and we may be unable to achieve our goals.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends upon the continuing services of members of our senior management team and scientific and engineering personnel. In particular, our scientists and engineers are critical to our technological and product innovations, and we will need to hire additional qualified personnel from time to time. Our industry, is characterized by high demand and intense competition for talent, and the turnover rate has been and may continue to be high. Our employees can leave our company with little to no prior notice and would be free to work for a competitor. We compete for qualified management and scientific personnel with other life science companies, academic institutions and research institutions, particularly those focusing on genomics. We also compete for qualified sales personnel to support the commercialization of our existing and new products. Workforce reductions, such as the workforce reduction we implemented in 2024 and 2025, and other expense reduction efforts may be negatively received by potential or current employees, and accordingly result in attrition or difficulty in recruiting desirable candidates. Additionally, we may face challenges in retaining and recruiting key personnel due to sustained declines in our stock price that could reduce the retentive value of stock options, restricted stock units and other equity awards we issue as compensation. We may not be able to provide adequate cash or other incentives to adequately counterbalance any negative perceptions about the value of our equity awards. Moreover, the value of any equity awards that we do grant to our personnel may be significantly affected by movements in our stock price that are beyond our control. The loss of qualified employees, or an inability to attract, retain, and motivate employees, could prevent us from pursuing collaborations and materially and adversely affect our support of existing products, product development and launches, business growth prospects, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, changes to U.S. immigration policies, such as the implementation of more restrictive interpretations by the U.S. Citizenship and Immigration Services of regulatory requirements for H-1B and other visa programs, could restrain the flow of technical and professional talent into the U.S. and may inhibit our ability to hire and increase the cost of qualified personnel. If some of our employees&#8217; temporary work permits expire and are not renewed, we may face increased turnover rates and labor shortages, which could result in higher labor costs.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-55"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If one or more of our senior executives or other key personnel were unable or unwilling to continue in their present positions, we may not be able to replace them easily or at all, and other senior management may be required to divert attention from other aspects of the business. In addition, we do not have &#8220;key person&#8221; life insurance policies covering any member of our management team or other key personnel. The loss of any of these individuals or any inability to attract or retain qualified personnel, including scientists, engineers, sales personnel and others, could prevent us from pursuing collaborations and materially and adversely affect our support of existing products, product development and introductions, business growth prospects, results of operations and financial condition.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success is highly dependent on our ability to further penetrate nucleic acid sequencing applications as well as on the growth and expansion of the demand for our products. If our products fail to achieve and sustain sufficient market acceptance, we will not generate expected revenue and our business may not succeed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although nucleic acid sequencing technology is well-established, our SMRT Sequencing technology is relatively new and evolving. We cannot be sure that our current or future products will gain acceptance in the marketplace at levels sufficient to support our costs. Our success depends, in part, on our ability to expand overall demand for nucleic acid sequencing to include new applications that are not practicable with other current technologies and to introduce new products that capture a larger share of growing overall demand for sequencing. To accomplish this, we must successfully commercialize, and continue development of, our proprietary SMRT Sequencing technology for use in a variety of life science and other research applications, including uses by academic, government and clinical laboratories, as well as pharmaceutical, diagnostic, biotechnology, and agriculture companies, among others. However, we may be unsuccessful in these efforts and the sale and commercialization of our products may not grow sufficiently to cover our costs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business currently depends on a limited number of products and there can be no assurance that we will be successful in adding new products or securing additional customers for our current and future products. If we are unable to successfully develop acquired technologies and sell acquired technology products, we may fail to achieve our strategic commercial initiatives in connection with the planned release of new products and anticipated entry into new markets. Our ability to further penetrate existing applications and any new applications depends on a number of factors, including the cost, performance and perceived value associated with our products, as well as customers&#8217; willingness to adopt a different approach to nucleic acid sequencing. Potential customers may have already made significant investments in other sequencing technologies and may be unwilling to invest in new technologies. We are experiencing pricing pressures caused by industry competition and increased demand for lower-priced instruments and lower operational costs. We have limited experience commercializing and selling products outside of the academic and research settings, and we cannot guarantee success in acquiring additional customers. Furthermore, we cannot guarantee that our products will be satisfactory to potential customers or that our products will perform in accordance with customer expectations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nucleic acid sequencing applications are new and dynamic, and there can be no assurance that they will develop as quickly as we anticipate, that they will reach their full potential or that our products will be appropriate or competitive for these applications. As a result, we may be required to refocus our marketing efforts, and we may have to make changes to the specifications of our products to enhance our ability to enter particular applications more quickly. We may also need to delay full-scale commercial deployment of new products as we develop them in order to perform quality control and early access user testing. We also need to maintain reliable supply chains for the various components in our new products and consumables to support large-scale commercial production. Even if we are able to implement our technology successfully, we and/or our sales and distribution partners may fail to achieve or sustain market acceptance of our current or future products across the full range of our intended life science and other applications. We need to continue to expand and update our internal capabilities or to collaborate with other partners, or both, in order to successfully expand sales of our products in the applications that we seek to reach, which we may be unable to do at the scale required to support our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the demand for our products grows more slowly than anticipated, if we are unable to successfully scale or otherwise ensure sufficient manufacturing capacity for new products to meet demand, if we are not able to successfully market and sell our products, if competitors develop better or more cost-effective products, if our product launches and commercialization are not successful, or if we are unable to further grow our customer base or do not realize the growth with existing customers that we are expecting, our current and future sales and revenue may be materially and adversely harmed, or we may recognize an impairment loss, and our business may not succeed.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-56"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on other companies for the manufacture of certain of our products, components and sub-assemblies and intend to outsource additional sub-assemblies in the future, some of which are sole sources. We may not be able to successfully scale the manufacturing process necessary to build and test multiple products on a full commercial basis, which could materially harm our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are complex and involve a large number of unique components, many of which require precise manufacturing. The nature of our products requires customized components that are currently available only from a limited number of sources, and in some cases, single sources. We have chosen to source certain products and critical components from a single source, including suppliers for our SMRT Cells, reagents, and instruments. We cannot assure you that products or product supplies will not be limited or interrupted, especially with respect to our sole source third-party manufacturing and supply collaborators, or that products or product supplies will be of satisfactory quality or continue to be available at acceptable prices. In particular, any replacement of our manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements. We may be unable to negotiate binding agreements with our current and future sole source third-party manufacturing and supply collaborators or, in the event that such collaborators&#8217; services become interrupted for any reason, find replacement manufacturers to support our development and commercial activities at commercially reasonable terms. We do not always have arrangements in place for a redundant or second-source supply for our sole source manufacturers and vendors in the event they cease to provide their products or services to us or fail to provide sufficient quantities in a timely manner. If we are required to purchase these products or components from alternative sources, it could take several months or longer to qualify the alternative sources. If we are unable to source these products or product components from sole-source third-party manufacturing and supply collaborators for any reason, including in connection with the U.S. federal government shutdown, acts of terrorism, hostilities, military conflict and acts of war, including between China and Taiwan, or secure a sufficient supply of these products or product components on a timely basis and at an acceptable cost, or if these products or components do not meet our expectations or specifications for quality and functionality, our operations and manufacturing would be materially and adversely affected, we could be unable to meet customer demand and our business and results of operations may be materially and adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operations of our third-party manufacturing partners and suppliers have had and may in the future be disrupted by conditions unrelated to our business or operations or that are beyond our control, including but not limited to changing international trade policies, inflation, supply chain disruptions, and conditions&#160;&#160;&#160;&#160;related to epidemics or pandemics. If our manufacturing partners or suppliers are unable or fail to fulfill their obligations to us for any reason, we may not be able to manufacture our products and satisfy customer demand or our obligations under sales agreements in a timely manner, and our business could be harmed as a result. We have and may continue to face challenges in our supply chain, which has and may continue to adversely impact margins. During periods of shortage or delay, the price of products or components may increase or the products or components may not be available at all. Our suppliers have raised prices and may continue to raise prices that we may not be able to pass on to our customers, which could adversely affect our business, including our competitive position, market share, revenues, and profit margins in material ways. We may not be able to secure enough components at reasonable prices or of acceptable quality to build new products in a timely manner in the quantities or configurations needed. Various government policies have had, and may continue to have in the future, a negative impact on manufacturing and/or supply chains, in addition to customer demand for our products and demand through certain distributors. As a result of global economic or political instability, such as the uncertainty in the Middle East, an escalation of the war in Ukraine, potential uncertainty related to Taiwan and its relationship with China, changing international trade policies, other disease outbreaks, or supply issues, we or our contractors could experience shortages, business disruptions or delays for materials sourced or manufactured in the affected countries, and their ability to supply us with instruments, products or components may be affected. Occasionally, system components and reagents reach the end of their life cycles or become obsolete, requiring us to source alternatives. If we encounter delays or difficulties in securing the quality and quantity of materials we require for our products, our supply chain would be interrupted, which would adversely affect sales. If any of these events occur, our business and operating results could be harmed. Accordingly, if any of the foregoing occurs, our ability to commercialize our products, revenue and gross margins could suffer until lockdowns related to epidemics or pandemics are lifted, supply issues or business disruptions are resolved and/or other sources can be developed.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-57"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current manufacturing process is also characterized by long lead times between the placement of orders for and delivery of our products. If we do not accurately anticipate our needs or if we receive insufficient products or components to manufacture our products on a timely basis to meet customer demand, our sales and our gross margin may be adversely affected, and our business could be materially harmed. If we are unable to reduce our manufacturing costs and establish and maintain reliable, high-volume manufacturing suppliers as we scale our operations and expand our product offerings, our business, operations, financial condition, and prospects could be materially and adversely harmed.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to consistently manufacture our instruments and consumables, including SMRT Cells and reagents, to the necessary specifications or in quantities necessary to meet demand at an acceptable cost or at an acceptable performance level.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to successfully generate revenue from our products, we need to supply our customers with products that meet their expectations for quality and functionality in accordance with established specifications. Our customers have experienced variability in the performance of our products. We have experienced and may continue to experience delays, quality issues or other difficulties leading to customer dissatisfaction with our products. Our production of SMRT Cells, flow cells and of reagents for both our long- and short-read technologies, involve a long and complex manufacturing process and has been and may in the future be below desired yields and resulting output levels. We have experienced and may experience in the future manufacturing delays, product defects, variability in the performance of SMRT Cells, flow cells and other products, inadequate reserves for inventory, or other issues.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no assurance that we will be able to manufacture our products so that they consistently achieve the product specifications and quality that our customers expect, including any products developed for clinical uses. Problems in the design or quality of our products, including low manufacturing yields of SMRT Cells, flow cells, or sub-performing reagent lots may have a material adverse </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effect</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on our brand, business, financial condition, and operating results, and could result in us losing our ISO certifications. If we were to lose our ISO certifications, then our customers might choose not to purchase products from us. There is also no assurance that we will be able to increase manufacturing yields and decrease costs, particularly if high rates of inflation continue, or that we will be successful in forecasting customer demand or manufacturing and supply costs, or that product supplies, including reagents or integrated chips, will not be limited or interrupted, or will be of satisfactory quality or continue to be available at acceptable prices. Furthermore, while we are undertaking efforts to increase our manufacturing scale and capability, we may not be able to increase manufacturing to meet anticipated demand or may experience downtime in our manufacturing facilities, including, for example, if our suppliers are unable to meet our increased demand at a time when the supply chain is under duress due to potential dislocations and disruptions in product and employee availability (whether due to pandemics, government policy or otherwise). An inability to manufacture products and components that consistently meet specifications, in necessary quantities and at commercially acceptable costs, will have a negative impact, and may have a material adverse effect on our business, product development timelines, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rapidly changing technology in life sciences and research diagnostics could make our products obsolete unless we continue to develop, manufacture and commercialize new and improved products and pursue new opportunities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our industry is characterized by rapid and significant technological changes, frequent new product introductions and enhancements and evolving industry standards. These new and evolving technologies may be superior to, impair, or render obsolete the products we currently offer or the technologies currently underlying our products. Our future success depends on our ability to continually improve our products, to develop and introduce new products that address the evolving needs of our customers on a timely and cost-effective basis and to pursue new opportunities. These new opportunities may be outside the scope of our proven expertise or in areas where demand is unproven, and new products and services developed by us may not gain market acceptance or may not adequately perform to capture market share. Our inability to develop and introduce new products and to gain market acceptance of our existing and new products could harm our future operating results. Unanticipated difficulties or delays in replacing existing products with new products or in commercializing our existing or new products in sufficient quantities and of acceptable quality to meet customer demand, including with respect to the SMRT Cell and the Revio, Onso and Vega systems, could diminish future demand for our products and may materially and adversely harm our future operating results.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-58"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The size of the markets for our products, including our Revio, Onso and Vega instruments, may be smaller than estimated, and new market opportunities may not develop as quickly as we expect, or at all, limiting our ability to successfully sell our products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market for sequencing systems and consumables products is evolving, making it difficult to accurately predict the size of the markets for our current and future products, including our Revio, Onso and Vega instruments. Our estimates of the total addressable market for our current and future products are based on a number of internal and third-party estimates and assumptions that may be incorrect, including the assumptions that academic, governmental, corporate, or other sources of funding will continue to be available to life sciences researchers at times and in amounts necessary to allow them to purchase our products. In addition, sales of new products may take time to develop and mature and we cannot be certain that these market opportunities will develop as we expect. While we believe our assumptions and the data underlying our estimates of the total addressable market for our products are reasonable, these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates, or those underlying the third-party data we have used, may change at any time, thereby reducing the accuracy of our estimates. As a result, our estimates of the total addressable market and growth opportunities for our products may be incorrect.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future growth of the market for our current and future products depends on many factors beyond our control, including recognition and acceptance of our products by the research and scientific communities, the growth, prevalence and costs of competing products and solutions and the development of robust ecosystems supporting our products and their methodologies. For example, the market acceptance and growth of long-read sequencing technologies, like our Revio and Vega systems, depends on a variety of factors, including the availability and cost-effectiveness of related tools for high quality sample collection and preparation and advanced bioinformatic tools to process results; as well as the perceived advantages and disadvantages of long-read sequencing compared to short-read or other sequencing technologies: consequently, if potential customers conclude the costs of adopting long-read sequencing technologies outweigh the benefits, the market for our Revio and Vega systems may be negatively impaired. There can be no assurance that our current or future products will gain traction in the market. If the markets for our current and future products are smaller than estimated or do not develop as we expect, our growth may be limited, and it could materially and adversely affect our business, operations, financial condition and prospects.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Increased market adoption of our products by customers may depend on the availability of sample preparation and informatics tools, some of which may be developed by third parties.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success may depend in part upon the development of sample preparation and software and informatics tools by third parties for use with our products. We cannot guarantee that product supplies, including reagents, will not be limited or interrupted, or will be of satisfactory quality or continue to be available at acceptable prices, or that third parties will develop tools that our current and future customers will find useful with our products, or that customers will adopt such third-party tools on a timely basis or at all. A lack of complementary sample preparation and informatics tools, or delayed updates of such tools, may impede the adoption of our products and may materially and adversely impact our business.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We operate in a highly competitive industry and if we are not able to compete effectively, our business and operating results will likely be harmed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a significant number of companies offering nucleic acid sequencing products and/or services, including Illumina, BGI Genomics (also known as MGI or Complete Genomics), Thermo, ONT Ltd., Roche, Bionano, and Qiagen. Other companies recently entering the market include Ultima, Element and Singular. Many of these companies currently have greater name recognition, more substantial intellectual property portfolios, longer operating histories, significantly greater financial, technical, research and/or other resources, more experience in new product development, larger and more established manufacturing capabilities and marketing, sales, and support functions, and/or more established distribution channels to deliver products to customers than we do. These companies may be able to respond more quickly and effectively than we can to new or changing opportunities, technologies, standards, or customer requirements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-59"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are also several companies that are in the process of developing or have already developed and commercialized new, competing or potentially competing technologies, products and/or services, including ONT Ltd. and its subsidiaries, against whom we have filed complaints for patent infringement in the U.S. District Court for the District of Delaware and, previously, with the U.S. International Trade Commission, in the High Court of England and Wales and in the District Court of Mannheim, Germany. ONT Ltd. previously filed claims against us in the High Court of England and Wales and the District Court of Mannheim, Germany, also for patent infringement. Roche is developing potentially competing sequencing products. Increased competition may result in pricing pressures, which could harm our sales, profitability or market share. Our failure to further enhance our existing products and to introduce new products to compete effectively could materially and adversely affect our business, operations, financial condition, and prospects.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to successfully increase sales of our current products or market and sell our future products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to achieve profitability depends, in part, on our ability to attract customers for our current and future products, and we may be unable to effectively market or sell our products or find appropriate partners to do so. To perform sales, marketing, distribution, and customer support functions successfully, we face a number of risks, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our ability to attract, retain and manage qualified sales, marketing, and service personnel necessary to expand market acceptance for our technologies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the performance and commercial availability expectations of our existing and potential customers with respect to new and existing products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">availability of potential sales and distribution partners to sell our technologies, and our ability to attract and retain such sales and distribution partners;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the time and cost of maintaining and growing a specialized sales, marketing and service force for a particular application, which may be difficult to justify in light of the revenue generated; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our sales, marketing and service force may be unable to execute successful commercial activities.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have, and may in the future, use promotional pricing and similar measures to attract purchases of our products. These measures may not be successful in attracting purchases and, even if successful, may negatively impact our gross margins. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have enlisted and may continue to enlist third parties to assist with sales, equipment leasing, distribution and customer support. There is no guarantee that we will be successful in attracting desirable sales and distribution partners, that we will be able to enter into arrangements with such partners on terms favorable to us or that we will be able to retain such partners on a going-forward basis. If our sales and marketing efforts, or those of any of our third-party sales and distribution partners, are not successful, or our products do not perform in accordance with customer expectations, our technologies and products may not gain market acceptance, which could materially and adversely impact our business, operations, financial condition, and prospects.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Large purchases by a limited number of customers represent a significant portion of our revenue, and any loss or delay of expected purchases has resulted, and in the future could result, in material quarter-to-quarter fluctuations of our revenue or otherwise adversely affect our results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive a significant portion of our revenue from a limited number of customers. While during the nine months ended September&#160;30, 2025, and 2024, no customer accounted for 10% or more of our total revenue, many of our customers make large purchases on a purchase-order basis rather than pursuant to long-term contracts. As a consequence of the concentrated nature of our customer base and their purchasing behavior, our quarterly revenue and results of operations have fluctuated, and may fluctuate in the future, from quarter to quarter and are difficult to forecast. For example, the cancellation of orders or acceleration or delay in anticipated product purchases or the acceptance of shipped products by our larger customers has materially affected, and in the future could materially affect, our revenue and results of operations in any quarterly period. We have been, and may in the future be, unable to sustain or increase our revenue from our larger customers, or offset any discontinuation or decrease of purchases by our larger customers with purchases by new or other existing customers. To the extent one or more of our larger customers experience significant financial difficulty, bankruptcy or insolvency, this could have a material adverse effect on our sales and our ability to collect on receivables, which could materially and adversely harm our financial condition and results of operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-60"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, many of our customers, including some of our larger customers, have negotiated, or may in the future negotiate, volume-based discounts or other more favorable terms from us or our sales and distribution partners, which have had and may have a negative effect on our gross margins or revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that such concentrated purchases will continue to contribute materially to our revenue for the foreseeable future and that our results of operations may fluctuate materially as a result of such larger customers&#8217; buying patterns. In addition, we may see consolidation of our customer base. The loss of one of our larger customers, a significant delay or reduction in its purchases, or any volume-based discount or other more favorable terms that we or our sales and distribution partner(s) may agree to provide, in light of the aggregated purchase volume or buying power resulting from such consolidation, has harmed, and in the future could harm, our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our products are highly complex, have recurring support requirements and could have unknown defects or errors, which may give rise to claims against us or divert application of our resources from other purposes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are highly complex and may develop or contain undetected defects or errors. Our customers have previously experienced reliability issues with our existing products, including the Sequel and Sequel II/IIe systems. In addition, it is possible our customers could experience reliability issues with current or future products, including the Revio, Onso and Vega systems. Despite internal and external testing, defects, or errors may arise in our products, which could result in a failure to obtain, maintain, or increase market acceptance of our products, diversion of development resources, injury to our reputation and increased warranty, service, and maintenance costs. New products, including the Revio, Onso and Vega systems, or enhancements to our existing products, including the SMRT Cell, in particular may contain undetected errors or performance problems that are discovered only after delivery to customers. If our products have reliability or other quality issues or require unexpected levels of support in the future, the market acceptance and utilization of our products may not grow to levels sufficient to support our costs and our reputation and business could be harmed. Low utilization rates of our products has and could in the future cause our revenue and gross margins to be adversely affected. We provide a warranty for our sequencing instruments and consumables, which is generally limited to replacing, repairing, or at our option, giving credit for any sequencing instrument or consumable with defects in material or workmanship. Service contracts for our sequencing instruments may be separately purchased. Defects or errors in our products may also discourage customers from purchasing our products. The costs incurred in correcting any defects or errors may be substantial and could materially and adversely affect our operating margins. If our service and support costs increase, our business and operations may be materially and adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, such defects or errors could lead to the filing of product liability claims against us or against third parties whom we may have an obligation to indemnify against such claims, which could be costly and time-consuming to defend and result in substantial damages. Although we have product liability insurance, any product liability insurance that we have or procure in the future may not protect our business from the financial impact of a product liability claim. Moreover, we may not be able to obtain adequate insurance coverage on acceptable terms. Any insurance that we have or obtain will be subject to deductibles and coverage limits. A product liability claim could have a material adverse effect on our business, financial condition, and results of operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A significant portion of our sales depends on customers&#8217; spending budgets that may be subject to significant and unexpected variation which could have a negative effect on the demand for our products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our instruments represent significant capital expenditures for our customers in research applications. Current and potential customers for our current or future products include academic and government institutions, genome centers, medical research institutions, clinical laboratories, pharmaceutical, agricultural, biotechnology, diagnostic and chemical companies. Their spending budgets can have a significant effect on the demand for our products. Spending budgets are based on a wide variety of factors, including the allocation of available resources to make purchases, funding from government sources which is highly uncertain and subject to change, including the persistent uncertainty surrounding NIH and academic funding, the spending priorities among various types of research equipment, policies regarding capital expenditures during economically uncertain periods and the potential impacts from health epidemics or pandemics. Any decrease in capital spending or change in spending priorities of our current and potential customers could significantly reduce the demand for our products. Any delay or reduction in purchases by current or potential customers or our inability to forecast fluctuations in demand could materially and adversely harm our future operating results.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-61"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to convert our orders in backlog into revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our backlog represents product orders from our customers that we have confirmed but have not been able to fulfill, and, accordingly, for which we have not yet recognized revenue. We may not receive revenue from these orders, and any order backlog we report may not be indicative of our future revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many events can cause an order to be delayed or not completed at all, some of which may be out of our control, including the potential impacts from health epidemics or pandemics and our suppliers, especially our sole source suppliers, not being able to provide us with products or components. If we delay fulfilling customer orders or if customers reconsider their orders, those customers may seek to cancel or modify their orders with us. Customers may otherwise seek to cancel or delay their orders even if we are prepared to fulfill them. If our orders in backlog do not result in sales, our operating results may suffer.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our sales cycles are unpredictable and lengthy, which makes it difficult to forecast revenue and may increase the magnitude of quarterly or annual fluctuations in our operating results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sales cycles for our sequencing instruments are lengthy because they represent a major capital expenditure and generally require the approval of our customers&#8217; senior management. This may contribute to substantial fluctuations in our quarterly or annual operating results, particularly during periods in which our sales volume is low. Because of these fluctuations, it is likely that in some future quarters our operating results will fall below the expectations of securities analysts or investors. If that happens, the market price of our stock would likely decrease. Past fluctuations in our quarterly and annual operating results have resulted in decreases in our stock price. Such fluctuations also mean that investors may not be able to rely on our operating results in any particular period as an indication of future performance. Sales to existing customers and the establishment of a business relationship with other potential customers is a lengthy process, generally taking several months and sometimes longer. Following the establishment of the relationship, the negotiation of purchase terms can be time-consuming, including as a result of seasonal factors, as discussed below, and a potential customer may require an extended evaluation and testing period. Our sales cycles may also lengthen, and those sales cycles may result in lower units sold per cycle, as we continue to introduce our Revio and Vega instruments and their associated consumables to the market, as our customers may have additional administrative, technical or other requirements associated with transitioning to new products and technologies. In anticipation of product orders, we may incur substantial costs before the sales cycle is complete and before we receive any customer payments. As a result, if a sale is not completed or is canceled or delayed, we may have incurred substantial expenses, making it more difficult for us to become profitable or otherwise negatively impacting our financial results. Even if our selling efforts are successful, the realization of revenue may be substantially delayed, our ability to forecast our future revenue may be more limited and our revenue may fluctuate significantly from quarter to quarter and year over year. For more information on the impact of these fluctuations on our results and stock price, see &#8220;</span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i443ff6acf0ff4b5dba4ef72478faf9d8_195441">&#8212;</a></span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i443ff6acf0ff4b5dba4ef72478faf9d8_195441">Our operating results fluctuate from quarter to quarter and year over year, which makes our future results difficult to predict and could negatively impact the market price of our common stock</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; below.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because some of our customers and suppliers are based in China, our business, financial condition and results of operations could be adversely affected by the political and economic tensions between the United States and China.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to risks associated with political conflicts between the U.S. and China. While during the nine months ended September&#160;30, 2025 and 2024, no customer accounted for 10% or more of our total revenue, a portion of our revenue is generated from China. In addition, certain components, some of which are critical components, of our products are manufactured in China. These components are either sourced directly from companies in China or indirectly from third parties that source from companies in China.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-62"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consequently, we are subject to significant risks associated with the trading relationship between the U.S. and China, which is currently characterized by significant uncertainty. Tariffs imposed by the U.S. and China have increased, and may continue to increase, our costs. Additionally, export restrictions imposed by the U.S. may impact our ability to export certain products to customers or distributors in China and restrict our ability to use certain integrated circuits in our products, and it is possible that additional restrictions will be put in place that could impact our ability to provide our products to customers or distributors in China or source components from China. Moreover, the Chinese government may continue to retaliate against U.S. trade restrictions in ways that could impact our business, including through the imposition of additional tariffs on imports from the U.S. and/or the imposition of additional export controls affecting the export of certain items from China. Given the relatively fluid regulatory environment in China and the United States and uncertainty how the U.S. or foreign governments will act with respect to export controls, tariffs, international trade agreements and policies, there could be additional import, export, tax, or other regulatory changes in the future. Any such changes could directly and adversely impact our financial results and results of operations. For more information, see &#8220;</span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i443ff6acf0ff4b5dba4ef72478faf9d8_195442">&#8212;</a></span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i443ff6acf0ff4b5dba4ef72478faf9d8_195442">Enhanced trade tariffs, import restrictions, export restrictions or other trade barriers may materially harm our business.</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other risks could include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">interruptions to operations in China as a result of potential disease outbreaks or natural catastrophic events, which have in the past and can result in the future in business closures, transportation restrictions, import and export complications and cause shortages in the supply of raw materials or disruptions in manufacturing;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">product supply disruptions and increased costs as a result of heightened exposure to changes in the policies of the Chinese government, political unrest or unstable economic conditions in China; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the nationalization or other expropriation of private enterprises or intellectual property by the Chinese government.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Difficulties in this relationship may require us to take actions adverse to our business to comply with governmental restrictions on business and trade with China.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face significant risks associated with doing business with Taiwanese suppliers and manufacturers due to the tense relationship between Taiwan and mainland China.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of our consumable chips are partly manufactured by a company based in Taiwan. Our supply of consumable chips and other critical components may be materially and adversely affected by diplomatic, geopolitical, military and other developments affecting the relationship between China and Taiwan. Recent military exercises in the Taiwan Strait have contributed to geopolitical uncertainty regarding the future of the relationship between China and Taiwan. Current or future diplomatic, geopolitical, military or other tensions between China and Taiwan, including trade disputes, may lead to circumstances that negatively affect the availability of such consumable chips and other critical components to us, which could limit or prohibit our ability to manufacture consumable chips and other critical components or lead to an increase in our supply costs if we cannot find a similar cost alternative supplier, which could materially and adversely impact our business, operations, prospects, financial condition and results, and results of operations.</span></div><div style="margin-top:9pt;text-align:justify"><span id="i443ff6acf0ff4b5dba4ef72478faf9d8_195441"></span><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operating results fluctuate from quarter to quarter and year over year, which makes our future results difficult to predict and could negatively impact the market price of our common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of our products, particularly our sequencing instruments, are subject to significant seasonality due to several factors, including the procurement and budgeting cycles of many of our customers, especially government-funded customers, which often coincide with government fiscal year ends and significant holidays disrupting business and sales activities in key markets. These factors have contributed, and in the future may contribute, to substantial fluctuations in our quarterly operating results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results during any given period can also be impacted by numerous other factors, including the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">market acceptance for our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our ability to attract new customers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the length of our sales cycles, as discussed above;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our ability to achieve economies of scale and other manufacturing efficiencies at the rate we anticipate;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-63"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">publications of studies by us, our competitors or third parties;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the timing and success of new product introductions by us or our competitors or other changes in the competitive dynamics of our industry, such as consolidation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the amount and timing of our costs and expenses;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">changes in our pricing policies or those of our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">general economic, industry and market conditions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the impact of catastrophic events, including health epidemics or pandemics and military or other armed conflicts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the regulatory environment in which we operate;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">expenses associated with warranty obligations or unforeseen product quality issues;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the hiring, training, and retention of key employees, including our ability to grow our sales organization;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">litigation or other claims against us for intellectual property infringement or otherwise;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our ability to obtain additional financing as necessary;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the impact of the U.S. federal government shutdown on the U.S. economy, capital markets and our business; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">changes or trends in new technologies and industry standards.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consequently, it is possible that in some quarters our operating results will fall below the expectations of securities analysts or investors. If that happens, the market price of our common stock would likely decrease. These fluctuations, among other factors, also mean that our operating results in any particular period may not be relied upon as an indication of future performance. Additionally, any bankruptcy of a customer or other party with whom we do business, or the failure of any such party to make payments when due, or any breach or default by any such party, or the loss of any significant partnerships, could impact our revenue recognition or result in material losses to us, which may have a material adverse impact on our business. Seasonal or cyclical variations in our sales have in the past, and may in the future, become more or less pronounced over time, and have in the past materially affected, and may in the future materially affect, our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use net operating losses and certain other tax attributes to offset future taxable income may be subject to substantial limitations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, a corporation that undergoes an &#8220;ownership change&#8221; is subject to limitations on its ability to utilize its pre-change net operating losses (&#8220;NOLs&#8221;) and other pre-change tax attributes, such as research and development credits, to offset its post-change taxable income or tax liability. An &#8220;ownership change&#8221; is generally defined as a greater than 50% change (by value) in a corporation&#8217;s equity ownership by &#8220;5 percent shareholders&#8221; over a rolling three-year period. We believe that we have had one or more ownership changes, and as a result our existing NOLs are currently subject to limitation. Future changes in our stock ownership could result in additional ownership changes, including potentially material changes, under Sections 382 and 383. Further, California has enacted legislation that limits the use of state NOLs for tax years beginning on or after January 1, 2024, and before January 1, 2027. Other limitations may also apply under state tax law. As a result of this legislation or other unforeseen reasons, we may not be able to utilize some or all of our NOLs even if we attain profitability.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax law and differences in interpretation of tax laws and regulations could adversely impact our business and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in multiple jurisdictions and are subject to tax laws and regulations of the U.S. federal, state and local and non-U.S. governments. Tax laws, regulations and administrative practices in these jurisdictions may be subject to significant changes, with or without advance notice. Changes in tax laws, regulations or rulings, changes in interpretations of existing laws and regulations or changes in accounting principles could negatively and materially affect our financial position, cash flows, and results of operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-64"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our facilities in California are located near earthquake faults, and the occurrence of an earthquake or other catastrophic disaster could cause damage to our facilities and equipment, which could require us to cease or curtail operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our facilities in California are located near earthquake fault zones and are vulnerable to damage from earthquakes. We are also vulnerable to damage from other types of disasters, including fire, floods, power loss, communications failures and similar events. If any disaster were to occur, our ability to operate our business at our facilities would be seriously, or potentially completely, impaired. In addition, the nature of our activities could cause significant delays in our research programs and commercial activities and make it difficult for us to recover from a disaster. The insurance we maintain may not be adequate to cover our losses resulting from disasters or other business interruptions. Accordingly, an earthquake or other disaster could materially and adversely harm our ability to conduct business.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to secure patent or other intellectual property protection for our products and improvements to our products may reduce our ability to maintain any technological or competitive advantage over our current and potential competitors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to protect and enforce our intellectual property rights is uncertain and depends on complex legal and factual questions. Our ability to establish or maintain a technological or competitive advantage over our competitors may be diminished because of these uncertainties. For example:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">we or our licensors might not have been the first to make the inventions covered by each of our pending patent applications or issued patents;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">we or our licensors might not have been the first to file patent applications for these inventions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">it is possible that neither our pending patent applications nor the pending patent applications of our licensors will result in issued patents;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the scope of the patent protection we or our licensors obtain may not be sufficiently broad to prevent others from practicing our technologies, developing competing products, designing around our patented technologies or independently developing similar or alternative technologies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our and our licensors&#8217; patent applications or patents have been, are and may in the future be, subject to interference, opposition or similar administrative proceedings, which could result in those patent applications failing to issue as patents, those patents being held invalid or the scope of those patents being substantially reduced;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">our enforcement of patents and proprietary rights in other countries may be problematic or unpredictable;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">we or our partners may not adequately protect our trade secrets;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">we may not develop additional proprietary technologies that are patentable; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the patents of others may limit our freedom to operate and prevent us from commercializing our technology in accordance with our plans.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of any of these events could impair our ability to operate without infringing upon the proprietary rights of others or prevent us from establishing or maintaining a competitive advantage over our competitors.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-65"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Variability in intellectual property laws may adversely affect our intellectual property position.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual property laws, and patent laws and regulations in particular, have been subject to significant variability either through administrative or legislative changes to such laws or regulations or changes or differences in judicial interpretation, and it is expected that such variability will continue to occur. Additionally, intellectual property laws and regulations differ by country. Variations in the patent laws and regulations or in interpretations of patent laws and regulations in the United States and other countries may diminish the value of our intellectual property and may change the impact of third-party intellectual property on us. Accordingly, we cannot predict the scope of the patents that may be granted to us with certainty, the extent to which we will be able to enforce our patents against third parties or the extent to which third parties may be able to enforce their patents against us.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Some of the intellectual property that is important to our business is owned by other companies or institutions and licensed to us, and changes to the rights we have licensed may adversely impact our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We license from third parties some of the intellectual property that is important to our business. If the third parties who license intellectual property to us fail to maintain the intellectual property that we have licensed, or lose rights to that intellectual property, the rights we have licensed may be reduced or eliminated, which would eliminate barriers against our competition. Termination of these licenses or reduction or elimination of our licensed rights may result in our having to negotiate new or reinstated licenses with less favorable terms, or could subject us to claims of intellectual property infringement or contract breach in litigation or other administrative proceedings that could result in damage awards against us and injunctions that could prohibit us from selling our products. In addition, some of our licenses from third parties limit the field in which we can use the licensed technology. Therefore, for us to use such licensed technology in potential future applications that are outside the licensed field of use, we may be required to negotiate new licenses with our licensors or expand our rights under our existing licenses. We cannot be certain that we will be able to obtain such licenses or expanded rights on reasonable terms or at all. In the event a dispute with our licensors were to occur, our licensors may seek to renegotiate the terms of our licenses, increase the royalty rates that we pay to obtain and maintain those licenses, limit the field or scope of the licenses, or terminate the license agreements. In addition, we have limited rights to participate in the prosecution and enforcement of the patents and patent applications that we have licensed. If we fail to meet our obligations under these licenses, or if we have a dispute regarding the terms of the licenses, these third parties could terminate the licenses, which could subject us to claims of intellectual property infringement. As a result, we cannot be certain that these patents and applications will be prosecuted and enforced in a manner consistent with the best interests of our business. Further, because of the rapid pace of technological change in our industry, we may need to rely on key technologies developed or licensed by third parties, and we may not be able to obtain licenses and technologies from these third parties at all or on reasonable terms. The occurrence of these events may have a material adverse effect on our business, financial condition or results of operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-66"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The measures that we use to protect the security of and enforce our intellectual property and other proprietary rights may not be adequate, which could result in the loss of legal protection for, and thereby diminish the value of, such intellectual property and other rights.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to patents, we also rely upon trademarks, trade secrets, copyrights, and unfair competition laws, as well as license agreements and other contractual provisions, to protect our intellectual property and other proprietary rights. Despite these measures, any of our intellectual property rights could be challenged, invalidated, circumvented, or misappropriated. In addition, we attempt to protect our intellectual property and proprietary information by requiring our employees and consultants to enter into confidentiality and assignment of inventions agreements, and by entering into confidentiality agreements with our third-party development, manufacturing, sales, and distribution partners, who may also acquire, develop and/or commercialize alternative or competing products or provide services to our competitors. For example, Roche had certain access to our trade secrets and other proprietary information pursuant to an agreement we had entered into with Roche, subject to the confidentiality provisions thereof (certain of which provisions survive the termination of the agreement); however, Roche is developing potentially competing sequencing products. There can be no assurance that our measures have provided or will provide adequate protection for our intellectual property and proprietary information. These agreements may be breached, and we may not have adequate remedies for any such breach. In addition, our trade secrets and other proprietary information may be disclosed to others, or others may gain access to or disclose our trade secrets and other proprietary information. Enforcing a claim that a third party illegally obtained and is using our trade secrets is expensive and time consuming, and the outcome is unpredictable. Additionally, others may independently develop proprietary information and techniques that are substantially equivalent to ours. The occurrence of these events may have a material adverse effect on our business, financial condition, or results of operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our intellectual property may be subject to challenges in the United States or foreign jurisdictions that could adversely affect our intellectual property position.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our pending, issued and granted U.S. and foreign patents and patent applications have been, are and may in the future be, subject to challenges by ONT Ltd., Oxford Nanopore Technologies, Inc. ("ONT Inc.") and Metrichor, Ltd. (&#8220;Metrichor&#8221; and, together with ONT Ltd. and ONT Inc., &#8220;ONT&#8221;) in addition to other parties asserting prior invention by others or invalidity on various grounds, through proceedings, such as </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">interferences</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, reexaminations, or opposition proceedings. Addressing these challenges to our intellectual property has been, and any future challenges can be, costly and distract management&#8217;s attention and resources. For example, we previously incurred significant legal expenses to litigate and settle a complaint seeking review of a patent interference decision of the U.S. Patent and Trademark Office. Additionally, ONT previously requested that the U.S. Patent and Trademark Office institute </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reviews of certain patents that we have asserted against ONT Inc. and ONT Ltd. in litigation proceedings for patent infringement. While none of the </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reviews requested by ONT were instituted by the U.S. Patent and Trademark Office, challenges of this nature before the Patent Trial and Appeal Board (&#8220;PTAB&#8221;) in the future could result in determinations that our patents or pending patent applications are unpatentable to us, or are invalidated or unenforceable in whole or in part and could require us to expend significant time, funds, and other resources in litigating such challenges. Accordingly, adverse rulings in such proceedings could negatively impact the scope of our intellectual property protection for our products and technology and could materially and adversely affect our business. Similar mechanisms for challenging the validity and enforceability of a patent exist in foreign patent offices and courts and may result in the revocation, cancellation, or amendment of any foreign patents we hold now or in the future. The outcome following legal assertions of invalidity and unenforceability is unpredictable, and prior art could render our patents invalid. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on such products. Such a loss of patent protection would have a material adverse impact on our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-67"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Some of our technology is subject to &#8220;march-in&#8221; rights by the U.S. government.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our patented technology was developed with U.S. federal government funding. When new technologies are </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">developed</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with U.S. government funding, the government obtains certain rights in any resulting patents, including a nonexclusive license authorizing the government to use the invention for non-commercial purposes. These rights may permit the government to disclose our confidential information to third parties and to exercise &#8220;march-in&#8221; rights to use or allow third parties to use our patented technology. The government can exercise its march-in rights if it determines that such action is necessary to (i) achieve practical application of the U.S. government-funded technology, (ii) alleviate health or safety needs, (iii) meet requirements of federal regulations, or (iv) give preference to U.S. industry. In addition, U.S. government-funded inventions must be reported to the government and such government funding must be disclosed in any resulting patent applications. Furthermore, our rights in such inventions are subject to government license rights and foreign manufacturing restrictions. The U.S. government has generally denied requests to exercise its march-in rights, even to provide access to potentially life-saving medications; however, if the U.S. government were to exercise its march-in rights to our patent technologies funded by the U.S. government, particularly for the benefit of one of more of our competitors, that may have a material adverse effect on our business.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are involved in legal proceedings to enforce our intellectual property rights.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our intellectual property rights involve complex factual, scientific, and legal questions. We operate in an industry characterized by significant intellectual property litigation. Even though we may believe that we have a valid patent on a particular technology, other companies have from time to time taken, and may in the future take, actions that we believe violate our patent rights. For example, we were previously involved in legal proceedings with ONT and Harvard University in several United States and European jurisdictions. We have in the past received adverse rulings against us with respect to our complaint with the United States International Trade Commission for one of these proceedings. Legal actions to enforce our patent rights have been, and will continue to be, expensive, and may divert significant management time and resources. Adverse parties from previous legal actions have brought, and they and others may in the future bring, claims against us and/or our intellectual property. Litigation is a significant ongoing expense, recognized in sales, general and administrative expense, with an uncertain outcome, and has been, and may in the future be, a material expense for us. Our enforcement actions may not be successful, have given rise to legal claims against us and could result in some of our intellectual property rights being determined to be invalid or not enforceable. Furthermore, an adverse determination or judgement could lead to an award of damages against us, or the issuance of an injunction against us or our products that could prevent us from selling any products found to be infringing the intellectual property rights of another party.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-68"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have been, are currently, and could in the future be, subject to legal proceedings with third parties who may claim that our products infringe or misappropriate their intellectual property rights.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are based on complex, rapidly developing technologies. We may not be aware of issued or previously filed patent applications that belong to third parties that mature into issued patents that cover some aspect of our products or their use. In addition, because patent litigation is complex and the outcome inherently uncertain, our belief that our products do not </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">infringe</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> third-party patents of which we are aware or that such third-party patents are invalid and unenforceable may be determined to be incorrect. As a result, third parties have claimed, and may in the future claim, that we infringe their patent rights and have filed, and may in the future file lawsuits or engage in other proceedings against us to enforce their patent rights. For example, we are involved in legal proceedings for alleged patent infringement and related matters in the United States with Personal Genomics of Taiwan, Inc. (&#8220;PGI&#8221;). In addition, ONT Ltd. and Harvard University have, in the past, filed claims against us in the High Court of England and Wales and the District Court of Mannheim, Germany for patent infringement, and PGI has filed claims against us in the U.S. District Court for the District of Delaware and in the Wuhan People&#8217;s Court in China. We are aware of other issued patents and patent applications owned by third parties that could be construed to read on our products, and related maintenance and support services. Although we do not believe that our products or services infringe any valid issued patents, the third-party owners of these patents and applications may in the future claim that we infringe their patent rights and file lawsuits against us. In addition, as we enter new markets, our competitors and other third parties may claim that our products infringe their intellectual property rights as part of a business strategy to impede our successful entry into those markets. Furthermore, parties making claims against us may be able to obtain injunctive or other relief, which effectively could block our ability to further develop or commercialize products or services and could result in the award of substantial damages against us. Patent litigation between competitors in our industry is common. Additionally, we have certain obligations to many of our customers and suppliers to indemnify and defend them against claims by third parties that our products or their use infringe any intellectual property of these third parties. In defending ourselves against any of these claims, we have in the past incurred, and could in the future incur, to defend ourselves or our customers, substantial costs, and the attention of our management and technical personnel could be diverted. For example, we previously incurred significant legal expenses to litigate and settle a complaint alleging patent infringement. Even if we have an agreement that indemnifies us against such costs, the indemnifying party may be unable to uphold its contractual obligations. To avoid or settle legal claims, it may be necessary or desirable in the future to obtain licenses relating to one or more products or relating to current or future technologies, which could negatively affect our gross margins. We may not be able to obtain these licenses on commercially reasonable terms, or at all. We may be unable to modify our products so that they do not infringe the intellectual property rights of third parties. In some situations, the results of litigation or settlement of claims may require us to cease allegedly infringing activities which could prevent us from selling some or all of our products. The occurrence of these events may have a material adverse effect on our business, financial condition, or results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in the course of our business, we may from time to time have access or be alleged to have access to confidential or proprietary information of others, which, though not patented, may be protected as trade secrets. Others could bring claims against us asserting that we improperly used their confidential or proprietary information, or that we misappropriated their technologies and incorporated those technologies into our products. A determination that we illegally used the confidential or proprietary information or misappropriated technologies of others in our products could result in us paying substantial damage awards or being prevented from further developing or selling some or all of our products, which could materially and adversely affect our business.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have not yet registered some of our trademarks in all of our potential markets, and failure to secure those registrations could adversely affect our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our trademark applications may not be allowed for registration, and our registered trademarks may not be maintained or enforced. In addition, in the U.S. Patent and Trademark Office and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our use of &#8220;open source&#8221; software could adversely affect our ability to sell our products and subject us to possible litigation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of the products or technologies developed and/or distributed by us incorporate &#8220;open source&#8221; software, and we may incorporate open source software into other products or technologies in the future. Some </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-69"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">open source software licenses require that we disclose the source code for any modifications to such open source software that we make and distribute to one or more third parties, and that we license the source code for such modifications to third parties, including our competitors, at no cost. We monitor the use of open source software in our products to avoid uses in a manner that would require us to disclose or grant licenses under our source code that we wish to maintain as proprietary; however, there can be no assurance that such efforts have been or will be successful. In some circumstances, distribution of our software that includes or is linked with open source software could require that we disclose and license some or all of our proprietary source code in that software, which could include permitting the use of such software and source code at no cost to the user. Open source license terms are often ambiguous and there is little legal precedent governing the interpretation of these licenses. Successful claims made by the licensors of open source software that we have violated the terms of these licenses could result in unanticipated obligations, including being subject to significant damages, being enjoined from distributing products that incorporate open source software and being required to make available our proprietary source code pursuant to an open source license, which could substantially help our competitors develop products that are similar to or better than ours or otherwise materially and adversely affect our business.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Risks Related to Regulation</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are, and may become, subject to governmental regulations that may impose burdens on our operations, and the markets for our products may be narrowed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject, both directly and indirectly, to the adverse impact of government regulation of our operations and markets. For example, export of our instruments may be subject to strict regulatory control in a number of jurisdictions, and we could experience disruption in our supply chain as a result of certain geopolitical events and conflicts and any related political or economic responses and counter-responses or otherwise by various global actors. On January 15, 2025, the United States Department of Commerce&#8217;s Bureau of Industry and Security (&#8220;BIS&#8221;) issued an Interim Final Rule (&#8220;IFR&#8221;) implementing targeted export controls on certain analytical instruments that are highly suitable for generating large, detailed biological datasets based upon the potential to exploit these techniques for asymmetric military advantage. While the Company&#8217;s products would not be included under the current IFR, future BIS or other government regulations could potentially apply to our products and/or negatively impact our ability to export those products to certain countries and markets. Additionally, restrictions on the ability to send certain products and technology related to semiconductors, semiconductor manufacturing, and supercomputing to China continue to increase in both product and country scope and may impact our ability to provide products to customers or distributors worldwide. We have expanded and are continuing to expand the international jurisdictions into which we supply products, which increases the risks surrounding governmental regulations relating to our business. The need to or failure to satisfy export control criteria or to obtain necessary clearances could delay or prevent shipment of products, which could materially and adversely affect our revenue and profitability. Moreover, the life sciences industry, which is expected to continue to be one of the primary markets for our technology, has historically been heavily regulated. There are, for example, laws in several jurisdictions restricting research in genetic engineering, which may narrow our markets. Given the evolving nature of this industry, legislative bodies or regulatory authorities may adopt additional regulations that may adversely affect our market opportunities. Additionally, if ethical and other concerns surrounding the use of genetic information, diagnostics or therapies become widespread, there may be less demand for our products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is also directly affected by a wide variety of government regulations applicable to business enterprises generally and to companies operating in the life science industry in particular. Failure to comply with government regulations or obtain or maintain necessary permits and licenses could result in a variety of fines or other censures or an interruption in our business operations which may have a negative impact on our ability to generate revenue and the cost of operating our business. In addition, changes to laws and government regulations could cause a material adverse effect on our business as we will need to adapt our business to comply with such changes. For example, a governmental prohibition on the use of human </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> diagnostics or other regulations that negatively impact the research and development activities of our customers would adversely impact our commercialization of products on which we have expended significant research and development resources, which would in turn have a material adverse impact on our business and prospects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-70"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our products could become subject to government regulation as medical devices by the U.S. Food and Drug Administration or other domestic and international regulatory agencies even if we do not elect to seek regulatory clearance or approval to market our products for diagnostic purposes, which could increase our costs and impede or delay our commercialization efforts, thereby materially and adversely affecting our business and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are currently labeled and promoted as research use only (&#8220;RUO&#8221;) products and are not currently designed, or intended to be used, for clinical diagnostic tests or as medical devices. However, in the future, certain of our products or related applications, such as those that may be developed for clinical uses, could be subject to regulation by the FDA, or the FDA&#8217;s regulatory jurisdiction could be expanded to include our products. Also, even if our products are labeled, promoted, and intended as RUO, the FDA or comparable agencies of other countries could disagree with our conclusion that our products are intended for research use only or deem our sales, marketing and promotional efforts as being inconsistent with the FDA&#8217;s guidance on RUO products. For example, our customers may independently elect to use our RUO labeled products in their own LDTs for clinical diagnostic use, which could subject our products to government regulation, and the regulatory clearance or approval and maintenance process for such products may be uncertain, expensive, and time-consuming.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, in 2013, the FDA issued Final Guidance &#8220;Distribution of In Vitro Diagnostic Products Labeled for Research Use Only.&#8221; The guidance emphasizes that the FDA will review the totality of the circumstances when it comes to evaluating whether equipment and testing components are properly labeled as RUO. The final guidance states that merely including a labeling statement that the product is for research purposes only will not necessarily render the device exempt from the FDA&#8217;s clearance, approval, and other regulatory requirements if the circumstances surrounding the distribution, marketing and promotional practices indicate that the manufacturer knows its products are, or intends for its products to be, used for clinical diagnostic purposes. These circumstances may include written or verbal sales and marketing claims or links to articles regarding a product&#8217;s performance in clinical applications and a manufacturer&#8217;s provision of technical support for clinical applications.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has historically exercised enforcement discretion in not enforcing the medical device regulations against laboratories developing and offering LDTs. In May 2024, the FDA issued a final rule that phases out its enforcement discretion for LDTs, unless exempt, and amends the FDA&#8217;s regulations to make explicit that in vitro diagnostics are medical devices under the Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;), including when the manufacturer of the diagnostic product is a laboratory. On March 31, 2025, a U.S. District Court in Texas ruled that the FDA exceeded its authority and vacated and set aside this LDT final rule in its entirety. We will continue to monitor this case, as well as any future lawsuits brought against the FDA, and future legislative and administration actions on our business. Additionally, in June 2024, the U.S. Supreme Court overruled the Chevron doctrine, which gave deference to regulatory agencies&#8217; statutory interpretations in litigation against federal government agencies, such as the FDA, where the law is ambiguous. This landmark Supreme Court decision may invite various stakeholders to bring lawsuits against the FDA to challenge longstanding decisions of the FDA, which could undermine the FDA&#8217;s authority and lead to uncertainties in the industry. We cannot predict the full impact of this decision on our business or that of our customers.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, under the new leadership at the Department of Health and Human Services under the Trump administration, agency reorganization, departure of high-profile regulators at the FDA, layoffs due to the reduction in force initiative may impact the normal operations of federal agencies, including the FDA. NIH funding cuts can impact the business operations of our customers and decrease the demand for our products. It is unclear how our industry and the businesses of our customers will be impacted by executive orders, policies and regulations implemented under the Trump administration. There is significant uncertainty in the industry.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future legislative or administrative actions can impact the sales of our products and how customers use our products, and may require us to change our business model in order to maintain compliance with applicable laws. Changes to the current regulatory framework could arise at any time during the development or marketing of our products, which may negatively affect our ability to obtain or maintain FDA or comparable regulatory approval of our products, if required. Further, sales of devices for diagnostic purposes may subject us to additional healthcare regulation and enforcement by the applicable government agencies. Such laws include, without limitation, state and federal anti-kickback or anti-referral laws, healthcare fraud and abuse laws, false claims laws, privacy and security laws, Physician Payments Sunshine Act and related transparency and manufacturer reporting laws, and other laws and regulations applicable to medical device manufacturers.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-71"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA determines our products or related applications should be subject to additional regulation as in vitro diagnostic devices based upon customers&#8217; use of our products for clinical diagnostic or therapeutic decision-making purposes, our ability to market and sell our products could be impeded and our business, prospects, results of operations and financial condition may be adversely affected. In addition, the FDA could consider our products to be misbranded or adulterated under the FDCA and subject to recall and/or other enforcement action.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">To the extent we elect to label and promote any of our products as medical devices, we would be required to obtain prior approval or clearance by the FDA or comparable foreign regulatory authority, which could take significant time and expense and could fail to result in a marketing authorization for the intended uses we believe are commercially attractive. Obtaining marketing authorization in one jurisdiction does not mean that we will be successful in obtaining marketing authorization in other jurisdictions where we conduct business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we elect to label and market our products for use as, or in the performance of, clinical diagnostics in the United States, thereby subjecting them to FDA regulation as medical devices, we would be required to obtain pre-market 510(k) clearance or pre-market approval from the FDA, unless an exception applies. It is possible, in the event we elect to submit 510(k) applications for certain of our products, that the FDA would take the position that a more burdensome pre-market application, such as a PMA or a </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> application is required for some of our products. If such applications were required, greater time and investment would be required to obtain FDA approval. Even if the FDA agreed that a 510(k) was appropriate, FDA clearance can be expensive and time consuming. It generally takes a significant amount of time to prepare a 510(k), including conducting appropriate testing on our products, and several months to years for the FDA to review a submission. Notwithstanding the effort and expense, FDA clearance or approval could be denied for some or all of our products for which we choose to market as a medical device or a clinical diagnostic device. Even if we were to seek and obtain regulatory approval or clearance, it may not be for the intended uses we request or that we believe are important or commercially attractive. There can be no assurance that future products for which we may seek pre-market clearance or approval will be approved or cleared by the FDA or a comparable foreign regulatory authority on a timely basis, if at all, nor can there be assurance that labeling claims will be consistent with our anticipated claims or adequate to support continued adoption of such products. Compliance with FDA or comparable foreign regulatory authority regulations will require substantial costs, and subject us to heightened scrutiny by regulators and substantial penalties for failure to comply with such requirements or the inability to market our products. The lengthy and unpredictable pre-market clearance or approval process, as well as the unpredictability of the results of any required clinical studies, may result in our failing to obtain regulatory clearance or approval to market such products, which would significantly harm our business, results of operations, reputation, and prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we sought and received regulatory clearance or approval for certain of our products, we would be subject to ongoing FDA obligations and continued regulatory oversight and review, including the general controls listed above and the FDA&#8217;s Quality System Regulations for our development and manufacturing operations. In addition, we would be required to obtain a new 510(k) clearance before we could introduce subsequent material modifications or improvements to such products. We could also be subject to additional FDA post-marketing obligations for such products, any or all of which would increase our costs and divert resources away from other projects. If we sought and received regulatory clearance or approval and are not able to maintain regulatory compliance with applicable laws, we could be prohibited from marketing our products for use as, or in the performance of, clinical diagnostics and/or could be subject to enforcement actions, including warning letters and adverse publicity, fines, injunctions, and civil penalties; recall or seizure of products; operating restrictions; and criminal prosecution.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, if we decide to seek regulatory clearance or approval for certain of our products in countries outside of the United States or if a foreign regulatory authority determines that our products are regulated as medical devices, we would be subject to extensive medical device laws and regulations outside of the United States. Sales of such products outside the United States will likely be subject to foreign regulatory requirements, which can vary greatly from country to country. As a result, the time required to obtain clearances or approvals outside the United States may differ from that required to obtain FDA clearance or approval and we may not be able to obtain foreign regulatory approvals on a timely basis or at all. In Europe, we would need to comply with the Medical Device Regulation 2017/745 and In Vitro Diagnostic Regulation 2017/746, which could make obtaining regulatory approvals in Europe more challenging. In addition, the FDA regulates exports of medical devices. The number and scope of these requirements are increasing. Unlike many of the other companies offering nucleic acid sequencing equipment or consumables, this is an area where we do not have expertise. We, or our other third-party sales and distribution partners, may not be able to obtain regulatory approvals in such countries or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-72"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may incur significant costs in obtaining or maintaining our foreign regulatory approvals. In addition, the export by us of certain of our products, which have not yet been cleared for domestic commercial distribution, may be subject to FDA or other export restrictions. Failure to comply with these regulatory requirements or obtain and maintain required approvals, clearances and certifications could impair our ability to commercialize our products for diagnostic use outside of the United States. Any action brought against us for violations of these laws or regulations, even if successfully defended, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business.</span></div><div style="margin-top:9pt;text-align:justify"><span id="i443ff6acf0ff4b5dba4ef72478faf9d8_195442"></span><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Enhanced trade tariffs, import restrictions, export restrictions, or other trade barriers may materially harm our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are continuing to expand our international operations as part of our growth strategy and have experienced an increasing concentration of sales in certain regions outside the United States, especially the Asia-Pacific region and in Europe. There is currently significant uncertainty about the future relationship between the United States and various other trading partners with respect to trade policies, treaties, government regulations, tariffs, and other similar policies affecting cross-border operations. The U.S. government has made and continues to make significant changes in U.S. trade policy, specifically tariffs, and may continue to take actions that could negatively impact our business. For example, since September 2018, the U.S. Trade Representative (the &#8220;USTR&#8221;) enacted various Section 301 tariffs on certain commodities from certain U.S. trading partners, most prominently China and Brazil, ranging from 7.5% to 100%. In addition, since February 2025, under authority of the International Emergency Economic Powers Act (&#8220;IEEPA&#8221;), the U.S. government enacted an additional 10% to 35% &#8220;fentanyl-related&#8221; ad valorem tariffs on virtually all goods from China, Canada, and Mexico, with an exception for items qualifying for duty-free treatment under the U.S.-Mexico-Canada Agreement (&#8220;USMCA&#8221;). Since March 2025, the U.S. government has also implemented new Section 232 tariffs of 10% to 50% on various commodities based on findings by the U.S. government that imports of these items threaten to impair U.S. national security, including but not limited to certain articles of steel and aluminum; passenger vehicles, trucks, and automotive components; certain articles of copper; and timber, lumber, and certain articles of wood. The U.S. Department of Commerce has initiated Section 232 investigations into the import of additional products, including but not limited to semiconductors, semiconductor manufacturing equipment, processed critical minerals, derivative electronic products, pharmaceuticals and pharmaceutical products; when these investigations are complete, the U.S. government may decide to levy additional tariffs on such products. Additional IEEPA &#8220;reciprocal&#8221; tariffs of 10% to 125% ad valorem have been imposed since April 2025 on most imports from most U.S. trading partners, initially at a baseline 10% reciprocal tariff rate and now at various country-specific reciprocal tariff rates since August 2025&#8212;with limited exceptions for certain pharmaceuticals, semiconductors, computers, and certain other imports, and certain other exceptions as negotiated in trade deals reached between the U.S. and various key trading partners. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to these and other U.S. trade measures, certain affected countries have taken retaliatory trade actions. For example, China has increased tariffs on U.S. exports to China and subjected additional items to export control requirements, including certain rare earth materials. These trade controls have and could continue to raise our costs. Furthermore, tariffs, trade restrictions, or trade barriers that have been, or may in the future be, placed on products such as ours by foreign governments, which have raised and could further raise amounts paid for some or all of our products, which may result in the loss of customers and our business, and our financial condition and results of operations may be harmed. Although some of these risks have been contained by trade deals reached between the U.S. and affected governments, including China, the EU, Japan, and South Korea. For example, the trade deal reached between the U.S. and the EU in July 2025 resulted in the implementation of a 15% all-in reciprocal tariff on imports of EU goods into the U.S as of August 2025, and short-term trade deals reached between the U.S. and China have resulted in implementation of a 10% reciprocal tariff on imports of Chinese goods into the U.S. through November 2025. However, these policies are subject to continued negotiation and effective policies may change over time. We may be unable to make changes in our supply chain quickly enough to avoid the impact of new or potential tariffs, or to do so on commercially reasonable terms. Uncertainty regarding the scope and amount of potential additional tariffs may also result in disruptions in our supply chain, particularly if such changes in applicable or potential tariffs makes current or planned production unprofitable. In addition, these tariff actions may also indirectly affect our business through impacts on our customers, who may be directly affected by some or all of these tariff actions, or indirectly affected by macroeconomic effects resulting from these or other tariff related actions, including potential risks associated with inflation or economic recession.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are subject to U.S. export control laws and regulations, including the Export Administration Regulations administered by BIS. Under these laws and regulations, exports of our products as well as the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-73"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">underlying technology may require export authorization, including by license, a license exception, or other appropriate government authorizations. Furthermore, our products and services are subject to U.S. economic and trade sanctions laws and regulations administered by the U.S. Department of Treasury&#8217;s Office of Foreign Assets Control that prohibit the provision of services and the export of hardware, software, and technology to embargoed jurisdictions or sanctioned parties without the required export authorizations. The U.S. government has continued to increase controls imposed in 2022 restricting the ability to send certain products and technology related to semiconductors, semiconductor manufacturing, and supercomputing including expanding the list of advanced integrated circuits subject to heightened export controls, expanding the list of destinations requiring export authorization for such items, and adding new restrictions based on the headquarters location of the parties involved. In many cases, these licenses are subject to a policy of denial and will not be issued. Regulations further expanding the controls to impose a worldwide licensing requirement on certain integrated circuits and computing resources that are used for training of AI models were introduced in January 2025, with a scheduled compliance date beginning in April 2025. Although these regulations were rescinded shortly before the compliance date, we expect that they will be replaced by a new regulation containing a version of these controls. The U.S. government also continues to add additional entities in China and other countries to restricted party lists impacting the ability of U.S. companies to provide items to these entities. These existing and future laws and regulations may impact our ability to export certain products to customers or distributors in China or other locations and may restrict our ability to use certain integrated circuits in our products. If we need to obtain any necessary export licenses or other authorizations for a particular sale, the process may be time-consuming and may result in the delay or loss of opportunities to sell our products. In April 2025, the Company received inquiries from BIS regarding a distributor based in Hong Kong and that distributor's customer located in China. In May 2025, following a review of sales to China, the Company responded to BIS's inquiries and submitted a voluntary self-disclosure to BIS related to a limited number of transactions. This self-disclosure was closed out by BIS in September 2025 without penalties with a warning letter. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are found to be in violation of U.S. economic sanctions or export control laws, it could result in fines and penalties. We may also be adversely affected through other penalties, business disruption, reputational harm, loss of access to certain markets, or otherwise.</span><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that our ability to export our products to customers or distributors may be further restricted in the future. For example, on January 15, 2025, BIS issued an IFR implementing targeted export controls on certain analytical instruments that are highly suitable for generating large, detailed biological datasets based upon the potential to exploit these techniques for asymmetric military advantage. While the Company&#8217;s products would not be included under the current IFR, future BIS or other government regulations could potentially apply to our products and/or negatively impact our ability to export those products to certain countries and markets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Chinese government has introduced and may in the future introduce retaliatory measures in response to existing or future U.S. export controls, tariffs and other trade restrictions and it is possible that the Chinese or U.S. governments will implement additional retaliatory measures which could impact our business. It is possible that additional restrictions will be put in place that could impact our ability to provide our products to customers or distributors in China or source components from China. The continued threats of tariffs, trade restrictions and trade barriers could have a generally disruptive impact on the global economy and, therefore, negatively impact our sales. Given the relatively fluid regulatory environment in China and the United States and uncertainty how the U.S. and foreign governments will act with respect to export controls, tariffs, international trade agreements and similar policies, there could be additional tax or other regulatory changes in the future. Any such changes could, directly or indirectly, adversely impact our financial results and results of operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our international business could expose us to business, regulatory, political, operational, financial, and economic risks associated with doing business outside of the United States.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Engaging in international business inherently involves a number of difficulties and risks, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.64pt">required compliance with existing and changing foreign regulatory requirements and laws that are or may be applicable to our business in the future, such as the European Union&#8217;s General Data Protection Regulation (&#8220;GDPR&#8221;), the UK General Data Protection Regulation and other data privacy requirements, labor and employment regulations, anti-competition regulations, the U.K. Bribery Act of 2010 and other anti-corruption laws, regulations relating to the use of certain hazardous substances or chemicals in commercial products, and require the collection, reuse, and recycling of waste from products we manufacture;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-74"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">required compliance with U.S. laws such as the Foreign Corrupt Practices Act, and other U.S. federal laws and trade and economic sanctions and other regulations established by the Office of Foreign Asset Control;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">export requirements and import or trade restrictions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">laws and business practices favoring local companies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">restrictions on both inbound and outbound cross-border investment;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">foreign currency exchange, longer payment cycles and difficulties in enforcing agreements and collecting receivables through certain foreign legal systems;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">changes in social, economic, and political conditions or in laws, regulations and policies governing foreign trade, manufacturing, research and development, and investment both domestically as well as in the other countries and jurisdictions in which we operate and into which we may sell our products including as a result of ongoing geopolitical tensions related to the political uncertainty and military actions associated with the war in Ukraine, resulting sanctions imposed by the U.S. and other countries, and retaliatory actions taken by Russia in response to such sanctions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">potentially adverse tax consequences, tariffs, customs charges, bureaucratic requirements, and other trade barriers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">difficulties and costs of staffing and managing foreign operations; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">difficulties protecting, maintaining, enforcing, or procuring intellectual property rights and defending against intellectual property claims under the law and judicial systems of other countries.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If one or more of these risks occurs, it could require us to dedicate significant resources to remedy such occurrence, and if we are unsuccessful in finding a solution, our financial results will suffer.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operations involve the use of hazardous materials, and we must comply with environmental, health and safety laws, which can be expensive and may adversely affect our business, operating results and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development and manufacturing activities involve the use of hazardous materials, including chemicals and biological materials, and some of our products include hazardous materials. Accordingly, we are subject to federal, state, local and foreign laws, regulations, and permits relating to environmental, health and safety matters, including, among others, those governing the use, storage, handling, exposure to and disposal of hazardous materials and wastes, the health and safety of our employees, and the shipment, labeling, collection, recycling, treatment, and disposal of products containing hazardous materials. Liability under environmental laws and regulations can be joint and several and without regard to fault or negligence. For example, under certain circumstances and under certain environmental laws, we could be held liable for costs relating to contamination at our or our predecessors&#8217; past or present facilities and at third-party waste disposal sites. We could also be held liable for damages arising out of human exposure to hazardous materials. There can be no assurance that violations of environmental, health and safety laws will not occur as a result of human error, accident, equipment failure or other causes. The failure to comply with past, present or future laws could result in the imposition of substantial fines and penalties, remediation costs, property damage and personal injury claims, investigations, the suspension of production or product sales, loss of permits or a cessation of operations. Any of these events could harm our business, operating results, and financial condition. We also expect that our operations will be affected by new environmental, health and safety laws and regulations on an ongoing basis, or more stringent enforcement of existing laws and regulations. New laws or changes to existing laws may result in additional costs and may increase penalties associated with violations or require us to change the content of our products or how we manufacture them, which could have a material adverse effect on our business, operating results, and financial condition.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ethical, legal, privacy, data protection and social concerns or governmental restrictions surrounding the use of genetic information could reduce demand for our technology.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products may be used to provide genetic information about humans, agricultural crops and other living organisms. The information obtained from our products could be used in a variety of applications which may have underlying ethical, legal, privacy, data protection and social concerns, including the genetic engineering or modification of agricultural products or testing for genetic predisposition for certain medical conditions. Governmental authorities could, for safety, social or other purposes, call for limits on or regulation of the use of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-75"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">genetic testing, and may consider or adopt such regulations or other restrictions. Such concerns or governmental restrictions could limit the use of our products or be costly and burdensome to comply with, and actual or perceived violations of any such restrictions may lead to the imposition of substantial fines and penalties, remediation costs, claims and litigation, regulatory investigations and proceedings, and other liability, any of which could have a material adverse effect on our business, financial condition, and results of operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulations related to conflict minerals has caused us to incur, and will continue to cause us to incur, additional expenses and could limit the supply and increase the costs of certain materials used in the manufacture of our products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to requirements under the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 that require us to conduct diligence and report on whether or not our products contain conflict minerals. These requirements could adversely affect the sourcing, availability and pricing of the materials used in the manufacture of components used in our products. Furthermore, the complex nature of our products requires components and materials that may be available only from a limited number of sources and, in some cases, from only a single source. We have incurred, and will continue to incur, additional costs to comply with the disclosure requirements, including costs related to conducting diligence procedures to determine the sources of conflict minerals that may be used or necessary to the production of our products and, if applicable, potential changes to components, processes, or sources of supply as a consequence of such verification activities. We may face reputational harm if we determine that certain of our products contain minerals that are not determined to be conflict free or if we are unable to alter our processes or sources of supply to avoid using such materials. In such circumstances, the reputational harm could materially and adversely affect our business, financial condition, or results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Risks Related to Owning Our Common Stock</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our common stock has been, is, and may continue to be, highly volatile, and you may be unable to sell your shares at or above the price you paid to acquire them.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock is highly volatile, and we expect it to continue to be volatile for the foreseeable future in response to many risk factors listed in this section, and others beyond our control, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">actual or anticipated fluctuations in our financial condition and operating results;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">announcements of new products, technological innovations or strategic partnerships by us or our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">announcements by us, our customers, partners, or suppliers relating directly or indirectly to our products, services or technologies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">overall conditions in our industry and market;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">addition or loss of significant customers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">changes in laws or regulations applicable to our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">actual or anticipated changes in our growth rate relative to our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, capital commitments or achievement of significant milestones;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">additions or departures of key personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">competition from existing products or new products that may emerge;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">issuance of new or updated research or reports by securities analysts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">fluctuations in the valuation of companies perceived by investors to be comparable to us;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">disputes or other developments related to proprietary rights, including patents, litigation matters or our ability to obtain intellectual property protection for our technologies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">announcement or expectation of additional financing efforts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">sales of our common stock by us or our stockholders;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-76"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">stock price and volume fluctuations attributable to inconsistent trading volume levels of our shares;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">reports, guidance and ratings issued by securities or industry analysts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">operating results below the expectations of securities analysts or investors; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">general economic and market conditions, which could be impacted by various events including health epidemics or pandemics, interest rate fluctuations, increases in fuel prices, foreign currency fluctuations, changing international trade policies, the U.S. federal government shutdown, acts of terrorism, hostilities or the perception that hostilities may be imminent, and military conflict and acts of war. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of the forgoing occurs, it would cause our stock price or trading volume to decline. Stock markets in general and the market for companies in our industry in particular have experienced price and volume fluctuations; these fluctuations have been, and may continue to be, exacerbated by current macroeconomic trends and geopolitical events. These fluctuations often have been unrelated or disproportionate to the operating performance of those companies. These broad market and industry fluctuations, as well as general economic, political and market conditions such as recessions, interest rate changes or international currency fluctuations, may negatively impact the market price of our common stock. You may not realize any return on your investment in us and may lose some or all of your investment. In the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We have been a party to this type of litigation in the past and may be the target of this type of litigation again in the future. Securities litigation against us could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of substantial amounts of our common stock in the public markets, or the perception that such sales might occur, could reduce the market price that our common stock might otherwise attain and may dilute your voting power and your ownership interest in us.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of a substantial number of shares of our common stock in the public market, or the perception that such sales could occur, could adversely affect the market price of our common stock and may make it more difficult for existing stockholders to sell their common stock at a time and price that they deem appropriate and may dilute their voting power and ownership interest in us.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if our stockholders sell, or indicate an intent to sell, a large number of shares of our common stock in the public market, it could cause our stock price to fall, particularly if such sales occur over a short period of time (for example, following delivery of shares upon achievement of milestones in our acquisition agreements). We may also issue shares of common stock or securities convertible into our common stock in connection with a financing, acquisition, our equity incentive plans, or otherwise. Any such issuances would result in dilution to our existing stockholders and the market price of our common stock may be adversely affected.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of ownership by our principal stockholders may result in control by such stockholders of the composition of our board of directors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our existing principal stockholders, holders of Notes, executive officers, directors, and their affiliates beneficially own, or following conversion of the Notes could own, a significant number of our outstanding shares of common stock. In addition, such parties may acquire additional control by purchasing stock that we issue in connection with our future fundraising efforts. These parties may now and in the future be able to exercise a significant level of control over all matters requiring stockholder approval, including the election of directors. This control could have the effect of delaying or preventing a change of control of our company or changes in management and will make the approval of certain transactions difficult or impossible without the support of these stockholders.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-77"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management and limit the market price of our common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws may have the effect of delaying or preventing a change of control or changes in our management. Our amended and restated certificate of incorporation and amended and restated bylaws include provisions that:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">authorize our board of directors to issue, without further action by the stockholders, up to 50,000,000 shares of undesignated preferred stock and up to approximately 1,000,000,000 shares of authorized but unissued shares of common stock;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">require that any action to be taken by our stockholders be effected at a duly called annual or special meeting and not by written consent;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">specify that special meetings of our stockholders can be called only by our board of directors, the Chair of the Board, the Chief Executive Officer or the President;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">establish advance notice procedures for stockholder approvals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">establish that our board of directors is divided into three classes, Class I, Class II and Class III, with each class serving staggered terms (until our board of directors is fully declassified beginning with the 2027 annual meeting of stockholders);</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">provide that our directors may be removed only for cause; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which limits the ability of stockholders owning in excess of 15% of our outstanding voting stock to merge or combine with us.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated bylaws designate a state or federal court located within the State of Delaware as the exclusive forum for certain stockholder litigation matters, and also provide that the federal district courts will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, each of which could limit our stockholders&#8217; ability to choose the judicial forum for disputes with us or our directors, officers, stockholders, or employees.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated bylaws provide that unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, another State court in Delaware or the federal district court for the District of Delaware) will, to the fullest extent permitted by law, be the sole and exclusive forum for: (i) any derivative action or proceeding brought on our behalf&#894; (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, stockholders, officers, or other employees to us or our stockholders&#894; (iii) any action arising pursuant to any provision of the Delaware General Corporation Law; (iv) any action to interpret, apply, enforce or determine the validity of our amended and restated certificate of incorporation or our amended and restated bylaws&#894; or (v) any action asserting a claim governed by the internal affairs doctrine, except as to each of (i) through (v) above, for any claim as to which such court determines that there is an indispensable party not subject to the jurisdiction of such court.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated bylaws also provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act including, without limitation and for the avoidance of doubt, any auditor, underwriter, expert, control person or other defendant.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-78"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any person or entity purchasing, holding or otherwise acquiring any interest in any of our securities shall be deemed to have notice of and consented to the foregoing bylaw provisions. Although we believe these exclusive forum provisions benefit us by providing increased consistency in the application of Delaware law and federal securities laws in the types of lawsuits to which each applies, the exclusive forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum of its choosing for disputes with us or any of our directors, stockholders, officers or other employees, which may discourage lawsuits with respect to such claims against us and our current and former directors, stockholders, officers or other employees. In addition, a stockholder that is unable to bring a claim in the judicial forum of its choosing may be required to incur additional costs in the pursuit of actions which are subject to the exclusive forum provisions described above. Our stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder as a result of our exclusive forum provisions. Further, in the event a court finds either exclusive forum provision contained in our bylaws to be unenforceable or inapplicable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our results of operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our large number of authorized but unissued shares of common stock may potentially dilute existing stockholders&#8217; stockholdings.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a significant number of authorized but unissued shares of common stock. Our board of directors may issue shares of common stock from this authorized but unissued pool from time to time without stockholder approval, resulting in the dilution of our existing stockholders.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not intend to pay dividends for the foreseeable future.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid any dividends on our common stock and do not intend to pay any dividends in the foreseeable future. We anticipate that we will retain all of our future earnings for use in the operation of our business and for general corporate purposes. Any determination to pay dividends in the future will be at the discretion of our board of directors. Accordingly, investors must rely on sales of their common stock after price appreciation, which may never occur, as the only way to realize any future gains on their investments.</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Risks Related to Our Notes</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not have the ability to raise the funds necessary to settle conversions of the Notes in cash or to repurchase the Notes upon a fundamental change, and our future debt may contain limitations on our ability to pay cash upon conversion or repurchase of the Notes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2025, we had outstanding approximately $200.0&#160;million aggregate principal amount of our 2029 Notes and $441.0&#160;million aggregate principal amount of our 2030 Notes. The 2029 Notes will mature on August 15, 2029, subject to earlier conversion, redemption or repurchase, including upon a fundamental change. The 2030 Notes will mature on December 15, 2030, subject to earlier conversion, redemption or repurchase, including upon a fundamental change. The 2029 Notes and the 2030 Notes are collectively referred to as the Notes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of each series of Notes will have the right to require us to repurchase all or a portion of their Notes upon the occurrence of a fundamental change before the maturity date at a repurchase price equal to 100% of the principal amount of the Notes of the applicable series to be repurchased, plus unpaid interest to, but excluding, the applicable maturity date. In addition, upon conversion of the Notes of a series, unless we elect to deliver solely shares of our common stock to settle such conversion (other than paying cash in lieu of delivering any fractional share), we will be required to settle a portion or all of our conversion obligation in cash in respect of the Notes being converted. Moreover, we will be required to repay the Notes of the applicable series in cash at the applicable maturity unless earlier converted, redeemed, or repurchased. However, we may not have enough available cash or be able to obtain financing at the time we are required to make repurchases of Notes surrendered therefor or pay cash with respect to Notes being converted or at their maturity.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-79"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our ability to repurchase the Notes or to pay cash upon conversions of Notes or at the applicable maturity may be limited by law, regulatory authority or agreements governing our future indebtedness. Our failure to repurchase Notes of a series at a time when the repurchase is required by the applicable indenture or to pay cash upon conversions of such Notes or at the applicable maturity as required by the applicable indenture would constitute a default under such indenture. A default under either indenture or the occurrence of a fundamental change under either indenture itself could also lead to a default under agreements governing our future indebtedness. Moreover, the occurrence of a fundamental change under either indenture could constitute an event of default under any such agreement. If the payment of the related indebtedness were to be accelerated after any applicable notice or grace periods, we may not have sufficient funds to repay the indebtedness or to pay cash amounts due upon conversion, upon required repurchase or at maturity of the applicable series of Notes.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Side Letter to our 2029 Notes imposes operating restrictions on us.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 21, 2024, in connection with the issuance of the 2029 Notes, the Company and SB Northstar LP (&#8220;SBN&#8221;) entered into a letter agreement (the &#8220;Letter Agreement&#8221;) pursuant to which the Company and SBN agreed that, for so long as SBN and its affiliates hold at least $180 million aggregate principal amount of the 2029 Notes, the Company and its subsidiaries are subject to certain negative covenants that restrict the Company&#8217;s and its subsidiaries&#8217; ability to incur additional indebtedness and create liens, in each case, subject to the exceptions set forth in the Letter Agreement, including exceptions which permit the Company to incur up to $75 million in aggregate principal amount of secured indebtedness pursuant to Credit Facilities (as defined in the Letter Agreement).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Letter Agreement restricts the ability of the Company and its subsidiaries from guaranteeing any indebtedness or incurring certain indebtedness outside of the ordinary course of business unless, in each case, the Company and its subsidiaries concurrently provide a guarantee of the Company&#8217;s obligations under the 2029 Notes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These covenants may adversely affect our ability to finance our operations, meet or otherwise address our capital needs, pursue business opportunities or react to market conditions, or otherwise restrict our activities or business plans. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A breach of any of the covenants under the Letter Agreement could result in an event of default under the 2029 Notes. As of September&#160;30, 2025, we were in compliance with all covenants under the Letter Agreement. However, if an event of default occurs, SBN could accelerate our obligations under the 2029 Notes. Any such acceleration could result in an event of default under our other indebtedness, including the 2030 Notes.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the Notes are converted, it may adversely affect our financial condition and operating results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of either series of Notes are entitled to convert their respective series of Notes at any time at their option. If one or more holders elect to convert the Notes of the applicable series, unless we elect to satisfy our conversion obligation by delivering solely shares of our common stock (other than paying cash in lieu of delivering any fractional share), we would be required to settle a portion or all of our conversion obligation in cash, which could adversely affect our liquidity. In addition, issuances of shares of common stock upon conversion of our Notes could depress the market price of our common stock and impair our ability to raise capital through the sale of additional equity securities. The existence of the Notes may encourage short selling by market participants because the conversion of the Notes could depress the price of our common stock. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-80"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">General Risk Factors</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unfavorable global economic or political conditions could adversely affect our business, financial condition or results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General conditions in the global economy and in the global financial markets could adversely affect our results of operations, and the overall demand for nucleic acid sequencing products may be particularly vulnerable to unfavorable economic conditions. A global financial crisis, inflation or a global or regional political disruption, as well as the U.S. federal government shutdown, acts of terrorism, hostilities, military conflict and acts of war, including any further escalation of the conflict in the Middle East and the war in Ukraine, as well as the related responses, could cause extreme volatility in the capital and credit markets. A severe or prolonged economic downturn or political disruption could result in a variety of risks to our business, including weakened demand for our products and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy or political disruption could also strain our manufacturers or suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our product and services. </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An impairment in value of our tangible or intangible assets could also be recorded as a result of weaker economic conditions. </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the political or economic climate and financial market conditions could adversely impact our business. For more information on impairment considerations, see &#8220;</span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i443ff6acf0ff4b5dba4ef72478faf9d8_195437">&#8212;The commercialization and sales of our current or future products may be unsuccessful or less successful than anticipated. While we plan to continue pursuing new products and expanding into adjacent markets, we have limited experience in managing and selling multiple products and, as a result, may face challenges selling in new markets and fail to successfully carry out these initiatives, which may adversely impact our business, financial condition or results of operation.</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; above.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delivery of our products could be delayed or disrupted by factors beyond our control, and we could lose customers as a result.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third-party carriers for the timely delivery of our products. As a result, we are subject to carrier disruptions and increased costs that are beyond our control. Any failure to deliver products to our customers in a safe and timely manner may damage our reputation and brand and could cause us to lose customers. If our relationship with any of these third-party carriers is terminated or impaired or if any of these carriers are unable to deliver our products, the delivery of our products by our customers may be delayed, which could harm our business and financial results. The failure to deliver our products in a safe and timely manner may harm our relationship with our customers, increase our costs and otherwise disrupt our operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Doing business internationally creates operational and financial risks for our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently conduct operations in various countries and jurisdictions, and continue to expand to new international jurisdictions as part of our growth strategy and have experienced an increasing concentration of sales in certain regions outside the U.S. We sell directly and through distribution partners throughout Europe, the Asia-Pacific region, Mexico, Brazil, and South Africa and have a significant portion of our sales and customer support personnel in Europe and the Asia-Pacific region. As a result, we or our distribution partners may be subject to additional regulations and increased diversion of management time and efforts. Conducting and launching operations on an international scale requires close coordination of activities across multiple jurisdictions and time zones and consumes significant management resources. If we fail to coordinate and manage these activities effectively, our business, financial condition or results of operations could be materially and adversely affected and failure to comply with laws and regulations applicable to business operations in foreign jurisdictions may also subject us to significant liabilities and other penalties. International operations entail a variety of other risks, including, without limitation:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">challenges in staffing and managing foreign operations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">potentially longer sales cycles and more time required to engage and educate customers on the benefits of our platform outside of the United States;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">the potential need for localized software and documentation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">reduced protection for intellectual property rights in some countries and practical difficulties of enforcing intellectual property and contract rights abroad;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">challenges with defending against intellectual property claims in other countries;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-81"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">restrictions on both inbound and outbound cross-border investment, including enhanced oversight by the Committee on Foreign Investment in the United States (&#8220;CFIUS&#8221;) and substantial restrictions on investment from China;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">U.S. and foreign government trade restrictions, including those which may impose restrictions on the importation, exportation, re-exportation, sale, shipment or other transfer of programming, technology, components, and/or services to foreign persons;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">changes in diplomatic and trade relationships, including new, increased, or enhanced tariffs, trade protection measures, import or export licensing requirements, trade embargoes, sanctions, and other trade barriers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">tariffs imposed by the U.S. on goods from other countries and tariffs imposed by other countries on U.S. goods, which may be imposed on products such as ours, the scope and duration of which, if implemented, remains uncertain;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">deterioration of political relations among, between, and within the U.S., Russia, China, Japan, Korea, Mexico, Canada, the United Kingdom (&#8220;U.K.&#8221;), and the European Union ("E.U."), which could have a material adverse effect on our sales and operations in these countries;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">changes in social, political, and economic conditions or in laws, regulations and policies governing foreign trade, manufacturing, development, and investment both domestically as well as in the other countries and jurisdictions into which we sell our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">difficulties in obtaining export licenses or in overcoming other trade barriers and restrictions resulting in delivery delays;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">fluctuations in currency exchange rates and the related effect on our results of operations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">increased financial accounting and reporting burdens and complexities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">potential limits to travel as a result of epidemics or pandemics;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">disruptions to global trade due to disease outbreaks or conflicts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">potential increases on tariffs or restrictions on trade generally; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">significant taxes or other burdens of complying with a variety of foreign laws and regulations, including laws and regulations relating to privacy and data protection such as the E.U. General Data Protection Regulation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conducting our international operations, we are subject to U.S. laws relating to our international activities, such as the Foreign Corrupt Practices Act of 1977, as well as foreign laws relating to our activities in other countries, such as the United Kingdom Bribery Act of 2010. Additionally, the inclusion of one of our foreign customers on any applicable U.S. Government sanctioned persons list, including but not limited to the U.S. Department of Commerce&#8217;s List of Denied Persons and the U.S. Department of Treasury&#8217;s List of Specially Designated Nationals and Blocked Persons List, could be material to our earnings. Failure to comply with these laws may subject us to claims or financial and/or other penalties in the United States and/or foreign countries that could materially and adversely impact our operations or financial condition. These risks have become increasingly prevalent as we have expanded our sales into countries that are generally recognized as having a higher risk of corruption.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face risks related to the current global economic environment, which could delay or prevent our customers from purchasing our products, which could in turn harm our business, financial condition, and results of operations. The state of the global economy continues to be uncertain. The current global economic conditions and uncertain credit markets and concerns regarding the availability of credit pose a risk that could impact customer demand for our products, as well as our ability to manage normal commercial relationships with our customers, suppliers, and creditors, including financial institutions. If the current global economic environment deteriorates, our business could be negatively affected.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-82"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, changes in the value of the relevant currencies may affect the cost of certain items required in our operations. Changes in currency exchange rates may also affect the relative prices at which we are able to sell products in the same market. Our revenue from international customers may be negatively impacted as increases in the U.S. dollar relative to our international customers&#8217; local currencies could make our products more expensive, impacting our ability to compete or as a result of financial or other instability in such locations which could result in decreased sales of our products. Our costs of materials from international suppliers may also increase as the value of the U.S. dollar decreases relative to their local currency. Foreign policies and actions regarding currency valuation could result in actions by the United States and other countries to offset the effects of such fluctuations. Such actions may materially and adversely impact our financial condition and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violations of complex foreign and U.S. laws and regulations could result in fines and penalties, criminal sanctions against us, our officers, or our employees, prohibitions on the conduct of our business and on our ability to offer our products and services in one or more countries, and could also materially affect our brand, our international growth efforts, our ability to attract and retain employees, our business, and our operating results. Even if we implement policies or procedures designed to ensure compliance with these laws and regulations, there can be no assurance that our distribution partners, our employees, contractors, or agents will not violate our policies and subject us to potential claims or penalties.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired, which would adversely affect our business and our stock price.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ensuring that we have adequate internal financial and accounting controls and procedures in place to produce accurate financial statements on a timely basis is a costly and time-consuming effort that needs to be evaluated frequently. We may in the future discover areas of our internal financial and accounting controls and procedures that need improvement. Operating as a public company requires sufficient resources within the accounting and finance functions in order to produce timely financial information, ensure the level of segregation of duties, and maintain adequate internal control over financial reporting customary for a U.S. public company.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP. Our management does not expect that our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within our company will have been detected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Section 404 of the Sarbanes-Oxley Act, we perform periodic evaluations of our internal control over financial reporting. While we have in the past performed this evaluation and concluded that our internal control over financial reporting was operating effectively, there can be no assurance that in the future material weaknesses or significant deficiencies will not exist or otherwise be discovered. In addition, if we are unable to produce accurate financial statements on a timely basis, investors could lose confidence in the reliability of our financial statements, which could cause the market price of our common stock to decline and make it more difficult for us to finance our operations and growth.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be negatively impacted by changes in the United States political environment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products depend on the availability of genetic data and its utilization in clinical research by academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, CROs, pharmaceutical companies, and agricultural companies. As a result, changes in the regulatory environment affecting such institutions could adversely affect our business or results of operations. For example, reduced allocations to government agencies that fund research and development activities, such as the recent announcements regarding NIH funding involving a cap on the institute&#8217;s indirect funding rates, or targeted cancellations by the U.S. federal government of certain grants or contracts may significantly impact the markets in which we compete.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-83"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is significant ongoing uncertainty with respect to potential legislation, regulation and government policy at the federal level, as well as the state and local levels. Specific legislative and regulatory proposals discussed or implemented that might materially impact us include, but are not limited to, changes to spending priorities and potential reductions in research funding. Uncertainty about U.S. government funding has posed, and may continue to pose, a risk as customers may choose to postpone or reduce spending in response to actual or anticipated restraints on funding. To the extent changes in the political environment have a negative impact on us or on our markets, our business, results of operation and financial condition could be materially and adversely impacted in the future.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disruption of critical information technology systems or material breaches in the security of our systems could harm our business, customer relations and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information technology (&#8220;IT&#8221;) helps us to operate efficiently, interface with customers, maintain financial accuracy and efficiently and accurately produce our financial statements. IT systems are used extensively in virtually all aspects of our business, including in our products, sales forecast, order fulfillment and billing, customer service, logistics, and management of data from running samples on our products. Our success depends, in part, on the continued and uninterrupted performance of our IT systems. Our IT systems, including those used in our products, may be vulnerable to damage from a variety of sources, including telecommunications or network failures, power loss, natural disasters, human acts, computer viruses, ransomware, computer denial-of-service attacks, unauthorized access to customer or employee data or company trade secrets, and other attempts to harm our systems. Furthermore, there may be a heightened risk of potential cybersecurity incidents and security breaches to which we could be vulnerable by state-sponsored or affiliated actors or others in connection with political uncertainty and conflict in the Middle East and the war in Ukraine. Certain of our systems are not redundant, and our disaster recovery planning is not sufficient for every eventuality. Despite any precautions we may take, such problems could result in, among other consequences, disruption of our operations, which could harm our reputation and financial results. Some of our IT infrastructure still utilizes outdated legacy systems, software and hardware, some of which may be approaching end-of-life or end of support, and that may be particularly susceptible to cybersecurity breaches, errors and operational failures. Upgrading, replacing and enhancing such infrastructure may be expensive and put the continuity of our operations at risk while a failure to do so may make us more susceptible to the risks discussed above.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not allocate and effectively manage the resources necessary to build and sustain the proper IT infrastructure, including those used in our products, we could be subject to transaction errors, processing inefficiencies, loss of customers, business disruptions or loss of or damage to intellectual property. If our data management systems do not effectively collect, store, process and report relevant data for the operation of our business, whether due to equipment malfunction or constraints, software deficiencies or human error, our ability to effectively plan, forecast and execute our business plan and comply with applicable laws and regulations will be impaired, perhaps materially. Any such impairment could materially and adversely affect our reputation, financial condition, results of operations, cash flows and the timeliness with which we report our internal and external operating results.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-84"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Security breaches and other disruptions could compromise our information and expose us to liability, which would cause our business and reputation to suffer.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we collect and store sensitive data, including intellectual property, our proprietary business information and that of our customers, suppliers and business partners, and personal information of our customers and employees, in our data centers and on our networks. The secure processing, maintenance and transmission of this information is critical to our operations. Despite our security measures, our IT infrastructure may be vulnerable to attacks by hackers, computer viruses, malicious codes, ransomware, unauthorized access attempts, and cyber- or phishing-attacks, or breached or otherwise disrupted due to employee error, malfeasance, faulty password management or other disruptions. Third parties may attempt to fraudulently induce employees or other persons into disclosing usernames, passwords or other sensitive information, which may in turn be used to access our IT systems, commit identity theft or carry out other unauthorized or illegal activities. Any such breach or incident could compromise our systems and networks and the information stored or otherwise processed there could be accessed, publicly disclosed, lost, stolen or otherwise processed in an unauthorized manner. We engage third-party vendors and service providers to store and otherwise process some of our data, including sensitive and personal information. Our vendors and service providers may also be the targets of the risks described above, including cyber-attacks, malicious software, ransomware, phishing schemes, and fraud. Our ability to monitor our vendors and service providers&#8217; data security is limited, and, in any event, third parties may be able to circumvent those security measures, resulting in the unauthorized access to, misuse, disclosure, loss or destruction of our data, including sensitive and personal information, and disruption of our or our third-party service providers&#8217; systems. We and our third-party service providers may face difficulties in identifying, or promptly responding to, potential security breaches and other instances of unauthorized access to, or disclosure, other processing, or loss or unavailability of, information. Any hacking or other attack on our or our third-party service providers&#8217; or vendors&#8217; systems, and any unauthorized access to, or disclosure, other processing, or loss or unavailability of, information suffered by us or our third-party service providers or vendors, or the perception that any of these have occurred, could result in legal claims or proceedings, loss of intellectual property, liability under laws that protect the privacy of personal information, negative publicity, disruption of our operations and damage to our reputation, and data integrity issues, which could divert our management&#8217;s attention from the operation of our business and materially and adversely affect our business, revenues and competitive position. Moreover, we may need to increase our efforts to train our personnel to detect and defend against cyber- or phishing-attacks, which are becoming more sophisticated and frequent, and we may need to implement additional protective measures to reduce the risk of potential security breaches and security incidents, which could cause us to incur significant additional expenses. Retaliatory acts by Russia in response to Western sanctions or otherwise in connection with the war in Ukraine could include cyber-attacks that could disrupt the economy generally or that may either directly or indirectly impact our operations specifically.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our insurance may be insufficient to cover our losses resulting from cyber-attacks, breaches, or other interruptions, and any incidents may result in loss of, or increased costs of, such insurance. The successful assertion of one or more large claims against us that exceed available insurance coverage, the occurrence of changes in our insurance policies, including premium increases or the imposition of large deductible or co-insurance requirements, or denials of coverage, could have a material adverse effect on our business, including our financial condition, results of operations and reputation.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-85"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our use of artificial intelligence and machine learning technologies may result in reputational harm or liability.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incorporated and may continue to incorporate additional artificial intelligence and machine learning, or AIML, technologies into our sequencing platforms, marketing programs, and analysis software, and these solutions and features are advantageous to describing, enhancing, and maximizing the capabilities of our differentiated technologies and to our future growth over time. We rely and expect to rely on AIML technologies such as basecalling, variant calling, epigenetic analysis and tertiary analysis, but there can be no assurance that we will realize the desired or anticipated benefits from AIML or any at all. We may also fail to properly implement or utilize AIML technologies. Our competitors or other third parties may incorporate AIML into their products, platforms, software and services or otherwise within their business more quickly or more successfully than us, which could impair our ability to compete effectively and adversely affect our results of operations. Additionally, our use of AIML technologies may expose us to additional claims, demands and proceedings by private parties and regulatory authorities and subject us to legal liability as well as brand and reputational harm. For example, if output from AIML technologies or that they assist in producing are or are alleged to be deficient, inaccurate, or biased, or for such output, or such technologies or their development or deployment, including the collection, use, or other processing of data used to train or create such AIML technologies, are alleged to infringe upon or to have misappropriated third-party intellectual property rights or to violate applicable laws, regulations, or other actual or asserted legal obligations to which we are or may become subject, then our business, financial condition, and results of operations may be adversely affected. The legal, regulatory, and policy environments around AIML are evolving rapidly, and we may become subject to new and evolving legal and other obligations. These and other developments may require us to make significant changes to our use of AIML, including by limiting or restricting our use of AIML, and may require us to make significant changes to our policies and practices, which may necessitate expenditure of significant time, expense, and other resources. AIML also presents emerging ethical issues, and if our use of AIML becomes controversial, we may experience brand or reputational harm.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are currently subject to, and may in the future become subject to additional, U.S. federal and state laws and regulations imposing obligations on how we collect, store and process personal information. Our actual or perceived failure to comply with such obligations could harm our business. Ensuring compliance with such laws could also impair our efforts to maintain and expand our future customer base, and thereby decrease our revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we currently, and in the future will, collect, store, transfer, use or process sensitive data, including personal information of employees, and intellectual property and proprietary business information owned or controlled by ourselves and other parties. The secure processing, storage, maintenance, and transmission of this critical information are vital to our operations and business strategy. We are, and may increasingly become, subject to various laws and regulations, as well as contractual obligations, relating to data privacy and security in the jurisdictions in which we operate. The regulatory environment related to data privacy and security is increasingly rigorous, with new and constantly changing requirements applicable to our business, and enforcement practices are likely to remain uncertain for the foreseeable future. These laws and regulations may be interpreted and applied differently over time and from jurisdiction to jurisdiction, and it is possible that they will be interpreted and applied in ways that may have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-86"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, various federal and state regulators, including governmental agencies like the Consumer Financial Protection </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bureau, the Department of Justice,</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the Federal Trade Commission, have adopted, or are considering adopting, laws and regulations concerning personal information and data security. For example, the Department of Justice issued a final rule which took effect in April 2025 that places limitations, and in some cases prohibitions, on certain transfers of sensitive personal data to business partners located in China and other designated countries, or with other specified links to China and other designated countries. These rules also may broadly require us to extract promises from other third-party service providers that they will not transfer data we share with them onward to parties linked to countries of concern. Certain state laws may be more stringent or broader in scope, or offer greater individual rights, with respect to personal information than federal, international or other state laws, and such laws may differ from each other, all of which may complicate compliance efforts. For example, the California Consumer Privacy Act (&#8220;CCPA&#8221;), which increases privacy rights for California residents and imposes obligations on companies that process their personal information, came into effect on January 1, 2020. Among other things, the CCPA requires covered companies to provide new disclosures to California consumers and provide such consumers new data protection and privacy rights, including the ability to opt-out of certain sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for certain data breaches that result in the loss of personal information. This private right of action may increase the likelihood of, and risks associated with, data breach litigation. In November 2020, California also passed the California Privacy Rights Act (&#8220;CPRA&#8221;), which significantly expanded the CCPA as of January 1, 2023, including by introducing additional obligations such as data minimization and storage limitations and granting additional rights to consumers, among others. The enactment of the CCPA has prompted similar legislative developments in other states, and numerous other states have proposed, and in certain cases enacted, legislation relating to privacy and data security, many of which are similar to the CCPA and CPRA. Similar laws are being considered by other state legislatures. In addition, laws in all 50 U.S. states require businesses to provide notice to consumers whose personal information has been disclosed as a result of a data breach. State laws are changing rapidly and there has been discussion in the U.S. Congress of a new comprehensive federal data privacy law. These and future laws and regulations may increase our compliance costs and potential liability.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, regulations promulgated pursuant to the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), establish privacy and security standards that limit the use and disclosure of individually identifiable health information (known as &#8220;protected health information&#8221;) and require the implementation of administrative, physical and technological safeguards to protect the privacy of protected health information and ensure the confidentiality, integrity and availability of electronic protected health information. Determining whether protected health information has been handled in compliance with applicable privacy standards and our contractual obligations can require complex factual and statistical analyses and may be subject to changing interpretation. Although we take measures to protect sensitive data from unauthorized access, use or disclosure, our information technology and infrastructure may be vulnerable to attacks by hackers or viruses or disrupted, breached or otherwise compromised due to employee error, malfeasance or other malicious or inadvertent disruptions. Any such breach or disruption could compromise our networks, and the information stored there could be accessed, manipulated, publicly disclosed, lost, stolen, made unavailable, or otherwise processed without authorization. Any such disruption, access, breach, unavailability, theft, loss or other unauthorized processing of information, or the perception that any of these has occurred could result in legal claims or proceedings, and liability under federal or state laws that protect the privacy of personal information, such as the HIPAA, the Health Information Technology for Economic and Clinical Health Act, and regulatory penalties. Notice of breaches must be made to affected individuals, the Secretary of the Department of Health and Human Services, and for extensive breaches, notice may need to be made to the media or state attorneys general. Such a notice could harm our reputation and our ability to compete.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-87"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have in place formal policies and procedures related to the storage, collection, and processing of information, and have conducted data privacy audits, we continue to evaluate our compliance needs, including the need to conduct additional internal and external data privacy audits or adopt additional policies and procedures, to ensure our compliance with all applicable data protection laws and regulations. Additionally, we do not currently have policies and procedures in place for assessing our third-party vendors&#8217; compliance with applicable data protection laws and regulations. All of these evolving compliance and operational requirements impose significant costs, such as costs related to organizational changes, implementing additional protection technologies, training employees and engaging consultants, which are likely to increase over time. In addition, such requirements may require us to modify our data processing practices and policies, distract management or divert resources from other initiatives and projects, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Any failure or perceived failure by us or our third-party vendors, collaborators, contractors and consultants to comply with any applicable federal, state or similar foreign laws and regulations relating to data privacy and security, could result in damage to our reputation, as well as proceedings or litigation by governmental agencies or other third parties, including class action privacy litigation in certain jurisdictions, which would subject us to significant fines, sanctions, awards, penalties or judgments, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Increased scrutiny of our environmental, social or governance responsibilities may result in additional costs and risks, and may adversely impact our reputation, employee retention, and willingness of customers and suppliers to do business with us.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain investor advocacy groups, institutional investors, investment funds, proxy advisory services, stockholders, and customers are focused on environmental, social, and governance (&#8220;ESG&#8221;) practices of companies. We have also seen public interest and governmental regulation related to public companies&#8217; ESG practices.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our ESG practices fail to meet regulatory requirements or investor or other industry stakeholders' evolving expectations and standards for responsible corporate citizenship in areas including environmental stewardship, support for local communities, board and employee diversity, human capital management, employee health and safety practices, product quality, supply chain management, corporate governance and transparency, and employing ESG strategies in our operations, our brand, reputation and employee retention may be negatively impacted and customers and suppliers may be unwilling to do business with us and potential or current investors may elect to invest in other companies with ESG practices that are perceived to be better than ours. In addition, ESG reporting and disclosure may result in additional costs and require additional resources to monitor, report, and comply with our various ESG practices as well as additional attention from our board of directors and management. If we fail to adopt ESG standards or practices as quickly as stakeholders desire, report on our ESG efforts or practices accurately, or satisfy the expectations of stakeholders, or comply with applicable regulatory requirements, our reputation, business, financial performance, and growth may be adversely impacted.</span></div><div id="ieb0962265ffb4e35ba6bd2d2c7eff64b_97"></div><div style="margin-top:21pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #df1995;border-top:1pt solid #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 2.  UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ieb0962265ffb4e35ba6bd2d2c7eff64b_100"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #df1995;border-top:1pt solid #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 3.  DEFAULTS UPON SENIOR SECURITIES</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ieb0962265ffb4e35ba6bd2d2c7eff64b_103"></div><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #df1995;border-top:1pt solid #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 4.  MINE SAFETY DISCLOSURES</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-88"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></td></tr></table></div></div></div><div id="ieb0962265ffb4e35ba6bd2d2c7eff64b_106"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #df1995;border-top:1pt solid #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 5.  OTHER INFORMATION</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Securities Trading Plans of Directors and Executive Officers</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During our last fiscal quarter, none of our directors or officers, as defined in Rule 16a-1(f), <ix:nonNumeric contextRef="c-13" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-1009"><ix:nonNumeric contextRef="c-13" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-1010">adopted</ix:nonNumeric></ix:nonNumeric> and/or <ix:nonNumeric contextRef="c-13" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-1011"><ix:nonNumeric contextRef="c-13" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-1012">terminated</ix:nonNumeric></ix:nonNumeric> a &#8220;Rule 10b5-1 trading arrangement&#8221; or a &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as defined in Regulation S-K Item 408.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-89"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></td></tr></table></div></div></div><div id="ieb0962265ffb4e35ba6bd2d2c7eff64b_109"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span><br/></span></div><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #df1995;border-top:1pt solid #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-indent:-49.5pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 6.  EXHIBITS</span></div></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:54.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.114%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Incorporated by reference herein</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibit<br/>No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Description</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Form</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibit<br/>No.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Filing Date</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1299130/000119312511075269/dex31.htm">3.1</a></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1299130/000119312511075269/dex31.htm">Amended and Restated Certificate of Incorporation of Pacific Biosciences of California, Inc.</a></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10-K</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">March 23, 2011</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001299130/000129913024000146/exhibit31-certificateofame.htm">3.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001299130/000129913024000146/exhibit31-certificateofame.htm">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Pacific Biosciences of California, Inc. to declassify the Board</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8-K</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">June 20, 2024</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001299130/000129913024000146/exhibit32-certificateofame.htm">3.3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001299130/000129913024000146/exhibit32-certificateofame.htm">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Pacific Biosciences of California, Inc. to limit the liability of officers</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8-K</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">June 20, 2024</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1299130/000129913022000128/pacb-20221103xex3_1.htm">3.4</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1299130/000129913022000128/pacb-20221103xex3_1.htm">Third Amended and Restated Bylaws of Pacific Biosciences of California, Inc.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">November 7, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="pacb-10qxexx311xq3x25.htm">31</a>.1</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="pacb-10qxexx311xq3x25.htm">Certification of Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="pacb-10qxexx312xq3x25.htm">31</a>.2</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="pacb-10qxexx312xq3x25.htm">Certification of Chief Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="pacb-10qxexx321xq3x25.htm">32.1</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="pacb-10qxexx321xq3x25.htm">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Furnished herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="pacb-10qxexx322xq3x25.htm">32.2</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="pacb-10qxexx322xq3x25.htm">Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Furnished herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Labels Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cover Page Interactive File (formatted as inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Filed herewith</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">______________________________________________________________________________</span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;The certification</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s att</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ached as Exhibit 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Pacific Biosciences of California, Inc. under the Securities Act or the Exchange Act, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-90"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></td></tr></table></div></div></div><div id="ieb0962265ffb4e35ba6bd2d2c7eff64b_112"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signatures</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:20pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:45.417%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pacific Biosciences of California, Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: November&#160;6, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;Christian O. Henry </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Christian O. Henry</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Principal Executive Officer)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: November&#160;6, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;Jim R. Gibson</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jim R. Gibson</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Principal Financial Officer)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: November&#160;6, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;Michele Farmer</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Michele Farmer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vice President and Chief Accounting Officer </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Principal Accounting Officer)</span></div></td></tr></table></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #df1995;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.854%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt;vertical-align:bottom"><div style="padding-left:4.5pt"><img src="pacb-20250930_g2.jpg" alt="pacb-20221231x10kg001.jpg" style="height:10px;margin-bottom:5pt;vertical-align:text-bottom;width:48px" id="i-91"/></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Q3 Fiscal 2025 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></td></tr></table></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>pacb-10qxexx311xq3x25.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i0bab1c597e2e48c3addfafb3c813926f_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">SECURITIES EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a), AS ADOPTED PURSUANT </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">I, Christian Henry, certify that&#58; </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6pt">I have reviewed this quarterly report on Form 10-Q of Pacific Biosciences of California, Inc.&#59; </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58; </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.74pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.17pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.74pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.17pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.74pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.17pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></div><div style="margin-top:6pt"><font><br></font></div><div style="margin-top:20pt"><font style="font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"></font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.333%"><tr><td style="width:1.0%"></td><td style="width:44.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November&#160;6, 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Christian O. Henry</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Christian O. Henry<br>&#160;President and Chief Executive Officer <br>(Principal Executive Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>pacb-10qxexx312xq3x25.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i735502336e7148718f3e87c4ba56c8df_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 31.2 </font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">SECURITIES EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a), AS ADOPTED PURSUANT </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">I, Jim Gibson, certify that&#58; </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6pt">I have reviewed this quarterly report on Form 10-Q of Pacific Biosciences of California, Inc.&#59; </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58; </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.74pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.17pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.74pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.17pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.74pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-top:6pt;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.17pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></div><div style="margin-top:6pt"><font><br></font></div><div style="margin-top:6pt;text-indent:40.5pt"><font><br></font></div><div style="margin-top:6pt;text-indent:40.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.333%"><tr><td style="width:1.0%"></td><td style="width:43.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.749%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November&#160;6, 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jim R. Gibson</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Jim R. Gibson<br>Chief Financial Officer <br>(Principal Financial Officer)</font></td></tr></table></div><div style="margin-top:9pt;padding-left:72pt;text-indent:24.5pt"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>pacb-10qxexx321xq3x25.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i2f2c15a9ea0b4eca82b3a3fb91c5fc24_1"></div><div style="min-height:45pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> </font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 32.1 </font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Certification of CEO Furnished Pursuant to 18 U.S.C. Section 1350, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">As Adopted Pursuant To </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Section 906 of The Sarbanes-Oxley Act of 2002 </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Pacific Biosciences of California, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended September&#160;30, 2025, as filed with the Securities and Exchange Commission on the date hereof, I, Christian Henry, Chief Executive Officer of the Company, certify for the purposes of section 1350 of chapter 63 of title 18 of the United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge, </font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">the Quarterly Report of the Company on Form 10-Q for the period ended September&#160;30, 2025 (the &#8220;Report&#8221;), fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, and </font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:20pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.787%"><tr><td style="width:1.0%"></td><td style="width:42.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.514%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November&#160;6, 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Christian O. Henry</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Christian O. Henry<br>&#160;President and Chief Executive Officer<br>(Principal Executive Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>pacb-10qxexx322xq3x25.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i0e95c1098bfe40e1bc98ba3e1301b7f9_1"></div><div style="min-height:45pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"> </font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Certification of CFO Furnished Pursuant to 18 U.S.C. Section 1350, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">As Adopted Pursuant To </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Section 906 of The Sarbanes-Oxley Act of 2002</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Pacific Biosciences of California, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended September&#160;30, 2025, as filed with the Securities and Exchange Commission on the date hereof, I, Jim Gibson, Chief Financial Officer of the Company, certify for the purposes of section 1350 of chapter 63 of title 18 of the United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge, </font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">the Quarterly Report of the Company on Form 10-Q for the period ended September&#160;30, 2025 (the &#8220;Report&#8221;), fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, and </font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:20pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November&#160;6, 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jim R. Gibson</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Jim R. Gibson </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Financial Officer)</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>pacb-20250930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:541066b6-d2f9-469d-bf86-6042e3dcfaa4,g:e6194c68-cd08-4fb8-9cf2-74de760e8618-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:pacb="http://www.pacificbiosciences.com/20250930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.pacificbiosciences.com/20250930">
  <xs:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pacb-20250930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pacb-20250930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pacb-20250930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pacb-20250930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.pacificbiosciences.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" roleURI="http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited">
        <link:definition>9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" roleURI="http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical">
        <link:definition>9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" roleURI="http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited">
        <link:definition>9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" roleURI="http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited">
        <link:definition>9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" roleURI="http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited">
        <link:definition>9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>9952156 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTS" roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTS">
        <link:definition>9952157 - Disclosure - FINANCIAL INSTRUMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTS" roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTS">
        <link:definition>9952158 - Disclosure - BALANCE SHEET COMPONENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONVERTIBLESENIORNOTES" roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTES">
        <link:definition>9952159 - Disclosure - CONVERTIBLE SENIOR NOTES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURING" roleURI="http://www.pacificbiosciences.com/role/RESTRUCTURING">
        <link:definition>9952160 - Disclosure - RESTRUCTURING</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>9952161 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYPLANSANDSHAREBASEDCOMPENSATION" roleURI="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATION">
        <link:definition>9952162 - Disclosure - EQUITY PLANS AND SHARE-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERSHARE" roleURI="http://www.pacificbiosciences.com/role/NETLOSSPERSHARE">
        <link:definition>9952163 - Disclosure - NET LOSS PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTANDGEOGRAPHICINFORMATION" roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATION">
        <link:definition>9952164 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>9955511 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSTables" roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSTables">
        <link:definition>9955512 - Disclosure - FINANCIAL INSTRUMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSTables" roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables">
        <link:definition>9955513 - Disclosure - BALANCE SHEET COMPONENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONVERTIBLESENIORNOTESTables" roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESTables">
        <link:definition>9955514 - Disclosure - CONVERTIBLE SENIOR NOTES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGTables" roleURI="http://www.pacificbiosciences.com/role/RESTRUCTURINGTables">
        <link:definition>9955515 - Disclosure - RESTRUCTURING (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYPLANSANDSHAREBASEDCOMPENSATIONTables" roleURI="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONTables">
        <link:definition>9955516 - Disclosure - EQUITY PLANS AND SHARE-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERSHARETables" roleURI="http://www.pacificbiosciences.com/role/NETLOSSPERSHARETables">
        <link:definition>9955517 - Disclosure - NET LOSS PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTANDGEOGRAPHICINFORMATIONTables" roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTables">
        <link:definition>9955518 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>9955519 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSContingentConsiderationDetails" roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSContingentConsiderationDetails">
        <link:definition>9955520 - Disclosure - FINANCIAL INSTRUMENTS - Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails" roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails">
        <link:definition>9955521 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Changes in Estimated Fair Value of Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails" roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails">
        <link:definition>9955522 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Cash, Cash Equivalents and Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSScheduleofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails" roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails">
        <link:definition>9955523 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Contractual Maturities of Cash Equivalents and Available-for-Sale Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSInvestmentIncomeDetails" roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSInvestmentIncomeDetails">
        <link:definition>9955524 - Disclosure - FINANCIAL INSTRUMENTS - Investment Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSScheduleofInventoryDetails" roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails">
        <link:definition>9955525 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails">
        <link:definition>9955526 - Disclosure - BALANCE SHEET COMPONENTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSNarrativeDetails_1" roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails_1">
        <link:definition>9955526 - Disclosure - BALANCE SHEET COMPONENTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails" roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails">
        <link:definition>9955527 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails" roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails">
        <link:definition>9955528 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Finite-Lived Intangible Assets From Business Acquisitions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails" roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails">
        <link:definition>9955529 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Estimated Future Amortization Expense of Acquisition-Related Intangible Assets with Definite Lives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BALANCESHEETCOMPONENTSScheduleofChangesinReserveforProductWarrantiesDetails" roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofChangesinReserveforProductWarrantiesDetails">
        <link:definition>9955530 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Changes in Reserve for Product Warranties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONVERTIBLESENIORNOTESNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails">
        <link:definition>9955531 - Disclosure - CONVERTIBLE SENIOR NOTES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONVERTIBLESENIORNOTESScheduleofChangestothe2029NotesDetails" roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofChangestothe2029NotesDetails">
        <link:definition>9955532 - Disclosure - CONVERTIBLE SENIOR NOTES - Schedule of Changes to the 2029 Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails" roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails">
        <link:definition>9955533 - Disclosure - CONVERTIBLE SENIOR NOTES - Schedule of Net Carrying Amount (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails" roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails">
        <link:definition>9955534 - Disclosure - CONVERTIBLE SENIOR NOTES - Schedule of Interest Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails" roleURI="http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails">
        <link:definition>9955535 - Disclosure - RESTRUCTURING - Schedule of Pre-Tax Restructuring Charges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails">
        <link:definition>9955536 - Disclosure - RESTRUCTURING - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails" roleURI="http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails">
        <link:definition>9955537 - Disclosure - RESTRUCTURING - Schedule of Restructuring Reserve by Type of Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESDetails" roleURI="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESDetails">
        <link:definition>9955538 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails">
        <link:definition>9955539 - Disclosure - EQUITY PLANS AND SHARE-BASED COMPENSATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" roleURI="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockOptionActivityDetails">
        <link:definition>9955540 - Disclosure - EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails" roleURI="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails">
        <link:definition>9955541 - Disclosure - EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Time-Based RSUs and PSUs Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails" roleURI="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails">
        <link:definition>9955542 - Disclosure - EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockOptionsDetails" roleURI="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockOptionsDetails">
        <link:definition>9955543 - Disclosure - EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Fair Value of Employee Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockPurchasePlanDetails" roleURI="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockPurchasePlanDetails">
        <link:definition>9955544 - Disclosure - EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Fair Value of Employee Stock Purchase Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails" roleURI="http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails">
        <link:definition>9955545 - Disclosure - NET LOSS PER SHARE - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERSHAREScheduleofAntidilutiveSharesExcludedFromComputationofDilutedNetLossperShareDetails" roleURI="http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSharesExcludedFromComputationofDilutedNetLossperShareDetails">
        <link:definition>9955546 - Disclosure - NET LOSS PER SHARE - Schedule of Antidilutive Shares Excluded From Computation of Diluted Net Loss per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails" roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails">
        <link:definition>9955547 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails" roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails">
        <link:definition>9955548 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Segment Profit or Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails" roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails">
        <link:definition>9955549 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Revenue by Geographic Location (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails" roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails">
        <link:definition>9955550 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Revenue by Category (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="pacb_ServiceAndOtherMember" abstract="false" name="ServiceAndOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_LossOnPurchaseCommitment" abstract="false" name="LossOnPurchaseCommitment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_AmortizationOfAcquiredIntangibleAssets" abstract="false" name="AmortizationOfAcquiredIntangibleAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_IncomeLossPerShareAbstract" abstract="true" name="IncomeLossPerShareAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" abstract="true" name="SupplementalBalanceSheetComponentsDisclosureAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pacb_ScheduleOfInterestExpenseTableTextBlock" abstract="false" name="ScheduleOfInterestExpenseTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="pacb_ShortTermRestrictedCashFairValueDisclosure" abstract="false" name="ShortTermRestrictedCashFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_LongTermRestrictedCashFairValueDisclosure" abstract="false" name="LongTermRestrictedCashFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_AptonMember" abstract="true" name="AptonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_AchievementOfMilestoneMember" abstract="false" name="AchievementOfMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone" abstract="false" name="BusinessCombinationConsiderationTransferredRevenueAchievementMilestone" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod" abstract="false" name="BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition" abstract="false" name="StockIssuedDuringPeriodAverageTradingPeriodAcquisition" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger" abstract="false" name="PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pacb_ScheduleOfBalanceSheetComponentsTable" abstract="true" name="ScheduleOfBalanceSheetComponentsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="pacb_A2025RestructuringMember" abstract="true" name="A2025RestructuringMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_DevelopedTechnologyAndIntellectualPropertyMember" abstract="true" name="DevelopedTechnologyAndIntellectualPropertyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_ScheduleOfBalanceSheetComponentsLineItems" abstract="true" name="ScheduleOfBalanceSheetComponentsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate" abstract="false" name="IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm" abstract="false" name="IntangibleAssetImpairmentDiscountedCashFlowModelTerm" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate" abstract="false" name="IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate" abstract="false" name="AdditionalIntangibleAssetImpairmentChangeInDiscountRate" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm" abstract="false" name="IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pacb_AdditionalIntangibleAssetImpairmentChangeInTerm" abstract="false" name="AdditionalIntangibleAssetImpairmentChangeInTerm" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_RestructuringAndRelatedCostAcceleratedAmortization" abstract="false" name="RestructuringAndRelatedCostAcceleratedAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_ChangeInEarningsPerShare" abstract="false" name="ChangeInEarningsPerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod" abstract="false" name="ContractWithCustomerLiabilityNoncurrentRecognitionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pacb_StandardProductWarrantyPeriod" abstract="false" name="StandardProductWarrantyPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" abstract="false" name="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_A2028ConvertibleSeniorNotesMember" abstract="false" name="A2028ConvertibleSeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_A2029NotesMember" abstract="true" name="A2029NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_ExchangeTransactionMember" abstract="true" name="ExchangeTransactionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_A2030ConvertibleSeniorNotesMember" abstract="true" name="A2030ConvertibleSeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_DebtInstrumentConvertibleTermsOfConversionAxis" abstract="true" name="DebtInstrumentConvertibleTermsOfConversionAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="pacb_DebtInstrumentConvertibleTermsOfConversionDomain" abstract="true" name="DebtInstrumentConvertibleTermsOfConversionDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_DebtConversionTermsOneMember" abstract="true" name="DebtConversionTermsOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_DebtConversionTermsTwoMember" abstract="true" name="DebtConversionTermsTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_PaymentsInConjunctionWithNotesExchange" abstract="false" name="PaymentsInConjunctionWithNotesExchange" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares" abstract="false" name="HoldingPeriodForTransferAssignmentOrSaleOfFounderShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pacb_DebtInstrumentDebtDefaultCalendarDays" abstract="false" name="DebtInstrumentDebtDefaultCalendarDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pacb_DebtInstrumentInterestInTheEventOfDefault" abstract="false" name="DebtInstrumentInterestInTheEventOfDefault" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pacb_DebtInstrumentAdditionalInterestInEventOfDefault" abstract="false" name="DebtInstrumentAdditionalInterestInEventOfDefault" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pacb_RestructuringOfDebtPricePerShare" abstract="false" name="RestructuringOfDebtPricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="pacb_DebtIssuanceCostLenderFees" abstract="false" name="DebtIssuanceCostLenderFees" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice" abstract="false" name="DebtInstrumentRedemptionPricePercentageOfConversionPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pacb_DebtInstrumentRedemptionPriceTradingDays" abstract="false" name="DebtInstrumentRedemptionPriceTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays" abstract="false" name="DebtInstrumentRedemptionPriceConsecutiveTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pacb_EmployeeSeparationCostsMember" abstract="true" name="EmployeeSeparationCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_A2024RestructuringMember" abstract="true" name="A2024RestructuringMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_SanDiegoOfficeMember" abstract="true" name="SanDiegoOfficeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember" abstract="false" name="InProcessResearchAndDevelopmentIndefiniteLivedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits" abstract="false" name="RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_RestructuringChargesAdditionalCostsIncurred" abstract="false" name="RestructuringChargesAdditionalCostsIncurred" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_GainLossOnPurchaseCommitments" abstract="false" name="GainLossOnPurchaseCommitments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations" abstract="false" name="AdditionalLiabilityAssociatedWithIndemnificationObligations" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pacb_EmployeeStockPurchasePlanMember" abstract="false" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_EquityIncentivePlan2020Member" abstract="false" name="EquityIncentivePlan2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_A2020PlanInducementPlanAndTheOmniomePlanMember" abstract="true" name="A2020PlanInducementPlanAndTheOmniomePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_TimeBasedRestrictedStockUnitsPSUMember" abstract="true" name="TimeBasedRestrictedStockUnitsPSUMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pacb_TimeBasedStockOptionMember" abstract="false" name="TimeBasedStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_TimeBasedRestrictedStockUnitsRsusMember" abstract="false" name="TimeBasedRestrictedStockUnitsRsusMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_StockBasedCompensationMember" abstract="false" name="StockBasedCompensationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_OptionsToPurchaseCommonStockMember" abstract="false" name="OptionsToPurchaseCommonStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_ReportableSegmentMember" abstract="true" name="ReportableSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_InstrumentMember" abstract="false" name="InstrumentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pacb_ConsumableMember" abstract="false" name="ConsumableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>pacb-20250930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:541066b6-d2f9-469d-bf86-6042e3dcfaa4,g:e6194c68-cd08-4fb8-9cf2-74de760e8618-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" xlink:type="simple" xlink:href="pacb-20250930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_bb4ce90c-a1d2-41f1-b052-775a04eeed8c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_72c78541-bf12-4c9c-9daa-393f2ad9e4d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bb4ce90c-a1d2-41f1-b052-775a04eeed8c" xlink:to="loc_us-gaap_AccountsPayableCurrent_72c78541-bf12-4c9c-9daa-393f2ad9e4d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_9ab82654-c6f3-49bc-8594-10a11fa3c389" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bb4ce90c-a1d2-41f1-b052-775a04eeed8c" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_9ab82654-c6f3-49bc-8594-10a11fa3c389" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_0239aeb1-d85b-464b-b7e6-44cfc31e17f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bb4ce90c-a1d2-41f1-b052-775a04eeed8c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_0239aeb1-d85b-464b-b7e6-44cfc31e17f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ece2070f-2949-4b11-a45e-de3dd5c50bae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bb4ce90c-a1d2-41f1-b052-775a04eeed8c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ece2070f-2949-4b11-a45e-de3dd5c50bae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_90f7df24-9815-4d1f-85b9-62b18da548f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bb4ce90c-a1d2-41f1-b052-775a04eeed8c" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_90f7df24-9815-4d1f-85b9-62b18da548f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_819b81fe-ac0f-4345-b4fd-2d949c026377" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_16b4c8fa-7247-43d7-97b9-0dafa72f216f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_819b81fe-ac0f-4345-b4fd-2d949c026377" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_16b4c8fa-7247-43d7-97b9-0dafa72f216f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_69612581-7ca2-43f2-bf44-78f145c37c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_819b81fe-ac0f-4345-b4fd-2d949c026377" xlink:to="loc_us-gaap_ShortTermInvestments_69612581-7ca2-43f2-bf44-78f145c37c6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_99dc20f1-f37e-4c17-85e7-2f571ff92f15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_819b81fe-ac0f-4345-b4fd-2d949c026377" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_99dc20f1-f37e-4c17-85e7-2f571ff92f15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_4dcc66c0-726e-4679-a4bb-fff5238acfa1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_819b81fe-ac0f-4345-b4fd-2d949c026377" xlink:to="loc_us-gaap_InventoryNet_4dcc66c0-726e-4679-a4bb-fff5238acfa1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8eb9a7fd-48e0-442b-8a36-679ff07b096e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_819b81fe-ac0f-4345-b4fd-2d949c026377" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8eb9a7fd-48e0-442b-8a36-679ff07b096e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_2b6b25f0-9d41-4980-899d-c13f12d271fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_819b81fe-ac0f-4345-b4fd-2d949c026377" xlink:to="loc_us-gaap_RestrictedCashCurrent_2b6b25f0-9d41-4980-899d-c13f12d271fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_0036bc10-bbc7-4c22-84dc-c8a3c4f124a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_dbd0e036-0575-4ea0-afb8-dfc0f9510e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_0036bc10-bbc7-4c22-84dc-c8a3c4f124a8" xlink:to="loc_us-gaap_Liabilities_dbd0e036-0575-4ea0-afb8-dfc0f9510e3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_054d0347-9779-48b6-9b04-2647c03bd8ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_0036bc10-bbc7-4c22-84dc-c8a3c4f124a8" xlink:to="loc_us-gaap_StockholdersEquity_054d0347-9779-48b6-9b04-2647c03bd8ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_70b31665-2343-4983-93f8-1714cebe98f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_0036bc10-bbc7-4c22-84dc-c8a3c4f124a8" xlink:to="loc_us-gaap_CommitmentsAndContingencies_70b31665-2343-4983-93f8-1714cebe98f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_1e4c9213-c8c9-4d91-9a29-65cf4060fe77" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5d97d833-e8c5-492c-8ab0-eb67aae895a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1e4c9213-c8c9-4d91-9a29-65cf4060fe77" xlink:to="loc_us-gaap_AssetsCurrent_5d97d833-e8c5-492c-8ab0-eb67aae895a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a0212e74-e382-4ec3-85be-fb7fe6343514" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1e4c9213-c8c9-4d91-9a29-65cf4060fe77" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a0212e74-e382-4ec3-85be-fb7fe6343514" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e209af07-1867-4c89-8352-45229d41150f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1e4c9213-c8c9-4d91-9a29-65cf4060fe77" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e209af07-1867-4c89-8352-45229d41150f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_1ccbd90f-8a02-4d0b-b597-14703c71e44c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1e4c9213-c8c9-4d91-9a29-65cf4060fe77" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_1ccbd90f-8a02-4d0b-b597-14703c71e44c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1d985bd4-fa73-4a65-bc69-4706920484e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1e4c9213-c8c9-4d91-9a29-65cf4060fe77" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_1d985bd4-fa73-4a65-bc69-4706920484e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6b79a7d9-a0a0-4f19-b0db-8c74a7d3d5b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1e4c9213-c8c9-4d91-9a29-65cf4060fe77" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6b79a7d9-a0a0-4f19-b0db-8c74a7d3d5b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d23e93ec-cece-4ece-9e10-43ad66d27da1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1e4c9213-c8c9-4d91-9a29-65cf4060fe77" xlink:to="loc_us-gaap_Goodwill_d23e93ec-cece-4ece-9e10-43ad66d27da1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_df864892-ee4d-4462-b387-7fb639893e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_5216d95b-3411-42ae-8868-f61b640f674f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_df864892-ee4d-4462-b387-7fb639893e1e" xlink:to="loc_us-gaap_PreferredStockValue_5216d95b-3411-42ae-8868-f61b640f674f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_3ecb32a0-d954-4ded-bda6-7e4322fad32c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_df864892-ee4d-4462-b387-7fb639893e1e" xlink:to="loc_us-gaap_CommonStockValue_3ecb32a0-d954-4ded-bda6-7e4322fad32c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_a735f0b1-4425-4319-a490-b6a21d81854d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_df864892-ee4d-4462-b387-7fb639893e1e" xlink:to="loc_us-gaap_AdditionalPaidInCapital_a735f0b1-4425-4319-a490-b6a21d81854d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ccf54fc3-739f-49c2-b248-8e29386b86f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_df864892-ee4d-4462-b387-7fb639893e1e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ccf54fc3-739f-49c2-b248-8e29386b86f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_dc26ac4f-d084-48e1-832b-78a369feb187" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_df864892-ee4d-4462-b387-7fb639893e1e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_dc26ac4f-d084-48e1-832b-78a369feb187" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_af00184c-8d50-49d5-9ae3-3ad89b1772ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_93969c52-a18d-4896-978c-c79aae683558" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_af00184c-8d50-49d5-9ae3-3ad89b1772ea" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_93969c52-a18d-4896-978c-c79aae683558" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_e9335c2d-304c-4ef1-bb0e-f3f907c6fa66" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_af00184c-8d50-49d5-9ae3-3ad89b1772ea" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_e9335c2d-304c-4ef1-bb0e-f3f907c6fa66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d0a2093a-e21f-405c-85ee-9c4ec3778268" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_af00184c-8d50-49d5-9ae3-3ad89b1772ea" xlink:to="loc_us-gaap_LiabilitiesCurrent_d0a2093a-e21f-405c-85ee-9c4ec3778268" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6057e9e2-f50b-4ffc-b9c5-bc525109d2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_af00184c-8d50-49d5-9ae3-3ad89b1772ea" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6057e9e2-f50b-4ffc-b9c5-bc525109d2ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_aa2abf3a-e14c-4094-8aae-2e6834714d52" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_af00184c-8d50-49d5-9ae3-3ad89b1772ea" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_aa2abf3a-e14c-4094-8aae-2e6834714d52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_1067ebd1-8a5f-482a-a1af-68d9333279fd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_af00184c-8d50-49d5-9ae3-3ad89b1772ea" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_1067ebd1-8a5f-482a-a1af-68d9333279fd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" xlink:type="simple" xlink:href="pacb-20250930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_9adbbf2a-d8ca-49d1-944f-d511b99c199a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_6e409faa-d36b-43ae-b3fb-a872393c68e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_9adbbf2a-d8ca-49d1-944f-d511b99c199a" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_6e409faa-d36b-43ae-b3fb-a872393c68e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d139cfde-e0b7-4028-81b0-fcb83ad390d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_9adbbf2a-d8ca-49d1-944f-d511b99c199a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d139cfde-e0b7-4028-81b0-fcb83ad390d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_7cd03249-8813-4a62-98e3-3d220cf88a40" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_9adbbf2a-d8ca-49d1-944f-d511b99c199a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_7cd03249-8813-4a62-98e3-3d220cf88a40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AmortizationOfAcquiredIntangibleAssets_0be607dc-e952-4baa-b34a-31bd66b383da" xlink:href="pacb-20250930.xsd#pacb_AmortizationOfAcquiredIntangibleAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_9adbbf2a-d8ca-49d1-944f-d511b99c199a" xlink:to="loc_pacb_AmortizationOfAcquiredIntangibleAssets_0be607dc-e952-4baa-b34a-31bd66b383da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_808d142a-0661-4367-b93e-bda1ceff5461" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_9adbbf2a-d8ca-49d1-944f-d511b99c199a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_808d142a-0661-4367-b93e-bda1ceff5461" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2fa6ffaa-9a5c-480c-bd0b-7a9361a06a74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_bddd1c92-2234-48b5-8e31-562d1b0d2991" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2fa6ffaa-9a5c-480c-bd0b-7a9361a06a74" xlink:to="loc_us-gaap_InterestExpenseNonoperating_bddd1c92-2234-48b5-8e31-562d1b0d2991" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_14bdc1a0-af0a-4179-b005-13e18ea2160b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2fa6ffaa-9a5c-480c-bd0b-7a9361a06a74" xlink:to="loc_us-gaap_OperatingIncomeLoss_14bdc1a0-af0a-4179-b005-13e18ea2160b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_fae195d6-fe59-426b-a616-666a506f18f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2fa6ffaa-9a5c-480c-bd0b-7a9361a06a74" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_fae195d6-fe59-426b-a616-666a506f18f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_e1ae5e3e-c820-4c65-923e-e28d667d071f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LossOnPurchaseCommitment_b65a7a2c-bf23-4cd3-9853-4483732cdaa2" xlink:href="pacb-20250930.xsd#pacb_LossOnPurchaseCommitment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostOfRevenue_e1ae5e3e-c820-4c65-923e-e28d667d071f" xlink:to="loc_pacb_LossOnPurchaseCommitment_b65a7a2c-bf23-4cd3-9853-4483732cdaa2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_e672f7b3-e0b9-4e6e-9ef4-9682f2006480" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostOfRevenue_e1ae5e3e-c820-4c65-923e-e28d667d071f" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_e672f7b3-e0b9-4e6e-9ef4-9682f2006480" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_0e54991d-4c38-43c9-9e86-e581c570ed5c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostOfRevenue_e1ae5e3e-c820-4c65-923e-e28d667d071f" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_0e54991d-4c38-43c9-9e86-e581c570ed5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_be9243ea-d7fb-4475-a6ee-4d98a5cd7a33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_bf39e44e-986d-4ded-abae-6b3ef42e19b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_be9243ea-d7fb-4475-a6ee-4d98a5cd7a33" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_bf39e44e-986d-4ded-abae-6b3ef42e19b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_81353e81-2d42-4def-b981-b12f816b6734" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_be9243ea-d7fb-4475-a6ee-4d98a5cd7a33" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_81353e81-2d42-4def-b981-b12f816b6734" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_68eae04a-4586-4517-b9c6-a4675bfec844" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e1b4f46d-c0a1-4e2c-8bbd-36fe0eedbbf9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_68eae04a-4586-4517-b9c6-a4675bfec844" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e1b4f46d-c0a1-4e2c-8bbd-36fe0eedbbf9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_587ebd29-7362-4126-b25f-7abf5f007776" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_68eae04a-4586-4517-b9c6-a4675bfec844" xlink:to="loc_us-gaap_CostOfRevenue_587ebd29-7362-4126-b25f-7abf5f007776" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c7ab1846-b23c-4277-821c-771cc7e1b966" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_6026d71b-0c82-480d-a632-c76499eb6cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_c7ab1846-b23c-4277-821c-771cc7e1b966" xlink:to="loc_us-gaap_GrossProfit_6026d71b-0c82-480d-a632-c76499eb6cf0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_d9394a23-626e-4200-9824-df4e62bf692e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_c7ab1846-b23c-4277-821c-771cc7e1b966" xlink:to="loc_us-gaap_OperatingExpenses_d9394a23-626e-4200-9824-df4e62bf692e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_f9f8bb07-bc95-4683-b4d0-c0e9f823167a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9180fb9c-74fc-441b-a130-363705b3fd54" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_f9f8bb07-bc95-4683-b4d0-c0e9f823167a" xlink:to="loc_us-gaap_NetIncomeLoss_9180fb9c-74fc-441b-a130-363705b3fd54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_5fb838bb-78af-455a-981d-954cc149ecff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_f9f8bb07-bc95-4683-b4d0-c0e9f823167a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_5fb838bb-78af-455a-981d-954cc149ecff" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" xlink:type="simple" xlink:href="pacb-20250930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c2c0cd0e-17b7-4d58-a372-2cdbc79298fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_d56e3a87-e48e-4f1e-9982-05b954e3fb88" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c2c0cd0e-17b7-4d58-a372-2cdbc79298fb" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_d56e3a87-e48e-4f1e-9982-05b954e3fb88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_36b2c198-42b8-4a7d-b4cb-9c9345f05829" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c2c0cd0e-17b7-4d58-a372-2cdbc79298fb" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_36b2c198-42b8-4a7d-b4cb-9c9345f05829" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a036adae-5f74-4856-812b-78157f589755" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_06f558a8-685f-45fb-bd3b-3d0c4b57fe2d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a036adae-5f74-4856-812b-78157f589755" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_06f558a8-685f-45fb-bd3b-3d0c4b57fe2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_12311d61-60ed-4410-8f3b-9db7a5da32ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a036adae-5f74-4856-812b-78157f589755" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_12311d61-60ed-4410-8f3b-9db7a5da32ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c54b6e5c-f9d7-46bb-a66b-c49c68300e64" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a036adae-5f74-4856-812b-78157f589755" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c54b6e5c-f9d7-46bb-a66b-c49c68300e64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b45a565f-434d-47c4-a109-08316fb140be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6404cd2e-841c-4d7e-8a14-2e52641f79f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b45a565f-434d-47c4-a109-08316fb140be" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6404cd2e-841c-4d7e-8a14-2e52641f79f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_d7485654-376a-462a-9dc4-0b04eca3eb3b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b45a565f-434d-47c4-a109-08316fb140be" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_d7485654-376a-462a-9dc4-0b04eca3eb3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1d314ed1-80c6-45c2-99db-897d31aa60c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b580c52e-8733-4b6f-bac5-882cd793b81c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1d314ed1-80c6-45c2-99db-897d31aa60c4" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b580c52e-8733-4b6f-bac5-882cd793b81c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_25a7e65b-cf91-4574-b843-ada934809841" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1d314ed1-80c6-45c2-99db-897d31aa60c4" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_25a7e65b-cf91-4574-b843-ada934809841" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_0709c343-721f-47a7-a487-d745c82b4560" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1d314ed1-80c6-45c2-99db-897d31aa60c4" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_0709c343-721f-47a7-a487-d745c82b4560" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_69cf4915-36a4-49ba-8a88-1dc24ef0b77a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1d314ed1-80c6-45c2-99db-897d31aa60c4" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_69cf4915-36a4-49ba-8a88-1dc24ef0b77a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_cb810978-f276-4c13-986d-fba23fa15fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1d314ed1-80c6-45c2-99db-897d31aa60c4" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_cb810978-f276-4c13-986d-fba23fa15fcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2a9c61a5-ca88-4775-9824-14168d4b5e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_34f4d3f4-395c-4c9e-9139-84ba8ef2bf96" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2a9c61a5-ca88-4775-9824-14168d4b5e5c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_34f4d3f4-395c-4c9e-9139-84ba8ef2bf96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_083e6fd7-3d0f-4c41-a032-31c7702cdbd1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2a9c61a5-ca88-4775-9824-14168d4b5e5c" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_083e6fd7-3d0f-4c41-a032-31c7702cdbd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_b3ffdaf8-4db4-4d5b-8e40-fc92f9c1c10b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2a9c61a5-ca88-4775-9824-14168d4b5e5c" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_b3ffdaf8-4db4-4d5b-8e40-fc92f9c1c10b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_cea63e11-ebc5-45f3-beaa-56bb70713242" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2a9c61a5-ca88-4775-9824-14168d4b5e5c" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_cea63e11-ebc5-45f3-beaa-56bb70713242" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d787d663-fb71-4d2d-bef4-d8373bb17764" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2a9c61a5-ca88-4775-9824-14168d4b5e5c" xlink:to="loc_us-gaap_NetIncomeLoss_d787d663-fb71-4d2d-bef4-d8373bb17764" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_4655239e-313d-468b-a6f8-ad68f5610c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2a9c61a5-ca88-4775-9824-14168d4b5e5c" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_4655239e-313d-468b-a6f8-ad68f5610c9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ea02413c-88e9-4057-abb0-f9c72ffe8fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2a9c61a5-ca88-4775-9824-14168d4b5e5c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ea02413c-88e9-4057-abb0-f9c72ffe8fcf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_d75ed812-f06a-49ef-a077-5e3f8a6962f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2a9c61a5-ca88-4775-9824-14168d4b5e5c" xlink:to="loc_us-gaap_Depreciation_d75ed812-f06a-49ef-a077-5e3f8a6962f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_f7c80f1a-db2f-41b7-bc38-9492a44e7682" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2a9c61a5-ca88-4775-9824-14168d4b5e5c" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_f7c80f1a-db2f-41b7-bc38-9492a44e7682" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_da615851-d9c6-4d0b-a525-49f06ef706e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2a9c61a5-ca88-4775-9824-14168d4b5e5c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_da615851-d9c6-4d0b-a525-49f06ef706e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_893fb245-f6f9-426f-8e92-7911975e5519" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2a9c61a5-ca88-4775-9824-14168d4b5e5c" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_893fb245-f6f9-426f-8e92-7911975e5519" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_112ab3ec-0c36-44cd-9878-fb7ae929b118" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2a9c61a5-ca88-4775-9824-14168d4b5e5c" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_112ab3ec-0c36-44cd-9878-fb7ae929b118" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_ac69dd87-f7e9-4dcf-b17e-5094b38fdfb0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2a9c61a5-ca88-4775-9824-14168d4b5e5c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_ac69dd87-f7e9-4dcf-b17e-5094b38fdfb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_89b41c2d-ce7c-4240-9800-fee38cc4dcba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2a9c61a5-ca88-4775-9824-14168d4b5e5c" xlink:to="loc_us-gaap_ShareBasedCompensation_89b41c2d-ce7c-4240-9800-fee38cc4dcba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_3e4633f7-e173-4d88-b44c-29e69b0b9ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2a9c61a5-ca88-4775-9824-14168d4b5e5c" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_3e4633f7-e173-4d88-b44c-29e69b0b9ec8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_946fb3d6-5573-466f-9ed1-13701b5fedb2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2a9c61a5-ca88-4775-9824-14168d4b5e5c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_946fb3d6-5573-466f-9ed1-13701b5fedb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_139ae8b8-d096-447b-af83-a8649cf524bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2a9c61a5-ca88-4775-9824-14168d4b5e5c" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_139ae8b8-d096-447b-af83-a8649cf524bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_62eab770-5a5d-4574-bc87-e21b5865dc81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWriteDown"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2a9c61a5-ca88-4775-9824-14168d4b5e5c" xlink:to="loc_us-gaap_InventoryWriteDown_62eab770-5a5d-4574-bc87-e21b5865dc81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_829bcec7-4b7e-4f3e-af68-25d1b06c3cfc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="19" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2a9c61a5-ca88-4775-9824-14168d4b5e5c" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_829bcec7-4b7e-4f3e-af68-25d1b06c3cfc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_d2a1e6ae-eb95-4813-8a87-e374b9dd5218" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_90d17651-041f-45e8-8c39-40325b7b52ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_d2a1e6ae-eb95-4813-8a87-e374b9dd5218" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_90d17651-041f-45e8-8c39-40325b7b52ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LongTermRestrictedCashFairValueDisclosure_1f8cbcf3-1465-4405-beaa-1d2812d46d56" xlink:href="pacb-20250930.xsd#pacb_LongTermRestrictedCashFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_d2a1e6ae-eb95-4813-8a87-e374b9dd5218" xlink:to="loc_pacb_LongTermRestrictedCashFairValueDisclosure_1f8cbcf3-1465-4405-beaa-1d2812d46d56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ShortTermRestrictedCashFairValueDisclosure_c51c7053-3fe2-4c95-a326-47b0e498c194" xlink:href="pacb-20250930.xsd#pacb_ShortTermRestrictedCashFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_d2a1e6ae-eb95-4813-8a87-e374b9dd5218" xlink:to="loc_pacb_ShortTermRestrictedCashFairValueDisclosure_c51c7053-3fe2-4c95-a326-47b0e498c194" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_865c6f93-5467-4a2d-bef3-38a379d72e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_d2a1e6ae-eb95-4813-8a87-e374b9dd5218" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_865c6f93-5467-4a2d-bef3-38a379d72e5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_116f5512-7673-4366-aed9-c39305249268" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_14d1a18b-e60d-4221-a3eb-bb27d1b23cff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_116f5512-7673-4366-aed9-c39305249268" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_14d1a18b-e60d-4221-a3eb-bb27d1b23cff" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_28eb785e-9d1c-4dfb-bb1f-df24477765bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_81a5eb96-b627-4f42-b5c2-9b5f74b54185" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_28eb785e-9d1c-4dfb-bb1f-df24477765bb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_81a5eb96-b627-4f42-b5c2-9b5f74b54185" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d5ea1a05-617b-4568-b52c-9922a9adc49d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_28eb785e-9d1c-4dfb-bb1f-df24477765bb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d5ea1a05-617b-4568-b52c-9922a9adc49d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_fdeaf878-fe86-4e11-8d28-1fbd41597fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_28eb785e-9d1c-4dfb-bb1f-df24477765bb" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_fdeaf878-fe86-4e11-8d28-1fbd41597fb7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#FINANCIALINSTRUMENTSScheduleofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_7338adf6-1ccb-42ea-ab8c-9a59eec2b312" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_f7363ea4-e9fa-41b9-8a46-d03a7b642d91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_7338adf6-1ccb-42ea-ab8c-9a59eec2b312" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_f7363ea4-e9fa-41b9-8a46-d03a7b642d91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_2da6670d-52f0-4d05-a5fe-739a36ef28f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_7338adf6-1ccb-42ea-ab8c-9a59eec2b312" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_2da6670d-52f0-4d05-a5fe-739a36ef28f9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#BALANCESHEETCOMPONENTSScheduleofInventoryDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_d40f2aef-c1cc-4efc-be47-40733798bf72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_5ef4f7dc-f04f-430b-a7a7-f9c02ccc06d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_d40f2aef-c1cc-4efc-be47-40733798bf72" xlink:to="loc_us-gaap_InventoryFinishedGoods_5ef4f7dc-f04f-430b-a7a7-f9c02ccc06d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_ce959ed9-a78d-4fa4-b4d0-9fdbb5b4a32c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_d40f2aef-c1cc-4efc-be47-40733798bf72" xlink:to="loc_us-gaap_InventoryRawMaterials_ce959ed9-a78d-4fa4-b4d0-9fdbb5b4a32c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_d47a3e27-b411-4390-afab-ce33cf8c96a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_d40f2aef-c1cc-4efc-be47-40733798bf72" xlink:to="loc_us-gaap_InventoryWorkInProcess_d47a3e27-b411-4390-afab-ce33cf8c96a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_4d9700d2-1a10-4e67-ad78-910112c2250a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_02017d76-9bc6-478b-ac73-3b87377d2f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_4d9700d2-1a10-4e67-ad78-910112c2250a" xlink:to="loc_us-gaap_InventoryGross_02017d76-9bc6-478b-ac73-3b87377d2f7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_8165109b-c04d-4cfe-9cfd-a2844b921dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryValuationReserves"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_4d9700d2-1a10-4e67-ad78-910112c2250a" xlink:to="loc_us-gaap_InventoryValuationReserves_8165109b-c04d-4cfe-9cfd-a2844b921dd4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_351255ea-18ec-4937-a873-d176aaaa9b01" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_bcbb428e-e44b-41c7-87b7-da3a4951bb84" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_351255ea-18ec-4937-a873-d176aaaa9b01" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_bcbb428e-e44b-41c7-87b7-da3a4951bb84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5494d986-c989-4de2-9f0c-732d0db250ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_351255ea-18ec-4937-a873-d176aaaa9b01" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5494d986-c989-4de2-9f0c-732d0db250ab" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a41e9799-937f-4798-b8af-e0328fd3e2ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_e93f906b-3f65-4de1-ae4d-c868b51f938e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a41e9799-937f-4798-b8af-e0328fd3e2ab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_e93f906b-3f65-4de1-ae4d-c868b51f938e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_7a901ca2-40dd-4e75-8116-a8dd3d8f24e6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a41e9799-937f-4798-b8af-e0328fd3e2ab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_7a901ca2-40dd-4e75-8116-a8dd3d8f24e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_bdd2b37f-ad5d-4197-88bf-3e35dfb7c3ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a41e9799-937f-4798-b8af-e0328fd3e2ab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_bdd2b37f-ad5d-4197-88bf-3e35dfb7c3ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_f1d46080-cda7-471c-a01a-6020d5bef53a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a41e9799-937f-4798-b8af-e0328fd3e2ab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_f1d46080-cda7-471c-a01a-6020d5bef53a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_621dede0-9d1d-4c57-9cb4-636201c3bf79" xlink:href="pacb-20250930.xsd#pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a41e9799-937f-4798-b8af-e0328fd3e2ab" xlink:to="loc_pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_621dede0-9d1d-4c57-9cb4-636201c3bf79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_e638bba4-803a-409b-b1a1-6ea8c8d893b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a41e9799-937f-4798-b8af-e0328fd3e2ab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_e638bba4-803a-409b-b1a1-6ea8c8d893b5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_abe81c56-f599-4862-bdde-192c39f607c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium_03552ba3-ab71-4e22-b89c-b2f690d5732c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_abe81c56-f599-4862-bdde-192c39f607c2" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremium_03552ba3-ab71-4e22-b89c-b2f690d5732c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_979f99f4-5221-4849-b996-a9fe2ca12b47" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_abe81c56-f599-4862-bdde-192c39f607c2" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_979f99f4-5221-4849-b996-a9fe2ca12b47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_9453cb99-f324-48c0-b0ed-a9f04c21a6d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_abe81c56-f599-4862-bdde-192c39f607c2" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_9453cb99-f324-48c0-b0ed-a9f04c21a6d7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_45d69b4b-de75-46e0-a93b-2c3485e01f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_6eed2e85-e9c9-46a2-bfd1-c069da88951b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_45d69b4b-de75-46e0-a93b-2c3485e01f8d" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_6eed2e85-e9c9-46a2-bfd1-c069da88951b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_7315c01f-083b-4e50-b1af-049e8272bd66" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_45d69b4b-de75-46e0-a93b-2c3485e01f8d" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_7315c01f-083b-4e50-b1af-049e8272bd66" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>pacb-20250930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:541066b6-d2f9-469d-bf86-6042e3dcfaa4,g:e6194c68-cd08-4fb8-9cf2-74de760e8618-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" xlink:type="simple" xlink:href="pacb-20250930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2d574fd1-3a9e-4e9b-85cb-c29911e1d28a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a7c3a316-64a8-4877-a662-bd85e913522a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2d574fd1-3a9e-4e9b-85cb-c29911e1d28a" xlink:to="loc_us-gaap_StatementTable_a7c3a316-64a8-4877-a662-bd85e913522a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_87d8bb9e-56ad-498e-b8ef-f5323f6f6be0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_a7c3a316-64a8-4877-a662-bd85e913522a" xlink:to="loc_srt_ProductOrServiceAxis_87d8bb9e-56ad-498e-b8ef-f5323f6f6be0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_87d8bb9e-56ad-498e-b8ef-f5323f6f6be0_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_87d8bb9e-56ad-498e-b8ef-f5323f6f6be0" xlink:to="loc_srt_ProductsAndServicesDomain_87d8bb9e-56ad-498e-b8ef-f5323f6f6be0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_284692de-60ff-4c60-9915-c5c7335221f2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_87d8bb9e-56ad-498e-b8ef-f5323f6f6be0" xlink:to="loc_srt_ProductsAndServicesDomain_284692de-60ff-4c60-9915-c5c7335221f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_881302a8-df33-474c-bf0d-89667adb771b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_284692de-60ff-4c60-9915-c5c7335221f2" xlink:to="loc_us-gaap_ProductMember_881302a8-df33-474c-bf0d-89667adb771b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ServiceAndOtherMember_b7397858-dfc0-4cea-978c-889591d2e737" xlink:href="pacb-20250930.xsd#pacb_ServiceAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_284692de-60ff-4c60-9915-c5c7335221f2" xlink:to="loc_pacb_ServiceAndOtherMember_b7397858-dfc0-4cea-978c-889591d2e737" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_5c619c1d-2762-4a6f-a8c7-fa8e2ca85b79" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2d574fd1-3a9e-4e9b-85cb-c29911e1d28a" xlink:to="loc_us-gaap_RevenuesAbstract_5c619c1d-2762-4a6f-a8c7-fa8e2ca85b79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a69e1edb-4d3e-4b1f-b7fa-e33eea07b74a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_5c619c1d-2762-4a6f-a8c7-fa8e2ca85b79" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a69e1edb-4d3e-4b1f-b7fa-e33eea07b74a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenueAbstract_d16b0e49-4320-406c-bdd2-ac584a23c7a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2d574fd1-3a9e-4e9b-85cb-c29911e1d28a" xlink:to="loc_us-gaap_CostOfRevenueAbstract_d16b0e49-4320-406c-bdd2-ac584a23c7a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_f09649ab-656a-44d1-ba1b-f186a9b24003" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostOfRevenueAbstract_d16b0e49-4320-406c-bdd2-ac584a23c7a3" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_f09649ab-656a-44d1-ba1b-f186a9b24003" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_32055333-064c-4808-b762-6dddb5c31c64" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostOfRevenueAbstract_d16b0e49-4320-406c-bdd2-ac584a23c7a3" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_32055333-064c-4808-b762-6dddb5c31c64" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LossOnPurchaseCommitment_277f6e76-7989-4d7b-8950-64a3fda492bb" xlink:href="pacb-20250930.xsd#pacb_LossOnPurchaseCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostOfRevenueAbstract_d16b0e49-4320-406c-bdd2-ac584a23c7a3" xlink:to="loc_pacb_LossOnPurchaseCommitment_277f6e76-7989-4d7b-8950-64a3fda492bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_caf33222-6730-4520-b225-183021832561" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostOfRevenueAbstract_d16b0e49-4320-406c-bdd2-ac584a23c7a3" xlink:to="loc_us-gaap_CostOfRevenue_caf33222-6730-4520-b225-183021832561" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_35cfe4ed-9373-45ac-a028-964ffe1b9b53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2d574fd1-3a9e-4e9b-85cb-c29911e1d28a" xlink:to="loc_us-gaap_GrossProfit_35cfe4ed-9373-45ac-a028-964ffe1b9b53" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_423a0d19-3e07-4b31-9dc6-69d40526dd53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2d574fd1-3a9e-4e9b-85cb-c29911e1d28a" xlink:to="loc_us-gaap_OperatingExpensesAbstract_423a0d19-3e07-4b31-9dc6-69d40526dd53" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7bff8139-0d23-487b-852b-ba5191607e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_423a0d19-3e07-4b31-9dc6-69d40526dd53" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7bff8139-0d23-487b-852b-ba5191607e3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a0faf73d-9a3e-4743-aee7-f14a7fbe637f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_423a0d19-3e07-4b31-9dc6-69d40526dd53" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a0faf73d-9a3e-4743-aee7-f14a7fbe637f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_1c0b7862-892d-4289-bb48-6573d4c23cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_423a0d19-3e07-4b31-9dc6-69d40526dd53" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_1c0b7862-892d-4289-bb48-6573d4c23cb2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AmortizationOfAcquiredIntangibleAssets_d8c23d71-6e46-493c-8360-93c6e41d43ac" xlink:href="pacb-20250930.xsd#pacb_AmortizationOfAcquiredIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_423a0d19-3e07-4b31-9dc6-69d40526dd53" xlink:to="loc_pacb_AmortizationOfAcquiredIntangibleAssets_d8c23d71-6e46-493c-8360-93c6e41d43ac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e2a42824-060c-4e67-9c65-d70060ff4996" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_423a0d19-3e07-4b31-9dc6-69d40526dd53" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e2a42824-060c-4e67-9c65-d70060ff4996" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_ec07f6e4-e948-4b58-a8e9-c5f72453c73b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_423a0d19-3e07-4b31-9dc6-69d40526dd53" xlink:to="loc_us-gaap_OperatingExpenses_ec07f6e4-e948-4b58-a8e9-c5f72453c73b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f8847716-4f74-4528-afc2-e129663949be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2d574fd1-3a9e-4e9b-85cb-c29911e1d28a" xlink:to="loc_us-gaap_OperatingIncomeLoss_f8847716-4f74-4528-afc2-e129663949be" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_6f893d7a-902e-4e05-ba30-1b71429a3b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2d574fd1-3a9e-4e9b-85cb-c29911e1d28a" xlink:to="loc_us-gaap_InterestExpenseNonoperating_6f893d7a-902e-4e05-ba30-1b71429a3b5d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_069b5131-b21c-4b3d-bbad-0d23f701bb59" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2d574fd1-3a9e-4e9b-85cb-c29911e1d28a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_069b5131-b21c-4b3d-bbad-0d23f701bb59" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_607a5246-2d43-4cde-ae6c-478e2d6f1b99" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2d574fd1-3a9e-4e9b-85cb-c29911e1d28a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_607a5246-2d43-4cde-ae6c-478e2d6f1b99" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9f2afb96-37c7-44a4-82ab-9e85475187a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2d574fd1-3a9e-4e9b-85cb-c29911e1d28a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9f2afb96-37c7-44a4-82ab-9e85475187a1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_72543af4-ffa5-4f6a-9959-3e17e2705421" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2d574fd1-3a9e-4e9b-85cb-c29911e1d28a" xlink:to="loc_us-gaap_NetIncomeLoss_72543af4-ffa5-4f6a-9959-3e17e2705421" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_f2189ae4-d5f7-418c-a3cb-b61827f8c414" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2d574fd1-3a9e-4e9b-85cb-c29911e1d28a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_f2189ae4-d5f7-418c-a3cb-b61827f8c414" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_828f7715-e275-4896-899a-f58b2dfa3cb4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_f2189ae4-d5f7-418c-a3cb-b61827f8c414" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_828f7715-e275-4896-899a-f58b2dfa3cb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_0cfde0bf-ac3c-41b9-8a3c-12dcb9e31a76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2d574fd1-3a9e-4e9b-85cb-c29911e1d28a" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_0cfde0bf-ac3c-41b9-8a3c-12dcb9e31a76" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IncomeLossPerShareAbstract_e629510a-a2f0-471c-ac81-e50bc3921574" xlink:href="pacb-20250930.xsd#pacb_IncomeLossPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2d574fd1-3a9e-4e9b-85cb-c29911e1d28a" xlink:to="loc_pacb_IncomeLossPerShareAbstract_e629510a-a2f0-471c-ac81-e50bc3921574" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_f2cc5625-e6ad-4685-afa4-5df7289912ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_IncomeLossPerShareAbstract_e629510a-a2f0-471c-ac81-e50bc3921574" xlink:to="loc_us-gaap_EarningsPerShareBasic_f2cc5625-e6ad-4685-afa4-5df7289912ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_445aec72-7bc5-47b7-98f8-fa0db9594a01" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_IncomeLossPerShareAbstract_e629510a-a2f0-471c-ac81-e50bc3921574" xlink:to="loc_us-gaap_EarningsPerShareDiluted_445aec72-7bc5-47b7-98f8-fa0db9594a01" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_60dd388b-3e30-4e40-849f-6fad9d92520d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2d574fd1-3a9e-4e9b-85cb-c29911e1d28a" xlink:to="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_60dd388b-3e30-4e40-849f-6fad9d92520d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_255db604-e2ca-4d13-a6f1-4f5c553b09db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_60dd388b-3e30-4e40-849f-6fad9d92520d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_255db604-e2ca-4d13-a6f1-4f5c553b09db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3226c74a-8806-48bb-9072-9f1e5908761c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_60dd388b-3e30-4e40-849f-6fad9d92520d" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3226c74a-8806-48bb-9072-9f1e5908761c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" xlink:type="simple" xlink:href="pacb-20250930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d4a05c9a-337e-4f3c-b48f-dfc4f83d916b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3fd6a966-e22f-4e19-92a2-c48f99ab237d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_d4a05c9a-337e-4f3c-b48f-dfc4f83d916b" xlink:to="loc_us-gaap_StatementTable_3fd6a966-e22f-4e19-92a2-c48f99ab237d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0fcfe910-c602-4f59-9e84-671f88912d54" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3fd6a966-e22f-4e19-92a2-c48f99ab237d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0fcfe910-c602-4f59-9e84-671f88912d54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0fcfe910-c602-4f59-9e84-671f88912d54_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0fcfe910-c602-4f59-9e84-671f88912d54" xlink:to="loc_us-gaap_EquityComponentDomain_0fcfe910-c602-4f59-9e84-671f88912d54_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ed1fe101-4f09-4830-a3ac-329cb06f8c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0fcfe910-c602-4f59-9e84-671f88912d54" xlink:to="loc_us-gaap_EquityComponentDomain_ed1fe101-4f09-4830-a3ac-329cb06f8c1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b0e658a2-8a28-49b9-9e02-1031da6f6947" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ed1fe101-4f09-4830-a3ac-329cb06f8c1f" xlink:to="loc_us-gaap_CommonStockMember_b0e658a2-8a28-49b9-9e02-1031da6f6947" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_a0295b07-1200-4716-8325-96016d9702b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ed1fe101-4f09-4830-a3ac-329cb06f8c1f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_a0295b07-1200-4716-8325-96016d9702b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_321bc3b1-cd38-4219-b300-9c13d79df5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ed1fe101-4f09-4830-a3ac-329cb06f8c1f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_321bc3b1-cd38-4219-b300-9c13d79df5bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_78e516e1-c495-4c9b-89ee-8da08fb67aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ed1fe101-4f09-4830-a3ac-329cb06f8c1f" xlink:to="loc_us-gaap_RetainedEarningsMember_78e516e1-c495-4c9b-89ee-8da08fb67aa3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28c1c404-bc95-4f91-8df4-fa141374240d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d4a05c9a-337e-4f3c-b48f-dfc4f83d916b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28c1c404-bc95-4f91-8df4-fa141374240d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_288e02ad-7b66-4a6b-9de1-a3534542137b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28c1c404-bc95-4f91-8df4-fa141374240d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_288e02ad-7b66-4a6b-9de1-a3534542137b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_25ce6583-030d-42fc-be68-ef8eee048126" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28c1c404-bc95-4f91-8df4-fa141374240d" xlink:to="loc_us-gaap_StockholdersEquity_25ce6583-030d-42fc-be68-ef8eee048126" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_70edf339-77a8-4721-bdc5-cb819dc68d00" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28c1c404-bc95-4f91-8df4-fa141374240d" xlink:to="loc_us-gaap_NetIncomeLoss_70edf339-77a8-4721-bdc5-cb819dc68d00" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7d26b26c-b74a-4401-9bbc-65f7bc932953" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28c1c404-bc95-4f91-8df4-fa141374240d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7d26b26c-b74a-4401-9bbc-65f7bc932953" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0f25030a-ac4e-4171-b01c-f30c8c1dde08" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28c1c404-bc95-4f91-8df4-fa141374240d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0f25030a-ac4e-4171-b01c-f30c8c1dde08" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_481b0e21-db4c-4265-aee3-22719633b059" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28c1c404-bc95-4f91-8df4-fa141374240d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_481b0e21-db4c-4265-aee3-22719633b059" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0c8b927f-e839-4017-abbc-5929b423361c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28c1c404-bc95-4f91-8df4-fa141374240d" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0c8b927f-e839-4017-abbc-5929b423361c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c3456a89-70a5-4eea-ac9e-7b090dcefdca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b4b89e6a-7f8f-4602-b8a3-5894018325a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_40161980-3dd3-4a5b-98cd-14bf80bed7da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_59bdf39c-9ace-468e-9d63-b5a10ca13bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_40161980-3dd3-4a5b-98cd-14bf80bed7da" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_59bdf39c-9ace-468e-9d63-b5a10ca13bd1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_93a03cf5-a636-4e0e-89b4-a00d353ca14b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_59bdf39c-9ace-468e-9d63-b5a10ca13bd1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_93a03cf5-a636-4e0e-89b4-a00d353ca14b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_93a03cf5-a636-4e0e-89b4-a00d353ca14b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_93a03cf5-a636-4e0e-89b4-a00d353ca14b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_93a03cf5-a636-4e0e-89b4-a00d353ca14b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2bcfcbb8-9b8a-47ca-8069-eef2cddc9a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_93a03cf5-a636-4e0e-89b4-a00d353ca14b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2bcfcbb8-9b8a-47ca-8069-eef2cddc9a1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_e7dd1f77-5591-41f0-a065-7748b99cc97a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2bcfcbb8-9b8a-47ca-8069-eef2cddc9a1f" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_e7dd1f77-5591-41f0-a065-7748b99cc97a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_98982933-b86f-4144-85c8-fae662a15040" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2bcfcbb8-9b8a-47ca-8069-eef2cddc9a1f" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_98982933-b86f-4144-85c8-fae662a15040" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_997718ec-cf9d-4677-8f8f-cbcad8f1e0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2bcfcbb8-9b8a-47ca-8069-eef2cddc9a1f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_997718ec-cf9d-4677-8f8f-cbcad8f1e0f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_f5453f41-dff2-48b1-a85d-d7e42bf4b256" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_59bdf39c-9ace-468e-9d63-b5a10ca13bd1" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_f5453f41-dff2-48b1-a85d-d7e42bf4b256" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f5453f41-dff2-48b1-a85d-d7e42bf4b256_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_f5453f41-dff2-48b1-a85d-d7e42bf4b256" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_f5453f41-dff2-48b1-a85d-d7e42bf4b256_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_39fe37a0-677f-4e60-a7de-52c89d71d253" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_f5453f41-dff2-48b1-a85d-d7e42bf4b256" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_39fe37a0-677f-4e60-a7de-52c89d71d253" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_2b3242a4-a812-4c66-a679-c73499b820da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_39fe37a0-677f-4e60-a7de-52c89d71d253" xlink:to="loc_us-gaap_InvestmentsMember_2b3242a4-a812-4c66-a679-c73499b820da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_143d1d44-e56a-4f4b-b437-75502b602439" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsMember_2b3242a4-a812-4c66-a679-c73499b820da" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_143d1d44-e56a-4f4b-b437-75502b602439" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_33c3343b-b305-410b-98d4-0bb0792b5257" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsMember_2b3242a4-a812-4c66-a679-c73499b820da" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_33c3343b-b305-410b-98d4-0bb0792b5257" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1ff84adc-7d10-4688-9a4e-f468569ed474" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_59bdf39c-9ace-468e-9d63-b5a10ca13bd1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1ff84adc-7d10-4688-9a4e-f468569ed474" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1ff84adc-7d10-4688-9a4e-f468569ed474_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1ff84adc-7d10-4688-9a4e-f468569ed474" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1ff84adc-7d10-4688-9a4e-f468569ed474_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cb805123-1c28-489a-a77e-87b79574f38c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1ff84adc-7d10-4688-9a4e-f468569ed474" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cb805123-1c28-489a-a77e-87b79574f38c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_120ca4a9-ea91-4bd9-9c50-8912126e500a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cb805123-1c28-489a-a77e-87b79574f38c" xlink:to="loc_us-gaap_InvestmentsMember_120ca4a9-ea91-4bd9-9c50-8912126e500a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_494e2e8f-6c86-4705-b3f4-008b0558034d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_40161980-3dd3-4a5b-98cd-14bf80bed7da" xlink:to="loc_us-gaap_AssetsAbstract_494e2e8f-6c86-4705-b3f4-008b0558034d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7a15467f-bb3d-42b2-b4aa-d10e4a46b34c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_494e2e8f-6c86-4705-b3f4-008b0558034d" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7a15467f-bb3d-42b2-b4aa-d10e4a46b34c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_e7be79bc-fc7f-4581-81e7-0657731f1ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_494e2e8f-6c86-4705-b3f4-008b0558034d" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_e7be79bc-fc7f-4581-81e7-0657731f1ffb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ShortTermRestrictedCashFairValueDisclosure_a209bc0e-45fc-44d1-bfaf-e59777a07559" xlink:href="pacb-20250930.xsd#pacb_ShortTermRestrictedCashFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_494e2e8f-6c86-4705-b3f4-008b0558034d" xlink:to="loc_pacb_ShortTermRestrictedCashFairValueDisclosure_a209bc0e-45fc-44d1-bfaf-e59777a07559" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LongTermRestrictedCashFairValueDisclosure_3c587056-5268-42d7-9485-e71b24f4336d" xlink:href="pacb-20250930.xsd#pacb_LongTermRestrictedCashFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_494e2e8f-6c86-4705-b3f4-008b0558034d" xlink:to="loc_pacb_LongTermRestrictedCashFairValueDisclosure_3c587056-5268-42d7-9485-e71b24f4336d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_dadf479c-8b29-4c8d-b675-4b4d085ce51b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_494e2e8f-6c86-4705-b3f4-008b0558034d" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_dadf479c-8b29-4c8d-b675-4b4d085ce51b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_b8e58576-d80a-4d48-a662-de05bd8bf3f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_40161980-3dd3-4a5b-98cd-14bf80bed7da" xlink:to="loc_us-gaap_LiabilitiesAbstract_b8e58576-d80a-4d48-a662-de05bd8bf3f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2ae457ed-cb4a-4859-be00-e76f18334736" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_b8e58576-d80a-4d48-a662-de05bd8bf3f6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2ae457ed-cb4a-4859-be00-e76f18334736" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_b5d644d1-a52d-4ff2-9ea0-5d096565f69d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_b8e58576-d80a-4d48-a662-de05bd8bf3f6" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_b5d644d1-a52d-4ff2-9ea0-5d096565f69d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSContingentConsiderationDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#FINANCIALINSTRUMENTSContingentConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_8cd08cac-fbfd-4cfa-9c41-959cb8e09a12" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e3863919-6125-4115-8b13-88e87b5f42f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8cd08cac-fbfd-4cfa-9c41-959cb8e09a12" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e3863919-6125-4115-8b13-88e87b5f42f4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_780e2d9a-88f4-4260-8a63-c0e871907644" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e3863919-6125-4115-8b13-88e87b5f42f4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_780e2d9a-88f4-4260-8a63-c0e871907644" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_780e2d9a-88f4-4260-8a63-c0e871907644_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_780e2d9a-88f4-4260-8a63-c0e871907644" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_780e2d9a-88f4-4260-8a63-c0e871907644_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9de23ae6-1aff-42ba-944d-768a943aa296" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_780e2d9a-88f4-4260-8a63-c0e871907644" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9de23ae6-1aff-42ba-944d-768a943aa296" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AptonMember_2870effb-24fc-4512-a59f-ea9f0fa0fe6c" xlink:href="pacb-20250930.xsd#pacb_AptonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9de23ae6-1aff-42ba-944d-768a943aa296" xlink:to="loc_pacb_AptonMember_2870effb-24fc-4512-a59f-ea9f0fa0fe6c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_a3c1a93b-7ee2-45fa-80af-d85670e3fb7e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e3863919-6125-4115-8b13-88e87b5f42f4" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_a3c1a93b-7ee2-45fa-80af-d85670e3fb7e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_a3c1a93b-7ee2-45fa-80af-d85670e3fb7e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_a3c1a93b-7ee2-45fa-80af-d85670e3fb7e" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_a3c1a93b-7ee2-45fa-80af-d85670e3fb7e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_9ea8ac30-5f05-4480-8e9a-0a5d99c023e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_a3c1a93b-7ee2-45fa-80af-d85670e3fb7e" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_9ea8ac30-5f05-4480-8e9a-0a5d99c023e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AchievementOfMilestoneMember_28617ea3-054b-4b03-a24d-3695c81a31fd" xlink:href="pacb-20250930.xsd#pacb_AchievementOfMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_9ea8ac30-5f05-4480-8e9a-0a5d99c023e8" xlink:to="loc_pacb_AchievementOfMilestoneMember_28617ea3-054b-4b03-a24d-3695c81a31fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_eef19677-fb86-4523-bd9e-c7a652b68875" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e3863919-6125-4115-8b13-88e87b5f42f4" xlink:to="loc_srt_RangeAxis_eef19677-fb86-4523-bd9e-c7a652b68875" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_eef19677-fb86-4523-bd9e-c7a652b68875_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_eef19677-fb86-4523-bd9e-c7a652b68875" xlink:to="loc_srt_RangeMember_eef19677-fb86-4523-bd9e-c7a652b68875_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3c928e26-1f82-4d6f-8745-ac53636b2500" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_eef19677-fb86-4523-bd9e-c7a652b68875" xlink:to="loc_srt_RangeMember_3c928e26-1f82-4d6f-8745-ac53636b2500" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1ea3e8e7-bb8c-4deb-a236-c04f0c781396" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3c928e26-1f82-4d6f-8745-ac53636b2500" xlink:to="loc_srt_MaximumMember_1ea3e8e7-bb8c-4deb-a236-c04f0c781396" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d1d41e6e-3b24-4b27-ae08-3afbadc4353b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8cd08cac-fbfd-4cfa-9c41-959cb8e09a12" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d1d41e6e-3b24-4b27-ae08-3afbadc4353b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone_19f90be2-0e07-4065-8d0f-ebaf06a210c4" xlink:href="pacb-20250930.xsd#pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8cd08cac-fbfd-4cfa-9c41-959cb8e09a12" xlink:to="loc_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone_19f90be2-0e07-4065-8d0f-ebaf06a210c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod_7658e5d0-c21a-41ea-a179-f348ca563ee2" xlink:href="pacb-20250930.xsd#pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8cd08cac-fbfd-4cfa-9c41-959cb8e09a12" xlink:to="loc_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod_7658e5d0-c21a-41ea-a179-f348ca563ee2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition_80a77e7a-5b13-4340-b35a-bb4541f062fc" xlink:href="pacb-20250930.xsd#pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8cd08cac-fbfd-4cfa-9c41-959cb8e09a12" xlink:to="loc_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition_80a77e7a-5b13-4340-b35a-bb4541f062fc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger_5e6fd3d2-14ab-433a-b9b5-8abd2b16b2af" xlink:href="pacb-20250930.xsd#pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8cd08cac-fbfd-4cfa-9c41-959cb8e09a12" xlink:to="loc_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger_5e6fd3d2-14ab-433a-b9b5-8abd2b16b2af" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4a75f311-1c08-408c-9213-20f1c9edef97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8242e9d8-9a4d-4680-9a42-69659aa7ff42" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4a75f311-1c08-408c-9213-20f1c9edef97" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8242e9d8-9a4d-4680-9a42-69659aa7ff42" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_64f3b68d-f131-49f5-8740-623531f21a83" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8242e9d8-9a4d-4680-9a42-69659aa7ff42" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_64f3b68d-f131-49f5-8740-623531f21a83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_64f3b68d-f131-49f5-8740-623531f21a83_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_64f3b68d-f131-49f5-8740-623531f21a83" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_64f3b68d-f131-49f5-8740-623531f21a83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_785f528e-741a-48a5-a290-b1436891187a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_64f3b68d-f131-49f5-8740-623531f21a83" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_785f528e-741a-48a5-a290-b1436891187a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_b98beadb-93ac-4d99-9ecc-c432a5e57e35" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_785f528e-741a-48a5-a290-b1436891187a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_b98beadb-93ac-4d99-9ecc-c432a5e57e35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_21f2c5a1-7c1a-44eb-8cfa-e1588cfa9696" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4a75f311-1c08-408c-9213-20f1c9edef97" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_21f2c5a1-7c1a-44eb-8cfa-e1588cfa9696" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ab8748c6-d5cc-440c-aec3-46614832d427" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_21f2c5a1-7c1a-44eb-8cfa-e1588cfa9696" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ab8748c6-d5cc-440c-aec3-46614832d427" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e39ccf20-2327-455c-906d-674f4bf8a0ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_21f2c5a1-7c1a-44eb-8cfa-e1588cfa9696" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e39ccf20-2327-455c-906d-674f4bf8a0ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ce6ca9bd-538c-482a-97dc-772f57a33993" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_37e94de4-491b-4efd-9531-328e2934c4d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_78dfc963-0060-4edc-a50e-9174b4daa7de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_37e94de4-491b-4efd-9531-328e2934c4d0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_78dfc963-0060-4edc-a50e-9174b4daa7de" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d5911a34-80ff-46e6-8b54-d4e55bb32024" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_78dfc963-0060-4edc-a50e-9174b4daa7de" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d5911a34-80ff-46e6-8b54-d4e55bb32024" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5911a34-80ff-46e6-8b54-d4e55bb32024_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d5911a34-80ff-46e6-8b54-d4e55bb32024" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5911a34-80ff-46e6-8b54-d4e55bb32024_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9e98c934-3f3a-4b3b-bf7d-c8217f2ee2c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d5911a34-80ff-46e6-8b54-d4e55bb32024" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9e98c934-3f3a-4b3b-bf7d-c8217f2ee2c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_84122f6f-f36d-495b-be37-979b2ee62ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9e98c934-3f3a-4b3b-bf7d-c8217f2ee2c6" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_84122f6f-f36d-495b-be37-979b2ee62ec8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_851717c5-2202-4385-95a4-63bfb8f867e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9e98c934-3f3a-4b3b-bf7d-c8217f2ee2c6" xlink:to="loc_us-gaap_InvestmentsMember_851717c5-2202-4385-95a4-63bfb8f867e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_992cc510-0049-4020-8b9c-87acd8d0f3d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsMember_851717c5-2202-4385-95a4-63bfb8f867e7" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_992cc510-0049-4020-8b9c-87acd8d0f3d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_4275d565-2125-4d22-88d2-98fd11815ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsMember_851717c5-2202-4385-95a4-63bfb8f867e7" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_4275d565-2125-4d22-88d2-98fd11815ca2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_f6eba34f-b31f-49d7-85fe-fdb35eb1d378" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_37e94de4-491b-4efd-9531-328e2934c4d0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_f6eba34f-b31f-49d7-85fe-fdb35eb1d378" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f895e915-da09-4401-b07e-49166f0a85f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_37e94de4-491b-4efd-9531-328e2934c4d0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f895e915-da09-4401-b07e-49166f0a85f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_bfa8a8eb-5104-4acd-858b-2877045444e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_37e94de4-491b-4efd-9531-328e2934c4d0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_bfa8a8eb-5104-4acd-858b-2877045444e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_0b11a07d-dd1e-4bbb-aefc-b2a22302e0f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_37e94de4-491b-4efd-9531-328e2934c4d0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_0b11a07d-dd1e-4bbb-aefc-b2a22302e0f5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_ac4611a5-7ca2-428a-9ce2-304b38ee7432" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_37e94de4-491b-4efd-9531-328e2934c4d0" xlink:to="loc_us-gaap_RestrictedCashCurrent_ac4611a5-7ca2-428a-9ce2-304b38ee7432" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_aed89b77-2a9d-4424-82fe-b620d0c6ba1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_37e94de4-491b-4efd-9531-328e2934c4d0" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_aed89b77-2a9d-4424-82fe-b620d0c6ba1f" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#BALANCESHEETCOMPONENTSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:href="pacb-20250930.xsd#pacb_ScheduleOfBalanceSheetComponentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ScheduleOfBalanceSheetComponentsTable_fcaddc24-d01b-433c-8971-e684c60611b4" xlink:href="pacb-20250930.xsd#pacb_ScheduleOfBalanceSheetComponentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_pacb_ScheduleOfBalanceSheetComponentsTable_fcaddc24-d01b-433c-8971-e684c60611b4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a4a1e95c-2096-4c29-b5d6-12c776eba790" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_fcaddc24-d01b-433c-8971-e684c60611b4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a4a1e95c-2096-4c29-b5d6-12c776eba790" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a4a1e95c-2096-4c29-b5d6-12c776eba790_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a4a1e95c-2096-4c29-b5d6-12c776eba790" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a4a1e95c-2096-4c29-b5d6-12c776eba790_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_97f73e58-ebe3-4b86-8215-50ae1f721ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a4a1e95c-2096-4c29-b5d6-12c776eba790" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_97f73e58-ebe3-4b86-8215-50ae1f721ae2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AptonMember_b57c35f3-1ca2-4444-94ef-1ceab3062837" xlink:href="pacb-20250930.xsd#pacb_AptonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_97f73e58-ebe3-4b86-8215-50ae1f721ae2" xlink:to="loc_pacb_AptonMember_b57c35f3-1ca2-4444-94ef-1ceab3062837" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c31ade45-340a-4501-a5d0-ace97b50f0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_fcaddc24-d01b-433c-8971-e684c60611b4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c31ade45-340a-4501-a5d0-ace97b50f0aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c31ade45-340a-4501-a5d0-ace97b50f0aa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c31ade45-340a-4501-a5d0-ace97b50f0aa" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c31ade45-340a-4501-a5d0-ace97b50f0aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_81baaa80-9006-4b1c-b17a-65ce29a250fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c31ade45-340a-4501-a5d0-ace97b50f0aa" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_81baaa80-9006-4b1c-b17a-65ce29a250fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_dbece446-f21f-432b-a4ad-a28ca39e336a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_81baaa80-9006-4b1c-b17a-65ce29a250fe" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_dbece446-f21f-432b-a4ad-a28ca39e336a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_a68bc764-60ce-499c-832d-2987d1949765" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_81baaa80-9006-4b1c-b17a-65ce29a250fe" xlink:to="loc_us-gaap_LicenseMember_a68bc764-60ce-499c-832d-2987d1949765" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fd5d1f08-5d9b-4301-b0a0-1687602cb42a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_fcaddc24-d01b-433c-8971-e684c60611b4" xlink:to="loc_srt_ProductOrServiceAxis_fd5d1f08-5d9b-4301-b0a0-1687602cb42a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fd5d1f08-5d9b-4301-b0a0-1687602cb42a_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_fd5d1f08-5d9b-4301-b0a0-1687602cb42a" xlink:to="loc_srt_ProductsAndServicesDomain_fd5d1f08-5d9b-4301-b0a0-1687602cb42a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_11dbd28a-e660-458b-9b1f-1fd9816fd990" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_fd5d1f08-5d9b-4301-b0a0-1687602cb42a" xlink:to="loc_srt_ProductsAndServicesDomain_11dbd28a-e660-458b-9b1f-1fd9816fd990" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_53e70445-16aa-476b-8a8f-e0e56275fd4c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_11dbd28a-e660-458b-9b1f-1fd9816fd990" xlink:to="loc_us-gaap_ServiceMember_53e70445-16aa-476b-8a8f-e0e56275fd4c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_009e4e72-b368-46f3-b024-494db28eb700" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_fcaddc24-d01b-433c-8971-e684c60611b4" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_009e4e72-b368-46f3-b024-494db28eb700" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_ff698efc-da2f-48be-b5f5-61e0f704fe6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_fcaddc24-d01b-433c-8971-e684c60611b4" xlink:to="loc_us-gaap_RestructuringPlanAxis_ff698efc-da2f-48be-b5f5-61e0f704fe6a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_ff698efc-da2f-48be-b5f5-61e0f704fe6a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_ff698efc-da2f-48be-b5f5-61e0f704fe6a" xlink:to="loc_us-gaap_RestructuringPlanDomain_ff698efc-da2f-48be-b5f5-61e0f704fe6a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_5dcad610-89ee-4e9d-8882-da256480df45" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_ff698efc-da2f-48be-b5f5-61e0f704fe6a" xlink:to="loc_us-gaap_RestructuringPlanDomain_5dcad610-89ee-4e9d-8882-da256480df45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2025RestructuringMember_f7c1d900-832b-4161-b734-d78d3dab5a41" xlink:href="pacb-20250930.xsd#pacb_A2025RestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_5dcad610-89ee-4e9d-8882-da256480df45" xlink:to="loc_pacb_A2025RestructuringMember_f7c1d900-832b-4161-b734-d78d3dab5a41" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_a2a85451-a898-40e8-9801-4249b261eead" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_fcaddc24-d01b-433c-8971-e684c60611b4" xlink:to="loc_us-gaap_AssetAcquisitionAxis_a2a85451-a898-40e8-9801-4249b261eead" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_a2a85451-a898-40e8-9801-4249b261eead_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_a2a85451-a898-40e8-9801-4249b261eead" xlink:to="loc_us-gaap_AssetAcquisitionDomain_a2a85451-a898-40e8-9801-4249b261eead_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_bc76b081-cbe7-4390-8a33-0624023ea292" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_a2a85451-a898-40e8-9801-4249b261eead" xlink:to="loc_us-gaap_AssetAcquisitionDomain_bc76b081-cbe7-4390-8a33-0624023ea292" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DevelopedTechnologyAndIntellectualPropertyMember_f156ea1a-21fd-42f2-ab15-35b38892d332" xlink:href="pacb-20250930.xsd#pacb_DevelopedTechnologyAndIntellectualPropertyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_bc76b081-cbe7-4390-8a33-0624023ea292" xlink:to="loc_pacb_DevelopedTechnologyAndIntellectualPropertyMember_f156ea1a-21fd-42f2-ab15-35b38892d332" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_6d2749c1-cc93-4a16-a8b8-91fc664a31dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_6d2749c1-cc93-4a16-a8b8-91fc664a31dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_2e0a5b4f-51ab-4ca0-94f8-a410231829f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_2e0a5b4f-51ab-4ca0-94f8-a410231829f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_5e08144f-0fde-450f-8164-aa90ed9e0ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_5e08144f-0fde-450f-8164-aa90ed9e0ab9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_ff7a0a89-7042-4556-ac2e-31a85f0a942f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_ff7a0a89-7042-4556-ac2e-31a85f0a942f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate_4e6e333e-09e9-485d-96d1-2a20606af5e2" xlink:href="pacb-20250930.xsd#pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate_4e6e333e-09e9-485d-96d1-2a20606af5e2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm_8ecb844b-eda4-46c0-b453-286dd0a340fd" xlink:href="pacb-20250930.xsd#pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm_8ecb844b-eda4-46c0-b453-286dd0a340fd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate_fffc2809-0271-4db7-b0f4-e4bbd6e4040a" xlink:href="pacb-20250930.xsd#pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate_fffc2809-0271-4db7-b0f4-e4bbd6e4040a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate_bb1dcd8d-4bb7-4b74-95b3-a38b07e743c9" xlink:href="pacb-20250930.xsd#pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate_bb1dcd8d-4bb7-4b74-95b3-a38b07e743c9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm_47f9d9b0-8739-4f52-a743-0cccfcd89424" xlink:href="pacb-20250930.xsd#pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm_47f9d9b0-8739-4f52-a743-0cccfcd89424" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AdditionalIntangibleAssetImpairmentChangeInTerm_3d4decd2-a368-4e40-8f1d-0059bc030664" xlink:href="pacb-20250930.xsd#pacb_AdditionalIntangibleAssetImpairmentChangeInTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_pacb_AdditionalIntangibleAssetImpairmentChangeInTerm_3d4decd2-a368-4e40-8f1d-0059bc030664" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_RestructuringAndRelatedCostAcceleratedAmortization_ea41b61c-149b-43dd-8eea-97b9bef5692c" xlink:href="pacb-20250930.xsd#pacb_RestructuringAndRelatedCostAcceleratedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_pacb_RestructuringAndRelatedCostAcceleratedAmortization_ea41b61c-149b-43dd-8eea-97b9bef5692c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ChangeInEarningsPerShare_795e8969-8e92-4d8b-80ab-995c93d62c66" xlink:href="pacb-20250930.xsd#pacb_ChangeInEarningsPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_pacb_ChangeInEarningsPerShare_795e8969-8e92-4d8b-80ab-995c93d62c66" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_16a8cdb3-dae7-4e77-b101-01804f21bc17" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_16a8cdb3-dae7-4e77-b101-01804f21bc17" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1a8d18b8-b41c-49c2-a6b7-6882710d86cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1a8d18b8-b41c-49c2-a6b7-6882710d86cc" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent_da06bfcd-eea9-4c9c-b5b4-d47489ab3fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent_da06bfcd-eea9-4c9c-b5b4-d47489ab3fb8" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_2ca73438-4adc-457d-9c28-f6dbaf3b580e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_us-gaap_ContractWithCustomerLiability_2ca73438-4adc-457d-9c28-f6dbaf3b580e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b796747c-4656-4d8f-ae3c-785ed49b137d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b796747c-4656-4d8f-ae3c-785ed49b137d" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_d05ec7c9-bb4d-4dc0-a193-d7fae14861eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_d05ec7c9-bb4d-4dc0-a193-d7fae14861eb" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod_7e5ea427-c5ce-4b7e-b6e5-274a26476993" xlink:href="pacb-20250930.xsd#pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod_7e5ea427-c5ce-4b7e-b6e5-274a26476993" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_f6274bbc-eb15-4914-ad07-cbca4f97279b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_f6274bbc-eb15-4914-ad07-cbca4f97279b" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_07851892-827e-4d30-bc15-500eaf4f0c17" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_07851892-827e-4d30-bc15-500eaf4f0c17" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_30bff09a-c0f1-424a-a4ba-7f94365dbe24" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_30bff09a-c0f1-424a-a4ba-7f94365dbe24" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_d2fb79bc-0eaa-4699-987d-9796b8fbfb8b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_d2fb79bc-0eaa-4699-987d-9796b8fbfb8b" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StandardProductWarrantyPeriod_f21ae456-69a1-4607-a839-1c05625c3f58" xlink:href="pacb-20250930.xsd#pacb_StandardProductWarrantyPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_pacb_StandardProductWarrantyPeriod_f21ae456-69a1-4607-a839-1c05625c3f58" xlink:type="arc" order="23"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails_1" xlink:type="simple" xlink:href="pacb-20250930.xsd#BALANCESHEETCOMPONENTSNarrativeDetails_1"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:href="pacb-20250930.xsd#pacb_ScheduleOfBalanceSheetComponentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ScheduleOfBalanceSheetComponentsTable_fcaddc24-d01b-433c-8971-e684c60611b4" xlink:href="pacb-20250930.xsd#pacb_ScheduleOfBalanceSheetComponentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_pacb_ScheduleOfBalanceSheetComponentsTable_fcaddc24-d01b-433c-8971-e684c60611b4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a4a1e95c-2096-4c29-b5d6-12c776eba790" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_fcaddc24-d01b-433c-8971-e684c60611b4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a4a1e95c-2096-4c29-b5d6-12c776eba790" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a4a1e95c-2096-4c29-b5d6-12c776eba790_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a4a1e95c-2096-4c29-b5d6-12c776eba790" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a4a1e95c-2096-4c29-b5d6-12c776eba790_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_97f73e58-ebe3-4b86-8215-50ae1f721ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a4a1e95c-2096-4c29-b5d6-12c776eba790" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_97f73e58-ebe3-4b86-8215-50ae1f721ae2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AptonMember_b57c35f3-1ca2-4444-94ef-1ceab3062837" xlink:href="pacb-20250930.xsd#pacb_AptonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_97f73e58-ebe3-4b86-8215-50ae1f721ae2" xlink:to="loc_pacb_AptonMember_b57c35f3-1ca2-4444-94ef-1ceab3062837" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c31ade45-340a-4501-a5d0-ace97b50f0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_fcaddc24-d01b-433c-8971-e684c60611b4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c31ade45-340a-4501-a5d0-ace97b50f0aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c31ade45-340a-4501-a5d0-ace97b50f0aa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c31ade45-340a-4501-a5d0-ace97b50f0aa" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c31ade45-340a-4501-a5d0-ace97b50f0aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_81baaa80-9006-4b1c-b17a-65ce29a250fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c31ade45-340a-4501-a5d0-ace97b50f0aa" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_81baaa80-9006-4b1c-b17a-65ce29a250fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_dbece446-f21f-432b-a4ad-a28ca39e336a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_81baaa80-9006-4b1c-b17a-65ce29a250fe" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_dbece446-f21f-432b-a4ad-a28ca39e336a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_a68bc764-60ce-499c-832d-2987d1949765" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_81baaa80-9006-4b1c-b17a-65ce29a250fe" xlink:to="loc_us-gaap_LicenseMember_a68bc764-60ce-499c-832d-2987d1949765" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fd5d1f08-5d9b-4301-b0a0-1687602cb42a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_fcaddc24-d01b-433c-8971-e684c60611b4" xlink:to="loc_srt_ProductOrServiceAxis_fd5d1f08-5d9b-4301-b0a0-1687602cb42a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fd5d1f08-5d9b-4301-b0a0-1687602cb42a_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_fd5d1f08-5d9b-4301-b0a0-1687602cb42a" xlink:to="loc_srt_ProductsAndServicesDomain_fd5d1f08-5d9b-4301-b0a0-1687602cb42a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_11dbd28a-e660-458b-9b1f-1fd9816fd990" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_fd5d1f08-5d9b-4301-b0a0-1687602cb42a" xlink:to="loc_srt_ProductsAndServicesDomain_11dbd28a-e660-458b-9b1f-1fd9816fd990" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_53e70445-16aa-476b-8a8f-e0e56275fd4c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_11dbd28a-e660-458b-9b1f-1fd9816fd990" xlink:to="loc_us-gaap_ServiceMember_53e70445-16aa-476b-8a8f-e0e56275fd4c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_ff698efc-da2f-48be-b5f5-61e0f704fe6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_fcaddc24-d01b-433c-8971-e684c60611b4" xlink:to="loc_us-gaap_RestructuringPlanAxis_ff698efc-da2f-48be-b5f5-61e0f704fe6a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_ff698efc-da2f-48be-b5f5-61e0f704fe6a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_ff698efc-da2f-48be-b5f5-61e0f704fe6a" xlink:to="loc_us-gaap_RestructuringPlanDomain_ff698efc-da2f-48be-b5f5-61e0f704fe6a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_5dcad610-89ee-4e9d-8882-da256480df45" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_ff698efc-da2f-48be-b5f5-61e0f704fe6a" xlink:to="loc_us-gaap_RestructuringPlanDomain_5dcad610-89ee-4e9d-8882-da256480df45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2025RestructuringMember_f7c1d900-832b-4161-b734-d78d3dab5a41" xlink:href="pacb-20250930.xsd#pacb_A2025RestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_5dcad610-89ee-4e9d-8882-da256480df45" xlink:to="loc_pacb_A2025RestructuringMember_f7c1d900-832b-4161-b734-d78d3dab5a41" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_a2a85451-a898-40e8-9801-4249b261eead" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_fcaddc24-d01b-433c-8971-e684c60611b4" xlink:to="loc_us-gaap_AssetAcquisitionAxis_a2a85451-a898-40e8-9801-4249b261eead" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_a2a85451-a898-40e8-9801-4249b261eead_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_a2a85451-a898-40e8-9801-4249b261eead" xlink:to="loc_us-gaap_AssetAcquisitionDomain_a2a85451-a898-40e8-9801-4249b261eead_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_bc76b081-cbe7-4390-8a33-0624023ea292" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_a2a85451-a898-40e8-9801-4249b261eead" xlink:to="loc_us-gaap_AssetAcquisitionDomain_bc76b081-cbe7-4390-8a33-0624023ea292" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DevelopedTechnologyAndIntellectualPropertyMember_f156ea1a-21fd-42f2-ab15-35b38892d332" xlink:href="pacb-20250930.xsd#pacb_DevelopedTechnologyAndIntellectualPropertyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_bc76b081-cbe7-4390-8a33-0624023ea292" xlink:to="loc_pacb_DevelopedTechnologyAndIntellectualPropertyMember_f156ea1a-21fd-42f2-ab15-35b38892d332" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_6d2749c1-cc93-4a16-a8b8-91fc664a31dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_6d2749c1-cc93-4a16-a8b8-91fc664a31dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_2e0a5b4f-51ab-4ca0-94f8-a410231829f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_2e0a5b4f-51ab-4ca0-94f8-a410231829f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_5e08144f-0fde-450f-8164-aa90ed9e0ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_5e08144f-0fde-450f-8164-aa90ed9e0ab9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_ff7a0a89-7042-4556-ac2e-31a85f0a942f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_ff7a0a89-7042-4556-ac2e-31a85f0a942f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate_4e6e333e-09e9-485d-96d1-2a20606af5e2" xlink:href="pacb-20250930.xsd#pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate_4e6e333e-09e9-485d-96d1-2a20606af5e2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm_8ecb844b-eda4-46c0-b453-286dd0a340fd" xlink:href="pacb-20250930.xsd#pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm_8ecb844b-eda4-46c0-b453-286dd0a340fd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate_fffc2809-0271-4db7-b0f4-e4bbd6e4040a" xlink:href="pacb-20250930.xsd#pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate_fffc2809-0271-4db7-b0f4-e4bbd6e4040a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate_bb1dcd8d-4bb7-4b74-95b3-a38b07e743c9" xlink:href="pacb-20250930.xsd#pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate_bb1dcd8d-4bb7-4b74-95b3-a38b07e743c9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm_47f9d9b0-8739-4f52-a743-0cccfcd89424" xlink:href="pacb-20250930.xsd#pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm_47f9d9b0-8739-4f52-a743-0cccfcd89424" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AdditionalIntangibleAssetImpairmentChangeInTerm_3d4decd2-a368-4e40-8f1d-0059bc030664" xlink:href="pacb-20250930.xsd#pacb_AdditionalIntangibleAssetImpairmentChangeInTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_pacb_AdditionalIntangibleAssetImpairmentChangeInTerm_3d4decd2-a368-4e40-8f1d-0059bc030664" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_RestructuringAndRelatedCostAcceleratedAmortization_ea41b61c-149b-43dd-8eea-97b9bef5692c" xlink:href="pacb-20250930.xsd#pacb_RestructuringAndRelatedCostAcceleratedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_pacb_RestructuringAndRelatedCostAcceleratedAmortization_ea41b61c-149b-43dd-8eea-97b9bef5692c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ChangeInEarningsPerShare_795e8969-8e92-4d8b-80ab-995c93d62c66" xlink:href="pacb-20250930.xsd#pacb_ChangeInEarningsPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_pacb_ChangeInEarningsPerShare_795e8969-8e92-4d8b-80ab-995c93d62c66" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_16a8cdb3-dae7-4e77-b101-01804f21bc17" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_16a8cdb3-dae7-4e77-b101-01804f21bc17" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1a8d18b8-b41c-49c2-a6b7-6882710d86cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1a8d18b8-b41c-49c2-a6b7-6882710d86cc" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent_da06bfcd-eea9-4c9c-b5b4-d47489ab3fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent_da06bfcd-eea9-4c9c-b5b4-d47489ab3fb8" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_2ca73438-4adc-457d-9c28-f6dbaf3b580e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_us-gaap_ContractWithCustomerLiability_2ca73438-4adc-457d-9c28-f6dbaf3b580e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b796747c-4656-4d8f-ae3c-785ed49b137d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b796747c-4656-4d8f-ae3c-785ed49b137d" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_d05ec7c9-bb4d-4dc0-a193-d7fae14861eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_d05ec7c9-bb4d-4dc0-a193-d7fae14861eb" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod_7e5ea427-c5ce-4b7e-b6e5-274a26476993" xlink:href="pacb-20250930.xsd#pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod_7e5ea427-c5ce-4b7e-b6e5-274a26476993" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_f6274bbc-eb15-4914-ad07-cbca4f97279b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_f6274bbc-eb15-4914-ad07-cbca4f97279b" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_07851892-827e-4d30-bc15-500eaf4f0c17" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_07851892-827e-4d30-bc15-500eaf4f0c17" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_30bff09a-c0f1-424a-a4ba-7f94365dbe24" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_30bff09a-c0f1-424a-a4ba-7f94365dbe24" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_d2fb79bc-0eaa-4699-987d-9796b8fbfb8b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_d2fb79bc-0eaa-4699-987d-9796b8fbfb8b" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StandardProductWarrantyPeriod_f21ae456-69a1-4607-a839-1c05625c3f58" xlink:href="pacb-20250930.xsd#pacb_StandardProductWarrantyPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_pacb_StandardProductWarrantyPeriod_f21ae456-69a1-4607-a839-1c05625c3f58" xlink:type="arc" order="23"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_19e129ca-9428-4c5f-9b08-da6d978fbf25" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_f850f0a4-1674-4e48-8d3e-62ddd7b8e640" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_19e129ca-9428-4c5f-9b08-da6d978fbf25" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_f850f0a4-1674-4e48-8d3e-62ddd7b8e640" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ce37765c-40d0-4502-9358-fa1bad171bee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_f850f0a4-1674-4e48-8d3e-62ddd7b8e640" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ce37765c-40d0-4502-9358-fa1bad171bee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ce37765c-40d0-4502-9358-fa1bad171bee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ce37765c-40d0-4502-9358-fa1bad171bee" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ce37765c-40d0-4502-9358-fa1bad171bee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_fa7435d4-1084-4468-92e5-aef5d7fea92d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ce37765c-40d0-4502-9358-fa1bad171bee" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_fa7435d4-1084-4468-92e5-aef5d7fea92d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_cf12eb35-1d52-4914-9a04-0720fee07268" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_fa7435d4-1084-4468-92e5-aef5d7fea92d" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_cf12eb35-1d52-4914-9a04-0720fee07268" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_6f8a0ecf-077a-4581-bb50-ba76a2c6a422" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_19e129ca-9428-4c5f-9b08-da6d978fbf25" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_6f8a0ecf-077a-4581-bb50-ba76a2c6a422" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c95880da-13dd-41e6-948c-9a5c9299e037" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_6f8a0ecf-077a-4581-bb50-ba76a2c6a422" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c95880da-13dd-41e6-948c-9a5c9299e037" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_39021e4b-56b5-4a46-9c02-3ef5f5fc0675" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_6f8a0ecf-077a-4581-bb50-ba76a2c6a422" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_39021e4b-56b5-4a46-9c02-3ef5f5fc0675" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_aa783485-5db4-4584-99d0-a8da494a73b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_39021e4b-56b5-4a46-9c02-3ef5f5fc0675" xlink:to="loc_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_aa783485-5db4-4584-99d0-a8da494a73b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c913d68b-3012-499e-acfe-ab75f12036ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2497faea-2355-411e-aeff-c800679bf7f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8890d552-a87c-4815-b472-9e14d84c7aef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2497faea-2355-411e-aeff-c800679bf7f0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8890d552-a87c-4815-b472-9e14d84c7aef" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_63d33642-fd91-4a43-9d43-49d3667e6948" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8890d552-a87c-4815-b472-9e14d84c7aef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_63d33642-fd91-4a43-9d43-49d3667e6948" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_63d33642-fd91-4a43-9d43-49d3667e6948_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_63d33642-fd91-4a43-9d43-49d3667e6948" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_63d33642-fd91-4a43-9d43-49d3667e6948_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_88146dd1-5877-45a0-a4ac-fd1a56fd2b39" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_63d33642-fd91-4a43-9d43-49d3667e6948" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_88146dd1-5877-45a0-a4ac-fd1a56fd2b39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_7fc6aff8-1dc6-413f-a72f-02638b67389e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_88146dd1-5877-45a0-a4ac-fd1a56fd2b39" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_7fc6aff8-1dc6-413f-a72f-02638b67389e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_6c8fe089-d146-44aa-9b34-491886cb40dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_88146dd1-5877-45a0-a4ac-fd1a56fd2b39" xlink:to="loc_us-gaap_CustomerRelationshipsMember_6c8fe089-d146-44aa-9b34-491886cb40dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c327fd73-4ec2-436d-98ce-e539c327bdea" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8890d552-a87c-4815-b472-9e14d84c7aef" xlink:to="loc_srt_RangeAxis_c327fd73-4ec2-436d-98ce-e539c327bdea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c327fd73-4ec2-436d-98ce-e539c327bdea_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c327fd73-4ec2-436d-98ce-e539c327bdea" xlink:to="loc_srt_RangeMember_c327fd73-4ec2-436d-98ce-e539c327bdea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_08cd3ff5-5d7b-4c44-9b03-db5bc4a6ad69" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c327fd73-4ec2-436d-98ce-e539c327bdea" xlink:to="loc_srt_RangeMember_08cd3ff5-5d7b-4c44-9b03-db5bc4a6ad69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c19398d2-5f15-45b5-8230-449a3705c89e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_08cd3ff5-5d7b-4c44-9b03-db5bc4a6ad69" xlink:to="loc_srt_MinimumMember_c19398d2-5f15-45b5-8230-449a3705c89e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b2007e45-1e50-48ec-80d1-ad1412f69d66" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_08cd3ff5-5d7b-4c44-9b03-db5bc4a6ad69" xlink:to="loc_srt_MaximumMember_b2007e45-1e50-48ec-80d1-ad1412f69d66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9a12187c-dd29-427c-99cb-2449e64c5c58" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2497faea-2355-411e-aeff-c800679bf7f0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9a12187c-dd29-427c-99cb-2449e64c5c58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_776a6f74-b365-4110-995a-f965eb948138" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2497faea-2355-411e-aeff-c800679bf7f0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_776a6f74-b365-4110-995a-f965eb948138" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_8b11b40b-897d-491d-8755-014813e80573" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2497faea-2355-411e-aeff-c800679bf7f0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_8b11b40b-897d-491d-8755-014813e80573" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2d2c64a1-fcac-4677-a63a-36fac9f1a05b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2497faea-2355-411e-aeff-c800679bf7f0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2d2c64a1-fcac-4677-a63a-36fac9f1a05b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#CONVERTIBLESENIORNOTESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_5176ab31-ce73-4b11-b203-45b6c63d4839" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_us-gaap_DebtInstrumentTable_5176ab31-ce73-4b11-b203-45b6c63d4839" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_42ae04c1-84ea-42a8-91aa-ad92e13a4ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5176ab31-ce73-4b11-b203-45b6c63d4839" xlink:to="loc_us-gaap_DebtInstrumentAxis_42ae04c1-84ea-42a8-91aa-ad92e13a4ba3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_42ae04c1-84ea-42a8-91aa-ad92e13a4ba3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_42ae04c1-84ea-42a8-91aa-ad92e13a4ba3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_42ae04c1-84ea-42a8-91aa-ad92e13a4ba3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_dace9b48-cc85-44af-8d7d-17087a2db66b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_42ae04c1-84ea-42a8-91aa-ad92e13a4ba3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_dace9b48-cc85-44af-8d7d-17087a2db66b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2028ConvertibleSeniorNotesMember_5595a55d-576f-420f-9f81-bee4db72ea44" xlink:href="pacb-20250930.xsd#pacb_A2028ConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dace9b48-cc85-44af-8d7d-17087a2db66b" xlink:to="loc_pacb_A2028ConvertibleSeniorNotesMember_5595a55d-576f-420f-9f81-bee4db72ea44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2029NotesMember_9d1d2e0d-0bc7-4d9e-a635-be90e1605bd9" xlink:href="pacb-20250930.xsd#pacb_A2029NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dace9b48-cc85-44af-8d7d-17087a2db66b" xlink:to="loc_pacb_A2029NotesMember_9d1d2e0d-0bc7-4d9e-a635-be90e1605bd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ExchangeTransactionMember_523a6889-64fd-4877-b91f-43c4f588a983" xlink:href="pacb-20250930.xsd#pacb_ExchangeTransactionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dace9b48-cc85-44af-8d7d-17087a2db66b" xlink:to="loc_pacb_ExchangeTransactionMember_523a6889-64fd-4877-b91f-43c4f588a983" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2030ConvertibleSeniorNotesMember_e3d67aac-bab7-4c89-9fa2-3e8c8b0bab2a" xlink:href="pacb-20250930.xsd#pacb_A2030ConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dace9b48-cc85-44af-8d7d-17087a2db66b" xlink:to="loc_pacb_A2030ConvertibleSeniorNotesMember_e3d67aac-bab7-4c89-9fa2-3e8c8b0bab2a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2c3261ed-2b57-4874-83a3-2e6b8f892421" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5176ab31-ce73-4b11-b203-45b6c63d4839" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2c3261ed-2b57-4874-83a3-2e6b8f892421" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2c3261ed-2b57-4874-83a3-2e6b8f892421_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2c3261ed-2b57-4874-83a3-2e6b8f892421" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2c3261ed-2b57-4874-83a3-2e6b8f892421_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ab9e4f64-ebe0-4d35-a97b-4c2599f28039" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2c3261ed-2b57-4874-83a3-2e6b8f892421" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ab9e4f64-ebe0-4d35-a97b-4c2599f28039" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_a5e02a92-5ca2-43b9-8875-fbcf7ee89d22" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ab9e4f64-ebe0-4d35-a97b-4c2599f28039" xlink:to="loc_us-gaap_ConvertibleDebtMember_a5e02a92-5ca2-43b9-8875-fbcf7ee89d22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentConvertibleTermsOfConversionAxis_de2f2d48-0d4e-436b-bc83-7d8a0a8e4a6b" xlink:href="pacb-20250930.xsd#pacb_DebtInstrumentConvertibleTermsOfConversionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5176ab31-ce73-4b11-b203-45b6c63d4839" xlink:to="loc_pacb_DebtInstrumentConvertibleTermsOfConversionAxis_de2f2d48-0d4e-436b-bc83-7d8a0a8e4a6b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_de2f2d48-0d4e-436b-bc83-7d8a0a8e4a6b_default" xlink:href="pacb-20250930.xsd#pacb_DebtInstrumentConvertibleTermsOfConversionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_pacb_DebtInstrumentConvertibleTermsOfConversionAxis_de2f2d48-0d4e-436b-bc83-7d8a0a8e4a6b" xlink:to="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_de2f2d48-0d4e-436b-bc83-7d8a0a8e4a6b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_3755290f-d553-4106-b711-15c9f7bcfb1c" xlink:href="pacb-20250930.xsd#pacb_DebtInstrumentConvertibleTermsOfConversionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_pacb_DebtInstrumentConvertibleTermsOfConversionAxis_de2f2d48-0d4e-436b-bc83-7d8a0a8e4a6b" xlink:to="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_3755290f-d553-4106-b711-15c9f7bcfb1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtConversionTermsOneMember_7eaa12f4-716f-44b3-a0ae-3cb90ecc2051" xlink:href="pacb-20250930.xsd#pacb_DebtConversionTermsOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_3755290f-d553-4106-b711-15c9f7bcfb1c" xlink:to="loc_pacb_DebtConversionTermsOneMember_7eaa12f4-716f-44b3-a0ae-3cb90ecc2051" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtConversionTermsTwoMember_41321bc1-1144-47da-81e8-34a54e6efa63" xlink:href="pacb-20250930.xsd#pacb_DebtConversionTermsTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_3755290f-d553-4106-b711-15c9f7bcfb1c" xlink:to="loc_pacb_DebtConversionTermsTwoMember_41321bc1-1144-47da-81e8-34a54e6efa63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_429979d9-d8d8-46e6-a9e1-8f33a3df2546" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5176ab31-ce73-4b11-b203-45b6c63d4839" xlink:to="loc_srt_RangeAxis_429979d9-d8d8-46e6-a9e1-8f33a3df2546" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_429979d9-d8d8-46e6-a9e1-8f33a3df2546_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_429979d9-d8d8-46e6-a9e1-8f33a3df2546" xlink:to="loc_srt_RangeMember_429979d9-d8d8-46e6-a9e1-8f33a3df2546_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ced2b1df-8d43-460c-b21f-b3a59ba2c29c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_429979d9-d8d8-46e6-a9e1-8f33a3df2546" xlink:to="loc_srt_RangeMember_ced2b1df-8d43-460c-b21f-b3a59ba2c29c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ebb5477c-0382-41af-a53e-9de8526a2db9" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ced2b1df-8d43-460c-b21f-b3a59ba2c29c" xlink:to="loc_srt_MinimumMember_ebb5477c-0382-41af-a53e-9de8526a2db9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_10119717-6e24-4e62-a9ab-0fec620ea6c1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ced2b1df-8d43-460c-b21f-b3a59ba2c29c" xlink:to="loc_srt_MaximumMember_10119717-6e24-4e62-a9ab-0fec620ea6c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_c1e4c25a-c815-4a20-8e10-3aee72680d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_c1e4c25a-c815-4a20-8e10-3aee72680d9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4aba03e9-8dab-4c48-825b-06c51440750a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4aba03e9-8dab-4c48-825b-06c51440750a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_32a11136-46fd-4fc9-8f29-c49e6489dd21" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_32a11136-46fd-4fc9-8f29-c49e6489dd21" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_462a112e-9bab-425d-85e4-08ee063a1bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_462a112e-9bab-425d-85e4-08ee063a1bf4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PaymentsInConjunctionWithNotesExchange_9cd35da2-b7f5-4380-8f2c-a843805994e7" xlink:href="pacb-20250930.xsd#pacb_PaymentsInConjunctionWithNotesExchange"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_pacb_PaymentsInConjunctionWithNotesExchange_9cd35da2-b7f5-4380-8f2c-a843805994e7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares_c43971f4-9438-4ec9-ad63-cbc9b5986bf0" xlink:href="pacb-20250930.xsd#pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares_c43971f4-9438-4ec9-ad63-cbc9b5986bf0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_df99ca4c-4411-4bc6-a6b1-bc98720407d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_df99ca4c-4411-4bc6-a6b1-bc98720407d4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_91b7c089-22f3-4f8b-9461-597b58b48897" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_91b7c089-22f3-4f8b-9461-597b58b48897" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_415e0183-bd74-4b0e-b945-b40164a8d8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_415e0183-bd74-4b0e-b945-b40164a8d8b9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_d6a80d5d-65a7-467c-b7b8-a202a9239b03" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_d6a80d5d-65a7-467c-b7b8-a202a9239b03" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_78c4adb0-e76b-45e7-a2d7-1cc5c8722c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_78c4adb0-e76b-45e7-a2d7-1cc5c8722c1f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_4d3b0a77-1830-44ed-b24b-fba31640a49b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_4d3b0a77-1830-44ed-b24b-fba31640a49b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentDebtDefaultCalendarDays_7128b606-604f-4dcf-8a04-788536d4469f" xlink:href="pacb-20250930.xsd#pacb_DebtInstrumentDebtDefaultCalendarDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_pacb_DebtInstrumentDebtDefaultCalendarDays_7128b606-604f-4dcf-8a04-788536d4469f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentInterestInTheEventOfDefault_00ad327f-5383-4529-bc3b-9060b8b328b9" xlink:href="pacb-20250930.xsd#pacb_DebtInstrumentInterestInTheEventOfDefault"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_pacb_DebtInstrumentInterestInTheEventOfDefault_00ad327f-5383-4529-bc3b-9060b8b328b9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentAdditionalInterestInEventOfDefault_9388cba9-0c83-409a-ba8c-62a758748364" xlink:href="pacb-20250930.xsd#pacb_DebtInstrumentAdditionalInterestInEventOfDefault"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_pacb_DebtInstrumentAdditionalInterestInEventOfDefault_9388cba9-0c83-409a-ba8c-62a758748364" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt_d1cd6fc9-7fe5-4b0b-99ef-e58c3dd76000" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnRestructuringOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_us-gaap_GainsLossesOnRestructuringOfDebt_d1cd6fc9-7fe5-4b0b-99ef-e58c3dd76000" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_RestructuringOfDebtPricePerShare_5225adbd-ade3-4067-9dd7-272d7a0cb023" xlink:href="pacb-20250930.xsd#pacb_RestructuringOfDebtPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_pacb_RestructuringOfDebtPricePerShare_5225adbd-ade3-4067-9dd7-272d7a0cb023" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_08edd9d8-4717-4cec-a254-573a78a365eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_08edd9d8-4717-4cec-a254-573a78a365eb" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtIssuanceCostLenderFees_f9c5221a-e82b-424e-a67c-b02e4eea59d0" xlink:href="pacb-20250930.xsd#pacb_DebtIssuanceCostLenderFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_pacb_DebtIssuanceCostLenderFees_f9c5221a-e82b-424e-a67c-b02e4eea59d0" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_73f70a28-6c7e-469f-8da1-8b3a7d942e44" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_73f70a28-6c7e-469f-8da1-8b3a7d942e44" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_349bbadf-3742-4cbc-8edf-95e3e25a1923" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_us-gaap_LongTermDebt_349bbadf-3742-4cbc-8edf-95e3e25a1923" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayable_473efd70-7cbc-4fff-8b8e-fc144ad23ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_us-gaap_ConvertibleNotesPayable_473efd70-7cbc-4fff-8b8e-fc144ad23ac7" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_673fea40-19b4-4e2d-99bf-bc9eec34f094" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_673fea40-19b4-4e2d-99bf-bc9eec34f094" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_28433e58-c737-4ff6-baa9-fe63cab796be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_28433e58-c737-4ff6-baa9-fe63cab796be" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_66151d8e-c9e2-45aa-861e-be355222f4c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_66151d8e-c9e2-45aa-861e-be355222f4c2" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice_1edb7be6-b4fa-4c82-be36-002980d11436" xlink:href="pacb-20250930.xsd#pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice_1edb7be6-b4fa-4c82-be36-002980d11436" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentRedemptionPriceTradingDays_01b8cfa7-2f03-4349-b682-5ae95b9357f8" xlink:href="pacb-20250930.xsd#pacb_DebtInstrumentRedemptionPriceTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_pacb_DebtInstrumentRedemptionPriceTradingDays_01b8cfa7-2f03-4349-b682-5ae95b9357f8" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays_e392c0c7-2680-40b5-a7b6-3b76c2ba071f" xlink:href="pacb-20250930.xsd#pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays_e392c0c7-2680-40b5-a7b6-3b76c2ba071f" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2357e4de-3353-46a9-991c-e8d5a695fe13" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2357e4de-3353-46a9-991c-e8d5a695fe13" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_805f4868-006f-4aa7-af94-f6b4205e6e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_805f4868-006f-4aa7-af94-f6b4205e6e3f" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_364182d7-6ad1-43b7-a826-81a040f480ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_364182d7-6ad1-43b7-a826-81a040f480ff" xlink:type="arc" order="30"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofChangestothe2029NotesDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#CONVERTIBLESENIORNOTESScheduleofChangestothe2029NotesDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofChangestothe2029NotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_f8440d83-60f9-405c-a50e-e6e1693da35b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_e2ddab0f-58eb-4ce3-881b-d33066b17aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f8440d83-60f9-405c-a50e-e6e1693da35b" xlink:to="loc_us-gaap_DebtInstrumentTable_e2ddab0f-58eb-4ce3-881b-d33066b17aeb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_78d108af-8a6d-4a69-b866-6bca34b99dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e2ddab0f-58eb-4ce3-881b-d33066b17aeb" xlink:to="loc_us-gaap_DebtInstrumentAxis_78d108af-8a6d-4a69-b866-6bca34b99dbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_78d108af-8a6d-4a69-b866-6bca34b99dbb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_78d108af-8a6d-4a69-b866-6bca34b99dbb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_78d108af-8a6d-4a69-b866-6bca34b99dbb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1a2fd9a1-6f07-4821-b3e6-7d493ebf40ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_78d108af-8a6d-4a69-b866-6bca34b99dbb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1a2fd9a1-6f07-4821-b3e6-7d493ebf40ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2029NotesMember_6b9953ea-4ccd-4c81-bcef-69892d488698" xlink:href="pacb-20250930.xsd#pacb_A2029NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1a2fd9a1-6f07-4821-b3e6-7d493ebf40ad" xlink:to="loc_pacb_A2029NotesMember_6b9953ea-4ccd-4c81-bcef-69892d488698" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayable_66c16902-1196-49fa-b818-26890548bddf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f8440d83-60f9-405c-a50e-e6e1693da35b" xlink:to="loc_us-gaap_ConvertibleNotesPayable_66c16902-1196-49fa-b818-26890548bddf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_fde5c015-05bb-4ee4-b1cf-8fd08f96b683" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f8440d83-60f9-405c-a50e-e6e1693da35b" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_fde5c015-05bb-4ee4-b1cf-8fd08f96b683" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayable_780222fe-39dc-4613-ada1-91ba73495efb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayable"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6661e90a-ca00-41e8-96de-6375c06cc24e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_8e865d42-692e-4fb7-9c6e-ee286ec53184" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6661e90a-ca00-41e8-96de-6375c06cc24e" xlink:to="loc_us-gaap_DebtInstrumentTable_8e865d42-692e-4fb7-9c6e-ee286ec53184" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d0488cd2-a1a1-4d74-9dc6-d31b6dd062ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8e865d42-692e-4fb7-9c6e-ee286ec53184" xlink:to="loc_us-gaap_DebtInstrumentAxis_d0488cd2-a1a1-4d74-9dc6-d31b6dd062ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d0488cd2-a1a1-4d74-9dc6-d31b6dd062ea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_d0488cd2-a1a1-4d74-9dc6-d31b6dd062ea" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d0488cd2-a1a1-4d74-9dc6-d31b6dd062ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_64f58c61-d74d-43f7-9a52-54ee89c202b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_d0488cd2-a1a1-4d74-9dc6-d31b6dd062ea" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_64f58c61-d74d-43f7-9a52-54ee89c202b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2030ConvertibleSeniorNotesMember_0013c62a-5314-41bd-b2f9-179e8bfe693f" xlink:href="pacb-20250930.xsd#pacb_A2030ConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_64f58c61-d74d-43f7-9a52-54ee89c202b9" xlink:to="loc_pacb_A2030ConvertibleSeniorNotesMember_0013c62a-5314-41bd-b2f9-179e8bfe693f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_8bf81464-9f6f-4498-9dad-58bfd7e632a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6661e90a-ca00-41e8-96de-6375c06cc24e" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_8bf81464-9f6f-4498-9dad-58bfd7e632a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium_66aace92-07ad-4c4f-8e34-f68a0b2bee0b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6661e90a-ca00-41e8-96de-6375c06cc24e" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremium_66aace92-07ad-4c4f-8e34-f68a0b2bee0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_7e8f9934-e8e2-4197-b633-3e66e3654a76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6661e90a-ca00-41e8-96de-6375c06cc24e" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_7e8f9934-e8e2-4197-b633-3e66e3654a76" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_9216f47c-8ea5-410a-aed5-2723dbb9e4c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6661e90a-ca00-41e8-96de-6375c06cc24e" xlink:to="loc_us-gaap_LongTermDebt_9216f47c-8ea5-410a-aed5-2723dbb9e4c2" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_8afc06dc-9eb9-41e4-98c5-0331055c13e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_250f2301-2135-4752-a975-2fd9ebc0c0c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8afc06dc-9eb9-41e4-98c5-0331055c13e3" xlink:to="loc_us-gaap_DebtInstrumentTable_250f2301-2135-4752-a975-2fd9ebc0c0c6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8fa917c5-3917-4432-af93-cb13945f593d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_250f2301-2135-4752-a975-2fd9ebc0c0c6" xlink:to="loc_us-gaap_DebtInstrumentAxis_8fa917c5-3917-4432-af93-cb13945f593d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8fa917c5-3917-4432-af93-cb13945f593d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_8fa917c5-3917-4432-af93-cb13945f593d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8fa917c5-3917-4432-af93-cb13945f593d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bc72d3f3-2fe7-418f-9c96-0825856cbde7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_8fa917c5-3917-4432-af93-cb13945f593d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bc72d3f3-2fe7-418f-9c96-0825856cbde7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2030ConvertibleSeniorNotesMember_cc032d38-2001-4ed8-b0fe-3bc6553a30cc" xlink:href="pacb-20250930.xsd#pacb_A2030ConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bc72d3f3-2fe7-418f-9c96-0825856cbde7" xlink:to="loc_pacb_A2030ConvertibleSeniorNotesMember_cc032d38-2001-4ed8-b0fe-3bc6553a30cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2028ConvertibleSeniorNotesMember_a79dc6af-c9d8-4bfc-9863-df0c28bf7de0" xlink:href="pacb-20250930.xsd#pacb_A2028ConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bc72d3f3-2fe7-418f-9c96-0825856cbde7" xlink:to="loc_pacb_A2028ConvertibleSeniorNotesMember_a79dc6af-c9d8-4bfc-9863-df0c28bf7de0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_7feae577-c497-4db5-981c-87b9f2a468de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8afc06dc-9eb9-41e4-98c5-0331055c13e3" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_7feae577-c497-4db5-981c-87b9f2a468de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_2c9a2a7d-0056-4a36-addb-3e11dca43872" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8afc06dc-9eb9-41e4-98c5-0331055c13e3" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_2c9a2a7d-0056-4a36-addb-3e11dca43872" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_f045ad73-5f60-4915-a142-9b91174857c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8afc06dc-9eb9-41e4-98c5-0331055c13e3" xlink:to="loc_us-gaap_InterestExpenseDebt_f045ad73-5f60-4915-a142-9b91174857c6" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_1d8f463b-959c-4d27-8186-71b26d25d2c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d30945b0-df94-46a8-94e5-a5d9b2c30f48" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1d8f463b-959c-4d27-8186-71b26d25d2c9" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d30945b0-df94-46a8-94e5-a5d9b2c30f48" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_b87a0f99-c973-4437-b065-f07b0664b50f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d30945b0-df94-46a8-94e5-a5d9b2c30f48" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_b87a0f99-c973-4437-b065-f07b0664b50f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_b87a0f99-c973-4437-b065-f07b0664b50f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_b87a0f99-c973-4437-b065-f07b0664b50f" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_b87a0f99-c973-4437-b065-f07b0664b50f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_0ef3aa25-93c8-48cf-b845-d8a30fdcc5d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_b87a0f99-c973-4437-b065-f07b0664b50f" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_0ef3aa25-93c8-48cf-b845-d8a30fdcc5d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EmployeeSeparationCostsMember_99301728-640b-497e-8c53-def8cc82cbd4" xlink:href="pacb-20250930.xsd#pacb_EmployeeSeparationCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_0ef3aa25-93c8-48cf-b845-d8a30fdcc5d0" xlink:to="loc_pacb_EmployeeSeparationCostsMember_99301728-640b-497e-8c53-def8cc82cbd4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_3f553337-5030-443a-adb4-091a345a3b85" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherRestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_0ef3aa25-93c8-48cf-b845-d8a30fdcc5d0" xlink:to="loc_us-gaap_OtherRestructuringMember_3f553337-5030-443a-adb4-091a345a3b85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e2838448-4768-4362-8998-e3372860a437" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d30945b0-df94-46a8-94e5-a5d9b2c30f48" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e2838448-4768-4362-8998-e3372860a437" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e2838448-4768-4362-8998-e3372860a437_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e2838448-4768-4362-8998-e3372860a437" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e2838448-4768-4362-8998-e3372860a437_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_afbb34e3-1f4a-4ab5-905d-a0a2620548cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e2838448-4768-4362-8998-e3372860a437" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_afbb34e3-1f4a-4ab5-905d-a0a2620548cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_7f419fcc-73a0-4bc0-b603-ecc50a4544dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_afbb34e3-1f4a-4ab5-905d-a0a2620548cd" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_7f419fcc-73a0-4bc0-b603-ecc50a4544dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4b19369d-03db-40e9-8da3-d7a6f00d53a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_afbb34e3-1f4a-4ab5-905d-a0a2620548cd" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4b19369d-03db-40e9-8da3-d7a6f00d53a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_aeb023be-3503-4de3-99f1-8468c35dc3a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_afbb34e3-1f4a-4ab5-905d-a0a2620548cd" xlink:to="loc_us-gaap_CostOfSalesMember_aeb023be-3503-4de3-99f1-8468c35dc3a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_771e3348-fbb3-4185-afc0-f9713d02e332" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d30945b0-df94-46a8-94e5-a5d9b2c30f48" xlink:to="loc_us-gaap_RestructuringPlanAxis_771e3348-fbb3-4185-afc0-f9713d02e332" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_771e3348-fbb3-4185-afc0-f9713d02e332_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_771e3348-fbb3-4185-afc0-f9713d02e332" xlink:to="loc_us-gaap_RestructuringPlanDomain_771e3348-fbb3-4185-afc0-f9713d02e332_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_a06d4956-25b2-4b00-93aa-86de3b5411ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_771e3348-fbb3-4185-afc0-f9713d02e332" xlink:to="loc_us-gaap_RestructuringPlanDomain_a06d4956-25b2-4b00-93aa-86de3b5411ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2025RestructuringMember_90083ad6-2d47-4c02-8f33-1d416ddbd680" xlink:href="pacb-20250930.xsd#pacb_A2025RestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_a06d4956-25b2-4b00-93aa-86de3b5411ba" xlink:to="loc_pacb_A2025RestructuringMember_90083ad6-2d47-4c02-8f33-1d416ddbd680" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2024RestructuringMember_11f673ed-c8c9-4c29-bce4-fb4979678e99" xlink:href="pacb-20250930.xsd#pacb_A2024RestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_a06d4956-25b2-4b00-93aa-86de3b5411ba" xlink:to="loc_pacb_A2024RestructuringMember_11f673ed-c8c9-4c29-bce4-fb4979678e99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_a31b803a-437a-4c8c-883c-0bcf47621866" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1d8f463b-959c-4d27-8186-71b26d25d2c9" xlink:to="loc_us-gaap_RestructuringCharges_a31b803a-437a-4c8c-883c-0bcf47621866" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_367dea1b-e490-47c8-a449-f4b1ee1e5d04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1d8f463b-959c-4d27-8186-71b26d25d2c9" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_367dea1b-e490-47c8-a449-f4b1ee1e5d04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_ab62cbc9-3d2d-498a-be87-9aa155ee76ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1d8f463b-959c-4d27-8186-71b26d25d2c9" xlink:to="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_ab62cbc9-3d2d-498a-be87-9aa155ee76ea" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#RESTRUCTURINGNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_8f0f8365-7abe-4a5e-bbed-59d9274d1a39" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_09794175-1b2b-44b1-9069-ed961d597404" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8f0f8365-7abe-4a5e-bbed-59d9274d1a39" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_09794175-1b2b-44b1-9069-ed961d597404" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_70435a4c-a208-4d30-a580-2f230dede9ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_09794175-1b2b-44b1-9069-ed961d597404" xlink:to="loc_us-gaap_RestructuringPlanAxis_70435a4c-a208-4d30-a580-2f230dede9ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_70435a4c-a208-4d30-a580-2f230dede9ef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_70435a4c-a208-4d30-a580-2f230dede9ef" xlink:to="loc_us-gaap_RestructuringPlanDomain_70435a4c-a208-4d30-a580-2f230dede9ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_0f440e63-febf-4013-930d-570d6fed606b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_70435a4c-a208-4d30-a580-2f230dede9ef" xlink:to="loc_us-gaap_RestructuringPlanDomain_0f440e63-febf-4013-930d-570d6fed606b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2025RestructuringMember_3c6543e6-6ab4-4b62-a445-6c80c53ab475" xlink:href="pacb-20250930.xsd#pacb_A2025RestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_0f440e63-febf-4013-930d-570d6fed606b" xlink:to="loc_pacb_A2025RestructuringMember_3c6543e6-6ab4-4b62-a445-6c80c53ab475" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2024RestructuringMember_feb0cab8-d448-4ec9-92c2-7035c7832d46" xlink:href="pacb-20250930.xsd#pacb_A2024RestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_0f440e63-febf-4013-930d-570d6fed606b" xlink:to="loc_pacb_A2024RestructuringMember_feb0cab8-d448-4ec9-92c2-7035c7832d46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SanDiegoOfficeMember_12c1ae4f-e1db-4efc-9c56-1bbb448621f2" xlink:href="pacb-20250930.xsd#pacb_SanDiegoOfficeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_0f440e63-febf-4013-930d-570d6fed606b" xlink:to="loc_pacb_SanDiegoOfficeMember_12c1ae4f-e1db-4efc-9c56-1bbb448621f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_3239a5db-b590-4909-aa95-49a61a4c5255" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_09794175-1b2b-44b1-9069-ed961d597404" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_3239a5db-b590-4909-aa95-49a61a4c5255" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3239a5db-b590-4909-aa95-49a61a4c5255_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_3239a5db-b590-4909-aa95-49a61a4c5255" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3239a5db-b590-4909-aa95-49a61a4c5255_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_eee2a12e-2ee6-477f-b226-f89fd43a66e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_3239a5db-b590-4909-aa95-49a61a4c5255" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_eee2a12e-2ee6-477f-b226-f89fd43a66e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember_bdcb5c0f-87e9-4fbb-b40c-104c870e5591" xlink:href="pacb-20250930.xsd#pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_eee2a12e-2ee6-477f-b226-f89fd43a66e7" xlink:to="loc_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember_bdcb5c0f-87e9-4fbb-b40c-104c870e5591" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits_52a69d7c-5874-4221-87a3-2a6009b1ff47" xlink:href="pacb-20250930.xsd#pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8f0f8365-7abe-4a5e-bbed-59d9274d1a39" xlink:to="loc_pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits_52a69d7c-5874-4221-87a3-2a6009b1ff47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_4ee08198-1925-4a27-9f84-d01faa3f063e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8f0f8365-7abe-4a5e-bbed-59d9274d1a39" xlink:to="loc_us-gaap_SeveranceCosts1_4ee08198-1925-4a27-9f84-d01faa3f063e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_RestructuringChargesAdditionalCostsIncurred_01690228-9c26-4c44-8d46-5aa3a88381bb" xlink:href="pacb-20250930.xsd#pacb_RestructuringChargesAdditionalCostsIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8f0f8365-7abe-4a5e-bbed-59d9274d1a39" xlink:to="loc_pacb_RestructuringChargesAdditionalCostsIncurred_01690228-9c26-4c44-8d46-5aa3a88381bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_RestructuringAndRelatedCostAcceleratedAmortization_4aac0489-d354-43e7-ab38-1dbb19430be2" xlink:href="pacb-20250930.xsd#pacb_RestructuringAndRelatedCostAcceleratedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8f0f8365-7abe-4a5e-bbed-59d9274d1a39" xlink:to="loc_pacb_RestructuringAndRelatedCostAcceleratedAmortization_4aac0489-d354-43e7-ab38-1dbb19430be2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_62ea2bd3-123b-49ce-bc9f-cde932001841" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8f0f8365-7abe-4a5e-bbed-59d9274d1a39" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_62ea2bd3-123b-49ce-bc9f-cde932001841" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_62ea743e-c254-4f86-92b7-85ff391ed98b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8f0f8365-7abe-4a5e-bbed-59d9274d1a39" xlink:to="loc_us-gaap_InventoryWriteDown_62ea743e-c254-4f86-92b7-85ff391ed98b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_GainLossOnPurchaseCommitments_04898369-3cc2-4d0b-b178-1c8b779752e1" xlink:href="pacb-20250930.xsd#pacb_GainLossOnPurchaseCommitments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8f0f8365-7abe-4a5e-bbed-59d9274d1a39" xlink:to="loc_pacb_GainLossOnPurchaseCommitments_04898369-3cc2-4d0b-b178-1c8b779752e1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_e0a87150-2c54-4003-ba92-41033b706393" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8f0f8365-7abe-4a5e-bbed-59d9274d1a39" xlink:to="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_e0a87150-2c54-4003-ba92-41033b706393" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_e76a82dc-7d41-4af8-af17-19092f2f01e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8f0f8365-7abe-4a5e-bbed-59d9274d1a39" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_e76a82dc-7d41-4af8-af17-19092f2f01e2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_4b368aad-3f1c-43c4-b531-3716f56e45f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8f0f8365-7abe-4a5e-bbed-59d9274d1a39" xlink:to="loc_us-gaap_OperatingLeaseLiability_4b368aad-3f1c-43c4-b531-3716f56e45f4" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_36c4b148-8746-4ff2-aafc-994ea4d42f0f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1d8f310f-c485-4efd-80ed-de343e9a924d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_36c4b148-8746-4ff2-aafc-994ea4d42f0f" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1d8f310f-c485-4efd-80ed-de343e9a924d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_9ce2a108-cf2f-4b6b-a667-e6c9ef585c94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1d8f310f-c485-4efd-80ed-de343e9a924d" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_9ce2a108-cf2f-4b6b-a667-e6c9ef585c94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_9ce2a108-cf2f-4b6b-a667-e6c9ef585c94_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_9ce2a108-cf2f-4b6b-a667-e6c9ef585c94" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_9ce2a108-cf2f-4b6b-a667-e6c9ef585c94_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_32e61027-bddb-4c7a-9e88-437b9e335c98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_9ce2a108-cf2f-4b6b-a667-e6c9ef585c94" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_32e61027-bddb-4c7a-9e88-437b9e335c98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EmployeeSeparationCostsMember_db201447-06f2-497f-8d2e-c6af4f47d75d" xlink:href="pacb-20250930.xsd#pacb_EmployeeSeparationCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_32e61027-bddb-4c7a-9e88-437b9e335c98" xlink:to="loc_pacb_EmployeeSeparationCostsMember_db201447-06f2-497f-8d2e-c6af4f47d75d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_9c08c9a4-0318-4fa6-85bb-986251e4cee8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherRestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_32e61027-bddb-4c7a-9e88-437b9e335c98" xlink:to="loc_us-gaap_OtherRestructuringMember_9c08c9a4-0318-4fa6-85bb-986251e4cee8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_8d27153a-a978-4612-af33-00ea73cc9894" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1d8f310f-c485-4efd-80ed-de343e9a924d" xlink:to="loc_us-gaap_RestructuringPlanAxis_8d27153a-a978-4612-af33-00ea73cc9894" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_8d27153a-a978-4612-af33-00ea73cc9894_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_8d27153a-a978-4612-af33-00ea73cc9894" xlink:to="loc_us-gaap_RestructuringPlanDomain_8d27153a-a978-4612-af33-00ea73cc9894_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_a53aede5-7599-4e9f-a480-7693b51a4137" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_8d27153a-a978-4612-af33-00ea73cc9894" xlink:to="loc_us-gaap_RestructuringPlanDomain_a53aede5-7599-4e9f-a480-7693b51a4137" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2025RestructuringMember_8ce86bf7-51ed-4a09-9ca6-471cdf00c702" xlink:href="pacb-20250930.xsd#pacb_A2025RestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_a53aede5-7599-4e9f-a480-7693b51a4137" xlink:to="loc_pacb_A2025RestructuringMember_8ce86bf7-51ed-4a09-9ca6-471cdf00c702" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2024RestructuringMember_82ea476b-f617-4e05-bc0b-65f1f733f3b6" xlink:href="pacb-20250930.xsd#pacb_A2024RestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_a53aede5-7599-4e9f-a480-7693b51a4137" xlink:to="loc_pacb_A2024RestructuringMember_82ea476b-f617-4e05-bc0b-65f1f733f3b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_61d3ff13-eaa5-48b5-8d59-b60081a1fa7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_36c4b148-8746-4ff2-aafc-994ea4d42f0f" xlink:to="loc_us-gaap_RestructuringReserve_61d3ff13-eaa5-48b5-8d59-b60081a1fa7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_3e492f7b-1233-4e7e-b06d-9fadf883cebc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_36c4b148-8746-4ff2-aafc-994ea4d42f0f" xlink:to="loc_us-gaap_RestructuringCharges_3e492f7b-1233-4e7e-b06d-9fadf883cebc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_7633c82c-7e01-42b0-904f-66dd27b9eb80" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_36c4b148-8746-4ff2-aafc-994ea4d42f0f" xlink:to="loc_us-gaap_PaymentsForRestructuring_7633c82c-7e01-42b0-904f-66dd27b9eb80" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_01d00b41-650d-4bbd-bdbd-aa3d06b6d53e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_88120c9e-0816-4cb4-9911-2e1174083efa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_36c4b148-8746-4ff2-aafc-994ea4d42f0f" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_88120c9e-0816-4cb4-9911-2e1174083efa" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_54669b5a-9f8e-426a-b371-32ab5a170e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fa44d35-79fd-4baa-87e9-163a4725bcdb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_54669b5a-9f8e-426a-b371-32ab5a170e0a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fa44d35-79fd-4baa-87e9-163a4725bcdb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_52e4a5f8-acc1-428a-a5f8-21d6d4db4e38" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fa44d35-79fd-4baa-87e9-163a4725bcdb" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_52e4a5f8-acc1-428a-a5f8-21d6d4db4e38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_52e4a5f8-acc1-428a-a5f8-21d6d4db4e38_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_52e4a5f8-acc1-428a-a5f8-21d6d4db4e38" xlink:to="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_52e4a5f8-acc1-428a-a5f8-21d6d4db4e38_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_9ec0adf3-de08-4f99-a698-8e2b1d7b0072" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_52e4a5f8-acc1-428a-a5f8-21d6d4db4e38" xlink:to="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_9ec0adf3-de08-4f99-a698-8e2b1d7b0072" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EmployeeStockPurchasePlanMember_63a09674-ce47-428f-ac45-d3e2b682ad89" xlink:href="pacb-20250930.xsd#pacb_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_9ec0adf3-de08-4f99-a698-8e2b1d7b0072" xlink:to="loc_pacb_EmployeeStockPurchasePlanMember_63a09674-ce47-428f-ac45-d3e2b682ad89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_e2c2ffeb-c919-4c96-a94b-a24139bf2a04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fa44d35-79fd-4baa-87e9-163a4725bcdb" xlink:to="loc_us-gaap_PlanNameAxis_e2c2ffeb-c919-4c96-a94b-a24139bf2a04" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e2c2ffeb-c919-4c96-a94b-a24139bf2a04_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_e2c2ffeb-c919-4c96-a94b-a24139bf2a04" xlink:to="loc_us-gaap_PlanNameDomain_e2c2ffeb-c919-4c96-a94b-a24139bf2a04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_539d377e-4234-45c2-b73c-08d8ef10865d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_e2c2ffeb-c919-4c96-a94b-a24139bf2a04" xlink:to="loc_us-gaap_PlanNameDomain_539d377e-4234-45c2-b73c-08d8ef10865d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EquityIncentivePlan2020Member_e659574d-358a-43ed-a769-77f7a98bdc81" xlink:href="pacb-20250930.xsd#pacb_EquityIncentivePlan2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_539d377e-4234-45c2-b73c-08d8ef10865d" xlink:to="loc_pacb_EquityIncentivePlan2020Member_e659574d-358a-43ed-a769-77f7a98bdc81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2020PlanInducementPlanAndTheOmniomePlanMember_0870e810-f9e4-4cec-87c0-16fba443855f" xlink:href="pacb-20250930.xsd#pacb_A2020PlanInducementPlanAndTheOmniomePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_539d377e-4234-45c2-b73c-08d8ef10865d" xlink:to="loc_pacb_A2020PlanInducementPlanAndTheOmniomePlanMember_0870e810-f9e4-4cec-87c0-16fba443855f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b1ba432b-db40-4ff4-9b2a-799583a600d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fa44d35-79fd-4baa-87e9-163a4725bcdb" xlink:to="loc_us-gaap_AwardTypeAxis_b1ba432b-db40-4ff4-9b2a-799583a600d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b1ba432b-db40-4ff4-9b2a-799583a600d7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b1ba432b-db40-4ff4-9b2a-799583a600d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b1ba432b-db40-4ff4-9b2a-799583a600d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_28bbed11-be34-4c1b-a0f4-2909d0890665" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b1ba432b-db40-4ff4-9b2a-799583a600d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_28bbed11-be34-4c1b-a0f4-2909d0890665" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedRestrictedStockUnitsPSUMember_c291908e-45b6-42c2-b8c1-1f66f9c68bc0" xlink:href="pacb-20250930.xsd#pacb_TimeBasedRestrictedStockUnitsPSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_28bbed11-be34-4c1b-a0f4-2909d0890665" xlink:to="loc_pacb_TimeBasedRestrictedStockUnitsPSUMember_c291908e-45b6-42c2-b8c1-1f66f9c68bc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_fde32e19-839a-4f62-b4fa-d03dd3a90917" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_54669b5a-9f8e-426a-b371-32ab5a170e0a" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_fde32e19-839a-4f62-b4fa-d03dd3a90917" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_bcc2eeee-16b8-4987-b53a-d6fbe8d4f934" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_54669b5a-9f8e-426a-b371-32ab5a170e0a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_bcc2eeee-16b8-4987-b53a-d6fbe8d4f934" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal_19013daa-9600-41ec-8146-e6cc456b1d28" xlink:href="pacb-20250930.xsd#pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_54669b5a-9f8e-426a-b371-32ab5a170e0a" xlink:to="loc_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal_19013daa-9600-41ec-8146-e6cc456b1d28" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_dbd2c212-ce3c-4fa6-8081-b34c3c0ae3f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_54669b5a-9f8e-426a-b371-32ab5a170e0a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_dbd2c212-ce3c-4fa6-8081-b34c3c0ae3f2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_562b2c3d-26f5-4daf-b4af-35cab6a6d920" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_54669b5a-9f8e-426a-b371-32ab5a170e0a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_562b2c3d-26f5-4daf-b4af-35cab6a6d920" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4dd7c288-5cc3-4e71-8795-759fdb79b81a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_54669b5a-9f8e-426a-b371-32ab5a170e0a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4dd7c288-5cc3-4e71-8795-759fdb79b81a" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c062f93-8f80-46ad-8d65-2e21a3793852" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17a5131b-e63c-4fe2-b3dc-de2b430951a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c062f93-8f80-46ad-8d65-2e21a3793852" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17a5131b-e63c-4fe2-b3dc-de2b430951a1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4b50ae8d-d85e-4a20-8148-f9c288442138" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17a5131b-e63c-4fe2-b3dc-de2b430951a1" xlink:to="loc_us-gaap_AwardTypeAxis_4b50ae8d-d85e-4a20-8148-f9c288442138" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4b50ae8d-d85e-4a20-8148-f9c288442138_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4b50ae8d-d85e-4a20-8148-f9c288442138" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4b50ae8d-d85e-4a20-8148-f9c288442138_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fb89bc6d-b49b-4492-a7f9-126956eac3f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4b50ae8d-d85e-4a20-8148-f9c288442138" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fb89bc6d-b49b-4492-a7f9-126956eac3f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedStockOptionMember_cfe7b43b-eb86-46b8-af13-d0757bf175cd" xlink:href="pacb-20250930.xsd#pacb_TimeBasedStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fb89bc6d-b49b-4492-a7f9-126956eac3f8" xlink:to="loc_pacb_TimeBasedStockOptionMember_cfe7b43b-eb86-46b8-af13-d0757bf175cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0c6bce82-7a00-4459-bb20-1e34a92ef7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c062f93-8f80-46ad-8d65-2e21a3793852" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0c6bce82-7a00-4459-bb20-1e34a92ef7cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a8e058b9-849f-46f9-8193-97c07e9c4ead" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0c6bce82-7a00-4459-bb20-1e34a92ef7cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a8e058b9-849f-46f9-8193-97c07e9c4ead" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ade8c648-d636-4683-8e75-d5b87e4978d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0c6bce82-7a00-4459-bb20-1e34a92ef7cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ade8c648-d636-4683-8e75-d5b87e4978d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_fd2dfd38-7426-42ab-9c35-1595260d36f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0c6bce82-7a00-4459-bb20-1e34a92ef7cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_fd2dfd38-7426-42ab-9c35-1595260d36f4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_a3f5dcc2-5f9b-43ba-96c2-e2060c3b254f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0c6bce82-7a00-4459-bb20-1e34a92ef7cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_a3f5dcc2-5f9b-43ba-96c2-e2060c3b254f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b6f521e1-b5ea-4127-8431-41f0562cbe87" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5fd969aa-399c-4edd-aea6-2f0546fdb3af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c062f93-8f80-46ad-8d65-2e21a3793852" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5fd969aa-399c-4edd-aea6-2f0546fdb3af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e6b5febd-6184-4568-9261-fc0f15ab33d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5fd969aa-399c-4edd-aea6-2f0546fdb3af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e6b5febd-6184-4568-9261-fc0f15ab33d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_eb40a94b-2ac8-4ce6-b34f-6a6a200f842d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5fd969aa-399c-4edd-aea6-2f0546fdb3af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_eb40a94b-2ac8-4ce6-b34f-6a6a200f842d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c4183baa-dd4b-4186-8818-c13e6d90e764" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5fd969aa-399c-4edd-aea6-2f0546fdb3af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c4183baa-dd4b-4186-8818-c13e6d90e764" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_07437046-7889-4d26-865f-bac50005fae7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5fd969aa-399c-4edd-aea6-2f0546fdb3af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_07437046-7889-4d26-865f-bac50005fae7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_cdce22d0-36e9-4cab-87bf-d3220baf3222" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8d87459-c8a9-4aa6-95b1-7c35353f33b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3135eabf-1a86-4d3b-96fd-659b80948a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8d87459-c8a9-4aa6-95b1-7c35353f33b8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3135eabf-1a86-4d3b-96fd-659b80948a3d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_30d34a6c-eac7-428b-bae8-9ebe0cb7cd32" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3135eabf-1a86-4d3b-96fd-659b80948a3d" xlink:to="loc_us-gaap_AwardTypeAxis_30d34a6c-eac7-428b-bae8-9ebe0cb7cd32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30d34a6c-eac7-428b-bae8-9ebe0cb7cd32_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_30d34a6c-eac7-428b-bae8-9ebe0cb7cd32" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30d34a6c-eac7-428b-bae8-9ebe0cb7cd32_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6cf5b2ab-181a-43fb-88d8-eb2a37eaf200" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_30d34a6c-eac7-428b-bae8-9ebe0cb7cd32" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6cf5b2ab-181a-43fb-88d8-eb2a37eaf200" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedRestrictedStockUnitsRsusMember_0b3d6d86-0f86-440a-989d-f1cc815ab7c8" xlink:href="pacb-20250930.xsd#pacb_TimeBasedRestrictedStockUnitsRsusMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6cf5b2ab-181a-43fb-88d8-eb2a37eaf200" xlink:to="loc_pacb_TimeBasedRestrictedStockUnitsRsusMember_0b3d6d86-0f86-440a-989d-f1cc815ab7c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_75344fa0-7eda-4fb4-8938-338c9f38cba7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6cf5b2ab-181a-43fb-88d8-eb2a37eaf200" xlink:to="loc_us-gaap_PerformanceSharesMember_75344fa0-7eda-4fb4-8938-338c9f38cba7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_7dbd116a-a095-4430-a578-e7c1b418981b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8d87459-c8a9-4aa6-95b1-7c35353f33b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_7dbd116a-a095-4430-a578-e7c1b418981b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2ab374be-c8d1-44df-9ded-4dc42601066f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_7dbd116a-a095-4430-a578-e7c1b418981b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2ab374be-c8d1-44df-9ded-4dc42601066f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b3919915-354b-49f6-bc04-8ff7be6bd6b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_7dbd116a-a095-4430-a578-e7c1b418981b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b3919915-354b-49f6-bc04-8ff7be6bd6b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_90b066cb-7f25-4d03-9f18-35d829e3136f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_7dbd116a-a095-4430-a578-e7c1b418981b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_90b066cb-7f25-4d03-9f18-35d829e3136f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f103a7ed-c449-4ae0-9606-0ba27ceceb74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_7dbd116a-a095-4430-a578-e7c1b418981b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f103a7ed-c449-4ae0-9606-0ba27ceceb74" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1e3a5be8-7644-4059-837a-302cba942a32" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e7edde96-288e-4051-be9a-7f71312d0d92" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8d87459-c8a9-4aa6-95b1-7c35353f33b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e7edde96-288e-4051-be9a-7f71312d0d92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_40eca02b-45e0-4b82-9421-2d4f85e05dee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e7edde96-288e-4051-be9a-7f71312d0d92" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_40eca02b-45e0-4b82-9421-2d4f85e05dee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_980cac31-c4aa-44fa-9112-63f02768c849" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e7edde96-288e-4051-be9a-7f71312d0d92" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_980cac31-c4aa-44fa-9112-63f02768c849" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_23b2c2e4-7d8b-4814-9d4a-51c0005a5155" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e7edde96-288e-4051-be9a-7f71312d0d92" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_23b2c2e4-7d8b-4814-9d4a-51c0005a5155" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9bb67888-64be-49e5-b64d-c5cf2771eaa4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e7edde96-288e-4051-be9a-7f71312d0d92" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9bb67888-64be-49e5-b64d-c5cf2771eaa4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f188d1ae-0f39-4d26-9c0a-fb2b7522eeab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_78772ff1-46d4-4fe0-a780-2774f2d395f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0a051f38-bee4-4f79-9621-4e1953f22fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_78772ff1-46d4-4fe0-a780-2774f2d395f9" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0a051f38-bee4-4f79-9621-4e1953f22fb0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9677e83e-e763-4e6b-946f-e4403f9b7299" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0a051f38-bee4-4f79-9621-4e1953f22fb0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9677e83e-e763-4e6b-946f-e4403f9b7299" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9677e83e-e763-4e6b-946f-e4403f9b7299_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9677e83e-e763-4e6b-946f-e4403f9b7299" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9677e83e-e763-4e6b-946f-e4403f9b7299_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c6bc5ace-0c6c-4080-a2ff-0359d641010b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9677e83e-e763-4e6b-946f-e4403f9b7299" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c6bc5ace-0c6c-4080-a2ff-0359d641010b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_fb50c201-0762-4e26-b598-c3a1c8100189" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c6bc5ace-0c6c-4080-a2ff-0359d641010b" xlink:to="loc_us-gaap_CostOfSalesMember_fb50c201-0762-4e26-b598-c3a1c8100189" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_46325134-fe88-4c4f-a5e7-2c0f8019b8df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c6bc5ace-0c6c-4080-a2ff-0359d641010b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_46325134-fe88-4c4f-a5e7-2c0f8019b8df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_721ae6b4-4eff-4154-a89f-f242838b1be2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c6bc5ace-0c6c-4080-a2ff-0359d641010b" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_721ae6b4-4eff-4154-a89f-f242838b1be2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockBasedCompensationMember_8a50b977-9a6c-47d9-9384-0b3fd6d3a139" xlink:href="pacb-20250930.xsd#pacb_StockBasedCompensationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c6bc5ace-0c6c-4080-a2ff-0359d641010b" xlink:to="loc_pacb_StockBasedCompensationMember_8a50b977-9a6c-47d9-9384-0b3fd6d3a139" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_92d9d264-7252-46ce-90f2-a8f0d40aafb6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_78772ff1-46d4-4fe0-a780-2774f2d395f9" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_92d9d264-7252-46ce-90f2-a8f0d40aafb6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockOptionsDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2e39459-7f00-473b-a342-8d460c7c2c07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_00613227-3b78-4862-88fb-b6b4000d1e74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2e39459-7f00-473b-a342-8d460c7c2c07" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_00613227-3b78-4862-88fb-b6b4000d1e74" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_710cfe71-79e1-43ee-bacc-34e9d62d4a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_00613227-3b78-4862-88fb-b6b4000d1e74" xlink:to="loc_us-gaap_AwardTypeAxis_710cfe71-79e1-43ee-bacc-34e9d62d4a6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_710cfe71-79e1-43ee-bacc-34e9d62d4a6c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_710cfe71-79e1-43ee-bacc-34e9d62d4a6c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_710cfe71-79e1-43ee-bacc-34e9d62d4a6c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5ced2b90-3cd7-45b4-8c3e-1efcadecd7c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_710cfe71-79e1-43ee-bacc-34e9d62d4a6c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5ced2b90-3cd7-45b4-8c3e-1efcadecd7c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OptionsToPurchaseCommonStockMember_f57e3022-b5de-49c2-8ed6-39e40b0b40b1" xlink:href="pacb-20250930.xsd#pacb_OptionsToPurchaseCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5ced2b90-3cd7-45b4-8c3e-1efcadecd7c6" xlink:to="loc_pacb_OptionsToPurchaseCommonStockMember_f57e3022-b5de-49c2-8ed6-39e40b0b40b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d7682c07-5fa9-46db-ac1e-3badd9d9a2df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2e39459-7f00-473b-a342-8d460c7c2c07" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d7682c07-5fa9-46db-ac1e-3badd9d9a2df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_7232ec4b-0cad-46ed-828a-000df7d44e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2e39459-7f00-473b-a342-8d460c7c2c07" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_7232ec4b-0cad-46ed-828a-000df7d44e9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_26bb1d4d-7479-4f6a-9ac1-f5c7e6bb743a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2e39459-7f00-473b-a342-8d460c7c2c07" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_26bb1d4d-7479-4f6a-9ac1-f5c7e6bb743a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_270e3405-5b7d-49f7-9b87-74499c03b1cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2e39459-7f00-473b-a342-8d460c7c2c07" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_270e3405-5b7d-49f7-9b87-74499c03b1cc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_998c2639-a587-4999-8381-fbc116922718" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2e39459-7f00-473b-a342-8d460c7c2c07" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_998c2639-a587-4999-8381-fbc116922718" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_522c8a90-1be4-410d-bc4d-3d48af3ca7d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2e39459-7f00-473b-a342-8d460c7c2c07" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_522c8a90-1be4-410d-bc4d-3d48af3ca7d3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_81a6c59a-e973-4b8b-87e9-f0c6a0f77908" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2e39459-7f00-473b-a342-8d460c7c2c07" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_81a6c59a-e973-4b8b-87e9-f0c6a0f77908" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockPurchasePlanDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockPurchasePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_34489fb7-df00-466d-ba60-fb7abfd24141" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4c4077f-3c50-47df-a878-3e6182dcae91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_34489fb7-df00-466d-ba60-fb7abfd24141" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4c4077f-3c50-47df-a878-3e6182dcae91" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5484f6e8-68e1-47ae-87b3-2021f1a0fc5b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4c4077f-3c50-47df-a878-3e6182dcae91" xlink:to="loc_srt_RangeAxis_5484f6e8-68e1-47ae-87b3-2021f1a0fc5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5484f6e8-68e1-47ae-87b3-2021f1a0fc5b_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5484f6e8-68e1-47ae-87b3-2021f1a0fc5b" xlink:to="loc_srt_RangeMember_5484f6e8-68e1-47ae-87b3-2021f1a0fc5b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9a0e2b65-d3e4-4a81-9932-e3a2b0add0ef" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5484f6e8-68e1-47ae-87b3-2021f1a0fc5b" xlink:to="loc_srt_RangeMember_9a0e2b65-d3e4-4a81-9932-e3a2b0add0ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_51ff161e-fa6f-49bd-ac8b-fc1dcc76abda" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9a0e2b65-d3e4-4a81-9932-e3a2b0add0ef" xlink:to="loc_srt_MinimumMember_51ff161e-fa6f-49bd-ac8b-fc1dcc76abda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9c8495dc-a791-42a3-835d-cfd810219019" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9a0e2b65-d3e4-4a81-9932-e3a2b0add0ef" xlink:to="loc_srt_MaximumMember_9c8495dc-a791-42a3-835d-cfd810219019" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_16700ca0-049c-48c5-855a-08d9388bf004" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4c4077f-3c50-47df-a878-3e6182dcae91" xlink:to="loc_us-gaap_PlanNameAxis_16700ca0-049c-48c5-855a-08d9388bf004" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_16700ca0-049c-48c5-855a-08d9388bf004_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_16700ca0-049c-48c5-855a-08d9388bf004" xlink:to="loc_us-gaap_PlanNameDomain_16700ca0-049c-48c5-855a-08d9388bf004_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d7479c30-fd28-429e-bfc0-cac2f25aad00" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_16700ca0-049c-48c5-855a-08d9388bf004" xlink:to="loc_us-gaap_PlanNameDomain_d7479c30-fd28-429e-bfc0-cac2f25aad00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EmployeeStockPurchasePlanMember_b189d79f-9d2d-4bc0-8717-5ca442495f69" xlink:href="pacb-20250930.xsd#pacb_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d7479c30-fd28-429e-bfc0-cac2f25aad00" xlink:to="loc_pacb_EmployeeStockPurchasePlanMember_b189d79f-9d2d-4bc0-8717-5ca442495f69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_242ad909-19d1-4c52-bea7-706d5ae3293d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_34489fb7-df00-466d-ba60-fb7abfd24141" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_242ad909-19d1-4c52-bea7-706d5ae3293d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_9459a471-c7b2-48e5-a5cc-2bcea324fcee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_34489fb7-df00-466d-ba60-fb7abfd24141" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_9459a471-c7b2-48e5-a5cc-2bcea324fcee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_5ae1b9fa-8695-4634-8275-32aa4bad13d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_34489fb7-df00-466d-ba60-fb7abfd24141" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_5ae1b9fa-8695-4634-8275-32aa4bad13d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_72eb76f2-3429-4e4b-93e9-0a0c54c1ccad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_34489fb7-df00-466d-ba60-fb7abfd24141" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_72eb76f2-3429-4e4b-93e9-0a0c54c1ccad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_4c88e4f4-5853-438e-9f07-35ef37d40024" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_34489fb7-df00-466d-ba60-fb7abfd24141" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_4c88e4f4-5853-438e-9f07-35ef37d40024" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5cbf3dfd-b4c8-406b-bb07-be65ea2c98e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_34489fb7-df00-466d-ba60-fb7abfd24141" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5cbf3dfd-b4c8-406b-bb07-be65ea2c98e2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_12830ef9-99db-4b70-aff6-7208c1be6118" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_34489fb7-df00-466d-ba60-fb7abfd24141" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_12830ef9-99db-4b70-aff6-7208c1be6118" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSharesExcludedFromComputationofDilutedNetLossperShareDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#NETLOSSPERSHAREScheduleofAntidilutiveSharesExcludedFromComputationofDilutedNetLossperShareDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSharesExcludedFromComputationofDilutedNetLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2a0b823c-a18e-4566-a5c2-0183117cf6a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_af4cd243-62b8-4c63-81c4-928a5ee17b40" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2a0b823c-a18e-4566-a5c2-0183117cf6a9" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_af4cd243-62b8-4c63-81c4-928a5ee17b40" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a24270ba-5ef6-4a19-a21f-2f35955702ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_af4cd243-62b8-4c63-81c4-928a5ee17b40" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a24270ba-5ef6-4a19-a21f-2f35955702ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a24270ba-5ef6-4a19-a21f-2f35955702ba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a24270ba-5ef6-4a19-a21f-2f35955702ba" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a24270ba-5ef6-4a19-a21f-2f35955702ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_45fd931e-5e8e-448a-8059-910e24e02dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a24270ba-5ef6-4a19-a21f-2f35955702ba" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_45fd931e-5e8e-448a-8059-910e24e02dc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_f7c7b9f8-0984-48ed-b913-092eac48bcbd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_45fd931e-5e8e-448a-8059-910e24e02dc0" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_f7c7b9f8-0984-48ed-b913-092eac48bcbd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_38e60370-29f8-407a-a86a-981915a2e8ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_45fd931e-5e8e-448a-8059-910e24e02dc0" xlink:to="loc_us-gaap_StockCompensationPlanMember_38e60370-29f8-407a-a86a-981915a2e8ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_dd9470e8-8718-4096-a77d-adadd664499f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2a0b823c-a18e-4566-a5c2-0183117cf6a9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_dd9470e8-8718-4096-a77d-adadd664499f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_2616a3d9-6c82-4a0b-b6fc-feb79aee774b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a684c5b2-5e22-4a5d-844b-3b28d77c1c64" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2616a3d9-6c82-4a0b-b6fc-feb79aee774b" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a684c5b2-5e22-4a5d-844b-3b28d77c1c64" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_5ea3f6b3-1bdd-450b-a8a5-64deb9547d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a684c5b2-5e22-4a5d-844b-3b28d77c1c64" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_5ea3f6b3-1bdd-450b-a8a5-64deb9547d3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5ea3f6b3-1bdd-450b-a8a5-64deb9547d3d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5ea3f6b3-1bdd-450b-a8a5-64deb9547d3d" xlink:to="loc_us-gaap_SegmentDomain_5ea3f6b3-1bdd-450b-a8a5-64deb9547d3d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_88fa4684-85a0-4485-8d31-0992ec7b827e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5ea3f6b3-1bdd-450b-a8a5-64deb9547d3d" xlink:to="loc_us-gaap_SegmentDomain_88fa4684-85a0-4485-8d31-0992ec7b827e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ReportableSegmentMember_71cf826c-0e65-47d5-a7be-48a1abd7cb0c" xlink:href="pacb-20250930.xsd#pacb_ReportableSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_88fa4684-85a0-4485-8d31-0992ec7b827e" xlink:to="loc_pacb_ReportableSegmentMember_71cf826c-0e65-47d5-a7be-48a1abd7cb0c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_0e8ea88e-befd-48c9-bb80-e1ee1ee4eae3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2616a3d9-6c82-4a0b-b6fc-feb79aee774b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_0e8ea88e-befd-48c9-bb80-e1ee1ee4eae3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_f652306a-0ff4-4a60-8d82-6869389445d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2616a3d9-6c82-4a0b-b6fc-feb79aee774b" xlink:to="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_f652306a-0ff4-4a60-8d82-6869389445d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_739a96ad-143b-4899-8619-62f66b4f62ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_f652306a-0ff4-4a60-8d82-6869389445d7" xlink:to="loc_us-gaap_CostOfRevenue_739a96ad-143b-4899-8619-62f66b4f62ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_28539b92-17ee-4bb2-851c-17be26f559d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_f652306a-0ff4-4a60-8d82-6869389445d7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_28539b92-17ee-4bb2-851c-17be26f559d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_f597b1c0-77a5-4eff-a5c5-51f461c1d05c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_f652306a-0ff4-4a60-8d82-6869389445d7" xlink:to="loc_us-gaap_SellingAndMarketingExpense_f597b1c0-77a5-4eff-a5c5-51f461c1d05c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_9aecc34e-57a2-402b-a9f2-1a7d116a75aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_f652306a-0ff4-4a60-8d82-6869389445d7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_9aecc34e-57a2-402b-a9f2-1a7d116a75aa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_823b4c22-133a-46ef-92b7-cbc8329c070d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_f652306a-0ff4-4a60-8d82-6869389445d7" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_823b4c22-133a-46ef-92b7-cbc8329c070d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_717bac7f-f5cd-4d09-b189-2cb135459da9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_f652306a-0ff4-4a60-8d82-6869389445d7" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_717bac7f-f5cd-4d09-b189-2cb135459da9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_cc407e8a-6c34-427e-969a-95167d1b7bca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_f652306a-0ff4-4a60-8d82-6869389445d7" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_cc407e8a-6c34-427e-969a-95167d1b7bca" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_66364b41-ea54-4195-9697-f3a00bcb4245" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2616a3d9-6c82-4a0b-b6fc-feb79aee774b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_66364b41-ea54-4195-9697-f3a00bcb4245" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a5caa3be-74f6-4a8c-86ed-a17c39a67d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2616a3d9-6c82-4a0b-b6fc-feb79aee774b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a5caa3be-74f6-4a8c-86ed-a17c39a67d5d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_45a269cf-10a7-4e2b-910a-ed10a30d3418" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2616a3d9-6c82-4a0b-b6fc-feb79aee774b" xlink:to="loc_us-gaap_NetIncomeLoss_45a269cf-10a7-4e2b-910a-ed10a30d3418" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_7738ec1b-e3c6-441d-9244-36fef0588758" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_79b90f82-2785-452a-a415-c72e904becf8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_7738ec1b-e3c6-441d-9244-36fef0588758" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_79b90f82-2785-452a-a415-c72e904becf8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_6fd06481-1fea-41ee-88e3-7748b07852c1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_79b90f82-2785-452a-a415-c72e904becf8" xlink:to="loc_srt_StatementGeographicalAxis_6fd06481-1fea-41ee-88e3-7748b07852c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6fd06481-1fea-41ee-88e3-7748b07852c1_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_6fd06481-1fea-41ee-88e3-7748b07852c1" xlink:to="loc_srt_SegmentGeographicalDomain_6fd06481-1fea-41ee-88e3-7748b07852c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1cba43bb-661e-4229-8f87-50b2129b5fff" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_6fd06481-1fea-41ee-88e3-7748b07852c1" xlink:to="loc_srt_SegmentGeographicalDomain_1cba43bb-661e-4229-8f87-50b2129b5fff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AmericasMember_1d2471e9-9955-4281-8a20-46f3699ff52a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_AmericasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1cba43bb-661e-4229-8f87-50b2129b5fff" xlink:to="loc_srt_AmericasMember_1d2471e9-9955-4281-8a20-46f3699ff52a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember_bbf27231-c138-43c0-8477-4073ac5edc4d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EMEAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1cba43bb-661e-4229-8f87-50b2129b5fff" xlink:to="loc_us-gaap_EMEAMember_bbf27231-c138-43c0-8477-4073ac5edc4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember_394d45ae-92cb-4b09-990c-d48cd4ee8b7e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_AsiaPacificMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1cba43bb-661e-4229-8f87-50b2129b5fff" xlink:to="loc_srt_AsiaPacificMember_394d45ae-92cb-4b09-990c-d48cd4ee8b7e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_a23fdde0-29d9-410f-ba1a-bd197e464f81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_7738ec1b-e3c6-441d-9244-36fef0588758" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_a23fdde0-29d9-410f-ba1a-bd197e464f81" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails"/>
  <link:definitionLink xlink:role="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0dda7d01-b30d-4447-b2cd-6d33a07db4c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_b47fd0d8-0450-47a7-af3e-df5b0489f695" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0dda7d01-b30d-4447-b2cd-6d33a07db4c1" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_b47fd0d8-0450-47a7-af3e-df5b0489f695" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f7803669-c168-49d0-b057-89a64d799673" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_b47fd0d8-0450-47a7-af3e-df5b0489f695" xlink:to="loc_srt_ProductOrServiceAxis_f7803669-c168-49d0-b057-89a64d799673" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f7803669-c168-49d0-b057-89a64d799673_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f7803669-c168-49d0-b057-89a64d799673" xlink:to="loc_srt_ProductsAndServicesDomain_f7803669-c168-49d0-b057-89a64d799673_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_32a9b750-142e-4259-a773-8d5dc6ec0226" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f7803669-c168-49d0-b057-89a64d799673" xlink:to="loc_srt_ProductsAndServicesDomain_32a9b750-142e-4259-a773-8d5dc6ec0226" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_ba549640-0dae-4f95-9996-2e5b532034f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_32a9b750-142e-4259-a773-8d5dc6ec0226" xlink:to="loc_us-gaap_ProductMember_ba549640-0dae-4f95-9996-2e5b532034f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_InstrumentMember_d112c321-1b42-4b12-996d-8c1d655411a6" xlink:href="pacb-20250930.xsd#pacb_InstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_ba549640-0dae-4f95-9996-2e5b532034f3" xlink:to="loc_pacb_InstrumentMember_d112c321-1b42-4b12-996d-8c1d655411a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ConsumableMember_4c482de8-f5f5-4436-b55c-8bfcbc2f6076" xlink:href="pacb-20250930.xsd#pacb_ConsumableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_ba549640-0dae-4f95-9996-2e5b532034f3" xlink:to="loc_pacb_ConsumableMember_4c482de8-f5f5-4436-b55c-8bfcbc2f6076" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ServiceAndOtherMember_75808362-5e13-4d4e-8276-7a3681ece986" xlink:href="pacb-20250930.xsd#pacb_ServiceAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_32a9b750-142e-4259-a773-8d5dc6ec0226" xlink:to="loc_pacb_ServiceAndOtherMember_75808362-5e13-4d4e-8276-7a3681ece986" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_6c8708d7-d8a6-4bf9-aec6-426848f96924" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0dda7d01-b30d-4447-b2cd-6d33a07db4c1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_6c8708d7-d8a6-4bf9-aec6-426848f96924" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:type="arc" order="691"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>pacb-20250930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:541066b6-d2f9-469d-bf86-6042e3dcfaa4,g:e6194c68-cd08-4fb8-9cf2-74de760e8618-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e96940f6-a371-4df4-9113-b798861b823a_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_TimeBasedRestrictedStockUnitsRsusMember_9d18af03-a12a-43b9-b542-70b99f3f1650_terseLabel_en-US" xlink:label="lab_pacb_TimeBasedRestrictedStockUnitsRsusMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSU)</link:label>
    <link:label id="lab_pacb_TimeBasedRestrictedStockUnitsRsusMember_label_en-US" xlink:label="lab_pacb_TimeBasedRestrictedStockUnitsRsusMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Time Based Restricted Stock Units Rsus [Member]</link:label>
    <link:label id="lab_pacb_TimeBasedRestrictedStockUnitsRsusMember_documentation_en-US" xlink:label="lab_pacb_TimeBasedRestrictedStockUnitsRsusMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Time-Based Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedRestrictedStockUnitsRsusMember" xlink:href="pacb-20250930.xsd#pacb_TimeBasedRestrictedStockUnitsRsusMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_TimeBasedRestrictedStockUnitsRsusMember" xlink:to="lab_pacb_TimeBasedRestrictedStockUnitsRsusMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_af6bcc27-5b64-420b-a7a1-d07edfdc6979_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_01b1fc1e-0381-443b-9869-3cccecfac1ce_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated total restructuring costs to still be incurred</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Expected Cost Remaining</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_eecdafa8-4d68-4b76-adc8-77ccd0caa53d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductWarrantyAccrual_5f742276-6429-46ce-9535-a470bba711b3_periodStartLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrual" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyAccrual_c43522c3-20c9-4554-a344-f18f21c2c34d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrual" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyAccrual_label_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Standard and Extended Product Warranty Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrual" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductWarrantyAccrual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductWarrantyAccrual" xlink:to="lab_us-gaap_ProductWarrantyAccrual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_a7bd5f70-62b2-4226-846c-268d219d179a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_53ed9f7b-473a-4f19-b8e4-443440104095_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_ec5f2e7e-2e70-4e14-a78a-02313bcd4b66_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_2f6ce314-645f-4379-9a32-efba9765ddc3_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_80059c55-5a33-4bc3-b0e8-dbdbbf58e78c_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtInstrumentDebtDefaultCalendarDays_75f24316-02d7-44b5-85c1-f650d1b96022_terseLabel_en-US" xlink:label="lab_pacb_DebtInstrumentDebtDefaultCalendarDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, debt default, calendar days</link:label>
    <link:label id="lab_pacb_DebtInstrumentDebtDefaultCalendarDays_label_en-US" xlink:label="lab_pacb_DebtInstrumentDebtDefaultCalendarDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Debt Default, Calendar Days</link:label>
    <link:label id="lab_pacb_DebtInstrumentDebtDefaultCalendarDays_documentation_en-US" xlink:label="lab_pacb_DebtInstrumentDebtDefaultCalendarDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Debt Default, Calendar Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentDebtDefaultCalendarDays" xlink:href="pacb-20250930.xsd#pacb_DebtInstrumentDebtDefaultCalendarDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtInstrumentDebtDefaultCalendarDays" xlink:to="lab_pacb_DebtInstrumentDebtDefaultCalendarDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_0469fc66-0cc3-4a79-83e9-e3983aafc1fa_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_96cfb35e-8154-4d29-934d-5e49995d073a_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_A2028ConvertibleSeniorNotesMember_0c42ecca-ee2e-4c47-9d98-7e3996167611_terseLabel_en-US" xlink:label="lab_pacb_A2028ConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028 Convertible Senior Notes</link:label>
    <link:label id="lab_pacb_A2028ConvertibleSeniorNotesMember_label_en-US" xlink:label="lab_pacb_A2028ConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2028 Convertible Senior Notes [Member]</link:label>
    <link:label id="lab_pacb_A2028ConvertibleSeniorNotesMember_documentation_en-US" xlink:label="lab_pacb_A2028ConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2028ConvertibleSeniorNotesMember" xlink:href="pacb-20250930.xsd#pacb_A2028ConvertibleSeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_A2028ConvertibleSeniorNotesMember" xlink:to="lab_pacb_A2028ConvertibleSeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_0b856dc2-bc0a-4195-912d-27d29c4b8c04_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_b7d12dd1-e1d8-46ca-83f3-fbfb8601e653_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_TimeBasedRestrictedStockUnitsPSUMember_2ca81479-1974-451c-8209-f48309d365dd_terseLabel_en-US" xlink:label="lab_pacb_TimeBasedRestrictedStockUnitsPSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Time Based Restricted Stock Units PSU</link:label>
    <link:label id="lab_pacb_TimeBasedRestrictedStockUnitsPSUMember_label_en-US" xlink:label="lab_pacb_TimeBasedRestrictedStockUnitsPSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Time Based Restricted Stock Units PSU [Member]</link:label>
    <link:label id="lab_pacb_TimeBasedRestrictedStockUnitsPSUMember_documentation_en-US" xlink:label="lab_pacb_TimeBasedRestrictedStockUnitsPSUMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Time Based Restricted Stock Units PSU</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedRestrictedStockUnitsPSUMember" xlink:href="pacb-20250930.xsd#pacb_TimeBasedRestrictedStockUnitsPSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_TimeBasedRestrictedStockUnitsPSUMember" xlink:to="lab_pacb_TimeBasedRestrictedStockUnitsPSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_c8c901bf-5a85-4c54-a4a2-835fcf494d2a_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity awards</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_4704b850-51eb-4dd1-9974-8746ec013221_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0ebd5173-c7df-40e4-bd2c-1daff1b8f1e1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_f4851f0c-8b72-4e7b-9f21-b793f446ee2a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_d6b1ba84-8eff-4380-96f3-7ff1a978aa93_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic net loss per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_b7f4cb5c-de84-4c04-b3ce-1b983f955dc1_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Inventory, gross</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0a30f467-74e8-4fc4-a65b-eb94445e1da6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_1d111cf3-c02b-4463-8491-cf0f0e3dec8a_terseLabel_en-US" xlink:label="lab_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Components [Abstract]</link:label>
    <link:label id="lab_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_label_en-US" xlink:label="lab_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Components [Abstract]</link:label>
    <link:label id="lab_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_documentation_en-US" xlink:label="lab_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Components Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:href="pacb-20250930.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:to="lab_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ScheduleOfInterestExpenseTableTextBlock_f34b8c4b-1eb6-41c2-9ef5-07e6bce0c398_terseLabel_en-US" xlink:label="lab_pacb_ScheduleOfInterestExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Interest Expense</link:label>
    <link:label id="lab_pacb_ScheduleOfInterestExpenseTableTextBlock_label_en-US" xlink:label="lab_pacb_ScheduleOfInterestExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Interest Expense [Table Text Block]</link:label>
    <link:label id="lab_pacb_ScheduleOfInterestExpenseTableTextBlock_documentation_en-US" xlink:label="lab_pacb_ScheduleOfInterestExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Interest Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ScheduleOfInterestExpenseTableTextBlock" xlink:href="pacb-20250930.xsd#pacb_ScheduleOfInterestExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ScheduleOfInterestExpenseTableTextBlock" xlink:to="lab_pacb_ScheduleOfInterestExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_fd2d8a72-1e9f-4d49-b8c0-70dfebed004c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Profit or Loss</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_2334b6c3-2a8e-464e-a752-b78a8f2d3f37_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional common stock purchased under plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_fe9ed570-5d15-4b1d-82d5-628c8e43fcfd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold percentage of stock price trigger</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_6e62bb55-3f72-4ed7-a932-550117acee47_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Asset, Indefinite-Lived [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Indefinite-Lived [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ExchangeTransactionMember_1cc562c3-60af-4c4e-a6c8-f4ea8df9802e_terseLabel_en-US" xlink:label="lab_pacb_ExchangeTransactionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exchange Transaction</link:label>
    <link:label id="lab_pacb_ExchangeTransactionMember_label_en-US" xlink:label="lab_pacb_ExchangeTransactionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exchange Transaction [Member]</link:label>
    <link:label id="lab_pacb_ExchangeTransactionMember_documentation_en-US" xlink:label="lab_pacb_ExchangeTransactionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exchange Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ExchangeTransactionMember" xlink:href="pacb-20250930.xsd#pacb_ExchangeTransactionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ExchangeTransactionMember" xlink:to="lab_pacb_ExchangeTransactionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_21016da2-7448-404f-9d63-1ec4ea7e8a3b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash, Cash Equivalents, Restricted Cash and Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, and Investment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_13df32e1-33e7-4699-b758-f1af5cc96350_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, non-current</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage_1802eb51-32b5-47af-ab82-10a440980f6e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, remaining performance obligation, percentage</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_9c9e2254-2bf6-40a9-abd4-30a319c6395d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_63b300f7-6552-45c5-8df8-0c8080df8e3a_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_A2025RestructuringMember_6a93a90a-8b94-4854-8371-11d8a818cdc6_terseLabel_en-US" xlink:label="lab_pacb_A2025RestructuringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025 Restructuring</link:label>
    <link:label id="lab_pacb_A2025RestructuringMember_label_en-US" xlink:label="lab_pacb_A2025RestructuringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2025 Restructuring [Member]</link:label>
    <link:label id="lab_pacb_A2025RestructuringMember_documentation_en-US" xlink:label="lab_pacb_A2025RestructuringMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2025 Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2025RestructuringMember" xlink:href="pacb-20250930.xsd#pacb_A2025RestructuringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_A2025RestructuringMember" xlink:to="lab_pacb_A2025RestructuringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_c3c4a4bb-ce4a-4f4a-8253-22987735ebae_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. government &amp; agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government Corporations and Agencies Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_f54eb101-f8b5-4911-a5be-8fabdb64410a_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_c87c7611-4bc1-49d2-8710-5d1b3643e8f5_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Investments</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ffccbd70-71d3-4fac-adf4-06a17845fd45_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_e8cecbfb-f844-40ac-b3fb-87ac856cc970_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_6b16f8a5-71a8-41c4-8a37-83787506561e_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_ad947a23-93a7-4055-b703-a229e95b2062_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_219c31ac-fba6-4d35-90e9-a1af26863df4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_1163bdfd-bd75-4b65-a0b3-40af04e83000_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_1b0f803a-505a-47ba-b630-456a5b81048c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_519018b7-2125-4087-ba4e-9d000a34e060_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_caa5e2e8-abce-463a-ad49-01f50ab2ff21_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_AmortizationOfAcquiredIntangibleAssets_8da4123e-034c-405e-93e9-5ebad7e2d32b_terseLabel_en-US" xlink:label="lab_pacb_AmortizationOfAcquiredIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of acquired intangible assets</link:label>
    <link:label id="lab_pacb_AmortizationOfAcquiredIntangibleAssets_label_en-US" xlink:label="lab_pacb_AmortizationOfAcquiredIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization Of Acquired Intangible Assets</link:label>
    <link:label id="lab_pacb_AmortizationOfAcquiredIntangibleAssets_documentation_en-US" xlink:label="lab_pacb_AmortizationOfAcquiredIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amortization Of Acquired Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AmortizationOfAcquiredIntangibleAssets" xlink:href="pacb-20250930.xsd#pacb_AmortizationOfAcquiredIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_AmortizationOfAcquiredIntangibleAssets" xlink:to="lab_pacb_AmortizationOfAcquiredIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_54a704ae-65be-40f6-b7e6-98cdf4b49c9e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_StockBasedCompensationMember_b3dd6410-56a7-4ce6-b8dc-5f7794334eaa_terseLabel_en-US" xlink:label="lab_pacb_StockBasedCompensationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total share-based compensation expense</link:label>
    <link:label id="lab_pacb_StockBasedCompensationMember_label_en-US" xlink:label="lab_pacb_StockBasedCompensationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Based Compensation [Member]</link:label>
    <link:label id="lab_pacb_StockBasedCompensationMember_documentation_en-US" xlink:label="lab_pacb_StockBasedCompensationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock-based compensation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockBasedCompensationMember" xlink:href="pacb-20250930.xsd#pacb_StockBasedCompensationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_StockBasedCompensationMember" xlink:to="lab_pacb_StockBasedCompensationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_bb3153cc-15b6-48eb-b1f2-fbdddb0e2a13_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_7933f650-643a-4bf0-acb0-03e1e00ab763_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock purchased under plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Ownership Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_41820445-d99a-45e6-ab8e-69871baf8569_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_d0fc2414-3278-4f72-bc35-970f9b605116_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_6a9dc854-0c4e-4294-992b-84ba910c155c_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative amount incurred to date</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Incurred Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:to="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_99507c97-6b41-4518-bb83-d96aa1aabfda_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_15d1a21d-ec87-40fa-bcd3-d02af3b305ae_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold consecutive trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_c8ab146c-fdae-4ac7-ba04-e75f0418e828_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization_a4afa280-a9d4-4b94-bf24-5584442e18ff_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_13dd3399-7340-4572-8c77-09354b9fbc64_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated Useful Life (in years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm_c1e8959b-321c-4705-828d-747fef4110eb_terseLabel_en-US" xlink:label="lab_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible asset impairment, discounted cash flow model, term (in years)</link:label>
    <link:label id="lab_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm_label_en-US" xlink:label="lab_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset Impairment, Discounted Cash Flow Model, Term</link:label>
    <link:label id="lab_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm_documentation_en-US" xlink:label="lab_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible Asset Impairment, Discounted Cash Flow Model, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm" xlink:href="pacb-20250930.xsd#pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm" xlink:to="lab_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_4efb83d0-7508-49cb-ab65-6e6a11b6065c_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_8a497ec4-9d50-44df-b6f6-30288730efd5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6120700e-e478-4695-8a1e-b45283f20f38_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_fc9ceff7-0a9d-49a3-8795-790b3173cc78_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_StandardProductWarrantyPeriod_8b680090-1a02-47a4-855d-2c36a7225b49_terseLabel_en-US" xlink:label="lab_pacb_StandardProductWarrantyPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Standard product warranty, period</link:label>
    <link:label id="lab_pacb_StandardProductWarrantyPeriod_label_en-US" xlink:label="lab_pacb_StandardProductWarrantyPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Standard Product Warranty, Period</link:label>
    <link:label id="lab_pacb_StandardProductWarrantyPeriod_documentation_en-US" xlink:label="lab_pacb_StandardProductWarrantyPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Standard Product Warranty, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StandardProductWarrantyPeriod" xlink:href="pacb-20250930.xsd#pacb_StandardProductWarrantyPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_StandardProductWarrantyPeriod" xlink:to="lab_pacb_StandardProductWarrantyPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_3a165d53-f756-42cf-8c46-e92c900f80b9_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest_ea5b10b1-de6d-4872-be61-38b8ef7e73bd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Paid accrued but unpaid interest</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8a4e78cd-68a3-4be8-894e-f7c414a5138f_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_8ed346b7-0bdc-4335-ae65-bc05d202a89e_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_7f4c3ec1-86d9-4e3d-9373-31f4ae491c79_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities, non-current</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_8cf8bf1c-a633-4628-ad79-4b6569bd4ee8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_d40c4ec3-c5ad-4943-b93c-4c289e425f02_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment charges</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_8bab6616-decb-495d-9d83-0d643fc956d9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_5509b48a-3b5f-485b-a407-73d8575cc172_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_7fc1c5fa-69cf-4ac3-a2df-aaf8ad692efb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_28742151-fa12-4eae-82c6-6e4c61b20410_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays_6a21d7e5-e279-49b7-96b0-3e7c7f259053_terseLabel_en-US" xlink:label="lab_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt redemption, consecutive trading days</link:label>
    <link:label id="lab_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays_label_en-US" xlink:label="lab_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Consecutive Trading Days</link:label>
    <link:label id="lab_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays_documentation_en-US" xlink:label="lab_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays" xlink:href="pacb-20250930.xsd#pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays" xlink:to="lab_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_bc9e419f-fb50-428e-b449-d5e9c1927037_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_58641ab3-9e9c-4d92-a492-758165a76eff_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_42105c72-8e1a-49ce-8d6d-ed700630a5a6_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_b7f65138-d78b-41ed-99ff-a0d5a0dae227_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_0e77adaa-619b-48a7-afc1-fa61f959ee1f_negatedLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accretion of discount and amortization of premium on marketable securities, net</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Net, Amortization of Discount and Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_63987a71-e21c-4d95-9f8b-9af0013e97d5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_b0404a47-f664-46b0-bc49-10a6abad0e9e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Changes in the Estimated Fair Value of Contingent Consideration Liability</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_1e949896-bad3-4d9e-98f4-c5b1035f2585_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward_e11fa61c-a3aa-4d58-b56d-e7d2c7e14ae2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_cbc57ef1-14f5-474e-9cf3-221f0ab4d9e5_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageRateOfTimeDepositsAbstract_06e70c19-d610-4483-b22f-eaf372e35a77_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageRateOfTimeDepositsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageRateOfTimeDepositsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageRateOfTimeDepositsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Rate of Time Deposits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageRateOfTimeDepositsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageRateOfTimeDepositsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageRateOfTimeDepositsAbstract" xlink:to="lab_us-gaap_WeightedAverageRateOfTimeDepositsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualPayments_1f9f9090-1b15-4cb1-9bb7-2063a4639eaa_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repairs and replacements</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualPayments_label_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Standard and Extended Product Warranty Accrual, Decrease for Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductWarrantyAccrualPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductWarrantyAccrualPayments" xlink:to="lab_us-gaap_ProductWarrantyAccrualPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_GainLossOnPurchaseCommitments_99f584d6-8134-4383-88b5-1f9d9c632af4_terseLabel_en-US" xlink:label="lab_pacb_GainLossOnPurchaseCommitments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on purchase commitments</link:label>
    <link:label id="lab_pacb_GainLossOnPurchaseCommitments_label_en-US" xlink:label="lab_pacb_GainLossOnPurchaseCommitments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain Loss On Purchase Commitments</link:label>
    <link:label id="lab_pacb_GainLossOnPurchaseCommitments_documentation_en-US" xlink:label="lab_pacb_GainLossOnPurchaseCommitments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain Loss On Purchase Commitments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_GainLossOnPurchaseCommitments" xlink:href="pacb-20250930.xsd#pacb_GainLossOnPurchaseCommitments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_GainLossOnPurchaseCommitments" xlink:to="lab_pacb_GainLossOnPurchaseCommitments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_618ae5a8-2aab-4a48-af68-ad78270f8e63_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_512ff825-645b-48e8-9e5c-d7860ddb8d96_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_189ae812-dd38-4850-9777-7f1a6421df95_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, non-current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_5bfff28e-1d46-4ec2-9d06-8510b82f0072_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate outstanding balance</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_0ede08a7-cd8d-4afd-99a7-7aa1ee536082_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net carrying amount</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_2d0ba00b-5e7e-4466-ab96-ebeac1bfbf4d_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_7b2854d4-820e-4029-936e-d5690245ad87_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_bb32c790-3217-450a-9b50-8d629865e010_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_55ce9758-001e-42e1-8a1d-41088e6b66d1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualWarrantiesIssued_aa0701a6-842d-4dce-b603-d1c71f00872f_terseLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualWarrantiesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions charged to cost of product revenue</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualWarrantiesIssued_label_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualWarrantiesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Standard and Extended Product Warranty Accrual, Increase for Warranties Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualWarrantiesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductWarrantyAccrualWarrantiesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductWarrantyAccrualWarrantiesIssued" xlink:to="lab_us-gaap_ProductWarrantyAccrualWarrantiesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_ffa90b40-9c9b-44b7-932f-1aa07ec8d572_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment, Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_7aa291f3-6f4a-48ae-9046-b51644e443bd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets From Business Acquisitions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_3c0537ca-e102-4fb0-9585-61bccd2e03b4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in conjunction with equity plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_657f232e-cde1-4746-b8f6-bf5a42d608bc_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5cbd56a7-341d-4927-9524-c20c8a82e56a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_76076d1c-5ea8-4376-aa81-5fe6144a5835_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_554a28b1-bb55-467d-a47f-23968bb13739_terseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Severance costs</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_1c365d81-704c-454c-a102-bc583a4b484e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_91d039a2-4145-4f8c-9877-1c1d9109f94a_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_6ad789c0-d7d4-4d67-8b0c-be34c8163b78_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_b9bdd34e-c090-484c-af92-5bb402555045_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_b76f3351-2fe4-4d8e-b256-0a337fedf6d5_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use asset and lease liability recognized due to lease extension</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_94713cea-a6f7-42be-9ce0-c0f09639eb3d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_65370761-3924-49fc-b407-335510b0d6aa_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8b15012e-3038-4182-a885-7bf8023556df_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_1bc02881-5569-4fd9-aa5a-f24bfde6973d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_3e3f32a7-964e-4afd-a3f9-73498ad516a7_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_ce6d848b-7c6b-421c-b504-53878bb0621f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_b72c0217-006f-461a-83fe-a5a3d3384518_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_f0464682-9a38-4514-8939-066c800c7841_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_5be1f7cb-f2c5-4f29-bf76-11965c223ae5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_4e2157dc-f89f-41c8-8519-8f40d57d23d1_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_49561ff3-5fd0-4fc2-9f1d-aea892a703a8_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_3ca1d82a-13ae-452d-a2e7-8b3506b11b30_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_5ec9b69b-809a-438b-b708-3b66bf3f0838_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5afefed3-769c-40be-b05e-212444634641_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ServiceAndOtherMember_af660cc8-7746-4952-866e-8e4d535bd9d4_terseLabel_en-US" xlink:label="lab_pacb_ServiceAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Service and other revenue</link:label>
    <link:label id="lab_pacb_ServiceAndOtherMember_label_en-US" xlink:label="lab_pacb_ServiceAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Service And Other [Member]</link:label>
    <link:label id="lab_pacb_ServiceAndOtherMember_documentation_en-US" xlink:label="lab_pacb_ServiceAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Service and Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ServiceAndOtherMember" xlink:href="pacb-20250930.xsd#pacb_ServiceAndOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ServiceAndOtherMember" xlink:to="lab_pacb_ServiceAndOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock_9e3b2c24-8bfb-4591-afca-63e4bc1ed92e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Changes in Reserve for Product Warranties</link:label>
    <link:label id="lab_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Product Warranty Liability [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_0f7eafc2-3cd2-4ba2-8cef-806fa5efbee2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Estimated Future Amortization Expense of Acquisition-Related Intangible Assets with Definite Lives</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_5385f5a3-a73e-4c78-b14a-f6ba2e6be4f7_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c908918d-9b08-48c2-87d2-8e26483807a8_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_fbaca4df-c925-4162-8983-5e43be23843d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_85220907-bdad-4740-b5b9-18d73cacab1e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_39a737e5-56c4-457f-a97e-bef50a6bf26b_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_00ded2b9-ed97-4a57-bf8b-473cb4526d84_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bf2e85d7-c62c-4467-a1cf-93b878413b53_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_69bd4c2e-8b14-40b7-91d1-8172b2413517_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_d3c1491d-8250-4d5c-9a8b-5952182a725a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_7e3348be-e532-4835-9eec-e0ae8fd8d7cb_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income tax provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_LossOnPurchaseCommitment_12fb23bf-07c4-47d5-b45f-4b8a4dc67074_terseLabel_en-US" xlink:label="lab_pacb_LossOnPurchaseCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on purchase commitment</link:label>
    <link:label id="lab_pacb_LossOnPurchaseCommitment_label_en-US" xlink:label="lab_pacb_LossOnPurchaseCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss On Purchase Commitment</link:label>
    <link:label id="lab_pacb_LossOnPurchaseCommitment_documentation_en-US" xlink:label="lab_pacb_LossOnPurchaseCommitment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss On Purchase Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LossOnPurchaseCommitment" xlink:href="pacb-20250930.xsd#pacb_LossOnPurchaseCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_LossOnPurchaseCommitment" xlink:to="lab_pacb_LossOnPurchaseCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_449b121d-f9a3-41d0-a1ab-90b5970dedf6_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments:</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_7d2dfc87-4992-41d1-80f5-985f8250cab3_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_cfc1b28f-b239-498b-8734-466517e10b1d_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_438ee626-88db-4506-82c8-d626f807e5d1_periodStartLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_1a2ba351-0351-4863-9ef4-a700da0c1338_periodEndLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_e12de470-2043-4f41-8fda-7952f5437c26_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_98dc7706-fce0-4791-80c3-5d35a0c23f5a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ReportableSegmentMember_04191475-39b2-4951-bb11-646977bbd336_terseLabel_en-US" xlink:label="lab_pacb_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:label id="lab_pacb_ReportableSegmentMember_label_en-US" xlink:label="lab_pacb_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reportable Segment [Member]</link:label>
    <link:label id="lab_pacb_ReportableSegmentMember_documentation_en-US" xlink:label="lab_pacb_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ReportableSegmentMember" xlink:href="pacb-20250930.xsd#pacb_ReportableSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ReportableSegmentMember" xlink:to="lab_pacb_ReportableSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_6fd7a083-da7e-46f0-be90-d48c7bd2bce5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Contractual interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_1a814b97-63ce-44e2-9c45-97de07a5acf0_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares_ef2155e6-2e40-44a6-a7e9-2a4b7dcd2de4_terseLabel_en-US" xlink:label="lab_pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lock-up period restriction (in months)</link:label>
    <link:label id="lab_pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares_label_en-US" xlink:label="lab_pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Holding Period For Transfer, Assignment Or Sale Of Founder Shares</link:label>
    <link:label id="lab_pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares_documentation_en-US" xlink:label="lab_pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Holding Period For Transfer, Assignment Or Sale Of Founder Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares" xlink:href="pacb-20250930.xsd#pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares" xlink:to="lab_pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5664d976-564b-46ef-bf87-2adcc8837732_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_9e80afbe-bb72-4baf-8e01-ecf3efaf81e6_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities measured at fair value</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_62ffced7-049a-4709-8193-795ce0a1ce3b_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_348cd6e6-25bc-4b28-a42a-bbaa21de8028_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RESTRUCTURING</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_1d661c69-9485-455e-872f-7d42a7cd7199_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_2d40a894-3875-40ce-b263-197c858ecde1_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_afc830d8-f536-4b26-b797-d514a2d70445_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redemption price, percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_106a3c16-c441-47de-a5d2-02af67eb46cf_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_71435b8e-68db-4ef9-bd62-a054ba685ffe_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8eab8327-8ff9-43f2-9783-5afe333b34bf_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c90c34d2-30f8-4ee1-bec6-69c44262c654_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_f74fb8e7-2fab-4641-a43b-51c6974b3c47_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_49d2e554-cc9a-4563-bf13-c97e792ee11a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleLongTermNotesPayable_e59cc289-0c9d-45cb-82c5-24c9958107cb_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible senior notes, net, non-current</link:label>
    <link:label id="lab_us-gaap_ConvertibleLongTermNotesPayable_label_en-US" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Notes Payable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleLongTermNotesPayable" xlink:to="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember_9e053520-396a-451d-8b9d-82732803ef8e_terseLabel_en-US" xlink:label="lab_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In Process Research And Development Indefinite Lived</link:label>
    <link:label id="lab_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember_label_en-US" xlink:label="lab_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research And Development Indefinite Lived [Member]</link:label>
    <link:label id="lab_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember_documentation_en-US" xlink:label="lab_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In-process research and development indefinite lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember" xlink:href="pacb-20250930.xsd#pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember" xlink:to="lab_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_6235d13e-ca13-4d98-a025-438659aacdba_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_b73cae20-63be-40b1-b6ab-0f60f868a4ab_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Excluding Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_7121060a-52a7-430b-be5d-a298991ac849_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_32891e18-7ee8-49aa-9570-06328a4582fb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_0209c49e-1ff7-4123-be9a-10729696d205_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_2fc0d0c7-6e97-4b35-81a6-8c301d7b45ce_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtInstrumentInterestInTheEventOfDefault_83d2a321-5940-4b36-9990-fa777c4813f5_terseLabel_en-US" xlink:label="lab_pacb_DebtInstrumentInterestInTheEventOfDefault" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, interest in the event of default (as a percent)</link:label>
    <link:label id="lab_pacb_DebtInstrumentInterestInTheEventOfDefault_label_en-US" xlink:label="lab_pacb_DebtInstrumentInterestInTheEventOfDefault" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest in the Event of Default</link:label>
    <link:label id="lab_pacb_DebtInstrumentInterestInTheEventOfDefault_documentation_en-US" xlink:label="lab_pacb_DebtInstrumentInterestInTheEventOfDefault" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest in the Event of Default</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentInterestInTheEventOfDefault" xlink:href="pacb-20250930.xsd#pacb_DebtInstrumentInterestInTheEventOfDefault"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtInstrumentInterestInTheEventOfDefault" xlink:to="lab_pacb_DebtInstrumentInterestInTheEventOfDefault" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_11e75b56-9fa9-4e38-a1ae-fbdc33e09190_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value of Employee Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4ef3f0ec-1cf4-4485-906b-c1f716692bb7_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_EmployeeSeparationCostsMember_3dd748e4-2c41-483f-8fd3-185ddc81b91d_terseLabel_en-US" xlink:label="lab_pacb_EmployeeSeparationCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee separation costs</link:label>
    <link:label id="lab_pacb_EmployeeSeparationCostsMember_label_en-US" xlink:label="lab_pacb_EmployeeSeparationCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Separation Costs [Member]</link:label>
    <link:label id="lab_pacb_EmployeeSeparationCostsMember_documentation_en-US" xlink:label="lab_pacb_EmployeeSeparationCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Separation Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EmployeeSeparationCostsMember" xlink:href="pacb-20250930.xsd#pacb_EmployeeSeparationCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_EmployeeSeparationCostsMember" xlink:to="lab_pacb_EmployeeSeparationCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_edf591cb-ed87-4dee-99cf-0207d0d4bf46_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_cb7d20ad-1f9b-4763-bf3a-8aa90d070b09_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_196ab035-a87c-4e37-9cb6-b2fc0761eaa9_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_994d3cd1-ec4c-4ead-8b23-d5fa0183ace4_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtConversionTermsTwoMember_9f2740a1-5130-497a-8668-2003cf788146_terseLabel_en-US" xlink:label="lab_pacb_DebtConversionTermsTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Conversion Terms Two</link:label>
    <link:label id="lab_pacb_DebtConversionTermsTwoMember_label_en-US" xlink:label="lab_pacb_DebtConversionTermsTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion Terms Two [Member]</link:label>
    <link:label id="lab_pacb_DebtConversionTermsTwoMember_documentation_en-US" xlink:label="lab_pacb_DebtConversionTermsTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Conversion Terms Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtConversionTermsTwoMember" xlink:href="pacb-20250930.xsd#pacb_DebtConversionTermsTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtConversionTermsTwoMember" xlink:to="lab_pacb_DebtConversionTermsTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_978d3d6d-e60b-4c32-b9e0-be5893cfe4ce_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remainder of 2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_bbec0d0f-1b3b-40c7-998e-ca3db42d8afa_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_2c4a2fc9-b885-4957-95ca-0362b1ca3ead_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_79725c6b-e6a3-4171-bba3-e9690d46a4b0_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_f98d0b60-a864-43de-a527-29db6d608109_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product revenue</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_a726f873-cf28-49e7-8c29-a3de95cb2692_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_355e8522-624a-432f-a05b-aaa1da9b0cf8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_536e09d7-5477-46af-9fb9-cf81d775e875_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward" xlink:to="lab_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_0f3098a8-04bb-454f-a6d8-9a89c1a964eb_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate_4bcdfd28-9b70-4743-a4f6-548101bcf849_terseLabel_en-US" xlink:label="lab_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible asset impairment, discounted cash flow model, discount rate</link:label>
    <link:label id="lab_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate_label_en-US" xlink:label="lab_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset Impairment, Discounted Cash Flow Model, Discount Rate</link:label>
    <link:label id="lab_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate_documentation_en-US" xlink:label="lab_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible Asset Impairment, Discounted Cash Flow Model, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate" xlink:href="pacb-20250930.xsd#pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate" xlink:to="lab_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_8a88b197-dcf9-4f68-ab29-aabb13ef420c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_dcc886fb-fbc1-4b34-9dcb-df563bf3545b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_EquityIncentivePlan2020Member_eb87a155-a0c4-4214-afe5-d5e5a1ac7ebb_terseLabel_en-US" xlink:label="lab_pacb_EquityIncentivePlan2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Incentive Plan2020</link:label>
    <link:label id="lab_pacb_EquityIncentivePlan2020Member_label_en-US" xlink:label="lab_pacb_EquityIncentivePlan2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Incentive Plan 2020 [Member]</link:label>
    <link:label id="lab_pacb_EquityIncentivePlan2020Member_documentation_en-US" xlink:label="lab_pacb_EquityIncentivePlan2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2020 Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EquityIncentivePlan2020Member" xlink:href="pacb-20250930.xsd#pacb_EquityIncentivePlan2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_EquityIncentivePlan2020Member" xlink:to="lab_pacb_EquityIncentivePlan2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_8d1f5b2d-7c50-4477-b8fe-b008602290b3_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_57b0d2f8-773c-4e03-82f7-b6681c85602c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm_2004bbdd-ccd8-453e-b7f6-044a1736d746_terseLabel_en-US" xlink:label="lab_pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible asset impairment, increase in term (in years)</link:label>
    <link:label id="lab_pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm_label_en-US" xlink:label="lab_pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset Impairment, Increase In Obsolescence Factor, Term</link:label>
    <link:label id="lab_pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm_documentation_en-US" xlink:label="lab_pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible Asset Impairment, Increase In Obsolescence Factor, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm" xlink:href="pacb-20250930.xsd#pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm" xlink:to="lab_pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations_efea8fe5-3a08-416a-b703-dc9239c6437d_terseLabel_en-US" xlink:label="lab_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional liability associated with indemnification obligations</link:label>
    <link:label id="lab_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations_label_en-US" xlink:label="lab_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Liability Associated With Indemnification Obligations</link:label>
    <link:label id="lab_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations_documentation_en-US" xlink:label="lab_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional Liability Associated With Indemnification Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations" xlink:href="pacb-20250930.xsd#pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations" xlink:to="lab_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_bba03faf-318b-4476-8f9a-11ccf93ab129_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherRestructuringMember_db80e949-cea0-4a69-a785-0084b7435caf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other costs</link:label>
    <link:label id="lab_us-gaap_OtherRestructuringMember_label_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Restructuring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherRestructuringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherRestructuringMember" xlink:to="lab_us-gaap_OtherRestructuringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0c4507e5-8fdb-4570-93bb-75ebbcafafef_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_e96eff67-7491-4dd2-b4a1-68dc201d7357_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining performance obligation period</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_c2dfe762-b816-4e1a-b250-a58b71c25a10_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f76f4e85-4b77-41cb-b4c5-19d4ddfbc9c1_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Consolidation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_3b91a900-a032-4f3a-8b9a-fd651bc37ba3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtInstrumentConvertibleTermsOfConversionAxis_d61e655c-e5b0-4cd9-a89f-e9cfcce1fff4_terseLabel_en-US" xlink:label="lab_pacb_DebtInstrumentConvertibleTermsOfConversionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible Terms Of Conversion [Axis]</link:label>
    <link:label id="lab_pacb_DebtInstrumentConvertibleTermsOfConversionAxis_label_en-US" xlink:label="lab_pacb_DebtInstrumentConvertibleTermsOfConversionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible Terms Of Conversion [Axis]</link:label>
    <link:label id="lab_pacb_DebtInstrumentConvertibleTermsOfConversionAxis_documentation_en-US" xlink:label="lab_pacb_DebtInstrumentConvertibleTermsOfConversionAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible Terms Of Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentConvertibleTermsOfConversionAxis" xlink:href="pacb-20250930.xsd#pacb_DebtInstrumentConvertibleTermsOfConversionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtInstrumentConvertibleTermsOfConversionAxis" xlink:to="lab_pacb_DebtInstrumentConvertibleTermsOfConversionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDisclosures_8a963f69-006d-4d9f-9d7d-e92cfaed5271_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDisclosures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_LossContingencyDisclosures_label_en-US" xlink:label="lab_us-gaap_LossContingencyDisclosures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDisclosures" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyDisclosures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDisclosures" xlink:to="lab_us-gaap_LossContingencyDisclosures" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_58d9d74a-e969-49b5-8d48-f7dff46f0c37_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_f4bc3718-8c0c-412d-bd5c-7059250ef131_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_ea7449ae-6904-4fc9-963e-2dff0ffd15e7_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_94c89ec5-3e83-4bf8-bc83-2dd18e4413b4_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less:</link:label>
    <link:label id="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_label_en-US" xlink:label="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:to="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_6336f009-9abd-417d-9ed3-0dbf4dd7629d_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">SEGMENT AND GEOGRAPHIC INFORMATION</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4526d38b-5f7c-49d9-bc08-c06fefeb4555_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e3e8a30e-aa06-4ede-a74f-2c028290c417_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_0316e2c9-abdb-4974-a0e6-afad4d554144_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone_f04ba968-d438-4caa-85f4-91474e64aea7_terseLabel_en-US" xlink:label="lab_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone revenue</link:label>
    <link:label id="lab_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone_label_en-US" xlink:label="lab_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Revenue Achievement Milestone</link:label>
    <link:label id="lab_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone_documentation_en-US" xlink:label="lab_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone" xlink:href="pacb-20250930.xsd#pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone" xlink:to="lab_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_639c4fb0-8f70-4554-8fe5-6156168eeb9f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_ed6df0ae-07dd-453c-b730-bce7929675b6_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_4e867307-0707-4b5f-861d-647b71d0571a_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_952a839a-d916-4d6f-80c0-09f30843ba43_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_a58cb5cf-c79e-41ee-aa9a-d4f2e2396e5e_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_bb5aa2ed-04d5-4166-8413-7824e2bb47b9_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal_10390b51-fff1-407d-88de-bec3deae80f7_terseLabel_en-US" xlink:label="lab_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount eligible to vest upon achievement of goal</link:label>
    <link:label id="lab_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal_label_en-US" xlink:label="lab_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Amount Eligible To Vest Upon Achievement Of Goal</link:label>
    <link:label id="lab_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal_documentation_en-US" xlink:label="lab_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Amount Eligible To Vest Upon Achievement Of Goal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal" xlink:href="pacb-20250930.xsd#pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal" xlink:to="lab_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtInstrumentRedemptionPriceTradingDays_6274befd-4a4c-451c-98d0-fccf950aa567_terseLabel_en-US" xlink:label="lab_pacb_DebtInstrumentRedemptionPriceTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt redemption, trading days</link:label>
    <link:label id="lab_pacb_DebtInstrumentRedemptionPriceTradingDays_label_en-US" xlink:label="lab_pacb_DebtInstrumentRedemptionPriceTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Trading Days</link:label>
    <link:label id="lab_pacb_DebtInstrumentRedemptionPriceTradingDays_documentation_en-US" xlink:label="lab_pacb_DebtInstrumentRedemptionPriceTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentRedemptionPriceTradingDays" xlink:href="pacb-20250930.xsd#pacb_DebtInstrumentRedemptionPriceTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtInstrumentRedemptionPriceTradingDays" xlink:to="lab_pacb_DebtInstrumentRedemptionPriceTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_7e15cdf1-574a-4db1-98e9-aa61adb27bb1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_cf802eab-3d9c-47bf-8da8-308273d600cd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, convertible, conversion ratio</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_48b5affd-c5fb-46bb-8296-dd9239d4a0d9_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_3bc491fd-7ccc-43f8-a2db-53ec4eaa3dd7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_ccf3459a-4f6e-4135-a54c-4fc3f2cb880c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DevelopedTechnologyAndIntellectualPropertyMember_d198d8bb-3285-43ac-bb2c-8390f5a41dc2_terseLabel_en-US" xlink:label="lab_pacb_DevelopedTechnologyAndIntellectualPropertyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Developed Technology and Intellectual Property</link:label>
    <link:label id="lab_pacb_DevelopedTechnologyAndIntellectualPropertyMember_label_en-US" xlink:label="lab_pacb_DevelopedTechnologyAndIntellectualPropertyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developed Technology and Intellectual Property [Member]</link:label>
    <link:label id="lab_pacb_DevelopedTechnologyAndIntellectualPropertyMember_documentation_en-US" xlink:label="lab_pacb_DevelopedTechnologyAndIntellectualPropertyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Developed Technology and Intellectual Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DevelopedTechnologyAndIntellectualPropertyMember" xlink:href="pacb-20250930.xsd#pacb_DevelopedTechnologyAndIntellectualPropertyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DevelopedTechnologyAndIntellectualPropertyMember" xlink:to="lab_pacb_DevelopedTechnologyAndIntellectualPropertyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_5e9a30d9-d146-4787-a2c4-475d9bf7cb0d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_02468f57-918e-4c77-8c10-131f357c3a0b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration liability, non-current</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_6f1cfc0d-7ead-4ffe-b164-cc5cef216959_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_c5c86dc9-3a42-4d32-9ce2-45a365c581de_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_37d197aa-7df8-496a-b3e8-b6d437f53c4e_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FINANCIAL INSTRUMENTS</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_6721a069-6dac-42d7-abf7-a041a6204479_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_bd77c38b-30d5-4e64-8bd4-0cf5dd341c20_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1be6ec05-b3c1-4a4b-b9b4-5fac9281255f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_d20be7ca-5040-41a3-8470-04a26b97a715_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_b37de7f7-dcdd-4441-94f6-979ed406d57d_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_RestructuringChargesAdditionalCostsIncurred_5f7c471a-d925-4556-813a-96184a45d5f2_terseLabel_en-US" xlink:label="lab_pacb_RestructuringChargesAdditionalCostsIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional costs incurred</link:label>
    <link:label id="lab_pacb_RestructuringChargesAdditionalCostsIncurred_label_en-US" xlink:label="lab_pacb_RestructuringChargesAdditionalCostsIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges, Additional Costs Incurred</link:label>
    <link:label id="lab_pacb_RestructuringChargesAdditionalCostsIncurred_documentation_en-US" xlink:label="lab_pacb_RestructuringChargesAdditionalCostsIncurred" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring Charges, Additional Costs Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_RestructuringChargesAdditionalCostsIncurred" xlink:href="pacb-20250930.xsd#pacb_RestructuringChargesAdditionalCostsIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_RestructuringChargesAdditionalCostsIncurred" xlink:to="lab_pacb_RestructuringChargesAdditionalCostsIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_RestructuringAndRelatedCostAcceleratedAmortization_1c7c8a13-d85a-472e-8acb-5a4a7f9020ba_terseLabel_en-US" xlink:label="lab_pacb_RestructuringAndRelatedCostAcceleratedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring and related cost, accelerated amortization</link:label>
    <link:label id="lab_pacb_RestructuringAndRelatedCostAcceleratedAmortization_label_en-US" xlink:label="lab_pacb_RestructuringAndRelatedCostAcceleratedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Accelerated Amortization</link:label>
    <link:label id="lab_pacb_RestructuringAndRelatedCostAcceleratedAmortization_documentation_en-US" xlink:label="lab_pacb_RestructuringAndRelatedCostAcceleratedAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Accelerated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_RestructuringAndRelatedCostAcceleratedAmortization" xlink:href="pacb-20250930.xsd#pacb_RestructuringAndRelatedCostAcceleratedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_RestructuringAndRelatedCostAcceleratedAmortization" xlink:to="lab_pacb_RestructuringAndRelatedCostAcceleratedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_PaymentsInConjunctionWithNotesExchange_9ab8f984-971f-40ae-ac5b-bfd06125c019_terseLabel_en-US" xlink:label="lab_pacb_PaymentsInConjunctionWithNotesExchange" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments made in conjunction with convertible notes exchange</link:label>
    <link:label id="lab_pacb_PaymentsInConjunctionWithNotesExchange_label_en-US" xlink:label="lab_pacb_PaymentsInConjunctionWithNotesExchange" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments In Conjunction With Notes Exchange</link:label>
    <link:label id="lab_pacb_PaymentsInConjunctionWithNotesExchange_documentation_en-US" xlink:label="lab_pacb_PaymentsInConjunctionWithNotesExchange" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments In Conjunction With Notes Exchange</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PaymentsInConjunctionWithNotesExchange" xlink:href="pacb-20250930.xsd#pacb_PaymentsInConjunctionWithNotesExchange"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_PaymentsInConjunctionWithNotesExchange" xlink:to="lab_pacb_PaymentsInConjunctionWithNotesExchange" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_bdc22768-e8d7-4ca9-b35f-b9707f34c192_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_9385f12a-1152-4b06-9601-8599de4d2590_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e225ff2-a79d-4aaf-8aa4-9b5aec56ff4c_terseLabel_en-US" xlink:label="lab_pacb_ScheduleOfBalanceSheetComponentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Balance Sheet Components [Line Items]</link:label>
    <link:label id="lab_pacb_ScheduleOfBalanceSheetComponentsLineItems_label_en-US" xlink:label="lab_pacb_ScheduleOfBalanceSheetComponentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Balance Sheet Components [Line Items]</link:label>
    <link:label id="lab_pacb_ScheduleOfBalanceSheetComponentsLineItems_documentation_en-US" xlink:label="lab_pacb_ScheduleOfBalanceSheetComponentsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Balance Sheet Components [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems" xlink:href="pacb-20250930.xsd#pacb_ScheduleOfBalanceSheetComponentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems" xlink:to="lab_pacb_ScheduleOfBalanceSheetComponentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_58982039-9aaa-4e04-839a-f57284a6fc73_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_56a11b07-cb8a-437d-867a-38266b73946b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_bb57fe35-12a2-4581-a0de-0712d85aef09_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_5622fa59-b6dc-4981-92ed-266e59a684f5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_5c78b24c-a7cb-4fd3-9509-3920aa1a4dd2_terseLabel_en-US" xlink:label="lab_pacb_DebtInstrumentConvertibleTermsOfConversionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible Terms Of Conversion [Domain]</link:label>
    <link:label id="lab_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_label_en-US" xlink:label="lab_pacb_DebtInstrumentConvertibleTermsOfConversionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible Terms Of Conversion [Domain]</link:label>
    <link:label id="lab_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_documentation_en-US" xlink:label="lab_pacb_DebtInstrumentConvertibleTermsOfConversionDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible Terms Of Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain" xlink:href="pacb-20250930.xsd#pacb_DebtInstrumentConvertibleTermsOfConversionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain" xlink:to="lab_pacb_DebtInstrumentConvertibleTermsOfConversionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_6252ada9-6dc8-484b-b382-73fcddec2c9f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_e2df2b9e-8387-4a93-a638-061c727c8eee_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_b96db22e-968a-4f4e-b542-b529a3dbeebd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_4f65fbd8-cbdc-4faf-ab0c-7ba2430f5f8a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ff865473-069a-42ca-bcd4-0d75caee2ea4_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_A2020PlanInducementPlanAndTheOmniomePlanMember_9fdf749a-5e37-4667-8e60-822d03513ff1_terseLabel_en-US" xlink:label="lab_pacb_A2020PlanInducementPlanAndTheOmniomePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020 Plan, Inducement Plan, And The Omniome Plan</link:label>
    <link:label id="lab_pacb_A2020PlanInducementPlanAndTheOmniomePlanMember_label_en-US" xlink:label="lab_pacb_A2020PlanInducementPlanAndTheOmniomePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2020 Plan, Inducement Plan, And The Omniome Plan [Member]</link:label>
    <link:label id="lab_pacb_A2020PlanInducementPlanAndTheOmniomePlanMember_documentation_en-US" xlink:label="lab_pacb_A2020PlanInducementPlanAndTheOmniomePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2020 Plan, Inducement Plan, And The Omniome Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2020PlanInducementPlanAndTheOmniomePlanMember" xlink:href="pacb-20250930.xsd#pacb_A2020PlanInducementPlanAndTheOmniomePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_A2020PlanInducementPlanAndTheOmniomePlanMember" xlink:to="lab_pacb_A2020PlanInducementPlanAndTheOmniomePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_21ec7976-6719-4c4c-b9f8-7f90918059f0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, stated interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_884986ff-3eb3-49b6-8916-0beaa05c3ba5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenue by Category</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits_fdf22169-ae84-4df5-ac40-20287d0eba1f_terseLabel_en-US" xlink:label="lab_pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">WARN act and other employee benefits</link:label>
    <link:label id="lab_pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits_label_en-US" xlink:label="lab_pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges, Worker Adjustment and Retraining Notification (WARN) Act and Other Employee Benefits</link:label>
    <link:label id="lab_pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits_documentation_en-US" xlink:label="lab_pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring Charges, Worker Adjustment and Retraining Notification (WARN) Act and Other Employee Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits" xlink:href="pacb-20250930.xsd#pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits" xlink:to="lab_pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_59f0bce8-e061-4051-8e25-a63db2a42e45_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, non-current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_d2568bee-c522-48a8-a522-38e77b6b48d8_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AmericasMember_ec3d47e6-3f8b-4142-94bf-1adf9842e4a7_terseLabel_en-US" xlink:label="lab_srt_AmericasMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Americas</link:label>
    <link:label id="lab_srt_AmericasMember_label_en-US" xlink:label="lab_srt_AmericasMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Americas [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AmericasMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_AmericasMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AmericasMember" xlink:to="lab_srt_AmericasMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_TimeBasedStockOptionMember_ee8bda48-4e18-4f8c-a7c0-d4adcb19041a_terseLabel_en-US" xlink:label="lab_pacb_TimeBasedStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Time-based stock option</link:label>
    <link:label id="lab_pacb_TimeBasedStockOptionMember_label_en-US" xlink:label="lab_pacb_TimeBasedStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Time Based Stock Option [Member]</link:label>
    <link:label id="lab_pacb_TimeBasedStockOptionMember_documentation_en-US" xlink:label="lab_pacb_TimeBasedStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Time-based stock option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedStockOptionMember" xlink:href="pacb-20250930.xsd#pacb_TimeBasedStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_TimeBasedStockOptionMember" xlink:to="lab_pacb_TimeBasedStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_LongTermRestrictedCashFairValueDisclosure_996baea5-cb86-477f-952f-46bc09c8d80c_terseLabel_en-US" xlink:label="lab_pacb_LongTermRestrictedCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term restricted cash</link:label>
    <link:label id="lab_pacb_LongTermRestrictedCashFairValueDisclosure_label_en-US" xlink:label="lab_pacb_LongTermRestrictedCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long Term Restricted Cash Fair Value Disclosure</link:label>
    <link:label id="lab_pacb_LongTermRestrictedCashFairValueDisclosure_documentation_en-US" xlink:label="lab_pacb_LongTermRestrictedCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long-Term Restricted Cash Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LongTermRestrictedCashFairValueDisclosure" xlink:href="pacb-20250930.xsd#pacb_LongTermRestrictedCashFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_LongTermRestrictedCashFairValueDisclosure" xlink:to="lab_pacb_LongTermRestrictedCashFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_b65df816-b2de-4ee1-8d22-5543fdbccba2_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_3f4446dc-bd33-4a49-a65e-480a12aad865_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8f59095f-0f50-40d5-813a-11005b794729_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_2a089f15-4562-4f5e-b415-b09640688761_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_24a6839c-ea4f-4376-a7b2-8291fd112e24_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ScheduleOfBalanceSheetComponentsTable_09d19648-cd96-404c-942b-228da5cbf483_terseLabel_en-US" xlink:label="lab_pacb_ScheduleOfBalanceSheetComponentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Balance Sheet Components [Table]</link:label>
    <link:label id="lab_pacb_ScheduleOfBalanceSheetComponentsTable_label_en-US" xlink:label="lab_pacb_ScheduleOfBalanceSheetComponentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Balance Sheet Components [Table]</link:label>
    <link:label id="lab_pacb_ScheduleOfBalanceSheetComponentsTable_documentation_en-US" xlink:label="lab_pacb_ScheduleOfBalanceSheetComponentsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Balance Sheet Components [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ScheduleOfBalanceSheetComponentsTable" xlink:href="pacb-20250930.xsd#pacb_ScheduleOfBalanceSheetComponentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable" xlink:to="lab_pacb_ScheduleOfBalanceSheetComponentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_ef71d326-1174-4c45-a11e-c708ea368eff_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_8b430e97-3add-4b1d-b04c-83f749778203_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets measured at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_dd7bbc3a-1850-4932-b724-2dfdefb89f63_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_c61e0604-78a3-4152-8515-82e8c283e0f5_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9090355e-d842-4f6b-8038-ca3bd492f1c8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60624b10-52bf-48c0-855e-744e4f70a1cd_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value per share (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_b1fcc492-dd8f-4737-ae4d-0b5828315ed4_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Service</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_31000299-8dcd-4b9a-a3e5-adee7127a398_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in conjunction with equity plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_e6744e90-7255-4294-b4d7-40ba3f7c3919_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Pre-Tax Restructuring Charges</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_8904be62-0084-492f-8032-751f265f6827_totalLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_AchievementOfMilestoneMember_e4ae6426-172f-4cc2-a6a1-95168038af09_terseLabel_en-US" xlink:label="lab_pacb_AchievementOfMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Achievement of milestone</link:label>
    <link:label id="lab_pacb_AchievementOfMilestoneMember_label_en-US" xlink:label="lab_pacb_AchievementOfMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Achievement Of Milestone [Member]</link:label>
    <link:label id="lab_pacb_AchievementOfMilestoneMember_documentation_en-US" xlink:label="lab_pacb_AchievementOfMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upon achievement of a milestone.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AchievementOfMilestoneMember" xlink:href="pacb-20250930.xsd#pacb_AchievementOfMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_AchievementOfMilestoneMember" xlink:to="lab_pacb_AchievementOfMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_bb57dd6e-0d6d-47c5-9c15-83e061688011_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b5b0879b-c273-443e-bc7f-50085e42744c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_e94d6ab1-a812-4d71-9550-732b56e9b568_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_a401b82f-bc5b-4789-ac5f-bdd603641527_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal amount of notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate_edb7c216-0c5a-4c03-80c6-94607167c1d3_terseLabel_en-US" xlink:label="lab_pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional intangible asset impairment, change in discount rate</link:label>
    <link:label id="lab_pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate_label_en-US" xlink:label="lab_pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Intangible Asset Impairment, Change In Discount Rate</link:label>
    <link:label id="lab_pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate_documentation_en-US" xlink:label="lab_pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional Intangible Asset Impairment, Change In Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate" xlink:href="pacb-20250930.xsd#pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate" xlink:to="lab_pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_6c2c0b1e-8c6d-42cb-b75b-4290e4ccae86_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1809cb93-e54a-451b-8514-56eb8c17c196_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_49d8e2ce-49ec-4171-b616-b3eea749e685_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_EmployeeStockPurchasePlanMember_9c8c0ac0-857e-4a4b-9004-e589c7bb41fb_terseLabel_en-US" xlink:label="lab_pacb_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_pacb_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_pacb_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_pacb_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_pacb_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EmployeeStockPurchasePlanMember" xlink:href="pacb-20250930.xsd#pacb_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_EmployeeStockPurchasePlanMember" xlink:to="lab_pacb_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_18f26fe0-7756-4b73-8a5c-9ef03fa35b28_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_95c9e6ec-65d2-4b6f-be07-d4057f8da967_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_5b4829ac-18a0-4732-8973-db5adf5acf36_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_5c4eb9ee-c974-489a-8934-befbb6b91bf6_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod_43aa256f-2b35-4a5e-8d76-047df1aa6fce_terseLabel_en-US" xlink:label="lab_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business acquisition, anniversary</link:label>
    <link:label id="lab_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod_label_en-US" xlink:label="lab_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Liability, Measurement Period</link:label>
    <link:label id="lab_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod_documentation_en-US" xlink:label="lab_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Liability, Measurement Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod" xlink:href="pacb-20250930.xsd#pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod" xlink:to="lab_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_2f45a066-17f6-4cf2-8502-e3321524554f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_6de9eb59-f8bf-434e-b162-9a9624d23fbf_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Change in the estimated fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Change in Contingent Consideration, Liability, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_652b7da7-e517-4352-975e-2113ac25f358_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8e97cb57-5eea-4fe7-9aa6-3ea1585621a1_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_22972fe5-66fe-4124-bbf1-1b9fc2d81837_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In Process Research and Development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9c41c2fe-730c-49f2-8239-99e1c5aa37e3_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_836305ea-d263-41d1-9044-eb75f3d3dff6_terseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling and Marketing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense" xlink:to="lab_us-gaap_SellingAndMarketingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5b7061f0-87fa-41bb-9349-adfed4cdfe0e_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Option, Eligible Item or Group [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_7d1681f3-dbe9-4ddf-9eb1-f189a67de5aa_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_13bf3a12-118a-422b-b4fb-06afda12bf89_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EMEAMember_3785e7d1-8265-401b-94ca-65c8fb95e2ca_terseLabel_en-US" xlink:label="lab_us-gaap_EMEAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Europe, Middle East and Africa</link:label>
    <link:label id="lab_us-gaap_EMEAMember_label_en-US" xlink:label="lab_us-gaap_EMEAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">EMEA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EMEAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EMEAMember" xlink:to="lab_us-gaap_EMEAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_c33582a0-5df3-484f-ba8a-1b757cac6a99_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Stock Units (PSU)</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_63e58d99-ea15-4c31-ab39-6c46b7d41cfe_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_2bb267ca-e60d-4e64-9bc8-570d56cbcf5f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_7c5b71f6-3914-46d0-b9d6-75e125dde6dd_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_b23c1740-c9f3-41e5-866b-f89071cf6f7d_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_4c663c33-691d-4568-8ddd-1728199154b2_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Developed technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2c560e69-d0db-4fe0-940c-3803ab6d0fe3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_a78d9f0c-ec50-42b6-9fc0-cec37faf47a1_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_3651b4ad-8858-487d-8a4f-3c7f0c7739d9_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Notes payable principal payoff</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenueAbstract_2fc35da0-d2f2-44dc-aaa6-fb971934257b_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of Revenue:</link:label>
    <link:label id="lab_us-gaap_CostOfRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_CostOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Revenue [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenueAbstract" xlink:to="lab_us-gaap_CostOfRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition_fb1bd99a-090c-4fbe-b7de-b9974b3b5462_terseLabel_en-US" xlink:label="lab_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average trading period</link:label>
    <link:label id="lab_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition_label_en-US" xlink:label="lab_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Average Trading Period, Acquisition</link:label>
    <link:label id="lab_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition_documentation_en-US" xlink:label="lab_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Average Trading Period, Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition" xlink:href="pacb-20250930.xsd#pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition" xlink:to="lab_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_3f1598eb-96bd-4a12-a55b-aea2be7ebc37_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CONVERTIBLE SENIOR NOTES</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_9d2f844e-15ec-46b0-bd9a-9b35296f7ad9_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_4446202e-2db6-47da-86fd-2a31734f4072_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock_a166b208-1701-4ed6-a52e-489a847f7387_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Impaired Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Impaired Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock" xlink:to="lab_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_c7af8c26-c344-463f-836a-965039153219_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Impairment charge</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtIssuanceCostLenderFees_95d0726d-e1c3-402c-be63-c162e92b213e_terseLabel_en-US" xlink:label="lab_pacb_DebtIssuanceCostLenderFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt issuance cost, lender fees</link:label>
    <link:label id="lab_pacb_DebtIssuanceCostLenderFees_label_en-US" xlink:label="lab_pacb_DebtIssuanceCostLenderFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Cost, Lender Fees</link:label>
    <link:label id="lab_pacb_DebtIssuanceCostLenderFees_documentation_en-US" xlink:label="lab_pacb_DebtIssuanceCostLenderFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Issuance Cost, Lender Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtIssuanceCostLenderFees" xlink:href="pacb-20250930.xsd#pacb_DebtIssuanceCostLenderFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtIssuanceCostLenderFees" xlink:to="lab_pacb_DebtIssuanceCostLenderFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_f5291648-714f-4302-a8f3-83af934360b2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_f6f3043d-5e71-4e67-b60e-b233eafc3a2a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_485536dc-c57b-4d87-b8a2-8b453060d80e_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_a869b5bd-2628-4f6a-8fe6-d7fa1a950b58_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2c6748a8-15c4-47f0-b46e-ba529c9df9e7_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c7beb11f-cdd1-4f91-bfd9-9d349bb6435c_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares used in computing diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_8486d597-e5a8-4f96-8843-2b0d466fe58d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_e84bd81b-760e-43a9-ad8f-9dfbb991c2d4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_f1a2212d-b891-4585-9667-067ed2070b85_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_2b97e956-4f8c-4976-ba55-b4e998e72a01_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenue by Geographic Location</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_7c998d70-1bf9-4594-a9e7-cd686ce14cda_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_3999936d-4364-45c2-b382-41c6137f3406_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_b5e61f8e-c5da-4676-b33e-01af73c3dee9_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_ded6aefe-da15-4848-baba-3af4b41b289b_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_689758fd-da33-4819-83f6-89e737b5cc67_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedPremium_45442d4b-271a-496b-bbf0-a78fe21bc876_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unamortized debt premium</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedPremium_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedPremium" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_f21d76c4-3517-485b-8789-2a8c61eb34ab_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BALANCE SHEET COMPONENTS</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_0e199e59-80e6-4983-9ecd-3e8158208444_terseLabel_en-US" xlink:label="lab_pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2030 and thereafter</link:label>
    <link:label id="lab_pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_label_en-US" xlink:label="lab_pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:label id="lab_pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_documentation_en-US" xlink:label="lab_pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:href="pacb-20250930.xsd#pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:to="lab_pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_e549c997-a746-4649-b7bf-8b6196214c8d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_469b1b76-9ca1-41b0-9021-c87836496bbd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Decrease in operating lease liability</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_1aeea6aa-73ff-47f6-8f4c-36bdda2242c7_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of convertible debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_f1aa7834-4c63-4d09-a198-31a0297d91e4_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_8c1b5943-9b49-418f-aa01-db5ade4109d5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_c9c89be4-22e4-4c61-8fae-3b811c30571e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NET LOSS PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_8aadbb1f-4cce-41b7-907a-20a256f6bb87_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_f0700ab1-ac1a-44cc-b6ff-a99e427ae4d8_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_cf8e13c0-08af-42e6-9980-04e760207657_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_302ed0c2-d970-451e-8d1c-f06fd0fb979d_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3af2c82a-8c21-4a0f-b3dc-3f2b6306a0c6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_d6062b36-5326-4b43-a85e-a9e8b48309ff_terseLabel_en-US" xlink:label="lab_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_label_en-US" xlink:label="lab_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="lab_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_ac54988b-1bf5-4827-bba5-56d388d4329a_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7f2e9ca7-4a66-45ca-9853-6952a6b7ad11_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferred_065639cd-1159-4aa3-b2f7-5d8e950626be_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset acquisition, consideration transferred</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferred_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_c8ecbcb3-101e-4d13-80f7-47203c925ea8_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_cb65fe27-b516-4a14-b8ea-9b9c91735fe6_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_fa4a6265-8e97-45e0-9cf5-09b61bfb6f0b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock from equity plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_6fb164c9-e261-4b4e-ba21-aeac6fba4e02_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_5bade089-36e3-4964-a7ad-fe0680490a22_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_A2029NotesMember_23ae8f3b-15a9-4b5a-a939-f9fe88d18490_terseLabel_en-US" xlink:label="lab_pacb_A2029NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029 Convertible Senior Notes</link:label>
    <link:label id="lab_pacb_A2029NotesMember_label_en-US" xlink:label="lab_pacb_A2029NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2029 Notes [Member]</link:label>
    <link:label id="lab_pacb_A2029NotesMember_documentation_en-US" xlink:label="lab_pacb_A2029NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2029 Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2029NotesMember" xlink:href="pacb-20250930.xsd#pacb_A2029NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_A2029NotesMember" xlink:to="lab_pacb_A2029NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_76ac0c07-4444-4817-a5bf-57df20506295_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_eeb7f270-56f0-4ad8-a1bc-3b0d6e16eb89_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_90e852d9-19c8-4965-a861-77c70965d5f5_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtConversionTermsOneMember_ec80dc0d-e9c6-4912-97df-765fa6185c3f_terseLabel_en-US" xlink:label="lab_pacb_DebtConversionTermsOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Conversion Terms One</link:label>
    <link:label id="lab_pacb_DebtConversionTermsOneMember_label_en-US" xlink:label="lab_pacb_DebtConversionTermsOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion Terms One [Member]</link:label>
    <link:label id="lab_pacb_DebtConversionTermsOneMember_documentation_en-US" xlink:label="lab_pacb_DebtConversionTermsOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Conversion Terms One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtConversionTermsOneMember" xlink:href="pacb-20250930.xsd#pacb_DebtConversionTermsOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtConversionTermsOneMember" xlink:to="lab_pacb_DebtConversionTermsOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_8a0eaa31-7dee-4670-8698-208cfa5bdd01_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt conversion, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_b9e37472-bda7-4d3e-98a8-2d39054eae66_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expense</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_b17b21e6-5e8c-4706-9dfa-df3acbb65774_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtInstrumentAdditionalInterestInEventOfDefault_80cc76bd-16ca-4334-9205-0c96b2d04850_terseLabel_en-US" xlink:label="lab_pacb_DebtInstrumentAdditionalInterestInEventOfDefault" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional interest in the event of default (as a percent)</link:label>
    <link:label id="lab_pacb_DebtInstrumentAdditionalInterestInEventOfDefault_label_en-US" xlink:label="lab_pacb_DebtInstrumentAdditionalInterestInEventOfDefault" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Additional Interest in the Event of Default</link:label>
    <link:label id="lab_pacb_DebtInstrumentAdditionalInterestInEventOfDefault_documentation_en-US" xlink:label="lab_pacb_DebtInstrumentAdditionalInterestInEventOfDefault" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Additional Interest in the Event of Default</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentAdditionalInterestInEventOfDefault" xlink:href="pacb-20250930.xsd#pacb_DebtInstrumentAdditionalInterestInEventOfDefault"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtInstrumentAdditionalInterestInEventOfDefault" xlink:to="lab_pacb_DebtInstrumentAdditionalInterestInEventOfDefault" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_05a031b2-196b-42f7-8f0f-89da4d6e499f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0a2b775d-a507-4521-8cdf-8af2786205a4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate_f900fc82-0182-42a4-b36a-24ae9e25568a_terseLabel_en-US" xlink:label="lab_pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible asset impairment, increase in basis point discount rate</link:label>
    <link:label id="lab_pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate_label_en-US" xlink:label="lab_pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset Impairment, Increase In Basis Point Discount Rate</link:label>
    <link:label id="lab_pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate_documentation_en-US" xlink:label="lab_pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible Asset Impairment, Increase In Basis Point Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate" xlink:href="pacb-20250930.xsd#pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate" xlink:to="lab_pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_0a5822be-1f78-4a6c-ad5e-b53d2f21a088_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AsiaPacificMember_361a6fc8-6674-465e-9ff2-ed6a63040cfb_terseLabel_en-US" xlink:label="lab_srt_AsiaPacificMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asia-Pacific</link:label>
    <link:label id="lab_srt_AsiaPacificMember_label_en-US" xlink:label="lab_srt_AsiaPacificMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asia Pacific [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_AsiaPacificMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AsiaPacificMember" xlink:to="lab_srt_AsiaPacificMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_43dc9d83-b06e-4352-9be8-f8b7f7ec3887_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_f71282be-143d-4885-9964-c691259b4c38_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted net loss per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_cc4ea9af-398b-4fa8-9753-dc51aa559889_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_1b3de3c8-07b5-4dde-8085-06c0fe58acc7_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accelerated depreciation</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Accelerated Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:to="lab_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_fc098de0-ea58-42f4-ad52-9ba6281f820c_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_a2764986-9cfe-4b53-874a-b2cb8e60cee8_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1e140f1b-0921-4485-bfbd-97ee0f753d99_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_b8165bd8-7112-4d49-ae08-b8354fce4c6f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_255f41c7-960c-4f9c-ad68-fa20c561e706_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_af4a847e-49e7-47f8-bd08-7f67183f6bdf_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_955f5f4a-3ed5-42f2-bfa0-084156efba90_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0184ce98-66d4-4859-a4ca-030c7f79bccb_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Shares Excluded From Computation of Diluted Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_19292f46-f024-4254-9682-4464cc152e7e_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_5bef9595-1b83-4ac4-b0b3-99a9312e504a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_AptonMember_a9600e86-16c4-4f62-af97-c9d4485e8043_terseLabel_en-US" xlink:label="lab_pacb_AptonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Apton</link:label>
    <link:label id="lab_pacb_AptonMember_label_en-US" xlink:label="lab_pacb_AptonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Apton [Member]</link:label>
    <link:label id="lab_pacb_AptonMember_documentation_en-US" xlink:label="lab_pacb_AptonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Apton</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AptonMember" xlink:href="pacb-20250930.xsd#pacb_AptonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_AptonMember" xlink:to="lab_pacb_AptonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9409c58b-8c5b-4dba-a29b-eb8e2d685710_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_06aad528-cb88-4690-afd3-a2b8795c2210_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt, gross</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_e9151520-ef35-4f11-abfb-455df8c01221_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_bbc49b9e-7cde-4c02-9bc4-9be61691fa4b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_AdditionalIntangibleAssetImpairmentChangeInTerm_515ac8b7-573d-417d-915a-6fad6ba1b6e5_terseLabel_en-US" xlink:label="lab_pacb_AdditionalIntangibleAssetImpairmentChangeInTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional intangible asset impairment, change in term</link:label>
    <link:label id="lab_pacb_AdditionalIntangibleAssetImpairmentChangeInTerm_label_en-US" xlink:label="lab_pacb_AdditionalIntangibleAssetImpairmentChangeInTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Intangible Asset Impairment, Change In Term</link:label>
    <link:label id="lab_pacb_AdditionalIntangibleAssetImpairmentChangeInTerm_documentation_en-US" xlink:label="lab_pacb_AdditionalIntangibleAssetImpairmentChangeInTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional Intangible Asset Impairment, Change In Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AdditionalIntangibleAssetImpairmentChangeInTerm" xlink:href="pacb-20250930.xsd#pacb_AdditionalIntangibleAssetImpairmentChangeInTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_AdditionalIntangibleAssetImpairmentChangeInTerm" xlink:to="lab_pacb_AdditionalIntangibleAssetImpairmentChangeInTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ConsumableMember_41166796-44b9-40aa-b153-8fa46c9046eb_terseLabel_en-US" xlink:label="lab_pacb_ConsumableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consumable revenue</link:label>
    <link:label id="lab_pacb_ConsumableMember_label_en-US" xlink:label="lab_pacb_ConsumableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consumable [Member]</link:label>
    <link:label id="lab_pacb_ConsumableMember_documentation_en-US" xlink:label="lab_pacb_ConsumableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Consumable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ConsumableMember" xlink:href="pacb-20250930.xsd#pacb_ConsumableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ConsumableMember" xlink:to="lab_pacb_ConsumableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_SanDiegoOfficeMember_e7296f9d-5674-4d5a-8f32-0eec88bee88e_terseLabel_en-US" xlink:label="lab_pacb_SanDiegoOfficeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">San Diego Office</link:label>
    <link:label id="lab_pacb_SanDiegoOfficeMember_label_en-US" xlink:label="lab_pacb_SanDiegoOfficeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">San Diego Office [Member]</link:label>
    <link:label id="lab_pacb_SanDiegoOfficeMember_documentation_en-US" xlink:label="lab_pacb_SanDiegoOfficeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">San Diego Office</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SanDiegoOfficeMember" xlink:href="pacb-20250930.xsd#pacb_SanDiegoOfficeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_SanDiegoOfficeMember" xlink:to="lab_pacb_SanDiegoOfficeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_d0c61e3e-ad3d-4fd5-8f16-a086815274a3_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">EQUITY PLANS AND SHARE-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger_4ff03c55-48ca-4e2b-a5fe-7b75f5193eda_terseLabel_en-US" xlink:label="lab_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of outstanding shares of common to be issued in merger</link:label>
    <link:label id="lab_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger_label_en-US" xlink:label="lab_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Outstanding Shares Of Common To Be Issued In Merger</link:label>
    <link:label id="lab_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger_documentation_en-US" xlink:label="lab_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of outstanding shares of common to be issued in merger.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger" xlink:href="pacb-20250930.xsd#pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger" xlink:to="lab_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_631735c2-a7fd-442a-bcb9-929531665e48_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Consolidated net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_e47b83b1-4b5c-4e21-b186-dbf4580c0906_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_29fbb350-6bde-422f-af19-a6c3f03946c6_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_378a2988-3562-426b-a265-cc288303111f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_f54a63bf-43f6-4c86-85ab-c72f66d3c13c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_93cd7567-0205-4e91-82a1-ddb3c5f26851_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsMember_4b3fa4db-c38f-4f1d-abd1-06f930a8f916_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments:</link:label>
    <link:label id="lab_us-gaap_InvestmentsMember_7717bf29-a1bc-4a6f-8f98-797748abb120_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsMember_label_en-US" xlink:label="lab_us-gaap_InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsMember" xlink:to="lab_us-gaap_InvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_4e8e345e-5e46-4aa1-80d6-552614d8e39c_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_9636d397-cb66-4bc6-8b1a-1f2a6d7356f4_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additional expense recorded</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_1644323a-7931-4678-90c4-e463e2972740_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_e2087191-563d-41fb-badf-80dbf15a2142_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_52307b2f-4170-4274-b8f7-1733a9b4f5fa_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2a1223d5-b645-4cb5-9536-9165123cb7b3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Cost [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_19458438-2969-4595-bbd7-878c41463c83_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_583a9976-14b6-4c08-b6a6-2dcca963c3f5_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_6f979d3a-185b-4ec8-957b-2e1f4dbafb2c_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_63d69caf-707d-45ed-b55d-66da9d15d060_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_A2030ConvertibleSeniorNotesMember_f6439cb5-4a8d-46ce-9195-5fd9d47cefbc_terseLabel_en-US" xlink:label="lab_pacb_A2030ConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2030 Convertible Senior Notes</link:label>
    <link:label id="lab_pacb_A2030ConvertibleSeniorNotesMember_label_en-US" xlink:label="lab_pacb_A2030ConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2030 Convertible Senior Notes [Member]</link:label>
    <link:label id="lab_pacb_A2030ConvertibleSeniorNotesMember_documentation_en-US" xlink:label="lab_pacb_A2030ConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2030 Convertible Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2030ConvertibleSeniorNotesMember" xlink:href="pacb-20250930.xsd#pacb_A2030ConvertibleSeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_A2030ConvertibleSeniorNotesMember" xlink:to="lab_pacb_A2030ConvertibleSeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleNotesPayable_41abed74-ef9c-4acc-8742-a28ffdff0c6b_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible notes payable</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayable_3c7c3585-5163-4dc6-8d44-e47e497180c9_periodStartLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayable" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayable_0cab7f2e-37f2-469f-87e6-3dea9a179b7d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayable" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayable_label_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayable" xlink:to="lab_us-gaap_ConvertibleNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_e8c5b055-5578-48c3-acf8-96a528b5a54a_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_RestructuringOfDebtPricePerShare_1ecdfdc9-9c88-4a8c-9d0a-c2e70f281b24_terseLabel_en-US" xlink:label="lab_pacb_RestructuringOfDebtPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring of debt (in dollar per share)</link:label>
    <link:label id="lab_pacb_RestructuringOfDebtPricePerShare_label_en-US" xlink:label="lab_pacb_RestructuringOfDebtPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Of Debt Price Per Share</link:label>
    <link:label id="lab_pacb_RestructuringOfDebtPricePerShare_documentation_en-US" xlink:label="lab_pacb_RestructuringOfDebtPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring Of Debt Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_RestructuringOfDebtPricePerShare" xlink:href="pacb-20250930.xsd#pacb_RestructuringOfDebtPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_RestructuringOfDebtPricePerShare" xlink:to="lab_pacb_RestructuringOfDebtPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_b1a14b72-6ac0-4def-954c-250585216996_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_IncomeLossPerShareAbstract_1d51299a-ad27-4ec5-9923-beb3881cdf22_terseLabel_en-US" xlink:label="lab_pacb_IncomeLossPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share:</link:label>
    <link:label id="lab_pacb_IncomeLossPerShareAbstract_label_en-US" xlink:label="lab_pacb_IncomeLossPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Loss per Share Abstrct</link:label>
    <link:label id="lab_pacb_IncomeLossPerShareAbstract_documentation_en-US" xlink:label="lab_pacb_IncomeLossPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Loss per Share Abstract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IncomeLossPerShareAbstract" xlink:href="pacb-20250930.xsd#pacb_IncomeLossPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_IncomeLossPerShareAbstract" xlink:to="lab_pacb_IncomeLossPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_0a664cf3-6a52-4bb7-b0c8-e5630f93f804_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserves_88c40d24-692d-40d3-a23c-5ebf5f673501_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventory reserve</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryValuationReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_f79dc2f7-af7e-4f10-9cf6-5561f11a0ef6_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_9f8e35ee-9932-4535-9b4d-b7b95cc5fb65_terseLabel_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Technology-Based Intangible Assets</link:label>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Technology-Based Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:to="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_fffa470e-a345-441d-b5fe-b0ca423bc5ca_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ad9e4b2b-6aec-4e54-a116-55387fb90fb7_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_482819a8-0385-417a-af0e-0ddecd8fb45a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1a3b49b4-0acf-4b13-a9ab-876882fc68f9_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_08840cad-2e5a-4323-810c-150f0f272012_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock remain available for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_aba67dc8-9400-4d94-a6fa-ebad0746fcf8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_b88f0578-2ec8-456c-a2c8-39b8a0b8a5b6_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_6cd4c36d-8ce0-4771-9b14-789cac0bfec6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e4972bbe-4821-4a95-aaf8-5819505b9eb7_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_75867596-f259-4870-9523-a4ea5e79c96a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0041564e-ed84-4a4c-8c65-e50898c6b894_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_e7a39020-c451-44e3-bbbc-124b44868bdc_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding used in calculating net loss per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_86ac8e5c-ee44-4d7b-8937-98095a34dd7d_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic, Other Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_5a6f5fbb-ec75-41c3-a8a1-c9e18f7d2b1e_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with customer, liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638a6415-c1dc-4c42-a9bf-ab03f265b67a_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_A2024RestructuringMember_3edb1d7a-850e-411d-aee3-e5d78005b109_terseLabel_en-US" xlink:label="lab_pacb_A2024RestructuringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024 Restructuring</link:label>
    <link:label id="lab_pacb_A2024RestructuringMember_label_en-US" xlink:label="lab_pacb_A2024RestructuringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2024 Restructuring [Member]</link:label>
    <link:label id="lab_pacb_A2024RestructuringMember_documentation_en-US" xlink:label="lab_pacb_A2024RestructuringMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2024 Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2024RestructuringMember" xlink:href="pacb-20250930.xsd#pacb_A2024RestructuringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_A2024RestructuringMember" xlink:to="lab_pacb_A2024RestructuringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b03c8279-0083-4125-b753-b53c8037c456_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded from the computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_de9ddba1-d443-4114-9893-b77148131baa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_447ef86d-fd73-4715-b1c3-10a2d6423ee1_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_79c277f3-5a07-4c83-821f-e8309d30177d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_OptionsToPurchaseCommonStockMember_b4836245-8f2b-4edb-977f-6fc1c16ee2b9_terseLabel_en-US" xlink:label="lab_pacb_OptionsToPurchaseCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_pacb_OptionsToPurchaseCommonStockMember_label_en-US" xlink:label="lab_pacb_OptionsToPurchaseCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options To Purchase Common Stock [Member]</link:label>
    <link:label id="lab_pacb_OptionsToPurchaseCommonStockMember_documentation_en-US" xlink:label="lab_pacb_OptionsToPurchaseCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Options to purchase common stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OptionsToPurchaseCommonStockMember" xlink:href="pacb-20250930.xsd#pacb_OptionsToPurchaseCommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_OptionsToPurchaseCommonStockMember" xlink:to="lab_pacb_OptionsToPurchaseCommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_a5f91675-6fce-49cf-b7ac-4e31155d8b09_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allocation of purchase price</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Asset Acquired, Identifiable Intangible Asset, Indefinite-Lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_513770eb-698e-4106-b9e6-e375eeb74b1d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent_9ab0e206-044f-4e8e-901e-4bd4b13a9e59_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset acquisition amount unpaid</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ChangeInEarningsPerShare_33ba55d0-7122-41aa-bd82-1c06d5f93b8a_terseLabel_en-US" xlink:label="lab_pacb_ChangeInEarningsPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction in net loss, basic (in dollars per share)</link:label>
    <link:label id="lab_pacb_ChangeInEarningsPerShare_label_en-US" xlink:label="lab_pacb_ChangeInEarningsPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Earnings Per Share</link:label>
    <link:label id="lab_pacb_ChangeInEarningsPerShare_documentation_en-US" xlink:label="lab_pacb_ChangeInEarningsPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in Earnings Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ChangeInEarningsPerShare" xlink:href="pacb-20250930.xsd#pacb_ChangeInEarningsPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ChangeInEarningsPerShare" xlink:to="lab_pacb_ChangeInEarningsPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d5da8f1e-8995-4120-b89d-e02f37297f2c_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0f31c8ac-cfca-4ed0-9925-3d7d40b90c0a_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares used in computing basic net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_cac09e65-5a96-44b2-ae11-0511a808d3e6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_41767228-7ede-41ca-bd61-d8c102fc5e16_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory provision</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_f7a27107-91ed-49ab-907f-b861938c9f11_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5ae99c3a-57e9-4910-992f-57e24fe05cf6_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Computation of Basic and Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_46655352-7397-4a13-b6e6-4dcd7240edb1_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalent, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ShortTermRestrictedCashFairValueDisclosure_c95e49a2-4dce-4cea-b356-a815fd46b81a_terseLabel_en-US" xlink:label="lab_pacb_ShortTermRestrictedCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term restricted cash</link:label>
    <link:label id="lab_pacb_ShortTermRestrictedCashFairValueDisclosure_label_en-US" xlink:label="lab_pacb_ShortTermRestrictedCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Restricted Cash Fair Value Disclosure</link:label>
    <link:label id="lab_pacb_ShortTermRestrictedCashFairValueDisclosure_documentation_en-US" xlink:label="lab_pacb_ShortTermRestrictedCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Short-Term Restricted Cash Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ShortTermRestrictedCashFairValueDisclosure" xlink:href="pacb-20250930.xsd#pacb_ShortTermRestrictedCashFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ShortTermRestrictedCashFairValueDisclosure" xlink:to="lab_pacb_ShortTermRestrictedCashFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenue_0d7557d5-87f3-4bbf-972c-b393ca6c6799_totalLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_78fe14b1-e4c0-4590-820f-7ace30b0b48a_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_0ec3b450-79c7-4f29-93e5-560e46b1a02c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_7f83c91e-c020-40a0-a82a-08daf8920aa6_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_60f64272-6350-42a9-9bb4-4d237257ab87_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_83381044-20a8-4eea-b43e-26236ea671a6_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2d85e9ad-1587-49e8-badb-e9c4aa1e6604_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_77be7368-8a10-42a2-8724-9a57fc2418fc_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_InstrumentMember_3bf7c35d-fcbc-45a4-9707-f9eb60f5d683_terseLabel_en-US" xlink:label="lab_pacb_InstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Instrument revenue</link:label>
    <link:label id="lab_pacb_InstrumentMember_label_en-US" xlink:label="lab_pacb_InstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Instrument [Member]</link:label>
    <link:label id="lab_pacb_InstrumentMember_documentation_en-US" xlink:label="lab_pacb_InstrumentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_InstrumentMember" xlink:href="pacb-20250930.xsd#pacb_InstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_InstrumentMember" xlink:to="lab_pacb_InstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33663ee1-fb38-42d2-ad35-01b908ab104a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_e09eceb3-8b23-42dd-b2fa-2fdc1263700d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice_d1a4bfc6-0221-4927-bd28-0235ab5eb69d_terseLabel_en-US" xlink:label="lab_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt redemption, percentage of conversion price</link:label>
    <link:label id="lab_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice_label_en-US" xlink:label="lab_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage of Conversion Price</link:label>
    <link:label id="lab_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice_documentation_en-US" xlink:label="lab_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage of Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice" xlink:href="pacb-20250930.xsd#pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice" xlink:to="lab_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_a0ba3ba4-4991-4df0-a90d-39df9ac8b1b9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a1b051fa-4a31-4736-a863-9576da0f722e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_41e639bc-d7fe-42e2-8f90-b3392876bbc4_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_f7357b2a-8c6c-4e95-a02a-e1f842de1a94_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value of Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_e3f5a815-f149-4e33-9689-ee6fe0b80bd5_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issuable upon conversion of convertible senior notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_7e2dd934-a19e-4d1e-939d-8acb6eb76e81_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_label_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseNonoperating" xlink:to="lab_us-gaap_InterestExpenseNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_23330398-2e4e-4092-854b-0b196d58dadf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_58cf71cd-36d5-43d6-a8e6-75c10292ea7a_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_991f2cfd-54d6-44c4-8bec-cd5aa4c4e3fd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Canceled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_cfdb3e30-2eed-4d3d-bfca-f3cf5e340d47_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_3bd2f28d-6027-4a03-84ae-39d1f94677fd_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_5261d75f-105a-4e4f-95d3-f281e42e1404_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment charges</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Asset Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_69e8068a-8345-49c2-96d9-ddf879df5015_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchased materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_f4aa119f-4063-4c88-9e57-42598bf14ca6_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_e67fdea6-9f18-472e-8406-513a99e5f37e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_63d1703c-929f-4586-a631-b9bd30d487cc_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment income, net</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet" xlink:to="lab_us-gaap_InvestmentIncomeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnRestructuringOfDebt_89eb4f27-3238-4a17-b7c2-a0003b2f280d_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on debt restructuring</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnRestructuringOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (Losses) on Restructuring of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnRestructuringOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:to="lab_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_e0e9d583-aeba-4623-ba77-a3ac305cfd21_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_14da1ded-cd70-47ef-a0c5-7d4fa4734528_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Expense:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_28210e0b-7d88-402c-9770-ba0eded54205_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities, current</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_9cd5a55e-f249-4b4f-b60b-aac07cd8f6c6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_fd1b4981-f6fd-4231-ace3-17399dcb76c2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_557ceab0-225c-41ef-b419-1561c8bc9db2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unamortized debt issuance costs</link:label>
    <link:label id="lab_us-gaap_UnamortizedDebtIssuanceExpense_label_en-US" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unamortized Debt Issuance Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="lab_us-gaap_UnamortizedDebtIssuanceExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_5ceccc06-c0c7-4db8-a973-ad5dc881806a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_f385347c-781d-4923-a7ab-18e15f145ac2_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_e6fd1b30-ffe1-4e2a-b70a-8efd8c49fee3_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod_4d55ddc2-4014-4151-a572-f62814e396d0_terseLabel_en-US" xlink:label="lab_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with customer, liability, noncurrent, recognition (in years)</link:label>
    <link:label id="lab_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod_label_en-US" xlink:label="lab_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent, Recognition Period</link:label>
    <link:label id="lab_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod_documentation_en-US" xlink:label="lab_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent, Recognition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod" xlink:href="pacb-20250930.xsd#pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod" xlink:to="lab_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_ac0b342c-8398-4dd0-9e74-c990ef6e5d3c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Time-Based RSUs and PSUs Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_8045a64d-9166-4d24-bce5-199bf69461e5_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_a275de83-37f6-4674-bff9-0fc5a16990fb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_6f9b4ade-b934-4a35-926e-51eb599347f5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_c697c8c7-7d88-45db-9b5e-58af7bb26b07_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_751dbe79-a08a-4237-b066-74740b5e5e12_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_970f7107-bc11-4a6d-8dd0-2e9c73c45b6d_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_f43e1f03-9afc-463e-bed6-97c0d02bd5ee_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5ab2046f-c7e4-43d7-9b05-9f99b587e8c1_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>pacb-20250930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:541066b6-d2f9-469d-bf86-6042e3dcfaa4,g:e6194c68-cd08-4fb8-9cf2-74de760e8618-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CoverPage" xlink:type="simple" xlink:href="pacb-20250930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_27417f0c-2554-43d8-8825-5d5fd8cc5cdc" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_86d058ae-4361-41cd-a5d8-0934f989ea80" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_27417f0c-2554-43d8-8825-5d5fd8cc5cdc" xlink:to="loc_dei_DocumentType_86d058ae-4361-41cd-a5d8-0934f989ea80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_0475a1b3-a35c-4fb9-b282-26fb5d6101fd" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_27417f0c-2554-43d8-8825-5d5fd8cc5cdc" xlink:to="loc_dei_DocumentQuarterlyReport_0475a1b3-a35c-4fb9-b282-26fb5d6101fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_8d00e161-a477-4d29-88e9-e3357e05ce5c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_27417f0c-2554-43d8-8825-5d5fd8cc5cdc" xlink:to="loc_dei_DocumentPeriodEndDate_8d00e161-a477-4d29-88e9-e3357e05ce5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_10aa9ce6-61ae-4993-aab9-c82e2bd13d66" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_27417f0c-2554-43d8-8825-5d5fd8cc5cdc" xlink:to="loc_dei_DocumentTransitionReport_10aa9ce6-61ae-4993-aab9-c82e2bd13d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_32a46b77-936b-43e3-bfcb-a9d12ba0f008" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_27417f0c-2554-43d8-8825-5d5fd8cc5cdc" xlink:to="loc_dei_EntityFileNumber_32a46b77-936b-43e3-bfcb-a9d12ba0f008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_03b978c2-1159-405a-b40a-d7f3e45348b8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_27417f0c-2554-43d8-8825-5d5fd8cc5cdc" xlink:to="loc_dei_EntityRegistrantName_03b978c2-1159-405a-b40a-d7f3e45348b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_306c7488-9741-401a-aae9-5059d7e05279" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_27417f0c-2554-43d8-8825-5d5fd8cc5cdc" xlink:to="loc_dei_EntityIncorporationStateCountryCode_306c7488-9741-401a-aae9-5059d7e05279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_b76b6da9-d111-4de6-b9db-7a9ecf5af97f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_27417f0c-2554-43d8-8825-5d5fd8cc5cdc" xlink:to="loc_dei_EntityTaxIdentificationNumber_b76b6da9-d111-4de6-b9db-7a9ecf5af97f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_5779e3aa-bf49-410a-b9f0-10e8c08d12ea" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_27417f0c-2554-43d8-8825-5d5fd8cc5cdc" xlink:to="loc_dei_EntityAddressAddressLine1_5779e3aa-bf49-410a-b9f0-10e8c08d12ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_0e527835-3441-462b-9951-2fbe091eb99b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_27417f0c-2554-43d8-8825-5d5fd8cc5cdc" xlink:to="loc_dei_EntityAddressCityOrTown_0e527835-3441-462b-9951-2fbe091eb99b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_51441357-ae6f-432c-833e-a17815dd6986" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_27417f0c-2554-43d8-8825-5d5fd8cc5cdc" xlink:to="loc_dei_EntityAddressStateOrProvince_51441357-ae6f-432c-833e-a17815dd6986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_4e8d8980-83a9-4971-9210-63ac404ed6b0" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_27417f0c-2554-43d8-8825-5d5fd8cc5cdc" xlink:to="loc_dei_EntityAddressPostalZipCode_4e8d8980-83a9-4971-9210-63ac404ed6b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_32fa3f04-06c2-46c3-b63b-6f2ef71753ab" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_27417f0c-2554-43d8-8825-5d5fd8cc5cdc" xlink:to="loc_dei_CityAreaCode_32fa3f04-06c2-46c3-b63b-6f2ef71753ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_431bf2f6-3066-495e-a6dc-4658f81654d1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_27417f0c-2554-43d8-8825-5d5fd8cc5cdc" xlink:to="loc_dei_LocalPhoneNumber_431bf2f6-3066-495e-a6dc-4658f81654d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_4cf7c7d3-8249-4b15-845f-51b807b32e64" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_27417f0c-2554-43d8-8825-5d5fd8cc5cdc" xlink:to="loc_dei_Security12bTitle_4cf7c7d3-8249-4b15-845f-51b807b32e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_f69271ce-8374-481f-b902-fd1903392f84" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_27417f0c-2554-43d8-8825-5d5fd8cc5cdc" xlink:to="loc_dei_TradingSymbol_f69271ce-8374-481f-b902-fd1903392f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_6fbd9a66-e196-4717-a11b-205cca0c73d1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_27417f0c-2554-43d8-8825-5d5fd8cc5cdc" xlink:to="loc_dei_SecurityExchangeName_6fbd9a66-e196-4717-a11b-205cca0c73d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_6646dfa4-513b-4586-8bad-3d02b9d13a6c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_27417f0c-2554-43d8-8825-5d5fd8cc5cdc" xlink:to="loc_dei_EntityCurrentReportingStatus_6646dfa4-513b-4586-8bad-3d02b9d13a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_02cb6b71-d537-45a2-be12-d7853e1d1164" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_27417f0c-2554-43d8-8825-5d5fd8cc5cdc" xlink:to="loc_dei_EntityInteractiveDataCurrent_02cb6b71-d537-45a2-be12-d7853e1d1164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_be071dbe-5da9-4406-9676-032b94d59d3a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_27417f0c-2554-43d8-8825-5d5fd8cc5cdc" xlink:to="loc_dei_EntityFilerCategory_be071dbe-5da9-4406-9676-032b94d59d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_1bf2a1ca-fa70-478e-9684-3db7ff2309ad" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_27417f0c-2554-43d8-8825-5d5fd8cc5cdc" xlink:to="loc_dei_EntitySmallBusiness_1bf2a1ca-fa70-478e-9684-3db7ff2309ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_89894f0a-6c03-49a1-aef6-0f23b8c8b3ac" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_27417f0c-2554-43d8-8825-5d5fd8cc5cdc" xlink:to="loc_dei_EntityEmergingGrowthCompany_89894f0a-6c03-49a1-aef6-0f23b8c8b3ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_d74c05c9-7657-4903-9117-f0d6ecf83f59" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_27417f0c-2554-43d8-8825-5d5fd8cc5cdc" xlink:to="loc_dei_EntityShellCompany_d74c05c9-7657-4903-9117-f0d6ecf83f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_6deef767-29ab-48be-85b0-7eeb823f815b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_27417f0c-2554-43d8-8825-5d5fd8cc5cdc" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_6deef767-29ab-48be-85b0-7eeb823f815b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_14b11f59-cb30-4d49-94d2-473b44793a1a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_27417f0c-2554-43d8-8825-5d5fd8cc5cdc" xlink:to="loc_dei_EntityCentralIndexKey_14b11f59-cb30-4d49-94d2-473b44793a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_b183a2ed-3572-4514-adef-35b81115c364" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_27417f0c-2554-43d8-8825-5d5fd8cc5cdc" xlink:to="loc_dei_CurrentFiscalYearEndDate_b183a2ed-3572-4514-adef-35b81115c364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_2b3820d8-97c6-402d-b830-cde9ed8b8485" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_27417f0c-2554-43d8-8825-5d5fd8cc5cdc" xlink:to="loc_dei_DocumentFiscalYearFocus_2b3820d8-97c6-402d-b830-cde9ed8b8485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_a9fae05a-48dc-485b-b682-15e648205b12" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_27417f0c-2554-43d8-8825-5d5fd8cc5cdc" xlink:to="loc_dei_DocumentFiscalPeriodFocus_a9fae05a-48dc-485b-b682-15e648205b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_17a55e09-60e6-45ae-afae-e759a9cc4e83" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_27417f0c-2554-43d8-8825-5d5fd8cc5cdc" xlink:to="loc_dei_AmendmentFlag_17a55e09-60e6-45ae-afae-e759a9cc4e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" xlink:type="simple" xlink:href="pacb-20250930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_fb6804e0-d140-4a36-be39-2592627a8929" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_9b70dcdf-6946-4fa4-97a0-0cb6ae47eb78" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fb6804e0-d140-4a36-be39-2592627a8929" xlink:to="loc_us-gaap_AssetsAbstract_9b70dcdf-6946-4fa4-97a0-0cb6ae47eb78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_4302dfa9-2c59-4d68-8155-dbeb19877226" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9b70dcdf-6946-4fa4-97a0-0cb6ae47eb78" xlink:to="loc_us-gaap_AssetsCurrentAbstract_4302dfa9-2c59-4d68-8155-dbeb19877226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ddb21514-1c7d-4339-9070-df16bbce95f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4302dfa9-2c59-4d68-8155-dbeb19877226" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ddb21514-1c7d-4339-9070-df16bbce95f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_e3ee66f0-b088-40ed-87b0-449d6a17f548" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4302dfa9-2c59-4d68-8155-dbeb19877226" xlink:to="loc_us-gaap_ShortTermInvestments_e3ee66f0-b088-40ed-87b0-449d6a17f548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_70363939-b285-40a0-87d4-9ff0b3c5bb76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4302dfa9-2c59-4d68-8155-dbeb19877226" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_70363939-b285-40a0-87d4-9ff0b3c5bb76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_26e4ed4c-b4bb-4915-b8d4-7d278a89e0d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4302dfa9-2c59-4d68-8155-dbeb19877226" xlink:to="loc_us-gaap_InventoryNet_26e4ed4c-b4bb-4915-b8d4-7d278a89e0d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c0312cac-b742-439f-8bf9-c55155cae3d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4302dfa9-2c59-4d68-8155-dbeb19877226" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c0312cac-b742-439f-8bf9-c55155cae3d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_7567175e-0123-4563-91d0-fa28367481a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4302dfa9-2c59-4d68-8155-dbeb19877226" xlink:to="loc_us-gaap_RestrictedCashCurrent_7567175e-0123-4563-91d0-fa28367481a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5f2c7a43-23cb-4401-9833-d87326c943c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4302dfa9-2c59-4d68-8155-dbeb19877226" xlink:to="loc_us-gaap_AssetsCurrent_5f2c7a43-23cb-4401-9833-d87326c943c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7a5798af-d649-4f6c-9280-5b73cdfcb24d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9b70dcdf-6946-4fa4-97a0-0cb6ae47eb78" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7a5798af-d649-4f6c-9280-5b73cdfcb24d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_7097a635-b430-48ab-b881-755b7d661a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9b70dcdf-6946-4fa4-97a0-0cb6ae47eb78" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_7097a635-b430-48ab-b881-755b7d661a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_64bed644-bc07-42b1-a9d8-4874452a1d55" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9b70dcdf-6946-4fa4-97a0-0cb6ae47eb78" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_64bed644-bc07-42b1-a9d8-4874452a1d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c4b9bc29-7c2e-4508-9184-73e9bfd8d905" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9b70dcdf-6946-4fa4-97a0-0cb6ae47eb78" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c4b9bc29-7c2e-4508-9184-73e9bfd8d905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_4868a283-0a4f-4f55-aadd-a1d50dd4df39" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9b70dcdf-6946-4fa4-97a0-0cb6ae47eb78" xlink:to="loc_us-gaap_Goodwill_4868a283-0a4f-4f55-aadd-a1d50dd4df39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_71836992-e46d-4ed5-ad60-39db04e6507e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9b70dcdf-6946-4fa4-97a0-0cb6ae47eb78" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_71836992-e46d-4ed5-ad60-39db04e6507e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f36b20aa-3ebd-4a6c-826e-8f9f6d6ddc07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9b70dcdf-6946-4fa4-97a0-0cb6ae47eb78" xlink:to="loc_us-gaap_Assets_f36b20aa-3ebd-4a6c-826e-8f9f6d6ddc07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6191916-b794-45fb-988d-e8695246ac3d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fb6804e0-d140-4a36-be39-2592627a8929" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6191916-b794-45fb-988d-e8695246ac3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_1c2b249a-2c1f-4e7b-9cc7-d1c25efa5bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6191916-b794-45fb-988d-e8695246ac3d" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_1c2b249a-2c1f-4e7b-9cc7-d1c25efa5bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_d40fcfe7-e648-4f9b-b207-2b65689a531d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1c2b249a-2c1f-4e7b-9cc7-d1c25efa5bd4" xlink:to="loc_us-gaap_AccountsPayableCurrent_d40fcfe7-e648-4f9b-b207-2b65689a531d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_993da57c-46b7-47e5-9ccb-818422dcc7cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1c2b249a-2c1f-4e7b-9cc7-d1c25efa5bd4" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_993da57c-46b7-47e5-9ccb-818422dcc7cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d7245881-2969-4c0d-ac6f-883b7833c130" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1c2b249a-2c1f-4e7b-9cc7-d1c25efa5bd4" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d7245881-2969-4c0d-ac6f-883b7833c130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_7297b2a8-b1b5-4af1-820c-c905e655b194" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1c2b249a-2c1f-4e7b-9cc7-d1c25efa5bd4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_7297b2a8-b1b5-4af1-820c-c905e655b194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_cf31add0-da2e-4844-b653-f84f569a8db1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1c2b249a-2c1f-4e7b-9cc7-d1c25efa5bd4" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_cf31add0-da2e-4844-b653-f84f569a8db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4f3b51fd-1af3-44c8-b254-28b99eb6517d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1c2b249a-2c1f-4e7b-9cc7-d1c25efa5bd4" xlink:to="loc_us-gaap_LiabilitiesCurrent_4f3b51fd-1af3-44c8-b254-28b99eb6517d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_415e5c03-11e0-4cb1-8b70-4ea6d478c866" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6191916-b794-45fb-988d-e8695246ac3d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_415e5c03-11e0-4cb1-8b70-4ea6d478c866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_2b901336-e5ad-45b8-8a67-3ab30ce5f8f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6191916-b794-45fb-988d-e8695246ac3d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_2b901336-e5ad-45b8-8a67-3ab30ce5f8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ee504c57-fb93-4364-bf8f-59669b15f742" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6191916-b794-45fb-988d-e8695246ac3d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ee504c57-fb93-4364-bf8f-59669b15f742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_069ab5b5-7eac-4513-955d-dc0c43ca7fd5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6191916-b794-45fb-988d-e8695246ac3d" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_069ab5b5-7eac-4513-955d-dc0c43ca7fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_a7c12c80-c5fe-4500-b0bd-0f96f59a7785" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6191916-b794-45fb-988d-e8695246ac3d" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_a7c12c80-c5fe-4500-b0bd-0f96f59a7785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_01816870-6667-47cd-9f7d-46ca2b9612ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6191916-b794-45fb-988d-e8695246ac3d" xlink:to="loc_us-gaap_Liabilities_01816870-6667-47cd-9f7d-46ca2b9612ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_1136ea16-877b-4062-b01a-9293c0d6fb4a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6191916-b794-45fb-988d-e8695246ac3d" xlink:to="loc_us-gaap_CommitmentsAndContingencies_1136ea16-877b-4062-b01a-9293c0d6fb4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_964f3341-4fc9-455a-8eb9-7463868b9a12" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6191916-b794-45fb-988d-e8695246ac3d" xlink:to="loc_us-gaap_StockholdersEquityAbstract_964f3341-4fc9-455a-8eb9-7463868b9a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_4531c76c-f739-439b-99ac-a28ea08ad439" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_964f3341-4fc9-455a-8eb9-7463868b9a12" xlink:to="loc_us-gaap_PreferredStockValue_4531c76c-f739-439b-99ac-a28ea08ad439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_bc86007b-956a-4813-bcec-0df92abf582c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_964f3341-4fc9-455a-8eb9-7463868b9a12" xlink:to="loc_us-gaap_CommonStockValue_bc86007b-956a-4813-bcec-0df92abf582c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_e0544af9-19d1-45af-a424-5840ef03b527" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_964f3341-4fc9-455a-8eb9-7463868b9a12" xlink:to="loc_us-gaap_AdditionalPaidInCapital_e0544af9-19d1-45af-a424-5840ef03b527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d19a6203-25a7-4edc-9242-ad77109beb83" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_964f3341-4fc9-455a-8eb9-7463868b9a12" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d19a6203-25a7-4edc-9242-ad77109beb83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d68bc43c-70be-4b97-930d-026f7e1f200c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_964f3341-4fc9-455a-8eb9-7463868b9a12" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d68bc43c-70be-4b97-930d-026f7e1f200c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_cfc66f16-ce21-4709-b340-750f35aaa88a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_964f3341-4fc9-455a-8eb9-7463868b9a12" xlink:to="loc_us-gaap_StockholdersEquity_cfc66f16-ce21-4709-b340-750f35aaa88a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_8ff424a1-28f6-4d4d-aedc-a3946bf1255b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f6191916-b794-45fb-988d-e8695246ac3d" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_8ff424a1-28f6-4d4d-aedc-a3946bf1255b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" xlink:type="simple" xlink:href="pacb-20250930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_46bfe5c0-fd36-4840-a61b-073d2e91773a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4fd78f8a-ef9f-407d-8d31-a6953d5d04d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_46bfe5c0-fd36-4840-a61b-073d2e91773a" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4fd78f8a-ef9f-407d-8d31-a6953d5d04d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_57fbbde6-5a3a-46fe-99be-3a835c26d557" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_46bfe5c0-fd36-4840-a61b-073d2e91773a" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_57fbbde6-5a3a-46fe-99be-3a835c26d557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_7a42827d-9561-4db6-8f58-b52e6a56d6dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_46bfe5c0-fd36-4840-a61b-073d2e91773a" xlink:to="loc_us-gaap_PreferredStockSharesIssued_7a42827d-9561-4db6-8f58-b52e6a56d6dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_6da60dee-8729-4d60-9ba1-a976a3a611c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_46bfe5c0-fd36-4840-a61b-073d2e91773a" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_6da60dee-8729-4d60-9ba1-a976a3a611c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_9b846959-2ee7-49b8-a55a-5540c60e4151" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_46bfe5c0-fd36-4840-a61b-073d2e91773a" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_9b846959-2ee7-49b8-a55a-5540c60e4151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_f535a4a7-490f-46d2-ac5a-4c4ff1384c06" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_46bfe5c0-fd36-4840-a61b-073d2e91773a" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_f535a4a7-490f-46d2-ac5a-4c4ff1384c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_2cb98cbc-0391-4aae-bfac-0e0c56e89587" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_46bfe5c0-fd36-4840-a61b-073d2e91773a" xlink:to="loc_us-gaap_CommonStockSharesIssued_2cb98cbc-0391-4aae-bfac-0e0c56e89587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_5c1be52f-d877-4fcc-a1d0-3db6d86b12f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_46bfe5c0-fd36-4840-a61b-073d2e91773a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_5c1be52f-d877-4fcc-a1d0-3db6d86b12f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" xlink:type="simple" xlink:href="pacb-20250930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_290afb1a-6259-40ed-93b6-6953e3514c27" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a7c3a316-64a8-4877-a662-bd85e913522a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_290afb1a-6259-40ed-93b6-6953e3514c27" xlink:to="loc_us-gaap_StatementTable_a7c3a316-64a8-4877-a662-bd85e913522a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_87d8bb9e-56ad-498e-b8ef-f5323f6f6be0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a7c3a316-64a8-4877-a662-bd85e913522a" xlink:to="loc_srt_ProductOrServiceAxis_87d8bb9e-56ad-498e-b8ef-f5323f6f6be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_284692de-60ff-4c60-9915-c5c7335221f2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_87d8bb9e-56ad-498e-b8ef-f5323f6f6be0" xlink:to="loc_srt_ProductsAndServicesDomain_284692de-60ff-4c60-9915-c5c7335221f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_881302a8-df33-474c-bf0d-89667adb771b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_284692de-60ff-4c60-9915-c5c7335221f2" xlink:to="loc_us-gaap_ProductMember_881302a8-df33-474c-bf0d-89667adb771b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ServiceAndOtherMember_b7397858-dfc0-4cea-978c-889591d2e737" xlink:href="pacb-20250930.xsd#pacb_ServiceAndOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_284692de-60ff-4c60-9915-c5c7335221f2" xlink:to="loc_pacb_ServiceAndOtherMember_b7397858-dfc0-4cea-978c-889591d2e737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2d574fd1-3a9e-4e9b-85cb-c29911e1d28a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a7c3a316-64a8-4877-a662-bd85e913522a" xlink:to="loc_us-gaap_StatementLineItems_2d574fd1-3a9e-4e9b-85cb-c29911e1d28a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_5c619c1d-2762-4a6f-a8c7-fa8e2ca85b79" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2d574fd1-3a9e-4e9b-85cb-c29911e1d28a" xlink:to="loc_us-gaap_RevenuesAbstract_5c619c1d-2762-4a6f-a8c7-fa8e2ca85b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a69e1edb-4d3e-4b1f-b7fa-e33eea07b74a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_5c619c1d-2762-4a6f-a8c7-fa8e2ca85b79" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a69e1edb-4d3e-4b1f-b7fa-e33eea07b74a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenueAbstract_d16b0e49-4320-406c-bdd2-ac584a23c7a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2d574fd1-3a9e-4e9b-85cb-c29911e1d28a" xlink:to="loc_us-gaap_CostOfRevenueAbstract_d16b0e49-4320-406c-bdd2-ac584a23c7a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_f09649ab-656a-44d1-ba1b-f186a9b24003" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfRevenueAbstract_d16b0e49-4320-406c-bdd2-ac584a23c7a3" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_f09649ab-656a-44d1-ba1b-f186a9b24003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_32055333-064c-4808-b762-6dddb5c31c64" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfRevenueAbstract_d16b0e49-4320-406c-bdd2-ac584a23c7a3" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_32055333-064c-4808-b762-6dddb5c31c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LossOnPurchaseCommitment_277f6e76-7989-4d7b-8950-64a3fda492bb" xlink:href="pacb-20250930.xsd#pacb_LossOnPurchaseCommitment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfRevenueAbstract_d16b0e49-4320-406c-bdd2-ac584a23c7a3" xlink:to="loc_pacb_LossOnPurchaseCommitment_277f6e76-7989-4d7b-8950-64a3fda492bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_caf33222-6730-4520-b225-183021832561" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfRevenueAbstract_d16b0e49-4320-406c-bdd2-ac584a23c7a3" xlink:to="loc_us-gaap_CostOfRevenue_caf33222-6730-4520-b225-183021832561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_35cfe4ed-9373-45ac-a028-964ffe1b9b53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2d574fd1-3a9e-4e9b-85cb-c29911e1d28a" xlink:to="loc_us-gaap_GrossProfit_35cfe4ed-9373-45ac-a028-964ffe1b9b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_423a0d19-3e07-4b31-9dc6-69d40526dd53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2d574fd1-3a9e-4e9b-85cb-c29911e1d28a" xlink:to="loc_us-gaap_OperatingExpensesAbstract_423a0d19-3e07-4b31-9dc6-69d40526dd53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7bff8139-0d23-487b-852b-ba5191607e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_423a0d19-3e07-4b31-9dc6-69d40526dd53" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7bff8139-0d23-487b-852b-ba5191607e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a0faf73d-9a3e-4743-aee7-f14a7fbe637f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_423a0d19-3e07-4b31-9dc6-69d40526dd53" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a0faf73d-9a3e-4743-aee7-f14a7fbe637f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_1c0b7862-892d-4289-bb48-6573d4c23cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_423a0d19-3e07-4b31-9dc6-69d40526dd53" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_1c0b7862-892d-4289-bb48-6573d4c23cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AmortizationOfAcquiredIntangibleAssets_d8c23d71-6e46-493c-8360-93c6e41d43ac" xlink:href="pacb-20250930.xsd#pacb_AmortizationOfAcquiredIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_423a0d19-3e07-4b31-9dc6-69d40526dd53" xlink:to="loc_pacb_AmortizationOfAcquiredIntangibleAssets_d8c23d71-6e46-493c-8360-93c6e41d43ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e2a42824-060c-4e67-9c65-d70060ff4996" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_423a0d19-3e07-4b31-9dc6-69d40526dd53" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e2a42824-060c-4e67-9c65-d70060ff4996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_ec07f6e4-e948-4b58-a8e9-c5f72453c73b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_423a0d19-3e07-4b31-9dc6-69d40526dd53" xlink:to="loc_us-gaap_OperatingExpenses_ec07f6e4-e948-4b58-a8e9-c5f72453c73b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f8847716-4f74-4528-afc2-e129663949be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2d574fd1-3a9e-4e9b-85cb-c29911e1d28a" xlink:to="loc_us-gaap_OperatingIncomeLoss_f8847716-4f74-4528-afc2-e129663949be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_6f893d7a-902e-4e05-ba30-1b71429a3b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2d574fd1-3a9e-4e9b-85cb-c29911e1d28a" xlink:to="loc_us-gaap_InterestExpenseNonoperating_6f893d7a-902e-4e05-ba30-1b71429a3b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_069b5131-b21c-4b3d-bbad-0d23f701bb59" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2d574fd1-3a9e-4e9b-85cb-c29911e1d28a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_069b5131-b21c-4b3d-bbad-0d23f701bb59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_607a5246-2d43-4cde-ae6c-478e2d6f1b99" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2d574fd1-3a9e-4e9b-85cb-c29911e1d28a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_607a5246-2d43-4cde-ae6c-478e2d6f1b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9f2afb96-37c7-44a4-82ab-9e85475187a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2d574fd1-3a9e-4e9b-85cb-c29911e1d28a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9f2afb96-37c7-44a4-82ab-9e85475187a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_72543af4-ffa5-4f6a-9959-3e17e2705421" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2d574fd1-3a9e-4e9b-85cb-c29911e1d28a" xlink:to="loc_us-gaap_NetIncomeLoss_72543af4-ffa5-4f6a-9959-3e17e2705421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_f2189ae4-d5f7-418c-a3cb-b61827f8c414" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2d574fd1-3a9e-4e9b-85cb-c29911e1d28a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_f2189ae4-d5f7-418c-a3cb-b61827f8c414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_828f7715-e275-4896-899a-f58b2dfa3cb4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_f2189ae4-d5f7-418c-a3cb-b61827f8c414" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_828f7715-e275-4896-899a-f58b2dfa3cb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_0cfde0bf-ac3c-41b9-8a3c-12dcb9e31a76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2d574fd1-3a9e-4e9b-85cb-c29911e1d28a" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_0cfde0bf-ac3c-41b9-8a3c-12dcb9e31a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IncomeLossPerShareAbstract_e629510a-a2f0-471c-ac81-e50bc3921574" xlink:href="pacb-20250930.xsd#pacb_IncomeLossPerShareAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2d574fd1-3a9e-4e9b-85cb-c29911e1d28a" xlink:to="loc_pacb_IncomeLossPerShareAbstract_e629510a-a2f0-471c-ac81-e50bc3921574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_f2cc5625-e6ad-4685-afa4-5df7289912ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_IncomeLossPerShareAbstract_e629510a-a2f0-471c-ac81-e50bc3921574" xlink:to="loc_us-gaap_EarningsPerShareBasic_f2cc5625-e6ad-4685-afa4-5df7289912ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_445aec72-7bc5-47b7-98f8-fa0db9594a01" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_IncomeLossPerShareAbstract_e629510a-a2f0-471c-ac81-e50bc3921574" xlink:to="loc_us-gaap_EarningsPerShareDiluted_445aec72-7bc5-47b7-98f8-fa0db9594a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_60dd388b-3e30-4e40-849f-6fad9d92520d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2d574fd1-3a9e-4e9b-85cb-c29911e1d28a" xlink:to="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_60dd388b-3e30-4e40-849f-6fad9d92520d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_255db604-e2ca-4d13-a6f1-4f5c553b09db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_60dd388b-3e30-4e40-849f-6fad9d92520d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_255db604-e2ca-4d13-a6f1-4f5c553b09db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3226c74a-8806-48bb-9072-9f1e5908761c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_60dd388b-3e30-4e40-849f-6fad9d92520d" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3226c74a-8806-48bb-9072-9f1e5908761c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" xlink:type="simple" xlink:href="pacb-20250930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_57ca8d73-8f8b-47b3-a426-26babefcc6ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3fd6a966-e22f-4e19-92a2-c48f99ab237d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_57ca8d73-8f8b-47b3-a426-26babefcc6ab" xlink:to="loc_us-gaap_StatementTable_3fd6a966-e22f-4e19-92a2-c48f99ab237d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0fcfe910-c602-4f59-9e84-671f88912d54" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3fd6a966-e22f-4e19-92a2-c48f99ab237d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0fcfe910-c602-4f59-9e84-671f88912d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ed1fe101-4f09-4830-a3ac-329cb06f8c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0fcfe910-c602-4f59-9e84-671f88912d54" xlink:to="loc_us-gaap_EquityComponentDomain_ed1fe101-4f09-4830-a3ac-329cb06f8c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b0e658a2-8a28-49b9-9e02-1031da6f6947" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ed1fe101-4f09-4830-a3ac-329cb06f8c1f" xlink:to="loc_us-gaap_CommonStockMember_b0e658a2-8a28-49b9-9e02-1031da6f6947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_a0295b07-1200-4716-8325-96016d9702b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ed1fe101-4f09-4830-a3ac-329cb06f8c1f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_a0295b07-1200-4716-8325-96016d9702b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_321bc3b1-cd38-4219-b300-9c13d79df5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ed1fe101-4f09-4830-a3ac-329cb06f8c1f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_321bc3b1-cd38-4219-b300-9c13d79df5bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_78e516e1-c495-4c9b-89ee-8da08fb67aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ed1fe101-4f09-4830-a3ac-329cb06f8c1f" xlink:to="loc_us-gaap_RetainedEarningsMember_78e516e1-c495-4c9b-89ee-8da08fb67aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d4a05c9a-337e-4f3c-b48f-dfc4f83d916b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3fd6a966-e22f-4e19-92a2-c48f99ab237d" xlink:to="loc_us-gaap_StatementLineItems_d4a05c9a-337e-4f3c-b48f-dfc4f83d916b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28c1c404-bc95-4f91-8df4-fa141374240d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d4a05c9a-337e-4f3c-b48f-dfc4f83d916b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28c1c404-bc95-4f91-8df4-fa141374240d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_288e02ad-7b66-4a6b-9de1-a3534542137b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28c1c404-bc95-4f91-8df4-fa141374240d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_288e02ad-7b66-4a6b-9de1-a3534542137b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_25ce6583-030d-42fc-be68-ef8eee048126" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28c1c404-bc95-4f91-8df4-fa141374240d" xlink:to="loc_us-gaap_StockholdersEquity_25ce6583-030d-42fc-be68-ef8eee048126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_70edf339-77a8-4721-bdc5-cb819dc68d00" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28c1c404-bc95-4f91-8df4-fa141374240d" xlink:to="loc_us-gaap_NetIncomeLoss_70edf339-77a8-4721-bdc5-cb819dc68d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7d26b26c-b74a-4401-9bbc-65f7bc932953" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28c1c404-bc95-4f91-8df4-fa141374240d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7d26b26c-b74a-4401-9bbc-65f7bc932953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0f25030a-ac4e-4171-b01c-f30c8c1dde08" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28c1c404-bc95-4f91-8df4-fa141374240d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0f25030a-ac4e-4171-b01c-f30c8c1dde08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_481b0e21-db4c-4265-aee3-22719633b059" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28c1c404-bc95-4f91-8df4-fa141374240d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_481b0e21-db4c-4265-aee3-22719633b059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0c8b927f-e839-4017-abbc-5929b423361c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28c1c404-bc95-4f91-8df4-fa141374240d" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0c8b927f-e839-4017-abbc-5929b423361c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c3456a89-70a5-4eea-ac9e-7b090dcefdca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28c1c404-bc95-4f91-8df4-fa141374240d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c3456a89-70a5-4eea-ac9e-7b090dcefdca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b4b89e6a-7f8f-4602-b8a3-5894018325a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28c1c404-bc95-4f91-8df4-fa141374240d" xlink:to="loc_us-gaap_StockholdersEquity_b4b89e6a-7f8f-4602-b8a3-5894018325a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" xlink:type="simple" xlink:href="pacb-20250930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_02fbe313-f0b4-4570-a167-55943d2e1c6d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3334a339-1ac4-470d-bb4b-951bfff7709d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_02fbe313-f0b4-4570-a167-55943d2e1c6d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3334a339-1ac4-470d-bb4b-951bfff7709d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_77872298-30e6-4cef-97cb-c01cc7c882d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3334a339-1ac4-470d-bb4b-951bfff7709d" xlink:to="loc_us-gaap_NetIncomeLoss_77872298-30e6-4cef-97cb-c01cc7c882d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_60a16d23-dadd-4463-8d6d-be6aa7164ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3334a339-1ac4-470d-bb4b-951bfff7709d" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_60a16d23-dadd-4463-8d6d-be6aa7164ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_9d6a10e8-4a94-428e-b46a-f2c2770df4e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_60a16d23-dadd-4463-8d6d-be6aa7164ed7" xlink:to="loc_us-gaap_Depreciation_9d6a10e8-4a94-428e-b46a-f2c2770df4e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_3feba670-9ec5-4347-9139-90b4b5f7d2e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_60a16d23-dadd-4463-8d6d-be6aa7164ed7" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_3feba670-9ec5-4347-9139-90b4b5f7d2e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_0a8e7952-c284-4ce6-818b-ff5493e97151" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_60a16d23-dadd-4463-8d6d-be6aa7164ed7" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_0a8e7952-c284-4ce6-818b-ff5493e97151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a4ca026f-6889-487d-be6e-1317ce5cfbcd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_60a16d23-dadd-4463-8d6d-be6aa7164ed7" xlink:to="loc_us-gaap_ShareBasedCompensation_a4ca026f-6889-487d-be6e-1317ce5cfbcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_d2dd2352-2b7a-4186-bae4-0edaa44bd876" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_60a16d23-dadd-4463-8d6d-be6aa7164ed7" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_d2dd2352-2b7a-4186-bae4-0edaa44bd876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_bb696d48-a1e8-4cd8-a444-917493d49bfe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_60a16d23-dadd-4463-8d6d-be6aa7164ed7" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_bb696d48-a1e8-4cd8-a444-917493d49bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_8bae4175-259d-45b7-ac4c-58db116a007a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_60a16d23-dadd-4463-8d6d-be6aa7164ed7" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_8bae4175-259d-45b7-ac4c-58db116a007a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_80f92569-2bb6-4c3e-a55a-8b4defa68ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_60a16d23-dadd-4463-8d6d-be6aa7164ed7" xlink:to="loc_us-gaap_InventoryWriteDown_80f92569-2bb6-4c3e-a55a-8b4defa68ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_ba098ee0-3081-4189-9413-d3e284bb6da7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_60a16d23-dadd-4463-8d6d-be6aa7164ed7" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_ba098ee0-3081-4189-9413-d3e284bb6da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_29325aa3-7af2-44b0-b89f-ed4cb418206a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_60a16d23-dadd-4463-8d6d-be6aa7164ed7" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_29325aa3-7af2-44b0-b89f-ed4cb418206a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1acf64bb-fbcd-4ffd-a0df-bd9ebd283e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_60a16d23-dadd-4463-8d6d-be6aa7164ed7" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1acf64bb-fbcd-4ffd-a0df-bd9ebd283e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c365b114-e026-4d4f-9faa-34f430eb6fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1acf64bb-fbcd-4ffd-a0df-bd9ebd283e6d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c365b114-e026-4d4f-9faa-34f430eb6fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_3da20ad3-2316-4cd1-aecf-cfc719791525" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1acf64bb-fbcd-4ffd-a0df-bd9ebd283e6d" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_3da20ad3-2316-4cd1-aecf-cfc719791525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_68c7da35-2a31-4cf3-87b1-b834d37a44c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1acf64bb-fbcd-4ffd-a0df-bd9ebd283e6d" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_68c7da35-2a31-4cf3-87b1-b834d37a44c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ab30eb54-44ca-4d77-9072-5985cf766897" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1acf64bb-fbcd-4ffd-a0df-bd9ebd283e6d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ab30eb54-44ca-4d77-9072-5985cf766897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_b90d3fbb-c373-4035-8b7a-6fba91938e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1acf64bb-fbcd-4ffd-a0df-bd9ebd283e6d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_b90d3fbb-c373-4035-8b7a-6fba91938e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_418af16e-e787-46da-9f7f-55140f20972f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1acf64bb-fbcd-4ffd-a0df-bd9ebd283e6d" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_418af16e-e787-46da-9f7f-55140f20972f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_cd186d7d-8316-4fb0-a5f8-0698e94fd353" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1acf64bb-fbcd-4ffd-a0df-bd9ebd283e6d" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_cd186d7d-8316-4fb0-a5f8-0698e94fd353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_ff4d9cb8-4873-42fd-9bf8-08729fab4b88" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1acf64bb-fbcd-4ffd-a0df-bd9ebd283e6d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_ff4d9cb8-4873-42fd-9bf8-08729fab4b88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6e58ea9f-b6bb-4937-bafe-f99128730b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3334a339-1ac4-470d-bb4b-951bfff7709d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6e58ea9f-b6bb-4937-bafe-f99128730b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f06f103-22f8-4e56-9b8f-fe8f393fd44f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_02fbe313-f0b4-4570-a167-55943d2e1c6d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f06f103-22f8-4e56-9b8f-fe8f393fd44f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c0454bd9-1300-4660-be85-a60fb22d5316" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f06f103-22f8-4e56-9b8f-fe8f393fd44f" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c0454bd9-1300-4660-be85-a60fb22d5316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_65fde4c7-8f9f-459b-9763-be03942ff2df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f06f103-22f8-4e56-9b8f-fe8f393fd44f" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_65fde4c7-8f9f-459b-9763-be03942ff2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_2fc2f8f9-a623-420d-bd4e-8d4c80bbcbde" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f06f103-22f8-4e56-9b8f-fe8f393fd44f" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_2fc2f8f9-a623-420d-bd4e-8d4c80bbcbde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_e682eb43-6442-4cde-ab2d-54a87983b759" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f06f103-22f8-4e56-9b8f-fe8f393fd44f" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_e682eb43-6442-4cde-ab2d-54a87983b759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_258edc15-ab83-4067-8c98-88528aef48bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f06f103-22f8-4e56-9b8f-fe8f393fd44f" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_258edc15-ab83-4067-8c98-88528aef48bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5724b0cf-871e-49e3-8680-e605dadc9698" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f06f103-22f8-4e56-9b8f-fe8f393fd44f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5724b0cf-871e-49e3-8680-e605dadc9698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e47b8c69-0f61-4441-8e08-2d317afc4d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_02fbe313-f0b4-4570-a167-55943d2e1c6d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e47b8c69-0f61-4441-8e08-2d317afc4d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_d8d1f5e0-5935-4f72-b95b-0f922dd146fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e47b8c69-0f61-4441-8e08-2d317afc4d3f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_d8d1f5e0-5935-4f72-b95b-0f922dd146fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_4a8c37db-8471-4b69-bd0f-ce6405b81f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e47b8c69-0f61-4441-8e08-2d317afc4d3f" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_4a8c37db-8471-4b69-bd0f-ce6405b81f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5cdf7bbf-e9d2-464e-8eeb-8476d6bc8317" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e47b8c69-0f61-4441-8e08-2d317afc4d3f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5cdf7bbf-e9d2-464e-8eeb-8476d6bc8317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_78d92508-9f85-4794-aba1-1b492d3935fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_02fbe313-f0b4-4570-a167-55943d2e1c6d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_78d92508-9f85-4794-aba1-1b492d3935fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6d203ac4-67fe-4b79-9060-e9d6c93f4a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_02fbe313-f0b4-4570-a167-55943d2e1c6d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6d203ac4-67fe-4b79-9060-e9d6c93f4a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e3368a68-8977-4289-931d-631e0e56f801" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_02fbe313-f0b4-4570-a167-55943d2e1c6d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e3368a68-8977-4289-931d-631e0e56f801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0cbd0eda-ba60-4d24-85e1-bf9f774ee342" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_02fbe313-f0b4-4570-a167-55943d2e1c6d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0cbd0eda-ba60-4d24-85e1-bf9f774ee342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_a386cd01-287c-4267-80d6-01ccb96ac9b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_02fbe313-f0b4-4570-a167-55943d2e1c6d" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_a386cd01-287c-4267-80d6-01ccb96ac9b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4e387859-6766-45d5-8302-379b83ef307d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_02fbe313-f0b4-4570-a167-55943d2e1c6d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4e387859-6766-45d5-8302-379b83ef307d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_9180fe17-b9b3-4a2f-af7f-08449facf094" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_02fbe313-f0b4-4570-a167-55943d2e1c6d" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_9180fe17-b9b3-4a2f-af7f-08449facf094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_734200ac-76f3-487d-819d-f879e8d4e1e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_9180fe17-b9b3-4a2f-af7f-08449facf094" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_734200ac-76f3-487d-819d-f879e8d4e1e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="pacb-20250930.xsd#ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c8577faa-ea0a-4583-a68d-528fe97d3e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_9fa03437-0c92-489d-84ee-0c375c69a1d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c8577faa-ea0a-4583-a68d-528fe97d3e6d" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_9fa03437-0c92-489d-84ee-0c375c69a1d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTS" xlink:type="simple" xlink:href="pacb-20250930.xsd#FINANCIALINSTRUMENTS"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_b7d08e45-396f-413e-b08f-8f35e141a5e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_f3008a4d-a1e7-45ea-ab78-59c580a29e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_b7d08e45-396f-413e-b08f-8f35e141a5e5" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_f3008a4d-a1e7-45ea-ab78-59c580a29e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTS" xlink:type="simple" xlink:href="pacb-20250930.xsd#BALANCESHEETCOMPONENTS"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_76456c81-409c-40f9-952f-dcee4abe9f94" xlink:href="pacb-20250930.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_eac36c6b-7e5f-476a-9330-1e44ca96b9a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_76456c81-409c-40f9-952f-dcee4abe9f94" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_eac36c6b-7e5f-476a-9330-1e44ca96b9a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTES" xlink:type="simple" xlink:href="pacb-20250930.xsd#CONVERTIBLESENIORNOTES"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_40f1bdfe-65bf-41d8-9334-5a874e607eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_65e8a2b5-c605-4ed7-931e-bc625b78487f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_40f1bdfe-65bf-41d8-9334-5a874e607eb8" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_65e8a2b5-c605-4ed7-931e-bc625b78487f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/RESTRUCTURING" xlink:type="simple" xlink:href="pacb-20250930.xsd#RESTRUCTURING"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/RESTRUCTURING" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_8bed618f-6c25-40fb-98a9-124f49e57a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_5fe7e1e8-071c-400a-ae62-37fce353e8f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_8bed618f-6c25-40fb-98a9-124f49e57a5d" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_5fe7e1e8-071c-400a-ae62-37fce353e8f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="pacb-20250930.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1d09c114-3a84-4fa3-af7c-84b9f145c52b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDisclosures_32dcb77c-b431-4150-8666-20b2a0b73118" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyDisclosures"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1d09c114-3a84-4fa3-af7c-84b9f145c52b" xlink:to="loc_us-gaap_LossContingencyDisclosures_32dcb77c-b431-4150-8666-20b2a0b73118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATION" xlink:type="simple" xlink:href="pacb-20250930.xsd#EQUITYPLANSANDSHAREBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9ad433c6-186f-471d-b94e-fc7c9bbb779e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_46d1b98a-4344-47ed-9a1b-e3db1e8edbfe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9ad433c6-186f-471d-b94e-fc7c9bbb779e" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_46d1b98a-4344-47ed-9a1b-e3db1e8edbfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/NETLOSSPERSHARE" xlink:type="simple" xlink:href="pacb-20250930.xsd#NETLOSSPERSHARE"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/NETLOSSPERSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5cbdefc0-1989-49ba-8228-b375842cf5f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_6c6f025e-c9b3-4850-bd44-5e0c949227bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5cbdefc0-1989-49ba-8228-b375842cf5f5" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_6c6f025e-c9b3-4850-bd44-5e0c949227bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATION" xlink:type="simple" xlink:href="pacb-20250930.xsd#SEGMENTANDGEOGRAPHICINFORMATION"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_feac86c3-cba2-4e84-8faa-2516172d7516" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_c3772e31-d5a9-47ef-b31e-fc801eee1970" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_feac86c3-cba2-4e84-8faa-2516172d7516" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_c3772e31-d5a9-47ef-b31e-fc801eee1970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="pacb-20250930.xsd#ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_75cea44a-2551-4df3-b470-dc20eb1357c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_96066a5d-d5c6-42bf-85a7-9144c4285971" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_75cea44a-2551-4df3-b470-dc20eb1357c2" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_96066a5d-d5c6-42bf-85a7-9144c4285971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_54649eef-a434-4582-ba84-4f90fc72180b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_75cea44a-2551-4df3-b470-dc20eb1357c2" xlink:to="loc_us-gaap_UseOfEstimates_54649eef-a434-4582-ba84-4f90fc72180b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_3c9f1ac3-6d50-4152-bc8c-002065ef0254" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_75cea44a-2551-4df3-b470-dc20eb1357c2" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_3c9f1ac3-6d50-4152-bc8c-002065ef0254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_90c8dd80-c542-424c-9aa7-4f46bfd48848" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_75cea44a-2551-4df3-b470-dc20eb1357c2" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_90c8dd80-c542-424c-9aa7-4f46bfd48848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_46fc44ec-88fd-4ae5-892f-c4244b33d9a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_75cea44a-2551-4df3-b470-dc20eb1357c2" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_46fc44ec-88fd-4ae5-892f-c4244b33d9a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSTables" xlink:type="simple" xlink:href="pacb-20250930.xsd#FINANCIALINSTRUMENTSTables"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_f9274ffd-6825-4713-92ad-47695b89794c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_479ca50b-ea41-4bf4-8156-7363c6b1b2d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_f9274ffd-6825-4713-92ad-47695b89794c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_479ca50b-ea41-4bf4-8156-7363c6b1b2d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_6efedd1a-3195-46d5-a38f-25f397bc3846" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_f9274ffd-6825-4713-92ad-47695b89794c" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_6efedd1a-3195-46d5-a38f-25f397bc3846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_8a191a6c-beac-4e9b-91ae-1209376c1180" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_f9274ffd-6825-4713-92ad-47695b89794c" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_8a191a6c-beac-4e9b-91ae-1209376c1180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables" xlink:type="simple" xlink:href="pacb-20250930.xsd#BALANCESHEETCOMPONENTSTables"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_28b26225-d21f-4b2a-b82f-d185087eb982" xlink:href="pacb-20250930.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_c9cba806-0d7c-4b48-a648-98201439c10d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_28b26225-d21f-4b2a-b82f-d185087eb982" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_c9cba806-0d7c-4b48-a648-98201439c10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock_d1861570-945f-487b-8efa-55e101d2b5de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_28b26225-d21f-4b2a-b82f-d185087eb982" xlink:to="loc_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock_d1861570-945f-487b-8efa-55e101d2b5de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_b1138454-b805-4316-adc0-cc77817572c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_28b26225-d21f-4b2a-b82f-d185087eb982" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_b1138454-b805-4316-adc0-cc77817572c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_03437da0-1b55-48cb-9553-f2d2589edd5c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_28b26225-d21f-4b2a-b82f-d185087eb982" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_03437da0-1b55-48cb-9553-f2d2589edd5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock_a587bc86-e8f2-42ca-b9b0-dad905f5bf1b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_28b26225-d21f-4b2a-b82f-d185087eb982" xlink:to="loc_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock_a587bc86-e8f2-42ca-b9b0-dad905f5bf1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESTables" xlink:type="simple" xlink:href="pacb-20250930.xsd#CONVERTIBLESENIORNOTESTables"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_81350aba-de52-43cc-aaa0-ef80c4222eed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ScheduleOfInterestExpenseTableTextBlock_155d88e8-70b2-45e6-8810-02d0f9db6058" xlink:href="pacb-20250930.xsd#pacb_ScheduleOfInterestExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_81350aba-de52-43cc-aaa0-ef80c4222eed" xlink:to="loc_pacb_ScheduleOfInterestExpenseTableTextBlock_155d88e8-70b2-45e6-8810-02d0f9db6058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_504e43dc-038f-4c8a-8a2c-32e1aa4f8b23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_81350aba-de52-43cc-aaa0-ef80c4222eed" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_504e43dc-038f-4c8a-8a2c-32e1aa4f8b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/RESTRUCTURINGTables" xlink:type="simple" xlink:href="pacb-20250930.xsd#RESTRUCTURINGTables"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/RESTRUCTURINGTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_0ecbf8e3-1222-4246-993e-03591801a17b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_0685fb68-0e91-4eae-9790-3f7e6ece0662" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_0ecbf8e3-1222-4246-993e-03591801a17b" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_0685fb68-0e91-4eae-9790-3f7e6ece0662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_525b8e90-eb57-4029-90be-8775efc1c620" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_0ecbf8e3-1222-4246-993e-03591801a17b" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_525b8e90-eb57-4029-90be-8775efc1c620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="pacb-20250930.xsd#EQUITYPLANSANDSHAREBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7b7006c8-9bb1-46db-a17a-7755946b697a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_407cdecf-f065-4770-9308-125add2f2585" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7b7006c8-9bb1-46db-a17a-7755946b697a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_407cdecf-f065-4770-9308-125add2f2585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_37aca3b3-fb93-4d73-904c-97669647c586" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7b7006c8-9bb1-46db-a17a-7755946b697a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_37aca3b3-fb93-4d73-904c-97669647c586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_51ca1cae-6ff7-469d-8f12-fc7db6585b50" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7b7006c8-9bb1-46db-a17a-7755946b697a" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_51ca1cae-6ff7-469d-8f12-fc7db6585b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0126dfa5-06b2-484f-9547-657794a628af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7b7006c8-9bb1-46db-a17a-7755946b697a" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0126dfa5-06b2-484f-9547-657794a628af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_bb6b17ad-381b-4e4b-8451-793a9f8cbab6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7b7006c8-9bb1-46db-a17a-7755946b697a" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_bb6b17ad-381b-4e4b-8451-793a9f8cbab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/NETLOSSPERSHARETables" xlink:type="simple" xlink:href="pacb-20250930.xsd#NETLOSSPERSHARETables"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/NETLOSSPERSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_50bef146-85bf-45aa-b1df-ab1806c24124" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_bdf926c6-aca5-4653-a984-eb4892fca2e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_50bef146-85bf-45aa-b1df-ab1806c24124" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_bdf926c6-aca5-4653-a984-eb4892fca2e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_f885a599-1874-4849-9119-61f351732318" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_50bef146-85bf-45aa-b1df-ab1806c24124" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_f885a599-1874-4849-9119-61f351732318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTables" xlink:type="simple" xlink:href="pacb-20250930.xsd#SEGMENTANDGEOGRAPHICINFORMATIONTables"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_9b47f75b-23fc-4302-b8a3-26774dc5a915" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_5d83f182-5f90-4ee5-8d08-44df66dec081" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_9b47f75b-23fc-4302-b8a3-26774dc5a915" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_5d83f182-5f90-4ee5-8d08-44df66dec081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_301b91d2-8b6f-4cf3-9068-68337d59b5de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_9b47f75b-23fc-4302-b8a3-26774dc5a915" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_301b91d2-8b6f-4cf3-9068-68337d59b5de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_5a1ddaf7-8d4b-44b1-bd09-1fc7cae4ae77" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_9b47f75b-23fc-4302-b8a3-26774dc5a915" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_5a1ddaf7-8d4b-44b1-bd09-1fc7cae4ae77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_043e112c-d081-45db-81a1-31e25228f638" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_59bdf39c-9ace-468e-9d63-b5a10ca13bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_043e112c-d081-45db-81a1-31e25228f638" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_59bdf39c-9ace-468e-9d63-b5a10ca13bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_93a03cf5-a636-4e0e-89b4-a00d353ca14b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_59bdf39c-9ace-468e-9d63-b5a10ca13bd1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_93a03cf5-a636-4e0e-89b4-a00d353ca14b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2bcfcbb8-9b8a-47ca-8069-eef2cddc9a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_93a03cf5-a636-4e0e-89b4-a00d353ca14b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2bcfcbb8-9b8a-47ca-8069-eef2cddc9a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_e7dd1f77-5591-41f0-a065-7748b99cc97a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2bcfcbb8-9b8a-47ca-8069-eef2cddc9a1f" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_e7dd1f77-5591-41f0-a065-7748b99cc97a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_98982933-b86f-4144-85c8-fae662a15040" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2bcfcbb8-9b8a-47ca-8069-eef2cddc9a1f" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_98982933-b86f-4144-85c8-fae662a15040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_997718ec-cf9d-4677-8f8f-cbcad8f1e0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2bcfcbb8-9b8a-47ca-8069-eef2cddc9a1f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_997718ec-cf9d-4677-8f8f-cbcad8f1e0f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_f5453f41-dff2-48b1-a85d-d7e42bf4b256" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_59bdf39c-9ace-468e-9d63-b5a10ca13bd1" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_f5453f41-dff2-48b1-a85d-d7e42bf4b256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_39fe37a0-677f-4e60-a7de-52c89d71d253" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_f5453f41-dff2-48b1-a85d-d7e42bf4b256" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_39fe37a0-677f-4e60-a7de-52c89d71d253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_2b3242a4-a812-4c66-a679-c73499b820da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_39fe37a0-677f-4e60-a7de-52c89d71d253" xlink:to="loc_us-gaap_InvestmentsMember_2b3242a4-a812-4c66-a679-c73499b820da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_143d1d44-e56a-4f4b-b437-75502b602439" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsMember_2b3242a4-a812-4c66-a679-c73499b820da" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_143d1d44-e56a-4f4b-b437-75502b602439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_33c3343b-b305-410b-98d4-0bb0792b5257" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsMember_2b3242a4-a812-4c66-a679-c73499b820da" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_33c3343b-b305-410b-98d4-0bb0792b5257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1ff84adc-7d10-4688-9a4e-f468569ed474" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_59bdf39c-9ace-468e-9d63-b5a10ca13bd1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1ff84adc-7d10-4688-9a4e-f468569ed474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cb805123-1c28-489a-a77e-87b79574f38c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1ff84adc-7d10-4688-9a4e-f468569ed474" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cb805123-1c28-489a-a77e-87b79574f38c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_120ca4a9-ea91-4bd9-9c50-8912126e500a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cb805123-1c28-489a-a77e-87b79574f38c" xlink:to="loc_us-gaap_InvestmentsMember_120ca4a9-ea91-4bd9-9c50-8912126e500a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_40161980-3dd3-4a5b-98cd-14bf80bed7da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_59bdf39c-9ace-468e-9d63-b5a10ca13bd1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_40161980-3dd3-4a5b-98cd-14bf80bed7da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_494e2e8f-6c86-4705-b3f4-008b0558034d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_40161980-3dd3-4a5b-98cd-14bf80bed7da" xlink:to="loc_us-gaap_AssetsAbstract_494e2e8f-6c86-4705-b3f4-008b0558034d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7a15467f-bb3d-42b2-b4aa-d10e4a46b34c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_494e2e8f-6c86-4705-b3f4-008b0558034d" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7a15467f-bb3d-42b2-b4aa-d10e4a46b34c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_e7be79bc-fc7f-4581-81e7-0657731f1ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_494e2e8f-6c86-4705-b3f4-008b0558034d" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_e7be79bc-fc7f-4581-81e7-0657731f1ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ShortTermRestrictedCashFairValueDisclosure_a209bc0e-45fc-44d1-bfaf-e59777a07559" xlink:href="pacb-20250930.xsd#pacb_ShortTermRestrictedCashFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_494e2e8f-6c86-4705-b3f4-008b0558034d" xlink:to="loc_pacb_ShortTermRestrictedCashFairValueDisclosure_a209bc0e-45fc-44d1-bfaf-e59777a07559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_LongTermRestrictedCashFairValueDisclosure_3c587056-5268-42d7-9485-e71b24f4336d" xlink:href="pacb-20250930.xsd#pacb_LongTermRestrictedCashFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_494e2e8f-6c86-4705-b3f4-008b0558034d" xlink:to="loc_pacb_LongTermRestrictedCashFairValueDisclosure_3c587056-5268-42d7-9485-e71b24f4336d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_dadf479c-8b29-4c8d-b675-4b4d085ce51b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_494e2e8f-6c86-4705-b3f4-008b0558034d" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_dadf479c-8b29-4c8d-b675-4b4d085ce51b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_b8e58576-d80a-4d48-a662-de05bd8bf3f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_40161980-3dd3-4a5b-98cd-14bf80bed7da" xlink:to="loc_us-gaap_LiabilitiesAbstract_b8e58576-d80a-4d48-a662-de05bd8bf3f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2ae457ed-cb4a-4859-be00-e76f18334736" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_b8e58576-d80a-4d48-a662-de05bd8bf3f6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2ae457ed-cb4a-4859-be00-e76f18334736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_b5d644d1-a52d-4ff2-9ea0-5d096565f69d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_b8e58576-d80a-4d48-a662-de05bd8bf3f6" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_b5d644d1-a52d-4ff2-9ea0-5d096565f69d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSContingentConsiderationDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#FINANCIALINSTRUMENTSContingentConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_acec5bad-3d21-47e9-93ef-6ca7dce74c31" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e3863919-6125-4115-8b13-88e87b5f42f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_acec5bad-3d21-47e9-93ef-6ca7dce74c31" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e3863919-6125-4115-8b13-88e87b5f42f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_780e2d9a-88f4-4260-8a63-c0e871907644" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e3863919-6125-4115-8b13-88e87b5f42f4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_780e2d9a-88f4-4260-8a63-c0e871907644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9de23ae6-1aff-42ba-944d-768a943aa296" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_780e2d9a-88f4-4260-8a63-c0e871907644" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9de23ae6-1aff-42ba-944d-768a943aa296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AptonMember_2870effb-24fc-4512-a59f-ea9f0fa0fe6c" xlink:href="pacb-20250930.xsd#pacb_AptonMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9de23ae6-1aff-42ba-944d-768a943aa296" xlink:to="loc_pacb_AptonMember_2870effb-24fc-4512-a59f-ea9f0fa0fe6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_a3c1a93b-7ee2-45fa-80af-d85670e3fb7e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e3863919-6125-4115-8b13-88e87b5f42f4" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_a3c1a93b-7ee2-45fa-80af-d85670e3fb7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_9ea8ac30-5f05-4480-8e9a-0a5d99c023e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_a3c1a93b-7ee2-45fa-80af-d85670e3fb7e" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_9ea8ac30-5f05-4480-8e9a-0a5d99c023e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AchievementOfMilestoneMember_28617ea3-054b-4b03-a24d-3695c81a31fd" xlink:href="pacb-20250930.xsd#pacb_AchievementOfMilestoneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_9ea8ac30-5f05-4480-8e9a-0a5d99c023e8" xlink:to="loc_pacb_AchievementOfMilestoneMember_28617ea3-054b-4b03-a24d-3695c81a31fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_eef19677-fb86-4523-bd9e-c7a652b68875" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e3863919-6125-4115-8b13-88e87b5f42f4" xlink:to="loc_srt_RangeAxis_eef19677-fb86-4523-bd9e-c7a652b68875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3c928e26-1f82-4d6f-8745-ac53636b2500" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_eef19677-fb86-4523-bd9e-c7a652b68875" xlink:to="loc_srt_RangeMember_3c928e26-1f82-4d6f-8745-ac53636b2500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1ea3e8e7-bb8c-4deb-a236-c04f0c781396" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3c928e26-1f82-4d6f-8745-ac53636b2500" xlink:to="loc_srt_MaximumMember_1ea3e8e7-bb8c-4deb-a236-c04f0c781396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_8cd08cac-fbfd-4cfa-9c41-959cb8e09a12" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e3863919-6125-4115-8b13-88e87b5f42f4" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_8cd08cac-fbfd-4cfa-9c41-959cb8e09a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d1d41e6e-3b24-4b27-ae08-3afbadc4353b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8cd08cac-fbfd-4cfa-9c41-959cb8e09a12" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d1d41e6e-3b24-4b27-ae08-3afbadc4353b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone_19f90be2-0e07-4065-8d0f-ebaf06a210c4" xlink:href="pacb-20250930.xsd#pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8cd08cac-fbfd-4cfa-9c41-959cb8e09a12" xlink:to="loc_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone_19f90be2-0e07-4065-8d0f-ebaf06a210c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod_7658e5d0-c21a-41ea-a179-f348ca563ee2" xlink:href="pacb-20250930.xsd#pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8cd08cac-fbfd-4cfa-9c41-959cb8e09a12" xlink:to="loc_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod_7658e5d0-c21a-41ea-a179-f348ca563ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition_80a77e7a-5b13-4340-b35a-bb4541f062fc" xlink:href="pacb-20250930.xsd#pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8cd08cac-fbfd-4cfa-9c41-959cb8e09a12" xlink:to="loc_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition_80a77e7a-5b13-4340-b35a-bb4541f062fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger_5e6fd3d2-14ab-433a-b9b5-8abd2b16b2af" xlink:href="pacb-20250930.xsd#pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8cd08cac-fbfd-4cfa-9c41-959cb8e09a12" xlink:to="loc_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger_5e6fd3d2-14ab-433a-b9b5-8abd2b16b2af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_1a3ba242-02b0-4cae-9d13-47fd5d175e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8242e9d8-9a4d-4680-9a42-69659aa7ff42" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_1a3ba242-02b0-4cae-9d13-47fd5d175e9b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8242e9d8-9a4d-4680-9a42-69659aa7ff42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_64f3b68d-f131-49f5-8740-623531f21a83" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8242e9d8-9a4d-4680-9a42-69659aa7ff42" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_64f3b68d-f131-49f5-8740-623531f21a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_785f528e-741a-48a5-a290-b1436891187a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_64f3b68d-f131-49f5-8740-623531f21a83" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_785f528e-741a-48a5-a290-b1436891187a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_b98beadb-93ac-4d99-9ecc-c432a5e57e35" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_785f528e-741a-48a5-a290-b1436891187a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_b98beadb-93ac-4d99-9ecc-c432a5e57e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4a75f311-1c08-408c-9213-20f1c9edef97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8242e9d8-9a4d-4680-9a42-69659aa7ff42" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4a75f311-1c08-408c-9213-20f1c9edef97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_21f2c5a1-7c1a-44eb-8cfa-e1588cfa9696" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4a75f311-1c08-408c-9213-20f1c9edef97" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_21f2c5a1-7c1a-44eb-8cfa-e1588cfa9696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ab8748c6-d5cc-440c-aec3-46614832d427" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_21f2c5a1-7c1a-44eb-8cfa-e1588cfa9696" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ab8748c6-d5cc-440c-aec3-46614832d427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e39ccf20-2327-455c-906d-674f4bf8a0ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_21f2c5a1-7c1a-44eb-8cfa-e1588cfa9696" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e39ccf20-2327-455c-906d-674f4bf8a0ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ce6ca9bd-538c-482a-97dc-772f57a33993" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_21f2c5a1-7c1a-44eb-8cfa-e1588cfa9696" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ce6ca9bd-538c-482a-97dc-772f57a33993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_f4e67b85-6ea8-4d85-82b6-dd2c92b8c432" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_78dfc963-0060-4edc-a50e-9174b4daa7de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_f4e67b85-6ea8-4d85-82b6-dd2c92b8c432" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_78dfc963-0060-4edc-a50e-9174b4daa7de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d5911a34-80ff-46e6-8b54-d4e55bb32024" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_78dfc963-0060-4edc-a50e-9174b4daa7de" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d5911a34-80ff-46e6-8b54-d4e55bb32024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9e98c934-3f3a-4b3b-bf7d-c8217f2ee2c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d5911a34-80ff-46e6-8b54-d4e55bb32024" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9e98c934-3f3a-4b3b-bf7d-c8217f2ee2c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_84122f6f-f36d-495b-be37-979b2ee62ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9e98c934-3f3a-4b3b-bf7d-c8217f2ee2c6" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_84122f6f-f36d-495b-be37-979b2ee62ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_851717c5-2202-4385-95a4-63bfb8f867e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9e98c934-3f3a-4b3b-bf7d-c8217f2ee2c6" xlink:to="loc_us-gaap_InvestmentsMember_851717c5-2202-4385-95a4-63bfb8f867e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_992cc510-0049-4020-8b9c-87acd8d0f3d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsMember_851717c5-2202-4385-95a4-63bfb8f867e7" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_992cc510-0049-4020-8b9c-87acd8d0f3d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_4275d565-2125-4d22-88d2-98fd11815ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsMember_851717c5-2202-4385-95a4-63bfb8f867e7" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_4275d565-2125-4d22-88d2-98fd11815ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_37e94de4-491b-4efd-9531-328e2934c4d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_78dfc963-0060-4edc-a50e-9174b4daa7de" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_37e94de4-491b-4efd-9531-328e2934c4d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_f6eba34f-b31f-49d7-85fe-fdb35eb1d378" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_37e94de4-491b-4efd-9531-328e2934c4d0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_f6eba34f-b31f-49d7-85fe-fdb35eb1d378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f895e915-da09-4401-b07e-49166f0a85f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_37e94de4-491b-4efd-9531-328e2934c4d0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f895e915-da09-4401-b07e-49166f0a85f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_bfa8a8eb-5104-4acd-858b-2877045444e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_37e94de4-491b-4efd-9531-328e2934c4d0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_bfa8a8eb-5104-4acd-858b-2877045444e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_0b11a07d-dd1e-4bbb-aefc-b2a22302e0f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_37e94de4-491b-4efd-9531-328e2934c4d0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_0b11a07d-dd1e-4bbb-aefc-b2a22302e0f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_ac4611a5-7ca2-428a-9ce2-304b38ee7432" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_37e94de4-491b-4efd-9531-328e2934c4d0" xlink:to="loc_us-gaap_RestrictedCashCurrent_ac4611a5-7ca2-428a-9ce2-304b38ee7432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_aed89b77-2a9d-4424-82fe-b620d0c6ba1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_37e94de4-491b-4efd-9531-328e2934c4d0" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_aed89b77-2a9d-4424-82fe-b620d0c6ba1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#FINANCIALINSTRUMENTSScheduleofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_ef4ba6e7-2bad-43bd-a03e-69a8c9a77d58" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_7365718e-0eef-4944-8bf4-79d83fa6028f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_ef4ba6e7-2bad-43bd-a03e-69a8c9a77d58" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue_7365718e-0eef-4944-8bf4-79d83fa6028f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_6d31861d-6e18-4043-9370-9b3972576aea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_ef4ba6e7-2bad-43bd-a03e-69a8c9a77d58" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_6d31861d-6e18-4043-9370-9b3972576aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_06ba6a90-4baf-48ae-9976-25a02eababcd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_ef4ba6e7-2bad-43bd-a03e-69a8c9a77d58" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_06ba6a90-4baf-48ae-9976-25a02eababcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSInvestmentIncomeDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#FINANCIALINSTRUMENTSInvestmentIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSInvestmentIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_211f0e79-83db-44cc-afbc-90ec2b96e770" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_83771421-b1d0-48f8-86bb-9827b1adad8f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_211f0e79-83db-44cc-afbc-90ec2b96e770" xlink:to="loc_us-gaap_InvestmentIncomeNet_83771421-b1d0-48f8-86bb-9827b1adad8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#BALANCESHEETCOMPONENTSScheduleofInventoryDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_28abb2c6-ff72-4a64-83c5-b438ac96d62b" xlink:href="pacb-20250930.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_b621728a-04cd-4fa6-8e70-5ccc76d1cb94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_28abb2c6-ff72-4a64-83c5-b438ac96d62b" xlink:to="loc_us-gaap_InventoryRawMaterials_b621728a-04cd-4fa6-8e70-5ccc76d1cb94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_52b8162d-499c-4173-8235-2d639f651e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_28abb2c6-ff72-4a64-83c5-b438ac96d62b" xlink:to="loc_us-gaap_InventoryWorkInProcess_52b8162d-499c-4173-8235-2d639f651e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_99d4eda8-0ea6-45d3-97f5-2e12dcaa5218" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_28abb2c6-ff72-4a64-83c5-b438ac96d62b" xlink:to="loc_us-gaap_InventoryFinishedGoods_99d4eda8-0ea6-45d3-97f5-2e12dcaa5218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_4b609b46-fd9b-45d1-aca2-3b92d17a1870" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_28abb2c6-ff72-4a64-83c5-b438ac96d62b" xlink:to="loc_us-gaap_InventoryGross_4b609b46-fd9b-45d1-aca2-3b92d17a1870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_5c0591ae-7eaf-4343-9981-61ede114ba0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_28abb2c6-ff72-4a64-83c5-b438ac96d62b" xlink:to="loc_us-gaap_InventoryValuationReserves_5c0591ae-7eaf-4343-9981-61ede114ba0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_38126122-1751-4225-a63a-15b63b2c3cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_28abb2c6-ff72-4a64-83c5-b438ac96d62b" xlink:to="loc_us-gaap_InventoryNet_38126122-1751-4225-a63a-15b63b2c3cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#BALANCESHEETCOMPONENTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_ef1b6fe6-abf5-4131-95a0-bb5a7f86f423" xlink:href="pacb-20250930.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ScheduleOfBalanceSheetComponentsTable_fcaddc24-d01b-433c-8971-e684c60611b4" xlink:href="pacb-20250930.xsd#pacb_ScheduleOfBalanceSheetComponentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_ef1b6fe6-abf5-4131-95a0-bb5a7f86f423" xlink:to="loc_pacb_ScheduleOfBalanceSheetComponentsTable_fcaddc24-d01b-433c-8971-e684c60611b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a4a1e95c-2096-4c29-b5d6-12c776eba790" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_fcaddc24-d01b-433c-8971-e684c60611b4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a4a1e95c-2096-4c29-b5d6-12c776eba790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_97f73e58-ebe3-4b86-8215-50ae1f721ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a4a1e95c-2096-4c29-b5d6-12c776eba790" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_97f73e58-ebe3-4b86-8215-50ae1f721ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AptonMember_b57c35f3-1ca2-4444-94ef-1ceab3062837" xlink:href="pacb-20250930.xsd#pacb_AptonMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_97f73e58-ebe3-4b86-8215-50ae1f721ae2" xlink:to="loc_pacb_AptonMember_b57c35f3-1ca2-4444-94ef-1ceab3062837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c31ade45-340a-4501-a5d0-ace97b50f0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_fcaddc24-d01b-433c-8971-e684c60611b4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c31ade45-340a-4501-a5d0-ace97b50f0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_81baaa80-9006-4b1c-b17a-65ce29a250fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c31ade45-340a-4501-a5d0-ace97b50f0aa" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_81baaa80-9006-4b1c-b17a-65ce29a250fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_dbece446-f21f-432b-a4ad-a28ca39e336a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_81baaa80-9006-4b1c-b17a-65ce29a250fe" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_dbece446-f21f-432b-a4ad-a28ca39e336a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_a68bc764-60ce-499c-832d-2987d1949765" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_81baaa80-9006-4b1c-b17a-65ce29a250fe" xlink:to="loc_us-gaap_LicenseMember_a68bc764-60ce-499c-832d-2987d1949765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fd5d1f08-5d9b-4301-b0a0-1687602cb42a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_fcaddc24-d01b-433c-8971-e684c60611b4" xlink:to="loc_srt_ProductOrServiceAxis_fd5d1f08-5d9b-4301-b0a0-1687602cb42a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_11dbd28a-e660-458b-9b1f-1fd9816fd990" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_fd5d1f08-5d9b-4301-b0a0-1687602cb42a" xlink:to="loc_srt_ProductsAndServicesDomain_11dbd28a-e660-458b-9b1f-1fd9816fd990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_53e70445-16aa-476b-8a8f-e0e56275fd4c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_11dbd28a-e660-458b-9b1f-1fd9816fd990" xlink:to="loc_us-gaap_ServiceMember_53e70445-16aa-476b-8a8f-e0e56275fd4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_009e4e72-b368-46f3-b024-494db28eb700" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_fcaddc24-d01b-433c-8971-e684c60611b4" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_009e4e72-b368-46f3-b024-494db28eb700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_ff698efc-da2f-48be-b5f5-61e0f704fe6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_fcaddc24-d01b-433c-8971-e684c60611b4" xlink:to="loc_us-gaap_RestructuringPlanAxis_ff698efc-da2f-48be-b5f5-61e0f704fe6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_5dcad610-89ee-4e9d-8882-da256480df45" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_ff698efc-da2f-48be-b5f5-61e0f704fe6a" xlink:to="loc_us-gaap_RestructuringPlanDomain_5dcad610-89ee-4e9d-8882-da256480df45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2025RestructuringMember_f7c1d900-832b-4161-b734-d78d3dab5a41" xlink:href="pacb-20250930.xsd#pacb_A2025RestructuringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_5dcad610-89ee-4e9d-8882-da256480df45" xlink:to="loc_pacb_A2025RestructuringMember_f7c1d900-832b-4161-b734-d78d3dab5a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_a2a85451-a898-40e8-9801-4249b261eead" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_fcaddc24-d01b-433c-8971-e684c60611b4" xlink:to="loc_us-gaap_AssetAcquisitionAxis_a2a85451-a898-40e8-9801-4249b261eead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_bc76b081-cbe7-4390-8a33-0624023ea292" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_a2a85451-a898-40e8-9801-4249b261eead" xlink:to="loc_us-gaap_AssetAcquisitionDomain_bc76b081-cbe7-4390-8a33-0624023ea292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DevelopedTechnologyAndIntellectualPropertyMember_f156ea1a-21fd-42f2-ab15-35b38892d332" xlink:href="pacb-20250930.xsd#pacb_DevelopedTechnologyAndIntellectualPropertyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_bc76b081-cbe7-4390-8a33-0624023ea292" xlink:to="loc_pacb_DevelopedTechnologyAndIntellectualPropertyMember_f156ea1a-21fd-42f2-ab15-35b38892d332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:href="pacb-20250930.xsd#pacb_ScheduleOfBalanceSheetComponentsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsTable_fcaddc24-d01b-433c-8971-e684c60611b4" xlink:to="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_6d2749c1-cc93-4a16-a8b8-91fc664a31dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_6d2749c1-cc93-4a16-a8b8-91fc664a31dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_2e0a5b4f-51ab-4ca0-94f8-a410231829f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_2e0a5b4f-51ab-4ca0-94f8-a410231829f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_5e08144f-0fde-450f-8164-aa90ed9e0ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_5e08144f-0fde-450f-8164-aa90ed9e0ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_ff7a0a89-7042-4556-ac2e-31a85f0a942f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_ff7a0a89-7042-4556-ac2e-31a85f0a942f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate_4e6e333e-09e9-485d-96d1-2a20606af5e2" xlink:href="pacb-20250930.xsd#pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate_4e6e333e-09e9-485d-96d1-2a20606af5e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm_8ecb844b-eda4-46c0-b453-286dd0a340fd" xlink:href="pacb-20250930.xsd#pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm_8ecb844b-eda4-46c0-b453-286dd0a340fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate_fffc2809-0271-4db7-b0f4-e4bbd6e4040a" xlink:href="pacb-20250930.xsd#pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate_fffc2809-0271-4db7-b0f4-e4bbd6e4040a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate_bb1dcd8d-4bb7-4b74-95b3-a38b07e743c9" xlink:href="pacb-20250930.xsd#pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate_bb1dcd8d-4bb7-4b74-95b3-a38b07e743c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm_47f9d9b0-8739-4f52-a743-0cccfcd89424" xlink:href="pacb-20250930.xsd#pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm_47f9d9b0-8739-4f52-a743-0cccfcd89424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AdditionalIntangibleAssetImpairmentChangeInTerm_3d4decd2-a368-4e40-8f1d-0059bc030664" xlink:href="pacb-20250930.xsd#pacb_AdditionalIntangibleAssetImpairmentChangeInTerm"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_pacb_AdditionalIntangibleAssetImpairmentChangeInTerm_3d4decd2-a368-4e40-8f1d-0059bc030664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_RestructuringAndRelatedCostAcceleratedAmortization_ea41b61c-149b-43dd-8eea-97b9bef5692c" xlink:href="pacb-20250930.xsd#pacb_RestructuringAndRelatedCostAcceleratedAmortization"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_pacb_RestructuringAndRelatedCostAcceleratedAmortization_ea41b61c-149b-43dd-8eea-97b9bef5692c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ChangeInEarningsPerShare_795e8969-8e92-4d8b-80ab-995c93d62c66" xlink:href="pacb-20250930.xsd#pacb_ChangeInEarningsPerShare"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_pacb_ChangeInEarningsPerShare_795e8969-8e92-4d8b-80ab-995c93d62c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_16a8cdb3-dae7-4e77-b101-01804f21bc17" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_16a8cdb3-dae7-4e77-b101-01804f21bc17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1a8d18b8-b41c-49c2-a6b7-6882710d86cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1a8d18b8-b41c-49c2-a6b7-6882710d86cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent_da06bfcd-eea9-4c9c-b5b4-d47489ab3fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent_da06bfcd-eea9-4c9c-b5b4-d47489ab3fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_2ca73438-4adc-457d-9c28-f6dbaf3b580e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_us-gaap_ContractWithCustomerLiability_2ca73438-4adc-457d-9c28-f6dbaf3b580e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b796747c-4656-4d8f-ae3c-785ed49b137d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b796747c-4656-4d8f-ae3c-785ed49b137d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_d05ec7c9-bb4d-4dc0-a193-d7fae14861eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_d05ec7c9-bb4d-4dc0-a193-d7fae14861eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod_7e5ea427-c5ce-4b7e-b6e5-274a26476993" xlink:href="pacb-20250930.xsd#pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod_7e5ea427-c5ce-4b7e-b6e5-274a26476993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_f6274bbc-eb15-4914-ad07-cbca4f97279b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_f6274bbc-eb15-4914-ad07-cbca4f97279b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_07851892-827e-4d30-bc15-500eaf4f0c17" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_07851892-827e-4d30-bc15-500eaf4f0c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_30bff09a-c0f1-424a-a4ba-7f94365dbe24" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_30bff09a-c0f1-424a-a4ba-7f94365dbe24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_d2fb79bc-0eaa-4699-987d-9796b8fbfb8b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_d2fb79bc-0eaa-4699-987d-9796b8fbfb8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StandardProductWarrantyPeriod_f21ae456-69a1-4607-a839-1c05625c3f58" xlink:href="pacb-20250930.xsd#pacb_StandardProductWarrantyPeriod"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_ScheduleOfBalanceSheetComponentsLineItems_1e164b13-b221-412d-aa0e-1213c58068f1" xlink:to="loc_pacb_StandardProductWarrantyPeriod_f21ae456-69a1-4607-a839-1c05625c3f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_095e7c09-01f3-4f0e-b297-c8b370a3a1b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_f850f0a4-1674-4e48-8d3e-62ddd7b8e640" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_095e7c09-01f3-4f0e-b297-c8b370a3a1b3" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_f850f0a4-1674-4e48-8d3e-62ddd7b8e640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ce37765c-40d0-4502-9358-fa1bad171bee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_f850f0a4-1674-4e48-8d3e-62ddd7b8e640" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ce37765c-40d0-4502-9358-fa1bad171bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_fa7435d4-1084-4468-92e5-aef5d7fea92d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ce37765c-40d0-4502-9358-fa1bad171bee" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_fa7435d4-1084-4468-92e5-aef5d7fea92d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_cf12eb35-1d52-4914-9a04-0720fee07268" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_fa7435d4-1084-4468-92e5-aef5d7fea92d" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_cf12eb35-1d52-4914-9a04-0720fee07268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_19e129ca-9428-4c5f-9b08-da6d978fbf25" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_f850f0a4-1674-4e48-8d3e-62ddd7b8e640" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_19e129ca-9428-4c5f-9b08-da6d978fbf25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_6f8a0ecf-077a-4581-bb50-ba76a2c6a422" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_19e129ca-9428-4c5f-9b08-da6d978fbf25" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_6f8a0ecf-077a-4581-bb50-ba76a2c6a422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c95880da-13dd-41e6-948c-9a5c9299e037" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_6f8a0ecf-077a-4581-bb50-ba76a2c6a422" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c95880da-13dd-41e6-948c-9a5c9299e037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_39021e4b-56b5-4a46-9c02-3ef5f5fc0675" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_6f8a0ecf-077a-4581-bb50-ba76a2c6a422" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_39021e4b-56b5-4a46-9c02-3ef5f5fc0675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_aa783485-5db4-4584-99d0-a8da494a73b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_39021e4b-56b5-4a46-9c02-3ef5f5fc0675" xlink:to="loc_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_aa783485-5db4-4584-99d0-a8da494a73b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c913d68b-3012-499e-acfe-ab75f12036ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_6f8a0ecf-077a-4581-bb50-ba76a2c6a422" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c913d68b-3012-499e-acfe-ab75f12036ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_5fa66371-d3e9-4c2e-bff0-22380d1c03aa" xlink:href="pacb-20250930.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8890d552-a87c-4815-b472-9e14d84c7aef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_5fa66371-d3e9-4c2e-bff0-22380d1c03aa" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8890d552-a87c-4815-b472-9e14d84c7aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_63d33642-fd91-4a43-9d43-49d3667e6948" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8890d552-a87c-4815-b472-9e14d84c7aef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_63d33642-fd91-4a43-9d43-49d3667e6948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_88146dd1-5877-45a0-a4ac-fd1a56fd2b39" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_63d33642-fd91-4a43-9d43-49d3667e6948" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_88146dd1-5877-45a0-a4ac-fd1a56fd2b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_7fc6aff8-1dc6-413f-a72f-02638b67389e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_88146dd1-5877-45a0-a4ac-fd1a56fd2b39" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_7fc6aff8-1dc6-413f-a72f-02638b67389e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_6c8fe089-d146-44aa-9b34-491886cb40dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_88146dd1-5877-45a0-a4ac-fd1a56fd2b39" xlink:to="loc_us-gaap_CustomerRelationshipsMember_6c8fe089-d146-44aa-9b34-491886cb40dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c327fd73-4ec2-436d-98ce-e539c327bdea" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8890d552-a87c-4815-b472-9e14d84c7aef" xlink:to="loc_srt_RangeAxis_c327fd73-4ec2-436d-98ce-e539c327bdea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_08cd3ff5-5d7b-4c44-9b03-db5bc4a6ad69" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c327fd73-4ec2-436d-98ce-e539c327bdea" xlink:to="loc_srt_RangeMember_08cd3ff5-5d7b-4c44-9b03-db5bc4a6ad69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c19398d2-5f15-45b5-8230-449a3705c89e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_08cd3ff5-5d7b-4c44-9b03-db5bc4a6ad69" xlink:to="loc_srt_MinimumMember_c19398d2-5f15-45b5-8230-449a3705c89e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b2007e45-1e50-48ec-80d1-ad1412f69d66" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_08cd3ff5-5d7b-4c44-9b03-db5bc4a6ad69" xlink:to="loc_srt_MaximumMember_b2007e45-1e50-48ec-80d1-ad1412f69d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2497faea-2355-411e-aeff-c800679bf7f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8890d552-a87c-4815-b472-9e14d84c7aef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2497faea-2355-411e-aeff-c800679bf7f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9a12187c-dd29-427c-99cb-2449e64c5c58" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2497faea-2355-411e-aeff-c800679bf7f0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9a12187c-dd29-427c-99cb-2449e64c5c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_776a6f74-b365-4110-995a-f965eb948138" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2497faea-2355-411e-aeff-c800679bf7f0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_776a6f74-b365-4110-995a-f965eb948138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_8b11b40b-897d-491d-8755-014813e80573" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2497faea-2355-411e-aeff-c800679bf7f0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_8b11b40b-897d-491d-8755-014813e80573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2d2c64a1-fcac-4677-a63a-36fac9f1a05b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2497faea-2355-411e-aeff-c800679bf7f0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2d2c64a1-fcac-4677-a63a-36fac9f1a05b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_d54a48a6-0cd0-4a90-8caf-a017fca7074c" xlink:href="pacb-20250930.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_65e099e1-5c2b-4ecf-8051-6990654d545f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_d54a48a6-0cd0-4a90-8caf-a017fca7074c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_65e099e1-5c2b-4ecf-8051-6990654d545f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_f35fe7f7-fece-4455-960d-165bb38de3e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_d54a48a6-0cd0-4a90-8caf-a017fca7074c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_f35fe7f7-fece-4455-960d-165bb38de3e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_6f85aebe-2f95-426f-86f7-7910b2a16f40" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_d54a48a6-0cd0-4a90-8caf-a017fca7074c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_6f85aebe-2f95-426f-86f7-7910b2a16f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_d1f5c4df-c502-460c-8c92-a8a9fc4f31dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_d54a48a6-0cd0-4a90-8caf-a017fca7074c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_d1f5c4df-c502-460c-8c92-a8a9fc4f31dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_1cf23a29-dc73-4f73-8714-2ef70a0f87c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_d54a48a6-0cd0-4a90-8caf-a017fca7074c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_1cf23a29-dc73-4f73-8714-2ef70a0f87c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_07412561-3c19-44eb-849b-458562825cfd" xlink:href="pacb-20250930.xsd#pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_d54a48a6-0cd0-4a90-8caf-a017fca7074c" xlink:to="loc_pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_07412561-3c19-44eb-849b-458562825cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5c6e09f5-0803-4575-b5dd-05db18611e72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_d54a48a6-0cd0-4a90-8caf-a017fca7074c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5c6e09f5-0803-4575-b5dd-05db18611e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofChangesinReserveforProductWarrantiesDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#BALANCESHEETCOMPONENTSScheduleofChangesinReserveforProductWarrantiesDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofChangesinReserveforProductWarrantiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_0a4393d2-51c9-4893-ba55-699553d3a306" xlink:href="pacb-20250930.xsd#pacb_SupplementalBalanceSheetComponentsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_becb4063-073a-42b8-aa3e-3419f716a888" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract_0a4393d2-51c9-4893-ba55-699553d3a306" xlink:to="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_becb4063-073a-42b8-aa3e-3419f716a888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrual_ef0a09a9-46e5-43e5-b194-f8b4465f8abf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductWarrantyAccrual"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_becb4063-073a-42b8-aa3e-3419f716a888" xlink:to="loc_us-gaap_ProductWarrantyAccrual_ef0a09a9-46e5-43e5-b194-f8b4465f8abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualWarrantiesIssued_bf75a434-1058-4f47-93bb-9b31dd7475dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductWarrantyAccrualWarrantiesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_becb4063-073a-42b8-aa3e-3419f716a888" xlink:to="loc_us-gaap_ProductWarrantyAccrualWarrantiesIssued_bf75a434-1058-4f47-93bb-9b31dd7475dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualPayments_ad721377-7796-4122-8adf-e39e21d2a815" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductWarrantyAccrualPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_becb4063-073a-42b8-aa3e-3419f716a888" xlink:to="loc_us-gaap_ProductWarrantyAccrualPayments_ad721377-7796-4122-8adf-e39e21d2a815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrual_96c77234-725e-4d1e-8b23-fef0e76a25f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductWarrantyAccrual"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_becb4063-073a-42b8-aa3e-3419f716a888" xlink:to="loc_us-gaap_ProductWarrantyAccrual_96c77234-725e-4d1e-8b23-fef0e76a25f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#CONVERTIBLESENIORNOTESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_533255d9-d081-4b3a-a92b-b96d71c9e35f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_5176ab31-ce73-4b11-b203-45b6c63d4839" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_533255d9-d081-4b3a-a92b-b96d71c9e35f" xlink:to="loc_us-gaap_DebtInstrumentTable_5176ab31-ce73-4b11-b203-45b6c63d4839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_42ae04c1-84ea-42a8-91aa-ad92e13a4ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5176ab31-ce73-4b11-b203-45b6c63d4839" xlink:to="loc_us-gaap_DebtInstrumentAxis_42ae04c1-84ea-42a8-91aa-ad92e13a4ba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_dace9b48-cc85-44af-8d7d-17087a2db66b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_42ae04c1-84ea-42a8-91aa-ad92e13a4ba3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_dace9b48-cc85-44af-8d7d-17087a2db66b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2028ConvertibleSeniorNotesMember_5595a55d-576f-420f-9f81-bee4db72ea44" xlink:href="pacb-20250930.xsd#pacb_A2028ConvertibleSeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dace9b48-cc85-44af-8d7d-17087a2db66b" xlink:to="loc_pacb_A2028ConvertibleSeniorNotesMember_5595a55d-576f-420f-9f81-bee4db72ea44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2029NotesMember_9d1d2e0d-0bc7-4d9e-a635-be90e1605bd9" xlink:href="pacb-20250930.xsd#pacb_A2029NotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dace9b48-cc85-44af-8d7d-17087a2db66b" xlink:to="loc_pacb_A2029NotesMember_9d1d2e0d-0bc7-4d9e-a635-be90e1605bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ExchangeTransactionMember_523a6889-64fd-4877-b91f-43c4f588a983" xlink:href="pacb-20250930.xsd#pacb_ExchangeTransactionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dace9b48-cc85-44af-8d7d-17087a2db66b" xlink:to="loc_pacb_ExchangeTransactionMember_523a6889-64fd-4877-b91f-43c4f588a983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2030ConvertibleSeniorNotesMember_e3d67aac-bab7-4c89-9fa2-3e8c8b0bab2a" xlink:href="pacb-20250930.xsd#pacb_A2030ConvertibleSeniorNotesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_dace9b48-cc85-44af-8d7d-17087a2db66b" xlink:to="loc_pacb_A2030ConvertibleSeniorNotesMember_e3d67aac-bab7-4c89-9fa2-3e8c8b0bab2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2c3261ed-2b57-4874-83a3-2e6b8f892421" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5176ab31-ce73-4b11-b203-45b6c63d4839" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2c3261ed-2b57-4874-83a3-2e6b8f892421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ab9e4f64-ebe0-4d35-a97b-4c2599f28039" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2c3261ed-2b57-4874-83a3-2e6b8f892421" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ab9e4f64-ebe0-4d35-a97b-4c2599f28039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_a5e02a92-5ca2-43b9-8875-fbcf7ee89d22" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ab9e4f64-ebe0-4d35-a97b-4c2599f28039" xlink:to="loc_us-gaap_ConvertibleDebtMember_a5e02a92-5ca2-43b9-8875-fbcf7ee89d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentConvertibleTermsOfConversionAxis_de2f2d48-0d4e-436b-bc83-7d8a0a8e4a6b" xlink:href="pacb-20250930.xsd#pacb_DebtInstrumentConvertibleTermsOfConversionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5176ab31-ce73-4b11-b203-45b6c63d4839" xlink:to="loc_pacb_DebtInstrumentConvertibleTermsOfConversionAxis_de2f2d48-0d4e-436b-bc83-7d8a0a8e4a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_3755290f-d553-4106-b711-15c9f7bcfb1c" xlink:href="pacb-20250930.xsd#pacb_DebtInstrumentConvertibleTermsOfConversionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_DebtInstrumentConvertibleTermsOfConversionAxis_de2f2d48-0d4e-436b-bc83-7d8a0a8e4a6b" xlink:to="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_3755290f-d553-4106-b711-15c9f7bcfb1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtConversionTermsOneMember_7eaa12f4-716f-44b3-a0ae-3cb90ecc2051" xlink:href="pacb-20250930.xsd#pacb_DebtConversionTermsOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_3755290f-d553-4106-b711-15c9f7bcfb1c" xlink:to="loc_pacb_DebtConversionTermsOneMember_7eaa12f4-716f-44b3-a0ae-3cb90ecc2051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtConversionTermsTwoMember_41321bc1-1144-47da-81e8-34a54e6efa63" xlink:href="pacb-20250930.xsd#pacb_DebtConversionTermsTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pacb_DebtInstrumentConvertibleTermsOfConversionDomain_3755290f-d553-4106-b711-15c9f7bcfb1c" xlink:to="loc_pacb_DebtConversionTermsTwoMember_41321bc1-1144-47da-81e8-34a54e6efa63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_429979d9-d8d8-46e6-a9e1-8f33a3df2546" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5176ab31-ce73-4b11-b203-45b6c63d4839" xlink:to="loc_srt_RangeAxis_429979d9-d8d8-46e6-a9e1-8f33a3df2546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ced2b1df-8d43-460c-b21f-b3a59ba2c29c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_429979d9-d8d8-46e6-a9e1-8f33a3df2546" xlink:to="loc_srt_RangeMember_ced2b1df-8d43-460c-b21f-b3a59ba2c29c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ebb5477c-0382-41af-a53e-9de8526a2db9" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ced2b1df-8d43-460c-b21f-b3a59ba2c29c" xlink:to="loc_srt_MinimumMember_ebb5477c-0382-41af-a53e-9de8526a2db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_10119717-6e24-4e62-a9ab-0fec620ea6c1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ced2b1df-8d43-460c-b21f-b3a59ba2c29c" xlink:to="loc_srt_MaximumMember_10119717-6e24-4e62-a9ab-0fec620ea6c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5176ab31-ce73-4b11-b203-45b6c63d4839" xlink:to="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_c1e4c25a-c815-4a20-8e10-3aee72680d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_c1e4c25a-c815-4a20-8e10-3aee72680d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4aba03e9-8dab-4c48-825b-06c51440750a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4aba03e9-8dab-4c48-825b-06c51440750a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_32a11136-46fd-4fc9-8f29-c49e6489dd21" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_32a11136-46fd-4fc9-8f29-c49e6489dd21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_462a112e-9bab-425d-85e4-08ee063a1bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_462a112e-9bab-425d-85e4-08ee063a1bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_PaymentsInConjunctionWithNotesExchange_9cd35da2-b7f5-4380-8f2c-a843805994e7" xlink:href="pacb-20250930.xsd#pacb_PaymentsInConjunctionWithNotesExchange"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_pacb_PaymentsInConjunctionWithNotesExchange_9cd35da2-b7f5-4380-8f2c-a843805994e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares_c43971f4-9438-4ec9-ad63-cbc9b5986bf0" xlink:href="pacb-20250930.xsd#pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares_c43971f4-9438-4ec9-ad63-cbc9b5986bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_df99ca4c-4411-4bc6-a6b1-bc98720407d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_df99ca4c-4411-4bc6-a6b1-bc98720407d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_91b7c089-22f3-4f8b-9461-597b58b48897" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_91b7c089-22f3-4f8b-9461-597b58b48897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_415e0183-bd74-4b0e-b945-b40164a8d8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_415e0183-bd74-4b0e-b945-b40164a8d8b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_d6a80d5d-65a7-467c-b7b8-a202a9239b03" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_d6a80d5d-65a7-467c-b7b8-a202a9239b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_78c4adb0-e76b-45e7-a2d7-1cc5c8722c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_78c4adb0-e76b-45e7-a2d7-1cc5c8722c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_4d3b0a77-1830-44ed-b24b-fba31640a49b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_4d3b0a77-1830-44ed-b24b-fba31640a49b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentDebtDefaultCalendarDays_7128b606-604f-4dcf-8a04-788536d4469f" xlink:href="pacb-20250930.xsd#pacb_DebtInstrumentDebtDefaultCalendarDays"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_pacb_DebtInstrumentDebtDefaultCalendarDays_7128b606-604f-4dcf-8a04-788536d4469f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentInterestInTheEventOfDefault_00ad327f-5383-4529-bc3b-9060b8b328b9" xlink:href="pacb-20250930.xsd#pacb_DebtInstrumentInterestInTheEventOfDefault"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_pacb_DebtInstrumentInterestInTheEventOfDefault_00ad327f-5383-4529-bc3b-9060b8b328b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentAdditionalInterestInEventOfDefault_9388cba9-0c83-409a-ba8c-62a758748364" xlink:href="pacb-20250930.xsd#pacb_DebtInstrumentAdditionalInterestInEventOfDefault"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_pacb_DebtInstrumentAdditionalInterestInEventOfDefault_9388cba9-0c83-409a-ba8c-62a758748364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt_d1cd6fc9-7fe5-4b0b-99ef-e58c3dd76000" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnRestructuringOfDebt"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_us-gaap_GainsLossesOnRestructuringOfDebt_d1cd6fc9-7fe5-4b0b-99ef-e58c3dd76000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_RestructuringOfDebtPricePerShare_5225adbd-ade3-4067-9dd7-272d7a0cb023" xlink:href="pacb-20250930.xsd#pacb_RestructuringOfDebtPricePerShare"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_pacb_RestructuringOfDebtPricePerShare_5225adbd-ade3-4067-9dd7-272d7a0cb023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_08edd9d8-4717-4cec-a254-573a78a365eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_08edd9d8-4717-4cec-a254-573a78a365eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtIssuanceCostLenderFees_f9c5221a-e82b-424e-a67c-b02e4eea59d0" xlink:href="pacb-20250930.xsd#pacb_DebtIssuanceCostLenderFees"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_pacb_DebtIssuanceCostLenderFees_f9c5221a-e82b-424e-a67c-b02e4eea59d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_73f70a28-6c7e-469f-8da1-8b3a7d942e44" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_73f70a28-6c7e-469f-8da1-8b3a7d942e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_349bbadf-3742-4cbc-8edf-95e3e25a1923" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_us-gaap_LongTermDebt_349bbadf-3742-4cbc-8edf-95e3e25a1923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayable_473efd70-7cbc-4fff-8b8e-fc144ad23ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayable"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_us-gaap_ConvertibleNotesPayable_473efd70-7cbc-4fff-8b8e-fc144ad23ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_673fea40-19b4-4e2d-99bf-bc9eec34f094" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_673fea40-19b4-4e2d-99bf-bc9eec34f094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_28433e58-c737-4ff6-baa9-fe63cab796be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_28433e58-c737-4ff6-baa9-fe63cab796be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_66151d8e-c9e2-45aa-861e-be355222f4c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_66151d8e-c9e2-45aa-861e-be355222f4c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice_1edb7be6-b4fa-4c82-be36-002980d11436" xlink:href="pacb-20250930.xsd#pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice_1edb7be6-b4fa-4c82-be36-002980d11436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentRedemptionPriceTradingDays_01b8cfa7-2f03-4349-b682-5ae95b9357f8" xlink:href="pacb-20250930.xsd#pacb_DebtInstrumentRedemptionPriceTradingDays"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_pacb_DebtInstrumentRedemptionPriceTradingDays_01b8cfa7-2f03-4349-b682-5ae95b9357f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays_e392c0c7-2680-40b5-a7b6-3b76c2ba071f" xlink:href="pacb-20250930.xsd#pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays_e392c0c7-2680-40b5-a7b6-3b76c2ba071f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2357e4de-3353-46a9-991c-e8d5a695fe13" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2357e4de-3353-46a9-991c-e8d5a695fe13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_805f4868-006f-4aa7-af94-f6b4205e6e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_805f4868-006f-4aa7-af94-f6b4205e6e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_364182d7-6ad1-43b7-a826-81a040f480ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_99b0f58f-4f2a-49cc-a734-4b1d9d888d0a" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_364182d7-6ad1-43b7-a826-81a040f480ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofChangestothe2029NotesDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#CONVERTIBLESENIORNOTESScheduleofChangestothe2029NotesDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofChangestothe2029NotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7b826d21-7f2b-4f01-ab7f-09217b921d34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_e2ddab0f-58eb-4ce3-881b-d33066b17aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7b826d21-7f2b-4f01-ab7f-09217b921d34" xlink:to="loc_us-gaap_DebtInstrumentTable_e2ddab0f-58eb-4ce3-881b-d33066b17aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_78d108af-8a6d-4a69-b866-6bca34b99dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e2ddab0f-58eb-4ce3-881b-d33066b17aeb" xlink:to="loc_us-gaap_DebtInstrumentAxis_78d108af-8a6d-4a69-b866-6bca34b99dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1a2fd9a1-6f07-4821-b3e6-7d493ebf40ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_78d108af-8a6d-4a69-b866-6bca34b99dbb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1a2fd9a1-6f07-4821-b3e6-7d493ebf40ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2029NotesMember_6b9953ea-4ccd-4c81-bcef-69892d488698" xlink:href="pacb-20250930.xsd#pacb_A2029NotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1a2fd9a1-6f07-4821-b3e6-7d493ebf40ad" xlink:to="loc_pacb_A2029NotesMember_6b9953ea-4ccd-4c81-bcef-69892d488698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_f8440d83-60f9-405c-a50e-e6e1693da35b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e2ddab0f-58eb-4ce3-881b-d33066b17aeb" xlink:to="loc_us-gaap_DebtInstrumentLineItems_f8440d83-60f9-405c-a50e-e6e1693da35b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayable_66c16902-1196-49fa-b818-26890548bddf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f8440d83-60f9-405c-a50e-e6e1693da35b" xlink:to="loc_us-gaap_ConvertibleNotesPayable_66c16902-1196-49fa-b818-26890548bddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_fde5c015-05bb-4ee4-b1cf-8fd08f96b683" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f8440d83-60f9-405c-a50e-e6e1693da35b" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_fde5c015-05bb-4ee4-b1cf-8fd08f96b683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayable_780222fe-39dc-4613-ada1-91ba73495efb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f8440d83-60f9-405c-a50e-e6e1693da35b" xlink:to="loc_us-gaap_ConvertibleNotesPayable_780222fe-39dc-4613-ada1-91ba73495efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2c7ba0a2-290e-45bf-ab8e-ec7a0bb13107" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_8e865d42-692e-4fb7-9c6e-ee286ec53184" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2c7ba0a2-290e-45bf-ab8e-ec7a0bb13107" xlink:to="loc_us-gaap_DebtInstrumentTable_8e865d42-692e-4fb7-9c6e-ee286ec53184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d0488cd2-a1a1-4d74-9dc6-d31b6dd062ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8e865d42-692e-4fb7-9c6e-ee286ec53184" xlink:to="loc_us-gaap_DebtInstrumentAxis_d0488cd2-a1a1-4d74-9dc6-d31b6dd062ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_64f58c61-d74d-43f7-9a52-54ee89c202b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_d0488cd2-a1a1-4d74-9dc6-d31b6dd062ea" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_64f58c61-d74d-43f7-9a52-54ee89c202b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2030ConvertibleSeniorNotesMember_0013c62a-5314-41bd-b2f9-179e8bfe693f" xlink:href="pacb-20250930.xsd#pacb_A2030ConvertibleSeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_64f58c61-d74d-43f7-9a52-54ee89c202b9" xlink:to="loc_pacb_A2030ConvertibleSeniorNotesMember_0013c62a-5314-41bd-b2f9-179e8bfe693f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6661e90a-ca00-41e8-96de-6375c06cc24e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8e865d42-692e-4fb7-9c6e-ee286ec53184" xlink:to="loc_us-gaap_DebtInstrumentLineItems_6661e90a-ca00-41e8-96de-6375c06cc24e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_8bf81464-9f6f-4498-9dad-58bfd7e632a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6661e90a-ca00-41e8-96de-6375c06cc24e" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_8bf81464-9f6f-4498-9dad-58bfd7e632a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium_66aace92-07ad-4c4f-8e34-f68a0b2bee0b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6661e90a-ca00-41e8-96de-6375c06cc24e" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremium_66aace92-07ad-4c4f-8e34-f68a0b2bee0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_7e8f9934-e8e2-4197-b633-3e66e3654a76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnamortizedDebtIssuanceExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6661e90a-ca00-41e8-96de-6375c06cc24e" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_7e8f9934-e8e2-4197-b633-3e66e3654a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_9216f47c-8ea5-410a-aed5-2723dbb9e4c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6661e90a-ca00-41e8-96de-6375c06cc24e" xlink:to="loc_us-gaap_LongTermDebt_9216f47c-8ea5-410a-aed5-2723dbb9e4c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_bcb2b111-06c4-44ff-b5c4-882eb322eeee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_250f2301-2135-4752-a975-2fd9ebc0c0c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_bcb2b111-06c4-44ff-b5c4-882eb322eeee" xlink:to="loc_us-gaap_DebtInstrumentTable_250f2301-2135-4752-a975-2fd9ebc0c0c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8fa917c5-3917-4432-af93-cb13945f593d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_250f2301-2135-4752-a975-2fd9ebc0c0c6" xlink:to="loc_us-gaap_DebtInstrumentAxis_8fa917c5-3917-4432-af93-cb13945f593d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bc72d3f3-2fe7-418f-9c96-0825856cbde7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_8fa917c5-3917-4432-af93-cb13945f593d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bc72d3f3-2fe7-418f-9c96-0825856cbde7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2030ConvertibleSeniorNotesMember_cc032d38-2001-4ed8-b0fe-3bc6553a30cc" xlink:href="pacb-20250930.xsd#pacb_A2030ConvertibleSeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bc72d3f3-2fe7-418f-9c96-0825856cbde7" xlink:to="loc_pacb_A2030ConvertibleSeniorNotesMember_cc032d38-2001-4ed8-b0fe-3bc6553a30cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2028ConvertibleSeniorNotesMember_a79dc6af-c9d8-4bfc-9863-df0c28bf7de0" xlink:href="pacb-20250930.xsd#pacb_A2028ConvertibleSeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bc72d3f3-2fe7-418f-9c96-0825856cbde7" xlink:to="loc_pacb_A2028ConvertibleSeniorNotesMember_a79dc6af-c9d8-4bfc-9863-df0c28bf7de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_8afc06dc-9eb9-41e4-98c5-0331055c13e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_250f2301-2135-4752-a975-2fd9ebc0c0c6" xlink:to="loc_us-gaap_DebtInstrumentLineItems_8afc06dc-9eb9-41e4-98c5-0331055c13e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_7feae577-c497-4db5-981c-87b9f2a468de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8afc06dc-9eb9-41e4-98c5-0331055c13e3" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_7feae577-c497-4db5-981c-87b9f2a468de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_2c9a2a7d-0056-4a36-addb-3e11dca43872" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8afc06dc-9eb9-41e4-98c5-0331055c13e3" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_2c9a2a7d-0056-4a36-addb-3e11dca43872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_f045ad73-5f60-4915-a142-9b91174857c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8afc06dc-9eb9-41e4-98c5-0331055c13e3" xlink:to="loc_us-gaap_InterestExpenseDebt_f045ad73-5f60-4915-a142-9b91174857c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_d17bb3e4-dd9b-46b2-9464-a69ddf8bdee2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d30945b0-df94-46a8-94e5-a5d9b2c30f48" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_d17bb3e4-dd9b-46b2-9464-a69ddf8bdee2" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d30945b0-df94-46a8-94e5-a5d9b2c30f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_b87a0f99-c973-4437-b065-f07b0664b50f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d30945b0-df94-46a8-94e5-a5d9b2c30f48" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_b87a0f99-c973-4437-b065-f07b0664b50f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_0ef3aa25-93c8-48cf-b845-d8a30fdcc5d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_b87a0f99-c973-4437-b065-f07b0664b50f" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_0ef3aa25-93c8-48cf-b845-d8a30fdcc5d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EmployeeSeparationCostsMember_99301728-640b-497e-8c53-def8cc82cbd4" xlink:href="pacb-20250930.xsd#pacb_EmployeeSeparationCostsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_0ef3aa25-93c8-48cf-b845-d8a30fdcc5d0" xlink:to="loc_pacb_EmployeeSeparationCostsMember_99301728-640b-497e-8c53-def8cc82cbd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_3f553337-5030-443a-adb4-091a345a3b85" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherRestructuringMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_0ef3aa25-93c8-48cf-b845-d8a30fdcc5d0" xlink:to="loc_us-gaap_OtherRestructuringMember_3f553337-5030-443a-adb4-091a345a3b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e2838448-4768-4362-8998-e3372860a437" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d30945b0-df94-46a8-94e5-a5d9b2c30f48" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e2838448-4768-4362-8998-e3372860a437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_afbb34e3-1f4a-4ab5-905d-a0a2620548cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e2838448-4768-4362-8998-e3372860a437" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_afbb34e3-1f4a-4ab5-905d-a0a2620548cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_7f419fcc-73a0-4bc0-b603-ecc50a4544dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_afbb34e3-1f4a-4ab5-905d-a0a2620548cd" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_7f419fcc-73a0-4bc0-b603-ecc50a4544dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4b19369d-03db-40e9-8da3-d7a6f00d53a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_afbb34e3-1f4a-4ab5-905d-a0a2620548cd" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4b19369d-03db-40e9-8da3-d7a6f00d53a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_aeb023be-3503-4de3-99f1-8468c35dc3a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_afbb34e3-1f4a-4ab5-905d-a0a2620548cd" xlink:to="loc_us-gaap_CostOfSalesMember_aeb023be-3503-4de3-99f1-8468c35dc3a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_771e3348-fbb3-4185-afc0-f9713d02e332" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d30945b0-df94-46a8-94e5-a5d9b2c30f48" xlink:to="loc_us-gaap_RestructuringPlanAxis_771e3348-fbb3-4185-afc0-f9713d02e332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_a06d4956-25b2-4b00-93aa-86de3b5411ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_771e3348-fbb3-4185-afc0-f9713d02e332" xlink:to="loc_us-gaap_RestructuringPlanDomain_a06d4956-25b2-4b00-93aa-86de3b5411ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2025RestructuringMember_90083ad6-2d47-4c02-8f33-1d416ddbd680" xlink:href="pacb-20250930.xsd#pacb_A2025RestructuringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_a06d4956-25b2-4b00-93aa-86de3b5411ba" xlink:to="loc_pacb_A2025RestructuringMember_90083ad6-2d47-4c02-8f33-1d416ddbd680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2024RestructuringMember_11f673ed-c8c9-4c29-bce4-fb4979678e99" xlink:href="pacb-20250930.xsd#pacb_A2024RestructuringMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_a06d4956-25b2-4b00-93aa-86de3b5411ba" xlink:to="loc_pacb_A2024RestructuringMember_11f673ed-c8c9-4c29-bce4-fb4979678e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_1d8f463b-959c-4d27-8186-71b26d25d2c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d30945b0-df94-46a8-94e5-a5d9b2c30f48" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_1d8f463b-959c-4d27-8186-71b26d25d2c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_a31b803a-437a-4c8c-883c-0bcf47621866" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1d8f463b-959c-4d27-8186-71b26d25d2c9" xlink:to="loc_us-gaap_RestructuringCharges_a31b803a-437a-4c8c-883c-0bcf47621866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_367dea1b-e490-47c8-a449-f4b1ee1e5d04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1d8f463b-959c-4d27-8186-71b26d25d2c9" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_367dea1b-e490-47c8-a449-f4b1ee1e5d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_ab62cbc9-3d2d-498a-be87-9aa155ee76ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1d8f463b-959c-4d27-8186-71b26d25d2c9" xlink:to="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_ab62cbc9-3d2d-498a-be87-9aa155ee76ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#RESTRUCTURINGNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_461c45b5-c709-45a2-a214-57634ba8b1a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_09794175-1b2b-44b1-9069-ed961d597404" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_461c45b5-c709-45a2-a214-57634ba8b1a7" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_09794175-1b2b-44b1-9069-ed961d597404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_70435a4c-a208-4d30-a580-2f230dede9ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_09794175-1b2b-44b1-9069-ed961d597404" xlink:to="loc_us-gaap_RestructuringPlanAxis_70435a4c-a208-4d30-a580-2f230dede9ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_0f440e63-febf-4013-930d-570d6fed606b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_70435a4c-a208-4d30-a580-2f230dede9ef" xlink:to="loc_us-gaap_RestructuringPlanDomain_0f440e63-febf-4013-930d-570d6fed606b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2025RestructuringMember_3c6543e6-6ab4-4b62-a445-6c80c53ab475" xlink:href="pacb-20250930.xsd#pacb_A2025RestructuringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_0f440e63-febf-4013-930d-570d6fed606b" xlink:to="loc_pacb_A2025RestructuringMember_3c6543e6-6ab4-4b62-a445-6c80c53ab475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2024RestructuringMember_feb0cab8-d448-4ec9-92c2-7035c7832d46" xlink:href="pacb-20250930.xsd#pacb_A2024RestructuringMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_0f440e63-febf-4013-930d-570d6fed606b" xlink:to="loc_pacb_A2024RestructuringMember_feb0cab8-d448-4ec9-92c2-7035c7832d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_SanDiegoOfficeMember_12c1ae4f-e1db-4efc-9c56-1bbb448621f2" xlink:href="pacb-20250930.xsd#pacb_SanDiegoOfficeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_0f440e63-febf-4013-930d-570d6fed606b" xlink:to="loc_pacb_SanDiegoOfficeMember_12c1ae4f-e1db-4efc-9c56-1bbb448621f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_3239a5db-b590-4909-aa95-49a61a4c5255" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_09794175-1b2b-44b1-9069-ed961d597404" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_3239a5db-b590-4909-aa95-49a61a4c5255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_eee2a12e-2ee6-477f-b226-f89fd43a66e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_3239a5db-b590-4909-aa95-49a61a4c5255" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_eee2a12e-2ee6-477f-b226-f89fd43a66e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember_bdcb5c0f-87e9-4fbb-b40c-104c870e5591" xlink:href="pacb-20250930.xsd#pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_eee2a12e-2ee6-477f-b226-f89fd43a66e7" xlink:to="loc_pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember_bdcb5c0f-87e9-4fbb-b40c-104c870e5591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_8f0f8365-7abe-4a5e-bbed-59d9274d1a39" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_09794175-1b2b-44b1-9069-ed961d597404" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_8f0f8365-7abe-4a5e-bbed-59d9274d1a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits_52a69d7c-5874-4221-87a3-2a6009b1ff47" xlink:href="pacb-20250930.xsd#pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8f0f8365-7abe-4a5e-bbed-59d9274d1a39" xlink:to="loc_pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits_52a69d7c-5874-4221-87a3-2a6009b1ff47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_4ee08198-1925-4a27-9f84-d01faa3f063e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8f0f8365-7abe-4a5e-bbed-59d9274d1a39" xlink:to="loc_us-gaap_SeveranceCosts1_4ee08198-1925-4a27-9f84-d01faa3f063e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_RestructuringChargesAdditionalCostsIncurred_01690228-9c26-4c44-8d46-5aa3a88381bb" xlink:href="pacb-20250930.xsd#pacb_RestructuringChargesAdditionalCostsIncurred"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8f0f8365-7abe-4a5e-bbed-59d9274d1a39" xlink:to="loc_pacb_RestructuringChargesAdditionalCostsIncurred_01690228-9c26-4c44-8d46-5aa3a88381bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_RestructuringAndRelatedCostAcceleratedAmortization_4aac0489-d354-43e7-ab38-1dbb19430be2" xlink:href="pacb-20250930.xsd#pacb_RestructuringAndRelatedCostAcceleratedAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8f0f8365-7abe-4a5e-bbed-59d9274d1a39" xlink:to="loc_pacb_RestructuringAndRelatedCostAcceleratedAmortization_4aac0489-d354-43e7-ab38-1dbb19430be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_62ea2bd3-123b-49ce-bc9f-cde932001841" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8f0f8365-7abe-4a5e-bbed-59d9274d1a39" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_62ea2bd3-123b-49ce-bc9f-cde932001841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_62ea743e-c254-4f86-92b7-85ff391ed98b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8f0f8365-7abe-4a5e-bbed-59d9274d1a39" xlink:to="loc_us-gaap_InventoryWriteDown_62ea743e-c254-4f86-92b7-85ff391ed98b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_GainLossOnPurchaseCommitments_04898369-3cc2-4d0b-b178-1c8b779752e1" xlink:href="pacb-20250930.xsd#pacb_GainLossOnPurchaseCommitments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8f0f8365-7abe-4a5e-bbed-59d9274d1a39" xlink:to="loc_pacb_GainLossOnPurchaseCommitments_04898369-3cc2-4d0b-b178-1c8b779752e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_e0a87150-2c54-4003-ba92-41033b706393" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8f0f8365-7abe-4a5e-bbed-59d9274d1a39" xlink:to="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_e0a87150-2c54-4003-ba92-41033b706393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_e76a82dc-7d41-4af8-af17-19092f2f01e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8f0f8365-7abe-4a5e-bbed-59d9274d1a39" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_e76a82dc-7d41-4af8-af17-19092f2f01e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_4b368aad-3f1c-43c4-b531-3716f56e45f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8f0f8365-7abe-4a5e-bbed-59d9274d1a39" xlink:to="loc_us-gaap_OperatingLeaseLiability_4b368aad-3f1c-43c4-b531-3716f56e45f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3c19706f-2c26-4e20-9ef4-996c55f00dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1d8f310f-c485-4efd-80ed-de343e9a924d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3c19706f-2c26-4e20-9ef4-996c55f00dbe" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1d8f310f-c485-4efd-80ed-de343e9a924d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_9ce2a108-cf2f-4b6b-a667-e6c9ef585c94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1d8f310f-c485-4efd-80ed-de343e9a924d" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_9ce2a108-cf2f-4b6b-a667-e6c9ef585c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_32e61027-bddb-4c7a-9e88-437b9e335c98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_9ce2a108-cf2f-4b6b-a667-e6c9ef585c94" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_32e61027-bddb-4c7a-9e88-437b9e335c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EmployeeSeparationCostsMember_db201447-06f2-497f-8d2e-c6af4f47d75d" xlink:href="pacb-20250930.xsd#pacb_EmployeeSeparationCostsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_32e61027-bddb-4c7a-9e88-437b9e335c98" xlink:to="loc_pacb_EmployeeSeparationCostsMember_db201447-06f2-497f-8d2e-c6af4f47d75d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_9c08c9a4-0318-4fa6-85bb-986251e4cee8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherRestructuringMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_32e61027-bddb-4c7a-9e88-437b9e335c98" xlink:to="loc_us-gaap_OtherRestructuringMember_9c08c9a4-0318-4fa6-85bb-986251e4cee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_8d27153a-a978-4612-af33-00ea73cc9894" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1d8f310f-c485-4efd-80ed-de343e9a924d" xlink:to="loc_us-gaap_RestructuringPlanAxis_8d27153a-a978-4612-af33-00ea73cc9894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_a53aede5-7599-4e9f-a480-7693b51a4137" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_8d27153a-a978-4612-af33-00ea73cc9894" xlink:to="loc_us-gaap_RestructuringPlanDomain_a53aede5-7599-4e9f-a480-7693b51a4137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2025RestructuringMember_8ce86bf7-51ed-4a09-9ca6-471cdf00c702" xlink:href="pacb-20250930.xsd#pacb_A2025RestructuringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_a53aede5-7599-4e9f-a480-7693b51a4137" xlink:to="loc_pacb_A2025RestructuringMember_8ce86bf7-51ed-4a09-9ca6-471cdf00c702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2024RestructuringMember_82ea476b-f617-4e05-bc0b-65f1f733f3b6" xlink:href="pacb-20250930.xsd#pacb_A2024RestructuringMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_a53aede5-7599-4e9f-a480-7693b51a4137" xlink:to="loc_pacb_A2024RestructuringMember_82ea476b-f617-4e05-bc0b-65f1f733f3b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_36c4b148-8746-4ff2-aafc-994ea4d42f0f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1d8f310f-c485-4efd-80ed-de343e9a924d" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_36c4b148-8746-4ff2-aafc-994ea4d42f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_61d3ff13-eaa5-48b5-8d59-b60081a1fa7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_36c4b148-8746-4ff2-aafc-994ea4d42f0f" xlink:to="loc_us-gaap_RestructuringReserve_61d3ff13-eaa5-48b5-8d59-b60081a1fa7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_3e492f7b-1233-4e7e-b06d-9fadf883cebc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_36c4b148-8746-4ff2-aafc-994ea4d42f0f" xlink:to="loc_us-gaap_RestructuringCharges_3e492f7b-1233-4e7e-b06d-9fadf883cebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_7633c82c-7e01-42b0-904f-66dd27b9eb80" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_36c4b148-8746-4ff2-aafc-994ea4d42f0f" xlink:to="loc_us-gaap_PaymentsForRestructuring_7633c82c-7e01-42b0-904f-66dd27b9eb80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_01d00b41-650d-4bbd-bdbd-aa3d06b6d53e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_36c4b148-8746-4ff2-aafc-994ea4d42f0f" xlink:to="loc_us-gaap_RestructuringReserve_01d00b41-650d-4bbd-bdbd-aa3d06b6d53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_88120c9e-0816-4cb4-9911-2e1174083efa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_36c4b148-8746-4ff2-aafc-994ea4d42f0f" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_88120c9e-0816-4cb4-9911-2e1174083efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_13fa8d95-7271-4ce4-a6b3-7ddb50cb700a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations_5f42d295-f5db-4724-a4f6-c14f119a5123" xlink:href="pacb-20250930.xsd#pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_13fa8d95-7271-4ce4-a6b3-7ddb50cb700a" xlink:to="loc_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations_5f42d295-f5db-4724-a4f6-c14f119a5123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0f90ea29-82fd-4432-8aaf-b49054d81d00" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fa44d35-79fd-4baa-87e9-163a4725bcdb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0f90ea29-82fd-4432-8aaf-b49054d81d00" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fa44d35-79fd-4baa-87e9-163a4725bcdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_52e4a5f8-acc1-428a-a5f8-21d6d4db4e38" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fa44d35-79fd-4baa-87e9-163a4725bcdb" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_52e4a5f8-acc1-428a-a5f8-21d6d4db4e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_9ec0adf3-de08-4f99-a698-8e2b1d7b0072" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_52e4a5f8-acc1-428a-a5f8-21d6d4db4e38" xlink:to="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_9ec0adf3-de08-4f99-a698-8e2b1d7b0072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EmployeeStockPurchasePlanMember_63a09674-ce47-428f-ac45-d3e2b682ad89" xlink:href="pacb-20250930.xsd#pacb_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_9ec0adf3-de08-4f99-a698-8e2b1d7b0072" xlink:to="loc_pacb_EmployeeStockPurchasePlanMember_63a09674-ce47-428f-ac45-d3e2b682ad89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_e2c2ffeb-c919-4c96-a94b-a24139bf2a04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fa44d35-79fd-4baa-87e9-163a4725bcdb" xlink:to="loc_us-gaap_PlanNameAxis_e2c2ffeb-c919-4c96-a94b-a24139bf2a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_539d377e-4234-45c2-b73c-08d8ef10865d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_e2c2ffeb-c919-4c96-a94b-a24139bf2a04" xlink:to="loc_us-gaap_PlanNameDomain_539d377e-4234-45c2-b73c-08d8ef10865d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EquityIncentivePlan2020Member_e659574d-358a-43ed-a769-77f7a98bdc81" xlink:href="pacb-20250930.xsd#pacb_EquityIncentivePlan2020Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_539d377e-4234-45c2-b73c-08d8ef10865d" xlink:to="loc_pacb_EquityIncentivePlan2020Member_e659574d-358a-43ed-a769-77f7a98bdc81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_A2020PlanInducementPlanAndTheOmniomePlanMember_0870e810-f9e4-4cec-87c0-16fba443855f" xlink:href="pacb-20250930.xsd#pacb_A2020PlanInducementPlanAndTheOmniomePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_539d377e-4234-45c2-b73c-08d8ef10865d" xlink:to="loc_pacb_A2020PlanInducementPlanAndTheOmniomePlanMember_0870e810-f9e4-4cec-87c0-16fba443855f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b1ba432b-db40-4ff4-9b2a-799583a600d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fa44d35-79fd-4baa-87e9-163a4725bcdb" xlink:to="loc_us-gaap_AwardTypeAxis_b1ba432b-db40-4ff4-9b2a-799583a600d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_28bbed11-be34-4c1b-a0f4-2909d0890665" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b1ba432b-db40-4ff4-9b2a-799583a600d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_28bbed11-be34-4c1b-a0f4-2909d0890665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedRestrictedStockUnitsPSUMember_c291908e-45b6-42c2-b8c1-1f66f9c68bc0" xlink:href="pacb-20250930.xsd#pacb_TimeBasedRestrictedStockUnitsPSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_28bbed11-be34-4c1b-a0f4-2909d0890665" xlink:to="loc_pacb_TimeBasedRestrictedStockUnitsPSUMember_c291908e-45b6-42c2-b8c1-1f66f9c68bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_54669b5a-9f8e-426a-b371-32ab5a170e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fa44d35-79fd-4baa-87e9-163a4725bcdb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_54669b5a-9f8e-426a-b371-32ab5a170e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_fde32e19-839a-4f62-b4fa-d03dd3a90917" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_54669b5a-9f8e-426a-b371-32ab5a170e0a" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_fde32e19-839a-4f62-b4fa-d03dd3a90917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_bcc2eeee-16b8-4987-b53a-d6fbe8d4f934" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_54669b5a-9f8e-426a-b371-32ab5a170e0a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_bcc2eeee-16b8-4987-b53a-d6fbe8d4f934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal_19013daa-9600-41ec-8146-e6cc456b1d28" xlink:href="pacb-20250930.xsd#pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_54669b5a-9f8e-426a-b371-32ab5a170e0a" xlink:to="loc_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal_19013daa-9600-41ec-8146-e6cc456b1d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_dbd2c212-ce3c-4fa6-8081-b34c3c0ae3f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_54669b5a-9f8e-426a-b371-32ab5a170e0a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_dbd2c212-ce3c-4fa6-8081-b34c3c0ae3f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_562b2c3d-26f5-4daf-b4af-35cab6a6d920" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_54669b5a-9f8e-426a-b371-32ab5a170e0a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_562b2c3d-26f5-4daf-b4af-35cab6a6d920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4dd7c288-5cc3-4e71-8795-759fdb79b81a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_54669b5a-9f8e-426a-b371-32ab5a170e0a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4dd7c288-5cc3-4e71-8795-759fdb79b81a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ecd4aa74-daf7-46c8-8db7-3ec1bb9696a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17a5131b-e63c-4fe2-b3dc-de2b430951a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ecd4aa74-daf7-46c8-8db7-3ec1bb9696a8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17a5131b-e63c-4fe2-b3dc-de2b430951a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4b50ae8d-d85e-4a20-8148-f9c288442138" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17a5131b-e63c-4fe2-b3dc-de2b430951a1" xlink:to="loc_us-gaap_AwardTypeAxis_4b50ae8d-d85e-4a20-8148-f9c288442138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fb89bc6d-b49b-4492-a7f9-126956eac3f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4b50ae8d-d85e-4a20-8148-f9c288442138" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fb89bc6d-b49b-4492-a7f9-126956eac3f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedStockOptionMember_cfe7b43b-eb86-46b8-af13-d0757bf175cd" xlink:href="pacb-20250930.xsd#pacb_TimeBasedStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fb89bc6d-b49b-4492-a7f9-126956eac3f8" xlink:to="loc_pacb_TimeBasedStockOptionMember_cfe7b43b-eb86-46b8-af13-d0757bf175cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c062f93-8f80-46ad-8d65-2e21a3793852" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17a5131b-e63c-4fe2-b3dc-de2b430951a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c062f93-8f80-46ad-8d65-2e21a3793852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0c6bce82-7a00-4459-bb20-1e34a92ef7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c062f93-8f80-46ad-8d65-2e21a3793852" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0c6bce82-7a00-4459-bb20-1e34a92ef7cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a8e058b9-849f-46f9-8193-97c07e9c4ead" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0c6bce82-7a00-4459-bb20-1e34a92ef7cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a8e058b9-849f-46f9-8193-97c07e9c4ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ade8c648-d636-4683-8e75-d5b87e4978d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0c6bce82-7a00-4459-bb20-1e34a92ef7cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ade8c648-d636-4683-8e75-d5b87e4978d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_fd2dfd38-7426-42ab-9c35-1595260d36f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0c6bce82-7a00-4459-bb20-1e34a92ef7cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_fd2dfd38-7426-42ab-9c35-1595260d36f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_a3f5dcc2-5f9b-43ba-96c2-e2060c3b254f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0c6bce82-7a00-4459-bb20-1e34a92ef7cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_a3f5dcc2-5f9b-43ba-96c2-e2060c3b254f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b6f521e1-b5ea-4127-8431-41f0562cbe87" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_0c6bce82-7a00-4459-bb20-1e34a92ef7cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b6f521e1-b5ea-4127-8431-41f0562cbe87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5fd969aa-399c-4edd-aea6-2f0546fdb3af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c062f93-8f80-46ad-8d65-2e21a3793852" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5fd969aa-399c-4edd-aea6-2f0546fdb3af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e6b5febd-6184-4568-9261-fc0f15ab33d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5fd969aa-399c-4edd-aea6-2f0546fdb3af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e6b5febd-6184-4568-9261-fc0f15ab33d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_eb40a94b-2ac8-4ce6-b34f-6a6a200f842d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5fd969aa-399c-4edd-aea6-2f0546fdb3af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_eb40a94b-2ac8-4ce6-b34f-6a6a200f842d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c4183baa-dd4b-4186-8818-c13e6d90e764" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5fd969aa-399c-4edd-aea6-2f0546fdb3af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c4183baa-dd4b-4186-8818-c13e6d90e764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_07437046-7889-4d26-865f-bac50005fae7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5fd969aa-399c-4edd-aea6-2f0546fdb3af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_07437046-7889-4d26-865f-bac50005fae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_cdce22d0-36e9-4cab-87bf-d3220baf3222" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_5fd969aa-399c-4edd-aea6-2f0546fdb3af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_cdce22d0-36e9-4cab-87bf-d3220baf3222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62479acb-aac9-4dce-a4aa-faa8c39db9f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3135eabf-1a86-4d3b-96fd-659b80948a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62479acb-aac9-4dce-a4aa-faa8c39db9f3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3135eabf-1a86-4d3b-96fd-659b80948a3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_30d34a6c-eac7-428b-bae8-9ebe0cb7cd32" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3135eabf-1a86-4d3b-96fd-659b80948a3d" xlink:to="loc_us-gaap_AwardTypeAxis_30d34a6c-eac7-428b-bae8-9ebe0cb7cd32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6cf5b2ab-181a-43fb-88d8-eb2a37eaf200" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_30d34a6c-eac7-428b-bae8-9ebe0cb7cd32" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6cf5b2ab-181a-43fb-88d8-eb2a37eaf200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_TimeBasedRestrictedStockUnitsRsusMember_0b3d6d86-0f86-440a-989d-f1cc815ab7c8" xlink:href="pacb-20250930.xsd#pacb_TimeBasedRestrictedStockUnitsRsusMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6cf5b2ab-181a-43fb-88d8-eb2a37eaf200" xlink:to="loc_pacb_TimeBasedRestrictedStockUnitsRsusMember_0b3d6d86-0f86-440a-989d-f1cc815ab7c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_75344fa0-7eda-4fb4-8938-338c9f38cba7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6cf5b2ab-181a-43fb-88d8-eb2a37eaf200" xlink:to="loc_us-gaap_PerformanceSharesMember_75344fa0-7eda-4fb4-8938-338c9f38cba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8d87459-c8a9-4aa6-95b1-7c35353f33b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3135eabf-1a86-4d3b-96fd-659b80948a3d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8d87459-c8a9-4aa6-95b1-7c35353f33b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_7dbd116a-a095-4430-a578-e7c1b418981b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8d87459-c8a9-4aa6-95b1-7c35353f33b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_7dbd116a-a095-4430-a578-e7c1b418981b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2ab374be-c8d1-44df-9ded-4dc42601066f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_7dbd116a-a095-4430-a578-e7c1b418981b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2ab374be-c8d1-44df-9ded-4dc42601066f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b3919915-354b-49f6-bc04-8ff7be6bd6b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_7dbd116a-a095-4430-a578-e7c1b418981b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b3919915-354b-49f6-bc04-8ff7be6bd6b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_90b066cb-7f25-4d03-9f18-35d829e3136f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_7dbd116a-a095-4430-a578-e7c1b418981b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_90b066cb-7f25-4d03-9f18-35d829e3136f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f103a7ed-c449-4ae0-9606-0ba27ceceb74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_7dbd116a-a095-4430-a578-e7c1b418981b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f103a7ed-c449-4ae0-9606-0ba27ceceb74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1e3a5be8-7644-4059-837a-302cba942a32" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_7dbd116a-a095-4430-a578-e7c1b418981b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1e3a5be8-7644-4059-837a-302cba942a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e7edde96-288e-4051-be9a-7f71312d0d92" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b8d87459-c8a9-4aa6-95b1-7c35353f33b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e7edde96-288e-4051-be9a-7f71312d0d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_40eca02b-45e0-4b82-9421-2d4f85e05dee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e7edde96-288e-4051-be9a-7f71312d0d92" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_40eca02b-45e0-4b82-9421-2d4f85e05dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_980cac31-c4aa-44fa-9112-63f02768c849" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e7edde96-288e-4051-be9a-7f71312d0d92" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_980cac31-c4aa-44fa-9112-63f02768c849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_23b2c2e4-7d8b-4814-9d4a-51c0005a5155" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e7edde96-288e-4051-be9a-7f71312d0d92" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_23b2c2e4-7d8b-4814-9d4a-51c0005a5155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9bb67888-64be-49e5-b64d-c5cf2771eaa4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e7edde96-288e-4051-be9a-7f71312d0d92" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9bb67888-64be-49e5-b64d-c5cf2771eaa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f188d1ae-0f39-4d26-9c0a-fb2b7522eeab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e7edde96-288e-4051-be9a-7f71312d0d92" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f188d1ae-0f39-4d26-9c0a-fb2b7522eeab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6b6dfee9-ea96-4d7a-86b2-799043bdf900" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0a051f38-bee4-4f79-9621-4e1953f22fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6b6dfee9-ea96-4d7a-86b2-799043bdf900" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0a051f38-bee4-4f79-9621-4e1953f22fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9677e83e-e763-4e6b-946f-e4403f9b7299" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0a051f38-bee4-4f79-9621-4e1953f22fb0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9677e83e-e763-4e6b-946f-e4403f9b7299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c6bc5ace-0c6c-4080-a2ff-0359d641010b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9677e83e-e763-4e6b-946f-e4403f9b7299" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c6bc5ace-0c6c-4080-a2ff-0359d641010b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_fb50c201-0762-4e26-b598-c3a1c8100189" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c6bc5ace-0c6c-4080-a2ff-0359d641010b" xlink:to="loc_us-gaap_CostOfSalesMember_fb50c201-0762-4e26-b598-c3a1c8100189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_46325134-fe88-4c4f-a5e7-2c0f8019b8df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c6bc5ace-0c6c-4080-a2ff-0359d641010b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_46325134-fe88-4c4f-a5e7-2c0f8019b8df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_721ae6b4-4eff-4154-a89f-f242838b1be2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c6bc5ace-0c6c-4080-a2ff-0359d641010b" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_721ae6b4-4eff-4154-a89f-f242838b1be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_StockBasedCompensationMember_8a50b977-9a6c-47d9-9384-0b3fd6d3a139" xlink:href="pacb-20250930.xsd#pacb_StockBasedCompensationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c6bc5ace-0c6c-4080-a2ff-0359d641010b" xlink:to="loc_pacb_StockBasedCompensationMember_8a50b977-9a6c-47d9-9384-0b3fd6d3a139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_78772ff1-46d4-4fe0-a780-2774f2d395f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0a051f38-bee4-4f79-9621-4e1953f22fb0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_78772ff1-46d4-4fe0-a780-2774f2d395f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_92d9d264-7252-46ce-90f2-a8f0d40aafb6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_78772ff1-46d4-4fe0-a780-2774f2d395f9" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_92d9d264-7252-46ce-90f2-a8f0d40aafb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockOptionsDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b353ede1-be0e-4fb6-a813-dabc9c858932" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_00613227-3b78-4862-88fb-b6b4000d1e74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b353ede1-be0e-4fb6-a813-dabc9c858932" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_00613227-3b78-4862-88fb-b6b4000d1e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_710cfe71-79e1-43ee-bacc-34e9d62d4a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_00613227-3b78-4862-88fb-b6b4000d1e74" xlink:to="loc_us-gaap_AwardTypeAxis_710cfe71-79e1-43ee-bacc-34e9d62d4a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5ced2b90-3cd7-45b4-8c3e-1efcadecd7c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_710cfe71-79e1-43ee-bacc-34e9d62d4a6c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5ced2b90-3cd7-45b4-8c3e-1efcadecd7c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_OptionsToPurchaseCommonStockMember_f57e3022-b5de-49c2-8ed6-39e40b0b40b1" xlink:href="pacb-20250930.xsd#pacb_OptionsToPurchaseCommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5ced2b90-3cd7-45b4-8c3e-1efcadecd7c6" xlink:to="loc_pacb_OptionsToPurchaseCommonStockMember_f57e3022-b5de-49c2-8ed6-39e40b0b40b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2e39459-7f00-473b-a342-8d460c7c2c07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_00613227-3b78-4862-88fb-b6b4000d1e74" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2e39459-7f00-473b-a342-8d460c7c2c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d7682c07-5fa9-46db-ac1e-3badd9d9a2df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2e39459-7f00-473b-a342-8d460c7c2c07" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d7682c07-5fa9-46db-ac1e-3badd9d9a2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_7232ec4b-0cad-46ed-828a-000df7d44e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2e39459-7f00-473b-a342-8d460c7c2c07" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_7232ec4b-0cad-46ed-828a-000df7d44e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_26bb1d4d-7479-4f6a-9ac1-f5c7e6bb743a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2e39459-7f00-473b-a342-8d460c7c2c07" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_26bb1d4d-7479-4f6a-9ac1-f5c7e6bb743a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_270e3405-5b7d-49f7-9b87-74499c03b1cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2e39459-7f00-473b-a342-8d460c7c2c07" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_270e3405-5b7d-49f7-9b87-74499c03b1cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_998c2639-a587-4999-8381-fbc116922718" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2e39459-7f00-473b-a342-8d460c7c2c07" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_998c2639-a587-4999-8381-fbc116922718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_522c8a90-1be4-410d-bc4d-3d48af3ca7d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2e39459-7f00-473b-a342-8d460c7c2c07" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_522c8a90-1be4-410d-bc4d-3d48af3ca7d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_81a6c59a-e973-4b8b-87e9-f0c6a0f77908" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2e39459-7f00-473b-a342-8d460c7c2c07" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_81a6c59a-e973-4b8b-87e9-f0c6a0f77908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockPurchasePlanDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockPurchasePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_943fdbc4-0bef-47db-b123-508225b61047" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4c4077f-3c50-47df-a878-3e6182dcae91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_943fdbc4-0bef-47db-b123-508225b61047" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4c4077f-3c50-47df-a878-3e6182dcae91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5484f6e8-68e1-47ae-87b3-2021f1a0fc5b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4c4077f-3c50-47df-a878-3e6182dcae91" xlink:to="loc_srt_RangeAxis_5484f6e8-68e1-47ae-87b3-2021f1a0fc5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9a0e2b65-d3e4-4a81-9932-e3a2b0add0ef" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5484f6e8-68e1-47ae-87b3-2021f1a0fc5b" xlink:to="loc_srt_RangeMember_9a0e2b65-d3e4-4a81-9932-e3a2b0add0ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_51ff161e-fa6f-49bd-ac8b-fc1dcc76abda" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9a0e2b65-d3e4-4a81-9932-e3a2b0add0ef" xlink:to="loc_srt_MinimumMember_51ff161e-fa6f-49bd-ac8b-fc1dcc76abda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9c8495dc-a791-42a3-835d-cfd810219019" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9a0e2b65-d3e4-4a81-9932-e3a2b0add0ef" xlink:to="loc_srt_MaximumMember_9c8495dc-a791-42a3-835d-cfd810219019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_16700ca0-049c-48c5-855a-08d9388bf004" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4c4077f-3c50-47df-a878-3e6182dcae91" xlink:to="loc_us-gaap_PlanNameAxis_16700ca0-049c-48c5-855a-08d9388bf004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d7479c30-fd28-429e-bfc0-cac2f25aad00" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_16700ca0-049c-48c5-855a-08d9388bf004" xlink:to="loc_us-gaap_PlanNameDomain_d7479c30-fd28-429e-bfc0-cac2f25aad00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_EmployeeStockPurchasePlanMember_b189d79f-9d2d-4bc0-8717-5ca442495f69" xlink:href="pacb-20250930.xsd#pacb_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d7479c30-fd28-429e-bfc0-cac2f25aad00" xlink:to="loc_pacb_EmployeeStockPurchasePlanMember_b189d79f-9d2d-4bc0-8717-5ca442495f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_34489fb7-df00-466d-ba60-fb7abfd24141" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4c4077f-3c50-47df-a878-3e6182dcae91" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_34489fb7-df00-466d-ba60-fb7abfd24141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_242ad909-19d1-4c52-bea7-706d5ae3293d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_34489fb7-df00-466d-ba60-fb7abfd24141" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_242ad909-19d1-4c52-bea7-706d5ae3293d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_9459a471-c7b2-48e5-a5cc-2bcea324fcee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_34489fb7-df00-466d-ba60-fb7abfd24141" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_9459a471-c7b2-48e5-a5cc-2bcea324fcee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_5ae1b9fa-8695-4634-8275-32aa4bad13d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_34489fb7-df00-466d-ba60-fb7abfd24141" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_5ae1b9fa-8695-4634-8275-32aa4bad13d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_72eb76f2-3429-4e4b-93e9-0a0c54c1ccad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_34489fb7-df00-466d-ba60-fb7abfd24141" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_72eb76f2-3429-4e4b-93e9-0a0c54c1ccad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_4c88e4f4-5853-438e-9f07-35ef37d40024" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_34489fb7-df00-466d-ba60-fb7abfd24141" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_4c88e4f4-5853-438e-9f07-35ef37d40024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5cbf3dfd-b4c8-406b-bb07-be65ea2c98e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_34489fb7-df00-466d-ba60-fb7abfd24141" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5cbf3dfd-b4c8-406b-bb07-be65ea2c98e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_12830ef9-99db-4b70-aff6-7208c1be6118" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_34489fb7-df00-466d-ba60-fb7abfd24141" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_12830ef9-99db-4b70-aff6-7208c1be6118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f3d017b7-1623-4df2-a598-66370c8d46ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageRateOfTimeDepositsAbstract_3348b96e-8c84-4c65-bdbf-0c5d11b86cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageRateOfTimeDepositsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f3d017b7-1623-4df2-a598-66370c8d46ec" xlink:to="loc_us-gaap_WeightedAverageRateOfTimeDepositsAbstract_3348b96e-8c84-4c65-bdbf-0c5d11b86cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_5cc3391b-3cac-48a9-ac87-c9cca4d2e1be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageRateOfTimeDepositsAbstract_3348b96e-8c84-4c65-bdbf-0c5d11b86cc0" xlink:to="loc_us-gaap_NetIncomeLossAbstract_5cc3391b-3cac-48a9-ac87-c9cca4d2e1be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_62458a79-c240-42b6-a422-5930ada336f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_5cc3391b-3cac-48a9-ac87-c9cca4d2e1be" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_62458a79-c240-42b6-a422-5930ada336f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_97bd618b-2ee6-4a6b-bec7-f3ca17c06be5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageRateOfTimeDepositsAbstract_3348b96e-8c84-4c65-bdbf-0c5d11b86cc0" xlink:to="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_97bd618b-2ee6-4a6b-bec7-f3ca17c06be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_6e557db1-33cd-4839-8bda-f3eac5a17e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_97bd618b-2ee6-4a6b-bec7-f3ca17c06be5" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_6e557db1-33cd-4839-8bda-f3eac5a17e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f513a809-45d3-4019-b3a5-314fbe152e11" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_6e557db1-33cd-4839-8bda-f3eac5a17e0c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f513a809-45d3-4019-b3a5-314fbe152e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_9f32ef44-5c5a-47cf-baaf-38b19cfccad0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_97bd618b-2ee6-4a6b-bec7-f3ca17c06be5" xlink:to="loc_us-gaap_EarningsPerShareBasic_9f32ef44-5c5a-47cf-baaf-38b19cfccad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_9377f7ea-4aa8-432e-b312-784ff0d1f049" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_97bd618b-2ee6-4a6b-bec7-f3ca17c06be5" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_9377f7ea-4aa8-432e-b312-784ff0d1f049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ed91c436-1dc3-4497-a188-4ee1f9967b63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_9377f7ea-4aa8-432e-b312-784ff0d1f049" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ed91c436-1dc3-4497-a188-4ee1f9967b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1a679873-1d73-428c-a586-49e1308ffee4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_97bd618b-2ee6-4a6b-bec7-f3ca17c06be5" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1a679873-1d73-428c-a586-49e1308ffee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSharesExcludedFromComputationofDilutedNetLossperShareDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#NETLOSSPERSHAREScheduleofAntidilutiveSharesExcludedFromComputationofDilutedNetLossperShareDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSharesExcludedFromComputationofDilutedNetLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c1e61078-d1e7-474a-9492-1497cd250f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_af4cd243-62b8-4c63-81c4-928a5ee17b40" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c1e61078-d1e7-474a-9492-1497cd250f0a" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_af4cd243-62b8-4c63-81c4-928a5ee17b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a24270ba-5ef6-4a19-a21f-2f35955702ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_af4cd243-62b8-4c63-81c4-928a5ee17b40" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a24270ba-5ef6-4a19-a21f-2f35955702ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_45fd931e-5e8e-448a-8059-910e24e02dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a24270ba-5ef6-4a19-a21f-2f35955702ba" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_45fd931e-5e8e-448a-8059-910e24e02dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_f7c7b9f8-0984-48ed-b913-092eac48bcbd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_45fd931e-5e8e-448a-8059-910e24e02dc0" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_f7c7b9f8-0984-48ed-b913-092eac48bcbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_38e60370-29f8-407a-a86a-981915a2e8ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_45fd931e-5e8e-448a-8059-910e24e02dc0" xlink:to="loc_us-gaap_StockCompensationPlanMember_38e60370-29f8-407a-a86a-981915a2e8ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2a0b823c-a18e-4566-a5c2-0183117cf6a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_af4cd243-62b8-4c63-81c4-928a5ee17b40" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2a0b823c-a18e-4566-a5c2-0183117cf6a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_dd9470e8-8718-4096-a77d-adadd664499f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2a0b823c-a18e-4566-a5c2-0183117cf6a9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_dd9470e8-8718-4096-a77d-adadd664499f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_d1cfd3bb-055e-49f7-ab9d-f6488d99d402" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_658ab513-46f9-40c1-b541-343ef734fc4f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_d1cfd3bb-055e-49f7-ab9d-f6488d99d402" xlink:to="loc_us-gaap_NumberOfReportableSegments_658ab513-46f9-40c1-b541-343ef734fc4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_b750d469-04cd-4e28-8c5c-d12bf339ccc0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a684c5b2-5e22-4a5d-844b-3b28d77c1c64" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_b750d469-04cd-4e28-8c5c-d12bf339ccc0" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a684c5b2-5e22-4a5d-844b-3b28d77c1c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_5ea3f6b3-1bdd-450b-a8a5-64deb9547d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a684c5b2-5e22-4a5d-844b-3b28d77c1c64" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_5ea3f6b3-1bdd-450b-a8a5-64deb9547d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_88fa4684-85a0-4485-8d31-0992ec7b827e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5ea3f6b3-1bdd-450b-a8a5-64deb9547d3d" xlink:to="loc_us-gaap_SegmentDomain_88fa4684-85a0-4485-8d31-0992ec7b827e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ReportableSegmentMember_71cf826c-0e65-47d5-a7be-48a1abd7cb0c" xlink:href="pacb-20250930.xsd#pacb_ReportableSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_88fa4684-85a0-4485-8d31-0992ec7b827e" xlink:to="loc_pacb_ReportableSegmentMember_71cf826c-0e65-47d5-a7be-48a1abd7cb0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_2616a3d9-6c82-4a0b-b6fc-feb79aee774b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a684c5b2-5e22-4a5d-844b-3b28d77c1c64" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_2616a3d9-6c82-4a0b-b6fc-feb79aee774b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_0e8ea88e-befd-48c9-bb80-e1ee1ee4eae3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2616a3d9-6c82-4a0b-b6fc-feb79aee774b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_0e8ea88e-befd-48c9-bb80-e1ee1ee4eae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_f652306a-0ff4-4a60-8d82-6869389445d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2616a3d9-6c82-4a0b-b6fc-feb79aee774b" xlink:to="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_f652306a-0ff4-4a60-8d82-6869389445d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_739a96ad-143b-4899-8619-62f66b4f62ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_f652306a-0ff4-4a60-8d82-6869389445d7" xlink:to="loc_us-gaap_CostOfRevenue_739a96ad-143b-4899-8619-62f66b4f62ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_28539b92-17ee-4bb2-851c-17be26f559d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_f652306a-0ff4-4a60-8d82-6869389445d7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_28539b92-17ee-4bb2-851c-17be26f559d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_f597b1c0-77a5-4eff-a5c5-51f461c1d05c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_f652306a-0ff4-4a60-8d82-6869389445d7" xlink:to="loc_us-gaap_SellingAndMarketingExpense_f597b1c0-77a5-4eff-a5c5-51f461c1d05c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_9aecc34e-57a2-402b-a9f2-1a7d116a75aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_f652306a-0ff4-4a60-8d82-6869389445d7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_9aecc34e-57a2-402b-a9f2-1a7d116a75aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_823b4c22-133a-46ef-92b7-cbc8329c070d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_f652306a-0ff4-4a60-8d82-6869389445d7" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_823b4c22-133a-46ef-92b7-cbc8329c070d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_717bac7f-f5cd-4d09-b189-2cb135459da9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_f652306a-0ff4-4a60-8d82-6869389445d7" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_717bac7f-f5cd-4d09-b189-2cb135459da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_cc407e8a-6c34-427e-969a-95167d1b7bca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_f652306a-0ff4-4a60-8d82-6869389445d7" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_cc407e8a-6c34-427e-969a-95167d1b7bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_66364b41-ea54-4195-9697-f3a00bcb4245" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2616a3d9-6c82-4a0b-b6fc-feb79aee774b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_66364b41-ea54-4195-9697-f3a00bcb4245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a5caa3be-74f6-4a8c-86ed-a17c39a67d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2616a3d9-6c82-4a0b-b6fc-feb79aee774b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a5caa3be-74f6-4a8c-86ed-a17c39a67d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_45a269cf-10a7-4e2b-910a-ed10a30d3418" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2616a3d9-6c82-4a0b-b6fc-feb79aee774b" xlink:to="loc_us-gaap_NetIncomeLoss_45a269cf-10a7-4e2b-910a-ed10a30d3418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_eb86e2aa-b839-4b17-b3dd-8fad5224cc77" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_79b90f82-2785-452a-a415-c72e904becf8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_eb86e2aa-b839-4b17-b3dd-8fad5224cc77" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_79b90f82-2785-452a-a415-c72e904becf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_6fd06481-1fea-41ee-88e3-7748b07852c1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_79b90f82-2785-452a-a415-c72e904becf8" xlink:to="loc_srt_StatementGeographicalAxis_6fd06481-1fea-41ee-88e3-7748b07852c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1cba43bb-661e-4229-8f87-50b2129b5fff" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_6fd06481-1fea-41ee-88e3-7748b07852c1" xlink:to="loc_srt_SegmentGeographicalDomain_1cba43bb-661e-4229-8f87-50b2129b5fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AmericasMember_1d2471e9-9955-4281-8a20-46f3699ff52a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_AmericasMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1cba43bb-661e-4229-8f87-50b2129b5fff" xlink:to="loc_srt_AmericasMember_1d2471e9-9955-4281-8a20-46f3699ff52a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember_bbf27231-c138-43c0-8477-4073ac5edc4d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EMEAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1cba43bb-661e-4229-8f87-50b2129b5fff" xlink:to="loc_us-gaap_EMEAMember_bbf27231-c138-43c0-8477-4073ac5edc4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember_394d45ae-92cb-4b09-990c-d48cd4ee8b7e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_AsiaPacificMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1cba43bb-661e-4229-8f87-50b2129b5fff" xlink:to="loc_srt_AsiaPacificMember_394d45ae-92cb-4b09-990c-d48cd4ee8b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_7738ec1b-e3c6-441d-9244-36fef0588758" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_79b90f82-2785-452a-a415-c72e904becf8" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_7738ec1b-e3c6-441d-9244-36fef0588758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_a23fdde0-29d9-410f-ba1a-bd197e464f81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_7738ec1b-e3c6-441d-9244-36fef0588758" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_a23fdde0-29d9-410f-ba1a-bd197e464f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails" xlink:type="simple" xlink:href="pacb-20250930.xsd#SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails"/>
  <link:presentationLink xlink:role="http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_c2d2f3de-0456-466b-830c-421290545019" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_b47fd0d8-0450-47a7-af3e-df5b0489f695" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c2d2f3de-0456-466b-830c-421290545019" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_b47fd0d8-0450-47a7-af3e-df5b0489f695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f7803669-c168-49d0-b057-89a64d799673" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_b47fd0d8-0450-47a7-af3e-df5b0489f695" xlink:to="loc_srt_ProductOrServiceAxis_f7803669-c168-49d0-b057-89a64d799673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_32a9b750-142e-4259-a773-8d5dc6ec0226" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_f7803669-c168-49d0-b057-89a64d799673" xlink:to="loc_srt_ProductsAndServicesDomain_32a9b750-142e-4259-a773-8d5dc6ec0226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_ba549640-0dae-4f95-9996-2e5b532034f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_32a9b750-142e-4259-a773-8d5dc6ec0226" xlink:to="loc_us-gaap_ProductMember_ba549640-0dae-4f95-9996-2e5b532034f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_InstrumentMember_d112c321-1b42-4b12-996d-8c1d655411a6" xlink:href="pacb-20250930.xsd#pacb_InstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_ba549640-0dae-4f95-9996-2e5b532034f3" xlink:to="loc_pacb_InstrumentMember_d112c321-1b42-4b12-996d-8c1d655411a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ConsumableMember_4c482de8-f5f5-4436-b55c-8bfcbc2f6076" xlink:href="pacb-20250930.xsd#pacb_ConsumableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_ba549640-0dae-4f95-9996-2e5b532034f3" xlink:to="loc_pacb_ConsumableMember_4c482de8-f5f5-4436-b55c-8bfcbc2f6076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pacb_ServiceAndOtherMember_75808362-5e13-4d4e-8276-7a3681ece986" xlink:href="pacb-20250930.xsd#pacb_ServiceAndOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_32a9b750-142e-4259-a773-8d5dc6ec0226" xlink:to="loc_pacb_ServiceAndOtherMember_75808362-5e13-4d4e-8276-7a3681ece986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0dda7d01-b30d-4447-b2cd-6d33a07db4c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_b47fd0d8-0450-47a7-af3e-df5b0489f695" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0dda7d01-b30d-4447-b2cd-6d33a07db4c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_6c8708d7-d8a6-4bf9-aec6-426848f96924" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0dda7d01-b30d-4447-b2cd-6d33a07db4c1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_6c8708d7-d8a6-4bf9-aec6-426848f96924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>pacb-20250930_g1.jpg
<TEXT>
begin 644 pacb-20250930_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  ^ 08# 2(  A$! Q$!_\0
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M^UZAYC//M."ZA& 53V)R<$$@=!]%? 7XW67QP\&C5X+4Z??02_9[RS9MWE2
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MHYSJ\(_4U]'@9<F&YNUS]KX6K/#Y![=*[CS/[CD?^%5^-?\ H3_$'_@KG_\
MB*?'\*/&\KK''X,\0/*YPJKI<Y8_0;:_=98UQ\J@#Z4[RQZ#\JX?[4E_*?,?
M\1 Q%M*$?O9^0GPC_84^*'Q*O(&U#2)/"&C,5,E]JZ%) O&0D!^<MCH"%!QC
M(K]0?@W\(- ^"/@:R\,^'X62WAS)-/)@RW$S8WR.1U8X_   <"NYVX]J.%&.
MU<&(Q=3$:/1'QN<<0XO.+1K/E@NB/Q)_:;UB;6_VA/B+<3%G=-<NK?+==D4A
MB4?]\H!^%?=G_!,3PG86'P;UK7TC5M2U'57ADFQ\WE1(FQ/IEG/_  *OC?\
M;2\#S^!_VD/&$,B.(-3N?[5MY&7&]9QN8CV$GF+[E#7N/_!.']H;3/!]QJ7P
MZ\07D-A:ZC<B]TNZF?:K3E51X2Q. 6"H5'&2&')(%>YB8N>#7(?J>=4ZF,X<
MIO#*ZM%NW9+4_2'CZFN1^+GA&P\>?#3Q-H.IQ+):7MA-$V]0=C;3M<>ZMA@>
MQ4&NM616&=P(KY__ &R/VA=*^"_PQU&T2XCE\3ZQ;R6FGV<;CS%WJ5,S#LB=
M<]S@?3YRC&4II16I^+Y?0JXC%TZ=%/F;5OO/Q]7G&/6OVK_9GD\C]FGX?28)
M"^'[4\?]<A7XJ_=SZU^UW[+_ .\_9S^'*$<?V#:?^BQ7OYEI3A?N?KO'7NX/
M#J7\WZ'XO:UJT^O:U?ZG=,6NKR>2XE9CDEV8L?U)K]<?V$/"=AX;_9H\+RV:
M+Y^IB6_NI0,-)(\C ;OHH5?^ U^6_P ;/ $WPO\ BQXI\,2PM!'I]_*EN&'W
MK<DM"WT*,IK[G_X)U_M':-<>"XOAKKNH0V.LV,S?V4+A@@NX78OY:D]9%8O\
MO4J1C.#3QT74PZY-CHXKI5<7DU*IAKN*LW;M;]#[DV@]>U4->\.:5XJTN;3=
M9TVTU;39L>99WT"S1/A@PW(P(." >1U J]N)YXQBO ?VJOVLM*_9VT"".T%K
MK'BV[D7[/I+2'Y(MWSRR;>57 ('JQ&,@-CYVG"=25H+4_%<)AJ^+KQHX>-YO
M:W]:'N]CI=GI=JEO9VT5K!&-J10H$50.P X KQC]M ?\8\>(S_TTM#_Y,Q5Y
M7\*/^"D_A+QMJFGZ/KOAO5M!U6]G2"+[*!>P,[L%4 J%DR21P(S7J?[9S%OV
M=O$9(Q^\M/\ TJBKMHTJE/$04][GT&"P.+P&;X:.*BU)SCOUU1^:/8=N*^Z-
M+_X)_P#A2^T^VN'\1ZRAEC5R!Y..1G^Y7POZ'%?L9X=EC_L'3AN7_CW3O_LB
MO?S3$5:*BZ;M<_8^/LVQ^5^P>"J.'->]OD?,O_#O7PE_T,FM?^0?_B*\U^-/
M[$-QX%\+WFO^&=7EU:"QC::YL[Q LOE*,ED9>"0.<$#@'!SP?O3SDXY7ZYKS
MWXW?$[0OAW\/]6N]5NHA++;20VUHS#?<2$8"*.IY(SZ#)->+1QV*=1>\V?FF
M6\6<03QE*,:LIW:TM>_X'Y@>"_&&I^ ?%&G:_HT_V:_LY1)&_.UQW5@",JPR
M".X)K]9?A_XPMO'_ (+T;Q#:?+!J-LEP(^Z$CE3[@Y!^E?C^?4_Q<YQ7Z@?L
MDZ==:7^S_P"$X[P,))(9)DW?W'FD=,>VUEKU,XIQ<(U'N?=^)6$H_5J&+:M4
MOR_*U_S/SV^.7_)9?''_ &&;O_T:U?</["W_ "0N+_L(7'\Q7P]\<O\ DLOC
MC_L,W?\ Z-:ON+]A7_DA<?\ V$+C^8J\P_W./R.GC*_^K.'_ .W/_23Y#_:R
ML9+#]H#Q8KAL220RJ3W!@CZ>V<C\*\BK[(_;^^&5U_:&C^.+6+S+7RAI]YM'
M,;!F:)C['<RDGT0=Z^-^P]*]+ U54H1DC[CA3&PQV34)Q>J2B_5:!1117<?6
MA1_G_"BI+>"2ZGCAAC:2:1@B*HR2Q. /S('XTFTDV^@.2A%R;LNI]Y?\$]+-
MX_ASXCNFW!)=5V*", [8H\D?]]8_"BO9OV??ANWPK^%6BZ%-C[:L9FNR.?WS
MDLPSWQG;GT445^?8JHJE><UU9_&6?XR&/S3$8FG\,I.WY'S'_P %4/\ DG_@
MO/3^U'_]%-7QC^RF0/VCOAV<X_XG$7.>G6OUT^+7P.\&_'#3;&P\9:6^J6UE
M,9X%2YE@*.1@G,;*3QZUQ'A']B;X/^!?$VG>(-%\,S6FJZ?,L]M.=2NGV..A
MVM(0?Q%=U'&0IT'2>Y]3E?$N%P64RP%2+<FI:JUM3W).1UI:%7;2UXQ^;";:
M39[TZB@#YA_;@_9AF^/'@VVU30(U/C'1$<VD3$*+R%B"\!8]&^4,A/ ;(. Q
M8?E#J6EWFBZC<Z??VLUE>VTACFMKB,I)'(IP0RD9!!SP1^%?OTR[N<D5YE\5
MOV:_AW\:-LGBGP[!=WRC":A 3!<KZ#S$PQ ]#D>U>MA,=[%<DU='Z%P]Q2\K
MI_5<3'FI].Z_S1^2FC_M,?%7P_I*:;8^/=<BLU3RDC:Z9RB]@K-EEQVP1@<=
MJX>2;6?&WB#?+)>Z[KE_*!EV>XN)W)]3EF/2OTX;_@F'\)6N!(-3\5)'Q^X6
M^@V'\?(W?K7L_P *_P!F/X<?!M7;PSX=AM[QUVO?W!,UR1@ @2-DJ#CD+@>U
M=TL?AX:TUJ?65>+\HPJ<\'1O-^27XGXE]>H)[@8]J_;']EOG]G7X<\C_ ) 5
MH,C_ *Y+7*G]@SX&G_F25'_;_=<?^1*]K\+^%]-\&>'=/T/1[?[)I>GPK;VT
M&]GV1J,*N6))P/4UPXS%QQ$4DCY/B7B/#YU0ITZ4&G%W=[=CYE_;<_9)'QNT
M=?%'AF)4\;:;!Y8A+!5U" $GRCG@.,DJQ_W3P05_+/4M-O\ P_JD]E?VUSIV
MI6DA2:VN(VBFA<=0RD!E(/L*_?G9SG)KSCXH_LZ_#SXR+N\5^&K74+H*%6]3
M,-RH'( E3#8![$D>U&%QSHKDFKH>0\5RRVG]5Q4>>GT[K_-'Y(6O[3?Q9L-+
M6PB^(>OK;+P-UZYD Z8$A^8#VSBO/+R^O=<U!KF[N+B_O[B3+33NTLLC$\Y)
MR2<X]:_46?\ X)D_".:[$JWGB:&+)_T>._BV')SC)A+<?[U>J?#']D?X6_"6
M\BOM!\,PMJD?*ZA?N;F=3_>5GSL/NH%=_P#:&'IZTUKZ'UM3C#*,*G/"4;R?
ME;[SYD_83_8ZO] U.T^(WCBR>RO8EWZ1I,RX>(D8\^4=FP3M4\C.3R!CZ'_;
M.(_X9Y\1J>,R6A_\FHJ]S\L#&.,=*Q/&7@?1OB!X>N=#UZS^W:9<[?-@+LF[
M:P9>5(/#*#U[5Y#Q,IUE5GT/S6IG=7%9I3S#$ZJ,D[+HD[V1^/0[?Y^O-;2^
M-/$*J%&OZF !@#[;+Q_X]7Z0?\,=?"7_ *%?_P G9_\ XNC_ (8Z^$O_ $*_
M_DY/_P#%U] \VH2WB?L<_$;*JO\ $P\GZJ+_ %/S?_X3;Q%_T'M4^OVV7_XJ
MLV\U"[U*8S75S-=2GK)+(7)^I)K],O\ ACKX2_\ 0K_^3D__ ,76MH?[,/PP
M\/7 GM?"-C)(.0;Q3< >A D+8J?[5P\=8PU,EXAY12]ZEA6I>D4?"/[/_P"S
MGK7QBUVUN)[::R\*QR!KK4&7:)5'.R+/WB>F<8&<GG /Z::9I\&D:=;6-I$D
M-K;1K%%$@P$11@ #MP!4UO90V<:QPQK%$HPJ(H 'T%2A ,5X6+QD\5)7T2/R
M?B'B+$\0UU4JKEA':/;_ ()^2OQP_P"2R^-LG_F,W?;_ *;,*^X?V%#_ ,6+
MC_["%QW]Q78:Y^RK\,O$>M7VJZAX=\^_O9GN)Y1=2KO=B2QP& Y)KN/ OP]T
M+X:Z$NC^';,V&G+(THA\QG^8XR<L2>U=F*QT*U!4DM58^FS[BO"YKE%++Z4)
M*4>75VMHK=RWXH\.:=XPT.]T?5K6.\T^\B,4T,@R&!_D1U!['!'2OS:^//[,
MOB'X-ZA/=PQ2ZMX69LPZE$F3 #T2<#[I' W?=/!!!.T?ITT8;&:CGLXKJ-XY
ME\R-P59&Y4@]L5R83&5,)+W=4SYOA[B3%</UG*C[T);Q>S\UV9^,?%'MW^E?
MISXM_8]^&'BZY:Y?1&TJ=CDMI4OV=3_P #9_X[7+6?[ ?PTM9F>2ZU^Z4](Y
M;R(*/;Y8@?UKZ*.;4&M;H_:J/B-E,Z?-4C*,NUK_ (GYZV=G<:C=16MK!+=7
M,I"I# A=V)[!>I/^?3/VY^RK^R9<^&;RS\9>,K=4U%1YECI;C+6Y[229_C]!
M_#U^]P/H/P%\"_ _PSVMX?T&WL[A05%VX\R?!QD>8V6P<#C-=X(P/>O,Q>:2
CJKDI:(^!XBX\K9G2>%P,>2#W;W?^2!!A<44H&**\ _)3_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>pacb-20250930_g2.jpg
<TEXT>
begin 644 pacb-20250930_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  T .\# 2(  A$! Q$!_\0
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M;OA3]J#X7^,KI;:P\76<-RV (M05[0DGHH,JJK'V!-?E?17LO)Z%K*3O\O\
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M>_;,U;QEXDU3P#X-OY-/\,6,KVM_>6[;9-0E4E74,#_J0<C ^]C)R,"ONO\
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MI[94XR.:^9]0_P""9_P]U;XA:IKL^K:E;:'=SFXAT#3T2".#/+(),,=F[.%
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M5JPC%-7:<FUZ>ZM>VIYE7ZO_ +.]Y<7_ ,#?!$UUDS?V5"F6.255=JG_ +Y
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5]%%?#-N3NS^3YU)U).<W=O=O<__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>pacb-20250930_g3.jpg
<TEXT>
begin 644 pacb-20250930_g3.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@!
M,@%8 P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HHHH ***^=/^"F7_  4J^!'_  3(_9NUKXY?%+7M
M#O-:M+,3>&_ EUXHM]/U#Q'()8T>*T60,\A4.78JC8"G..M 'T717(? CX[_
M  G_ &E/A=I7Q@^"OQ#T+Q/H.JVZO#J?AW68;^V$FT%XO-A8KO0G:R\$$8(!
MXKSOQ/\ \%.O^"<O@OXGO\%O%W[=?PETSQ7%=_99]"OO'^GQW$%QG;Y$BM*/
M+ESQY;8;) QDB@#W.BJ.N^)_#7A;P[=>+_$WB&QT[2;&T:ZO=4O[M(;:W@5=
MS2O(Y"H@4$EB0 .<UY1\$?\ @HI^P5^TIXZD^&/[/W[97PS\9^(T5W&A^&_&
MEE=W4J)DN\<4<A:55 R60$ <DX(H ]EHHJ'4-0L-)L)]5U6]AMK6VA:6YN;B
M4)'%&H)9V8\*H ))/  H FHK@O@'^U/^S3^U3HE_XE_9G^/G@_Q_IVEW8M=2
MOO!_B&WU&*UF*AQ'(T#L$8J0<'G!S6A\:OCU\$?V;O TGQ-_:"^+?ASP3X<B
MN8[>37?%.L0V-HLTAPD9EF95#,00!G)H ZVBN6^#?QO^#?[1'@*U^*?P%^*G
MA_QGX:O998[37_#&KPWUG,\;E)%66%F4E74J0#P1@UR7Q3_;J_8M^!WQ0L_@
MG\9?VK_AWX5\8Z@MNUCX6\0>,+.TU"X$[E(2D$D@=M[ JN!\QX&: /5J***
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M/U(>+/V@/B.EMX/^&6GV%D/.U77I8XX9M02WR?DB9Q($^8&66"(\29K\PO\
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MM3X7>)/%QE>*+P[HGCFQN;N>1,[TBC24F5EP<A-Q&#G&#7R9_P '5?QU\=?
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M6%S=Z39[+&TC!,<!W2)!,+T20(&<27"S>60ZL?Z(*_&C]L#_ (+$>*_V1?\
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M5_#<W,UG:1OO.YTM3Y#R+(P#31*TC;2PY']L7_@O!^PY^VS^P;\2?@1^VO\
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M,NO#Q'\/?$^@:(+J/48(KR_N;>-"SHKEH]2:)R&Q'- 5?:#N'K'_  ;G:/\
M$?\ 9X^ G[8'_!93X_?!SQ+I?A_XE:O=>+?#WAJVTXMJ-]IMB=2U">2VB;;Y
MBR->B*-B55C QR%^:OVFU+2-*UF%;?5],M[J-)%D2.YA615<'(8!@<$=C5B@
M#\E/^"C_ (XU;_@X'_X-Z]<^.?[)7P:\5V>K6^O1ZUI'@[5[13>W[:9=M%=)
M;^46%QF!YWCV9+NGE@;^*^$/VS?^"L'AO_@J+_P2F^!__!(/]ESX#>/-6^.J
MW'AS1O%6@2:'L@LWTJU-M)(L@<G:\RQOEE58H_,,K(4Y_I8BBCAC6&&-411A
M548 'H!4,&D:5:WTVJ6NF6\=S< "XN(X5$DH'3<P&6Q[T <=^S%\(Y/V?_V:
M_AY\!I;Y+I_!/@;2= :YC!VS&SLXK<N,]CY>?QK\0?V0/@5X3_:G_P"#DO\
M;\_9A\?*#H?CWX->)M'U!M@8PB:_T*-9E!_CC+[U/9E![5^^]% '\YO_  ;A
M?L[_ +27QS_X*0[?VJU>XT_]A;P7JG@_0+.>,LEIK%QJ.H)'$V[AV02ZAM?
M*K:VHQ\@->^?\&1CM)^R3\;)'8EF^)%F23W/V!:_;:B@ HHHH **** "BBB@
M HHHH **** "O,_VPOV2O@[^W-^SIXB_9:^/NG7MUX3\4+;+JL6FWIMYSY%S
M%<QE) "4/F0IDCJ,CO7IE% "1QQPQK%$@55 "JHP !T %5WT71Y-437)-)MF
MO8XS''>- IE5#U4/C(!],U9HH *K6&BZ-I4\]SIFDVUM)=2;[J2"!4:9O[S$
M#YC[FK-% #3%&T@F:-2Z@A6(Y .,C/X#\J=110 4444 %%%% !1110 4444
M%%%% !117S/_ ,%6_P!H+XO?LU_LRVGQ"^"GB[^Q=8E\66MG)>?8+>YS \-P
MS)LGC=>2BG.,\=>371A<-/%XB-&#5Y.ROL>5G>;X;(,IK9CB$W"E%R:C9MI=
MKM*_JT?3%%?B9_P]T_X*&?\ 1P?_ ):>D_\ R)1_P]T_X*&?]'!_^6GI/_R)
M7TG^IV9_SP^^7_R)^/\ _$P?!G_0/B/_  "G_P#+3]LZ*_$S_A[I_P %#/\
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MP4,_Z.#_ /+3TG_Y$H_X>Z?\%#/^C@__ "T])_\ D2OFZBNC^R\L_P"?$/\
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M_P /=/\ @H9_T<'_ .6GI/\ \B5\W44?V7EG_/B'_@,?\@_UVXS_ .AEB/\
MP=4_^2/I'_A[I_P4,_Z.#_\ +3TG_P"1*/\ A[I_P4,_Z.#_ /+3TG_Y$KYN
MHH_LO+/^?$/_  &/^0?Z[<9_]#+$?^#JG_R1](_\/=/^"AG_ $<'_P"6GI/_
M ,B5^C?_  2D_:"^+W[2G[,MW\0OC7XN_MK6(O%EU9QWGV"WML0)#;LJ;((T
M7@NQSC//7@5^*=?KS_P0P_Y,RO\ _L>K[_TGM:^>XFP."P^6<]*E&+NM5%)_
M@C]9\%^)>(LUXT5#&XRK5A[.;Y9U)R5U:SM)M71]ET445^=']<!7QI_P7/\
M^3,K#_L>K'_TGNJ^RZ^,/^"[%W;V?[%MA-<R;5_X3NQ&<$\_9[OTKU,D_P"1
MM1_Q(^7XVRO,\[X3QF RZA.O7J0<84Z<93G.3V4813E)OLDV?D515/\ M_2?
M^?O_ ,AM_A1_;^D_\_?_ )#;_"OV _D+_B!?C;_T3&8_^$6)_P#E1<HJG_;^
MD_\ /W_Y#;_"C^W])_Y^_P#R&W^% ?\ $"_&W_HF,Q_\(L3_ /*BY15/^W])
M_P"?O_R&W^%']OZ3_P _?_D-O\* _P"(%^-O_1,9C_X18G_Y47**I_V_I/\
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M_80HHHH _!+]NO\ Y/-^*/\ V/6I?^E#UY177?\ !0#_ )/?^+'_ &/^J?\
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MK]KP7^YT_P#"OR1_J3PS_P DY@O^O5/_ -(B%%%%=)[84444 %%%% !1110
M4444 %%%% !1110 5^S/_! K_DR#4/\ L?[_ /\ 2:TK\9J_9G_@@5_R9!J'
M_8_W_P#Z36E?-<6?\BE_XE^I^&?2'_Y-V_\ K[3_ /;C[;HHHK\P/X."OB3_
M (+Z_P#)D&G_ /8_V'_I-=U]MU\2?\%]?^3(-/\ ^Q_L/_2:[KU,D_Y&U'_$
MC[[PM_Y.)EG_ %]B?C-1117[ ?Z3!1110 4444 %%%% !1110 4444 %%%%
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M5_0M7\]/_!/_ /Y/?^$__8_Z7_Z4I7]"U?GO&7^]TO\ #^I_&?TFO^2CP/\
MUZ?_ *6PHHHKXT_F<**** /YZ?\ @H!_R>_\6/\ L?\ 5/\ TI>O(:]>_P""
M@'_)[_Q8_P"Q_P!4_P#2EZ\AK]KP7^YT_P#"OR1_J3PS_P DY@O^O5/_ -(B
M%%%%=)[84444 %%%% !1110 4444 %%%% !1110 5^S/_! K_DR#4/\ L?[_
M /\ 2:TK\9J_9G_@@5_R9!J'_8_W_P#Z36E?-<6?\BE_XE^I^&?2'_Y-V_\
MK[3_ /;C[;HHHK\P/X."OB3_ (+Z_P#)D&G_ /8_V'_I-=U]MU\2?\%]?^3(
M-/\ ^Q_L/_2:[KU,D_Y&U'_$C[[PM_Y.)EG_ %]B?C-1117[ ?Z3!1110 44
M44 %%%% !1110 4444 %%%% !1110!Z]_P $_P#_ )/?^$__ &/^E_\ I2E?
MT+5_/3_P3_\ ^3W_ (3_ /8_Z7_Z4I7]"U?GO&7^]TO\/ZG\9_2:_P"2CP/_
M %Z?_I;"BBBOC3^9PHHHH _GI_X* ?\ )[_Q8_['_5/_ $I>O(:]>_X* ?\
M)[_Q8_['_5/_ $I>O(:_:\%_N=/_  K\D?ZD\,_\DY@O^O5/_P!(B%%%%=)[
M84444 %%%% !1110 4444 %%%% !1110 5^S/_! K_DR#4/^Q_O_ /TFM*_&
M:OV9_P""!7_)D&H?]C_?_P#I-:5\UQ9_R*7_ (E^I^&?2'_Y-V_^OM/_ -N/
MMNBBBOS _@X*^)/^"^O_ "9!I_\ V/\ 8?\ I-=U]MU\2?\ !?7_ ),@T_\
M['^P_P#2:[KU,D_Y&U'_ !(^^\+?^3B99_U]B?C-1117[ ?Z3!1110 4444
M%%%% !1110 4444 %%%% !1110!Z]_P3_P#^3W_A/_V/^E_^E*5_0M7\]/\
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M110 4444 >O?\$__ /D]_P"$_P#V/^E_^E*5_0M7\]/_  3_ /\ D]_X3_\
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M_$<O"W_H8?\ E*O_ /*CXYHK[&_X<[?&S_H#^.__  AK;_Y94?\ #G;XV?\
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M=HIIO^D?7\ YI@<EXSP..QL^2E3J1E*5F[);NT4V_DFS\;:*^QO^'.WQL_Z
M_CO_ ,(:V_\ EE1_PYV^-G_0'\=_^$-;?_+*OTC_ %ER3_G[_P"2R_R/[<_X
MCEX6_P#0P_\ *5?_ .5'QS17V-_PYV^-G_0'\=_^$-;?_+*C_ASM\;/^@/X[
M_P#"&MO_ )94?ZRY)_S]_P#)9?Y!_P 1R\+?^AA_Y2K_ /RH^.:*^QO^'.WQ
ML_Z _CO_ ,(:V_\ EE1_PYV^-G_0'\=_^$-;?_+*C_67)/\ G[_Y++_(/^(Y
M>%O_ $,/_*5?_P"5'QS17V-_PYV^-G_0'\=_^$-;?_+*C_ASM\;/^@/X[_\
M"&MO_EE1_K+DG_/W_P EE_D'_$<O"W_H8?\ E*O_ /*CXYHK[&_X<[?&S_H#
M^.__  AK;_Y94?\ #G;XV?\ 0'\=_P#A#6W_ ,LJ/]9<D_Y^_P#DLO\ (/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OS,^*&I_M"?
M\%=O^"G'Q5_8N\'?M/\ CGX3_ ?]G>PTNT\;7/POUC^S-;\8>(K^)IA;_;@I
M>&TA1)$=%'S,ASGS$:+],Z_-'_@G%XET7]F/_@N!^V3^RK\6=1BTG7?BOJVA
M_$#X;?;7$8\0:<UK.MV+<MCS&@D?847)_=3$#$;&@#)UO3/CS_P1*_;G^!WA
M#3OVL/B-\4?V>_C_ .,AX&U+0/BSXA.L:CX3\17 SI\]E>NHD$$KDJT+?*H6
M1CN8H4]H_:!_8%_:X_;A_;9\4WO[0W[3OC;P'^SWX;T/3X/AKX2^$'CN;1KW
MQ!J,D>^^O=6E@42[8I/W<4(<J0$<;2'#^7?\%O?$>C?'_P#;6_8L_8/^'&HQ
M:EXVB_:(TGXBZ]IEDXDFTG0='262>YG _P!2KI))Y9;&\PL!G%>__&;6?V$/
M^"H/Q2^(_P#P3,^+4WB67Q'\);S2=:\0Z);:S?:%.WVJUD:VNK6>UFCDNH5C
MGP^"8U:6,,"2M 'DG_!'3XD?&3PE^V+^U3^P#KGQ^\4?%KX=?!3Q!X?7P%X[
M\9:I_:.IVKZA8O/>:/<7V,W36TJ",;LO'M8-C*JOOG_!4F#]O;6OV6F\!?\
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M)>$?$5AXKT#]F[7H;_3+V*[LIG^,'BN01S1N'1BCZH58!E!PP(/0@BOM*B@
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MB7_P4\UW]@W]@O7_ (1Z)I7@KX0Z;XI\6Z]\2O#&HZBXU&\OIXH[2/['>0A
M;=8I!N!/#\\C&I^R[^WQ^U%X&_;*\;?L$?\ !233_AK:^(?#GPD'Q.T3XB_#
MI[NTT>\\.I>FRN3=V]])(]I-#,,D^8R,@9OEVC=X1^3'VO17D?P:_;X_8M_:
M(\5:IX*^!7[3W@OQ;J6B>'H-=UB#0=<BN5LM.F56CN970E$1E96Y((# D $&
ML_X#?\%(OV!_VH?B9??!K]GC]KWP!XR\4Z<DCSZ'H'B2"XGD1/OR1!6_?HO\
M3Q;E&1DB@#VRBO(?VE?V_/V*?V.=6TK0/VI?VHO!/@34-;7?I6G^(]>BMY[B
M/=M\T1D[A$&!!D(" @@M7SM^QE_P4@7XC?%?]KO]H3XY?M(>'K3X _#3XEZ5
MX4\!:M>26,&F:48+"W6_F%]&@:X%Q=W<!#2R2 %D6/:&P0#[GHKF?B%\9_A/
M\)KGPY9?$SXAZ3H4WB_Q!!H7A>'5+U86U34IE=HK2 ,<R2LL;D(.<*?2O/?V
MB/\ @HQ^PA^R7XVT[X;_ +2W[6W@+P3K^J(LEIH_B#Q%#!<>6QPLLB%LPQ$@
M@22;4.#SP: /:**^1?\ @I5_P6,_9C_X)S^$_"ESKGB_PGX@\3>,M9T:/1O"
M]QXUAT]GTB^NC"^M&7RYO]#A599#)LV-Y>-RYW#ZD\">.O!WQ/\ !.D?$CX=
M^);/6M U_38-0T36-.G$MO?6DR"2*>)QPZ.C*RL."""* -:BOF[_ (*Z?\H\
M_B#_ -PG_P!.UG7XF5])D_#W]K85UO:\MG:W+?HGW7<_'?$'Q8_U$SJG@/J?
MMN:FJG-[3DM>4XVM[.7\M[WZ[:'](E%?S=U^V?\ P2+_ .4>?P^_[BW_ *=K
MRC..'O[)PJK>UYKNUN6W1ON^P>'WBQ_KWG53 ?4_8\M-U.;VG/>TH1M;V<?Y
MKWOTVU/I&BOEG_@I3^W%\7_V9M>^$W[.'[+G@/P]KOQ<^.?BNYT7P2WC.ZFA
MT72HK2V^TWM_>>01+*D417$,95Y"W#97:W(?"_XX?\%1_P!G3]K_ .'O[/G[
M:.E^"/BAX(^*D&I16'Q#^%O@O4=,?PCJ5I;BX$.I1237$7V69?W4,VY&\S.[
MMGYL_8C[5HKQ7X@_\%'_ -@?X4_'*U_9H^)/[8/P\T3Q[>7$4$7A74?%-O'=
MI-+CRHI%+?NI'RNU'*LVY< [AG:_:"_;8_9%_91N([/]I3]H[P?X'GFTF;4X
M+?Q)KD-K)-:12)&\J(Y#.!))&GR@DLZJ 20* /4**X;X+?M,? #]HN*_D^!G
MQ=T+Q2=+M["?4X](OEE>SCO;5+NT:5!\T?FV\B2IN W(P(KR[X__ +7FB>*/
MAAHM]^R%^U=\(K#6M6^+UAX+M=4\87;W=A?:@ES_ *=H]N+>13)?F&.940$X
M92#MQN4 ^BJ*\<_:4_X*$_L/?L=Z_IOA3]J+]JKP1X&U76(Q)IVE^(=>B@N9
M8BQ43>43O6+<"/,8!,@C/!KM_%WQY^"'@'X1R?'[QM\7_#.E>!H]-CU!O&-_
MKD$6F?99 ICG%RS^6R.&7:P8AMRXSD4 =917FG[,_P"V3^RK^V7X<O\ Q9^R
MO^T!X6\>V&E70M]4F\-ZM'<-9RL"565 =T>X E=P&X D9 KJ_BE\5_AA\$/
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M6Q$INU,<9)3RO(GR6P,PN!DJ0/9: "BBB@ HHHH _,7_ (..?^:-_P#<P_\
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ML/%K_"32KJSTJ2=I[G5XA=I<SRN]W'!:/&6+#$850HVG/FWB;]FSX4?LT_\
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M+XM.L'Q%HZZ[?227C:JTK7[FZDG:X5I3-)\RR ID;"FU< 'XL^&?!OQKU/\
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# ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>pacb-20250930_g4.jpg
<TEXT>
begin 644 pacb-20250930_g4.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?YA_Q WPM_Z%_P#Y5K__ "T_3K_B(Y_ZLW_\R'_][Z/^(CG_ *LW_P#,A_\
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MM7\]/_!/_P#Y/?\ A/\ ]C_I?_I2E?T+5^>\9?[W2_P_J?QG])K_ )*/ _\
M7I_^EL****^-/YG"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *^)/\ @OK_ ,F0:?\ ]C_8?^DUW7VW7Q)_P7U_Y,@T_P#[
M'^P_])KNO4R3_D;4?\2/OO"W_DXF6?\ 7V)^,U%%%?L!_I,>A_LM_M+?$/\
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MO%?Q<\,PJ?$VJVEQY\T$0M@DJRR'Y\R2^61OPS^27(&>?-?^"%W_ "?OI_\
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M444#"BBB@ HHHH *_9G_ ((%?\F0:A_V/]__ .DUI7XS5^S/_! K_DR#4/\
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M/^12_P#$OU/PSZ0__)NW_P!?:?\ [<?;=%%%?F!_!P5\2?\ !?7_ ),@T_\
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M]?:?_MQ]MT445^8'\'!7Q)_P7U_Y,@T__L?[#_TFNZ^VZ^)/^"^O_)D&G_\
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M3_O[KG_R;1_PXOT'_GP\"?\ ?W7/_DVC_7'+/Y)_='_Y(/\ B97@7_H&Q/\
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MO1;^&[L[RW2>TNK>0/'-$ZAE=6'#*0001P0:GH **** "BBB@ HHHH ****
M"BBO#M:_X*:?\$Z_#?Q6;X&^(/VYOA/9>+X[S[)+X>NO'U@ES'<YQY#J9?DE
MSQY9P^2!C)% 'N-%-DG@A@:YEF18U0LTC, H4#))/IBO%_AS_P %(/\ @G[\
M8/BI_P */^%?[:WPM\1>+VF:&'PYHWCFQN+N>5?O1Q1I*3*ZX.53<1@Y'!H
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M+G\*Z1INO?M ?$']FC3W\/76JS1*9)9-0F#7$L)E9PLYC.\+D J-U?I5I/\
MP4Q^$_[3O['OQ*^,_P#P2=U;0_C+XB^'>E?Z!X6@M+RRANKI(_-2Q4211MO>
M%'$80$%]B\9KXS_X*(?\%K?V(OV[_P#@E_XL_9;^#Z:OXJ^.?Q8\-1^'-.^!
MEOX4OFUK3=?E:,/%/$\(6/[)*&D\PMM)@!4DD4 ?K;H<6B0Z+9P^&H[5-.2U
MC73TL0H@6 *-@C"?*$VXQCC&,5:KSO\ 9#^&/BOX)_LG?"_X,^/+];K7/"/P
M[T31=9NDEWB:[M;"&"9PW\0+QL<]\UZ)0 4444 %%%% !1110 4444 ?#W_!
MQ'^TC\5/V;/^"7'B^[^"'B";1_%?C?6=+\':/K5M*8Y+#^T;E8II49?F1_LX
MF574AD9PP.5%=?X _P""('_!,+P3^RC:_LC7O['_ (&UC15T-;'4]<U'PY;M
MJ^H3^7M>_>^V^>MTS9<2*X,9(";550*O_!<W]B[XE?MV?\$W?&GP@^""+)X[
MTJZL?$G@JV=U476H:?<).MN"V%#2QB6)"Q"AY$+$ &O%[/\ X.B_^":?@W]G
MZ3QE^T)XH\1^"_BGHVE;/%/P6U/P=J,6M6FL(G[RQ3? (<&3(25Y%7:07*'<
MH .)_P""6/PI^(/[>W_!([XX?\$N/B[^T)XJTMOA=\7]?^$@\=Z5*CZI-H>G
MW-M*D1:0%2KPO)9D$<0?*.U>4_\ !6[5/^"4WBW]GW3_ /@E+_P3<\$>$+G]
MIS1?'VC:!\,=.\%^&39:EX5U6PU"$W=Y<:EY*"+9##<"20RLSN^_YB"Z^Q?\
M$^/#_P"V[^P;_P $8OB/^VUX&_9_L?'7QD^+/CW4OC!>_#>*]>0O;:I/;%K>
M)H,M)*MC']I6-06+L8\%_EKS'_@K7_P4@_X)J_\ !4#]A.7X&?L?6DOQ _:*
M\7ZEI8^&?A+1_!MU%XF\.:RE]!)+-+,85-@8$6999/,"$;@&9"6H _932(=1
MM])M;?6+M+B[CMT6ZGC3:LD@4!F [ G)QVS7R=\&O^"4OP/^&O[3GQO_ &U/
MVH]7\.?%;Q)\3->^V:?J?C+PC!L\'^'X(=D.DPM<33KY<:#YYE$(D"J60;:^
MG_AOIOBO1_AWH.D>/-66_P!<M=%M8=9OD^[<7:PJLT@X'#.&/3O7Y#?\%:?^
M"M/[+'[1?[9&I?\ !*CXL_M7)\'O@QX1E4_'WQ6;:]&I>+I05;_A&=.^S0N\
M,#9 N;AMNX;D7*C$P O[ GBVZ_9]_8)_X*)?MD_L?PR>'_@U=Z[XIUC]GJWL
MT:&S2>RTRXCN-3L(^ EI)=K"(PH  M2H"[,#T;X'?\$P?V,_$G_!N#I6@ZY\
M!/"UWK/BG]G >,K[Q7<Z) ^J_P!O7>C_ -I"_P#M;*9C+'/(-K%N$01_<^6O
M6]"_:1_X)O\ _!3C]A;XL_\ !.?_ ()H?&?PWJDL7P4U/0M&\/:)I%W8VVD0
M36<EG:'_ $B"-1&LKQ@X)/4GN:^6_AE_P6G_ &9?A?\ \$7+?]B#QL?$%A^T
MIX6^#Q^%T7P.E\*7YURXU^'3SI=LBQ+"5:.3;',7#$!&(Y?"$ ]A_9B_9$U?
M_@L3_P $Z?V(_BO^TM\7Y+[PGX%TN#7/'_@+5=%-]!\0+VU@%G9M>2M.@41O
M%)*X>.99O/96"]3F?MN?!3X%M_P6V_9#^'7[$?PW\/\ ASXH^$+S4_$7Q2O?
M!>DPV2Z=X*%NL1AU'[.J@K<.SPP*X)!D.-HD!9?BO^VB?^#>_P#X(E_ WX4>
M.M'M+CXMZAX3L_#WAS2-29O[.LM:DB$UY/>S1@XM;1YR7V9>7:JK@,SISO\
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M2TO3-9LVT_6-.@N[=\;X+F%9$;'(RK @U/10 D<:1((HD"JH 55& !Z4M%%
M!3+FVM[R![6[@26*12LD<BAE8'J"#P13Z* (K*RLM-M([#3K2*W@B7;%##&$
M1!Z #@"I:** "J\>D:3#J<FM0Z7;I>31B.:[6!1*Z#HI;&2!Z$U8HH ****
M"BBB@ HHHH **** "BBB@ KGOB)\(_A9\7/#NH^$?BE\.=$\1:9J^G26&J6.
MLZ7%<Q75K(,/"ZNIW(>ZGBNAHH \E_8M_8I^!G[ GP9/P _9TMM;M?"J:W>:
ME8Z;K7B&YU :>;B3>;:W,[L8;=. D2X'5FW2.[MZC;Z/I-I?S:K:Z7;175R
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MD _E'$O_ ".ZO_;O_I*/\]/'+_DZ68?]PO\ TQ2.7_; _:\_;^B_X*E^%/\
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M^-VG:=X?N;F#Q!/INJ6D,<NF2-<*;($LCL9%F#?, $&,?=_[$G[,/QR^$/\
MP4H_;%^/WQ#\$?V?X1^*FN^"[CP%JW]IVTO]J1V&B&UNV\J*1I8-DQV8F1"W
M5=PYKYOM_P#@F)^U[XG_ ."2'[9/[)6I?#^VTGQK\5_C;XS\3> +"[URS>/5
M+&YO[6[LG,L4KI 9Q RA961D+#S @R: /O7]BS1/COX?_9J\+:=^T;X_\.^)
M?$HTV)WU3POX?ETRU-LR*8(_(EGG;>J85FWX8@D!<XK\T-6_:L_X)Y_LN_\
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MO--$C,(# &61\L=H((!]6?!W]NWQQX>_;6_:0_9A_:IO=$TW2OAGX>TWQYX
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8H **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>pacb-20250930_g5.jpg
<TEXT>
begin 644 pacb-20250930_g5.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@!
M1@%8 P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH _&_]L#_ (*K?M[?"W]J?XA?#CP)\>/L.BZ'XOO[+2[+_A%]+E\B
M".=E1-\EJSM@ #+$D]R:\X_X?)?\%(O^CC?_ "T-'_\ D2N _P""@'_)[_Q8
M_P"Q_P!4_P#2EZ\AK]>PF69;+"TVZ,&W%?97;T/](.'N!N":^082I4RS#RE*
ME3;;HTVVW!-MMQU;ZL^G?^'R7_!2+_HXW_RT-'_^1*/^'R7_  4B_P"CC?\
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M11_9>6?\^(?^ Q_R#_4'@7_H58;_ ,$4O_D3Z=_X?)?\%(O^CC?_ "T-'_\
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M^&_B5XDLXK+7_#TEQ,$6/[,9FVP2L3!Y<F,J,,/M&'RPS7FG_!"[_D_?3_\
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MIGXQ4445^@G]BA7[,_\ ! K_ ),@U#_L?[__ -)K2OQFK]F?^"!7_)D&H?\
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M7[7@O]SI_P"%?DC_ %)X9_Y)S!?]>J?_ *1$****Z3VPHHHH **** "BBB@
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M]D_]K'XSV^G:/-$@F\5^'+A%CMI9H?,@\XSH1""VU&W#"[PV=OS5]D_L8_\
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MP4445[I^KGKW_!/_ /Y/?^$__8_Z7_Z4I7]"U?ST_P#!/_\ Y/?^$_\ V/\
MI?\ Z4I7]"U?GO&7^]TO\/ZG\9_2:_Y*/ _]>G_Z6PHHHKXT_F<**** /YZ?
M^"@'_)[_ ,6/^Q_U3_TI>O(:]>_X* ?\GO\ Q8_['_5/_2EZ\AK]KP7^YT_\
M*_)'^I/#/_).8+_KU3_](B%%%%=)[84444 %%%% !1110 4444 %%%% !111
M0 5^S/\ P0*_Y,@U#_L?[_\ ])K2OQFK]F?^"!7_ "9!J'_8_P!__P"DUI7S
M7%G_ "*7_B7ZGX9](?\ Y-V_^OM/_P!N/MNBBBOS _@X*^)/^"^O_)D&G_\
M8_V'_I-=U]MU\2?\%]?^3(-/_P"Q_L/_ $FNZ]3)/^1M1_Q(^^\+?^3B99_U
M]B?C-1117[ ?Z3!1110 4444 %%%% !1110 4444 %%%% !1110!Z]_P3_\
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MI,%%%% !1110 4444 %%%% !1110 4444 %%%% 'KW_!/_\ Y/?^$_\ V/\
MI?\ Z4I7]"U?ST_\$_\ _D]_X3_]C_I?_I2E?T+5^>\9?[W2_P /ZG\9_2:_
MY*/ _P#7I_\ I;"BBBOC3^9PHHHH _GI_P""@'_)[_Q8_P"Q_P!4_P#2EZ\A
MKU[_ (* ?\GO_%C_ +'_ %3_ -*7KR&OVO!?[G3_ ,*_)'^I/#/_ "3F"_Z]
M4_\ TB(4445TGMA1110 4444 %%%% !1110 4444 %%%% !7[,_\$"O^3(-0
M_P"Q_O\ _P!)K2OQFK]F?^"!7_)D&H?]C_?_ /I-:5\UQ9_R*7_B7ZGX9](?
M_DW;_P"OM/\ ]N/MNBBBOS _@X*^)/\ @OK_ ,F0:?\ ]C_8?^DUW7VW7Q)_
MP7U_Y,@T_P#['^P_])KNO4R3_D;4?\2/OO"W_DXF6?\ 7V)^,U%%%?L!_I,%
M%%% !1110 4444 %%%% !1110 4444 %%%% 'KW_  3_ /\ D]_X3_\ 8_Z7
M_P"E*5_0M7\]/_!/_P#Y/?\ A/\ ]C_I?_I2E?T+5^>\9?[W2_P_J?QG])K_
M )*/ _\ 7I_^EL****^-/YG"BBB@#^>G_@H!_P GO_%C_L?]4_\ 2EZ\AKU[
M_@H!_P GO_%C_L?]4_\ 2EZ\AK]KP7^YT_\ "OR1_J3PS_R3F"_Z]4__ $B(
M4445TGMA1110 4444 %%%% !1110 4444 %%%% !7[,_\$"O^3(-0_['^_\
M_2:TK\9J_9G_ ((%?\F0:A_V/]__ .DUI7S7%G_(I?\ B7ZGX9](?_DW;_Z^
MT_\ VX^VZ***_,#^#@KXD_X+Z_\ )D&G_P#8_P!A_P"DUW7VW7Q)_P %]?\
MDR#3_P#L?[#_ -)KNO4R3_D;4?\ $C[[PM_Y.)EG_7V)^,U%%%?L!_I,%%%%
M !1110 4444 %%%% !1110 4444 %%%% 'KW_!/_ /Y/?^$__8_Z7_Z4I7]"
MU?ST_P#!/_\ Y/?^$_\ V/\ I?\ Z4I7]"U?GO&7^]TO\/ZG\9_2:_Y*/ _]
M>G_Z6PHHHKXT_F<**** /YZ?^"@'_)[_ ,6/^Q_U3_TI>O(:]>_X* ?\GO\
MQ8_['_5/_2EZ\AK]KP7^YT_\*_)'^I/#/_).8+_KU3_](B%%%%=)[84444 %
M%%% !1110 4444 %%%% !1110 5^S/\ P0*_Y,@U#_L?[_\ ])K2OQFK]F?^
M"!7_ "9!J'_8_P!__P"DUI7S7%G_ "*7_B7ZGX9](?\ Y-V_^OM/_P!N/MNB
MBBOS _@X*^)/^"^O_)D&G_\ 8_V'_I-=U]MU\2?\%]?^3(-/_P"Q_L/_ $FN
MZ]3)/^1M1_Q(^^\+?^3B99_U]B?C-1117[ ?Z3!1110 4444 %%%% !1110
M4444 %%%% !1110!Z]_P3_\ ^3W_ (3_ /8_Z7_Z4I7]"U?ST_\ !/\ _P"3
MW_A/_P!C_I?_ *4I7]"U?GO&7^]TO\/ZG\9_2:_Y*/ _]>G_ .EL****^-/Y
MG"BBB@#^>G_@H!_R>_\ %C_L?]4_]*7KR&O7O^"@'_)[_P 6/^Q_U3_TI>O(
M:_:\%_N=/_"OR1_J3PS_ ,DY@O\ KU3_ /2(A11172>V%%%% !1110 4444
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MW.K7/BKQNLEU.\TBQ>+[E5#,Q8@ '@9/ [5!_P .]_@G_P!#;X[_ /"RN?\
M&O=** /"_P#AWO\ !/\ Z&WQW_X65S_C1_P[W^"?_0V^._\ PLKG_&O=** /
M"_\ AWO\$_\ H;?'?_A97/\ C1_P[W^"?_0V^.__  LKG_&O=** /"_^'>_P
M3_Z&WQW_ .%E<_XT?\.]_@G_ -#;X[_\+*Y_QKW2B@#PO_AWO\$_^AM\=_\
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M_P#!8C]OOXX^,X5NO$VD>-/#OA+2;J<9>PTB"SEVPQ?W$E,,+L!PS0JW7)H
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MCXT?%GPKXOUR^T..[2&STS7];M9A#8K(25C6'=!&YR5WI(02N#7AOA/XK?\
M!=C_ ((W_L ^!/'_ ,8?V>?V?_$OP>^$?A#2M.\9^"?"6KZHWBVRTV%(H9KT
MW3M]BDF5BTD@B5T4'C<H:0 'ZX>&M9?Q%X<T_P 02:1>:>U_917#6&H1>7<6
MQ= WE2KD[77.UADX((J[6'\,?B+X5^+_ ,-?#WQ:\"WQNM#\4:'::OHURR;3
M-:7,*30OCME'4X]ZW* "BBB@ HHHH **** "BBB@#)\>^//!GPM\$:O\2OB-
MXGLM%T#0--FU#6M7U&<1065K"A>6:1SPJJJDD^@KX&/_  <6?!O4/#=Q\;?!
M_P"P#^TYKWP:M7<R_&?2_AAG1GM4)#W\:O.L[6:X):4H"H5LKD8J/_@Z,\0Z
MW8_\$HM3\$:=JLUE8^-/B)X:T'7[BW?:PL9;]))!N[ F% >Q!(/!(K[_ /#7
M@KPEX.\&:?\ #KPOX=L['0M*TR+3M.TF" """TCC$4<"IT"*BA0O3 Q0!YY>
M_MQ?LIV7[(4G[>3_ !HTJ3X31^&SKO\ PF$)=X&L^F0@7S#+O_=>3M\WS?W>
MW?\ +7R[H_\ P< _!S3U\->/?CE^Q/\ M ?"[X6^,M2MK/P[\7_'?@JWM]$)
MN2!;371BN9);2";(*2NFTAE8[1DCRO\ X(.? ;X._&K]C[]I_P#8:^+_ ,/-
M,\5_"KP9^USXM\/Z!X7UB#SK)=-MKBSNX+<(>"J7'[X#^\^:Y+_@O+^TM^T-
M\3_A%J7["'QZ_8UU;X-?L_>*?B'I>B^+/VE=5U.'6-.L-&MM3AF@N8K+3TDD
MM#<200(C7)18_,"L 6W* ?KUUZ5\@?M#_P#!8?X;?"O]HG7?V4/@!^R_\6OC
MOX[\(6<%SXYT_P"%'AV&YM?#0F3?%#>75Q/%&L[K\RQ(6) 8'#*5KZTT"TTV
MPT*RL='G\VS@M(X[67S?,WQA0%.[^+( Y[]:\)\2:#^PK_P2K^&OQ?\ VPM8
MM+7P/I'B?79_%_Q-UVZU6ZNI-5U.3Y<QI<2R$22,1'%;0!4W.%1 6H L?L.?
M\%&?V<_V^/@_KGQ;^%EQK/A]_"&KW.D^//"WCG3AIFK>%K^!=TUO?0LS+$57
M)W!V3AANW(ZK\WW/_!Q5^S\?"]W\>]"_8V_:!U;X%6&J/977QYT_P'&V@;$F
M,#WR(;@7+V:R#:TPBR"&79N&T^)_#OX3?&SPG_P2<_;R_P""D'Q6\%7G@;Q1
M^TOX4\2>*='\%SC9=:!H4>D7,&G"X ^Y>/%+)-)C!&],A6W*OTO^SIX'\*R?
M\&YGA#P8^CP'3-1_8XM3>VI0;)3<^%Q).2.Y=Y'8^[&@#V/]KC_@I+^R_P#L
M<? /PW^T'XXU[4O$EAXYNK*T^'.A>!=..IZIXONKN,26T&G0(1Y[2(0P8LJ8
M*Y8%E!\S^ /_  66^&WQ*_:4\._LD?M!_LK?%[X$^-_&UI/<> K;XK>'8+:S
M\1^2F^6"VN;>>5/M"+R8GVD949+.JG@_^",W[,_P1_:5_P""9O[&O[0_QN\#
MMKGB_P"$?@V:3X>ZI/JMW&NE/+NM&?R8Y5AG/D01*OG))LVY3:22><^,&OZ?
M_P %7?\ @KO\+? GP)M_MOPU_9 \577B'XE?$6 9MKOQ2T2QVN@64HXEDB*B
M2Y*DJHRAVL%W@'Z(^._'/A#X8^"=7^)'Q!\16ND:#H&F3ZCK.JWTH2&SM88V
MDEF=CT545F)]!7@W_!,7_@IQ\"O^"K?P+UW]H3]GKPOXFTO0="\;W?AEU\56
MD$$]S/!;6MP9T2&:4")DNX\;BKY# J,#/A'[>^L:G_P4Z_;+TS_@D;\.-1G'
MPU\'+8^*OVJ==L)2H>TWB;3/"PD4Y$MXZ":8 @K!&"&)WH<?_@VRTO3-#^$/
M[4VBZ+I\%I9V?[;/CJ"TM+:(1QPQ)%IJJB*H 50   . !B@#]':*** "BBB@
M HHHH **** "BBB@ K\\_P!H/]EO]NK]AS_@H;XR_P""CG_!.[X*Z5\7/#GQ
MAT33[/XS?!RZ\40:)?/J%A&8K75M/NK@>06$197B?EB\A 8RAHOT,HH _&?Q
M-^TQ\9OVS/\ @M%^SWX#_P""J/P#N_V9O"?@663Q+\%_!6O:DFJKX[\6.4BM
MP^J6RBUCE@.QX[?(</B,[FG4#ZS^-WB'_@K-^R%^VSXW^,?PA^"-_P#M(?!+
MX@:9IS:7X'L?&MAI&J^ -1MHC'-]G6]V1W-M<L3(P5BX8CA1'F7[7UCPOX9\
M0W>GZAK_ (=L+Z?2+S[7I4]Y:)*]E<>6\?G1%@3&^R21-RX.UV&<$BKU 'PW
M_P $T?V4_P!K"7]LOXW_ /!33]L_X9Z7\.?$OQ:L-'T3PW\+],U^+59=#TG3
MH=@DO;N#]S-<RL$;$9(0 C/S!5]I_P""EWC#]NGP=^R#XDG_ ."</P?L_&7Q
M9O\ R['P_;7^L65G%IJRDK)J&;V6*&5H5Y6)GPSE20RJRM[W10!^5G_!/Z;_
M (*6?\$^O@B?ACX$_P"""_BW7O$.M7[ZO\0?'VN?M+>$9-4\6:U*=T]_=R&8
ML2S%MB;B(UP,D[F;U3]M#]GO]MWP-^V_\*/^"N/[)'[.=KXU\467PME\#?%S
MX-S^+K2POIM+GF%]']DOI3]FDFMKMGWY.)!&@3(8E?O^B@#X%_8[_9Z_;-_:
M5_X*::E_P5&_;5_9^@^$6G^&_AA_P@WPJ^&L_B>UU;40DUT;F[U2\FM"88W;
M)B6(,3M?# % TGS[I'AC_@L1KG_!1/7_ -N[]J+_ ((X:K\3;OPS<3Z9\!=
MM?COX5LM)\%Z6Q(>[CAFN7:;4;@!2]RX5E'RJJ@(L?Z^44 ?+%GXA_X*"_MJ
M_LC_ !.\">,/V?\ 6/V4_B)<Z<UK\/\ 76^(.E^('%T4\R.Z\S3BZQ1K*JQN
MC#>R.Q45\L?M%:[_ ,%S/VU/V.-0_P""<7C'_@G-I7@_Q-XOT2'PUX^^.6H_
M%'3+KP\MBVV.[U*VM(2;N1YXU?$&S?$9><[:_4ZB@#D_@+\(]"_9_P#@9X+^
M _A>[EGTSP3X3T[0-.GG #R06=M';QLV.Y6,$^YKK*** "BBB@ HHHH ****
M "BBB@#PO_@I1^P[X0_X*-?L5^.?V0_%^M-I0\3Z?&VDZVD6]M,U&"5+BUN=
MN0659HTWJ""R%UR-V:^+O''[?7_!P%^RU^RYJO@/QK_P2/@^(GCSP?X9DA'Q
M:\)_$BSN]*UGR(]HU3^RE47LLIP':U4(\C;BHC!VK^HM% 'Y6_\ !-/]GK4/
MBS_P0-U'P?\ \$R_VX3'\7O%VJW7B3Q#\3HX7M98_&LMQ!=7UE>0O&TEN#&L
M=HQ*%C&4G"L&4-/^U]-_P65_X*=_LI7_ /P3P\=?\$S=.^$MQXU^P6'Q$^+6
ML_$_2]2T73[2&YAGGN;"TMG:YN'E\G]W&P!CWX9LC>/T]\/^%_#/A*TFT_PK
MX=L-,@N+R:[G@T^T2%)+B:1I)IF"  N[LSLQY9F))).:O4 9'P_\&Z;\.O >
MB?#[1II9+/0M(MM.M))VS(T<$2QJ6/=B%&3ZU^7'[<'PV_X*J?'[_@I9;?$;
MXF?\$L]1^+OP%^$M\MS\(/!6G?&3PWI6GZQK"@?\3_4XKNX,EPZ9806[QHL0
MP3DF3S/U>HH ^3O GBK]KO\ ;\^%WQ._9B_;8_X)R:M\#?"WBWP!J&BC7KGX
MIZ)XA-[]MA>UEB2+3W+1,L<K2!WPN5 SFOD;POX?_P""Y?PQ_P"">,O_  2+
MTK_@G_H^L:U:>#)_A_H7[0$/Q0TZ'P^FA-$UG%J3V;G[8DT5HP00["Q= ^TC
M]V?UJHH _.O]MG]G'_@HY^RM_P $LOA;_P $_?\ @E-\,;KQ9JEIH-GX7\;>
M-=,\4:9H^HZ7ID-NBW=U9?VA<1(MU=.9=DBEC!N8@;BCK'^Q7\0OV_/V//A-
MX0_9:^"W_!OGK/A#P3HSQ6TMZW[1GA.XE4.X^T7]QLDWW,S$M*[?><Y  X _
M1BB@#XU^(O\ P;_?\$FOBO\ %/Q1\:O''[,^JW'B;QIKUSK/B;4K3XI^)[3[
M=?7$K2RRF.WU)(TRSMA$544':JJ  /(?^"$O_!&[1_V#/%?Q>^,WQ:^ E[X7
M\:7/QE\36WPVO9/'L^H1R>")Q9FQ+017LT!=FCE_>7"?:_E^<@$5^E%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI=QIVIVQ;'FV\\;12)GME&8?C7YOQC_R,X?X%_Z5(_B'Z2O_ "76&_[!H?\
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M_!/PQ\%M6BT*_P#$/Q<B%]?^+-?\D2W%O!;F]MA:V4!987FQ([/DH",A6_\
M!/[_ ()9_'O]GK_@IYX_^)/Q.L+7_A2?PYEUVX_9HMTO8'%M+XIN8K[6!'"D
MC26XMGB>U7S43>MP2N\9(Y+QQ_P3[^('[*'[:/QG^*:?\$EO G[5OP_^,WBH
M^+M&U&X7P\NO^%-7FB5+RQF_MK:);.65?-C>%\19;<A+$T -\4?\%N/VKO'?
M["_P'^-'P ^&WP_;XI^-OVI;7X.>.-!O[Z:;0GU +?QRR6EU&Q=+>1X+69)<
M2E(I64"0@,?7OA?^U#_P42_9P_X*5?#;]B[]M[X@_#3Q_H'QO\)Z]J7A/6O
MOA&ZT6?0=2TF**XN+5XYKJX$]L89,*['S"Q!.T*0W(?&K]AO]ISXE_ K]E"#
MP=^Q'\./AIJW@O\ ;!T#XA?$#P#\+M0T^WT[P]H=O]N5[B1R+>.\NHX9+5)O
MLZNTC@F-60#'L_[57[,/QR^)/_!6K]D_]IOP7X(^V^!_AIH?CVW\;:W_ &G;
M1_V;)J.FVT-DODR2+--YDD;KF)'"XR^T$&@"M_P3W_;G^-7[3W[(/QB^.7Q)
MM=#CUKP)\2_&N@Z(FF6+Q0-:Z5*ZVIE5I&+.0HWD$!NP%>#K_P %H?CQ<_\
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M?AO3/#LL%IK_ )6@MXHU#499(P4A&C(\<%F(A*',DP>1FCVJ%#5]J4 %%%%
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FBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>pacb-20250930_g6.jpg
<TEXT>
begin 644 pacb-20250930_g6.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB/XCZA=6/@K2Y;>5GU2XMH#<3QHR(50K$"Y+E00."3Q7:5_,W^QI\)?VV_\
M@OUX?^,'[;^N_P#!3'Q?H'Q^^%6JWM]\(?A+X=U8V@TM_LOF(+6,7$9LH9F/
MV$31@-NC9IGD)(/ZS? +XL_\%Q+/_@C[INI:_P#LWZ+J/[5FF:BFC#3?&^H6
MD=IJ%H+M4&JW!M[J.+<MHQ9E60%Y(F(0[@A /OZBOQ(_X([_ +6?_!5'QK_P
M7^^)'[)7_!1K]I7_ (26^\$?"B_EN?"_AB<0>'K2ZDFT>:-H;>**%))(XKDQ
M^;(C.,R .P)9OM'_ (+">/\ _@L_X>M;;1?^"86@?#[1/#-MX0O]6\;_ !+\
M92127&E2P;F6"U@D:0.S1(S9-K*N=H++W /N:BOS)_X-2OVHOVA_VOO^">/C
M3XQ?M.?&/7O&_B6;XV:I;_VMX@OVF>&!=,TIU@B4_+#$K.["*,*@+L0 6.<K
M_@Y=_P""GGQ3_9Q^#,/[#7[%^K:E_P +F^(7AW4-;U6_\/7317GA;PK86\US
M?:@)$(:&1X[:=4<$%8X;AE*NL9(!^I=%?G1_P:S_ !?^+7QQ_P""2F@^/OC7
M\4?$7C#79?&FMPRZUXIUN?4+MXTN $0S3N[E5' &<#M7HG_!P5^UY^T#^Q!_
MP2P^('QX_9FEDL_%4-QIVFP:]%;"4Z+#=W<<$EX%8%=P5]B,1A7E1N<8(!]I
MT5_,?\=/&'[<'_!,S]E']F;_ (*@_!/_ (+#?$#XI>-?B]<6-WXA^&>O^*;C
M4[*Z,]K]JEMC;R7,GGI#)_H<V] ZRRJ4,38 _IGT:]NM1TBUU"^TY[2:>V22
M:TD;+0LR@E">Y!./PH LT5_+]\6?^"H/[9?[(_\ P<!>/_B[XA_:,^(FH?![
MP!^T9-I/BSPM=^,;Z?1[/2+RYN;=HQ9-*80J0+.\8V;4DBCQ@[:_67_@YD_;
M4^)/[-_[ 6D_"7]FCQAJ6G_$[XW^--.\+>"+SPUJ3V]_'&TJ3SSVTL3!E+!8
M;?<IR/MJD>H /T<HK\D_^#/KX^?'7]H/]A;XE>)_CY\:O%OCC4[+XM26MGJ/
MB_Q'=:G/! -,L7\I)+EW94W,S;00,L3C)-?K90 4444 %%%% !1110 4444
M?G!_P6X_:\_X)PVWQH^&/_!-;_@IC^S;>ZWX0^+'E7>C?$:\OHK+3O#EW]HD
MM3-]K\Q)K:2+=$SR(0HCN1ORA85\,?LGZK<_\$@?^"\_PP_X)\?L ?MGZI\6
M_@?\5+2.3Q%X'NM>@U6+P_+/]K+?/;_N8YX5@CNC)&L;M"^V16&';]JOVQ_V
M#_V1_P#@H!\-X?A/^U[\$=*\::-:W)N-/6\>6"YL9B-IDM[F!TF@8C .QUW
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MO&B>,?%RNFV3^TM4UO0Y3'(/[\,$=M;G_KWK^H.O#OVF_P#@F]^Q=^V-\6O
M'QS_ &CO@R/$7BGX77ZWO@75!XAU&S_LR=9XK@/Y5K<1QS8E@B;$JN/EQC!(
M/N- !1110 4444 %%%% !7._%[Q[/\*OA/XH^*%MX5O]=D\-^';W5(]#TL W
M6HM;P/,+>$-QYDA38N>-S"NBHH _G?\ CGX)_P"",G_!3C]E/XF_\%=_V2?B
MU??LL_'+P.^J:K)I=MXTMK"ZU+58(//BD>SBEWJ]XS>6DUHT;-*S$K*X=3^G
MG_!NM^V5\?\ ]NC_ ():>#OC3^TO>RZCXHMM4U'1I?$,T C?6X+2;RX[MPH
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MX=SFI!2C2T>OQ1_S/S?$>+OAYA<1.C5QMI1;37LZVC3LUI3MOV/TBHK\W?\
MB(._ZM&_\O[_ .X*/^(@[_JT;_R_O_N"J_U:SO\ Y]?^31_S,?\ B,GAO_T'
M?^4JW_RL_2*BOS=_XB#O^K1O_+^_^X*/^(@[_JT;_P O[_[@H_U:SO\ Y]?^
M31_S#_B,GAO_ -!W_E*M_P#*S](J*_-W_B(._P"K1O\ R_O_ +@H_P"(@[_J
MT;_R_O\ [@H_U:SO_GU_Y-'_ ##_ (C)X;_]!W_E*M_\K/TBHK\W?^(@[_JT
M;_R_O_N"C_B(._ZM&_\ +^_^X*/]6L[_ .?7_DT?\P_XC)X;_P#0=_Y2K?\
MRL_2*BOS=_XB#O\ JT;_ ,O[_P"X*/\ B(._ZM&_\O[_ .X*/]6L[_Y]?^31
M_P P_P"(R>&__0=_Y2K?_*S](J*_-W_B(._ZM&_\O[_[@H_XB#O^K1O_ "_O
M_N"C_5K._P#GU_Y-'_,/^(R>&_\ T'?^4JW_ ,K/TBHK\W?^(@[_ *M&_P#+
M^_\ N"C_ (B#O^K1O_+^_P#N"C_5K._^?7_DT?\ ,/\ B,GAO_T'?^4JW_RL
M_2*BOS=_XB#O^K1O_+^_^X*^O?V&/VN/^&TO@Q<?%W_A7W_"->1KL^F_V?\
MVM]LW>7'$_F>9Y46,^;C;MXV]3GCFQ>39E@:/M:].T=KWB_R;/9R'Q#X.XFQ
M_P!2RW$^TJV<K<E2.BW=Y0BNO<]EHHHKRS[4***\:_;G_:X_X8M^#%O\7?\
MA7W_  DOGZ[!IO\ 9_\ :WV/;YD<K^9YGE2YQY6-NWG=U&.=:%"KB:T:5-7D
M]$O^'.',LRP648"IC<7+EI4U>3LW9+K9)M_),]EHK\W?^(@[_JT;_P O[_[@
MH_XB#O\ JT;_ ,O[_P"X*]C_ %:SO_GU_P"31_S/S_\ XC)X;_\ 0=_Y2K?_
M "L_2*BOS=_XB#O^K1O_ "_O_N"C_B(._P"K1O\ R_O_ +@H_P!6L[_Y]?\
MDT?\P_XC)X;_ /0=_P"4JW_RL_2*BOS=_P"(@[_JT;_R_O\ [@H_XB#O^K1O
M_+^_^X*/]6L[_P"?7_DT?\P_XC)X;_\ 0=_Y2K?_ "L_2*BOS=_XB#O^K1O_
M "_O_N"C_B(._P"K1O\ R_O_ +@H_P!6L[_Y]?\ DT?\P_XC)X;_ /0=_P"4
MJW_RL_2*BOS=_P"(@[_JT;_R_O\ [@H_XB#O^K1O_+^_^X*/]6L[_P"?7_DT
M?\P_XC)X;_\ 0=_Y2K?_ "L_2*BOS=_XB#O^K1O_ "_O_N"C_B(._P"K1O\
MR_O_ +@H_P!6L[_Y]?\ DT?\P_XC)X;_ /0=_P"4JW_RL_2*BOS=_P"(@[_J
MT;_R_O\ [@H_XB#O^K1O_+^_^X*/]6L[_P"?7_DT?\P_XC)X;_\ 0=_Y2K?_
M "L_2*BOS=_XB#O^K1O_ "_O_N"C_B(._P"K1O\ R_O_ +@H_P!6L[_Y]?\
MDT?\P_XC)X;_ /0=_P"4JW_RL_2*BO@GX$_\%O\ _A=?QG\+?"+_ (9B_LS_
M (277;;3?[0_X33SOLWG2!/,\O[$N_&<[=PSZBOO:O.QN7XO+YJ.(CRMZK5/
M\FSZWAWBK(.*\/.OE5;VD8/E;Y9QL[7M[\8O;L%%%%<9]"%%%% 'X)?MU_\
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M .76"_\ FDV**Q_^$L_Z</\ R+_]:C_A+/\ IP_\B_\ UJ _XDI^DU_T(?\
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M0Y_;X:I[TK<JY:5:<M;/7ELNK/M.BBBOS _8@KXT_P""Y_\ R9E8?]CU8_\
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MOSWC+_>Z7^']3^,_I-?\E'@?^O3_ /2V%%%%?&G\SA1110!_/3_P4 _Y/?\
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M_P"DUI7XS5^S/_! K_DR#4/^Q_O_ /TFM*^:XL_Y%+_Q+]3\,^D/_P F[?\
MU]I_^W'VW1117Y@?P<%?$G_!?7_DR#3_ /L?[#_TFNZ^VZ^)/^"^O_)D&G_]
MC_8?^DUW7J9)_P C:C_B1]]X6_\ )Q,L_P"OL3\9J***_8#_ $F"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@#U[_ ()__P#)[_PG_P"Q_P!+_P#2E*_H
M6K^>G_@G_P#\GO\ PG_['_2__2E*_H6K\]XR_P![I?X?U/XS^DU_R4>!_P"O
M3_\ 2V%%%%?&G\SGB6J?L$?!K5]3N=6N?%7C=9+J=YI%B\7W*J&9BQ  / R>
M!VJ#_AWO\$_^AM\=_P#A97/^->Z44 >%_P##O?X)_P#0V^.__"RN?\:/^'>_
MP3_Z&WQW_P"%E<_XU[I10!X7_P .]_@G_P!#;X[_ /"RN?\ &C_AWO\ !/\
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M#;X[_P#"RN?\:/\ AWO\$_\ H;?'?_A97/\ C7NE% 'A?_#O?X)_]#;X[_\
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M)Z?M*?$Z]^%&OKI'C#6/ACX&LM5M8)V0NFT"^20A@&P&56.UL#BNU_X(*?\
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M)NJ^._$!UN^2=EU34!")UB*1ILA_<)M0[B.<L<UZ_10 4444 %%%% !1110
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M6?LP_MO?LB?MI:7J>L?LI_M%>$_'D.BS+%JZ^'=62>6R9MVSS8\[XU;:VUF
M#;6VDX-<=XA_X*Q_\$SO"FMZ/X<\1_MV?"ZSO=>OIK/2[>;QA:AI98IWMY W
MSXC431R1;WVKO1ESE2* /H2BN$_:%_:>_9W_ &3/ #?%/]I?XT>'/ _A\7"V
MZ:IXDU6.UCFF8$K%'O(,LA 8A$!;"DXP#7RK\.O^"C4G[67_  5P\"_ K]D3
M]HG0O$_P<M/V?=3\;^,)O#0LKZVU.]DU9-.LX6N=C2P21,LKF)'C/7S%. *
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MV+\-]%^%/Q[^$-IJ.D^&+N*Z\*OI=Y/IEUH4\2;(Y+*YLI(IK4JH"XC=5(4
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$0!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>pacb-20250930_g7.jpg
<TEXT>
begin 644 pacb-20250930_g7.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MCG]DO]J'X8^%KKQO\1OV>?&>A:-9;/MFJZMX;N;>WAWNL:;I'0*N795&3R6
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M +8'_!5;]O;X6_M3_$+X<>!/CQ]AT70_%]_9:79?\(OI<OD01SLJ)ODM6=L
M 98DGN37G'_#Y+_@I%_T<;_Y:&C_ /R)7U%+A+,JM.,U.%FD]WU_[=/WO _1
MUXVS#!4L53Q&'4:D8R5YU+VDDU>U)ZZZZL_=>BOPH_X?)?\ !2+_ *.-_P#+
M0T?_ .1*/^'R7_!2+_HXW_RT-'_^1*T_U.S/^>'WR_\ D3K_ .):N.O^@G#?
M^!U?_E)^Z]%?A1_P^2_X*1?]'&_^6AH__P B4?\ #Y+_ (*1?]'&_P#EH:/_
M /(E'^IV9_SP^^7_ ,B'_$M7'7_03AO_  .K_P#*3]UZ*_"C_A\E_P %(O\
MHXW_ ,M#1_\ Y$H_X?)?\%(O^CC?_+0T?_Y$H_U.S/\ GA]\O_D0_P"):N.O
M^@G#?^!U?_E)^Z]%?A1_P^2_X*1?]'&_^6AH_P#\B4?\/DO^"D7_ $<;_P"6
MAH__ ,B4?ZG9G_/#[Y?_ "(?\2U<=?\ 03AO_ ZO_P I/W7HK\*/^'R7_!2+
M_HXW_P M#1__ )$H_P"'R7_!2+_HXW_RT-'_ /D2C_4[,_YX??+_ .1#_B6K
MCK_H)PW_ ('5_P#E)^Z]%?A1_P /DO\ @I%_T<;_ .6AH_\ \B4?\/DO^"D7
M_1QO_EH:/_\ (E'^IV9_SP^^7_R(?\2U<=?]!.&_\#J__*3]UZ*_"C_A\E_P
M4B_Z.-_\M#1__D2C_A\E_P %(O\ HXW_ ,M#1_\ Y$H_U.S/^>'WR_\ D0_X
MEJXZ_P"@G#?^!U?_ )2?NO17X4?\/DO^"D7_ $<;_P"6AH__ ,B5^F7_  2(
M_:-^,O[4'[+%Y\1_CIXQ_MS6HO%]W91WO]G6]MB!(;=E39;QQIP9'.<9YZ\"
MN#,.'L;EN']M5E%J]M&[Z^J1\GQGX-<3\#Y,\SQ]:C*GS*-H2FY7E>VDJ<5;
M3N?4M%%%>$?DH5\2?\%]?^3(-/\ ^Q_L/_2:[K[;KXD_X+Z_\F0:?_V/]A_Z
M37=>IDG_ "-J/^)'WWA;_P G$RS_ *^Q/QFHHHK]@/\ 28]__P""7?C'X4^
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M@I??6G5^21^>-%%%?9G].GKW_!/_ /Y/?^$__8_Z7_Z4I7]"U?ST_P#!/_\
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M "BBB@ HHHH **** "BBB@ K]F?^"!7_ "9!J'_8_P!__P"DUI7XS5^S/_!
MK_DR#4/^Q_O_ /TFM*^:XL_Y%+_Q+]3\,^D/_P F[?\ U]I_^W'VW1117Y@?
MP<%?$G_!?7_DR#3_ /L?[#_TFNZ^VZ^)/^"^O_)D&G_]C_8?^DUW7J9)_P C
M:C_B1]]X6_\ )Q,L_P"OL3\9J***_8#_ $F"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@#U[_ ()__P#)[_PG_P"Q_P!+_P#2E*_H6K^>G_@G_P#\GO\
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M-.M3334$FFG+1KJCSJBO1?\ AE/XU?\ 0+T'_P +72?_ )*H_P"&4_C5_P!
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M+T'_ ,+72?\ Y*H_M3+/^?\ #_P*/^8?Z_<"_P#0UPW_ (/I?_)'G5%>B_\
M#*?QJ_Z!>@_^%KI/_P E4?\ #*?QJ_Z!>@_^%KI/_P E4?VIEG_/^'_@4?\
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M/_A:Z3_\E4?\,I_&K_H%Z#_X6ND__)5?JG]J99_S_A_X%'_,_P! O]?N!?\
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M36[10!A?\*N^&?\ T3O0O_!1#_\ $T?\*N^&?_1.]"_\%$/_ ,36[10!A?\
M"KOAG_T3O0O_  40_P#Q-'_"KOAG_P!$[T+_ ,%$/_Q-;M% &%_PJ[X9_P#1
M.]"_\%$/_P 31_PJ[X9_]$[T+_P40_\ Q-;M% &%_P *N^&?_1.]"_\ !1#_
M /$T?\*N^&?_ $3O0O\ P40__$UNT4 87_"KOAG_ -$[T+_P40__ !-'_"KO
MAG_T3O0O_!1#_P#$UNT4 87_  J[X9_]$[T+_P %$/\ \31_PJ[X9_\ 1.]"
M_P#!1#_\36[10!A?\*N^&?\ T3O0O_!1#_\ $T?\*N^&?_1.]"_\%$/_ ,36
M[10!A?\ "KOAG_T3O0O_  40_P#Q-'_"KOAG_P!$[T+_ ,%$/_Q-;M% &%_P
MJ[X9_P#1.]"_\%$/_P 31_PJ[X9_]$[T+_P40_\ Q-;M% &%_P *N^&?_1.]
M"_\ !1#_ /$T?\*N^&?_ $3O0O\ P40__$UNT4 87_"KOAG_ -$[T+_P40__
M !-'_"KOAG_T3O0O_!1#_P#$UNT4 87_  J[X9_]$[T+_P %$/\ \31_PJ[X
M9_\ 1.]"_P#!1#_\36[10!A?\*N^&?\ T3O0O_!1#_\ $T?\*N^&?_1.]"_\
M%$/_ ,36[10!A?\ "KOAG_T3O0O_  40_P#Q-'_"KOAG_P!$[T+_ ,%$/_Q-
M;M% &%_PJ[X9_P#1.]"_\%$/_P 31_PJ[X9_]$[T+_P40_\ Q-;M% &%_P *
MN^&?_1.]"_\ !1#_ /$T?\*N^&?_ $3O0O\ P40__$UNT4 87_"KOAG_ -$[
MT+_P40__ !-'_"KOAG_T3O0O_!1#_P#$UNT4 87_  J[X9_]$[T+_P %$/\
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MX$HF)97V;"GRD@U%\;/^5I'X,?\ 9JVL_P#ISNJ3_@Z5_P"49>F?]EF\*?\
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M$_86TJX\$?#GXW_%*T^&7Q=^&EEJ,\FC7\^H*5T_4XX)7803PLDC%DQE8PH
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M:W/JPTV)KN-&'GK#&T;HK< F08VNX;C_ /@GG^T?^Q)\2_CA/_P55_X*0?\
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MS\+OV9/AOJZ)\6M6\0?$K3]%U+XGZG"^X:+8+//'*-+C=/W]THQ,R[8S@!R
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MK0_^6GZ=45\Q?\$XO^"CO_#P+_A,O^+-_P#")?\ ")?V=_S,/V_[7]J^T_\
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MUXMU+Q/XYTFZNVT26+5?LS7,<,$T?VOY-L:VY:,;YA(TFV,HV9^S'_P4+_;
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
'!1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>pacb-20250930_g8.jpg
<TEXT>
begin 644 pacb-20250930_g8.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@!
M1@%8 P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** /YZ?\ @H!_R>_\6/\ L?\ 5/\ TI>O(:]>_P""@'_)[_Q8_P"Q_P!4
M_P#2EZ\AK]KP7^YT_P#"OR1_J3PS_P DY@O^O5/_ -(B%%%>K?LA?LC_ !)_
M:_\ BSI_PY\&:;J-OI\\^S5O$L.CRW5KI2[&97G*8502NT989)XK6K5IT*;J
M5'9+5L[\PS#!95@JF,Q<U"G33E*3V27XOR2U>R5SRFBMWXE?#7QO\)/&5[X#
M^(/A;4M'U*RE*R6FJV$EM*5R=K[) #M8#(/0CH35_P"&'P'^-GQKGFM_A!\)
M/$?B8VY N6T/1IKE8">F]HU(3_@1%-U::ASMJW?H5+'8*&$6*E5BJ;2?,VE&
MSV=WI9G)T58LM*U34M3BT33=.GN+R><0P6D$1>220G 15 )9B> !R37:?$;]
MES]I'X0^'8O%_P 4O@/XM\/:5*RJNHZOH%Q;PAF^ZK.Z (Q[*V"?2B52G&2C
M*23>VNX5<;@J%:%*K5C&<_A3DDY>B;N_D<'1178_"S]GGX[_ !P%P_P>^#WB
M3Q-':-MNIM%T>:XCA;&0KNBE5)'0$Y-.<X4X\TG9>9>)Q6&P=%U<1-0@MW)I
M)>K>AQU%:_CCP!XZ^&?B*;PA\1O!NJ:#JMN 9]-UBPDMIT!Z$I( P!['&#4O
MP^^&?Q$^+/B-?!_PO\#ZKXAU5X7E33=&L)+F=D7EF"1@G [G'%'/#DY[Z=^@
M/%898?ZPYKV=K\UURV[WVMY[&'16SX]^'7C[X5^)IO!GQ+\%ZIH&KVZ(\^F:
MQ8R6\\:NH924D 8 J00<<@UN>#/V;OV@OB-X.G^(?@'X)^*=:T&U,HN=9TS0
MIY[6(QKNDW2HI4;0<GG@=:EU:48*3DK/K?0SJ8_ TL/&O.K%0E:TG)*+OM9W
ML[]+;G%4445H=85^S/\ P0*_Y,@U#_L?[_\ ])K2OQFK]F?^"!7_ "9!J'_8
M_P!__P"DUI7S7%G_ "*7_B7ZGX9](?\ Y-V_^OM/_P!N/MNBBBOS _@X****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1$N)Y852ZB;^(-!(Y5N.)NQX':?\$MOVJOC#^WG\1OBU\"_VE_$I\1>&=?\
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M/S//8YE4X76254_8Y:Z=52>TEB*M)8=7_N0J5HOS@C\E****_1#^T K]F?\
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MBB@ HHHH *_9G_@@5_R9!J'_ &/]_P#^DUI7XS5^S/\ P0*_Y,@U#_L?[_\
M])K2OFN+/^12_P#$OU/PSZ0__)NW_P!?:?\ [<?;=%%%?F!_!P5\2?\ !?7_
M ),@T_\ ['^P_P#2:[K[;KXD_P""^O\ R9!I_P#V/]A_Z37=>IDG_(VH_P")
M'WWA;_R<3+/^OL3\9J***_8#_28]_P#^"7?C'X4^ _VZ? 7B?XRW5G;:-!>S
MJE[J)406MVUO*MM*Y;A0LQCPYX1MK$C;D??/QY^._P"WK^QQ^T#X\^+OQ?\
MAY>_%+X':[:3II>GZ3- ;33+=V0Q&8")WB"Q;XY"Z^7(9,[B<8_/']@/P#^S
M/\4_VC+#X=_M5Z[=:7X=U>RF@LM0M]16T6&_RK0^9*P(5& =.<#<ZY(K])OV
M*_V:/V@_V$O&GCF^^/WQZT>3X"6NDW(T6UU?76N(A&TJM#((Y5VP8@\Q713A
MV< *_##Y#/7AH8MSFE)\J7+)/WE?[$EJI7/YP\6I9)A^(I8G$QC5J>PC#V%6
M,DJT'4;_ -FJQ?-"NI:.R>EO4\7_ .",6G:A/\(OVCO'/PAU&P\.:KJ%I%;>
M$I]7OE6+27$-Z\,DLC*?DC::$LQ4@^7T[5QG[??@O_@J+X1_9OGUWXR?M*Z+
M\1_AEK,UO%JUYX5D@FMXG6=&A,I%M$P3ST0!T)&X!6P6 / ?LC_L<_L[?MMV
MOQ(T3P3\7;CPOX^@U2ZF\ ^&[ZYBALM0T]SN@1@4:1BI!5PA)4-&VT\Y]]\:
M?#FZ_P""=O\ P27\<?L_?M%>,M'N/%_CS6Y)/#_ANPO_ #VB60VJ;E! .U!;
MO,S@; 65<[FY59TJ.:\\6I3E.'N2A[R5DKJ7E:]UI?<C,ZF R[Q!>)H2A6Q5
M7$8=/#U</>K&')"//3JMMV@H\_/%**DGS:H7_@C-^V/HFM?$CPQ^RMX+_9[\
M+Z D7AFZD\0^+8(PVI:Q<1+O$CNJIM!) VMYG"C!';X2_;&_Y.[^*G_92-<_
M].$]>^?\$,O^3^M,_P"Q9U+_ -%BO(?CI\/]2^*__!07QK\,-'U.RLKOQ#\8
M-3TZVN]1F\NWA>;5)8U>1L$A06R< G'0$\5Z&&I4<+G=9QT7(F]WU=WJ?99+
M@,MR+Q2S.5%<D'AJ=2;;E+5U*CE)N3;V6VR2LDD:W_!,[]G3PY^U!^V-X6^&
MOC:V\_086FU+6K;./M$%O&9!"<?PO)Y:-C!VNV.:_0O]M/X"?M\?M(0^+?A1
M\$_C7\/= \)Z98M9V7PGTF[C6]N;! %C-PXB/DM*%!2/<D:JR*2#N-?*/[+^
MB6'_  2T_P""H.F^!/CEXZT>ZT_^SVL-2U[3I6\BU2\@#1/*' ,6V01A]WW5
M);)'-?3GP(_8@\:?LS?M[>-?V[_B)\9?#=I\,;EM7U6VUDZSDWD-\S2)%)D!
M=L>\'=N(9HTV@[OE\S-L1?&K$1DK*"E3O&ZD[[+S>GGL?!^(><NKQ/3S>EB(
M>SAA8U<(JE+VL*U1S;<::=N6I)<BNE[1)Q:LKGY):II>HZ'J=SHNL6,MK=V<
M[P75M.A5XI$8JR,#R"""".Q%?MI^R@? WBW_ ()T?";]GWX@J!8_$[P?>>'X
M9>,K,;6YFP,]_+BF93U#(N.M?CU^TG\0=#^+/[0_CKXH^&+5H=-\1>+]1U*P
MC=-K"&:YDD3<.S%6!(]2:_0#XZ_$G6_@Q_P26_9D^,/ADD:CX9\?:/?VHW8#
M^7;:DYC/^RP7:1W!-=N?4JF+I8>&TI2^Y\KM]S/J/%O 8OB#+LFPUG3K5:RM
MK\%3V-1QU_NSM?T/+/\ @E%\"1\(?VFOB3\<?C38>18? 31M1?52PX740)H=
MJY^\?*BNB.^[9CJ*Z3_@X.N9KWXO_#6\N(1')+X,E=XP<A2;@DBO5/\ @K#\
M5/A+\./V3<_!8K%=?M(>(++7=3GC8!I["*TM6=QCE0Q2URO<S3'^(BO,O^#A
M]57XX?#U5& /"=P !_U\FN+!UJF,SBABYJW,II+LHQ5__)G(^6X:S'&\3>).
M5<0XJ#@Z\<13C%_9C0I04OOK3J_)(_/&BBBOLS^G3U[_ ()__P#)[_PG_P"Q
M_P!+_P#2E*_H6K^>G_@G_P#\GO\ PG_['_2__2E*_H6K\]XR_P![I?X?U/XS
M^DU_R4>!_P"O3_\ 2V%%%%?&G\SA1110!_/3_P % /\ D]_XL?\ 8_ZI_P"E
M+UY#7KW_  4 _P"3W_BQ_P!C_JG_ *4O7D-?M>"_W.G_ (5^2/\ 4GAG_DG,
M%_UZI_\ I$0HHHKI/;"BBB@ HHHH **** "BBB@ HHHH **** "OV9_X(%?\
MF0:A_P!C_?\ _I-:5^,U?LS_ ,$"O^3(-0_['^__ /2:TKYKBS_D4O\ Q+]3
M\,^D/_R;M_\ 7VG_ .W'VW1117Y@?P<%?$G_  7U_P"3(-/_ .Q_L/\ TFNZ
M^VZ^)/\ @OK_ ,F0:?\ ]C_8?^DUW7J9)_R-J/\ B1]]X6_\G$RS_K[$_&:B
MBBOV _TF"NP\8_'+Q_XZ^$_@[X+>(+R!]#\"MJ#:!%'!MD0WLRRS;VS\_P R
M#;G[HR*X^BIE"$FFUMJO+2WY-F%7#8>O4ISJ13=-\T6U\,N5QNNSY927HVNH
MJ.\;AT8JRG((."#4EW>WFH3FZO[N6>5@-TDTA9CCW-1451M97N%%%% Q7=Y'
M,DCEF8Y+$Y)-2/?WTEFFGR7LK6\;EHX#(2BL>I"] ?>HJ*!63"BBB@84444
M%%%% 'KW_!/_ /Y/?^$__8_Z7_Z4I7]"U?ST_P#!/_\ Y/?^$_\ V/\ I?\
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M]*7KR&O7O^"@'_)[_P 6/^Q_U3_TI>O(:_:\%_N=/_"OR1_J3PS_ ,DY@O\
MKU3_ /2(A11172>V%%%% !1110 4444 %%%% !1110 4444 %?LS_P $"O\
MDR#4/^Q_O_\ TFM*_&:OV9_X(%?\F0:A_P!C_?\ _I-:5\UQ9_R*7_B7ZGX9
M](?_ )-V_P#K[3_]N/MNBBBOS _@X*^)/^"^O_)D&G_]C_8?^DUW7VW7Q)_P
M7U_Y,@T__L?[#_TFNZ]3)/\ D;4?\2/OO"W_ ).)EG_7V)^,U%%%?L!_I,%%
M%% !1110 4444 %%%% !1110 4444 %%%% 'KW_!/_\ Y/?^$_\ V/\ I?\
MZ4I7]"U?ST_\$_\ _D]_X3_]C_I?_I2E?T+5^>\9?[W2_P /ZG\9_2:_Y*/
M_P#7I_\ I;"BBBOC3^9PHHHH _GI_P""@'_)[_Q8_P"Q_P!4_P#2EZ\AKU[_
M (* ?\GO_%C_ +'_ %3_ -*7KR&OVO!?[G3_ ,*_)'^I/#/_ "3F"_Z]4_\
MTB(4445TGMA1110 4444 %%%% !1110 4444 %%%% !7[,_\$"O^3(-0_P"Q
M_O\ _P!)K2OQFK]F?^"!7_)D&H?]C_?_ /I-:5\UQ9_R*7_B7ZGX9](?_DW;
M_P"OM/\ ]N/MNBBBOS _@X*^)/\ @OK_ ,F0:?\ ]C_8?^DUW7VW7Q)_P7U_
MY,@T_P#['^P_])KNO4R3_D;4?\2/OO"W_DXF6?\ 7V)^,U%%%?L!_I,%%%%
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M*7_0P_\ *5#_ .5'XH_\.=OC9_T!_'?_ (0UM_\ +*C_ (<[?&S_ * _CO\
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M?&S_ * _CO\ \(:V_P#EE7[744?ZRYW_ ,_?_)8_Y!_Q'+Q2_P"AA_Y2H?\
MRH_%'_ASM\;/^@/X[_\ "&MO_EE1_P .=OC9_P! ?QW_ .$-;?\ RRK]KJ*/
M]9<[_P"?O_DL?\@_XCEXI?\ 0P_\I4/_ )4?BC_PYV^-G_0'\=_^$-;?_+*C
M_ASM\;/^@/X[_P#"&MO_ )95^UU%'^LN=_\ /W_R6/\ D'_$<O%+_H8?^4J'
M_P J/Q1_X<[?&S_H#^.__"&MO_EE1_PYV^-G_0'\=_\ A#6W_P LJ_:ZBC_6
M7._^?O\ Y+'_ "#_ (CEXI?]##_RE0_^5'XH_P##G;XV?] ?QW_X0UM_\LJ/
M^'.WQL_Z _CO_P (:V_^65?M=11_K+G?_/W_ ,EC_D'_ !'+Q2_Z&'_E*A_\
MJ/Q1_P"'.WQL_P"@/X[_ /"&MO\ Y94?\.=OC9_T!_'?_A#6W_RRK]KJ*/\
M67._^?O_ )+'_(/^(Y>*7_0P_P#*5#_Y4?BC_P .=OC9_P! ?QW_ .$-;?\
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M&/U>\(>$O#/@#PGI?@3P5H=MIFC:+IT%AI.FV<82&TMH8UCBA11PJJBJH'8
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M /#^AZO^TAX[NK.^\57[V7A+PUHFCW&IZMKEP@4O':VELCR2;0R;GP$4N@+
MNH/R)_P73NO#O[:?CSX/?\$CO@I:QZM\3=?^(6D>,M>O;) W_" ^&]/E9I]7
MF<?ZB1PWDPH<&3>R@@L@?3U.&V^(G_!T[I>E^*(%N;?X?_L83ZKX9BE7<+._
MNO$2VLUPF?NNUO,T1(Y*@"@#Z<_8K_X*3?LF_M\OXAT?X!>,]27Q%X0EBC\6
M>#?%.@76D:SHYD!,9FM+I$?8P'#KN3/&<\5YI\??^"[/_!/']GWXI>(_A#JW
MC3Q9XIU3P3*8_'EQ\/\ P%J6MV7AAESO6^N;6%HHF3#!U#,R%65@&!%>7?%^
M&W\!?\'.OP@UOPO MI/X\_9FUS3/$[0#;]NBM+YKB R8^^RLB ,><(HZ "O8
M]"\(?L0_\$&?V"O%/B'4/$NIV_@S2]4O]>U>_P#$%W%=ZOXBU>]D+>3N5(_M
M-S,^R&-=OW57<0JLP /<_AA^U'\ OC7^SU;?M6?"3XFZ?XA^']YHLVJVOB/3
M2SQ/:PAS*2I =70QNKQLH=&1E90P(KXYT_\ X.>/^"1VK64>I:5\4/'5S;S+
MNBGM_A/KCHX]0PM<$?2N4_X)Z_L=_M*?L[_\$ OB=X E^&%U9?$CXE>%/&WB
M?P[\-K,!9-%N=6M)SI^DH'VB-U'D%D.W8\CJ0"IKS']G3]OK_@I)_P $EOV
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MU\Z_\$7/V9OA9^U=_P $Z/VC?^"7W[0$&JZW\,?AS^TYXG\%:+8P:W<6TO\
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M+P_X1\9>(G&D>)=+D%D8/$<]J\*_:KV?:X-X& <1X"\5^H5% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 45^8O_$1S_P!6;_\ F0__ +WT?\1'/_5F_P#YD/\
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M.H9)$=25=64@A@2"""*Y#YXLT444 %%%% !1110 4444 %%%<%X-_:>^!OQ
M^/WC/]E[PCXW^U^.OA[I^FWWB_0_[,N8_L$%_&\EH_G/&(9?,5&.(W<KCY@I
M(H [VBN,_:%_:#^$/[*GP7\0?M"_'OQ=_8/@_P +60N]>U?[!<77V6$NJ;O*
MMHY)7^9U&$1CSTKJ="UO3/$NB6?B/1+GS[+4+6.YM)MC+YD3J&1L, 1D$'!
M/K0!:HHHH **H^)O$OA[P9X<U#QAXNURTTS2=)L9;S5-2OYUB@M+>)"\DTCL
M0J(J*S,Q(  )->&^%O\ @J[_ ,$P_&_B"T\*>$O^"AGP6U#4[^98;*QMOB9I
MC2W$A.%1%\_+,3P%')/2@#Z HH!!&0:* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#^8NBBBOW0_P!9#Z=_X(V?\I(OAQ_W&/\
MTSWM?L[^U#\2]7^"_P"S/\1/C%X?@26_\)^!=7UFQCE7<KS6ME+.@([@L@XK
M\8O^"-G_ "DB^''_ '&/_3/>U^X?CGP9X>^(W@K6/A[XML?M.E:]I=QIVIVQ
M;'FV\\;12)GME&8?C7YOQC_R,X?X%_Z5(_B'Z2O_ "76&_[!H?\ IVL?#?\
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MI-+%F%9;@VD\,L)CN%5W #913MRR?L3?M<?\%4?C<?A1^T)X9^,/[/\ \?\
MX?>/[ZQ3XF^$/AA%'I>H?#>VNXMYNH[BYU%_MBVK?+/!(@N6(*I&3DIW'[/7
MP9_:G7X-?%[QA^SI_P $Z_@Q^R;XTU/1H+7X4HNG:5=:C?7$6^1VUG^RHOLZ
M6SOY:1QI)*\>9'8$A5/SP_[&?[6/[1/[5_P/^+?@C_@DKHW[+WC[P1\1=/US
MXM_&K0/&NBI;:YI<(8ZAI<-OI4AFU%+[( :YC&P *YPS4 ?H9_P4,_Y,#^.7
M_9'O$W_IJN:_(CX,?MT_\$1M7_X(I>"?V6?'O@GP]X^^+FK?!VS\.6?@30?A
M7=7>N:GXEELO)@@M[A;/'VG[05*S++D, RL6P#^Q_P"V3X!\6_%;]D+XJ_"[
MP#I/V_7?$GPWUS2M%L?/CB^TW=QI\\,,>^1E1-SNHW,P49R2!DU\G0?\$OO'
MWQR_X(3?#G]A3XJ67_"'_%;P5\.M%N/#.HQW\4LOACQ=ID*O:3I<6[NGRS*8
MWDB9LQRR;3R#0!YQ;_M>?M8_\$_?V./V0?\ @GGK7BOP/H?QY^(/@HVVO>,?
MBQJN[1_!FFZ;:(]Q-=;9HS=W2))#:Q1"4+),C%G*CYM3X8_\%'/VWKWQ[\:/
MV%+#XQ?!SXL_%GP]\$9_B)\&?B+\/M./]F:Z(9OLTNEZC8QWDP@NA<&)5$<V
M#'.KX!'-#]J/]C3]M7]J;PK^S+^W]\7OV%O!?C7XN_"[1-1T?XO_ +/?C?4M
M'N+/Q';7D:137%C<L\]C%.DT(NX%=\!9]C,K(5;W?_@GC\+?$EM\8_$'Q.NO
M^"0?PQ_9G\/Q>'TL=$O;*+1&\4ZK</,'G$O]CHT,%EM2/Y&F,C21JQ7&-H!Q
MOC3_ (*L?$3XI?LA?LG>/_V4K30I?B#^T[XNT33(;/4;-[FWT>U2%[CQ#<>4
MLB,XLUMYX_O<,5)SBN8^*_\ P4G_ &C_ -H']K7XK_ 3]E;]JWX#_!/PQ\%M
M6BT*_P#$/Q<B%]?^+-?\D2W%O!;F]MA:V4!987FQ([/DH",A6_\ !/[_ ()9
M_'O]GK_@IYX_^)/Q.L+7_A2?PYEUVX_9HMTO8'%M+XIN8K[6!'"DC26XMGB>
MU7S43>MP2N\9(Y+QQ_P3[^('[*'[:/QG^*:?\$EO G[5OP_^,WBH^+M&U&X7
MP\NO^%-7FB5+RQF_MK:);.65?-C>%\19;<A+$T -\4?\%N/VKO'?["_P'^-'
MP ^&WP_;XI^-OVI;7X.>.-!O[Z:;0GU +?QRR6EU&Q=+>1X+69)<2E(I64"0
M@,?7OA?^U#_P42_9P_X*5?#;]B[]M[X@_#3Q_H'QO\)Z]J7A/6O OA&ZT6?0
M=2TF**XN+5XYKJX$]L89,*['S"Q!.T*0W(?&K]AO]ISXE_ K]E"#P=^Q'\./
MAIJW@O\ ;!T#XA?$#P#\+M0T^WT[P]H=O]N5[B1R+>.\NHX9+5)OLZNTC@F-
M60#'L_[57[,/QR^)/_!6K]D_]IOP7X(^V^!_AIH?CVW\;:W_ &G;1_V;)J.F
MVT-DODR2+--YDD;KF)'"XR^T$&@"M_P3W_;G^-7[3W[(/QB^.7Q)M=#CUKP)
M\2_&N@Z(FF6+Q0-:Z5*ZVIE5I&+.0HWD$!NP%>#K_P %H?CQ<_\ !/C]E;Q;
M9/\ #C3?C9^T\UQ#9ZWXPF>P\+^'K>T6274-3G4S!W6*+R@D'FJ9))5&[C:V
M?\&_A;_P5)_8=\)_'O\ 8K^$O_!/Z#XCZ3\0_B5XJ\0_#WXJ#XEZ9IVD6]EK
M1WJNH6\K_:UDMV8[ECC/FGY4( \P\M+_ ,$BOVH;?_@GG^QGXCU3]F7P;XX^
M*7[,=OJ*>)O@;X]O].N-.\2Z=J:&&^LEN6,UF+I5CMY89'+1*Z;B=R@$ ][_
M &)?^"A7QS3]O0_\$_?VE?V@?A)\7QXB\ 3^*O GQ,^$\"VBE[:=(KO2[^S6
MZN5CE"R+-'(K@,BG.6.%^]Z^*_V!OA7XEE_:!N?B*_\ P1?^%_[-?AO3/#LL
M%IK_ )6@MXHU#499(P4A&C(\<%F(A*',DP>1FCVJ%#5]J4 %%%% !1110 44
M44 %%%% !1110 4444 ?,7_#FW_@F[_T;E_Y=^L?_)='_#FW_@F[_P!&Y?\
MEWZQ_P#)=%%=_P#:F9_\_P"?_@4O\SZW_7[CK_H:XG_P?5_^2.G^#7_!-']B
M7]G[XDZ;\7?A%\%?[(\1:1YW]GZA_P )'J5QY7FPO#)^[FN71LQR.OS*<;LC
M! (]VHHKEK8BOB)<U6;D]KMM_F>'F>;YMG5=5\PQ$ZTTN52J3E-I)MV3DV[7
M;=MKM]PHHHK(\X**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
@H **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Oct. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-34899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Pacific Biosciences of California, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">16-1590339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1305 O&#8217;Brien Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Menlo Park<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">521-8000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PACB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">301,907,431<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001299130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 56,467<span></span>
</td>
<td class="nump">$ 55,370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Investments</a></td>
<td class="nump">242,187<span></span>
</td>
<td class="nump">334,561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">30,616<span></span>
</td>
<td class="nump">27,524<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">53,153<span></span>
</td>
<td class="nump">58,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">11,513<span></span>
</td>
<td class="nump">18,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Short-term restricted cash</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">690<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">394,236<span></span>
</td>
<td class="nump">495,681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">22,127<span></span>
</td>
<td class="nump">30,505<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net</a></td>
<td class="nump">42,583<span></span>
</td>
<td class="nump">16,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Long-term restricted cash</a></td>
<td class="nump">1,532<span></span>
</td>
<td class="nump">1,532<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">16,143<span></span>
</td>
<td class="nump">389,572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">317,761<span></span>
</td>
<td class="nump">317,761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">8,776<span></span>
</td>
<td class="nump">9,305<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">803,158<span></span>
</td>
<td class="nump">1,260,447<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">16,362<span></span>
</td>
<td class="nump">16,590<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">29,172<span></span>
</td>
<td class="nump">22,595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">16,049<span></span>
</td>
<td class="nump">13,864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">621<span></span>
</td>
<td class="nump">10,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other liabilities, current</a></td>
<td class="nump">1,005<span></span>
</td>
<td class="nump">3,224<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">63,209<span></span>
</td>
<td class="nump">66,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, non-current</a></td>
<td class="nump">4,400<span></span>
</td>
<td class="nump">5,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration liability, non-current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">18,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">54,300<span></span>
</td>
<td class="nump">14,914<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible senior notes, net, non-current</a></td>
<td class="nump">645,159<span></span>
</td>
<td class="nump">647,494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities, non-current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">546<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">767,068<span></span>
</td>
<td class="nump">753,853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">302<span></span>
</td>
<td class="nump">294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">2,690,304<span></span>
</td>
<td class="nump">2,654,804<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">415<span></span>
</td>
<td class="nump">422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(2,654,931)<span></span>
</td>
<td class="num">(2,148,926)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">36,090<span></span>
</td>
<td class="nump">506,594<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 803,158<span></span>
</td>
<td class="nump">$ 1,260,447<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478064/805-740-55-13<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 39<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-39<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">301,853,000<span></span>
</td>
<td class="nump">294,418,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">301,853,000<span></span>
</td>
<td class="nump">294,418,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 38,441<span></span>
</td>
<td class="nump">$ 39,967<span></span>
</td>
<td class="nump">$ 115,360<span></span>
</td>
<td class="nump">$ 114,790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Cost of Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAmortization', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">183<span></span>
</td>
<td class="nump">3,201<span></span>
</td>
<td class="nump">4,711<span></span>
</td>
<td class="nump">7,172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_LossOnPurchaseCommitment', window );">Loss on purchase commitment</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,167<span></span>
</td>
<td class="nump">998<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Total cost of revenue</a></td>
<td class="nump">22,540<span></span>
</td>
<td class="nump">29,963<span></span>
</td>
<td class="nump">86,146<span></span>
</td>
<td class="nump">87,566<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">15,901<span></span>
</td>
<td class="nump">10,004<span></span>
</td>
<td class="nump">29,214<span></span>
</td>
<td class="nump">27,224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">22,846<span></span>
</td>
<td class="nump">25,516<span></span>
</td>
<td class="nump">74,428<span></span>
</td>
<td class="nump">107,456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Sales, general and administrative</a></td>
<td class="nump">31,099<span></span>
</td>
<td class="nump">43,746<span></span>
</td>
<td class="nump">107,442<span></span>
</td>
<td class="nump">133,376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Impairment charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">93,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_AmortizationOfAcquiredIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">833<span></span>
</td>
<td class="nump">3,649<span></span>
</td>
<td class="nump">363,708<span></span>
</td>
<td class="nump">13,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,170<span></span>
</td>
<td class="num">(18,700)<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expense</a></td>
<td class="nump">54,778<span></span>
</td>
<td class="nump">74,081<span></span>
</td>
<td class="nump">541,878<span></span>
</td>
<td class="nump">348,509<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(38,877)<span></span>
</td>
<td class="num">(64,077)<span></span>
</td>
<td class="num">(512,664)<span></span>
</td>
<td class="num">(321,285)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(1,739)<span></span>
</td>
<td class="num">(3,538)<span></span>
</td>
<td class="num">(5,214)<span></span>
</td>
<td class="num">(10,655)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">2,999<span></span>
</td>
<td class="nump">6,890<span></span>
</td>
<td class="nump">11,989<span></span>
</td>
<td class="nump">19,718<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(37,617)<span></span>
</td>
<td class="num">(60,725)<span></span>
</td>
<td class="num">(505,889)<span></span>
</td>
<td class="num">(312,222)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="nump">383<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Consolidated net loss</a></td>
<td class="num">(38,000)<span></span>
</td>
<td class="num">(60,725)<span></span>
</td>
<td class="num">(506,005)<span></span>
</td>
<td class="num">(312,222)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on investments</a></td>
<td class="nump">148<span></span>
</td>
<td class="nump">2,076<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="nump">1,334<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (37,852)<span></span>
</td>
<td class="num">$ (58,649)<span></span>
</td>
<td class="num">$ (506,012)<span></span>
</td>
<td class="num">$ (310,888)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_IncomeLossPerShareAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="num">$ (1.69)<span></span>
</td>
<td class="num">$ (1.15)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="num">$ (1.69)<span></span>
</td>
<td class="num">$ (1.15)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract', window );"><strong>Weighted average shares outstanding used in calculating net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">300,844<span></span>
</td>
<td class="nump">272,915<span></span>
</td>
<td class="nump">299,303<span></span>
</td>
<td class="nump">271,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">300,844<span></span>
</td>
<td class="nump">272,915<span></span>
</td>
<td class="nump">299,303<span></span>
</td>
<td class="nump">271,631<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 32,597<span></span>
</td>
<td class="nump">$ 35,296<span></span>
</td>
<td class="nump">$ 96,793<span></span>
</td>
<td class="nump">$ 102,051<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Cost of Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Cost of revenue</a></td>
<td class="nump">19,204<span></span>
</td>
<td class="nump">23,278<span></span>
</td>
<td class="nump">65,559<span></span>
</td>
<td class="nump">68,808<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pacb_ServiceAndOtherMember', window );">Service and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">5,844<span></span>
</td>
<td class="nump">4,671<span></span>
</td>
<td class="nump">18,567<span></span>
</td>
<td class="nump">12,739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Cost of Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Cost of revenue</a></td>
<td class="nump">$ 3,078<span></span>
</td>
<td class="nump">$ 3,484<span></span>
</td>
<td class="nump">$ 11,709<span></span>
</td>
<td class="nump">$ 10,588<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_AmortizationOfAcquiredIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization Of Acquired Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_AmortizationOfAcquiredIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_IncomeLossPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Loss per Share Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_IncomeLossPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_LossOnPurchaseCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss On Purchase Commitment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_LossOnPurchaseCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in value of liability in contingent consideration arrangement in business combination, including, but not limited to, difference arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pacb_ServiceAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pacb_ServiceAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">267,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">$ 701,304<span></span>
</td>
<td class="nump">$ 268<span></span>
</td>
<td class="nump">$ 2,539,892<span></span>
</td>
<td class="nump">$ 219<span></span>
</td>
<td class="num">$ (1,839,075)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(312,222)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(312,222)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">1,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock in conjunction with equity plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock in conjunction with equity plans</a></td>
<td class="nump">7,703<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">7,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">55,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">273,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2024</a></td>
<td class="nump">453,122<span></span>
</td>
<td class="nump">$ 274<span></span>
</td>
<td class="nump">2,602,592<span></span>
</td>
<td class="nump">1,553<span></span>
</td>
<td class="num">(2,151,297)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">272,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jun. 30, 2024</a></td>
<td class="nump">492,700<span></span>
</td>
<td class="nump">$ 272<span></span>
</td>
<td class="nump">2,583,523<span></span>
</td>
<td class="num">(523)<span></span>
</td>
<td class="num">(2,090,572)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(60,725)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(60,725)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">2,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock in conjunction with equity plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock in conjunction with equity plans</a></td>
<td class="nump">812<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">18,259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">273,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2024</a></td>
<td class="nump">$ 453,122<span></span>
</td>
<td class="nump">$ 274<span></span>
</td>
<td class="nump">2,602,592<span></span>
</td>
<td class="nump">1,553<span></span>
</td>
<td class="num">(2,151,297)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">294,418<span></span>
</td>
<td class="nump">294,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2024</a></td>
<td class="nump">$ 506,594<span></span>
</td>
<td class="nump">$ 294<span></span>
</td>
<td class="nump">2,654,804<span></span>
</td>
<td class="nump">422<span></span>
</td>
<td class="num">(2,148,926)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(506,005)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(506,005)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock in conjunction with equity plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock in conjunction with equity plans</a></td>
<td class="nump">3,428<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">3,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">$ 32,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2025</a></td>
<td class="nump">301,853<span></span>
</td>
<td class="nump">301,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2025</a></td>
<td class="nump">$ 36,090<span></span>
</td>
<td class="nump">$ 302<span></span>
</td>
<td class="nump">2,690,304<span></span>
</td>
<td class="nump">415<span></span>
</td>
<td class="num">(2,654,931)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Jun. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jun. 30, 2025</a></td>
<td class="nump">61,489<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">2,677,853<span></span>
</td>
<td class="nump">267<span></span>
</td>
<td class="num">(2,616,931)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(38,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(38,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock in conjunction with equity plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock in conjunction with equity plans</a></td>
<td class="nump">1,469<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">1,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">$ 10,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2025</a></td>
<td class="nump">301,853<span></span>
</td>
<td class="nump">301,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2025</a></td>
<td class="nump">$ 36,090<span></span>
</td>
<td class="nump">$ 302<span></span>
</td>
<td class="nump">$ 2,690,304<span></span>
</td>
<td class="nump">$ 415<span></span>
</td>
<td class="num">$ (2,654,931)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (506,005)<span></span>
</td>
<td class="num">$ (312,222)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">10,251<span></span>
</td>
<td class="nump">10,932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">368,429<span></span>
</td>
<td class="nump">20,558<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use assets</a></td>
<td class="nump">3,083<span></span>
</td>
<td class="nump">10,912<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">32,080<span></span>
</td>
<td class="nump">55,003<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Impairment charges</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">93,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Accretion of discount and amortization of premium on marketable securities, net</a></td>
<td class="num">(3,905)<span></span>
</td>
<td class="num">(10,663)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in the estimated fair value of contingent consideration</a></td>
<td class="num">(18,700)<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory provision</a></td>
<td class="nump">9,768<span></span>
</td>
<td class="nump">3,715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred income taxes</a></td>
<td class="num">(546)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">1,456<span></span>
</td>
<td class="nump">1,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="num">(3,092)<span></span>
</td>
<td class="nump">7,232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory, net</a></td>
<td class="num">(4,926)<span></span>
</td>
<td class="num">(15,394)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">7,797<span></span>
</td>
<td class="nump">3,534<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">761<span></span>
</td>
<td class="num">(2,222)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(1,396)<span></span>
</td>
<td class="num">(26,665)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">685<span></span>
</td>
<td class="nump">875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(661)<span></span>
</td>
<td class="num">(9,252)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="num">(2,219)<span></span>
</td>
<td class="num">(7,053)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(92,140)<span></span>
</td>
<td class="num">(175,408)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1,853)<span></span>
</td>
<td class="num">(4,571)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchases of intangible assets</a></td>
<td class="num">(5,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(183,817)<span></span>
</td>
<td class="num">(418,164)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Sales of investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of investments</a></td>
<td class="nump">280,089<span></span>
</td>
<td class="nump">480,440<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">89,419<span></span>
</td>
<td class="nump">65,766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from issuance of common stock from equity plans</a></td>
<td class="nump">3,428<span></span>
</td>
<td class="nump">7,703<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Notes payable principal payoff</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(490)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">3,428<span></span>
</td>
<td class="nump">7,213<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents, and restricted cash</a></td>
<td class="nump">707<span></span>
</td>
<td class="num">(102,429)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of period</a></td>
<td class="nump">57,592<span></span>
</td>
<td class="nump">182,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">58,299<span></span>
</td>
<td class="nump">80,204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">56,467<span></span>
</td>
<td class="nump">77,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash at end of period</a></td>
<td class="nump">1,832<span></span>
</td>
<td class="nump">2,222<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">58,299<span></span>
</td>
<td class="nump">80,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset and lease liability recognized due to lease extension</a></td>
<td class="nump">$ 29,575<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in value of liability in contingent consideration arrangement in business combination, including, but not limited to, difference arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 1.  ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Business Overview</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a life science technology company that designs, develops, and manufactures advanced sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products and technology, which include our HiFi long-read sequencing technology, address solutions across a broad set of applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our focus is on creating some of the world's most advanced sequencing systems to provide our customers with the most complete and accurate view of genomes, transcriptomes, and epigenomes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations ("CROs"), pharmaceutical companies, and agricultural companies.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References in this report to &#8220;PacBio,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; the &#8220;Company,&#8221; and &#8220;our&#8221; refer to Pacific Biosciences of California, Inc. and its consolidated subsidiaries.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Basis of Presentation and Consolidation</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States, or U.S. GAAP, as set forth in the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC. The unaudited condensed consolidated financial statements include the accounts of Pacific Biosciences and our wholly owned subsidiaries. Certain information and footnote disclosures typically included in our audited financial statements have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements have been prepared on a consistent basis with the December&#160;31, 2024 audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state our financial position, results of operations, comprehensive loss, and cash flows for the period, but are not necessarily indicative of the results to be expected for the entire year or any future periods. All intercompany transactions and balances have been eliminated.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2024 (the "2024 Annual Report").</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Use of Estimates</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes to the financial statements. On an ongoing basis, we evaluate our significant estimates, including those relating to the valuation of inventory, fair value of contingent consideration, valuation of acquired intangible assets, useful lives assigned to finite-lived assets, asset impairment assessments, computation of provisions for income taxes, and valuations related to our convertible senior notes. While the extent of the potential impact of current macroeconomic conditions on our business is highly uncertain, we considered information available related to assumptions and estimates used to determine the results reported and asset valuations as of September&#160;30, 2025. Actual results could differ materially from these estimates.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash, and Investments</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments purchased with an original maturity of 90 days or less to be cash equivalents. Cash equivalents may be comprised of money market funds, certificates of deposit, commercial paper, corporate bonds and notes, and government agencies&#8217; securities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify our investments in debt securities as available-for-sale and report the investments at fair value in current assets. We evaluate our available-for-sale investments in unrealized loss positions and assess whether the unrealized loss is credit-related. Unrealized gains and losses that are not credit-related are recognized in accumulated other comprehensive income (loss) in stockholders&#8217; equity. Realized gains and losses, expected credit losses, as well as interest income, on available-for-sale securities are reported in other income, net. The cost used in the determination of gains and losses of securities sold is based on the specific identification method. The cost of marketable securities is adjusted for the amortization of premiums and discounts to expected maturity. Premium and discount amortization is recorded in other income, net. We have the ability to hold, and do not intend to sell investments in unrealized loss positions before the recovery of their amortized cost bases.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment portfolio at any point in time contains investments in cash deposits, money market funds, commercial paper, corporate debt securities and U.S. government and agency securities with high credit ratings. We have established guidelines regarding diversification and maturities of investments with the objectives of maintaining safety and liquidity, while maximizing yield. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash includes cash that is not readily available for use in the Company&#8217;s operating activities. Restricted cash is primarily comprised of cash pledged under letters of credit.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Pronouncements Pending Adoption</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This new standard requires a company to expand its existing income tax disclosures, specifically related to the rate reconciliation and income taxes paid. The standard is effective for annual periods beginning in 2025 and is expected to be applied retrospectively. We expect that the adoption of this new standard will result in incremental income tax related disclosures to the notes to the consolidated financial statements but will not have a material impact on the consolidated financial statements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-04, </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt With Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This new standard clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion or extinguishment of convertible debt. The standard will be effective for us beginning in the first quarter of 2026, with early adoption permitted. The new standard is expected to be applied prospectively, but retrospective application is permitted. We do not expect the adoption of this new standard to have a material impact on the consolidated financial statements and related disclosures.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This new standard requires a company to provide disaggregated disclosures, within the notes to the financial statements, of specified categories of expenses that are included in line items on the face of the income statement. The standard will be effective for us beginning in 2027, and interim periods within 2028, with early adoption permitted. The new standard is expected to be applied prospectively, but retrospective application is permitted. We are currently evaluating the impact of ASU 2024-03 on the consolidated financial statements and related disclosures.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2025, the FASB issued ASU 2025-06, </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This new standard clarifies and modernizes the recognition and disclosure framework for capitalized internal-use software costs by removing all references to project stages and introduces a more judgment-based approach. The standard also clarifies the threshold to be applied to begin capitalizing. The standard will be effective for us beginning in the first quarter of 2028, with early adoption permitted, and can be applied using a prospective, retrospective, or modified transition approach. We are currently evaluating the impact of ASU 2025-06 on the consolidated financial statements and related disclosures.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes to our significant accounting policies as disclosed in our 2024 Annual Report.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480922/205-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481034/205-10-S45-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">FINANCIAL INSTRUMENTS</a></td>
<td class="text"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 2.  FINANCIAL INSTRUMENTS</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy established under U.S. GAAP requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs that may be used to measure fair value are as follows: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Level 1: quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider an active market as one in which transactions for the asset or liability occurs with sufficient frequency and volume to provide pricing information on an ongoing basis. Conversely, we view an inactive market as one in which there are few transactions for the asset or liability, the prices are not current, or price quotations vary substantially either over time or among market makers. Where appropriate, our non-performance risk, or that of our counterparty, is considered in determining the fair values of liabilities and assets, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify our cash deposits and money market funds within Level 1 of the fair value hierarchy because they are valued using bank balances or quoted market prices. We classify our investments as Level 2 instruments based on market pricing and other observable inputs. We did not classify any of our investments within Level 3 of the fair value hierarchy.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the entire fair value measurement requires management to make judgments and consider factors specific to the asset or liability. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of our accounts receivable, prepaid expenses, other current assets, accounts payable, accrued expenses and other liabilities, current, approximate fair value due to their short maturities.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the fair value of our financial assets and liabilities that were measured on a recurring basis:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash and cash equivalents </span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">52,483&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,984&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">56,467&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">55,370&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">55,370&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Corporate debt securities </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">23,420&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">23,420&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">46,905&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">46,905&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">U.S. government &amp; agency securities</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">218,767&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">218,767&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">287,656&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">287,656&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total investments </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">242,187&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">242,187&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">334,561&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">334,561&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Short-term restricted cash</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">300&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">300&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">690&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">690&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Long-term restricted cash</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,532&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,532&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,532&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,532&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total assets measured at fair value </span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">54,315&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">246,171&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">300,486&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">57,592&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">334,561&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">392,153&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,700&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,700&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total liabilities measured at fair value </span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,700&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,700&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2025, there were no transfers between Level 1, Level 2, or Level 3 assets or liabilities reported at fair value on a recurring basis, and our valuation techniques did not change compared to the prior year.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Contingent Consideration</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the August 2023 </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apton Biosystems, Inc. (&#8220;Apton&#8221;)</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> acquisition, contingent consideration of $25.0&#160;million, which we may elect to pay in cash, shares of our common stock or a combination of cash and shares of our common stock, is due upon the achievement of a milestone, defined as the achievement of $50.0&#160;million in revenue associated with Apton's technology, provided that the milestone event occurs prior to the five-year anniversary of the closing date of the acquisition. The number of shares, if any, to be issued in connection with the achievement of the specified milestone is not known and will be calculated based on the daily volume-weighted average price of our common stock for the <span style="-sec-ix-hidden:f-465">twenty</span> trading days ending on and including the fifth trading day immediately prior to the occurrence of the specified milestone. Upon achievement of the milestone, we may pay cash in lieu of our common stock to ensure that the issuance of our common stock does not exceed 19.9% of our outstanding shares of common stock then outstanding.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration is accounted for as a liability at fair value, with changes during each reporting period recognized in our condensed consolidated statements of operations and comprehensive loss. The fair value of the contingent consideration liability was calculated using a Monte Carlo Simulation to estimate the volatility and systematic relative risk of revenues subject to sales milestone payments and discounting the associated cash payment amounts to their present values using a credit-risk-adjusted interest rate.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify contingent consideration within Level 3, as factors used to develop the estimate of fair value include unobservable inputs that are not supported by market activity and are significant to the fair value. Estimates and assumptions used in the Monte Carlo simulation include risk-adjusted forecasted revenues for products and services leveraging Apton's technology and an estimated credit spread.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of the contingent consideration liability based on the simulated revenue of the Company through the five-year anniversary of the closing date of the acquisition. The key input used in the determination of the fair value included projected revenues of the high-throughput short-read products and services leveraging Apton's technology. Primarily due to management's decision to cease development of the high-throughput short-read system, and the resulting changes in the expected future revenues, among other factors, and as the milestone event must occur prior to the five-year anniversary of the closing date of the acquisition, the estimated fair value of the contingent consideration liability is $0. An increase in the fair value of the liability may result from an acceleration in the timing of or increase in projected revenues and from a </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decrease in discount rates, including the risk-free rate and estimated subordinated credit spread for a CCC credit rating.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the estimated fair value of the contingent consideration liability during the nine months ended September&#160;30, 2025 were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Beginning balance as of December 31, 2024</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,700&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Change in estimated fair value</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(18,700)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Ending balance as of September 30, 2025</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to the fair value are recorded as change in fair value of contingent consideration in the condensed consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash, and Investments</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize our cash, cash equivalents, restricted cash, and investments:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="21" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of September 30, 2025</span></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortized<br/>Cost </span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">56,467&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">56,467&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23,298&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">123&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23,420&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. government &amp; agency securities</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">218,475&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">309&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(17)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">218,767&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total investments </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">241,773&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">432&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(18)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">242,187&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total cash, cash equivalents and investments </span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">298,240&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">432&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(18)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">298,654&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Short-term restricted cash</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">300&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">300&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-term restricted cash</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,532&#160;</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,532&#160;</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">55,370&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">55,370&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">46,746&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">184&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(25)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">46,905&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. government &amp; agency securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">287,393&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">418&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(155)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">287,656&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total investments</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">334,139&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">602&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(180)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">334,561&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total cash, cash equivalents and investments</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">389,509&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">602&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(180)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">389,931&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Short-term restricted cash</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">690&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">690&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-term restricted cash</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,532&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,532&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the contractual maturities of our cash equivalents and available-for-sale investments, excluding money market funds, as of September&#160;30, 2025:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due in one year or less </span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">181,705&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due after one year through five years </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">64,466&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">246,171&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual maturities may differ from contractual maturities because issuers may have the right to call or prepay obligations without call or prepayment penalties.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment income included in other income, net </span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the condensed consolidated statements of operations and comprehensive loss </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was $3.1 million and $10.4 million for the three and nine months ended September&#160;30, 2025, respectively, and $6.0 million and $19.8 million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the three and nine months ended September&#160;30, 2024, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/825/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract', window );"><strong>Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">BALANCE SHEET COMPONENTS</a></td>
<td class="text"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#1383c6;border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 3.  BALANCE SHEET COMPONENTS </span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Inventory, Net</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inventory, net, consisted of the following components:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Purchased materials</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41,788&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">45,270&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Work in process</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25,189&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,172&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,435&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,081&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 8.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory, gross</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">83,412&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">81,523&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 2.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory reserve</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(30,259)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(22,768)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 8.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory, net</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">53,153&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">58,755&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Goodwill and Intangible Assets</span></div></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is reviewed for impairment at least annually during the second quarter, or more frequently if an event occurs indicating the potential for impairment. Based on quantitative interim impairment tests performed in 2024, we recorded impairment charges of $93.2&#160;million in the second quarter of 2024 and $51.3&#160;million in the fourth quarter of 2024.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted a quantitative interim impairment test as of March 31, 2025, based on a decline in stock price and market capitalization during the first quarter of 2025, macroeconomic uncertainties, and revised strategic plans emphasizing HiFi sequencing and discontinuing short-read platform development, and concluded there was no impairment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We completed our annual goodwill impairment assessment on April 1, 2025 and noted no impairment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in our future operating results, cash flows, share price, market capitalization or discount rates used when conducting future goodwill impairment tests could affect the implied fair value of goodwill and may result in additional impairment charges in the future.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets include developed technology, customer relationships, and acquired in-process research and development ("IPR&amp;D"). In connection with the Apton acquisition in August 2023, we allocated $55.0 million of the purchase price to IPR&amp;D. This asset is considered indefinite-lived until the associated research and development activities are either completed or abandoned, and it is tested for impairment annually and more </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized a $40.0&#160;million impairment charge in the fourth quarter of 2024 as a result of a quantitative interim impairment test.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our decision to cease development of the high-throughput short-read sequencing platform, which would utilize the IPR&amp;D, and the resulting changes to the expected future cash flows, among other factors, we concluded that it was more likely than not that the fair value of the IPR&amp;D was less than its carrying amount, requiring an interim impairment assessment. Using a discounted cash flow model under the income approach, we determined the fair value was below carrying value and recorded a $15.0&#160;million impairment charge. The decline in the fair value of the IPR&amp;D below its carrying amount as of March 31, 2025 resulted primarily from changes in the timing of expected future cash flows as compared to the fair value as of December 31, 2024, driven by the restructuring initiatives that prioritize the adoption of HiFi sequencing. The impairment charge is included in our consolidated statements of operations and comprehensive loss for the nine months ended September 30, 2025. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant estimates and assumptions used in the income approach include timing of future cash flows, revenue growth assumptions, a selected discount rate of 14.0%, and a selected obsolescence factor of 11 years. The discount rate was based primarily on the weighted average cost of capital, determined using market, peer company, industry data, and related risk factors. The assessment is a level 3 measurement due to its reliance on certain unobservable inputs and significant management judgment. The assumptions used were inherently subject to uncertainty and small changes in these assumptions could have had a significant impact on the concluded value. A decrease of 200 basis points to the discount rate used in our analysis would have resulted in an increase in the estimated fair value of the IPR&amp;D of approximately $3&#160;million, and an increase of one year to the obsolescence factor used in our analysis would have resulted in an increase in the estimated fair value of the IPR&amp;D of approximately $3&#160;million. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to IPR&amp;D during the nine months ended September&#160;30, 2025 were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance as of December&#160;31, 2024</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,000&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-559">Impairment charge</span></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(15,000)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance as of September&#160;30, 2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_46" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 5. Restructuring</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information on costs incurred in connection with our current year restructuring activities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to IPR&amp;D, we had the following acquired finite-lived intangible assets:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.056%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except years)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>Useful Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Developed technology</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3 &#8212; 15</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">421,179&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(405,036)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,143&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">411,179&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(36,607)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">374,572&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Customer relationships</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">360&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(360)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">360&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(360)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">421,539&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(405,396)</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,143&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">411,539&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(36,967)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">374,572&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization expense of intangible assets with finite lives is as follows:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Remainder of 2025</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,020&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,078&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,078&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,301&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2029</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">745&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2030 and thereafter</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,921&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,143&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of acquired intangible assets is included within our cost of revenue if the costs and expenses related to the intangible assets are attributable to revenue generating activities. Amortization expense for intangible assets that are not directly related to sales generating activities are amortized to operating expenses. For developed technology intangible assets that are utilized in both revenue generating activities and in research and development activities, we allocate the amortization expense between cost of revenue and operating expenses. The finite-lived intangible assets are amortized using the straight-line method over their estimated useful lives.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2025, we revised the estimated useful life of the developed technology acquired in the 2021 Omniome, Inc. ("Omniome") acquisition. This change reflects updated strategic plans and restructuring initiatives focused on accelerating HiFi sequencing adoption, leading to ceased development of our high-throughput short-read platform and revised expectations for the timing and amount of future cash flows from short-read sequencing products and services. As a result of the change in estimate, during the three months ended March 31, 2025, we recognized accelerated amortization of $359.3&#160;million within amortization of acquired intangible assets in operating expenses, reflecting our revised estimate that the asset will no longer generate economic benefit beyond March 31, 2025. This expense had a negative impact on basic and diluted net loss per share of $1.20 for the nine months ended September 30, 2025.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review finite-lived intangible assets for impairment when indication of potential impairment exists, such as a significant reduction in cash flows associated with the assets. In the first quarter of 2025, as part of our interim goodwill impairment test, we also performed a recoverability test for the definite-lived asset group and noted no impairment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;7, 2025, the Company entered into an agreement to acquire certain developed technology and related intellectual property from The Chinese University of Hong Kong for total consideration of $9.7&#160;million. In addition, the Company entered into a license agreement for complementary developed technology during the three months ended March 31, 2025. Both the acquired technology and license are classified as intangible assets and are being amortized over an estimated useful life of three years. As of September&#160;30, 2025, $5.0&#160;million of these intangible assets remained unpaid. This amount is included in accrued liabilities on the condensed consolidated balance sheets and is expected to be paid in 2026.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_46" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 5. Restructuring</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information on costs incurred in connection with our current year restructuring activities.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Deferred Revenue</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2025, we had a total of $20.4&#160;million of deferred revenue, $16.0&#160;million of which was recorded as deferred revenue, current, and $4.4&#160;million of which was recorded as deferred revenue, non-current, which primarily relates to deferred service contract revenues and is scheduled to be recognized in the next four years. Revenue recorded in the three and nine months ended September&#160;30, 2025 includes $2.4&#160;million and $10.5&#160;million, respectively, that was included in deferred revenue as of December&#160;31, 2024.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Obligations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly enter into contracts with multiple performance obligations. These contracts are believed to be firm as of the balance sheet date. However, we may allow customers to make product substitutions or certain modifications at our discretion. The timing of shipments depends on several factors, including agreed upon shipping schedules, which may span multiple quarters. Most performance obligations are generally satisfied within a year of the contract execution date. As of September&#160;30, 2025, the aggregate amount of the transaction price allocated to remaining performance obligations was $48.7&#160;million, of which approximately 72% is expected to be converted to revenue over the next twelve months, approximately 23% in the following twelve months, and the remainder thereafter.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Product Warranties</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally provide a one-year warranty on instruments. In addition, we provide a limited warranty on consumables. At the time revenue is recognized, an accrual is established for estimated warranty costs based on historical experience as well as anticipated product performance. We periodically review the warranty reserve for adequacy and adjust the warranty accrual, if necessary, based on actual experience and estimated costs to be incurred. Warranties are recorded as part of accrued expenses on the condensed consolidated balance sheets and warranty expense is recorded as a component of cost of product revenue in the condensed consolidated statements of operations and comprehensive loss. There were no material changes in estimates for the periods presented below. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the reserve for product warranties were as follows for the periods indicated:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.778%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.782%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance at beginning of period</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,688&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,462&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,100&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,681&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additions charged to cost of product revenue</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,252&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,414&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,809&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,787&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repairs and replacements</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,384)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,610)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,353)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6,202)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance at end of period</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,556&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,266&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,556&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,266&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Components Disclosure [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_SupplementalBalanceSheetComponentsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE SENIOR NOTES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">CONVERTIBLE SENIOR NOTES</a></td>
<td class="text"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 4.  CONVERTIBLE SENIOR NOTES</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2029 Convertible Senior Notes</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 7, 2024, we entered into an exchange agreement with SB Northstar LP (&#8220;SBN&#8221;), a subsidiary of SoftBank Group Corp., pursuant to which we agreed to exchange the remaining approximately $459.0&#160;million in aggregate principal amount of our previously held 1.50% Convertible Senior Notes due 2028 (the &#8220;2028 Notes&#8221;) outstanding for (i) $200.0&#160;million aggregate principal amount of 1.50% Convertible Senior Notes due 2029 (the &#8220;2029 Notes&#8221;), (ii) 20,451,570 shares of common stock (the &#8220;Exchange Shares&#8221;) and (iii) $50.0&#160;million of cash (the &#8220;2024 Exchange Transaction&#8221;). The Exchange Shares were issued on November 21, 2024 (the &#8220;Closing Date&#8221;). The 2029 Notes, the Exchange Shares, and shares of common stock issuable upon conversion of the 2029 Notes were subject to certain lock-up restrictions for a six-month period (the &#8220;Lock-Up Period&#8221;) beginning on the Closing Date of the 2024 Exchange Transaction.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon any conversion of the 2029 Notes, SBN will not be entitled to be issued a number of shares of the Company&#8217;s common stock which would cause SBN's beneficial ownership of common stock to exceed either 9.9% of the total number of issued and outstanding shares of common stock or 9.9% of the combined voting power of all of the securities of the Company, in each case, following such conversion.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2029 Notes are governed by an indenture (the &#8220;2029 Indenture&#8221;) between the Company and U.S. Bank Trust Company, National Association, as trustee. The 2029 Notes bear interest at a rate of 1.50% per annum. Interest on the 2029 Notes is payable semi-annually in arrears on February 15 and August 15, commencing on February 15, 2025. The 2029 Notes will mature on August 15, 2029, subject to earlier conversion, redemption or repurchase.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2029 Notes are convertible at the option of the holder at any time from the expiration of the Lock-Up Period until the second scheduled trading day prior to the maturity date, including in connection with a redemption by the Company. The 2029 Notes are convertible into shares of our common stock based on an initial conversion rate of 204.5157 shares of common stock per $1,000 principal amount of the 2029 Notes (which is equal to an initial conversion price of approximately $4.89 per share of common stock), in each case subject to customary anti-dilution and other adjustments as a result of certain extraordinary transactions. Upon conversion of the 2029 Notes, we may elect to settle such conversion obligation in cash, shares of our common stock, or a combination of cash and shares of our common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after August 20, 2027, and prior to the 31st scheduled trading day immediately preceding the maturity date, the 2029 Notes will be redeemable by the Company in the event that the closing sale price of our common stock has been at least 150% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide the redemption notice at a redemption price of 100% of the principal amount of such 2029 Notes, plus accrued and unpaid interest up to, but excluding, the redemption date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a Fundamental Change (as defined in the 2029 Indenture), the holders of the 2029 Notes may require that we repurchase all or part of the principal amount of the 2029 Notes at a purchase price of par plus unpaid interest up to, but excluding, the maturity date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2029 Notes are subject to certain debt and lien covenants as well as springing guarantees, in each case, the terms of which are set forth in a second letter agreement between the Company and SBN entered into in connection with the Indenture.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2029 Indenture includes customary &#8220;events of default,&#8221; which may result in the acceleration of the maturity of the 2029 Notes under the 2029 Indenture. The 2029 Indenture also includes customary covenants for convertible notes of this type.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent we elect, the sole remedy for an event of default relating to our failure to comply with certain of our reporting obligations shall, for the first 360 calendar days after the occurrence of such an event of default, consist exclusively of the right to receive additional interest on the 2029 Notes at a rate equal to (i) 0.25% per annum of the principal amount of the 2029 Notes outstanding for each day during the first 180 calendar days of the 360-day period after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived) and (ii) 0.50% per annum of the principal amount of the 2029 Notes outstanding for each day from, and including, the 181</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> calendar day to, and including, the 360</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> calendar day after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived as provided for in the 2029 Indenture). On the 361</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> day after such event of default (if the event of default relating to our failure to comply with its obligations is not cured or waived prior to such 361</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> day), the 2029 Notes shall be subject to acceleration as provided for in the 2029 Indenture.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2029 Notes are accounted for in accordance with the authoritative guidance for convertible debt instruments that may be settled in cash upon conversion. Under ASU 2020-06, the guidance requires that debt with an embedded conversion feature is accounted for in its entirety as a liability and no portion of the proceeds from the issuance of the convertible debt instrument is accounted for as attributable to the conversion feature unless the conversion feature is required to be accounted for separately as an embedded derivative or the conversion feature results in a substantial premium. The conversion feature of the 2029 Notes is not accounted for as an embedded derivative because it is considered to be indexed to our common stock, and the 2029 Notes were not issued at a substantial premium; therefore, the 2029 Notes are accounted for in their entirety as a liability. Because we may elect to settle any conversions entirely in shares, and because settlement in shares is the default settlement method, the liability is classified as non-current.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The requirement to repurchase the 2029 Notes, including unpaid interest to the maturity date in the event of a Fundamental Change, is considered a put option for certain periods requiring bifurcation under ASC 815 &#8211; </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> However, given the low probability of such a Fundamental Change occurring during the applicable periods, the value of the embedded derivative is immaterial.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The additional interest feature in the event of our failure to comply with certain reporting obligations is also considered an embedded derivative requiring bifurcation under ASC 815. However, due to the nature and terms of the reporting obligations, the value of the embedded derivative is immaterial.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exchange qualified as a troubled debt restructuring under ASC 470-60 &#8211; </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Troubled Debt Restructurings by Debtors</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Since the undiscounted cash flows of the 2029 Notes were less than the carrying amount of the exchanged 2028 Notes, the carrying value of the 2029 Notes was determined based on the total undiscounted cash flows. As a result, no interest expense will be recognized for the 2029 Notes. The Company recorded a gain on debt restructuring of $154.4&#160;million, which resulted in a decrease of basic net loss per share of $0.56, during the year ended December 31, 2024 in our consolidated statements of operations and comprehensive loss. The gain was calculated as the difference between the carrying amount of the old debt and the carrying amount of the new debt, adjusted for debt issuance costs. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred issuance costs related to the 2029 Notes of approximately $3.1&#160;million, including $0.2&#160;million of lender fees, which were recorded as a reduction to the gain on debt restructuring in our consolidated statements of operations and comprehensive loss. We also paid accrued but unpaid interest of $1.8&#160;million on the 2028 Notes in connection with the 2024 Exchange Transaction.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not receive any cash proceeds from the 2024 Exchange Transaction. In exchange for issuing the 2029 Notes, Exchange Shares and paying $50.0&#160;million of cash pursuant to the 2024 Exchange Transaction, we received and cancelled the exchanged 2028 Notes. Following the closing of the 2024 Exchange Transaction, no amounts were outstanding on the 2028 Notes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of the liability for the 2029 Notes as of September&#160;30, 2025 is $212.0&#160;million, of which $209.0 million is included as convertible senior notes, net, non-current, and $3.0 million is included as accrued expenses on our consolidated balance sheets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to the 2029 Notes during the nine months ended September 30, 2025 were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Carrying amount as of December&#160;31, 2024</span></div></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">214,200&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contractual interest expense</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,200)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Carrying amount as of September&#160;30, 2025</span></div></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">212,000&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2025, the estimated fair value (Level 2) of the 2029 Notes was $169.4&#160;million. The fair value of the 2029 Notes is estimated using a binomial lattice model that is primarily affected by the trading price of our common stock, market interest rates and volatility.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2030 Convertible Senior Notes</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, we entered into a privately negotiated exchange agreement with a holder of our outstanding 2028 Notes, pursuant to which we issued $441.0&#160;million in aggregate principal amount of our 1.375% Convertible Senior Notes due 2030 (the &#8220;2030 Notes&#8221; and together with the 2029 Notes, the &#8220;Notes&#8221;) in exchange for $441.0&#160;million principal amount of the 2028 Notes (the &#8220;2023 Exchange Transaction&#8221;), pursuant to exemptions from registration under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and the rules and regulations thereunder. The 2030 Notes were issued on June 30, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2030 Notes are governed by an indenture (the &#8220;2030 Indenture&#8221;) between the Company and U.S. Bank Trust Company, National Association, as trustee. The 2030 Notes bear interest at a rate of 1.375% per annum. Interest on the 2030 Notes is payable semi-annually in arrears on June 15 and December 15, commencing on December 15, 2023. The 2030 Notes will mature on December 15, 2030, subject to earlier conversion, redemption or repurchase.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2030 Notes are convertible at the option of the holder at any time until the second scheduled trading day prior to the maturity date, including in connection with a redemption by the Company. The 2030 Notes are convertible into shares of our common stock based on an initial conversion rate of 46.5116 shares of common stock per $1,000 principal amount of the 2030 Notes (which is equal to an initial conversion price of approximately $21.50 per share of common stock), in each case subject to customary anti-dilution and other adjustments as a result of certain extraordinary transactions. Upon conversion of the 2030 Notes, we may elect to settle such conversion obligation in cash, shares of our common stock, or a combination of cash and shares of our common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after June 20, 2028, and prior to the 31st scheduled trading day immediately preceding the maturity date, the 2030 Notes will be redeemable by the Company in the event that the closing sale price of our common stock has been at least 150% of the conversion price then in effect for at least 20 trading days (whether or not </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide the redemption notice at a redemption price of 100% of the principal amount of such 2030 Notes, plus accrued and unpaid interest up to, but excluding, the redemption date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a Fundamental Change (as defined in the 2030 Indenture), the holders of the 2030 Notes may require that we repurchase all or part of the principal amount of the 2030 Notes at a purchase price equal to 100% of the principal amount of the notes to be repurchased, plus any accrued and unpaid interest up to, but excluding, the fundamental change repurchase date, and all unpaid interest from the fundamental change repurchase date thereon, but excluding, the maturity date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2030 Indenture includes customary &#8220;events of default,&#8221; which may result in the acceleration of the maturity of the 2030 Notes under the 2030 Indenture. The 2030 Indenture also includes customary covenants for convertible notes of this type.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent we elect, the sole remedy for an event of default relating to our failure to comply with certain of our reporting obligations shall, for the first 360 calendar days after the occurrence of such an event of default, consist exclusively of the right to receive additional interest on the 2030 Notes at a rate equal to (i) 0.25% per annum of the principal amount of the 2030 Notes outstanding for each day during the first 180 calendar days of the 360-day period after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived) and (ii) 0.50% per annum of the principal amount of the 2030 Notes outstanding for each day from, and including, the 181</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> calendar day to, and including, the 360</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> calendar day after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived as provided for in the 2030 Indenture). On the 361</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> day after such event of default (if the event of default relating to our failure to comply with its obligations is not cured or waived prior to such 361</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> day), the 2030 Notes shall be subject to acceleration as provided for in the 2030 Indenture.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2030 Notes are accounted for in accordance with the authoritative guidance for convertible debt instruments that may be settled in cash upon conversion. Under ASU 2020-06, the guidance requires that debt with an embedded conversion feature is accounted for in its entirety as a liability and no portion of the proceeds from the issuance of the convertible debt instrument is accounted for as attributable to the conversion feature unless the conversion feature is required to be accounted for separately as an embedded derivative or the conversion feature results in a substantial premium. The conversion feature of the 2030 Notes is not accounted for as an embedded derivative because it is considered to be indexed to our common stock, and the 2030 Notes were not issued at a substantial premium; therefore, the 2030 Notes are accounted for in their entirety as a liability. Because we may elect to settle any conversions entirely in shares, and because settlement in shares is the default settlement method, the liability is classified as non-current.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The requirement to repurchase the 2030 Notes, including unpaid interest to the maturity date in the event of a Fundamental Change, is considered a put option for certain periods requiring bifurcation under ASC 815 &#8211; </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> However, given the low probability of such a Fundamental Change occurring during the applicable periods, the value of the embedded derivative is immaterial.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The additional interest feature in the event of our failure to comply with certain reporting obligations is also considered an embedded derivative requiring bifurcation under ASC 815. However, due to the nature and terms of the reporting obligations, the value of the embedded derivative is immaterial.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2023 Exchange Transaction was accounted for as an extinguishment driven by the change in fair value of the embedded conversion option. We recorded a loss on extinguishment of debt of approximately $2.0&#160;million in connection with the 2023 Exchange Transaction during the year ended December 31, 2023, which represents the difference between the fair value and the principal amount of the 2030 Notes of the debt at the modification date, plus unamortized debt issuance costs of $1.5&#160;million related to the respective portion of the 2028 Notes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred issuance costs related to the 2030 Notes of approximately $7.3&#160;million, which were recorded as debt issuance costs and are presented as a reduction to the 2030 Notes on our condensed consolidated balance sheets. The debt issuance costs are amortized to interest expense using the effective interest method over the term of the 2030 Notes, resulting in an effective interest rate of 1.6%. We also paid accrued but unpaid interest of $2.5&#160;million on the 2028 Notes in connection with the 2023 Exchange Transaction on June 30, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not receive any cash proceeds from the 2023 Exchange Transaction. In exchange for issuing the 2030 Notes pursuant to the 2023 Exchange Transaction, we received and cancelled the exchanged 2028 Notes. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the closing of the 2023 Exchange Transaction, $459.0&#160;million in aggregate principal amount of 2028 Notes remained outstanding with terms unchanged.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net carrying amount of the liability for the 2030 Notes is included as convertible senior notes, net, non-current in the condensed consolidated balance sheets as follows:</span></div><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Principal amount</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">441,000&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">441,000&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unamortized debt premium</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">398&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">453&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,239)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,959)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net carrying amount</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">436,159&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">435,494&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the 2030 Notes was as follows:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.778%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.782%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contractual interest expense</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,516&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,516&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,548&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,565&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">241&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">237&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">720&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">712&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total interest expense</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,757&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,753&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,268&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,277&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2025, the estimated fair value (Level 2) of the 2030 Notes was $314.5 million. The fair value of the 2030 Notes is estimated using a binomial lattice model that is primarily affected by the trading price of our common stock, market interest rates and volatility.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2028 Convertible Senior Notes</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 9, 2021, we entered into an investment agreement with SBN relating to the issuance and sale to SBN of $900.0&#160;million in aggregate principal amount of the 2028 Notes. The 2028 Notes were issued on February 16, 2021 and bore interest at a rate of 1.50% per annum. As discussed above, in June 2023 we completed an exchange of $441.0&#160;million in aggregate principal amount of our 2028 Notes for $441.0&#160;million aggregate principal amount of the 2030 Notes, leaving approximately $459.0&#160;million in aggregate principal amount of 2028 Notes outstanding. Also as discussed above, in November 2024 we completed an exchange of the remaining $459.0&#160;million in aggregate principal amount of the 2028 Notes outstanding for (i) $200.0&#160;million aggregate principal amount of the 2029 Notes, (ii) the Exchange Shares and (iii) $50.0&#160;million of cash. As of December 31, 2024 no amounts were outstanding on the 2028 Notes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred issuance costs related to the 2028 Notes of approximately $4.5&#160;million, which were recorded as debt issuance costs and are presented as a reduction to the 2028 Notes on our consolidated balance sheets. The debt issuance costs were amortized to interest expense using the effective interest method over the term of the 2028 Notes, resulting in an effective interest rate of 1.6%. In connection with the 2024 Exchange Transaction, the remaining unamortized debt issuance costs related to the 2028 Notes of $1.1&#160;million were extinguished by offsetting the carrying amount of the convertible senior notes. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the 2028 Notes was as follows:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.778%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.778%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.778%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.782%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contractual interest expense</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,721&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,163&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">81&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">243&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total interest expense</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,802&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,406&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">RESTRUCTURING</a></td>
<td class="text"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 5.  RESTRUCTURING</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2025 Restructuring</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2025, we implemented an expense reduction initiative aimed at lowering our annualized run-rate operating expenses. These actions, which included workforce reductions and other cost-saving measures, were part of a broader strategic shift to prioritize the adoption of HiFi sequencing.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the pre-tax restructuring charges are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.687%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.175%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cumulative amount incurred to date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Employee separation costs</span></div></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,787&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other costs</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">66&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">629&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="-sec-ix-hidden:f-747"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total restructuring charges </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></span></div></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">66&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,416&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Cumulative charges incurred to date include $3.3&#160;million in sales, general and administrative expense and $2.1&#160;million in research and development expense.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Charges included employee separation costs comprised of approximately $2.5&#160;million related to salaries, wages and other employee benefits paid to terminated employees pursuant to the Worker Adjustment and Retraining Notification (WARN) Act and approximately $2.3&#160;million of severance costs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Charges included in other costs are primarily related to legal expenses incurred in connection with employee separation matters.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the restructuring and strategic shift, we incurred an additional $388.6&#160;million in costs. These include $359.3&#160;million of accelerated amortization of certain intangible assets, $15.0&#160;million of IPR&amp;D impairment charges, $8.0&#160;million related to excess inventory due to decreased external demand and $3.9&#160;million for estimated losses on purchase commitments tied to anticipated future excess inventory included in cost of revenue, and $2.4&#160;million of accelerated depreciation of fixed assets. See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_37" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 3. Balance Sheet Components</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information on the IPR&amp;D impairment assessment and the change in estimated useful life of the intangible asset and accelerated amortization.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the liabilities related to the restructuring is as follows:</span></div><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.115%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, excluding non-cash activities)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Employee Separation Costs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expense recorded in YTD 2025</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,787&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">629&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,416&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash paid during YTD 2025</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,787)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(528)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,315)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amount recorded in current liabilities<br/>as of September 30, 2025</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Estimated total restructuring costs to still be incurred</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2024 Restructuring</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2024, we implemented an expense reduction initiative that included workforce reductions, the closing of our San Diego office, and other actions to reduce annualized run-rate operating expenses.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the pre-tax restructuring charges are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.687%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.175%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cumulative amount incurred to date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Employee separation costs</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,008&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other costs</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,102&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="-sec-ix-hidden:f-777"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total restructuring charges</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></span></div></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26,110&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:40.5pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Cumulative charges incurred to date include $15.8 million in sales, general and administrative expense; $5.9 million in research and development expense; and $4.4 million in cost of revenue.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumulative charges incurred to date include employee separation costs comprised of approximately $5.5&#160;million related to salaries, wages and other employee benefits paid to terminated employees pursuant to the Worker Adjustment and Retraining Notification (WARN) Act and approximately $4.5&#160;million of severance costs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other costs in cumulative charges incurred to date are primarily related to accelerated amortization and depreciation of $8.1&#160;million for the right-of-use asset, leasehold improvements, and furniture and fixtures relating to the abandonment of the San Diego office. We also incurred cumulative charges to date for excess inventory of $3.6&#160;million primarily relating to a decrease in internal demand resulting from the expense reduction initiatives which were recognized in cost of product revenues. The accelerated amortization and depreciation, which was recognized in sales, general and administrative expense, was determined as a result of the Company's change in estimate pertaining to its remaining useful life of the San Diego office utilizing the estimated date on which it planned to abandon the San Diego office. The lease liability pertaining to the San Diego office was also remeasured during the three months ended June 30, 2024 resulting in a reduction in the operating lease liability balance of $4.4&#160;million, which was offset against the right-of-use asset on the condensed consolidated balance sheets. We fully exited our San Diego office in September 2024.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the liabilities related to the restructuring is as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amount recorded in current liabilities as of December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">170&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">170&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional expense recorded</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">888&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">888&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,058)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,058)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amount recorded in current liabilities as of September&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated total restructuring costs to still be incurred</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table above excludes noncash activities and amounts incurred relating to the San Diego office lease liability. The ending balance of the San Diego office lease liability was $0 at the end of the second quarter of 2025.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/420/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDisclosures', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 6.  COMMITMENTS AND CONTINGENCIES</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Leases</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into various operating lease agreements, primarily relating to our corporate offices. On March 7, 2025, we amended our existing lease covering our corporate headquarters, as well as our research and development, manufacturing, and distribution facilities in Menlo Park, California. The lease amendment extends the term to April 30, 2034. See </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6 &#8211; Commitments and Contingencies</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, subsection titled &#8220;Leases&#8221;, in Part I, Item 1 of the Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 for information regarding the Company&#8217;s maturity of lease liabilities under its lease agreements.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Contingencies</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may become involved in legal proceedings, claims and assessments from time to time in the ordinary course of business. We accrue liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe that the ultimate outcome of any such pending matters is probable or reasonably estimable, or that these matters will have a material adverse effect on our business; however, the results of litigation and claims are inherently unpredictable. Regardless of the outcome, litigation can have an adverse impact on us because of litigation and settlement costs, diversion of management resources, and other factors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see subsection titled </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_91" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Legal Proceedings, in Part II, Item 1</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Indemnification</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Delaware law and agreements entered into with each of our directors and officers, we may have obligations, under certain circumstances, to hold harmless and indemnify each of our directors and officers against losses suffered or incurred by the indemnified party in connection with their service to us, and judgements, fines, settlements and expenses related to claims arising against such directors and officers to the fullest extent permitted under Delaware law, our bylaws and our certificate of incorporation. We also enter and have entered into indemnification agreements with our directors and officers that may require us to indemnify them against liabilities that arise by reason of their status or service as directors or officers, except as prohibited by applicable law. In addition, we may have obligations to hold harmless and indemnify third parties involved with our fundraising efforts and their respective affiliates, directors, officers, employees, agents or other representatives against any and all losses, claims, damages and liabilities related to claims arising against such parties pursuant to the terms of agreements entered into between such third parties and us in connection with such fundraising efforts. To the extent that any such indemnification obligations apply to the lawsuits described above, any associated expenses incurred are included within the related accrued litigation expense amounts. No additional liability associated with such indemnification obligations has been recorded as of September&#160;30, 2025 and December&#160;31, 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482804/825-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480102/450-20-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.Y.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480102/450-20-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450-20/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450-30/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483049/450-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY PLANS AND SHARE-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">EQUITY PLANS AND SHARE-BASED COMPENSATION</a></td>
<td class="text"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 7.  EQUITY PLANS AND SHARE-BASED COMPENSATION</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Equity Plans</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2025, the Company had share-based compensation awards outstanding under the 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;), the 2020 Inducement Equity Incentive Plan (the &#8220;Inducement Plan&#8221;), the 2021 adopted Omniome Equity Incentive Plan of Pacific Biosciences of California, Inc. (the &#8220;Omniome Plan&#8221;) and the 2010 Employee Stock Purchase Plan, from which we issued equity awards and employee stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 4, 2025, our stockholders approved an amendment to the 2020 Plan to reserve an additional 23&#160;million shares of our common stock for issuance pursuant to equity awards granted under the 2020 Plan.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2025, we had 37.8&#160;million shares remaining and available for future issuance under the 2020 Plan, Inducement Plan, and the Omniome Plan. Shares remaining and available for future issuance reflect shares that may become eligible to vest upon the achievement of maximum targets for certain equity awards.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9 &#8211; Stockholders' Equity</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in Part II, Item 8 of our 2024 Annual Report for more information on the Company's equity plans</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Stock Options</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for time-based awards:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(shares in thousands)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Number<br/>of shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Weighted<br/>average<br/>exercise price</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at December 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,509</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11.09&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Granted </span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,290</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.22&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Canceled</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,501)</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.89&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expired</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(376)</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.44&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at September 30, 2025</span></td><td colspan="3" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,922</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.57&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Restricted Stock Units ("RSU") and Performance Stock Units ("PSU")</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant RSUs for which the respective shares vest when the requisite service period is achieved.&#160;We granted PSUs during the first quarter of 2023 for which the number of shares issuable is based on performance relative to specified revenue targets and continued employment through the vesting period. The PSUs are issuable following the third year of the performance period. Maximum achievement of the revenue goal under the PSUs will result in up to 200% of the target number of shares subject to the PSUs to become eligible to vest, while not meeting the minimum achievement of the revenue goal under the PSUs will result in no shares subject to the PSUs becoming eligible to vest. The following table summarizes the time-based RSUs and PSUs activity: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Restricted Stock Units (RSU)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Performance Stock Units (PSU)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Weighted average grant date<br/>fair value</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(shares in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">RSU</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PSU</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at December 31, 2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,211&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">392&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.41&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9.43&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,895&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.25&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,331)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9.47&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,652)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.08&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at September 30, 2025</span></td><td colspan="2" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,123&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">392&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.55&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9.43&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Employee Stock Purchase Plan ("ESPP")</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares issued under our ESPP wer</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e 3,102,930 and 1,906,529</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> durin</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g the nine months ended September&#160;30, 2025 and 2024, respectively. In the first quarter of 2025, an additional 4.0&#160;million shares were reserved under the ESPP. As of September&#160;30, 2025, 15.2&#160;million shares of our common stock remain avai</span><span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lable for issuance under our ESPP.</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Share-based Compensation</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.630%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of revenue</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">892&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,229&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,982&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,466&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,050&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,740&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,964&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,119&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales, general and administrative</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,042&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,290&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,134&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">35,418&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total share-based compensation expense</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,984&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,259&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">32,080&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">55,003&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Determining Fair Value</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of stock options granted using the Black-Scholes valuation method and a single option award approach. When determining the current share prices underlying the stock options for calculating the grant-date fair value, we reference the observable market prices of our stock. This fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. The fair market value of RSUs and PSUs granted is the closing price of our shares on the date of grant and is generally recognized as compensation expense on a straight-line basis over the respective vesting period. For shares purchased under our ESPP, we estimate the grant-date fair value, and the resulting share-based compensation expense, using the Black-Scholes option-pricing model. We estimate forfeitures of stock options, RSUs and shares purchased under our ESPP which is utilized to determine the compensation expense to be recorded over the requisite service period.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Expected Term - The expected term used in the Black-Scholes valuation method represents the period that the stock options are expected to be outstanding and is determined based on historical experience of similar awards, considering the contractual terms of the stock options and vesting schedules.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Expected Volatility - The expected volatility used in the Black-Scholes valuation method is derived from the implied volatility related to our share price over the expected term.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Expected Dividend - We have never paid dividends on our shares and, accordingly, the dividend yield percentage is zero for all periods.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">Risk-Free Interest Rate - The risk-free interest rate used in the Black-Scholes valuation method is the implied yield currently available on U.S. Treasury constant maturities issued with a term equivalent to the expected terms.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of employee stock options was estimated using the following assumptions:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected term in years</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.9</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.9</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected volatility </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;95% &#8212; 96%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">81% &#8212; 93%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk-free interest rate </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;3.89% &#8212; 4.29%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.48% &#8212; 4.32%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Dividend yield </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average grant date fair value per share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$0.90</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$1.40</span></td></tr></table></div><div style="margin-top:15pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of shares to be issued under the ESPP was estimated using the following assumptions:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected term in years</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.5 &#8212; 2.0</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.5 &#8212; 2.0</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected volatility </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">101% &#8212; 113%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">81% &#8212; 118%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk-free interest rate </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.66% &#8212; 4.31%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.88% &#8212; 5.27%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Dividend yield </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average grant date fair value per share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$0.89</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$1.53</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET LOSS PER SHARE</a></td>
<td class="text"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 8.  NET LOSS PER SHARE</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding and potential shares assuming the dilutive effect of the Notes, using the if-converted method, and outstanding equity awards using the treasury stock method.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of the basic and diluted net loss per share amounts presented in the condensed consolidated statements of operations and comprehensive loss:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.235%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except per share amounts)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Numerator:</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(38,000)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(60,725)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(506,005)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(312,222)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Denominator:</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average shares used in computing<br/>basic net loss per share</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">300,844</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">272,915</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">299,303</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">271,631</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic net loss per share</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.13)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.22)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.69)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.15)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Diluted</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average shares used in computing<br/>diluted net loss per share</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">300,844</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">272,915</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">299,303</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">271,631</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Diluted net loss per share</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.13)</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.22)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.69)</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.15)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:15pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following shares issuable upon conversion of the Notes and outstanding equity awards were excluded from the computation of diluted net loss per share for the periods presented because the effect of including such shares would have been antidilutive:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.235%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Shares issuable upon conversion of<br/>convertible senior notes</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">61,415</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,063</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">61,415</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,063</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity awards</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">42,599</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36,496</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">42,599</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36,496</span></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_52" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note 7. Equity Plans and Share-Based Compensation</a></span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for detailed information on equity awards.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT AND GEOGRAPHIC INFORMATION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT AND GEOGRAPHIC INFORMATION</a></td>
<td class="text"><div style="margin-top:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"><span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTE 9.  SEGMENT AND GEOGRAPHIC INFORMATION</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are organized as, and operate in, one reportable segment: the development, manufacturing, and marketing of integrated platforms for genetic analysis. Our chief operating decision-maker ("CODM") is our Chief Executive Officer. Our CODM reviews financial information presented on a consolidated basis for the purposes of evaluating financial performance and allocating resources.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a regular basis, our CODM reviews:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">total revenues by category</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">total expenses and expenses by function, including sales and marketing and general and administrative, which include depreciation and share-based compensation</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt">net loss per share</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our assets are primarily located in the United States of America and not allocated to any specific region, and we do not measure the performance of geographic regions based upon asset-based metrics. Therefore, geographic information is presented only for revenue.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the segment profit or loss, including significant segment expenses is as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.235%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total revenue</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,441&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">39,967&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">115,360&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">114,790&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less:</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of revenue</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,540&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29,963&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">86,146&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">87,566&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,846&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25,516&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">74,428&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">107,456&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales and marketing</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,465&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,435&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">55,057&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">64,779&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,634&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25,311&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">52,385&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">68,597&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Impairment charges</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,000&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">93,200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,170&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(18,700)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of acquired intangible assets</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">833&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,649&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">363,708&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,377&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other income, net</span></div></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,260&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,352&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,775&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,063&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income tax provision</span></div></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">383&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">116&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Consolidated net loss</span></td><td colspan="2" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(38,000)</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(60,725)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(506,005)</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(312,222)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:15pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our revenue by geographic location is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.235%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Americas</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,097&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,107&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">52,087&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">58,542&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,752&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,119&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29,459&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24,497&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Asia-Pacific</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,592&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,741&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33,814&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,751&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,441&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">39,967&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">115,360&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">114,790&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:15pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our revenue by category is as follows: </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.235%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Instrument revenue</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,318&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,788&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36,484&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50,491&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Consumable revenue</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21,279&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,508&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">60,309&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">51,560&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Product revenue</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">32,597&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">35,296&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">96,793&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">102,051&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Service and other revenue</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,844&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,671&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,567&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,739&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,441&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">39,967&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">115,360&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">114,790&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Consolidation</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Basis of Presentation and Consolidation</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States, or U.S. GAAP, as set forth in the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC. The unaudited condensed consolidated financial statements include the accounts of Pacific Biosciences and our wholly owned subsidiaries. Certain information and footnote disclosures typically included in our audited financial statements have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements have been prepared on a consistent basis with the December&#160;31, 2024 audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state our financial position, results of operations, comprehensive loss, and cash flows for the period, but are not necessarily indicative of the results to be expected for the entire year or any future periods. All intercompany transactions and balances have been eliminated.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Use of Estimates</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes to the financial statements. On an ongoing basis, we evaluate our significant estimates, including those relating to the valuation of inventory, fair value of contingent consideration, valuation of acquired intangible assets, useful lives assigned to finite-lived assets, asset impairment assessments, computation of provisions for income taxes, and valuations related to our convertible senior notes. While the extent of the potential impact of current macroeconomic conditions on our business is highly uncertain, we considered information available related to assumptions and estimates used to determine the results reported and asset valuations as of September&#160;30, 2025. Actual results could differ materially from these estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents, Restricted Cash and Investments</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash, and Investments</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments purchased with an original maturity of 90 days or less to be cash equivalents. Cash equivalents may be comprised of money market funds, certificates of deposit, commercial paper, corporate bonds and notes, and government agencies&#8217; securities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify our investments in debt securities as available-for-sale and report the investments at fair value in current assets. We evaluate our available-for-sale investments in unrealized loss positions and assess whether the unrealized loss is credit-related. Unrealized gains and losses that are not credit-related are recognized in accumulated other comprehensive income (loss) in stockholders&#8217; equity. Realized gains and losses, expected credit losses, as well as interest income, on available-for-sale securities are reported in other income, net. The cost used in the determination of gains and losses of securities sold is based on the specific identification method. The cost of marketable securities is adjusted for the amortization of premiums and discounts to expected maturity. Premium and discount amortization is recorded in other income, net. We have the ability to hold, and do not intend to sell investments in unrealized loss positions before the recovery of their amortized cost bases.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment portfolio at any point in time contains investments in cash deposits, money market funds, commercial paper, corporate debt securities and U.S. government and agency securities with high credit ratings. We have established guidelines regarding diversification and maturities of investments with the objectives of maintaining safety and liquidity, while maximizing yield. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash includes cash that is not readily available for use in the Company&#8217;s operating activities. Restricted cash is primarily comprised of cash pledged under letters of credit.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Pronouncements Pending Adoption</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This new standard requires a company to expand its existing income tax disclosures, specifically related to the rate reconciliation and income taxes paid. The standard is effective for annual periods beginning in 2025 and is expected to be applied retrospectively. We expect that the adoption of this new standard will result in incremental income tax related disclosures to the notes to the consolidated financial statements but will not have a material impact on the consolidated financial statements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-04, </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt With Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This new standard clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion or extinguishment of convertible debt. The standard will be effective for us beginning in the first quarter of 2026, with early adoption permitted. The new standard is expected to be applied prospectively, but retrospective application is permitted. We do not expect the adoption of this new standard to have a material impact on the consolidated financial statements and related disclosures.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This new standard requires a company to provide disaggregated disclosures, within the notes to the financial statements, of specified categories of expenses that are included in line items on the face of the income statement. The standard will be effective for us beginning in 2027, and interim periods within 2028, with early adoption permitted. The new standard is expected to be applied prospectively, but retrospective application is permitted. We are currently evaluating the impact of ASU 2024-03 on the consolidated financial statements and related disclosures.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2025, the FASB issued ASU 2025-06, </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software.</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This new standard clarifies and modernizes the recognition and disclosure framework for capitalized internal-use software costs by removing all references to project stages and introduces a more judgment-based approach. The standard also clarifies the threshold to be applied to begin capitalizing. The standard will be effective for us beginning in the first quarter of 2028, with early adoption permitted, and can be applied using a prospective, retrospective, or modified transition approach. We are currently evaluating the impact of ASU 2025-06 on the consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider an active market as one in which transactions for the asset or liability occurs with sufficient frequency and volume to provide pricing information on an ongoing basis. Conversely, we view an inactive market as one in which there are few transactions for the asset or liability, the prices are not current, or price quotations vary substantially either over time or among market makers. Where appropriate, our non-performance risk, or that of our counterparty, is considered in determining the fair values of liabilities and assets, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify our cash deposits and money market funds within Level 1 of the fair value hierarchy because they are valued using bank balances or quoted market prices. We classify our investments as Level 2 instruments based on market pricing and other observable inputs. We did not classify any of our investments within Level 3 of the fair value hierarchy.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the entire fair value measurement requires management to make judgments and consider factors specific to the asset or liability. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of our accounts receivable, prepaid expenses, other current assets, accounts payable, accrued expenses and other liabilities, current, approximate fair value due to their short maturities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the fair value of our financial assets and liabilities that were measured on a recurring basis:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash and cash equivalents </span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">52,483&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,984&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">56,467&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">55,370&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">55,370&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Corporate debt securities </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">23,420&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">23,420&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">46,905&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">46,905&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">U.S. government &amp; agency securities</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">218,767&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">218,767&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">287,656&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">287,656&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total investments </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">242,187&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">242,187&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">334,561&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">334,561&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Short-term restricted cash</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">300&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">300&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">690&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">690&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Long-term restricted cash</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,532&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,532&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,532&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1,532&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total assets measured at fair value </span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">54,315&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">246,171&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">300,486&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">57,592&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">334,561&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">392,153&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,700&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,700&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total liabilities measured at fair value </span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,700&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%">18,700&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Changes in the Estimated Fair Value of Contingent Consideration Liability</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the estimated fair value of the contingent consideration liability during the nine months ended September&#160;30, 2025 were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Beginning balance as of December 31, 2024</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,700&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Change in estimated fair value</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(18,700)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Ending balance as of September 30, 2025</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of Cash, Cash Equivalents, Restricted Cash and Investments</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize our cash, cash equivalents, restricted cash, and investments:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="21" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of September 30, 2025</span></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortized<br/>Cost </span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">56,467&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">56,467&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23,298&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">123&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23,420&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. government &amp; agency securities</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">218,475&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">309&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(17)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">218,767&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total investments </span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">241,773&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">432&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(18)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">242,187&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total cash, cash equivalents and investments </span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">298,240&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">432&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(18)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">298,654&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Short-term restricted cash</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">300&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">300&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-term restricted cash</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,532&#160;</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,532&#160;</span></td><td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross<br/>unrealized<br/>gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross<br/>unrealized<br/>losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">55,370&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">55,370&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">46,746&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">184&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(25)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">46,905&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. government &amp; agency securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">287,393&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">418&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(155)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">287,656&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total investments</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">334,139&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">602&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(180)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">334,561&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total cash, cash equivalents and investments</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">389,509&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">602&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(180)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">389,931&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Short-term restricted cash</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">690&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">690&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-term restricted cash</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,532&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,532&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the contractual maturities of our cash equivalents and available-for-sale investments, excluding money market funds, as of September&#160;30, 2025:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due in one year or less </span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">181,705&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due after one year through five years </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">64,466&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">246,171&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash, cash equivalent, and investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract', window );"><strong>Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inventory, net, consisted of the following components:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Purchased materials</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41,788&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">45,270&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Work in process</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25,189&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,172&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,435&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,081&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 8.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory, gross</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">83,412&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">81,523&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 2.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory reserve</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(30,259)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(22,768)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 8.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory, net</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">53,153&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">58,755&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock', window );">Schedule of Impaired Intangible Assets</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to IPR&amp;D during the nine months ended September&#160;30, 2025 were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance as of December&#160;31, 2024</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,000&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-559">Impairment charge</span></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(15,000)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance as of September&#160;30, 2025</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets From Business Acquisitions</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to IPR&amp;D, we had the following acquired finite-lived intangible assets:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.056%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except years)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>Useful Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Developed technology</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3 &#8212; 15</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">421,179&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(405,036)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,143&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">411,179&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(36,607)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">374,572&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Customer relationships</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">360&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(360)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">360&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(360)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">421,539&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(405,396)</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,143&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">411,539&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(36,967)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">374,572&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Estimated Future Amortization Expense of Acquisition-Related Intangible Assets with Definite Lives</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization expense of intangible assets with finite lives is as follows:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Remainder of 2025</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,020&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,078&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,078&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,301&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2029</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">745&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2030 and thereafter</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,921&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,143&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock', window );">Schedule of Changes in Reserve for Product Warranties</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the reserve for product warranties were as follows for the periods indicated:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.778%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.782%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance at beginning of period</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,688&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,462&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,100&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,681&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additions charged to cost of product revenue</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,252&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,414&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,809&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,787&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repairs and replacements</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,384)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,610)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,353)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6,202)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance at end of period</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,556&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,266&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,556&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,266&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Components Disclosure [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_SupplementalBalanceSheetComponentsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of impaired intangible assets excluding goodwill. This may include a description of the facts and circumstances leading to the recording of impairment charges of intangible assets in the period, the amount of the impairment charges, the methods of determining fair value of the associated assets, the caption in the income statement in which the impairment losses are aggregated, and the segment in which the impaired intangible assets are reported.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE SENIOR NOTES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ScheduleOfInterestExpenseTableTextBlock', window );">Schedule of Interest Expense</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to the 2029 Notes during the nine months ended September 30, 2025 were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Carrying amount as of December&#160;31, 2024</span></div></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">214,200&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contractual interest expense</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,200)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Carrying amount as of September&#160;30, 2025</span></div></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">212,000&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the 2030 Notes was as follows:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.778%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.782%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contractual interest expense</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,516&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,516&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,548&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,565&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">241&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">237&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">720&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">712&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total interest expense</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,757&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,753&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,268&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,277&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the 2028 Notes was as follows:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.778%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.778%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.778%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.782%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contractual interest expense</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,721&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,163&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">81&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">243&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total interest expense</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,802&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,406&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Net Carrying Amount</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net carrying amount of the liability for the 2030 Notes is included as convertible senior notes, net, non-current in the condensed consolidated balance sheets as follows:</span></div><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30,<br/>2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31,<br/>2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Principal amount</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">441,000&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">441,000&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unamortized debt premium</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">398&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">453&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,239)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,959)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net carrying amount</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">436,159&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">435,494&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ScheduleOfInterestExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Interest Expense [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ScheduleOfInterestExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Schedule of Pre-Tax Restructuring Charges</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the pre-tax restructuring charges are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.687%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.175%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cumulative amount incurred to date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Employee separation costs</span></div></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,787&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other costs</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">66&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">629&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="-sec-ix-hidden:f-747"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total restructuring charges </span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></span></div></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">66&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,416&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Cumulative charges incurred to date include $3.3&#160;million in sales, general and administrative expense and $2.1&#160;million in research and development expense.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the pre-tax restructuring charges are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.687%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.175%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cumulative amount incurred to date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Employee separation costs</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,008&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other costs</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,102&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="-sec-ix-hidden:f-777"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total restructuring charges</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></span></div></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26,110&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:40.5pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Cumulative charges incurred to date include $15.8 million in sales, general and administrative expense; $5.9 million in research and development expense; and $4.4 million in cost of revenue.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of Restructuring Reserve by Type of Cost</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the liabilities related to the restructuring is as follows:</span></div><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.115%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, excluding non-cash activities)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Employee Separation Costs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expense recorded in YTD 2025</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,787&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">629&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,416&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash paid during YTD 2025</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,787)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(528)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,315)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amount recorded in current liabilities<br/>as of September 30, 2025</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Estimated total restructuring costs to still be incurred</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the liabilities related to the restructuring is as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amount recorded in current liabilities as of December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">170&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">170&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional expense recorded</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">888&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">888&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash payments</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,058)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,058)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amount recorded in current liabilities as of September&#160;30, 2025</span></div></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated total restructuring costs to still be incurred</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY PLANS AND SHARE-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for time-based awards:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(shares in thousands)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Number<br/>of shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Weighted<br/>average<br/>exercise price</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at December 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,509</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11.09&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Granted </span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,290</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.22&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Canceled</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,501)</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.89&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expired</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(376)</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.44&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at September 30, 2025</span></td><td colspan="3" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,922</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.57&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Time-Based RSUs and PSUs Activity</a></td>
<td class="text">The following table summarizes the time-based RSUs and PSUs activity: <div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Restricted Stock Units (RSU)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Performance Stock Units (PSU)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Weighted average grant date<br/>fair value</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(shares in thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">RSU</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PSU</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at December 31, 2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,211&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">392&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.41&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9.43&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,895&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.25&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,331)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9.47&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,652)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.08&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at September 30, 2025</span></td><td colspan="2" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,123&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">392&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.55&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9.43&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.630%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of revenue</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">892&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,229&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,982&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,466&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development </span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,050&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,740&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,964&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,119&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales, general and administrative</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,042&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,290&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,134&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">35,418&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total share-based compensation expense</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,984&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,259&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">32,080&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">55,003&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Employee Stock Options</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of employee stock options was estimated using the following assumptions:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected term in years</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.9</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.9</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected volatility </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;95% &#8212; 96%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">81% &#8212; 93%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk-free interest rate </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;3.89% &#8212; 4.29%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.48% &#8212; 4.32%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Dividend yield </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average grant date fair value per share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$0.90</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$1.40</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Employee Stock Purchase Plan</a></td>
<td class="text"><div style="margin-top:15pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of shares to be issued under the ESPP was estimated using the following assumptions:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected term in years</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.5 &#8212; 2.0</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.5 &#8212; 2.0</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected volatility </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">101% &#8212; 113%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">81% &#8212; 118%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk-free interest rate </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.66% &#8212; 4.31%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.88% &#8212; 5.27%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Dividend yield </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average grant date fair value per share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$0.89</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$1.53</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718-50/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of the basic and diluted net loss per share amounts presented in the condensed consolidated statements of operations and comprehensive loss:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.235%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except per share amounts)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Numerator:</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(38,000)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(60,725)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(506,005)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(312,222)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Denominator:</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average shares used in computing<br/>basic net loss per share</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">300,844</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">272,915</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">299,303</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">271,631</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic net loss per share</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.13)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.22)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.69)</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.15)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Diluted</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted average shares used in computing<br/>diluted net loss per share</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">300,844</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">272,915</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">299,303</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">271,631</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Diluted net loss per share</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.13)</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.22)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.69)</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.15)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Shares Excluded From Computation of Diluted Net Loss per Share</a></td>
<td class="text"><div style="margin-top:15pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following shares issuable upon conversion of the Notes and outstanding equity awards were excluded from the computation of diluted net loss per share for the periods presented because the effect of including such shares would have been antidilutive:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.235%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Shares issuable upon conversion of<br/>convertible senior notes</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">61,415</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,063</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">61,415</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,063</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity awards</span></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">42,599</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36,496</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">42,599</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36,496</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT AND GEOGRAPHIC INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Profit or Loss</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the segment profit or loss, including significant segment expenses is as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.235%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total revenue</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,441&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">39,967&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">115,360&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">114,790&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less:</span></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of revenue</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,540&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29,963&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">86,146&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">87,566&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,846&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25,516&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">74,428&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">107,456&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales and marketing</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,465&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,435&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">55,057&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">64,779&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,634&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25,311&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">52,385&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">68,597&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Impairment charges</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,000&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">93,200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,170&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(18,700)</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of acquired intangible assets</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">833&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,649&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">363,708&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,377&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other income, net</span></div></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,260&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,352&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,775&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,063&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income tax provision</span></div></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">383&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">116&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Consolidated net loss</span></td><td colspan="2" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(38,000)</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(60,725)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(506,005)</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(312,222)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of Revenue by Geographic Location</a></td>
<td class="text"><div style="margin-top:15pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our revenue by geographic location is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.235%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Americas</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,097&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,107&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">52,087&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">58,542&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,752&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,119&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29,459&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24,497&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Asia-Pacific</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,592&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,741&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33,814&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,751&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,441&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">39,967&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">115,360&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">114,790&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Schedule of Revenue by Category</a></td>
<td class="text"><div style="margin-top:15pt;text-align:justify"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our revenue by category is as follows: </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.235%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Instrument revenue</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,318&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,788&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36,484&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50,491&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Consumable revenue</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21,279&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,508&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">60,309&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">51,560&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Product revenue</span></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">32,597&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">35,296&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">96,793&#160;</span></td><td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">102,051&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Service and other revenue</span></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,844&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,671&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,567&#160;</span></td><td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,739&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38,441&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">39,967&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">115,360&#160;</span></td><td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%">114,790&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 56,467<span></span>
</td>
<td class="nump">$ 55,370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ShortTermRestrictedCashFairValueDisclosure', window );">Short-term restricted cash</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">690<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_LongTermRestrictedCashFairValueDisclosure', window );">Long-term restricted cash</a></td>
<td class="nump">1,532<span></span>
</td>
<td class="nump">1,532<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">300,486<span></span>
</td>
<td class="nump">392,153<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">18,700<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">18,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_InvestmentsMember', window );">Investments:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">242,187<span></span>
</td>
<td class="nump">334,561<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">23,420<span></span>
</td>
<td class="nump">46,905<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government &amp; agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">218,767<span></span>
</td>
<td class="nump">287,656<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">52,483<span></span>
</td>
<td class="nump">55,370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ShortTermRestrictedCashFairValueDisclosure', window );">Short-term restricted cash</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">690<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_LongTermRestrictedCashFairValueDisclosure', window );">Long-term restricted cash</a></td>
<td class="nump">1,532<span></span>
</td>
<td class="nump">1,532<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">54,315<span></span>
</td>
<td class="nump">57,592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Investments:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. government &amp; agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">3,984<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ShortTermRestrictedCashFairValueDisclosure', window );">Short-term restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_LongTermRestrictedCashFairValueDisclosure', window );">Long-term restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">246,171<span></span>
</td>
<td class="nump">334,561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Investments:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">242,187<span></span>
</td>
<td class="nump">334,561<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">23,420<span></span>
</td>
<td class="nump">46,905<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. government &amp; agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">218,767<span></span>
</td>
<td class="nump">287,656<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ShortTermRestrictedCashFairValueDisclosure', window );">Short-term restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_LongTermRestrictedCashFairValueDisclosure', window );">Long-term restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">18,700<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">18,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Investments:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | U.S. government &amp; agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments:</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_LongTermRestrictedCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Restricted Cash Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_LongTermRestrictedCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ShortTermRestrictedCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short-Term Restricted Cash Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ShortTermRestrictedCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 43<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-43<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_InvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_InvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS - Contingent Consideration (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Aug. 02, 2023</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 18,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_AptonMember', window );">Apton</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone', window );">Milestone revenue</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod', window );">Business acquisition, anniversary</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition', window );">Average trading period</a></td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_AptonMember', window );">Apton | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger', window );">Percentage of outstanding shares of common to be issued in merger</a></td>
<td class="nump">19.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_AptonMember', window );">Apton | Achievement of milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration Liability, Measurement Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of outstanding shares of common to be issued in merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Average Trading Period, Acquisition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-47<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 37: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 43<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-43<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pacb_AptonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pacb_AptonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=pacb_AchievementOfMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=pacb_AchievementOfMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS - Schedule of Changes in Estimated Fair Value of Contingent Consideration (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,170<span></span>
</td>
<td class="num">(18,700)<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in value of liability in contingent consideration arrangement in business combination, including, but not limited to, difference arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 43<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-43<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS - Schedule of Cash, Cash Equivalents and Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">$ 298,240<span></span>
</td>
<td class="nump">$ 389,509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">432<span></span>
</td>
<td class="nump">602<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(180)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">298,654<span></span>
</td>
<td class="nump">389,931<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Short-term restricted cash</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Long-term restricted cash</a></td>
<td class="nump">1,532<span></span>
</td>
<td class="nump">1,532<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">56,467<span></span>
</td>
<td class="nump">55,370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">56,467<span></span>
</td>
<td class="nump">55,370<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_InvestmentsMember', window );">Total investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">241,773<span></span>
</td>
<td class="nump">334,139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">432<span></span>
</td>
<td class="nump">602<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(180)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">242,187<span></span>
</td>
<td class="nump">334,561<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">23,298<span></span>
</td>
<td class="nump">46,746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">123<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">23,420<span></span>
</td>
<td class="nump">46,905<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government &amp; agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">218,475<span></span>
</td>
<td class="nump">287,393<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">309<span></span>
</td>
<td class="nump">418<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(17)<span></span>
</td>
<td class="num">(155)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Fair Value</a></td>
<td class="nump">$ 218,767<span></span>
</td>
<td class="nump">$ 287,656<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_InvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_InvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS - Schedule of Contractual Maturities of Cash Equivalents and Available-for-Sale Investments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue', window );">Due in one year or less</a></td>
<td class="nump">$ 181,705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue', window );">Due after one year through five years</a></td>
<td class="nump">64,466<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate', window );">Total</a></td>
<td class="nump">$ 246,171<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security, measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through fifth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS - Investment Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment income, net</a></td>
<td class="nump">$ 3.1<span></span>
</td>
<td class="nump">$ 6.0<span></span>
</td>
<td class="nump">$ 10.4<span></span>
</td>
<td class="nump">$ 19.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - Schedule of Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract', window );"><strong>Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Purchased materials</a></td>
<td class="nump">$ 41,788<span></span>
</td>
<td class="nump">$ 45,270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">25,189<span></span>
</td>
<td class="nump">22,172<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">16,435<span></span>
</td>
<td class="nump">14,081<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory, gross</a></td>
<td class="nump">83,412<span></span>
</td>
<td class="nump">81,523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory reserve</a></td>
<td class="num">(30,259)<span></span>
</td>
<td class="num">(22,768)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">$ 53,153<span></span>
</td>
<td class="nump">$ 58,755<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Components Disclosure [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_SupplementalBalanceSheetComponentsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 07, 2025</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Aug. 02, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ScheduleOfBalanceSheetComponentsLineItems', window );"><strong>Schedule of Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 51,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="nump">$ 93,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate', window );">Intangible asset impairment, discounted cash flow model, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm', window );">Intangible asset impairment, discounted cash flow model, term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate', window );">Intangible asset impairment, increase in basis point discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate', window );">Additional intangible asset impairment, change in discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm', window );">Intangible asset impairment, increase in term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_AdditionalIntangibleAssetImpairmentChangeInTerm', window );">Additional intangible asset impairment, change in term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Deferred revenue, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_StandardProductWarrantyPeriod', window );">Standard product warranty, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=pacb_DevelopedTechnologyAndIntellectualPropertyMember', window );">Developed Technology and Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ScheduleOfBalanceSheetComponentsLineItems', window );"><strong>Schedule of Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Asset acquisition, consideration transferred</a></td>
<td class="nump">$ 9,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent', window );">Asset acquisition amount unpaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=pacb_A2025RestructuringMember', window );">2025 Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ScheduleOfBalanceSheetComponentsLineItems', window );"><strong>Schedule of Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_RestructuringAndRelatedCostAcceleratedAmortization', window );">Restructuring and related cost, accelerated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 359,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 359,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ChangeInEarningsPerShare', window );">Reduction in net loss, basic (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2025-10-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-10-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ScheduleOfBalanceSheetComponentsLineItems', window );"><strong>Schedule of Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Revenue, remaining performance obligation, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Remaining performance obligation period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2026-10-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-10-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ScheduleOfBalanceSheetComponentsLineItems', window );"><strong>Schedule of Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Revenue, remaining performance obligation, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Remaining performance obligation period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ScheduleOfBalanceSheetComponentsLineItems', window );"><strong>Schedule of Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod', window );">Contract with customer, liability, noncurrent, recognition (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember', window );">Technology-Based Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ScheduleOfBalanceSheetComponentsLineItems', window );"><strong>Schedule of Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated Useful Life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember', window );">License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ScheduleOfBalanceSheetComponentsLineItems', window );"><strong>Schedule of Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated Useful Life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pacb_AptonMember', window );">Apton</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ScheduleOfBalanceSheetComponentsLineItems', window );"><strong>Schedule of Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Allocation of purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Intangible Asset Impairment, Change In Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_AdditionalIntangibleAssetImpairmentChangeInTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Intangible Asset Impairment, Change In Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_AdditionalIntangibleAssetImpairmentChangeInTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ChangeInEarningsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in Earnings Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ChangeInEarningsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability, Noncurrent, Recognition Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible Asset Impairment, Discounted Cash Flow Model, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible Asset Impairment, Discounted Cash Flow Model, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible Asset Impairment, Increase In Basis Point Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible Asset Impairment, Increase In Obsolescence Factor, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_RestructuringAndRelatedCostAcceleratedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring and Related Cost, Accelerated Amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_RestructuringAndRelatedCostAcceleratedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ScheduleOfBalanceSheetComponentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Balance Sheet Components [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ScheduleOfBalanceSheetComponentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_StandardProductWarrantyPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Standard Product Warranty, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_StandardProductWarrantyPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized from contingent consideration in asset acquisition, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of identifiable indefinite-lived intangible asset acquired in business combination and recognized at acquisition date. Excludes goodwill and financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=pacb_DevelopedTechnologyAndIntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=pacb_DevelopedTechnologyAndIntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=pacb_A2025RestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=pacb_A2025RestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2025-10-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2025-10-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2026-10-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2026-10-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pacb_AptonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pacb_AptonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - Schedule of Intangible Assets (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRollForward', window );"><strong>Finite-Lived Intangible Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Beginning balance</a></td>
<td class="nump">$ 389,572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Ending balance</a></td>
<td class="nump">16,143<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRollForward', window );"><strong>Finite-Lived Intangible Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Beginning balance</a></td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment charge</a></td>
<td class="num">$ (15,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Impairment charges<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes impairment of intangible asset. Includes, but is not limited to, finite-lived and indefinite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - Schedule of Finite-Lived Intangible Assets From Business Acquisitions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 421,539<span></span>
</td>
<td class="nump">$ 411,539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(405,396)<span></span>
</td>
<td class="num">(36,967)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">16,143<span></span>
</td>
<td class="nump">374,572<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">421,179<span></span>
</td>
<td class="nump">411,179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(405,036)<span></span>
</td>
<td class="num">(36,607)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 16,143<span></span>
</td>
<td class="nump">374,572<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated Useful Life (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated Useful Life (in years)</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated Useful Life (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 360<span></span>
</td>
<td class="nump">360<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(360)<span></span>
</td>
<td class="num">(360)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-29<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-29<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 24: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 26: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 27: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 28: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - Schedule of Estimated Future Amortization Expense of Acquisition-Related Intangible Assets with Definite Lives (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract', window );"><strong>Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Remainder of 2025</a></td>
<td class="nump">$ 1,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2026</a></td>
<td class="nump">4,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2027</a></td>
<td class="nump">4,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2028</a></td>
<td class="nump">1,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2029</a></td>
<td class="nump">745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour', window );">2030 and thereafter</a></td>
<td class="nump">4,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 16,143<span></span>
</td>
<td class="nump">$ 374,572<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Expected Amortization, After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_SupplementalBalanceSheetComponentsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Components Disclosure [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_SupplementalBalanceSheetComponentsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS - Schedule of Changes in Reserve for Product Warranties (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward', window );"><strong>Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrual', window );">Beginning balance</a></td>
<td class="nump">$ 2,688<span></span>
</td>
<td class="nump">$ 3,462<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="nump">$ 4,681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrualWarrantiesIssued', window );">Additions charged to cost of product revenue</a></td>
<td class="nump">1,252<span></span>
</td>
<td class="nump">1,414<span></span>
</td>
<td class="nump">3,809<span></span>
</td>
<td class="nump">4,787<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrualPayments', window );">Repairs and replacements</a></td>
<td class="num">(1,384)<span></span>
</td>
<td class="num">(1,610)<span></span>
</td>
<td class="num">(4,353)<span></span>
</td>
<td class="num">(6,202)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrual', window );">Ending balance</a></td>
<td class="nump">$ 2,556<span></span>
</td>
<td class="nump">$ 3,266<span></span>
</td>
<td class="nump">$ 2,556<span></span>
</td>
<td class="nump">$ 3,266<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrualPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the standard and extended product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard and extended product warranty.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrualPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrualWarrantiesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in the standard and extended product warranty accrual from warranties issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrualWarrantiesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE SENIOR NOTES - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 21, 2024 </div>
<div>USD ($) </div>
<div>d </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 16, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 07, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares', window );">Lock-up period restriction (in months)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnRestructuringOfDebt', window );">Gain on debt restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 154,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_RestructuringOfDebtPricePerShare', window );">Restructuring of debt (in dollar per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible senior notes, net, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 645,159,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 645,159,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 647,494,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,172,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,172,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,595,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2028ConvertibleSeniorNotesMember', window );">2028 Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 81,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 243,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2028ConvertibleSeniorNotesMember', window );">2028 Convertible Senior Notes | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 459,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, stated interest rate</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">441,000,000<span></span>
</td>
<td class="nump">$ 900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_PaymentsInConjunctionWithNotesExchange', window );">Payments made in conjunction with convertible notes exchange</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold percentage of stock price trigger</a></td>
<td class="nump">9.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Aggregate outstanding balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">459,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 459,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Fair value of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2029NotesMember', window );">2029 Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtIssuanceCostLenderFees', window );">Debt issuance cost, lender fees</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible senior notes, net, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2029NotesMember', window );">2029 Convertible Senior Notes | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, stated interest rate</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of notes</a></td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt conversion, shares issued (in shares) | shares</a></td>
<td class="nump">20,451,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold percentage of stock price trigger</a></td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="nump">0.20451570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days | d</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold consecutive trading days | d</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentDebtDefaultCalendarDays', window );">Debt instrument, debt default, calendar days</a></td>
<td class="text">360 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2029NotesMember', window );">2029 Convertible Senior Notes | Convertible Debt | Debt Conversion Terms One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentDebtDefaultCalendarDays', window );">Debt instrument, debt default, calendar days</a></td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentInterestInTheEventOfDefault', window );">Debt instrument, interest in the event of default (as a percent)</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2029NotesMember', window );">2029 Convertible Senior Notes | Convertible Debt | Debt Conversion Terms Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentDebtDefaultCalendarDays', window );">Debt instrument, debt default, calendar days</a></td>
<td class="text">361 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentAdditionalInterestInEventOfDefault', window );">Additional interest in the event of default (as a percent)</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2029NotesMember', window );">2029 Convertible Senior Notes | Convertible Debt | Debt Conversion Terms Two | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentDebtDefaultCalendarDays', window );">Debt instrument, debt default, calendar days</a></td>
<td class="text">181 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2029NotesMember', window );">2029 Convertible Senior Notes | Convertible Debt | Debt Conversion Terms Two | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentDebtDefaultCalendarDays', window );">Debt instrument, debt default, calendar days</a></td>
<td class="text">360 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_ExchangeTransactionMember', window );">Exchange Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_ExchangeTransactionMember', window );">Exchange Transaction | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentInterest', window );">Paid accrued but unpaid interest</a></td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember', window );">2030 Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">441,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">441,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">441,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Aggregate outstanding balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">436,159,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">436,159,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 435,494,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241,000<span></span>
</td>
<td class="nump">$ 237,000<span></span>
</td>
<td class="nump">720,000<span></span>
</td>
<td class="nump">$ 712,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember', window );">2030 Convertible Senior Notes | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 441,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0465116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentDebtDefaultCalendarDays', window );">Debt instrument, debt default, calendar days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">360 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentInterestInTheEventOfDefault', window );">Debt instrument, interest in the event of default (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentAdditionalInterestInEventOfDefault', window );">Additional interest in the event of default (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Fair value of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 314,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 314,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice', window );">Debt redemption, percentage of conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentRedemptionPriceTradingDays', window );">Debt redemption, trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays', window );">Debt redemption, consecutive trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember', window );">2030 Convertible Senior Notes | Convertible Debt | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentDebtDefaultCalendarDays', window );">Debt instrument, debt default, calendar days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">181 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember', window );">2030 Convertible Senior Notes | Convertible Debt | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentDebtDefaultCalendarDays', window );">Debt instrument, debt default, calendar days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">360 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember', window );">2030 Convertible Senior Notes | Convertible Debt | Debt Conversion Terms One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentDebtDefaultCalendarDays', window );">Debt instrument, debt default, calendar days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember', window );">2030 Convertible Senior Notes | Convertible Debt | Debt Conversion Terms Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_DebtInstrumentDebtDefaultCalendarDays', window );">Debt instrument, debt default, calendar days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">361 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DebtInstrumentAdditionalInterestInEventOfDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Additional Interest in the Event of Default</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DebtInstrumentAdditionalInterestInEventOfDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DebtInstrumentDebtDefaultCalendarDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Debt Default, Calendar Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DebtInstrumentDebtDefaultCalendarDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DebtInstrumentInterestInTheEventOfDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Interest in the Event of Default</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DebtInstrumentInterestInTheEventOfDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Price, Consecutive Trading Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Price, Percentage of Conversion Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DebtInstrumentRedemptionPriceTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Price, Trading Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DebtInstrumentRedemptionPriceTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DebtIssuanceCostLenderFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Issuance Cost, Lender Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DebtIssuanceCostLenderFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Holding Period For Transfer, Assignment Or Sale Of Founder Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_PaymentsInConjunctionWithNotesExchange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments In Conjunction With Notes Exchange</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_PaymentsInConjunctionWithNotesExchange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_RestructuringOfDebtPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring Of Debt Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_RestructuringOfDebtPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 470<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnRestructuringOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 60<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481408/470-60-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (m)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnRestructuringOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pacb_A2028ConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pacb_A2028ConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pacb_A2029NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pacb_A2029NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DebtInstrumentConvertibleTermsOfConversionAxis=pacb_DebtConversionTermsOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DebtInstrumentConvertibleTermsOfConversionAxis=pacb_DebtConversionTermsOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_DebtInstrumentConvertibleTermsOfConversionAxis=pacb_DebtConversionTermsTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_DebtInstrumentConvertibleTermsOfConversionAxis=pacb_DebtConversionTermsTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pacb_ExchangeTransactionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pacb_ExchangeTransactionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE SENIOR NOTES - Schedule of Changes to the 2029 Notes (Details) - 2029 Convertible Senior Notes<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Beginning balance</a></td>
<td class="nump">$ 214,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest expense</a></td>
<td class="num">(2,200)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Ending balance</a></td>
<td class="nump">$ 212,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pacb_A2029NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pacb_A2029NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONVERTIBLE SENIOR NOTES - Schedule of Net Carrying Amount (Details) - 2030 Convertible Senior Notes - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">$ 441,000<span></span>
</td>
<td class="nump">$ 441,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedPremium', window );">Unamortized debt premium</a></td>
<td class="nump">398<span></span>
</td>
<td class="nump">453<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Unamortized debt issuance costs</a></td>
<td class="num">(5,239)<span></span>
</td>
<td class="num">(5,959)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying amount</a></td>
<td class="nump">$ 436,159<span></span>
</td>
<td class="nump">$ 435,494<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE SENIOR NOTES - Schedule of Interest Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember', window );">2030 Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest expense</a></td>
<td class="nump">$ 1,516<span></span>
</td>
<td class="nump">$ 1,516<span></span>
</td>
<td class="nump">$ 4,548<span></span>
</td>
<td class="nump">$ 4,565<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">241<span></span>
</td>
<td class="nump">237<span></span>
</td>
<td class="nump">720<span></span>
</td>
<td class="nump">712<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest expense</a></td>
<td class="nump">1,757<span></span>
</td>
<td class="nump">1,753<span></span>
</td>
<td class="nump">5,268<span></span>
</td>
<td class="nump">5,277<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pacb_A2028ConvertibleSeniorNotesMember', window );">2028 Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,721<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">243<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,802<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,406<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pacb_A2030ConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pacb_A2028ConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pacb_A2028ConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING - Schedule of Pre-Tax Restructuring Charges (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=pacb_A2025RestructuringMember', window );">2025 Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Additional expense recorded</a></td>
<td class="nump">$ 66<span></span>
</td>
<td class="nump">$ 5,416<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Cumulative amount incurred to date</a></td>
<td class="nump">$ 5,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Cost of revenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=pacb_A2024RestructuringMember', window );">2024 Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Additional expense recorded</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Cumulative amount incurred to date</a></td>
<td class="nump">$ 26,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Cost of revenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Sales, general and administrative | 2024 Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Cumulative amount incurred to date</a></td>
<td class="nump">$ 15,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | 2024 Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Cumulative amount incurred to date</a></td>
<td class="nump">5,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of revenue | 2024 Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Cumulative amount incurred to date</a></td>
<td class="nump">4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=pacb_EmployeeSeparationCostsMember', window );">Employee separation costs | 2025 Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Additional expense recorded</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Cumulative amount incurred to date</a></td>
<td class="nump">4,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=pacb_EmployeeSeparationCostsMember', window );">Employee separation costs | 2024 Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Additional expense recorded</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Cumulative amount incurred to date</a></td>
<td class="nump">10,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=pacb_EmployeeSeparationCostsMember', window );">Employee separation costs | Sales, general and administrative | 2025 Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Cumulative amount incurred to date</a></td>
<td class="nump">3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=pacb_EmployeeSeparationCostsMember', window );">Employee separation costs | Research and development | 2025 Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Cumulative amount incurred to date</a></td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Other costs | 2025 Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Additional expense recorded</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Cumulative amount incurred to date</a></td>
<td class="nump">629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Other costs | 2024 Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Additional expense recorded</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Cumulative amount incurred to date</a></td>
<td class="nump">$ 16,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostIncurredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostIncurredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes restructuring charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=pacb_A2025RestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=pacb_A2025RestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=pacb_A2024RestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=pacb_A2024RestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=pacb_EmployeeSeparationCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=pacb_EmployeeSeparationCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,768<span></span>
</td>
<td class="nump">$ 3,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Decrease in operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">661<span></span>
</td>
<td class="nump">$ 9,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=pacb_A2025RestructuringMember', window );">2025 Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits', window );">WARN act and other employee benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_RestructuringChargesAdditionalCostsIncurred', window );">Additional costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">388,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_RestructuringAndRelatedCostAcceleratedAmortization', window );">Restructuring and related cost, accelerated amortization</a></td>
<td class="nump">$ 359,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">359,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_GainLossOnPurchaseCommitments', window );">Loss on purchase commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveAcceleratedDepreciation', window );">Accelerated depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=pacb_A2025RestructuringMember', window );">2025 Restructuring | In Process Research And Development Indefinite Lived</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=pacb_A2024RestructuringMember', window );">2024 Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits', window );">WARN act and other employee benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=pacb_SanDiegoOfficeMember', window );">San Diego Office</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveAcceleratedDepreciation', window );">Accelerated depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Decrease in operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_GainLossOnPurchaseCommitments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain Loss On Purchase Commitments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_GainLossOnPurchaseCommitments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_RestructuringAndRelatedCostAcceleratedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring and Related Cost, Accelerated Amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_RestructuringAndRelatedCostAcceleratedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_RestructuringChargesAdditionalCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring Charges, Additional Costs Incurred</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_RestructuringChargesAdditionalCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring Charges, Worker Adjustment and Retraining Notification (WARN) Act and Other Employee Benefits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveAcceleratedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveAcceleratedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=pacb_A2025RestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=pacb_A2025RestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=pacb_A2024RestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=pacb_A2024RestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=pacb_SanDiegoOfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=pacb_SanDiegoOfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING - Schedule of Restructuring Reserve by Type of Cost (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=pacb_A2025RestructuringMember', window );">2025 Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Additional expense recorded</a></td>
<td class="nump">$ 66<span></span>
</td>
<td class="nump">$ 5,416<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,315)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending Balance</a></td>
<td class="nump">101<span></span>
</td>
<td class="nump">101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1', window );">Estimated total restructuring costs to still be incurred</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=pacb_A2024RestructuringMember', window );">2024 Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Additional expense recorded</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,058)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1', window );">Estimated total restructuring costs to still be incurred</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=pacb_EmployeeSeparationCostsMember', window );">Employee separation costs | 2025 Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Additional expense recorded</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,787)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1', window );">Estimated total restructuring costs to still be incurred</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=pacb_EmployeeSeparationCostsMember', window );">Employee separation costs | 2024 Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Additional expense recorded</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Other costs | 2025 Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Additional expense recorded</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">629<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(528)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending Balance</a></td>
<td class="nump">101<span></span>
</td>
<td class="nump">101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1', window );">Estimated total restructuring costs to still be incurred</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Other costs | 2024 Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Additional expense recorded</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,058)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1', window );">Estimated total restructuring costs to still be incurred</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expected cost remaining for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=pacb_A2025RestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=pacb_A2025RestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=pacb_A2024RestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=pacb_A2024RestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=pacb_EmployeeSeparationCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=pacb_EmployeeSeparationCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations', window );">Additional liability associated with indemnification obligations</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Liability Associated With Indemnification Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY PLANS AND SHARE-BASED COMPENSATION - Narrative (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 04, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan', window );">Common stock purchased under plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,102,930<span></span>
</td>
<td class="nump">1,906,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pacb_TimeBasedRestrictedStockUnitsPSUMember', window );">Time Based Restricted Stock Units PSU</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal', window );">Amount eligible to vest upon achievement of goal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pacb_EquityIncentivePlan2020Member', window );">Equity Incentive Plan2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pacb_A2020PlanInducementPlanAndTheOmniomePlanMember', window );">2020 Plan, Inducement Plan, And The Omniome Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock remain available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_EmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock remain available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Additional common stock purchased under plan (in shares)</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Amount Eligible To Vest Upon Achievement Of Goal</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pacb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480520/718-40-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pacb_TimeBasedRestrictedStockUnitsPSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pacb_TimeBasedRestrictedStockUnitsPSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pacb_EquityIncentivePlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pacb_EquityIncentivePlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pacb_A2020PlanInducementPlanAndTheOmniomePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pacb_A2020PlanInducementPlanAndTheOmniomePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=pacb_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Stock Option Activity (Details) - Time-based stock option<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">10,509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">8,290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled (in shares) | shares</a></td>
<td class="num">(2,501)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares) | shares</a></td>
<td class="num">(376)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">15,922<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 11.09<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">1.22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Canceled (in dollars per share) | $ / shares</a></td>
<td class="nump">7.89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in dollars per share) | $ / shares</a></td>
<td class="nump">6.44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.57<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pacb_TimeBasedStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pacb_TimeBasedStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Time-Based RSUs and PSUs Activity (Details)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pacb_TimeBasedRestrictedStockUnitsRsusMember', window );">Restricted Stock Units (RSU)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">14,211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">11,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(4,331)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(3,652)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">18,123<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average grant date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 7.41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">1.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">9.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">4.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.55<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Stock Units (PSU)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average grant date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 9.43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 9.43<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pacb_TimeBasedRestrictedStockUnitsRsusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pacb_TimeBasedRestrictedStockUnitsRsusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,080<span></span>
</td>
<td class="nump">$ 55,003<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 892<span></span>
</td>
<td class="nump">$ 1,229<span></span>
</td>
<td class="nump">2,982<span></span>
</td>
<td class="nump">4,466<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">3,050<span></span>
</td>
<td class="nump">4,740<span></span>
</td>
<td class="nump">8,964<span></span>
</td>
<td class="nump">15,119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Sales, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">7,042<span></span>
</td>
<td class="nump">12,290<span></span>
</td>
<td class="nump">$ 20,134<span></span>
</td>
<td class="nump">$ 35,418<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=pacb_StockBasedCompensationMember', window );">Total share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 10,984<span></span>
</td>
<td class="nump">$ 18,259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=pacb_StockBasedCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=pacb_StockBasedCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Fair Value of Employee Stock Options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pacb_OptionsToPurchaseCommonStockMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">95.00%<span></span>
</td>
<td class="nump">81.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">96.00%<span></span>
</td>
<td class="nump">93.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">3.89%<span></span>
</td>
<td class="nump">3.48%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.29%<span></span>
</td>
<td class="nump">4.32%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value per share (in dollars per share)</a></td>
<td class="nump">$ 0.90<span></span>
</td>
<td class="nump">$ 1.40<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pacb_OptionsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pacb_OptionsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Fair Value of Employee Stock Purchase Plan (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pacb_EmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="nump">81.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">113.00%<span></span>
</td>
<td class="nump">118.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">3.66%<span></span>
</td>
<td class="nump">3.88%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.31%<span></span>
</td>
<td class="nump">5.27%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value per share (in shares)</a></td>
<td class="nump">$ 0.89<span></span>
</td>
<td class="nump">$ 1.53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pacb_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pacb_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="num">$ (38,000)<span></span>
</td>
<td class="num">$ (60,725)<span></span>
</td>
<td class="num">$ (506,005)<span></span>
</td>
<td class="num">$ (312,222)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares used in computing basic net loss per share (in shares)</a></td>
<td class="nump">300,844<span></span>
</td>
<td class="nump">272,915<span></span>
</td>
<td class="nump">299,303<span></span>
</td>
<td class="nump">271,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share (in dollars per share)</a></td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="num">$ (1.69)<span></span>
</td>
<td class="num">$ (1.15)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares used in computing diluted net loss per share (in shares)</a></td>
<td class="nump">300,844<span></span>
</td>
<td class="nump">272,915<span></span>
</td>
<td class="nump">299,303<span></span>
</td>
<td class="nump">271,631<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share (in dollars per share)</a></td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="num">$ (1.69)<span></span>
</td>
<td class="num">$ (1.15)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE - Schedule of Antidilutive Shares Excluded From Computation of Diluted Net Loss per Share (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Shares issuable upon conversion of convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the computation of earnings per share (in shares)</a></td>
<td class="nump">61,415<span></span>
</td>
<td class="nump">31,063<span></span>
</td>
<td class="nump">61,415<span></span>
</td>
<td class="nump">31,063<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Equity awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from the computation of earnings per share (in shares)</a></td>
<td class="nump">42,599<span></span>
</td>
<td class="nump">36,496<span></span>
</td>
<td class="nump">42,599<span></span>
</td>
<td class="nump">36,496<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT AND GEOGRAPHIC INFORMATION - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2025 </div>
<div>customer</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Segment Profit or Loss (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 38,441<span></span>
</td>
<td class="nump">$ 39,967<span></span>
</td>
<td class="nump">$ 115,360<span></span>
</td>
<td class="nump">$ 114,790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="nump">22,540<span></span>
</td>
<td class="nump">29,963<span></span>
</td>
<td class="nump">86,146<span></span>
</td>
<td class="nump">87,566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">22,846<span></span>
</td>
<td class="nump">25,516<span></span>
</td>
<td class="nump">74,428<span></span>
</td>
<td class="nump">107,456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Impairment charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">93,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,170<span></span>
</td>
<td class="num">(18,700)<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">368,429<span></span>
</td>
<td class="nump">20,558<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">2,999<span></span>
</td>
<td class="nump">6,890<span></span>
</td>
<td class="nump">11,989<span></span>
</td>
<td class="nump">19,718<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="nump">383<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Consolidated net loss</a></td>
<td class="num">(38,000)<span></span>
</td>
<td class="num">(60,725)<span></span>
</td>
<td class="num">(506,005)<span></span>
</td>
<td class="num">(312,222)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pacb_ReportableSegmentMember', window );">Reportable Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">38,441<span></span>
</td>
<td class="nump">39,967<span></span>
</td>
<td class="nump">115,360<span></span>
</td>
<td class="nump">114,790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="nump">22,540<span></span>
</td>
<td class="nump">29,963<span></span>
</td>
<td class="nump">86,146<span></span>
</td>
<td class="nump">87,566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">22,846<span></span>
</td>
<td class="nump">25,516<span></span>
</td>
<td class="nump">74,428<span></span>
</td>
<td class="nump">107,456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="nump">15,465<span></span>
</td>
<td class="nump">18,435<span></span>
</td>
<td class="nump">55,057<span></span>
</td>
<td class="nump">64,779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">15,634<span></span>
</td>
<td class="nump">25,311<span></span>
</td>
<td class="nump">52,385<span></span>
</td>
<td class="nump">68,597<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Impairment charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">93,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,170<span></span>
</td>
<td class="num">(18,700)<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">833<span></span>
</td>
<td class="nump">3,649<span></span>
</td>
<td class="nump">363,708<span></span>
</td>
<td class="nump">13,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">1,260<span></span>
</td>
<td class="nump">3,352<span></span>
</td>
<td class="nump">6,775<span></span>
</td>
<td class="nump">9,063<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="nump">383<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Consolidated net loss</a></td>
<td class="num">$ (38,000)<span></span>
</td>
<td class="num">$ (60,725)<span></span>
</td>
<td class="num">$ (506,005)<span></span>
</td>
<td class="num">$ (312,222)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in value of liability in contingent consideration arrangement in business combination, including, but not limited to, difference arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pacb_ReportableSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pacb_ReportableSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Revenue by Geographic Location (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 38,441<span></span>
</td>
<td class="nump">$ 39,967<span></span>
</td>
<td class="nump">$ 115,360<span></span>
</td>
<td class="nump">$ 114,790<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_AmericasMember', window );">Americas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">18,097<span></span>
</td>
<td class="nump">20,107<span></span>
</td>
<td class="nump">52,087<span></span>
</td>
<td class="nump">58,542<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_EMEAMember', window );">Europe, Middle East and Africa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">10,752<span></span>
</td>
<td class="nump">9,119<span></span>
</td>
<td class="nump">29,459<span></span>
</td>
<td class="nump">24,497<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember', window );">Asia-Pacific</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 9,592<span></span>
</td>
<td class="nump">$ 10,741<span></span>
</td>
<td class="nump">$ 33,814<span></span>
</td>
<td class="nump">$ 31,751<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_AmericasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_AmericasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_EMEAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_EMEAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_AsiaPacificMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Revenue by Category (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 38,441<span></span>
</td>
<td class="nump">$ 39,967<span></span>
</td>
<td class="nump">$ 115,360<span></span>
</td>
<td class="nump">$ 114,790<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">32,597<span></span>
</td>
<td class="nump">35,296<span></span>
</td>
<td class="nump">96,793<span></span>
</td>
<td class="nump">102,051<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pacb_InstrumentMember', window );">Instrument revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">11,318<span></span>
</td>
<td class="nump">16,788<span></span>
</td>
<td class="nump">36,484<span></span>
</td>
<td class="nump">50,491<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pacb_ConsumableMember', window );">Consumable revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">21,279<span></span>
</td>
<td class="nump">18,508<span></span>
</td>
<td class="nump">60,309<span></span>
</td>
<td class="nump">51,560<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pacb_ServiceAndOtherMember', window );">Service and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 5,844<span></span>
</td>
<td class="nump">$ 4,671<span></span>
</td>
<td class="nump">$ 18,567<span></span>
</td>
<td class="nump">$ 12,739<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pacb_InstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pacb_InstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pacb_ConsumableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pacb_ConsumableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pacb_ServiceAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pacb_ServiceAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>262</ContextCount>
  <ElementCount>309</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>61</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952156 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - FINANCIAL INSTRUMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTS</Role>
      <ShortName>FINANCIAL INSTRUMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - BALANCE SHEET COMPONENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTS</Role>
      <ShortName>BALANCE SHEET COMPONENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - CONVERTIBLE SENIOR NOTES</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTES</Role>
      <ShortName>CONVERTIBLE SENIOR NOTES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - RESTRUCTURING</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/RESTRUCTURING</Role>
      <ShortName>RESTRUCTURING</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - EQUITY PLANS AND SHARE-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATION</Role>
      <ShortName>EQUITY PLANS AND SHARE-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - NET LOSS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/NETLOSSPERSHARE</Role>
      <ShortName>NET LOSS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATION</Role>
      <ShortName>SEGMENT AND GEOGRAPHIC INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - FINANCIAL INSTRUMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSTables</Role>
      <ShortName>FINANCIAL INSTRUMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTS</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - BALANCE SHEET COMPONENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables</Role>
      <ShortName>BALANCE SHEET COMPONENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTS</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - CONVERTIBLE SENIOR NOTES (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESTables</Role>
      <ShortName>CONVERTIBLE SENIOR NOTES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTES</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - RESTRUCTURING (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/RESTRUCTURINGTables</Role>
      <ShortName>RESTRUCTURING (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/RESTRUCTURING</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - EQUITY PLANS AND SHARE-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONTables</Role>
      <ShortName>EQUITY PLANS AND SHARE-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATION</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - NET LOSS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/NETLOSSPERSHARETables</Role>
      <ShortName>NET LOSS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/NETLOSSPERSHARE</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTables</Role>
      <ShortName>SEGMENT AND GEOGRAPHIC INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATION</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - FINANCIAL INSTRUMENTS - Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSContingentConsiderationDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS - Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Changes in Estimated Fair Value of Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS - Schedule of Changes in Estimated Fair Value of Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Cash, Cash Equivalents and Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS - Schedule of Cash, Cash Equivalents and Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Contractual Maturities of Cash Equivalents and Available-for-Sale Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS - Schedule of Contractual Maturities of Cash Equivalents and Available-for-Sale Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - FINANCIAL INSTRUMENTS - Investment Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSInvestmentIncomeDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS - Investment Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - Schedule of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - BALANCE SHEET COMPONENTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Finite-Lived Intangible Assets From Business Acquisitions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - Schedule of Finite-Lived Intangible Assets From Business Acquisitions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Estimated Future Amortization Expense of Acquisition-Related Intangible Assets with Definite Lives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - Schedule of Estimated Future Amortization Expense of Acquisition-Related Intangible Assets with Definite Lives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Changes in Reserve for Product Warranties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofChangesinReserveforProductWarrantiesDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS - Schedule of Changes in Reserve for Product Warranties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - CONVERTIBLE SENIOR NOTES - Narrative (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails</Role>
      <ShortName>CONVERTIBLE SENIOR NOTES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - CONVERTIBLE SENIOR NOTES - Schedule of Changes to the 2029 Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofChangestothe2029NotesDetails</Role>
      <ShortName>CONVERTIBLE SENIOR NOTES - Schedule of Changes to the 2029 Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - CONVERTIBLE SENIOR NOTES - Schedule of Net Carrying Amount (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails</Role>
      <ShortName>CONVERTIBLE SENIOR NOTES - Schedule of Net Carrying Amount (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - CONVERTIBLE SENIOR NOTES - Schedule of Interest Expense (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails</Role>
      <ShortName>CONVERTIBLE SENIOR NOTES - Schedule of Interest Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - RESTRUCTURING - Schedule of Pre-Tax Restructuring Charges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails</Role>
      <ShortName>RESTRUCTURING - Schedule of Pre-Tax Restructuring Charges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - RESTRUCTURING - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails</Role>
      <ShortName>RESTRUCTURING - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - RESTRUCTURING - Schedule of Restructuring Reserve by Type of Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails</Role>
      <ShortName>RESTRUCTURING - Schedule of Restructuring Reserve by Type of Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - EQUITY PLANS AND SHARE-BASED COMPENSATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails</Role>
      <ShortName>EQUITY PLANS AND SHARE-BASED COMPENSATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockOptionActivityDetails</Role>
      <ShortName>EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Time-Based RSUs and PSUs Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails</Role>
      <ShortName>EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Time-Based RSUs and PSUs Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails</Role>
      <ShortName>EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955543 - Disclosure - EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Fair Value of Employee Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockOptionsDetails</Role>
      <ShortName>EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Fair Value of Employee Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955544 - Disclosure - EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Fair Value of Employee Stock Purchase Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockPurchasePlanDetails</Role>
      <ShortName>EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Fair Value of Employee Stock Purchase Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955545 - Disclosure - NET LOSS PER SHARE - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails</Role>
      <ShortName>NET LOSS PER SHARE - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955546 - Disclosure - NET LOSS PER SHARE - Schedule of Antidilutive Shares Excluded From Computation of Diluted Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSharesExcludedFromComputationofDilutedNetLossperShareDetails</Role>
      <ShortName>NET LOSS PER SHARE - Schedule of Antidilutive Shares Excluded From Computation of Diluted Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9955547 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails</Role>
      <ShortName>SEGMENT AND GEOGRAPHIC INFORMATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9955548 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Segment Profit or Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails</Role>
      <ShortName>SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Segment Profit or Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9955549 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Revenue by Geographic Location (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails</Role>
      <ShortName>SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Revenue by Geographic Location (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="pacb-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9955550 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Revenue by Category (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails</Role>
      <ShortName>SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Revenue by Category (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="pacb-20250930.htm">pacb-20250930.htm</File>
    <File>pacb-20250930.xsd</File>
    <File>pacb-20250930_cal.xml</File>
    <File>pacb-20250930_def.xml</File>
    <File>pacb-20250930_lab.xml</File>
    <File>pacb-20250930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>pacb-20250930_g1.jpg</File>
    <File>pacb-20250930_g2.jpg</File>
    <File>pacb-20250930_g3.jpg</File>
    <File>pacb-20250930_g4.jpg</File>
    <File>pacb-20250930_g5.jpg</File>
    <File>pacb-20250930_g6.jpg</File>
    <File>pacb-20250930_g7.jpg</File>
    <File>pacb-20250930_g8.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="902">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>82
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "pacb-20250930.htm": {
   "nsprefix": "pacb",
   "nsuri": "http://www.pacificbiosciences.com/20250930",
   "dts": {
    "inline": {
     "local": [
      "pacb-20250930.htm"
     ]
    },
    "schema": {
     "local": [
      "pacb-20250930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "pacb-20250930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "pacb-20250930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "pacb-20250930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pacb-20250930_pre.xml"
     ]
    }
   },
   "keyStandard": 274,
   "keyCustom": 35,
   "axisStandard": 23,
   "axisCustom": 1,
   "memberStandard": 32,
   "memberCustom": 26,
   "hidden": {
    "total": 11,
    "http://fasb.org/us-gaap/2025": 5,
    "http://xbrl.sec.gov/dei/2025": 5,
    "http://www.pacificbiosciences.com/20250930": 1
   },
   "contextCount": 262,
   "entityCount": 1,
   "segmentCount": 61,
   "elementCount": 585,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 902,
    "http://xbrl.sec.gov/dei/2025": 29,
    "http://xbrl.sec.gov/ecd/2025": 4
   },
   "report": {
    "R1": {
     "role": "http://www.pacificbiosciences.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
     "longName": "9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:ShortTermInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical",
     "longName": "9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited",
     "longName": "9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited)",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited",
     "longName": "9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-51",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-51",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited",
     "longName": "9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES",
     "longName": "9952156 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTS",
     "longName": "9952157 - Disclosure - FINANCIAL INSTRUMENTS",
     "shortName": "FINANCIAL INSTRUMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTS",
     "longName": "9952158 - Disclosure - BALANCE SHEET COMPONENTS",
     "shortName": "BALANCE SHEET COMPONENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTES",
     "longName": "9952159 - Disclosure - CONVERTIBLE SENIOR NOTES",
     "shortName": "CONVERTIBLE SENIOR NOTES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.pacificbiosciences.com/role/RESTRUCTURING",
     "longName": "9952160 - Disclosure - RESTRUCTURING",
     "shortName": "RESTRUCTURING",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIES",
     "longName": "9952161 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LossContingencyDisclosures",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LossContingencyDisclosures",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATION",
     "longName": "9952162 - Disclosure - EQUITY PLANS AND SHARE-BASED COMPENSATION",
     "shortName": "EQUITY PLANS AND SHARE-BASED COMPENSATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.pacificbiosciences.com/role/NETLOSSPERSHARE",
     "longName": "9952163 - Disclosure - NET LOSS PER SHARE",
     "shortName": "NET LOSS PER SHARE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATION",
     "longName": "9952164 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION",
     "shortName": "SEGMENT AND GEOGRAPHIC INFORMATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-13",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "longName": "9955511 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSTables",
     "longName": "9955512 - Disclosure - FINANCIAL INSTRUMENTS (Tables)",
     "shortName": "FINANCIAL INSTRUMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables",
     "longName": "9955513 - Disclosure - BALANCE SHEET COMPONENTS (Tables)",
     "shortName": "BALANCE SHEET COMPONENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESTables",
     "longName": "9955514 - Disclosure - CONVERTIBLE SENIOR NOTES (Tables)",
     "shortName": "CONVERTIBLE SENIOR NOTES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "pacb:ScheduleOfInterestExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "pacb:ScheduleOfInterestExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.pacificbiosciences.com/role/RESTRUCTURINGTables",
     "longName": "9955515 - Disclosure - RESTRUCTURING (Tables)",
     "shortName": "RESTRUCTURING (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONTables",
     "longName": "9955516 - Disclosure - EQUITY PLANS AND SHARE-BASED COMPENSATION (Tables)",
     "shortName": "EQUITY PLANS AND SHARE-BASED COMPENSATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.pacificbiosciences.com/role/NETLOSSPERSHARETables",
     "longName": "9955517 - Disclosure - NET LOSS PER SHARE (Tables)",
     "shortName": "NET LOSS PER SHARE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTables",
     "longName": "9955518 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION (Tables)",
     "shortName": "SEGMENT AND GEOGRAPHIC INFORMATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
     "longName": "9955519 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "shortName": "FINANCIAL INSTRUMENTS - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSContingentConsiderationDetails",
     "longName": "9955520 - Disclosure - FINANCIAL INSTRUMENTS - Contingent Consideration (Details)",
     "shortName": "FINANCIAL INSTRUMENTS - Contingent Consideration (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-94",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails",
     "longName": "9955521 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Changes in Estimated Fair Value of Contingent Consideration (Details)",
     "shortName": "FINANCIAL INSTRUMENTS - Schedule of Changes in Estimated Fair Value of Contingent Consideration (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-95",
      "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails",
     "longName": "9955522 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Cash, Cash Equivalents and Investments (Details)",
     "shortName": "FINANCIAL INSTRUMENTS - Schedule of Cash, Cash Equivalents and Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails",
     "longName": "9955523 - Disclosure - FINANCIAL INSTRUMENTS - Schedule of Contractual Maturities of Cash Equivalents and Available-for-Sale Investments (Details)",
     "shortName": "FINANCIAL INSTRUMENTS - Schedule of Contractual Maturities of Cash Equivalents and Available-for-Sale Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSInvestmentIncomeDetails",
     "longName": "9955524 - Disclosure - FINANCIAL INSTRUMENTS - Investment Income (Details)",
     "shortName": "FINANCIAL INSTRUMENTS - Investment Income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:InvestmentIncomeNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:InvestmentIncomeNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails",
     "longName": "9955525 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Inventory (Details)",
     "shortName": "BALANCE SHEET COMPONENTS - Schedule of Inventory (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
     "longName": "9955526 - Disclosure - BALANCE SHEET COMPONENTS - Narrative (Details)",
     "shortName": "BALANCE SHEET COMPONENTS - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-105",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-105",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails",
     "longName": "9955527 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Intangible Assets (Details)",
     "shortName": "BALANCE SHEET COMPONENTS - Schedule of Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-106",
      "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails",
     "longName": "9955528 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Finite-Lived Intangible Assets From Business Acquisitions (Details)",
     "shortName": "BALANCE SHEET COMPONENTS - Schedule of Finite-Lived Intangible Assets From Business Acquisitions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails",
     "longName": "9955529 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Estimated Future Amortization Expense of Acquisition-Related Intangible Assets with Definite Lives (Details)",
     "shortName": "BALANCE SHEET COMPONENTS - Schedule of Estimated Future Amortization Expense of Acquisition-Related Intangible Assets with Definite Lives (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofChangesinReserveforProductWarrantiesDetails",
     "longName": "9955530 - Disclosure - BALANCE SHEET COMPONENTS - Schedule of Changes in Reserve for Product Warranties (Details)",
     "shortName": "BALANCE SHEET COMPONENTS - Schedule of Changes in Reserve for Product Warranties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-20",
      "name": "us-gaap:ProductWarrantyAccrual",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-20",
      "name": "us-gaap:ProductWarrantyAccrual",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
     "longName": "9955531 - Disclosure - CONVERTIBLE SENIOR NOTES - Narrative (Details)",
     "shortName": "CONVERTIBLE SENIOR NOTES - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-130",
      "name": "pacb:HoldingPeriodForTransferAssignmentOrSaleOfFounderShares",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-130",
      "name": "pacb:HoldingPeriodForTransferAssignmentOrSaleOfFounderShares",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofChangestothe2029NotesDetails",
     "longName": "9955532 - Disclosure - CONVERTIBLE SENIOR NOTES - Schedule of Changes to the 2029 Notes (Details)",
     "shortName": "CONVERTIBLE SENIOR NOTES - Schedule of Changes to the 2029 Notes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-139",
      "name": "us-gaap:ConvertibleNotesPayable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "pacb:ScheduleOfInterestExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-140",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "pacb:ScheduleOfInterestExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails",
     "longName": "9955533 - Disclosure - CONVERTIBLE SENIOR NOTES - Schedule of Net Carrying Amount (Details)",
     "shortName": "CONVERTIBLE SENIOR NOTES - Schedule of Net Carrying Amount (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-153",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-153",
      "name": "us-gaap:DebtInstrumentUnamortizedPremium",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails",
     "longName": "9955534 - Disclosure - CONVERTIBLE SENIOR NOTES - Schedule of Interest Expense (Details)",
     "shortName": "CONVERTIBLE SENIOR NOTES - Schedule of Interest Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-155",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-155",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails",
     "longName": "9955535 - Disclosure - RESTRUCTURING - Schedule of Pre-Tax Restructuring Charges (Details)",
     "shortName": "RESTRUCTURING - Schedule of Pre-Tax Restructuring Charges (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-171",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-171",
      "name": "us-gaap:RestructuringAndRelatedCostIncurredCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails",
     "longName": "9955536 - Disclosure - RESTRUCTURING - Narrative (Details)",
     "shortName": "RESTRUCTURING - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-103",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-116",
      "name": "pacb:RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails",
     "longName": "9955537 - Disclosure - RESTRUCTURING - Schedule of Restructuring Reserve by Type of Cost (Details)",
     "shortName": "RESTRUCTURING - Schedule of Restructuring Reserve by Type of Cost (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-171",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-116",
      "name": "us-gaap:PaymentsForRestructuring",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESDetails",
     "longName": "9955538 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "pacb:AdditionalLiabilityAssociatedWithIndemnificationObligations",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "pacb:AdditionalLiabilityAssociatedWithIndemnificationObligations",
       "span",
       "div",
       "us-gaap:LossContingencyDisclosures",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "pacb:AdditionalLiabilityAssociatedWithIndemnificationObligations",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "pacb:AdditionalLiabilityAssociatedWithIndemnificationObligations",
       "span",
       "div",
       "us-gaap:LossContingencyDisclosures",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails",
     "longName": "9955539 - Disclosure - EQUITY PLANS AND SHARE-BASED COMPENSATION - Narrative (Details)",
     "shortName": "EQUITY PLANS AND SHARE-BASED COMPENSATION - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockOptionActivityDetails",
     "longName": "9955540 - Disclosure - EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Stock Option Activity (Details)",
     "shortName": "EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-197",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-197",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails",
     "longName": "9955541 - Disclosure - EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Time-Based RSUs and PSUs Activity (Details)",
     "shortName": "EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Time-Based RSUs and PSUs Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-201",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-201",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails",
     "longName": "9955542 - Disclosure - EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Stock-Based Compensation Expense (Details)",
     "shortName": "EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockOptionsDetails",
     "longName": "9955543 - Disclosure - EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Fair Value of Employee Stock Options (Details)",
     "shortName": "EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Fair Value of Employee Stock Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-223",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockPurchasePlanDetails",
     "longName": "9955544 - Disclosure - EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Fair Value of Employee Stock Purchase Plan (Details)",
     "shortName": "EQUITY PLANS AND SHARE-BASED COMPENSATION - Schedule of Fair Value of Employee Stock Purchase Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-229",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails",
     "longName": "9955545 - Disclosure - NET LOSS PER SHARE - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)",
     "shortName": "NET LOSS PER SHARE - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSharesExcludedFromComputationofDilutedNetLossperShareDetails",
     "longName": "9955546 - Disclosure - NET LOSS PER SHARE - Schedule of Antidilutive Shares Excluded From Computation of Diluted Net Loss per Share (Details)",
     "shortName": "NET LOSS PER SHARE - Schedule of Antidilutive Shares Excluded From Computation of Diluted Net Loss per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-231",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-231",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails",
     "longName": "9955547 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Narrative (Details)",
     "shortName": "SEGMENT AND GEOGRAPHIC INFORMATION - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "customer",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "customer",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails",
     "longName": "9955548 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Segment Profit or Loss (Details)",
     "shortName": "SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Segment Profit or Loss (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-239",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails",
     "longName": "9955549 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Revenue by Geographic Location (Details)",
     "shortName": "SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Revenue by Geographic Location (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-243",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails",
     "longName": "9955550 - Disclosure - SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Revenue by Category (Details)",
     "shortName": "SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Revenue by Category (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pacb-20250930.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "pacb_A2020PlanInducementPlanAndTheOmniomePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "A2020PlanInducementPlanAndTheOmniomePlanMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2020 Plan, Inducement Plan, And The Omniome Plan",
        "label": "2020 Plan, Inducement Plan, And The Omniome Plan [Member]",
        "documentation": "2020 Plan, Inducement Plan, And The Omniome Plan"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_A2024RestructuringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "A2024RestructuringMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 Restructuring",
        "label": "2024 Restructuring [Member]",
        "documentation": "2024 Restructuring"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_A2025RestructuringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "A2025RestructuringMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025 Restructuring",
        "label": "2025 Restructuring [Member]",
        "documentation": "2025 Restructuring"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_A2028ConvertibleSeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "A2028ConvertibleSeniorNotesMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028 Convertible Senior Notes",
        "label": "2028 Convertible Senior Notes [Member]",
        "documentation": "Convertible Senior Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_A2029NotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "A2029NotesMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofChangestothe2029NotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029 Convertible Senior Notes",
        "label": "2029 Notes [Member]",
        "documentation": "2029 Notes"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_A2030ConvertibleSeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "A2030ConvertibleSeniorNotesMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2030 Convertible Senior Notes",
        "label": "2030 Convertible Senior Notes [Member]",
        "documentation": "2030 Convertible Senior Notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r924"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, net",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1132"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16",
      "r61",
      "r133",
      "r688",
      "r726",
      "r727",
      "r1223"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r9",
      "r16",
      "r548",
      "r551",
      "r602",
      "r722",
      "r723",
      "r1062",
      "r1063",
      "r1064",
      "r1120",
      "r1121",
      "r1122",
      "r1123"
     ]
    },
    "pacb_AchievementOfMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "AchievementOfMilestoneMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Achievement of milestone",
        "label": "Achievement Of Milestone [Member]",
        "documentation": "Upon achievement of a milestone."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "pacb_AdditionalIntangibleAssetImpairmentChangeInDiscountRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "AdditionalIntangibleAssetImpairmentChangeInDiscountRate",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional intangible asset impairment, change in discount rate",
        "label": "Additional Intangible Asset Impairment, Change In Discount Rate",
        "documentation": "Additional Intangible Asset Impairment, Change In Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_AdditionalIntangibleAssetImpairmentChangeInTerm": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "AdditionalIntangibleAssetImpairmentChangeInTerm",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional intangible asset impairment, change in term",
        "label": "Additional Intangible Asset Impairment, Change In Term",
        "documentation": "Additional Intangible Asset Impairment, Change In Term"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_AdditionalLiabilityAssociatedWithIndemnificationObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "AdditionalLiabilityAssociatedWithIndemnificationObligations",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional liability associated with indemnification obligations",
        "label": "Additional Liability Associated With Indemnification Obligations",
        "documentation": "Additional Liability Associated With Indemnification Obligations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r924",
      "r1290"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r734",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1224",
      "r1293"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expense",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1036"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r962",
      "r972",
      "r982",
      "r1014"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r965",
      "r975",
      "r985",
      "r1017"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1037"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r966",
      "r976",
      "r986",
      "r1010",
      "r1018",
      "r1022",
      "r1030"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r465",
      "r468",
      "r469"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "srt_AmericasMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "AmericasMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Americas",
        "label": "Americas [Member]"
       }
      }
     },
     "auth_ref": [
      "r1295",
      "r1296",
      "r1297",
      "r1298"
     ]
    },
    "pacb_AmortizationOfAcquiredIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "AmortizationOfAcquiredIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of acquired intangible assets",
        "label": "Amortization Of Acquired Intangible Assets",
        "documentation": "Amortization Of Acquired Intangible Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails": {
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt issuance costs",
        "label": "Amortization of Debt Issuance Costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r381",
      "r1111",
      "r1243"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of intangible assets",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r152",
      "r296",
      "r303",
      "r822",
      "r825",
      "r827",
      "r829",
      "r831"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSharesExcludedFromComputationofDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities excluded from the computation of earnings per share (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSharesExcludedFromComputationofDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSharesExcludedFromComputationofDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSharesExcludedFromComputationofDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "pacb_AptonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "AptonMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Apton",
        "label": "Apton [Member]",
        "documentation": "Apton"
       }
      }
     },
     "auth_ref": []
    },
    "srt_AsiaPacificMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "AsiaPacificMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asia-Pacific",
        "label": "Asia Pacific [Member]"
       }
      }
     },
     "auth_ref": [
      "r1295",
      "r1296",
      "r1297",
      "r1298"
     ]
    },
    "us-gaap_AssetAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition [Axis]",
        "label": "Asset Acquisition [Axis]",
        "documentation": "Information by asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r729",
      "r1219"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionConsiderationTransferred",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset acquisition, consideration transferred",
        "label": "Asset Acquisition, Consideration Transferred",
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer."
       }
      }
     },
     "auth_ref": [
      "r905",
      "r1220",
      "r1221",
      "r1222"
     ]
    },
    "us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionContingentConsiderationLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset acquisition amount unpaid",
        "label": "Asset Acquisition, Contingent Consideration, Liability, Noncurrent",
        "documentation": "Amount of liability recognized from contingent consideration in asset acquisition, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r1219"
     ]
    },
    "us-gaap_AssetAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition [Domain]",
        "label": "Asset Acquisition [Domain]",
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r729",
      "r1219"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r110",
      "r132",
      "r157",
      "r160",
      "r161",
      "r194",
      "r205",
      "r223",
      "r227",
      "r268",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r538",
      "r540",
      "r584",
      "r676",
      "r677",
      "r683",
      "r762",
      "r842",
      "r843",
      "r859",
      "r924",
      "r940",
      "r941",
      "r953",
      "r1168",
      "r1169",
      "r1245"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r135",
      "r157",
      "r160",
      "r161",
      "r268",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r538",
      "r540",
      "r584",
      "r924",
      "r1168",
      "r1169",
      "r1245"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets measured at fair value",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r564",
      "r910"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross unrealized gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r241"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gross unrealized losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r242"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due in one year or less",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Fair Value",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date."
       }
      }
     },
     "auth_ref": [
      "r1136"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due after one year through five years",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Fair Value",
        "documentation": "Fair value of investment in debt security, measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through fifth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date."
       }
      }
     },
     "auth_ref": [
      "r1137"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofContractualMaturitiesofCashEquivalentsandAvailableforSaleInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date."
       }
      }
     },
     "auth_ref": [
      "r1134",
      "r1135",
      "r1256"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1025"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r1026"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockOptionActivityDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r1024"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r1022"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1022"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation and Consolidation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r1113"
     ]
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination [Domain]",
        "label": "Business Combination [Domain]",
        "documentation": "Business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r729",
      "r869",
      "r870",
      "r1205",
      "r1207",
      "r1209"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination [Axis]",
        "label": "Business Combination [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r729",
      "r869",
      "r870",
      "r1205",
      "r1207",
      "r1209"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination [Line Items]",
        "label": "Business Combination [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r483",
      "r484",
      "r485",
      "r486",
      "r492",
      "r493",
      "r494",
      "r495",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r530",
      "r531",
      "r532",
      "r535",
      "r873",
      "r877",
      "r1205",
      "r1207",
      "r1209"
     ]
    },
    "pacb_BusinessCombinationConsiderationTransferredRevenueAchievementMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "BusinessCombinationConsiderationTransferredRevenueAchievementMilestone",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone revenue",
        "label": "Business Combination, Consideration Transferred, Revenue Achievement Milestone",
        "documentation": "Milestone Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited",
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of contingent consideration",
        "verboseLabel": "Change in the estimated fair value of contingent consideration",
        "label": "Business Combination, Contingent Consideration, Change in Contingent Consideration, Liability, Increase (Decrease)",
        "documentation": "Amount of increase (decrease) in value of liability in contingent consideration arrangement in business combination, including, but not limited to, difference arising upon settlement."
       }
      }
     },
     "auth_ref": [
      "r533",
      "r1110"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSContingentConsiderationDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Business Combination, Contingent Consideration, Liability",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r532",
      "r565",
      "r566",
      "r567",
      "r873",
      "r876"
     ]
    },
    "pacb_BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business acquisition, anniversary",
        "label": "Business Combination, Contingent Consideration Liability, Measurement Period",
        "documentation": "Business Combination, Contingent Consideration Liability, Measurement Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration liability, non-current",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1212",
      "r1215"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allocation of purchase price",
        "label": "Business Combination, Recognized Asset Acquired, Identifiable Intangible Asset, Indefinite-Lived",
        "documentation": "Amount of identifiable indefinite-lived intangible asset acquired in business combination and recognized at acquisition date. Excludes goodwill and financial asset."
       }
      }
     },
     "auth_ref": [
      "r1208",
      "r1210"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash and cash equivalents",
        "terseLabel": "Cash and cash equivalents at end of period",
        "label": "Cash and Cash Equivalent",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r128",
      "r823"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r580",
      "r581",
      "r582",
      "r1226",
      "r1227"
     ]
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents [Member]",
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, Cash Equivalents, Restricted Cash and Investments",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period",
        "totalLabel": "Cash, cash equivalents, and restricted cash at end of period",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r74",
      "r156"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash, cash equivalents, and restricted cash",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r74"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_ChangeInEarningsPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "ChangeInEarningsPerShare",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction in net loss, basic (in dollars per share)",
        "label": "Change in Earnings Per Share",
        "documentation": "Change in Earnings Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r100",
      "r684",
      "r749"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock shares reserved for future issuance (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r944",
      "r945",
      "r946",
      "r948",
      "r949",
      "r950",
      "r951",
      "r1120",
      "r1121",
      "r1123",
      "r1224",
      "r1289",
      "r1293"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r750"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical",
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r52",
      "r750",
      "r768",
      "r1293",
      "r1294"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r393",
      "r399",
      "r687",
      "r924"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r138",
      "r140",
      "r144",
      "r674",
      "r696",
      "r697"
     ]
    },
    "pacb_ConsumableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "ConsumableMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consumable revenue",
        "label": "Consumable [Member]",
        "documentation": "Consumable [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContingentConsiderationByTypeAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination, Contingent Consideration, Type [Axis]",
        "label": "Business Combination, Contingent Consideration, Type [Axis]",
        "documentation": "Information by type of contingent consideration arrangement in business combination."
       }
      }
     },
     "auth_ref": [
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217"
     ]
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContingentConsiderationTypeDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination, Contingent Consideration, Type [Domain]",
        "label": "Business Combination, Contingent Consideration, Type [Domain]",
        "documentation": "Type of contingent consideration arrangement in business combination."
       }
      }
     },
     "auth_ref": [
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217"
     ]
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract with customer, liability",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r417",
      "r418",
      "r422"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue, current",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r417",
      "r418",
      "r422"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue, non-current",
        "label": "Contract with Customer, Liability, Noncurrent",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r417",
      "r418",
      "r422"
     ]
    },
    "pacb_ContractWithCustomerLiabilityNoncurrentRecognitionPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "ContractWithCustomerLiabilityNoncurrentRecognitionPeriod",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract with customer, liability, noncurrent, recognition (in years)",
        "label": "Contract with Customer, Liability, Noncurrent, Recognition Period",
        "documentation": "Contract with Customer, Liability, Noncurrent, Recognition Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognized",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleDebtFairValueDisclosures",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of convertible debt",
        "label": "Convertible Debt, Fair Value Disclosures",
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1235",
      "r1236",
      "r1237",
      "r1238"
     ]
    },
    "us-gaap_ConvertibleDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleDebtMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Debt",
        "label": "Convertible Debt [Member]",
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r360",
      "r361",
      "r371",
      "r372",
      "r373",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858"
     ]
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleDebtSecuritiesMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSharesExcludedFromComputationofDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issuable upon conversion of convertible senior notes",
        "label": "Convertible Debt Securities [Member]",
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r1174",
      "r1175"
     ]
    },
    "us-gaap_ConvertibleLongTermNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleLongTermNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible senior notes, net, non-current",
        "label": "Convertible Notes Payable, Noncurrent",
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_ConvertibleNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofChangestothe2029NotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible notes payable",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Convertible Notes Payable",
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r99",
      "r1257"
     ]
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate debt securities",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r864",
      "r866",
      "r868",
      "r910",
      "r925",
      "r942",
      "r1286"
     ]
    },
    "us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": {
       "parentTag": "us-gaap_CostOfRevenue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of revenue",
        "label": "Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization",
        "documentation": "Cost of product sold and service rendered, excluding depreciation, depletion, and amortization."
       }
      }
     },
     "auth_ref": [
      "r828",
      "r829",
      "r1045",
      "r1046"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSoldAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfGoodsAndServicesSoldAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": {
       "parentTag": "us-gaap_CostOfRevenue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of acquired intangible assets",
        "label": "Cost, Amortization",
        "documentation": "Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service."
       }
      }
     },
     "auth_ref": [
      "r1065"
     ]
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total cost of revenue",
        "terseLabel": "Cost of revenue",
        "label": "Cost of Revenue",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r157",
      "r160",
      "r161",
      "r268",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r584",
      "r842",
      "r1168"
     ]
    },
    "us-gaap_CostOfRevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfRevenueAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of Revenue:",
        "label": "Cost of Revenue [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of revenue",
        "label": "Cost of Sales [Member]",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerRelationshipsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CustomerRelationshipsMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer relationships",
        "label": "Customer Relationships [Member]",
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships."
       }
      }
     },
     "auth_ref": [
      "r886",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1153",
      "r1154",
      "r1157",
      "r1158"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt conversion, shares issued (in shares)",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22"
     ]
    },
    "pacb_DebtConversionTermsOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "DebtConversionTermsOneMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Conversion Terms One",
        "label": "Debt Conversion Terms One [Member]",
        "documentation": "Debt Conversion Terms One"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_DebtConversionTermsTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "DebtConversionTermsTwoMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Conversion Terms Two",
        "label": "Debt Conversion Terms Two [Member]",
        "documentation": "Debt Conversion Terms Two"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Disclosure [Abstract]",
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CONVERTIBLE SENIOR NOTES",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r157",
      "r159",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r348",
      "r349",
      "r359",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r375",
      "r382",
      "r383",
      "r385",
      "r546",
      "r594"
     ]
    },
    "pacb_DebtInstrumentAdditionalInterestInEventOfDefault": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "DebtInstrumentAdditionalInterestInEventOfDefault",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional interest in the event of default (as a percent)",
        "label": "Debt Instrument, Additional Interest in the Event of Default",
        "documentation": "Debt Instrument, Additional Interest in the Event of Default"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofChangestothe2029NotesDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r42",
      "r43",
      "r97",
      "r99",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r366",
      "r371",
      "r372",
      "r373",
      "r374",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r922",
      "r1114",
      "r1115",
      "r1116",
      "r1119",
      "r1161",
      "r1162",
      "r1163",
      "r1242",
      "r1244",
      "r1254"
     ]
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt, gross",
        "verboseLabel": "Principal amount",
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r99",
      "r386"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion price per share (in dollars per share)",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r362"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, convertible, conversion ratio",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r46",
      "r88",
      "r89",
      "r362"
     ]
    },
    "pacb_DebtInstrumentConvertibleTermsOfConversionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "DebtInstrumentConvertibleTermsOfConversionAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Convertible Terms Of Conversion [Axis]",
        "label": "Debt Instrument, Convertible Terms Of Conversion [Axis]",
        "documentation": "Debt Instrument, Convertible Terms Of Conversion"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_DebtInstrumentConvertibleTermsOfConversionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "DebtInstrumentConvertibleTermsOfConversionDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Convertible Terms Of Conversion [Domain]",
        "label": "Debt Instrument, Convertible Terms Of Conversion [Domain]",
        "documentation": "Debt Instrument, Convertible Terms Of Conversion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Threshold consecutive trading days",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Threshold percentage of stock price trigger",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Threshold trading days",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature."
       }
      }
     },
     "auth_ref": []
    },
    "pacb_DebtInstrumentDebtDefaultCalendarDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "DebtInstrumentDebtDefaultCalendarDays",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, debt default, calendar days",
        "label": "Debt Instrument, Debt Default, Calendar Days",
        "documentation": "Debt Instrument, Debt Default, Calendar Days"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal amount of notes",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r594",
      "r595",
      "r855",
      "r856",
      "r922"
     ]
    },
    "pacb_DebtInstrumentInterestInTheEventOfDefault": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "DebtInstrumentInterestInTheEventOfDefault",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, interest in the event of default (as a percent)",
        "label": "Debt Instrument, Interest in the Event of Default",
        "documentation": "Debt Instrument, Interest in the Event of Default"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, effective interest rate",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r388",
      "r594",
      "r595",
      "r922"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, stated interest rate",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r361"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofChangestothe2029NotesDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r366",
      "r371",
      "r372",
      "r373",
      "r374",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r384",
      "r546",
      "r680",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r922",
      "r1114",
      "r1115",
      "r1116",
      "r1119",
      "r1242",
      "r1244"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofChangestothe2029NotesDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r366",
      "r371",
      "r372",
      "r373",
      "r374",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r922",
      "r1114",
      "r1115",
      "r1116",
      "r1119",
      "r1161",
      "r1162",
      "r1163",
      "r1242",
      "r1244",
      "r1254"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPaymentInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentPeriodicPaymentInterest",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paid accrued but unpaid interest",
        "label": "Debt Instrument, Periodic Payment, Interest",
        "documentation": "Amount of the required periodic payments applied to interest."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "pacb_DebtInstrumentRedemptionPriceConsecutiveTradingDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "DebtInstrumentRedemptionPriceConsecutiveTradingDays",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt redemption, consecutive trading days",
        "label": "Debt Instrument, Redemption Price, Consecutive Trading Days",
        "documentation": "Debt Instrument, Redemption Price, Consecutive Trading Days"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redemption price, percentage",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "pacb_DebtInstrumentRedemptionPricePercentageOfConversionPrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "DebtInstrumentRedemptionPricePercentageOfConversionPrice",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt redemption, percentage of conversion price",
        "label": "Debt Instrument, Redemption Price, Percentage of Conversion Price",
        "documentation": "Debt Instrument, Redemption Price, Percentage of Conversion Price"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_DebtInstrumentRedemptionPriceTradingDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "DebtInstrumentRedemptionPriceTradingDays",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt redemption, trading days",
        "label": "Debt Instrument, Redemption Price, Trading Days",
        "documentation": "Debt Instrument, Redemption Price, Trading Days"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofChangestothe2029NotesDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-Term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r35",
      "r36",
      "r40",
      "r87",
      "r89",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r366",
      "r371",
      "r372",
      "r373",
      "r374",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r384",
      "r546",
      "r680",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r922",
      "r1114",
      "r1115",
      "r1116",
      "r1119",
      "r1242",
      "r1244"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentUnamortizedPremium",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unamortized debt premium",
        "label": "Debt Instrument, Unamortized Premium",
        "documentation": "Amount, after accumulated amortization, of debt premium."
       }
      }
     },
     "auth_ref": [
      "r1171",
      "r1241",
      "r1242",
      "r1244"
     ]
    },
    "pacb_DebtIssuanceCostLenderFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "DebtIssuanceCostLenderFees",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt issuance cost, lender fees",
        "label": "Debt Issuance Cost, Lender Fees",
        "documentation": "Debt Issuance Cost, Lender Fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss",
        "documentation": "Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1143"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest",
        "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1143"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-Sale [Table]",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248"
     ]
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]",
        "label": "Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]",
        "documentation": "Information by type of deferred compensation related to equity-based payment arrangements. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes broad group equity-based compensation plans, defined benefit pension plans, defined benefit other postretirement benefit plans and other deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredFinanceCostsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt issuance costs",
        "label": "Debt Issuance Costs, Gross",
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r1242",
      "r1244"
     ]
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income taxes",
        "label": "Deferred Income Taxes and Tax Credits",
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r29",
      "r151",
      "r825",
      "r827",
      "r829",
      "r831"
     ]
    },
    "pacb_DevelopedTechnologyAndIntellectualPropertyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "DevelopedTechnologyAndIntellectualPropertyMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Developed Technology and Intellectual Property",
        "label": "Developed Technology and Intellectual Property [Member]",
        "documentation": "Developed Technology and Intellectual Property"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DevelopedTechnologyRightsMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Developed technology",
        "label": "Developed Technology Rights [Member]",
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1153",
      "r1154",
      "r1157",
      "r1158",
      "r1211"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r989"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1000"
     ]
    },
    "us-gaap_EMEAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EMEAMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Europe, Middle East and Africa",
        "label": "EMEA [Member]",
        "documentation": "Regions of Europe, Middle East and Africa."
       }
      }
     },
     "auth_ref": [
      "r1295",
      "r1296",
      "r1297",
      "r1298"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share [Abstract]",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited",
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in dollars per share)",
        "verboseLabel": "Basic net loss per share (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r145",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r181",
      "r184",
      "r187",
      "r188",
      "r189",
      "r193",
      "r391",
      "r467",
      "r481",
      "r537",
      "r560",
      "r561",
      "r675",
      "r698",
      "r833"
     ]
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasicAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic",
        "label": "Earnings Per Share, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasicOtherDisclosuresAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited",
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average shares outstanding used in calculating net loss per share:",
        "verboseLabel": "Denominator:",
        "label": "Earnings Per Share, Basic, Other Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited",
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in dollars per share)",
        "verboseLabel": "Diluted net loss per share (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r145",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r184",
      "r187",
      "r188",
      "r189",
      "r193",
      "r391",
      "r467",
      "r481",
      "r537",
      "r560",
      "r561",
      "r675",
      "r698",
      "r833"
     ]
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDilutedAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted",
        "label": "Earnings Per Share, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHARE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NET LOSS PER SHARE",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r190",
      "r191",
      "r192"
     ]
    },
    "pacb_EmployeeSeparationCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "EmployeeSeparationCostsMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee separation costs",
        "label": "Employee Separation Costs [Member]",
        "documentation": "Employee Separation Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1202"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Option",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201"
     ]
    },
    "pacb_EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ESPP",
        "label": "Employee Stock Purchase Plan [Member]",
        "documentation": "Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1039"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r994"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Domain]",
        "label": "Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Domain]",
        "documentation": "Deferred compensation related to equity-based payment arrangements. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes broad group equity-based compensation plans, defined benefit pension plans, defined benefit other postretirement benefit plans and other deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r118",
      "r119",
      "r120",
      "r141",
      "r142",
      "r143",
      "r164",
      "r165",
      "r166",
      "r168",
      "r175",
      "r177",
      "r179",
      "r195",
      "r269",
      "r270",
      "r311",
      "r390",
      "r415",
      "r467",
      "r475",
      "r476",
      "r478",
      "r479",
      "r480",
      "r482",
      "r536",
      "r537",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r559",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r596",
      "r597",
      "r602",
      "r694",
      "r722",
      "r723",
      "r724",
      "r734",
      "r787"
     ]
    },
    "pacb_EquityIncentivePlan2020Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "EquityIncentivePlan2020Member",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Incentive Plan2020",
        "label": "Equity Incentive Plan 2020 [Member]",
        "documentation": "2020 Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1004"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r962",
      "r972",
      "r982",
      "r1014"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r959",
      "r969",
      "r979",
      "r1011"
     ]
    },
    "pacb_ExchangeTransactionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "ExchangeTransactionMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange Transaction",
        "label": "Exchange Transaction [Member]",
        "documentation": "Exchange Transaction"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r564",
      "r575",
      "r910"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r564",
      "r575",
      "r910"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "documentation": "Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r910",
      "r1226",
      "r1227",
      "r1232"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class [Domain]",
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r576",
      "r819",
      "r912",
      "r921"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class [Axis]",
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r576",
      "r819",
      "r912",
      "r921"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r562",
      "r564",
      "r565",
      "r566",
      "r567",
      "r574",
      "r575",
      "r577",
      "r580",
      "r606",
      "r607",
      "r608",
      "r819",
      "r855",
      "r856",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r910",
      "r914",
      "r921"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r425",
      "r430",
      "r431",
      "r564",
      "r575",
      "r580",
      "r606",
      "r819",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r910",
      "r921"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r425",
      "r430",
      "r431",
      "r433",
      "r564",
      "r565",
      "r575",
      "r580",
      "r607",
      "r819",
      "r855",
      "r856",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r910",
      "r921"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r564",
      "r565",
      "r566",
      "r567",
      "r575",
      "r580",
      "r608",
      "r819",
      "r855",
      "r856",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r910",
      "r914",
      "r921"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Changes in the Estimated Fair Value of Contingent Consideration Liability",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r568",
      "r573",
      "r576"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofChangesinEstimatedFairValueofContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r562",
      "r564",
      "r565",
      "r566",
      "r567",
      "r574",
      "r575",
      "r577",
      "r580",
      "r606",
      "r607",
      "r608",
      "r819",
      "r855",
      "r856",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r910",
      "r914",
      "r921"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Financial Instruments",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r1234"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r384",
      "r413",
      "r546",
      "r557",
      "r578",
      "r583",
      "r586",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r682",
      "r695",
      "r848",
      "r910",
      "r912",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r925",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1225",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1233",
      "r1235",
      "r1236"
     ]
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FINANCIAL INSTRUMENTS",
        "label": "Financial Instruments Disclosure [Text Block]",
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures."
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "pacb_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2030 and thereafter",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "documentation": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Useful Life (in years)",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated Amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r280",
      "r302",
      "r822"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r818",
      "r822"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remainder of 2025",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r1299"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r818",
      "r822"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r818",
      "r822"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r818",
      "r822"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r297",
      "r298",
      "r299",
      "r301",
      "r302",
      "r306",
      "r307",
      "r637",
      "r638",
      "r729",
      "r818",
      "r822",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Carrying Amount",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r302",
      "r638",
      "r822"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r302",
      "r306",
      "r307",
      "r310",
      "r637",
      "r818",
      "r822",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r297",
      "r298",
      "r299",
      "r301",
      "r302",
      "r306",
      "r307",
      "r729",
      "r818",
      "r822",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofEstimatedFutureAmortizationExpenseofAcquisitionRelatedIntangibleAssetswithDefiniteLivesDetails",
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r637",
      "r1154"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsRollForward",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets [Roll Forward]",
        "label": "Finite-Lived Intangible Assets [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r966",
      "r976",
      "r986",
      "r1018"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r966",
      "r976",
      "r986",
      "r1018"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r966",
      "r976",
      "r986",
      "r1018"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r966",
      "r976",
      "r986",
      "r1018"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r966",
      "r976",
      "r986",
      "r1018"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r999"
     ]
    },
    "pacb_GainLossOnPurchaseCommitments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "GainLossOnPurchaseCommitments",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on purchase commitments",
        "label": "Gain Loss On Purchase Commitments",
        "documentation": "Gain Loss On Purchase Commitments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss on extinguishment of debt",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r33",
      "r34"
     ]
    },
    "us-gaap_GainsLossesOnRestructuringOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainsLossesOnRestructuringOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on debt restructuring",
        "label": "Gains (Losses) on Restructuring of Debt",
        "documentation": "For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r149"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r771"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r281",
      "r673",
      "r843",
      "r849",
      "r873",
      "r874",
      "r875",
      "r906",
      "r911",
      "r924",
      "r1145",
      "r1146",
      "r1218"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillAndIntangibleAssetImpairment",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited",
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment charges",
        "label": "Goodwill and Intangible Asset Impairment",
        "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment charges",
        "label": "Goodwill, Impairment Loss",
        "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r282",
      "r288",
      "r292",
      "r294",
      "r535",
      "r849",
      "r911"
     ]
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r64",
      "r109",
      "r157",
      "r160",
      "r161",
      "r268",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r584",
      "r837",
      "r842",
      "r1126",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1168"
     ]
    },
    "pacb_HoldingPeriodForTransferAssignmentOrSaleOfFounderShares": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "HoldingPeriodForTransferAssignmentOrSaleOfFounderShares",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lock-up period restriction (in months)",
        "label": "Holding Period For Transfer, Assignment Or Sale Of Founder Shares",
        "documentation": "Holding Period For Transfer, Assignment Or Sale Of Founder Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "label": "Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes impairment of intangible asset. Includes, but is not limited to, finite-lived and indefinite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r309"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Impairment charge",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r147",
      "r296",
      "r308"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of intangible assets",
        "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)",
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value."
       }
      }
     },
     "auth_ref": [
      "r296",
      "r1111",
      "r1156",
      "r1160"
     ]
    },
    "pacb_InProcessResearchAndDevelopmentIndefiniteLivedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "InProcessResearchAndDevelopmentIndefiniteLivedMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "In Process Research And Development Indefinite Lived",
        "label": "In Process Research And Development Indefinite Lived [Member]",
        "documentation": "In-process research and development indefinite lived"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InProcessResearchAndDevelopmentMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "In Process Research and Development",
        "label": "In Process Research and Development [Member]",
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process."
       }
      }
     },
     "auth_ref": [
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1156",
      "r1157",
      "r1158"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r104",
      "r109",
      "r676",
      "r678",
      "r692",
      "r828",
      "r830",
      "r832",
      "r837",
      "r842",
      "r1126",
      "r1128",
      "r1129",
      "r1130",
      "r1131"
     ]
    },
    "pacb_IncomeLossPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "IncomeLossPerShareAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share:",
        "label": "Income Loss per Share Abstrct",
        "documentation": "Income Loss per Share Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r319",
      "r324",
      "r542",
      "r543",
      "r544",
      "r545",
      "r569",
      "r573",
      "r576",
      "r585",
      "r586",
      "r587",
      "r719",
      "r721",
      "r772",
      "r818",
      "r819",
      "r873",
      "r875",
      "r908",
      "r909",
      "r913",
      "r921",
      "r1204",
      "r1206",
      "r1259"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r324",
      "r542",
      "r543",
      "r544",
      "r545",
      "r569",
      "r573",
      "r576",
      "r585",
      "r586",
      "r587",
      "r719",
      "r721",
      "r772",
      "r818",
      "r819",
      "r873",
      "r875",
      "r908",
      "r909",
      "r913",
      "r921",
      "r1204",
      "r1206",
      "r1259"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income tax provision",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r117",
      "r157",
      "r178",
      "r179",
      "r194",
      "r213",
      "r227",
      "r473",
      "r474",
      "r477",
      "r699",
      "r828",
      "r830",
      "r832",
      "r872"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable, net",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred revenue",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r635",
      "r1110"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventory, net",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in assets and liabilities",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "negatedTerseLabel": "Decrease in operating lease liability",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r1044",
      "r1110"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-Lived Intangible Assets [Axis]",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r300",
      "r305",
      "r822",
      "r878",
      "r879",
      "r880",
      "r889",
      "r890",
      "r904"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-Lived Intangible Assets [Line Items]",
        "label": "Indefinite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r305",
      "r310",
      "r822",
      "r878",
      "r879",
      "r880",
      "r889",
      "r890",
      "r904"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r300",
      "r305",
      "r822",
      "r878",
      "r879",
      "r880",
      "r889",
      "r890",
      "r904"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r966",
      "r976",
      "r986",
      "r1010",
      "r1018",
      "r1022",
      "r1030"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r958",
      "r1034"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r958",
      "r1034"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r958",
      "r1034"
     ]
    },
    "pacb_InstrumentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "InstrumentMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Instrument revenue",
        "label": "Instrument [Member]",
        "documentation": "Instrument [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible asset impairment, discounted cash flow model, discount rate",
        "label": "Intangible Asset Impairment, Discounted Cash Flow Model, Discount Rate",
        "documentation": "Intangible Asset Impairment, Discounted Cash Flow Model, Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_IntangibleAssetImpairmentDiscountedCashFlowModelTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "IntangibleAssetImpairmentDiscountedCashFlowModelTerm",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible asset impairment, discounted cash flow model, term (in years)",
        "label": "Intangible Asset Impairment, Discounted Cash Flow Model, Term",
        "documentation": "Intangible Asset Impairment, Discounted Cash Flow Model, Term"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible asset impairment, increase in basis point discount rate",
        "label": "Intangible Asset Impairment, Increase In Basis Point Discount Rate",
        "documentation": "Intangible Asset Impairment, Increase In Basis Point Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible asset impairment, increase in term (in years)",
        "label": "Intangible Asset Impairment, Increase In Obsolescence Factor, Term",
        "documentation": "Intangible Asset Impairment, Increase In Obsolescence Factor, Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails",
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r1154",
      "r1156"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total interest expense",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r379",
      "r389",
      "r857",
      "r858",
      "r1292"
     ]
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseDebtExcludingAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails": {
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofChangestothe2029NotesDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofInterestExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Contractual interest expense",
        "terseLabel": "Contractual interest expense",
        "label": "Interest Expense, Debt, Excluding Amortization",
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r380",
      "r857",
      "r858"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r828",
      "r832",
      "r1066"
     ]
    },
    "us-gaap_InventoryFinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryFinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails": {
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Gross",
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1056"
     ]
    },
    "us-gaap_InventoryGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryGross",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Inventory, gross",
        "label": "Inventory, Gross",
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r1059"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails",
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventory, net",
        "totalLabel": "Inventory, net",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r824",
      "r924"
     ]
    },
    "us-gaap_InventoryRawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryRawMaterials",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails": {
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchased materials",
        "label": "Inventory, Raw Materials, Gross",
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1058"
     ]
    },
    "us-gaap_InventoryValuationReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryValuationReserves",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Inventory reserve",
        "label": "Inventory Valuation Reserves",
        "documentation": "Amount of valuation reserve for inventory."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r1059"
     ]
    },
    "us-gaap_InventoryWorkInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryWorkInProcess",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails": {
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work in process",
        "label": "Inventory, Work in Process, Gross",
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1057"
     ]
    },
    "us-gaap_InventoryWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryWriteDown",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory provision",
        "label": "Inventory Write-down",
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels."
       }
      }
     },
     "auth_ref": [
      "r279"
     ]
    },
    "us-gaap_InvestmentIncomeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeNet",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSInvestmentIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment income, net",
        "label": "Investment Income, Net",
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r68",
      "r69"
     ]
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accretion of discount and amortization of premium on marketable securities, net",
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments, All Other Investments [Abstract]",
        "label": "Investments, All Other Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments:",
        "label": "Investments, Fair Value Disclosure",
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method."
       }
      }
     },
     "auth_ref": [
      "r1226",
      "r1227",
      "r1231",
      "r1235",
      "r1236",
      "r1237",
      "r1238"
     ]
    },
    "us-gaap_InvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments:",
        "verboseLabel": "Total investments",
        "label": "Investments [Member]",
        "documentation": "Assets held for their financial return, rather than for the entity's operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r42",
      "r43",
      "r44",
      "r47",
      "r48",
      "r49",
      "r50",
      "r157",
      "r160",
      "r161",
      "r268",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r539",
      "r540",
      "r541",
      "r584",
      "r748",
      "r836",
      "r859",
      "r953",
      "r1168",
      "r1245",
      "r1246"
     ]
    },
    "us-gaap_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities",
        "label": "Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r101",
      "r690",
      "r924",
      "r940",
      "r941",
      "r1114",
      "r1118",
      "r1142",
      "r1239"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and Stockholders\u2019 Equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r127",
      "r157",
      "r160",
      "r161",
      "r268",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r539",
      "r540",
      "r541",
      "r584",
      "r924",
      "r1168",
      "r1245",
      "r1246"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities measured at fair value",
        "label": "Liabilities, Fair Value Disclosure",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r564",
      "r1226"
     ]
    },
    "us-gaap_LicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LicenseMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License",
        "label": "License [Member]",
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r1172",
      "r1173"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate outstanding balance",
        "totalLabel": "Net carrying amount",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r99",
      "r158",
      "r163",
      "r372",
      "r387",
      "r680",
      "r855",
      "r856",
      "r922",
      "r1257"
     ]
    },
    "pacb_LongTermRestrictedCashFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "LongTermRestrictedCashFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term restricted cash",
        "label": "Long Term Restricted Cash Fair Value Disclosure",
        "documentation": "Long-Term Restricted Cash Fair Value Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r1161",
      "r1162",
      "r1163"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r32",
      "r1161",
      "r1162",
      "r1163"
     ]
    },
    "us-gaap_LossContingencyDisclosures": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingencyDisclosures",
     "presentation": [
      "http://www.pacificbiosciences.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r163",
      "r332",
      "r333",
      "r334",
      "r336",
      "r338",
      "r339",
      "r340",
      "r341",
      "r471",
      "r680",
      "r1240"
     ]
    },
    "pacb_LossOnPurchaseCommitment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "LossOnPurchaseCommitment",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": {
       "parentTag": "us-gaap_CostOfRevenue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on purchase commitment",
        "label": "Loss On Purchase Commitment",
        "documentation": "Loss On Purchase Commitment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockPurchasePlanDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r200",
      "r335",
      "r337",
      "r338",
      "r339",
      "r434",
      "r461",
      "r462",
      "r463",
      "r471",
      "r567",
      "r634",
      "r718",
      "r720",
      "r728",
      "r740",
      "r741",
      "r792",
      "r794",
      "r796",
      "r797",
      "r799",
      "r802",
      "r803",
      "r805",
      "r806",
      "r816",
      "r817",
      "r847",
      "r860",
      "r871",
      "r873",
      "r876",
      "r877",
      "r914",
      "r915",
      "r919",
      "r920",
      "r935",
      "r1170",
      "r1247",
      "r1248",
      "r1249",
      "r1250",
      "r1251",
      "r1252"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r200",
      "r335",
      "r337",
      "r338",
      "r339",
      "r434",
      "r461",
      "r462",
      "r463",
      "r471",
      "r567",
      "r634",
      "r718",
      "r720",
      "r728",
      "r740",
      "r741",
      "r792",
      "r794",
      "r796",
      "r797",
      "r799",
      "r802",
      "r803",
      "r805",
      "r806",
      "r816",
      "r817",
      "r847",
      "r860",
      "r871",
      "r873",
      "r876",
      "r877",
      "r914",
      "r915",
      "r919",
      "r935",
      "r1170",
      "r1247",
      "r1248",
      "r1249",
      "r1250",
      "r1251",
      "r1252"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofChangesinReserveforProductWarrantiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]",
        "label": "Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1029"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r75",
      "r76"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited",
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited",
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Consolidated net loss",
        "verboseLabel": "Net loss",
        "terseLabel": "Net loss",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r76",
      "r105",
      "r120",
      "r125",
      "r136",
      "r139",
      "r143",
      "r157",
      "r160",
      "r161",
      "r162",
      "r167",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r178",
      "r179",
      "r185",
      "r268",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r391",
      "r394",
      "r396",
      "r400",
      "r467",
      "r481",
      "r537",
      "r561",
      "r584",
      "r693",
      "r769",
      "r785",
      "r786",
      "r828",
      "r830",
      "r832",
      "r952",
      "r1168"
     ]
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Numerator:",
        "label": "Net Income (Loss) Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r146",
      "r171",
      "r172",
      "r173",
      "r174",
      "r181",
      "r182",
      "r186",
      "r189",
      "r394",
      "r396",
      "r400",
      "r537"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r966",
      "r976",
      "r986",
      "r1010",
      "r1018"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r993"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r992"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1029"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1029"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r838",
      "r846",
      "r1127"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expense",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Expense:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r828",
      "r832",
      "r837",
      "r1126",
      "r1128",
      "r1129",
      "r1130",
      "r1131"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, liability",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, current",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, non-current",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets, net",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r598"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r1111"
     ]
    },
    "pacb_OptionsToPurchaseCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "OptionsToPurchaseCommonStockMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options to purchase common stock",
        "label": "Options To Purchase Common Stock [Member]",
        "documentation": "Options to purchase common stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r121",
      "r122",
      "r123",
      "r730",
      "r731"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain (loss) on investments",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r9",
      "r94"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss)",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r9",
      "r94",
      "r137",
      "r140",
      "r175"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income:",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities, current",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r924"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities, non-current",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other",
        "label": "Other Noncash Income (Expense)",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income, net",
        "verboseLabel": "Other income, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r907"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "us-gaap_OtherRestructuringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherRestructuringMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other costs",
        "label": "Other Restructuring [Member]",
        "documentation": "Restructuring and related activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r826",
      "r850",
      "r851",
      "r852",
      "r853"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r964",
      "r974",
      "r984",
      "r1016"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r967",
      "r977",
      "r987",
      "r1019"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r967",
      "r977",
      "r987",
      "r1019"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r991"
     ]
    },
    "us-gaap_PaymentsForRestructuring": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRestructuring",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cash payments",
        "label": "Payments for Restructuring",
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r1109"
     ]
    },
    "pacb_PaymentsInConjunctionWithNotesExchange": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "PaymentsInConjunctionWithNotesExchange",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments made in conjunction with convertible notes exchange",
        "label": "Payments In Conjunction With Notes Exchange",
        "documentation": "Payments In Conjunction With Notes Exchange"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchases of intangible assets",
        "label": "Payments to Acquire Intangible Assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of investments",
        "label": "Payments to Acquire Investments",
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r993"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r992"
     ]
    },
    "pacb_PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of outstanding shares of common to be issued in merger",
        "label": "Percentage Of Outstanding Shares Of Common To Be Issued In Merger",
        "documentation": "Percentage of outstanding shares of common to be issued in merger."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Stock Units (PSU)",
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": [
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r994"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1038"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r993"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r402"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r750"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued (in share)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r402"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r750",
      "r768",
      "r1293",
      "r1294"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r393",
      "r398",
      "r686",
      "r924"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1061"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock from equity plans",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r13"
     ]
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturities of investments",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r154",
      "r1133"
     ]
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales of investments",
        "label": "Proceeds from Sale of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r153",
      "r236",
      "r267"
     ]
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProductMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product revenue",
        "label": "Product [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r827",
      "r832",
      "r861",
      "r862"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r230",
      "r636",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r820",
      "r827",
      "r830",
      "r832",
      "r861",
      "r862",
      "r934",
      "r935",
      "r936",
      "r939",
      "r943",
      "r1043",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1166",
      "r1167",
      "r1258",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1274",
      "r1275",
      "r1276",
      "r1277",
      "r1278",
      "r1279",
      "r1280",
      "r1281",
      "r1282",
      "r1283",
      "r1284",
      "r1285",
      "r1287",
      "r1288"
     ]
    },
    "us-gaap_ProductWarrantyAccrual": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProductWarrantyAccrual",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofChangesinReserveforProductWarrantiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Standard and Extended Product Warranty Accrual",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r342",
      "r344",
      "r347"
     ]
    },
    "us-gaap_ProductWarrantyAccrualPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProductWarrantyAccrualPayments",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofChangesinReserveforProductWarrantiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repairs and replacements",
        "label": "Standard and Extended Product Warranty Accrual, Decrease for Payments",
        "documentation": "Amount of decrease in the standard and extended product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard and extended product warranty."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "us-gaap_ProductWarrantyAccrualWarrantiesIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProductWarrantyAccrualWarrantiesIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofChangesinReserveforProductWarrantiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions charged to cost of product revenue",
        "label": "Standard and Extended Product Warranty Accrual, Increase for Warranties Issued",
        "documentation": "Amount of increase in the standard and extended product warranty accrual from warranties issued."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r230",
      "r636",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r820",
      "r827",
      "r830",
      "r832",
      "r861",
      "r862",
      "r934",
      "r935",
      "r936",
      "r939",
      "r943",
      "r1043",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1166",
      "r1167",
      "r1258",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1274",
      "r1275",
      "r1276",
      "r1277",
      "r1278",
      "r1279",
      "r1280",
      "r1281",
      "r1282",
      "r1283",
      "r1284",
      "r1285",
      "r1287",
      "r1288"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r601",
      "r681",
      "r691",
      "r924"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r991"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r991"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockPurchasePlanDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r200",
      "r335",
      "r337",
      "r338",
      "r339",
      "r424",
      "r434",
      "r461",
      "r462",
      "r463",
      "r466",
      "r471",
      "r567",
      "r609",
      "r618",
      "r634",
      "r718",
      "r720",
      "r728",
      "r740",
      "r741",
      "r792",
      "r794",
      "r796",
      "r797",
      "r799",
      "r802",
      "r803",
      "r805",
      "r806",
      "r816",
      "r817",
      "r847",
      "r860",
      "r871",
      "r873",
      "r876",
      "r877",
      "r914",
      "r915",
      "r919",
      "r920",
      "r935",
      "r946",
      "r1164",
      "r1170",
      "r1229",
      "r1248",
      "r1249",
      "r1250",
      "r1251",
      "r1252"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails",
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockPurchasePlanDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r200",
      "r335",
      "r337",
      "r338",
      "r339",
      "r424",
      "r434",
      "r461",
      "r462",
      "r463",
      "r466",
      "r471",
      "r567",
      "r609",
      "r618",
      "r634",
      "r718",
      "r720",
      "r728",
      "r740",
      "r741",
      "r792",
      "r794",
      "r796",
      "r797",
      "r799",
      "r802",
      "r803",
      "r805",
      "r806",
      "r816",
      "r817",
      "r847",
      "r860",
      "r871",
      "r873",
      "r876",
      "r877",
      "r914",
      "r915",
      "r919",
      "r920",
      "r935",
      "r946",
      "r1164",
      "r1170",
      "r1229",
      "r1248",
      "r1249",
      "r1250",
      "r1251",
      "r1252"
     ]
    },
    "us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReconciliationFromSegmentTotalsToConsolidatedAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less:",
        "label": "Segment Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r959",
      "r969",
      "r979",
      "r1011"
     ]
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Notes payable principal payoff",
        "label": "Repayments of Notes Payable",
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "pacb_ReportableSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "ReportableSegmentMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reportable Segment",
        "label": "Reportable Segment [Member]",
        "documentation": "Reportable Segment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r818",
      "r828",
      "r829",
      "r842",
      "r1253"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r960",
      "r970",
      "r980",
      "r1012"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r961",
      "r971",
      "r981",
      "r1013"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r968",
      "r978",
      "r988",
      "r1020"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash at end of period",
        "label": "Restricted Cash and Cash Equivalent",
        "documentation": "Amount of cash and cash equivalent restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r95",
      "r128",
      "r156",
      "r685"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term restricted cash",
        "label": "Restricted Cash and Cash Equivalent, Noncurrent",
        "documentation": "Amount of cash and cash equivalent restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r112",
      "r156"
     ]
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term restricted cash",
        "label": "Restricted Cash, Current",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r1055",
      "r1112"
     ]
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURING"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RESTRUCTURING",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r321",
      "r323",
      "r326",
      "r331"
     ]
    },
    "pacb_RestructuringAndRelatedCostAcceleratedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "RestructuringAndRelatedCostAcceleratedAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring and related cost, accelerated amortization",
        "label": "Restructuring and Related Cost, Accelerated Amortization",
        "documentation": "Restructuring and Related Cost, Accelerated Amortization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringAndRelatedCostExpectedCostRemaining1",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated total restructuring costs to still be incurred",
        "label": "Restructuring and Related Cost, Expected Cost Remaining",
        "documentation": "Amount of expected cost remaining for the specified restructuring cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostIncurredCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringAndRelatedCostIncurredCost",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative amount incurred to date",
        "label": "Restructuring and Related Cost, Incurred Cost",
        "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r325",
      "r328",
      "r330"
     ]
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Additional expense recorded",
        "label": "Restructuring Charges",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r148",
      "r150",
      "r327",
      "r328",
      "r829",
      "r1165"
     ]
    },
    "pacb_RestructuringChargesAdditionalCostsIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "RestructuringChargesAdditionalCostsIncurred",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional costs incurred",
        "label": "Restructuring Charges, Additional Costs Incurred",
        "documentation": "Restructuring Charges, Additional Costs Incurred"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "WARN act and other employee benefits",
        "label": "Restructuring Charges, Worker Adjustment and Retraining Notification (WARN) Act and Other Employee Benefits",
        "documentation": "Restructuring Charges, Worker Adjustment and Retraining Notification (WARN) Act and Other Employee Benefits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Type [Axis]",
        "label": "Restructuring Type [Axis]",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r150",
      "r322",
      "r323",
      "r328",
      "r329",
      "r829"
     ]
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Cost and Reserve [Line Items]",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r323",
      "r324",
      "r325",
      "r328",
      "r329",
      "r330"
     ]
    },
    "us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "label": "Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes restructuring charges."
       }
      }
     },
     "auth_ref": [
      "r1040",
      "r1041"
     ]
    },
    "pacb_RestructuringOfDebtPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "RestructuringOfDebtPricePerShare",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring of debt (in dollar per share)",
        "label": "Restructuring Of Debt Price Per Share",
        "documentation": "Restructuring Of Debt Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringPlanAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringPlanAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Plan [Axis]",
        "label": "Restructuring Plan [Axis]",
        "documentation": "Information by individual restructuring plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringPlanDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringPlanDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Plan [Domain]",
        "label": "Restructuring Plan [Domain]",
        "documentation": "Identification of the individual restructuring plans."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringReserve",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance",
        "label": "Restructuring Reserve",
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r329"
     ]
    },
    "us-gaap_RestructuringReserveAcceleratedDepreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringReserveAcceleratedDepreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accelerated depreciation",
        "label": "Restructuring and Related Cost, Accelerated Depreciation",
        "documentation": "Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r90",
      "r689",
      "r725",
      "r727",
      "r733",
      "r751",
      "r924"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r164",
      "r165",
      "r166",
      "r168",
      "r175",
      "r177",
      "r179",
      "r269",
      "r270",
      "r311",
      "r390",
      "r467",
      "r475",
      "r476",
      "r478",
      "r479",
      "r480",
      "r482",
      "r536",
      "r537",
      "r547",
      "r549",
      "r550",
      "r552",
      "r559",
      "r596",
      "r597",
      "r722",
      "r724",
      "r734",
      "r1293"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total revenue",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r108",
      "r194",
      "r206",
      "r207",
      "r221",
      "r227",
      "r230",
      "r232",
      "r234",
      "r419",
      "r420",
      "r421",
      "r636",
      "r828",
      "r832"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total revenue",
        "verboseLabel": "Revenue",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r108",
      "r194",
      "r206",
      "r207",
      "r221",
      "r227",
      "r230",
      "r232",
      "r234",
      "r419",
      "r420",
      "r421",
      "r636"
     ]
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenue by Geographic Location",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRemainingPerformanceObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue, non-current",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining performance obligation period",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRemainingPerformanceObligationPercentage",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, remaining performance obligation, percentage",
        "label": "Revenue, Remaining Performance Obligation, Percentage",
        "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r1042"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue:",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use asset and lease liability recognized due to lease extension",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r600",
      "r923"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1029"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1029"
     ]
    },
    "pacb_SanDiegoOfficeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "SanDiegoOfficeMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "San Diego Office",
        "label": "San Diego Office [Member]",
        "documentation": "San Diego Office"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSharesExcludedFromComputationofDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHARETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Antidilutive Shares Excluded From Computation of Diluted Net Loss per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Available-for-sale Securities [Line Items]",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248"
     ]
    },
    "pacb_ScheduleOfBalanceSheetComponentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "ScheduleOfBalanceSheetComponentsLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Balance Sheet Components [Line Items]",
        "label": "Schedule of Balance Sheet Components [Line Items]",
        "documentation": "Schedule of Balance Sheet Components [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_ScheduleOfBalanceSheetComponentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "ScheduleOfBalanceSheetComponentsTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Balance Sheet Components [Table]",
        "label": "Schedule of Balance Sheet Components [Table]",
        "documentation": "Schedule of Balance Sheet Components [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofFiniteLivedIntangibleAssetsFromBusinessAcquisitionsDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination [Table]",
        "label": "Business Combination [Table]",
        "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r483",
      "r484",
      "r485",
      "r486",
      "r492",
      "r493",
      "r494",
      "r495",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r530",
      "r531",
      "r532",
      "r535",
      "r873",
      "r877",
      "r1205",
      "r1207",
      "r1209"
     ]
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash, Cash Equivalents, Restricted Cash and Investments",
        "label": "Cash, Cash Equivalent, and Investment [Table Text Block]",
        "documentation": "Tabular disclosure of cash, cash equivalent, and investment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Net Carrying Amount",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r35",
      "r36",
      "r40",
      "r87",
      "r89",
      "r855",
      "r857",
      "r1115",
      "r1119",
      "r1242",
      "r1254"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHARETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Computation of Basic and Diluted Net Loss Per Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1124"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-Based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenue by Category",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfImpairedIntangibleAssetsTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Impaired Intangible Assets",
        "label": "Schedule of Impaired Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of impaired intangible assets excluding goodwill. This may include a description of the facts and circumstances leading to the recording of impairment charges of intangible assets in the period, the amount of the impairment charges, the methods of determining fair value of the associated assets, the caption in the income statement in which the impairment losses are aggregated, and the segment in which the impaired intangible assets are reported."
       }
      }
     },
     "auth_ref": [
      "r1159"
     ]
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Asset, Indefinite-Lived [Table]",
        "label": "Intangible Asset, Indefinite-Lived [Table]",
        "documentation": "Disclosure of information about indefinite-lived intangible asset. Excludes finite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r305",
      "r310",
      "r822",
      "r878",
      "r879",
      "r880",
      "r889",
      "r890",
      "r904"
     ]
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-Lived Intangible Assets From Business Acquisitions",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class."
       }
      }
     },
     "auth_ref": [
      "r1144",
      "r1147"
     ]
    },
    "pacb_ScheduleOfInterestExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "ScheduleOfInterestExpenseTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Interest Expense",
        "label": "Schedule of Interest Expense [Table Text Block]",
        "documentation": "Schedule of Interest Expense [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventory",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r58",
      "r59",
      "r60"
     ]
    },
    "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Changes in Reserve for Product Warranties",
        "label": "Schedule of Product Warranty Liability [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability."
       }
      }
     },
     "auth_ref": [
      "r343"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Cost [Table]",
        "label": "Restructuring Cost [Table]",
        "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r323",
      "r324",
      "r325",
      "r328",
      "r329",
      "r330"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Pre-Tax Restructuring Charges",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r80",
      "r81"
     ]
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restructuring Reserve by Type of Cost",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r82"
     ]
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "documentation": "Disclosure of information about revenue from external customer and long-lived asset by geographical area. Long-lived asset excludes financial instrument, customer relationship with financial institution, mortgage and other servicing right, deferred policy acquisition cost, and deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r62"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r26"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Profit or Loss",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r26"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockPurchasePlanDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockOptionActivityDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r466"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Time-Based RSUs and PSUs Activity",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r91"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value of Employee Stock Purchase Plan",
        "label": "Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r1203"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value of Employee Stock Options",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimated Future Amortization Expense of Acquisition-Related Intangible Assets with Definite Lives",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r822",
      "r1155"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r954"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r110",
      "r194",
      "r202",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r227",
      "r228",
      "r229",
      "r234",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r310",
      "r325",
      "r330",
      "r529",
      "r532",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r839",
      "r842",
      "r843",
      "r849",
      "r938",
      "r1258",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1274",
      "r1275",
      "r1276",
      "r1277",
      "r1278",
      "r1279",
      "r1280",
      "r1281",
      "r1282",
      "r1283",
      "r1284",
      "r1285",
      "r1287",
      "r1288"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment, Geographical [Domain]",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r197",
      "r232",
      "r233",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r676",
      "r677",
      "r678",
      "r679",
      "r737",
      "r738",
      "r739",
      "r793",
      "r795",
      "r798",
      "r800",
      "r802",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r821",
      "r834",
      "r861",
      "r863",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r937",
      "r946",
      "r1258",
      "r1260",
      "r1261",
      "r1263",
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1274",
      "r1275",
      "r1276",
      "r1277",
      "r1278",
      "r1279",
      "r1280",
      "r1281",
      "r1282",
      "r1283",
      "r1284",
      "r1285",
      "r1287",
      "r1288"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "SEGMENT AND GEOGRAPHIC INFORMATION",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r194",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r217",
      "r219",
      "r220",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r234",
      "r838",
      "r840",
      "r841",
      "r842",
      "r844",
      "r845",
      "r846"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting Information [Line Items]",
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingAndMarketingExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales and marketing",
        "label": "Selling and Marketing Expense",
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales, general and administrative",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r827",
      "r828",
      "r829",
      "r832",
      "r1104"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales, general and administrative",
        "label": "Selling, General and Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r873",
      "r875"
     ]
    },
    "pacb_ServiceAndOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "ServiceAndOtherMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited",
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyCategoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service and other revenue",
        "label": "Service And Other [Member]",
        "documentation": "Service and Other [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ServiceMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service",
        "label": "Service [Member]",
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service."
       }
      }
     },
     "auth_ref": [
      "r827",
      "r832",
      "r861",
      "r862"
     ]
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Severance costs",
        "label": "Severance Costs",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount eligible to vest upon achievement of goal",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Amount Eligible To Vest Upon Achievement Of Goal",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Amount Eligible To Vest Upon Achievement Of Goal"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r454"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r454"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockPurchasePlanDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "verboseLabel": "Weighted average grant date fair value per share (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r452"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r450"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in dollars per share)",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r450"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockOptionActivityDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price",
        "verboseLabel": "Weighted average grant date fair value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility, maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility, minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r463"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r463"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockPurchasePlanDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockOptionActivityDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r466"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockOptionActivityDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares",
        "verboseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock remain available for issuance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Expired (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r448"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Canceled (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value per share (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r442"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in dollars per share)",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r442"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockOptionActivityDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Award [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expired (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r448"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Canceled (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockOptionsDetails",
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofFairValueofEmployeeStockPurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term in years",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Short-Term Investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r1060"
     ]
    },
    "pacb_ShortTermRestrictedCashFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "ShortTermRestrictedCashFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term restricted cash",
        "label": "Short-Term Restricted Cash Fair Value Disclosure",
        "documentation": "Short-Term Restricted Cash Fair Value Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_StandardProductWarrantyPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "StandardProductWarrantyPeriod",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Standard product warranty, period",
        "label": "Standard Product Warranty, Period",
        "documentation": "Standard Product Warranty, Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r110",
      "r124",
      "r194",
      "r202",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r227",
      "r228",
      "r229",
      "r234",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r310",
      "r313",
      "r325",
      "r330",
      "r529",
      "r532",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r839",
      "r842",
      "r843",
      "r849",
      "r938",
      "r1258",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1274",
      "r1275",
      "r1276",
      "r1277",
      "r1278",
      "r1279",
      "r1280",
      "r1281",
      "r1282",
      "r1283",
      "r1284",
      "r1285",
      "r1287",
      "r1288"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r52",
      "r55",
      "r56",
      "r118",
      "r119",
      "r120",
      "r141",
      "r142",
      "r143",
      "r164",
      "r165",
      "r166",
      "r168",
      "r175",
      "r177",
      "r179",
      "r195",
      "r269",
      "r270",
      "r311",
      "r390",
      "r415",
      "r467",
      "r475",
      "r476",
      "r478",
      "r479",
      "r480",
      "r482",
      "r536",
      "r537",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r559",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r596",
      "r597",
      "r602",
      "r694",
      "r722",
      "r723",
      "r724",
      "r734",
      "r787"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.pacificbiosciences.com/role/SEGMENTANDGEOGRAPHICINFORMATIONScheduleofRevenuebyGeographicLocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r197",
      "r232",
      "r233",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r676",
      "r677",
      "r678",
      "r679",
      "r737",
      "r738",
      "r739",
      "r793",
      "r795",
      "r798",
      "r800",
      "r802",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r821",
      "r834",
      "r861",
      "r863",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r937",
      "r946",
      "r1258",
      "r1260",
      "r1261",
      "r1263",
      "r1264",
      "r1265",
      "r1266",
      "r1267",
      "r1268",
      "r1269",
      "r1270",
      "r1271",
      "r1272",
      "r1273",
      "r1274",
      "r1275",
      "r1276",
      "r1277",
      "r1278",
      "r1279",
      "r1280",
      "r1281",
      "r1282",
      "r1283",
      "r1284",
      "r1285",
      "r1287",
      "r1288"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited",
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r165",
      "r166",
      "r195",
      "r392",
      "r393",
      "r395",
      "r397",
      "r597",
      "r636",
      "r732",
      "r735",
      "r736",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r750",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r770",
      "r771",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r787",
      "r830",
      "r832",
      "r947",
      "r1291"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited",
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r165",
      "r166",
      "r195",
      "r235",
      "r392",
      "r393",
      "r395",
      "r397",
      "r597",
      "r636",
      "r732",
      "r735",
      "r736",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r750",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r770",
      "r771",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r787",
      "r830",
      "r832",
      "r947",
      "r1291"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r963",
      "r973",
      "r983",
      "r1015"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201"
     ]
    },
    "pacb_StockBasedCompensationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "StockBasedCompensationMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total share-based compensation expense",
        "label": "Stock Based Compensation [Member]",
        "documentation": "Stock-based compensation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockCompensationPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockCompensationPlanMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSharesExcludedFromComputationofDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity awards",
        "label": "Share-Based Payment Arrangement [Member]",
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares."
       }
      }
     },
     "auth_ref": [
      "r1125"
     ]
    },
    "pacb_StockIssuedDuringPeriodAverageTradingPeriodAcquisition": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "StockIssuedDuringPeriodAverageTradingPeriodAcquisition",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSContingentConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average trading period",
        "label": "Stock Issued During Period, Average Trading Period, Acquisition",
        "documentation": "Stock Issued During Period, Average Trading Period, Acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock purchased under plan (in shares)",
        "label": "Stock Issued During Period, Shares, Employee Stock Ownership Plan",
        "documentation": "Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r51",
      "r52",
      "r90",
      "r470"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional common stock purchased under plan (in shares)",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r51",
      "r52",
      "r90"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in conjunction with equity plans (in shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r51",
      "r52",
      "r90"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in conjunction with equity plans",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r51",
      "r52",
      "r90"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited",
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r55",
      "r56",
      "r78",
      "r752",
      "r768",
      "r788",
      "r789",
      "r924",
      "r953",
      "r1114",
      "r1117",
      "r1118",
      "r1142",
      "r1239",
      "r1293"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EQUITY PLANS AND SHARE-BASED COMPENSATION",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r414",
      "r415",
      "r546",
      "r558",
      "r790",
      "r791",
      "r801"
     ]
    },
    "pacb_SupplementalBalanceSheetComponentsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "SupplementalBalanceSheetComponentsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Components [Abstract]",
        "label": "Balance Sheet Components [Abstract]",
        "documentation": "Supplemental Balance Sheet Components Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BALANCE SHEET COMPONENTS",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r1054"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "us-gaap_TechnologyBasedIntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TechnologyBasedIntangibleAssetsMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/BALANCESHEETCOMPONENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Technology-Based Intangible Assets",
        "label": "Technology-Based Intangible Assets [Member]",
        "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights."
       }
      }
     },
     "auth_ref": [
      "r899",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1153",
      "r1154",
      "r1157",
      "r1158"
     ]
    },
    "pacb_TimeBasedRestrictedStockUnitsPSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "TimeBasedRestrictedStockUnitsPSUMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Time Based Restricted Stock Units PSU",
        "label": "Time Based Restricted Stock Units PSU [Member]",
        "documentation": "Time Based Restricted Stock Units PSU"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_TimeBasedRestrictedStockUnitsRsusMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "TimeBasedRestrictedStockUnitsRsusMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofTimeBasedRSUsandPSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units (RSU)",
        "label": "Time Based Restricted Stock Units Rsus [Member]",
        "documentation": "Time-Based Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "pacb_TimeBasedStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.pacificbiosciences.com/20250930",
     "localname": "TimeBasedStockOptionMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/EQUITYPLANSANDSHAREBASEDCOMPENSATIONScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Time-based stock option",
        "label": "Time Based Stock Option [Member]",
        "documentation": "Time-based stock option"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r1030"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Option, Eligible Item or Group [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r384",
      "r413",
      "r546",
      "r557",
      "r578",
      "r583",
      "r586",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r682",
      "r695",
      "r910",
      "r912",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r925",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1225",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1233",
      "r1235",
      "r1236"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1031"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1032"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r1032"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1030"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r1030"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r1033"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1031"
     ]
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofPreTaxRestructuringChargesDetails",
      "http://www.pacificbiosciences.com/role/RESTRUCTURINGScheduleofRestructuringReservebyTypeofCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Type of Restructuring [Domain]",
        "label": "Type of Restructuring [Domain]",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r150",
      "r322",
      "r323",
      "r328",
      "r329",
      "r829"
     ]
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "presentation": [
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pacificbiosciences.com/role/FINANCIALINSTRUMENTSScheduleofCashCashEquivalentsandInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. government &amp; agency securities",
        "label": "US Government Corporations and Agencies Securities [Member]",
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac)."
       }
      }
     },
     "auth_ref": [
      "r1255"
     ]
    },
    "us-gaap_UnamortizedDebtIssuanceExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnamortizedDebtIssuanceExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONVERTIBLESENIORNOTESScheduleofNetCarryingAmountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unamortized debt issuance costs",
        "label": "Unamortized Debt Issuance Expense",
        "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r1027"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.pacificbiosciences.com/role/ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r114",
      "r196",
      "r198",
      "r199",
      "r200",
      "r676",
      "r678",
      "r835"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited",
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in shares)",
        "verboseLabel": "Weighted average shares used in computing diluted net loss per share (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r189"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.pacificbiosciences.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited",
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted average shares used in computing basic net loss per share (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r189"
     ]
    },
    "us-gaap_WeightedAverageRateOfTimeDepositsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageRateOfTimeDepositsAbstract",
     "presentation": [
      "http://www.pacificbiosciences.com/role/NETLOSSPERSHAREScheduleofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss per share:",
        "label": "Weighted Average Rate of Time Deposits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r995"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "60",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481408/470-60-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-10"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "470",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(1)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481034/205-10-S45-5"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-3"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-4"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-6"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/420/tableOfContent"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450-20/tableOfContent"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450-30/tableOfContent"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483049/450-30-50-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-11"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480520/718-40-45-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/825/tableOfContent"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "805",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478072/944-805-50-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-18"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "39",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-39"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479908/805-50-55-1"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478064/805-740-55-13"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(1)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/210/tableOfContent"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718-50/tableOfContent"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-2"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1229": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1230": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1231": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1232": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1233": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1234": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r1235": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r1236": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1237": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1238": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1239": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1240": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r1241": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r1242": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1243": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1244": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1245": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1246": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1247": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1248": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1249": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1250": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1251": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1252": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1253": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1254": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1255": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1256": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r1257": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1258": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1259": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1260": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1261": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1262": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1263": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1264": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1265": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1266": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1267": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1268": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1269": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1270": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1271": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1272": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1273": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1274": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1275": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1276": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1277": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1278": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1279": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1280": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1281": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1282": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1283": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1284": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1285": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1286": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r1287": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1288": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1289": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1290": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1291": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1292": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1293": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1294": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1295": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1296": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1297": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1298": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1299": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>83
<FILENAME>0001299130-25-000168-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001299130-25-000168-xbrl.zip
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M/-0J5J5&"0:$+48E,K2[>%/Z1H:2:TD.2)>9+9=GI*DTE"WMZC,VM5JF4T;
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M1*Q] K4,@^7\YK(+]Q&+LECO\H6OIJJ_[@.N(_OAV'\!4$L#!!0    ( (6
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MC*2PZUV^\2U5^==_UG7@/B?[-U!+ P04    " "%@&9;)B#LL,0$   S$@
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M"S;*D0UE$X??A8"4(R'[7KG#;-ZQC)GJ=R$Q#"?_RI(D?A=RPFQJ+Y.<H,.
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MPP&8 _"RJ)A; 7C)_F,.<$+BQX04"3!_&I A3E]X)L)7/UQ4<3_"PPF]J'2
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M0 GKW$L0A@$"R=]<TI=,0U$,?3#H:T35^Y;1=Q1'L>MD,#"T_A\*N'2>'^'
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MK?^' @&]AV?4?OED-7?0\ AL1#<G&A)44@<'W",N>S3FL3 UEGBLX."&$7Q
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M"9UGZ\F$99+X<\8!!])$.<4EX$6(1!?HZ1+K<B.W%BMS2'S0B[894-X!_:2
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M,_@5S_K :]XOK=F/P+L=@:/+0->M49G8'JOU\=TE[F[[73?T'8H?>-4#QK7
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MP.%M?E*9^OL=4= *?@VG4&Z_5QYA&LUX702DXC9^F512]\@=HRZ-)$.JS.J
M8WFJCR)4DKAH*>SG#+B!UZT4'TO5A$/^Z">B:>S2[PZ;>TOELS%G]-]OP&--
M;'KOW$WAJV,MZ46(KD2;.U$42?]Q2X61!8BT??=G3;[;V<Q;><N X8!NL"3>
M=BZIMXUZ.#!S=]:["!))^93R67OY;'SJ\D,&ND,1]M@;U;Z,!^F_-:OW_NA9
M@YQ(76>2C-5]RL5YX,X9^F;;"Z^'O4@!7E#/*#($FZLO5;5SH#7U,?N9BN97
M-N1UAZS=!>;ESC[SIJJ;,V_YS.SL-*YA.+BZZ7?5ECJJ:@K;L9&+I61=K&25
M*Y[90[0BCF74IRPM;$/L9AZT.KWA_B4T4LZDG)V9!=L!1'PXHA%\:K]B6/X:
M >^?+[3^N8/GJVKWR-[<& >E[^+-2:Z77%^=I[4[VU?E:4VN;GK#UK S*NYH
M21&0(E #Q;^#$S3":72C?FM0=H1V788NUI"#[S+!?O<)$U>: SA)O%<MP<=E
M8JLCG**7&UJM**AZENU#Y932EO%HV[W1M.;IHIVM2U.=Y))*O+?=V237>TLS
M3B^;<6HR/57RS+%8)N7N;.P4&O6K[A22TW>KYX8M0P-WL3.#'>R,/-H#&(?=
MS[:$<1B6,P[RH.LDPR4U^FA'C7Z".=K=<2VOJH^6JRT/=ETZ; 90=I[+SO,\
M9,7#YTM&8U[],NA57/UR],9S*;%28D_C$AX@6E!2B">\JJ8WJ:ZJ1LJOE-_F
MRN]QQ'>'1-6X<YAJG9J(Z_:4[NF%[S0)WQ/*6 UNTWO'PTI*F<JK@,I[M5*:
MI#35/PAY@!!D20&CK&=K,BQ=721%Z]2<=G&B=1S)VL49[.U7M71T62H [O?W
MQ)1%.:]9SFL^ MWDO.9+G=?<D_.:+W)><T_.:S[S><W90)UJ=Q-0Z0UA=J2P
M5G/F/G<SYS[WME4!Y^&S6O,-_N$GFGD8O71]_+EFIL-R@%O'_8+ K9L)LJ^+
M75 <'^-#L?A\1RVR61H7:O+I82F$5HZERU%<E27-^#2<LE./>LU!<!T/P,<8
M-WPP4;U _LK#^AUZ^-#Q+KC?V4HS:*PR'^^=0KK<NR:WJ0DNF:CB4;^TU0EX
MYNN<.YS_0_TH)0,8 W#$6IUN7=H?&B_)(+S#W#JV2RVNKY3OO\!S'U_8\IG]
M9N'XQ=(LCP@FK<YH+%F^,I8?298_),NC9G]\L4IS^DAR>M6</I:<?G!.7]BL
MX!SL"*_C=,16KZ-*7J^,UR>2UP_-ZY\LS\[BYLG5S:@_D+Q<%2_W.HIFTO0A
MFU&\6+)V,=:F8?7Y?(VL/$N4HMPB?4/F+J?')QWT62;=9NIQS@R36@I!9HN5
M++B6!=<U+[B>J&=2<+WS8,TZ#/:+*G@,4@>3^]*I((,&+BX]'3[%M)!A\B&+
MEN/B+VWVS$R/*<:<A@'R"8UHG$5^R>%P10AM;]$WTF_0,#7ENK8Q]7BV"+[I
M/_:)F0S3F_'9C<IM5B8+9T>FG^XN-)=>85K &K#)F;M\C2[* 0YULE_$E\;?
MQ;]LK?UO^?MK8U$ "% :P7_38CS76-(S@9QPG(O-&R:"PC=MYH AGBWHO\4K
M:9IY^%4:S:@ME]8,]D<$S\SZ39G[PIB9.D9\<-8>,9^X>:IC@E:>@P_ ]SNN
MK2'K72,;*BOF+BQX!\@5?FK8D32EQ\<E4<*Q723%6 =1^L GB^).7;SJ*BN*
M8RK,1(GYC8Y+S/H:T.$ J0V'\=F9&7N?4TH6/\SDJ8BDTI?@L:KR=64:UHJU
ME'MSUE;>7(G_OOJ%?YU7Z>$A@C#/%G!NN(KY$D3!4;RU3@O 8W+9DS%3UDL@
M!W%"?'@J'K]!I8&8")YYN E@*6TV8TN?8_YI?#(4A_WE,7-&/*Q;:WQY2UDR
M32="6<J,:?C;* /#EE&K+("PUT!&RWM:K#W0UPO@IVMP\G5<E8NF1BR,TY"1
MP\K1T$C^Z1B,%;T:OJ?1L!!\NDB!SS1GH<PQAZW,;6L5?4%DU6O;TKV94&3
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M2ZDMPA_QU@,V+M@/HLOX&QI>W61@_/TM(Q\$:T-'P#]/?AGTJQ<+Q3WZ.VW
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MP_$CE/C--Y9-T]E$5K65X9;G/\9#,PG'_J*!A.A!O=P._-XMRN^W@1B&G%^
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M(2^WW[_<SO!SBKSX^8;WP+)SH_P@@4$7V6/+>(WHE 00$<TVJ-A >V+1DH2
MK%.Q%F6M&7RR K-!B.@)_I?@0\]&5!C7'[W *:"$)*!'AT10HE10WB =?E&
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M((?+R+D2^VI%=^6#L );/M%9X*;)O[(13="!OPG$0I^\Z.R2D(-_RN7$O[?
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MB7ITOQM@B<[\LZ7+C04S.1B:'-WO!FB";GQ-[N@'[M\IVL2(RGA1&5_7-C'
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M&L$U0KH5UPJV50'R=<8%_:"LJ;.R;]W'>=G22Z,?#J"'&WZX9+]5Q5*T0@U
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M*(W^X7"WI^_T8^3V)+9^BL;SF(J[&$;TJXD_N27E*5C+0I>+MSTC6!X8#ZX
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M%W@C3_EHS1M[),>6H[IISG*0,E%*.D.XP)-,:/$@Y_B@3&/:!698)"X,]&<
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MSTQ X,J2YTO&#[(TA/\-QP3^W_$'TM^1Y8,*@Q*5ZHRV-YU9V$[PQ0G']+[
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M96:4I@H/T;FE1MUX0<@# 4P-!V7W%Q_[UWSUO:$3[I(S50>[A.5%V'R7.3D
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M:)B2#>^6I7O2^#)?MB&';\@E86D!DF9(EJS52\+83#A@+4L0\B9<=#CZO.S
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M*A)>1<+K81)>-9'P>I8)KVV1\'J6":\B.>#LHCNGFE'V.ZWC8S5H.$Z"&V+
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M)"@QW"2U8+PF@%9A9?K<X!LWO69EP^Y8U:9OLFP;&SLC]=H$]&N*"+S@C9Z
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M;945M[JHN#W+BMN.J+@]RXK;4U75C%156[0E.HL.I\,H;06[8[8W=<>LIZF
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MM8@K3?%Z@TW&%!GS:Z_+K-@QC ^?HFCTWG0W"'M46*+H+$4>,Z(3C! O('T
ME'CCH !N19:?<L<-@4WMKSA.RGP6+Z7[(S\YT<2']@3L."@+'J1>*+CADQG^
M#=]S5U"B@O^"J-5-7R8[HKS#"Z24M2Z(-HVNH!=0#OK=OJP/CJ!CYRPETP25
M6J:BYSP!\A>&!,%H<>%JX+@4SD5I?X!S$=YY[VCXJ23$9/BD?!'R#>'+?*==
M]ENQZW<00.%L8A*"DP:V>X.Y!1%?B5L"%N?*JYSF/CGA8^[6#1X0347N\)4*
M#L]7;ITA(+;HE%"^U9GU@@1*8IB=9T75=CB8(R5MTB0@(X2W."#0"(-&_!Z\
M7$VR-2+N(Y_QNX!IYDEX'%GJDS*[;/N"9P2">7!=HK7FQ;ZNG(VC,72_P+B6
M;2V6# T,C1#]D]'1]56+CG8K+N@<5@ +25#.!N49G%654'D6SF%Y$X<#N?,S
M.Y$R*6"85P?)Z,C"+1I*C_4R1201P=&^/@/N4'D$E%-8PPF6$*ZMWA:K0C:E
M\09ASDD\1"5!O*H,#89-\\/#1T99H*'A==22<3N4:"3X84+6_R8K2+07O'OP
M75M5"RX:-7O4KK1!)07,[:3AO5+[5E,6A,WOP([XX24#AD=(6<JYD,K2AGMD
MN^S<C3-79LW++L Y(6=:KDH ?GWC?7R\!?95LV:BM;5RW27NU%Y A'BQX2".
M#B/ZU,10TE9G4]=YS67Z\' )1T4E6 >>P=3O_MRUZZ98<>IH"6_O4F?UN82W
M7Z'.*IZ: ??I^8D_8BS[>P-1]BV,=KCO._!G#Z:$?6.,4/MR8IIWG78L&$D6
M[3R1A/Y)\F-ME8P"_:VY<=@T5YCR;=;RH8G*\ T^4':5^[\ (Q=@Y *,7("1
M]P.,?+( (S]+8.2SVP,C;U[!>_;(5_ 6-.6_ 9KR].DP3?STZ<F3)Y-1=IPZ
MEL_]^_D/O]=9F*9S^31S^[<W/H]NE-L_>_?JA^3Q29+\S\\O?GQW]N[%N[-_
MO"+4%?SB[_KO[\[>OOS[Z[<_OT%$UK>O?WZ7_/#BS?]Y]2YY<_;V_R1_I *P
MZ%!\=CH49Y0::;OD#0*N, #^@?KWDS=%^_[8JTF88W[T\/'#!(-]#N_!_7DN
M_Z1,VZ;X#>-.QN<4.A@LB0/'PNG)XZ^?_A=]\_3DZ</_2DW&K#Q(?800>; L
M("C' E4=UZ=0X[C>D>*SN3I&U76+^>2ZF0+A)0V,_RBB-DP&\;-R/GW,YE+5
ME,_;UI<.UF9*&<9-V6.=!)[A<NN&%]+<H- X()B>,?&L7HV >'F($XC3%QC&
MW>:I'DJ>Z@GFJ2JR+FB(W[JJ@&5#R_C(4E14(C39(P.;.)H*QG>W9B=PTE[.
MN=TQW^?/)V]/DO,:)KBBS<]E5U>M#Q&'"FLOLZP7TIVM.O-G 912UT'N$*K(
M";UV=#^^O.K_/H )>("M]+8%_B1Y36K<-_NB>8@K,WC4ZO^?CYX;?JJCF?37
MK./--IOJCF0?R4SCFIXUS9):;6/NHMI3A#"_!^R3#;B\-?46-21.1H0'$UPZ
MA&GF[Q(@/*EZ6F_P>3,104'[AHN+/O8.RUY]<YME1T0D=>4..B2D,TT/F8'S
MM-M3:<95/' DOKYQPII 5:/FPF/2PZAP'Q<<BGLP$JQ<O3JP]CN^4^XV65_R
M\*?17# *W@PM_I:>9L<I;1=].>:P*"J2U$O.&]:P\Q>QH^]/6KFM/W"Y90#]
M"1HH,T925,YRF(06' >A)U(*#<,8-%@[L*=I8\*J )<A:RJ7,S+;K7&),HT5
M0[99MWSV4B?)BV1[V&.]CO'TX&4SZ/S!OH:/)E_ '&)Q&Q/;J&Y/O_TR,![!
M&K=T0X,'Q66;24E>'(ENW@Q0(9\]).H<</D$&]WL%N%*:E/_1E#T$EE:!EP=
M1V-5)C#G7%$=-8T556QR?-^BP1WZGLH/CSU_]O0Z[/G3)7A<$APW27" ,YN\
M?/WCNS>O_\XM93^]>?WRU7>8SUB2%TORXA;)B^^XV08="^I'AD&A\_\G[.[.
MD4?MV#,8Z'7NLBIC#&,:6OX(JX+>D76=7FX+MTE>,>H.CI37C-U)S1^_]ZD&
M^2.CI_S?#4A>/Z#M>'Q&NXT@%ZE%66Z<AXE8VXG8^XE(OB!NQ$U1\?'TAEH6
M3Q]G#TZ??N&^Y S+TUS^I:V+P8-Z]9L0U[Y8DZ=S^OSQDY2I?SGN^@*_((!_
M^V$!]W_YI80F] X$&.-Q)#0?//6%\P#5ZV+8D^1;:O/$1@/\L P0H;BH99%&
MTOEIJ <CS7\/21_].PR= #,(1G3#@<U\O,>:PYEM1L2NO(9PJ"628[/OWYA9
M).UI=ANFOR=4JK:Y(8 O5\XTO#'JU.-)]@0UTW;)#?JQ")[K5^"'FR;):&*+
MUF-!4G['ML4?6]+(A7V3BW\O/:8&P-(5NX#-Q!0=PXOEKV]?O?3RUZ%;%E]*
M,UX!MQ5>%1XG6Z_[72_8&(J#=KN^0C!+H *W&S2$77]@)?#"1A<78B#"D2+;
M;8F\IOB:Y<'+7K>FU\1/3%@T1^,'GU6RA@GGAUV]LJ<DSW+]/DC--- B@FO]
MRZ,ZJ\/\]YBB <&H6QA@XG$-^\GSM>(R7&?>QX;-7QZF=PQQ_<+$7OB'AZLQ
M[I>>(*E7O_+FNQEH=W%L/CO'YF4(^JA @YE2\7"2U_ ZYACG\PE>_]A=G1>5
M.4B9%)3;*)!0P1\7;;]'^+6G;+C:(9JWS+.NTE5NTJR+1%A^;C*@J@JS!J#1
M\6S[G,V0N?26 .<RF/]&YS*IUX+7-"0O_V2?9)ZL4J#OG#C =G_)K5#'"!VM
M8JTPD?;><2)R]/GT=H]Z+=O-K=_]%J^<\CM3_F3NQ>G![N;5%T#J DA= *D+
M(/5> *E/%T#J9PE(?7ZG@-1G"R#UZ &I4T[ /2;U?WKQYEUR=G:2O'[WMU=O
MDK,?OW_]YH<7[\Y>__A[BTW/3Z\I-LW&*T=QAA]IK>F^ZT2G)TGR]U=_??%W
M+A"]^N[LQ[^&"M%2&UI2*%<M(8*S?%>PAC)8T[[IN"[D\$6/OS!4F7#XT5<8
M#I\^3Y.?7-,2KNZOCD"G5/)XEQ67694F9]7Z)/E":B0__?5,2R.4G,^)HV('
MZQS!()(VGQI$%7?QOX8[? >A[276%0QC GY.:#HB'HXO7IZ\P![2D^3T^8/U
MQ8/39Z</OXS*-_!HPYMR@E8?6-DC*&DK2(BBM8_?"A-G727RHI3ZI_?YB1\*
MG^#K].NOODZ?/#F-[D\?_^H;_#5_-KYON$U6ENY<<\R8.GCK_MF[,FD/+2G-
M$5L6_^KLS/]61R/16T;W&MZC=>X]LBV&D@:"K3JDB+$=]$A\B7L\<=6O=4%I
M]%[8K>5^FE.1P;!WA,7T8WTA:^FAKB6IVG"E I;J)2>Z.OMX*%)7'1@Z9>:8
M&NOAP1FJM2Z1=A3E+@.G)2P:9$H9?:NH+F!7Y=A.+!6Z\0@=2U$#AO5_]Y5+
M'CVB;-5#,Z19LG==X>MI'GX&_^T\8THF**L'F-LD(.%%X2Z3+_YT]M.;/WVI
M<R'+^1TEW7 (7^SW+BO;Y-L:R8'LPJ;?^%V?,:?HSQ714[SM"+4E5^/$9O(%
MW F?_,'#T].O'G]IGQ6_RG> Y]@4N 21O(3HTYFV06S(:/YTCFG=\0!]/3%
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M1*5P\E!37F;J[F:**OQ#(N=-'VB\+NN&J'.%-C<-_+D8D\(,P8<8!S/-#A4
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MS7MNU/7?QIT'H6')A GHB<(#J25!.P&SABV,Q5[(J39Q@LTWL@RZ0JY%O,3
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MTKX5ED7TH/F@I$"J!(77%I=QS.N;?/\:5$*4;.%Z'?-^NB$8V IH$$3]%GF
MZ]>$\ !7E%3]H6X<YAJY0,]TSM=>0D#4PK:BB\K.E2F!!YEQDQBG3+:?T&EE
M@X%AQPOR&-[L*5-;]%-+/ +0:"UW(/6B"!+/ %\'NF08/#V&BDI2D^ML[]N/
M*<&),BFT!V244/Z<:^)6[(%PX6"IMRD7YDFI:1H_E$9GV\S1%O+Q=2,P!;.6
MJ/N GHS9!];;Z8&'U0[F#*_0.,WC2*+*Y/8_3LKDD_=\T'[!DTRN7F,4HX-)
MZB;8QV3HH;MQ$6P&L8.S+2HZ5C8R$G? (H3!=F#+\>!^T?DC#V!LX#7>6N2H
M'8V/<S:H!Q(61)L$M55#<1-=7.%.J<3A41N--S(^U;\ZS#F<OKZ6ZC[#H94;
M<?D@!IRE8MSW?9=Y8[J&CQ9R_QWU&</6$U,^<=. D%(@RCCKBXSB4O\8Y8=]
M>IO,)?6EM!V/1.'-"+5*3UEP]YM;$VV_*(2-!&2P/./!&HR)^%OQ?<$BN&"N
M<&;^V3L6U6$?R^\3\KM@+:ZWL+*N^H:<\F#[I-I4-!Z;9# " 5\PC!!\J67E
M=Z>4*_5  DM-'K,8:5O$O 'Z[G[T+@;]=E.>\BTJ)_+1,.RQ3S4YO@B9*0UD
M)<:IE'@5@8B@EHPJM: 2"R-7(KNHY2U7;7$]BFK 0.@E;'*R5IMZW;?J,HEC
M65>#T@(^'3XI#Z(\KC*OVP<.5I$5:Q2%"(L:P9&AG($7P)()E=^TPW#R.=/H
MB!T<KQIJ64C9"'3 Q9JK0J!A\:1Q:ZHDCS:G/*2);W@*45]X>@HIUI-%[.67
M%09010\O7ZQ@^[#:==9>:S@U-O55IC4.;SF_I+A<[3_(WA:-_GB%%*9(-Q4X
MFO"(7G.%^\2ANZ^HM9B5_PH8\&OZM85KD;-@/A0=U-ASB_L!/;(9%%@Z,P#A
M(RBA(@Q'A^B.=1/A8ST.5QNR6X^(Y4VX+EKM40P/&6O\#&T%C",L8M8(,]'3
MA#"VOL6$R/?(L>&PC' $4_Y-#*)MV1I>-C",#U [<@)UG?GXW#2*&DAF>%M^
M)_,B9U;9=,H-Y,>;F-T; 07G"IF_[UR;LME_Q'._>2'Y>%W\US=JR4#OS^V+
MW.V*M>U19D7!K<M*F&#8),TY.BA'I%X7O?Y$0[&&U#@ I!RI.,;-[<8##Z]6
MCXS6G[HDFH@@O,[[FYH^*M"RL'6$+;,(U]P=84>[[3NQG&8QY$7;]'L^J"PL
M>16U/&'0XUEA#9"XVQ9-3@F30I&[E]MZA\9494$7+JS[(#\,DUA+BLO_0GQJ
M[6#99A "+I-QITR]A I%AQ1WS)I"Z]AFCGCEXBS_KLZ1+3&*YCV;8)R3O8;G
M:($K+7"E!:ZTP)4^)%SIR0)7^BSA2L\6N-)G"5=:_, _Z)13-5KS<MRF[M.+
M'[Z38Y6MWY\W-:R5!_+:&_J_;^ZA 1#[?EA1G&N;F+72!,)U^8.#3QN,U'%#
M#DLK(T6%P U"XACN Y\V]I4&WS:&>0<AKN@K;*'+"BG(997 9?98FAO2JF&>
MT-+.AB8T?FZ,<^%RE6;C6[AWHPH<'!FOP=4?OO0.(1:-KX6ICK# %O#9BHY3
MM ZB RS6\N"DR&:(65\<R/8D>878%S*H"#6Q0STWR%@!0/P0?!)>]-XWRY_^
M(DGX 3Q#D^D(F)&JF10>)'X-"R+FC 3K6-7XSC0*[;9>OX^2L@TEFA"]TAQ\
M7HMQ%AL.P? /6@HX9AC#6YMBER!4ZW$NRQG1DG0N"S58'D9N8//H'UN[X%92
MKUDM&VQ<M3J61&BH6&C=[."R)DY]M3<>1TG-PP:K^W-"<JQ<2;@OKA?8CUOD
M1N,"%J/M.%^#/R@M"C9$"A5I.H'\&$,FM3H9Y,^DH<OMJ>)?=+T N%0K@>K;
M[ZOZLG3YN?-0*J'B"*423N%Z<DFTMWRNL8Q0W+7.B07X%T&GZ!&\[)=)(%I9
M*3+!OD:3LSV \]3E2K9BX6<PGU@$*SC=G/JB71[D%7;@+)5.*QQ40[U >\Q;
M7C^..#S$T#%X<03^@;71]$4G7U*B3VTL'NZFG4/"'7YA:?.L;<>WZ0LT@X96
M?/4K\\]@%H?Y87@"S!VF+/3'.N+#NO@(YP8M^P[F&2:8R@83H+4)>J,I2E4X
MQ$LG]>M+/WVR^X:SNX(39H>,// J!1SDOGG=T"X/B9!5'+X6'F1%\&&G+^'Q
MS X+MIA+?X'(U:9UX<OGY+($X?D+JN" E<(")5,#M0-,)-L.-6(",PMM[NPZ
MD5L@$!_AM;AZ1"1CN</GH='HR<VJ?7%'11E[,A@U."+GRB0D7Y/MFNOW?>48
M[H7OU9'KB&BJD^1%)7(,\+A@-WK/PXP^FW>P@F7"@3DO+ES0"& <.Y9,#<\*
M;L Y XV4$5+ %9?VTD5>2N!XM@>G&)4TS)'P/2#"R7P0%@ 1^M!;T4,6#%"B
M3O@6EQN^.N%T"CQA@HB!@)F<ZQ0($PKWC$R8.Z.59"BF/>CW'MREK=D"IM/9
M1_'&<*X(0M6>D3@'?)T!(0/XN+@*9".25TND'IO"121>_NK3V-8=:^_HH1JX
MU@O8D; AB5%Z6 *?WOAQ,!% 5Y]!!?P79UBFS(0;SC7O?[BJ8,XPO[+5:>21
MCY:$3AH1E PLQ\R5_!3&:TM@E3-P<EY!:70VP_J*%I5P/Y#?X"J8$,>E2P)M
MQ8N8'\"X)X/%BV:*;VC9(*_ ;WN;9/"8@:\CO)1U!<[KK#P>Y_DUE1&9FDVC
M[J'](-BFHG&1'.!&"X+YW"+>#IT^(2WT:ZTR-E]4!_RD1U^45IH!>55 ;BK:
M,Z"[P7@K:D8F+VHHV!9-9/G#L@LKBPF Q';S\?6:F@YRF+#F0 04<!RC6817
M^Q<7VNDLD+R0>IP5$QC&IP@L8P/T]N=-0M[IB-#,1M@KSGX(=LU+\6+C"Y^X
MZK5XE5#8!QTOV*I&3!S<'X[V0ORJ2UWLF\;1AR[KYCVW,!CGA[QK;9C9**?3
MT/P/)G\0P_ ^A6\)L\O:!6D&&(IUQAD/$^5H+"*])O8O:>PP0-S6"JJ4W/$J
M.7>43)#V-\0)3C_^T*(8^J%II/1UE!AP0QA!8O5A.*H\KW)&XE4OQY_ 15H@
MB Y'DAOT'CU\](0NC_4,R_HF'43FR[9/ /N? @,B!L?%!2_/X)#6 =]I#"<M
MV_6Z;C#?4MK0%!T KP$3XQ?%BC,FL2U8^")(-5D9C?+@B8^(%M,P+T6RQ3SK
M_K+QV2*190O;$#Y.W)EKIO21B,UH>+"/I<1?" T6!YW& 3;+15;VY!_QE^J]
M3!8&\0VE$.4OJ,YJ\3+HK&$L>IDU.2&:6=0D8VXTF!U:++ZC;M#'QZ2U+E#6
MKK-V&PY3<.WY^9A*2#Y$K*5$7[7*2J]>X]&],$*(<^9MLT)&'GQ5_X*T9NU#
MV_:SZ).4ZHU>3[WO'$*7)JM\)B],RB15IP7C[>!&C$F=FR6T\2MWJ*7Y@2*/
MNF04M69%PK:UQSUE3,$7'/FKJ7<UR)*"T;O P3;?E:0(8:$[C%[([._[INT9
MKFH;QL0>7]]YY?G+)N#-@?#1PN@)F,ZPW#9PW"%/Z66W#0#/6WK#1^./^)R5
MR=+]?/+V!"SBKCAOI$6E+@M.%EE3ZFVFM\[$+:8;F'#ON&?VN!1XM 0:23=X
M"0/U+T=Y+AK%,W/#M\;[,;VS$<(:#Y._/3C]UIB&BZ+-<,K@,CN_Q.AY,L6$
MDW+3QN3OQ'W92(*[% \!'[T.#QN@Y=MB58P(_=BM,=DQ.<$X'SGAY)##3T&J
M&@C=&4H(JEF: [L%\,U=P4U6>B_-%,!9XBZ)EM<8^'&:CCR<5M;[JA:1V.P\
MT (.:1K1VT&_@3[-='X+2&H!22T@J04D=2\@J:<+2.JS!$D]7T!2GRU(ZF/[
MP]@97U&"G)S9..7&O=P4'<ZD7XEI6O*41 &*V2_"M1@R#?9%"]+Y:"EY7_M.
MN&GVF<9Q0RU\;9=@+W!Y"#2Z-C\QS@U*?"BN,[=I,LE,8"BAT$LE'??:M42U
M]>GZ7&CT(R2 ,&^'H1 ";DXY%97RP6@<D1#/LXI?<'I3A_IF>>XX."7A8R6O
M*2 $@Q ??&ZF&JX.DQ$J,Q<,"BK^^A;]<MN$^"<6W$:,&_<<X7Z:91R;@Y<R
MHL? 4>?KJ JGC?;P"4="ITG5KTN':?9U$=$M2+N*#!WFIY"UIM6"D0RZD!%A
MM33P?\^A&I,A6X<7A_4$2;DFY8@+@\ =W9A3V/#[P,X]AW>A5_&\'5%3_54L
M&,>2W'BAJ**YV?*5#)1&IKEZX%IT,HIVBQ$UC@*QG[V=^XZ&N.4A\.6C?!=\
MDC/W'AK9]HWDVVR/?ST2:.$98J!"X$^(&(V$7:%3C10SZ0,.?R'AGZ@Z$?42
M9O+3B?6N7$]@A, DV94Y.Y*U]JCR.-AMX).,.!+2@T4GFRE.Z'A$2FA4I*F]
M!1O0JW&&.=LS[4)2PMK#$W";\;F-6XTJ$N.7",\-YTA-B??='N><@"5\"(_P
M3%'94DD6Y42/>3E2W:[[IH 3ICE<M8;P>7HZMN =4&O&,? UJM:$ S[0?YD1
MMJ<5\JU@GDVK.FERCB-0^?/ ,[/($50W7 4*MFJ/U5=883W%"<B:D)U7L)#P
M8JNB#@\O=8OSAFH2?1.7E2*0[=_J2T<);UO.-?SHO+X-[Y(6Z%I%HLW6@R)5
M$[)L,/-F3Y0']KXP!Q;VQ+'8L+CMW',G1FIUVOP=5.LBRHYK"/J,;& \(1Q(
MCC@-65:>9/]\'3? #_7XNH)N] :\=QXO,,46)'15N%A'?SX8C\CG0^/CDFL@
M*E=NM @MA^(,%:9H::#99P38!$.*E6N!$6@.G$LFF!P3TK%!OM*_"$7.R*$0
M%HN1B;VY>*$FIM,1SH_*6%2PY(+44-I@Q!2B]F(D9B5!#RU9*J/5>U@(5+UT
MO"B0!!-).W!<ID^4D^0G7S,ULCQ>N$B@:#NP<A&2RHC&!Y&IJ2-?%Y*W1B94
MXXO@]W&D8P92X72-,'!83./_"@2>%4FH_J:XA0B*$"-IS=%4@IUL'E!Q+H^$
M!9E Z=(U$9A7SG>%9*LA,# [:S:]-J#C-S5JJQTV,Z@GZA$!$0B@=1VNR(#L
M$-_FO,^P-.F"-"6Y+K@SYZS$F'9R="WO*<5^$1HI>/F65S9MGOW$.B$QGLD+
MR*KG9\2".ZU_6N"^OX@]XB/C+?[Q1A%)X[R?FA^JC!R$&YP1\.<#CY^WS"W$
MS<7Z/8:H QK$=/@=(MV4G ?:]Q@.,3_39"9@+Q!P/"""1<]4' ;[?B?)B]#9
M8GT-F_YH7.! F]!,-9@SVE.$8WOO;(&4_!)5?13*B($O@DXTL[*-?&N2P3)=
M3=$$4=9)!M9C& A$$Z0AD= +A_$!9I,C-5TX!LKZH/1P\<E$DZ2S1XDDR[VJ
MVT(5XP0$(/1*"/3)>&^#66M4LBD@?/3A%/$GFKBEBSDSO+0D.KIUSY"-NK+H
MA-%Q:B4,371#[OYX!(*(EC1V!8I&=31\W3H&LQTB#R3E)4TJ8.0P>!+)O,#Z
M]JKGRKBR 4\Z&HT/RV?U?:Z( [,U::4RE1GN(EQ_^CW"MV&'QTR<$.^*7]Q5
ME+[XOWZ?:WO&++LO?5LS5U'T%GI1KB?VE9M&)(!#:O)Q^#BD\$UCYM?5@,B7
MS4_"R\-N?AL<^^3FL9CXLRL3113WB 5IP54@<-Y0=ZNXSO/F(=.LZV6!(5E%
MN8LHM625[7"=K-%H4((@"M%K@ME[7>D;\*7J3E$7/_8ZX0*V+T3-V<I1*ZAF
M[=$K>A"$J:.OF^MYW,],?*G/::GVD1IH8@C5@:?0D_>U^!*KC/'VGH^=8<\F
M&<@]7NKO&[(]TWG!'@GI%_X!EMLXL\P8:WHEV46-6]?@2?^+6DA9()+L).;9
M9\33;I067, A"SAD 8<LX) /"0[Y:@&'?([@D*</%W#(9PD.^31+R;]0SS&U
M_DH=2PL@/M2U@D'P]LJ;,J)>-J$P%W17#[*V=;M5J9E*COFX!:!C[G:;71M\
M8Z#RI&#C0.4"S@#^/Y&BF6Z7F @-XG>2-"*E!KR<$75+]44I@M*82MTA1\:^
M-.$MI:HIL#7ANX@^6#SR0*7A.".WUY':QD">JJBP8NQKF"9_WU?%/WMGE@;I
M3QW"/"KGY;Y!4O+!Q#!(ILITZ47!HGQ3L_?41V>6H*_9AI)3=I$5)6_B"OY)
MD):IVI,7F]<^9UQYZXQT(+!';+#J*,FVQBXR8GF0=:W;)$X%:2.B>5!YC.C"
M$7K'4^YJO.SES CR B="U?F']?EV6[RG7*A+#G7/PV*+85X'GF_3!GS%*J3C
M+9\L1EQ$;\Y+>LAW3KFFL#&9'?@!YE<.@UW'1H*3:SXK4TL.YH;/N>(.+)M0
MUP1@W0R;'\/\9YU5Y&*R_U%;*:Y3P:UI0E+P78$1V;<<C*6T.!^K2!ET2UKL
M4F*E=\Y6*P?YQ!H,D"[S",'*1>FBRIW7'>685X@=PZ$];YSE\9\+N?_0/,$(
MIVJD&2<6Y-*B#VI5S;<$"YN&65(B?(4#GK4(T"/* SOZ\; /$F%#R)@QR!ES
MO] 19 4R2KT7CZ)K=CRZDN9@OTI*=0UE+GU)CM$KW.>*K8%5GG$"M$4>JOR!
MC*B,F>Y:.]CQR^ 3P_CE.*:#\70'DDZ).O\4>FD+VC*PQ"Y"J5C)Y.IW3.H+
M5E;5\8 41JUHAW7AQE:V;=91U",&&@BM%C4B4U92]I425]Z2>G4<)K=P!&E)
M=K _MR)&7YUSJI47/K=935QJIO2N:WCX<&HUA@^)D_'@]Z_\X6J]5H&2>K V
M+J?7-G@6Y6/')F8!K<*6J)NB19T6A*QP]AJ.3?PIHRILM0'?KI.66]'$R!K[
M%"O776(7^,MM467TP7=9<9E5J8<_H-4QBT+>TF-0KQG#D<P5/TR7Q%*'7*;G
MC..5"T<V':5:ZSZN7](CQ[4JWX8ME$Z;OEJS#PF_2:=(J>)Y]8WKUW)]<&E7
M/V[H2/!)AW2.H_SB//G0!^4:^13\0W34S/O)63F_M7S=R>^QPHL#S6L3H787
M\_LP-,&#>5N8&^5.&G(%UM%J4-]BNF<XVD1]1ZLR*%-P"96WN5@F[KAL$,01
MFDP]JV :50\MEY/'W\GS_Z__./WJX3?C_V]>*A+AP!*48Y*"LZ%?$HUOW5C1
MA@C<KX<$Q# ;=*;X8!&F)B6<ZL?6;AKB'X6)(VT^\M .HRTC9Z.])XOJ2C4@
M^#'CLVHBH3^B7PG%]."J3U%C3' *#/42-*A#BHVI2PR%5!+>H3!!W_5*8%+4
M.0N(2><JU56P',Y]]-S2;M%OL9F,N;M$V'#^HSI!D=M;EHJFC?9<DQ4MR3IY
M=8'A^]$G] -:VIDB*,A:1HO741UI$!1?(SL:=J%E4J-:F-125%>5\;*I%HU:
MKVNT*?P4L%:6Z/&A7S>;+>"CT54$NK8)C<YZBS((=</:GOZ\TS/)9P^&JM6#
M%:S6S;AD'+5LBO->#1;6O5&X\1^".##>@V]'4;.93LZ<DEW:;,JDMMO(^_ES
M'>^!L3;V=93&C#C@OW7;AL=50F,/1*B;&/A"Z.>R7J&RM3*[HLVK2PF?2<"2
M$2EQ2[^G]>W\T?$#I8"35UE+K#D0NZ+ZI^)OB5(EHYGX^3UVV</8!'"/O9RQ
MQ.Q,<<3=*82>&2_9Y2._*[WI<<&)-Q@-X>3K*,'+<;",/E&$,")4X:E"KU?[
M(-1@YDQG_*3(CYH=MNVZ-5KQH\DL&W/N-1,]*P>1B0CLFK%71001DJ?N)?PT
M:8GT*H.U"K< ([5>9ZWG?A'=T$&.4;,? :"5$+F9*JD1MF1]6)>\LR3NK+$*
MZSHR&@KR8\T5S4F&N,,''#"NS*"B(V?9;"28\L!BV=3>094-3@YV&.U+'V.-
MMDTZ.GZ"TQIE8@1$,FU3Z1"E%X@:S"BXA!=8P].F8X]U3!HX.%9AKP:F'Q4R
MU\V$.H3G-5ENO/Z84VV>/<T;<7J,<P(/J07G1V"A7-B6$!=!S+A^SUI6USI)
MY/C 8J AB[;4K X61\ MYC5SCZ-B+"Y'HHHU]&*R"WQ@@0\L\($%/G _\(&O
M%_C 9PD?.%W@ Y\E?.!32/*]-F6DZ0HZ9H*),'-(;XH)?E&'APBX]1EJZ4DS
M)3:6]^:<$X:.)9(]'(;EWX%<<X:^)A,=!K2PP/%=W@;4JW!:$J>#SW[/A"17
M);7&&?"9K' Z0-\3XZ]Q;>>%B*_*;PTP!>B33]5%A+ARG!YD,6VJ36J[N*0.
M!NT/*;$+/+@ OW,WA$V8O"(%,X*\'F??M1O;()=K=.2Y&2O._-Q2MGIJ1*90
MPD?,]C!5\L6>DJ+M&-<P7*3#KKM(1SQDU@*,((JE/>E]0,,,6X4H76*25A%N
MQN#EIRM"2OP2_<'V<A(IP-%4/L[F^D0\/X5&M<Q2$P6\EZ&O14MP-F?*Z9.8
M,(#&E],;49GLRJ+85+>@(8H8S#!GB,-34 +1JN-@]Y.&])(;LA,XLM6:>K?7
MF,I4FA069UE2_THA7-=TF<F]X,&B)$7>_,(W%!?B:['Q8QE0DZ0#+;2&J#;7
M?G\0DZ>DFS;2)<3*&'"T/> J!Z;='C1TRIF6V]0"I&JI*RM^:OH<Q4^,N+Q'
MM;"5PT<DZF08T$/ARMP6'3E]WNU[Y=FX>B+,X,=WBA]1)R;0]6R8?>?Z17'5
MZ'(;5FATJ3S!,?;O-A<"2,3&Y@IQ/JGA/*:E<30&XQUA?\!CN)+)X-JR6EN;
M+M7H/-#V/5,>&IIP24IR3BY0NNB&9\-B#PO,\/E;^Y0738GGXT#FCI/DIZ:&
M1]]Y* LNSW,B__;(K"%R--P&%T6\W&15SZX>R9*O'LA:X[PE[5.X6F<[[D,-
M2-7E/B5=)6[W^AB:2D*?LVK(70VNV*S[-<H0:S4[IM_M6VR\TB+>V=O75/FQ
MQPS[K,0Y!TN=Q$.F/TKUT6JP2EF7;KVM\7L8!5B@4B";PE,719'\ON.&WYML
M/E]LG5R3')_()T2H+)(6@)"#9!V8N!B6L <&^%,O@!UG64PPH[[.XN8Z4S^_
M K+$TFDQF-(#*&-]1#G8!.A)4F<PH2CAEMX($8H]>!\<D!ES+)!>EP]Q<BS,
MO;?"-7:^QA$/!R>T3+4K^# '99B9=G5N+3^*G8?H",7*!&F ")0@OA3\Y)%=
M?AI2,J?NMPP] ]_K.8G>T$=A=W] PX&#R?HCEUL)L:-*4J$@BQR9/KS@7J0Y
M5M;VJ+"%D8!IYMA.-?=D,OG\_P+NS&Z:7%LK,>FH?GV(>G6_1*FOF._0GH"#
MQOH8[1T'13@\\:F7,A^*QBHF@)%1B]"A@ZA%]X$<)8/J>2B\SQTU3F .U2#>
MG6(]I+P"_GW2!L_#RHXXR'V3[8N<5RB7S"U+7161! RD70*YEV8#B.TBSM9(
MQ1?6?8DK_M)%IDC&/HV6VK"E.O".P)0W]87+X]5(Y)C\H9J0R:C[41R17_K:
M:!1-2A0U.$=\PAB<>RRF)"0C*6H"(8-+9S$P,94GFP_F& G)"B4?#(^"0G4Y
MRXZ\H_KUD*<PID12/9&>\%88EJ?2"IXR92J9/K\B(@S5I6T7H125PJRB6X3/
M<"[XH#Y.'%HJRGZ@EC5F*Y2U2&9'%M? 0PZ+5!NI9@D%LSPGJ\XP<ADAR8)N
M!AZ4S6+R>H]X!P*TESVKZ?5M9B7Z@\Z$<C,QGP58*Q, (,%)Z([@Q%*&IQD>
M78UGBJ 3BS_.EG9$LN(A\"$V61$ Q7/JS;"8-/X31BQ'R61P;H2?T:+-5,_+
M3.$-9D?&<>Y!KM&&$MMVO0IS\G,5.2@V3Q)P/Y3BQ<0[>5!#,EY.E@QY\PC;
M'I-Q18\\),^(V5P'Q^TL<FXZB1Y\U6'#$2XK'QHJ'"EYXRX*V/BO*W#U\7?_
M@/-:0$2>WC@'7[;"S+>7C)^'L.$BN3+%?/6D+-"0!1JR0$,6:,B]0$.>+="0
MSQ(:\FB!AGR6T)!/,Z+'CK"6(+X;P_S>3D"=XV:/2<\M0I!KA+?#=IV&.>*0
MSW&7>=1$X"J>B$G0V9]E =72AU$GH9RG/EZ$<K?<$D.NMZ.)^]_YR1EPRZN_
M/&*Q#!Y^ZT-,G!9*QQ9=B#F83-)#<_:-R[%SM;MF:5Q!O7W;U2)BQ[(ZO"Q,
M5W>4FZ-0F7:?&8%K'H%;!RGA.F"K]L23'(6$WL=P?PH<6AC)O>&&E 4-;U;#
M7>/"&_5=#+\PQ8V/1/?P_3UQ6YKJJ,+5D4V[KR2$(M*2F5P\5F*B=)NFVB@'
MW0F 2[@QLAUV10P@(+!KZDNF:+4EF0%^R^KQ>#+-*(#$<:&&<173ME'V+O-I
MNDLK4Z'=15H<;=VT)1B2 ?N]?Y+\HJ6&E2L]X[J=!(TR\ZS+ACF@VZ^U:&&%
M-K-4^8$'-PXW,*4+63G^R4QGK! E> -F+E>;QY5*$=;2S!O1"YB53&]\*2@"
M9 AG<\QI/X;U'&BZ4N:XP+0A@M#\4B9KL/9%8'_[ ?/Q[492^D60C#*>Y-$0
M#[?:45EI,43ZIM9XWLAPF0PDL? (N_XU?=!"JNE+#^.DE;^!R.,&C8\J4G7'
M[)',3&H(1%,2FD+5VK7S:4B:=&G\M)DINB2F.N*-&.F7)$V]0OD3>' ]P@:;
M8"@O433)SL'BSSU+_O>V%&?&V;R]774;A@$1]F>&K!\="2E,T*DUD9>*5!",
MELJ,#$)4<AOG;[G[?6/:HR#JH85"56G-N;7TDL1P(;05#+%TL..S,.OY149P
MH551%Q6A>B <DFLRTPAEN27C]8W55Q HD(@ST)6H.U%KB^8W<P-)M&1*@1Q@
M5N&4FQ[S_R:_A2L1TJLVQ;8/'V+I'Q678%4VE'U@5,HU4XLY;MJ]=($5C/RF
MZ-IT:G].3[W:)2TK2A<YXKH4N#!+;7\-"W=08Z)^49S/2(N)4!BW],*8?FW2
M_S94P5.':ZH :-PU\M*"*1 *JRX9T:9-<6/<#C8<HX:/N$YZYHO]:H]HD4Z(
M":T.22P[PL9%A=PBVT&0C1VSV\7;/FSUEO?ZD(A/YC JNY##P%"8(ZM_&N(H
M+=N9H1/!L:3?U]74L3,SAFV]Z2XS+[ ^&-#1@'E%K0G$ZB]S0B,W0?=\-"1/
M "'%+QJYX'*2#"V:L3X6%@U?)(HP&">$24WH^^@M!]]B+1_B#+!^+=]]W-7A
MTP#@GR9EMGZO;@DK,! Z_L8[1\MO3N4*F R$GH4_03!?\'GD*)K=W->6I)34
MX;9<DY^FU?M%:VHB,R>*EY87Q,,%:.PG:?KYXPK%H5/V1NWOM&[0=RL/I@G^
M6,P:>P\9,WX9W$9(6P3*5^W*F55)M OPSX9YSIJ;L[+L=\1_\>U?SY*_.N+O
M:),O"';YOJHO*_0(?H"_P05>TE:"2='/?9F2O[/#I,Z/[Y*_=_E)FKRIUUMP
MP[_%=H:J9D?A?PJT:B?)ZP%M+79X$3:#JISJ*LMIJ1*//Y?HKJ3)*Q%2P0N^
MA<\B</,D^2&B2PB7#K@/"G_/P; B(425[9R-DE*1L.A7"%WI6)FM<^1>]RSQ
M@HB'0X(1R:8NBQIC V; "ZMO6[0J;6BF#?M*Y+;>S4G9%V6M0QM[!<X"9#(0
M*CYZMACK;R$ZYDA+59*2K U]S;2,C"4TO-0*6R<1)I+D3NJAJ4C:J,TI_.L_
MJ^Z%O7XD4X/YA<IQI"$M@9%(1R0Z47%CH )3POQIJYWOCFOWM;Z:SP)CAB48
M"'\]=+]%! ^//X6I1>F&=!#O>>02F7Z/:1#2#\Y/+LB !1FP( ,69,"]( .>
M+\B SQ(9\'A!!GR6R(!/+/[  $"YGX-7YNE8M6E4,LGPUN*,"K@TTLT-":<1
M4)_*_ZDI'A!WH&1]0]@X2L_?)+C1F,23_Z&77^1%)FQXF&AMN^1R6^]\F6Q3
ME*)-4"*] B=X$)U+:K\;])\Y"I$!(++H[\C]!8?\)3CNG1?C\+^&T?D.G$'-
M*W$-!0DB2?HQXIT^B]@'WQ'[(,1=NZ)M"V:OIL_^#?/7?#>X^*OJO*24 OSO
M%\]>(1\=/!Q\'$*F"J9]ET(@APV_AY,P5.')="A@'!!6((/5M[=YA!O>/^7E
M-C/4)QQ2(H#!K+'I13(1_N*8:A[6JB*S!IWV/XY$E6,*5(\:EOB(.4M]2E:U
M72WD'!E[^R82[+,BK6,<MV#.Y_H%)G,B=Y%_3_]M$O!3;!P1$,@W#T8"H9K.
MM'CZ*:7(H=+\L6297L?0*&U!C]>TE#=33:2G$[TP64=E*A/1WP@5)#"0T=38
M=:TPD&8,UJ+"&>:3K6*SY]!F2=86,PI!:%AVK<ESV(R%=$1KR#_*>XRU>HF"
MVJ*)FJ)];\^>_[[I6HB"D<?3JX-_!6\,(_K?#TZ?[>_,)9W>1J@)\NBK;^Z]
MW3T>G-,G)T_0]?_+]"+$;!IAB3BA52%C=Q!F&2\ TXB$RZ1%(8@RAD8)%=(8
M3*"KW+HDWRPS?F<S/J0GB;W(N#P:RU%,-&I-80J&?4J^:W%X2"^S?'>S/*QR
MAXFZ3@^=V.#EE(C#A$R@4A.'%C<FD\F@JMXU-UEF_F[W-\%&%1?%W-M,;Z?[
M%G$H]',B@F84/0X->V37P6!X\:= ]F$%W],!,L*"H66NN*4=V4L$Q*<48<H9
MEG^#-UV6QYT>^#>8Y[$_^9M;]UU$T3(I-O;!(YR[<MR%$2P06 R$(GKFTMG5
MDC[0H)9I . Y,H1.9A3?6E.HJ.]VB%W0LIS_DD$QQ\0W<BDZ*_W5*->!NP6+
M_%;8GBX3P^<D2HV8Y$^28PFI/%=;52*KR0QC'OUQ@*OI"".(OR<G1-8Y5AT9
MJE3"T(\BELF Q; F5?40<S3+6&0FCLCIN"AV]5F8SI(P44T24QAUK,3'[X;'
M;! [JEC)#X*IB[K1"_1!]6GB\O:\MA?*$I(Q> "&X#*#P24\D%=;"F\3S(<0
M$1D@?>VE$89J6->.AH)7[!(?@MD%9ZD1Z03'HY]/Z\*F(Z=&LS,!(S]/F3 K
M;GLM .DSRA+]G71P@]5:'295/D.TT#C,$E)Z(T+I$&@] ,#$3^"!PJ55UFV@
M=<!/\42[W-P<B20Y*^E!MA&_H^5M2R.M) AV&_@1!OJ!_)ALRAY1+%$LI-Z+
M)7*:3AC^?MJB3\0B*W_T369I7F'8S[OV&N5!-P:<4Z?*F,A5DR=O8><Y_"I+
MPCU^F%+!DZ<2?GJ2HG'V6QUM "K5,)/%Z</_2A1>HW:(VFC\4MH9$V41P^^=
MR#F;HQS-HO[S =/>,DX2IG*K6'!BBB%JH)JA\VB3O6"1=OIX8/[:]P$B#-_A
MIVBT(MEG_W;8>&>Z-N1A"A*]A..RJ$721M8KR;P&49EI-4:NTLC"=D9%R_]N
MZ!71S.J68-52^I&V93-P^I7 ;Z*I9(T6M0QR5,)^7M,LNE*>,&QPRD4%<A<%
M;9D9:K3-RO3HH##5WO)5K9AG6.!=ENBWC2QZQ$0^931&'TZC#3 _Y/0B!S-+
MK(X7&&J1^7;&*86_I5'VO65!^D"%-]Z%4Z_+!^IFTSIN6X.36)F8PJCK!3>Q
M-9\</F9KMA\3N!B#\'SFQVS_=TQ@ X:-,.25&V[6T4VLS)<Q0>$X]6OOD,)N
MJ=XCL)M9]L#]11KB:DUZ@T7@%+H)95U,81^Q5Q&R$3_'UE&8QF_D)@3JG ]#
M=+>@YA;4W(*:6U!S'Q U]]7#!37W6:+FGBRHN04U]_%410([QF2$9E%IVI(Y
M[>62?U>Y\[HK,FWQ&SO5_@-IPFH_#YCCA+SB7LC!V9$E_]2DV#CEQCSKFJ2Z
M-L&E:MH#P?<AOW+LA,:BH+5W\H\IA< 9&LY'4M8Q"GM#^#!B::$(&@<R4CL2
MG6T?[4@$B$%GZQQ-D,PP1\W9%9F80=!KO?98G9F>>[C2L,1S^O4WR:HGZA (
M41%W.*1Z$90./!NE -!-S&SR)(KT*?\L2:X-AT=SJSS.R$@^K&'V$>UZ1\"F
M'V#F>(*=-;G<KUGMFDV^T6K_HOV2WIGD[(4LX:+(73JJ V;G\)'S:"'(X[%0
M+0]L?>ET HE,'G>>KJ0PH"F%\]RM.!_!X]^'&ER3J=GI!?/ODK!]W0]X>$R+
M:>E^$R/:H,"SUSY#0)?MY9)2LP^I^XJ['44AA]AVFJ8.Q@_7Q#D:N083IKC#
M1\!84IE&5\E6F$.>4<F=.,?!&CI] U'LD?7=7S'T_F301G'I/L>4#_H'':>[
M1X,\*6)EH,A6 HG5[@HK-.4[RD=XG2$+RUO,8C+GE_QX=O;GLS.GW!X#^U=T
M6$V#*6J+E<CE62*2@9+[W)/-$WX,'^\J)N23Y#O7[HO.Q=1EF(VB?W2N%6BC
MBCSYX66#1@M7%"Z,JIG)_ 0X=&;AR_4*)S#UB(PT2M_-TF.'>]"N:&4S6!X&
MT^I:5+_VC3DA]WUG^_,5P7U)945,ETGQ7_..."@5W9XX84Z2'PUZ^C;CS.-F
MJ>[EF:Y?7,IL[4&S CC10O!@&\CD(.K=@-OVJLGD>RWHF(,1)!([RMZ*M#VK
M;=J66E_S])M4;&%8F?ZL'*NUJ<)]7_G*%(N1L1O!5G2079^G6X)CM2S^%1G!
M<=FR0?*Y6F]C*,A%90_OR%Q7*H(YL3S&FILJM/EWN+Q]#J_N,Q@C>QX,3MZL
M'^2H!8QD?%OAU1BI@E*&7/P'V%*Z=CU^U'0K7*D#R7L4+!%#CM#'TSH5%<6%
M&Q[/?>0AHA^9# /OPK04*9Y>E-!&8L=.1%L/T\\@=EN>@*V8&FU;<T3^D;IY
M#PL7RQ8G8%,9D./K1]>]JM*#,AT'\4Z**Y6CO1L<$T/KQ78-6T?8$VP0]&O
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MG"-/G4B"8R4(@9*(V-]DB([%;H/H*OX^9<VY6?JS57F%3U6P9!#2G8Z)'90
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M;ZIX5=W4XY-6\"Q^+-P]TV9HE0HBK6* 2$B7M\:TXAA&FK14I>.Y]YEI*7%
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MS]_$NZX7/Y5-NR/>\E=9A_.S9G6V^.3?Z.OTG__&Y/X_AN@.K"[(>Z>+F J
M_5WI[..7R7<\#S!A."CUSKB07K=0=OSX!Y,1J'(/.8FS5"Q=&+0IK6I="YHA
M(%3]AOS#BO$RA%!JAYXT\&(4B0H'XZFR!EI5)IAK/UF6J]?\ZWNR:#;XOV_>
M\1+R3<']>^^+^;?_3836Y&V) R*'6NI-=@,(NQ_-82_5I3[XM2<.V?S.)K9^
M6=;D!L=#>F-: WH!]DP*:%4+ 1K<4ZJH1P^VY!*2*3&0A]_8,1(?*]Y]%<;^
M(Q4<NW#)3'=4GJ0C8YVA\3AX->E,:"*@:L_[KP_[?1VDDZ2F4B6*HJQQ=%D1
MX(#4AF0W^^DD326X>QDQ^@O9]O'2KS3^6SPGUH+)P4J;R#T]Q2&A-VC>;:YH
M^* PN^C_^-HZ>OA<L]JQU?^2Q2XSAL-<O?,,-F?U5!@ALN8"MU![9L8-EBY'
M>'@DQ\:X D8%T%\OB%VF@: 'KXK3Q+B)26M<SC(@%&P52T'TYH5?>,NB\AK"
M6"DZ'G09N<(K]A#C=1[O=B'^Y[=M&8]./?U>O'K\K3^\W%D\ >L$%\WU*;*R
M+L/K66OHT(^^MO5_*HJ/(AN,@R5%N&5?TGVBE4-Q>QT$$$MS*2F**44LK%UN
M!EEJ:\/'ITN^J6'UBQW4#Y03M#$>TUV*LRWJ" L%M?@M,A$T$,1A!FR]QEF\
M@:+/08C2*!PEV'2^J=,]$U*.;:#B?M5O>5_K6RO(PAP1EX!5N+0_&X .HJ'(
MO4'20$(R1!ZSV_?F^.7IUKA)VE6I>@[QA*GKTN(4"$II:@DG[,CG)-O6THBW
M5[)$TCJ6B$H"ODU;U^T5<$S,H,<NF<"JG>?%F<G1*X_#195,J["($[[-4%/Z
M@')A)KXER:;XE1*IF<XH$D!G3.B.T9--'^P_\@V"9X,_(+*'%):35% @,3G:
M+/*<H;LH=SWA(8KC9$1M6L^277D)W](RXC/\1;CM6TKOG9 /)^3#"?EP0CZ\
M%^3#ER?DPT>)?'AP0CZ<D \?3'[ZI6M#\&T F<ZI!&9;$A"X5S6:E92"LH\1
MD\+<G<DJ^Q&8DDH>%E>E1PLC]^HE]]PK(YR+QHG2#F%.A;V;3S_\5<E0>ZN_
M(@61!G(Z@-Q"Y?[.Q;;>LDB);8]"KR0:8>B/) Y2(OOS)OX3%3A#;0S[B[9C
M\J#1S:1%)N.>1B1*.HI.,6,W=-&Q#[V65!VH9T=9B?W,A;,2I:]J9Y4Z5+TS
MQ'BSYCP"W3K^^OH-*2_ DJ10N??7TD_GESN'INZA*4]L]ZWP?GQ3FX0-=$(D
M$Z.%14[^<RQ&N:! =5IP<+6+3ZI/XT<7T-X5MCV*S5)F)LO@IF>Y1\LC>]HB
M7HLN5M?A$LTR%R%Z<B"5[\M-V',C0(^OQ>^AX4-2,UNEH=)][/J5$>%_4EU^
MNCCGGK&@.>;X]'@H;3@85;R//+"#GFSCS[@ABGH=N;X]6B9(@]/P33>&_3S5
MQX_L@2S192T66[2"N68JS11Y<$PN/^H>0O>._-97VC+,"ST,%;#DWJ^F,XD*
MA=>+;JJPUFQDGRWUF257L+0N@XT8(F$P (_0J*M-N-=SWR*!%F0T',:CFEUG
ME@*Y=MVK#@4/=][YP=,^?S 6CKV@/BC+>9S4)FPJI),D6\WRTYLQ9*=(+>=O
M5W2_PU5TT8J*J[2M+WG1&P@RM7.VM]:SN#/.R7'X@&U@#(F)<(CT1K'H0<M-
MZ6;.M/%X.46.7(^X;,RF4<:5K')\XG_Q*O:)ZR-<$U:7.5M\A\UY@8*P=8#.
M**V7G,JUO&R#W*UNC<S*CUOQ\7ONKR(T#=E0_&_Y6HN>TSH^?5C(D93J3_ID
MEU5;JYZ7/) "+L<53EB'K,QYW:JT8CT]U=_*[I)*';\T%>U4X8'IR1C%GTWI
M,;X;:(#+$=X#<X<A,+Z.GLZU5:CH,<;5 -?#C(>)UGDGQEU-"Q=:K6$O?Q#B
M:NFXQ!(?$J6?& )MMU7?6SF@<:B@K(;]3TX<ZZC/T5OH4O9H#$*@C:E/J%IM
M4*HTRVL:RGVV1E/]FM?%J&3]6 9H1/O+$ZJI[I6'B #=L#>LEH/H]G.($09^
M2JMFWD+^']<!]^)PI?IF1;V;_JW:YKREHTQJYP5TV.+'_^*E)SA3.57GA+SM
MAYAHZATW21^I1? ;YO"!>42,.W7DLM)ASE(_OF6W=#+AIAN  WLSU,+?0WX6
MG:P,N><IF!V_20G0]]%?:RF90]W\U#4O*4_ 3@_G2GPCKXGPJ[)PLK(C_?*W
M82WKC1^O#JR$0+\A(@%(%X)8P+]/H0PNA&4JDY)E8AGP+S^NNF7\ SE'I](/
MD&-HW]] .D%?VHA CW-A)#;0LDF@H<.I2G*JDIRJ)*<JR?NIDGQUJI)\E%62
MAZ<JR:E*\B'E'T98<9$'9;%A]4JO!8X?"0VGE&;@,DP-*)G3I^C&:5>>,/K]
MM\EZ)'09#65)J<ZD-5HP-TRN[^53< B1?7OM5<G)-&D;$&)[B>!)@O :'J%E
MO -3GXTRZ9R'PV2C@RU7L%,/G<CO$:64''=KK<EUZO'<#7T8Y9.5$$>Y-;/H
M4%,^DP:BAEK/T!)D 1XG?9'LV,PLJW6+@?J0BE.ZTO^*VI1O[72"%<:[AF81
M7E&=*W?,_<SA2,?XO=K8T6:"TFB&8W@_IG#*UQ],$BR%=NU-8W5\7%BZR^R'
MY__T"7W.K-%^.'9%Z'52-_10\>(-S7DI5$S:86<FSL6O1\A'CZ;9;D[X;KC"
M%<[3YLU( CGMPT+<6VI@Z(XT5L$0OX@?(\/U0VC:;;7"E+\JJZNRT?X=!2C_
M\$SQR:/]FC7ES"3[:'0+G[4KQ/9,<QWRI;_%T8E'Z=#!;GS7G-?<TK%>_$KY
M'MO\3RLNN:3O_E@VT1#0Y/\0%Y= 5.?&B2<ZOA02/S<\#XH9HYMI"</^'._^
M-([[E395R6]_'2[B'GX1VCC%UEC"EXC?>')1-27LMMM>&]4-SRWKL88NXVZ=
M,=2I[SU^<]\-2A!6KK50DA0G\Y5#9VJ#_ R7YG94NK.NZKA%ZY3M%DN:);S'
MUM[ZL6TWTNRPC<A?E OAWJ[0&W:]2[8>(VT[8@IN;PGR?>X8@O,E#T8$Z<0G
MQ -U!8!382S/G4#N4X+B&]V=FYT;EEODI5\F0E\D/\,YZLY5?)@U9YY3 I(>
M'8VR.-ZI-"]O,$K_I<=%,])T@XR(EH4>3G-YW*>O('\ZAI7I@XMUC,F7-5JW
MJ]=C+9\-/XQU^4XH 697V%S&%!WOFI5TS;\S&4IK^G">QS+LKXAMW<_MB(9/
MO),M58/R'BNM_5C>V3$O@J$WD5BLXJ6B.R,KAW9=#1)<2'NNP[:);JE(T1-T
MG5YK:X\NTS-O"8YZ7_F&/$(7KCLONS V!3^(M('W(1Y<:2PSZ29^NC0:OHRC
M37/'XPI\ U0B\N;I;I(CMJ$KLOFE5K\^-9RGECX9<5<V2;WBE*S8X6AL0IV,
M*%==B ODW3< XHQWT(:\Q0OE1D_.Z7DFA*:9EPLM@"%-"??4\)AP%EQ6%=_*
M]6@/C74'[=#448%')5&\N&5\MGC5+LK+EDL*\C:^H%$07$8NG& Q1%\0^JK3
MWB)?N)QR37)2G6,2U-XZ1@OX5>V_(]$J.LCEHEE[LN<<<BU"KDTGA@ ],!!Q
M(J;156[S]B/ZZ<99*C16YHR7A2?3_35,!WW;KFFO9]NV;ZTM\Z"'KC\M;JQI
M3+<O8K3HI@T* N(F(.,CR-FE>6:U TCL#3<1^=:O%?AYQ4NMC9\5U1FR^I6$
M_6G\CQ5SN-#5,75H'D+>$8:&#R&UD/DNLL]6,*!C7EKCDIWB#'@H&7/4=M@!
M$H;$;_@/1U1"0LHSR\YAHGNR&PN%4$"%0H!ZA5,3WK-N2'1[,L*1L\5SKDN+
MJ>[FO974]V\.X99W":4-0+R"4_&6CU]8)$R#EM-%R95R*"RB@ACD[BC=B.^0
MZY5]!RY9OLP?CTJO]NQ&RZ*/?OMQG]!;C13E30RQRJ.$B5\UD -Z& EUC_CD
ML5J8;2$PP18OKY%W)]J*M]CZN>U^JX;+.PT'PRZCK7$ I/.<.*?A:7@\NQ&^
M+42Z60?/&.XM6D'$4U:U'+@@^@NR*OGR8NFNXUFY<\H=+^=&:QI'ZC%/:.(
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M"MM>[KL0]HN?B4Q@R\(+8,**7W=MF[YK$MF]4;J*20L7ZTJR\;+N&:=,"*F
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M?@^]25!,=YS,UJ;*/ (2L_B-%-X.H_#C(@#MQF7- KA.PES&(V11$^XLWI=
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M-L-H"]C6,-8AVQ),^31':9(>??3L8@AV0T?80^!*Z6,[RVY[=M&U+S\=I>$
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M<I:BPY87B^>"I)&R3 (PW"SR8.F!+#UUAQ,B3Y-,*"#\,@%>/3%1CFE"&?
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MT)[-0#"EGC* CJA;F&YJ\@;59B=.'EX$X0W9;VV-JX,;%PQ M'3, RYG@L"
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MN3%I<(+3NO66X<2-FS5+A23:O\IES1#*QOAO]9K3% *+UO"WIMH6%77&>C4
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M/LO\2E]2'HFG9157<)TT)/&W2Q-(S9)@I55?\70 N?"3XT+R%'BKQ)9'<Y?
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M0YKDL\5+?3<X+R@RB3#D_]_>M3XECF7Q?R756[7;/85 0&RQ9[O*![;,V.J
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M9 !<:)7%F1 7 M9"9@%DX5KD E@PU1O<3P;4<_4Q- MXW/-5D?A RU=+ 5P
MR8*A+$Y6JXK']:E5E>21TYI+J2+T$D&&*+"##+B09*Y<XG92K.0\EA7G3RLX
MARU/5Y4+=3K2;Y//*#/7N\"A'B@EU8HZY&O%"' G:&'!+6\.>"PZ\_'O80?4
M5/ZFZF7/K/(Q[W4I+Q-#IG&I<8-'/,03Y#3]P2]S700/!U.:FZ5))Q"? ;S\
M#-%6NSS[EL-W\";'9)2H:E9N:.EEVMILX#5#=AR.VF_&Y.RVX#_$HN28&5.X
MEV*H^0C5V9FZ)OAK@K\F^&N"OZL)_GXTP=^M#/[:)OAK@K^O52N8;F*/,3<+
MS<Q!.E&?V< >WNVT_,@QMHX;"1 ,5=BBY6)GF>CP9WPGI.--T+1,IEI.O$#V
M1% EB_X/9S!QQC,N)S 29WSXPG+DK]!]KMD(]1DSP$@J1$X3X$#9^U+"&9*K
M(34_NLV#<U_=Z--!B2P_6[K@2W6O4/GXY*G-.2K]2+'VAA]'"L(KA3,VQP]1
M<-84'*.KEJQNT89%HUOKBY)(B:4X5;*$!'R*ZGY$+D:-#D?1';O5_BV&XQ4G
M)>5\2CG=M14DZZ>PS@J+0R2P)GF0[IP[X7!FMT1'PW%*YN(JKZBJ"$UXGW$-
MB?5FE-",/"8+%+JKQDE:#K H2@IXFQX*"2<Q1CF$F&IDH@6*V4*AQC7XH>@&
M/#YQ*KCY/&R;9V?<HL- %&1D5FGD(M%)T#FTYGE[>_R57&0"!U([Q'3)!]:U
M*G*7L6.Z9L)]DP<B(+6:$6BV>[Q0LOHLT-T<P#@5'-3K-+% 78388%^R\W"R
M:VD38)P#!T#BB"-D/$ -K<5^$KGU2;#I9!&HSK\]H(J2PB%C*X*4 BC3E0%1
M-LO_3;P[CK3TFB2XN=5:;0GA%;O1A)&@[ 2E%3@@/8]P8]B>$\EPK"N$C@MD
M17P2($$O()8Q'HP"JT*0=&_/&4J6GE/(\@^5-?"3VA*&?JI]$4_)$!C:U*U*
MYNP@STZ*G=@Z&%PB+R8(F= =HW'Q8^0"LT&RVSWR))O6>"(-%7H._P _RNZT
MU 5JBCL>Q.#2BZ5KC7W#_=8?#3R)+ZYM9P3&@(MUQ=!1*HLLZ#L:88C85*O[
M1<9YE"+"Q!^>O8&E0<2H$-*/(<)!/F8RNGS>0"DAJ+06QII.YU^30POKA$U"
MO7QC3IXWT$I,7J(E#'U_K'MG$^8!!@\XN6@P?QY;180!H6\^/^M_*5N+@"<T
MZ:8"1STJZR5.'X"!+< 47,;>?S,+MA_<([^#*-&41()6V( ^BG#V<$GTSL.Q
MJ8$T;Y1)BN9V!/EC:$C)7I0!5M*"&J0^7*YSCS5HRG[1A$5?^9$A) B8ZJIP
MF&,^6-\G/*:'X@(+KH(P,9Y:JD;<LEB.Z46F,'EQ(;T:E@U'QBO? H4^J/?)
M0K4#Q;^EM&-Y5MJ)()5 E-6[(*<X-2'X^-<F(1>4.9(P%7>'="&Z*2A10F7+
M Q[;HX]5:HC*P\(1D_1*<93(UXPR<LW?^N,QVA<.[DXZXP)&H09AHLNA%I8N
MHF2X=:RGS4B+5@%^E_A+N,S3S#I$ N<YS<DEZ6E7&@A.$EL7#QAI&' 9$*E4
MV)**O+!)'KNA"::F>R-1C^ ]#"9IKQ;8(DZ<8&2.Q2+6(TP;&$L4#"='DKV(
M":4"(KN]!]X;7!,$D FKO:8DFL%F-*O+D4:E&86>96]I_7NY+B&4G!GD!4'Z
M&6(<W:*/^F&:']_-E_TU\ HF7, ?:YGJ@#YB<I4M\V ''GI[L9;G!E;XWV$_
M\Z,N!5VP62[ZE*Y.>NR;X+)/G@Y]MBACNY92X#FF]77KJU4K6];-1:?UI=V]
M;G5:)U;W\+S5M2Y/K=8?-^WK_UK=UO%-IWW=9A\>7IQ8-]T6_/&J<WG<:IUT
MB[EZU]>(N1B%65'18JS*J/L17L63,+QJ>'4AO%IGO'K2.CV\.;_N6C=7EQ>,
M.2_:EQV-1[><'^N/\6,C;XV&UUZ#UY;G;WH"6^TRMOK:OF@QU7?:8AKOI-T]
M/K_LWG3> CN--1/8I/^8]!^3_F/2?U:3_K-OTG^V,OVG]O3TGZ>8>'O2Q#-)
M0V\@:<C.O@^_/;-@0RSR];W]-IB9?GE]UNI8[8O3R\[7P^OVY<52#/2MI3R/
M_>AOYGW/+D1(O%LY!(, <01B-U<#A^(()XDH2&O*'L4:KTMH9^9'\:;?!4\(
MSQ5;L3DQ9+"@.?-]XD1CP'\(L=N9Z!@@]H*0*W #,&D'@,9#*N[K /")O>?L
MV.]['TK6K\'T@(UQ 57$&.4.8<4=T"3NCLW(#EHU__N=[WH'\$V[>MNP#Z/H
MD"!>3@<.,T,IH9(9 M/Q02^8^A[;@4'LDTW9VV&LT@1;M_"++D;A\]]E5]]]
MY@ TOU82[_R<_AU(IL*VZOE3NXZ&X;CPS.PG[<+SWU-[]YFJ0)U"FR#*:HDR
MV!MW; A$>P1='T$*HVCX6;.Q'ZS\"AMGYY&OE<3W4F2H<BVZ.[];[;$_M':K
M^\;989P=QMEAG!VK<78TC;-C*YT=]>4Z.YI+<W:(Y]C*W1T.OG803X:,$>;8
MI:_E"4G,TI\B/MZGK7&//#N!@-YR&U4^YQI#.>>_$>K6.%]6YGS9*UM6Z\^S
M]E'[^J5!T8VAKG*U,=_6*3I28[=<7Y %ME=FALY"1EK<\NQ&V;;G+^\I5N'C
MYD+F8\TB5@5=PW(Y<Q'>F&8QIM)[6=Y"1BHVHG A,3SR@U#RF.2NQW=OG=?;
M(IV-NNAB5$XL;W-7=8)M.1&1I\"*LI4)S&L3U@J7@#>_R*>3Z6:O]S3 RHL3
M)H:>(G&$9@:7<;ZX?OVGBEE_3SN[+-..C;#($'+Z[-;DWO3":?%K4W\\OH\/
M*I6?/W^6V>S*=Z,?E</([4/1=L7W[IRH @7&%;O6;-KU:H7-TK:;=;O6L.WJ
MQT9MKUGQ_&G=+O?'C%?J93OC0K5@=C5'ODY'?CCT$0 9HG0='\O8/81GQ]+L
M,5ZVE7G%$3JO'$"P=ZVC8!2[V-P28WX*E;D$WRDOGY:R13]1TS+D?K;?RJ[N
M_+Y:Y;;J%:)@>,L+_.HP#K( Z;O&N&5!]P4CZ58CZ4#":<*.?JSMPL^[>Q6^
MEKJ]XRJQ-F++\(72JSU)4)D#W_ #3VDWU("(F\ !JY:I$K$LVT<XE8!7X!Y!
MX?!**'!>)'UUHG9?4Y8O6.EZZ(UBBG&S#^RW2>A;T)"CQG@LSUUM%.3&R\M:
MKH*L&P6Y30?^V@I2=:E00.J02BE31XVNW$Q=63.ZTNC*-1>=&7*SAC_O5U02
MG%VM3_UI_2_I-]TU&O+M'_,UPF-F:K^C!P3Z7))O=.U%^WXA!^C:+^/%M[GU
M6(;LH_@1]5#-N#/70C2A7+&KWYE(F=9M>_J]/JTUN +!N%LY"^O?'-/Z').Z
MX_!+S7$_\'NSU6V)QG^M*<&-8S>_#G9OMNO.CKW[WJ%N>';#H]]*A#*(-5*)
M(;H<BYPI*=%'J>M$MT[HQSN7TX$O.P4R%?8\9_9+<L4V2#*>!@-LMQ?Y@&=H
MY.(:,EPM0RYF@2"88UJ?8\J1BZ<2\-/(12,7#<.]A.%J27NQELS46AVE_&)$
M\5I3QK-,5'L?VX(?EZ5$M>N-ZJ-BMUG=,V+W16)W$H5!W#>B=[T9K)82O34C
M>@UES%+&LZQ@(WJW1O2N,B'9+K<ONLN*MJYN(7\>=<ZM=@@-,ES?.AFY$\Q#
M>$\][?G'GOC8&[$[9$@@O;X#37"00=I ;] *@UD_)]!M#6X[UJWO.I.8#3..
M+7S-V+FC]D?@._<\WK%>C@&3HP?%^SX\87^WA:M6>X]<+4=UC\\VGZ-T0KYV
MIJ-P-'Q@MX.Q'\:(^>3V_:$C.<U0^%91^/'A^9NG\&-GX J$L_,@_'8+S5@-
MO6\EO9^T3M\\O9\ ME]@R-V0>_G\\.C-D_NY<^L/8D/J6T[J5YW6FR?UJ\B/
MH=>JD>U;3_"[FT_LQ]!QU[J"!O>ZPP9]->\)6QE[X$*'7<46U,@UA*;9A%_,
M,6<L)@2,?^;)+) +.I? TK/WDVO+!$V$AU:ZMK\6^J]HW_!7W9B"N*J__/,?
M]E[UT^Q_K_N^Y>I1BZR@UJWC?H/N\Z&WP^?9PW^?ECSK&+HL+S+*5O"]CMLG
M.2-$"21;H*"!T!_O<>U2'VRHX YBZP]"_1\\6!W9D%G"_*)/V?/](1NU)Z,.
M,!ZXJGO(D=A=&8,YJJ4"]4W@.5+'H^$PB&/1-QR&A&]3=^T@%_XN"*'1-)MF
MCZ"IGE"'AY&O])PPN$2?ZNE;)>MGW\?VX$/' ]<Z&\E'0/K>F _B\;K Q_>K
M9 41])_W20&P[\ "[OR0Z82!ME;8BP&;P0141D('Q!.WSU>\!KCU69BPLYIA
M8W \#9B] ;,W8/;%P>R;50-FOY5@]KGEOPL!LX=F,J9SWQN#IE]=4ZN<AE[L
MS<YXPJROHM>?1RX[J[_K7&G)4F!W1O[W21!AQZ-89DPI@S91A,#^;#?KNR7^
MQ;L@9D8;&ZH/+9(FS%K%C!&/;-B(+%>RP&.V >P/S"*%=));O^\,>F")PT!(
M3_P!L)']"1CE.)XS&?='$5N=EV^G:AM>JVX.WOON?KG6K"_&X"DWFXM!:=]M
ME'?MCZ^-K;XNJ-P%A4+A@O99?VK:G)IW!UC.SB9O# OS\.KFZ&K;#K)K]($E
M"KS)B[.'5=Z-964'+Y?FLI=Y]'"P>(]VUAUB66@Q!==9B2MTAL?]B&F;@+WX
MLFR=^6'T8#T?/68Q++0P<.<UW/?9[<[5OZ\\4PCR!6!+H=\OIYCG%2>/ QT$
M8_82M\!RWE]%0>@&]^S^.+.*#_D4OWZ*9/UF9%2;46UK)+BD:OLM&%J=LO4E
MN(VUQBY&J2U\Q^=L]/I,,J\F:B-5V,PRC HS*LRHL#>GPKX&;M\?^-:I$PW3
MUK;188O<\GD[O3ZS_ ^3]5;6S>S0=4>3< RI%ANMV&;7D:O9<E/&1(BI6EYZ
MBH7)IC#9%":;8BNR*6R33;&5V119!O0CV125VY'WP/[7'P\'G_\/4$L#!!0
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MBHG5@I8HE^M79OL(8EJ.+7=4F*Y%V+3E.$0XV#:?*)Y0B\H'#Y\)ECUJ8O&
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M#48F>+C<:QYJ=O%O7VLJJT#+D421N,"! ?M>7]* $%E*D9G<\#/@;$H%XW*
M[ KY0DJU;*AR?,3&<LW3CCSUB'$O+!QHDH/8D+P2VR63U2-A,XZ7<VH$KZS;
M/5T**-?2)E&K+DT;WPIYPRFT P6&'.A3",$V%F2VS=ZY[57JJ'*1J%MO0Y5
M^_\[/WXYBK]STOL<>R^E?"NE_[);Q1[Y1KP_1H2_4H.T;+,OYH0_D\6$\ ;"
M$T?M3[YM3+$E7Z4GWZ<)A$N_VJ:6VIU\VQ#<E>_=DR\!OH$\CS)SK%Z,9[K>
MN0L-Y+@@F@I7?GKDS%W>-KS+J2"+!O+>H[=^*_"-R1:8VEWX30H*7[F9<$3.
M(7T[6"M##KJ@:BMMIB_9#<JXX_TVP99\"2W\0"94%'32^V;!;" F7Q5P,?I
M?M_;0\"3.P<R'2[:O*[N>WNBH\OJEN]HU&7/9L_CO!;OSEGO&Q!/[5D!;T;N
M<NE]AZT[K_]&<T*$7#U!G\@3"-8Q4.=G-5D_O ?\B-W??/90'38V)F_BSF+&
MU^Q@5+3]#L.3"+04\7<.XV],^$(]2$,-6!3+PQ[6%<D0HVR72XC0>^V].UM\
MWU'\Q.S9=IU00D)-^Z"U%,Q.3K71(1V[I [S:\N84TBKY)?]Z3.UY-8!FVCR
MA?Q&=7 KV(<)H7)";:4L=E#4F&/;F1(.,Z6?549\6GN4V0'O)7Z+.=D V;NC
M<KJ#:6>!!4< KOSS_U0%0CE0LO?*"B\1!$KT4=#?10*_O(W3=1R7F/?JX4G/
MLM8K&#\C0 $S_"[<6YD]"504MZ/YOD1'@%&&3%)F,&?W72$[7=KJ59'[\H8*
M,&_,[HCG71<"()_EA)?*\G88>9:>3:7RG_2<3:4QF2E?L<;OX*@I;N8KZ94[
M(=WJV5Y+OGL]]@BQ9@+,O+X.T\8]A&B++8DY)L;<9A:;K5KRT#I!+(NH8[T&
MW@OI5_E>EI=3!^]UY'N"J"W%.%79&Q'PHU<I&^OC[F()B::\1.:9<M>:GWY:
M[-LS,XD5?#W$(CLMV$[H>T]H58)760]DPOYNW>$)^^'S>J;971N2+NR0KJU.
M,1XP&KI2C1=ZB;OIC27D4D6"NVFJ) -;F1YX.W^[=J%^J"ROOK4K+;#]B<,@
MWS=DP?T!NH3Q:F-&+_&'#YP2\.;V06DY=:5'+,^!!, _5D5NJ&H9!ES.Y<=H
M 3>S3ZJ(JFNW!.!U,+?!FW45-]/Y[ :[S?B5DB(.^<>^?J%BWG9A;;\@?+UT
M[3%;'GX/#8;$8#/O+I!FA5Q=X(]?#8[D<@US,W[BS$KCL:;5CW<K^T0R69XV
M-@9?:RH(_YU@_L#<[(7N5C+K6@2%!=X5\/<55C?2G1&Q*>/J,!!=55'?L@ZK
MI-;Z6!7]2O>Z=M9WW@P53%6%$FRFNHIU3H,Z^ .]?'9<E&X;\.@:UL&_>S*!
MU$_._0NO.!K8*S,?50R3WS@R/+S1S(5Y62GO4U\R*6AS_/!:<9U>W/)[U:7;
M]T @IR[HAY9YIJ;=G=GT-+M-3;T:?V.EO8JTJ8-7 [Q2Q_9WY<V,?[FV"I4R
M@5,Q)0BCV47O@LUK>\OH,[/".Q0/L"CU[X%!/D-GMKI7J%[&T)]"_F*;?G:=
M_5Q+97D_/E>,!QOYZ9Y,L6N)MGSY Z2Y]WB5[7C!UG5S,WA: Q;E<])Y5?>&
M?<,+NIHKH1;W=N+VQNH4ON65'"\BJ!;^QZH0TKB)&'!J$.T*7M^P'BMYA8OC
MN#)@RMK*$Y&1Y8'DQ*F\)C5=H\79-R0F6:A-KP$DZ[NOX8RK?BI(YS(":T'K
M7//].^\E0G:>@+I%[0U;Y=,7Q%"[P+;V.TO6C^^"]19ALL3<?_[$$9H%HZ91
M'5)067(X+WDS/OWZ.G@SPO8])3/6GTZ!3?F>I%];!R^Z,!B801Q'GJR&N3%O
MV:;_>("7\YB1X^!-38FLFK Z=$/:691?&/\*^;SY+]=[/9:ZK0%N4UGDAV6/
MW*VBS/K2&O9:A@CV)P0C\8[8X&[.H_&[55K7VRMI7H<9I@I:7>\.0G8YOI2,
MNG;$(X":M1TDFS2:5K5=?X?PK.\4P5*9&53>&)2%!!D=%O::W_V)16?JKYR]
M)=O(K)[\[K:C,@\(T01?;;LZQ%GYBDFQ@K$)W\(<(,V#2?Y8YUI^JSHX)G.5
M8VD84,XUO">!X1.$Y_&<](&#;)$!XF;&4T9*'3P/#WM;[XQ0%'R!B=X9C%[R
M/2[:N@Z>JE5ZX@"REKP5/%.7WJW"2_R":>L;YJ9WT'P'@H\JZ;-?P=>7I3Q<
M,;)1X9%A*V<+SNY5U^$!OS4=(B=P:8)#7I,ZL":7X4/'U=UW+MR^#LZFG]&G
MV]^;VZ@.;OF'KHU9-.=BMC)<XUR1IG5P<4B6C NL;C6KDS+RXW;FY77P):SY
M:!>LFQ?6P7Q9F7(7T@J-^<D+OZOY:K>_8\S) G_ZZ;]02P,$%     @ A8!F
M6W['73+ '@  @"@! !4   !P86-B+3(P,C4P.3,P7V-A;"YX;6S=?5ES6\F1
M[KM_A4;W]6:K]J7#[0FV1(T5H185)-N>^X2H)4O$& 1D -0RO_YF'2X"29 "
M@3KDD1P.M4B!/%]E?J=RJ<RLO_[GE]/)LT\X7XQGT]^>\U_8\V<X3;,\GG[X
M[?F?QZ_!/?_/O_WE+W_]#X#__OWP[;-7LW1VBM/ELY=S#$O,SSZ/ER?/EB?X
M[)^S^;_&G\*S]Y.P++/Y*<#?NA][.?OX=3[^<+)\)IC0EQ^[_-?YKUIQ9DPT
MD$7QH(S/$(LS8)@2*',J(:C_^^%7--RK9!RDS!RH$AWX5 18E=$:ALYPU_W2
MR7CZKU_K'S$L\!DM;[KHOOSM^<ER^?'7%R\^?_[\RY<XG_PRFW]X(1B3+RX_
M_?SBXU]N??ZS[#[-O?<ONG^]^NABO.Z#]&OYB__^X^U1.L'3 ./I8AFFJ3Y@
M,?YUT7WS[2R%92?U[^)Z=N<GZE=P^3&HWP(N0/)?OBSR\[_]Y=FS<W',9Q,\
MQ/*L_O?/PS?7'ODQI'$9ISB>+=*8=(^+7]+L]$7]Z(N7!^]>[;\[VG]%?SDZ
M>/OFU=[Q_JO?]][NO7NY?_3W_?WCHS^GX2R/B0BTM.Y1RZ\?\;?GB_'IQPE>
M?N]DCN6WY_2@")4#S$M6 ?Z?A_SZ%]]6D\(DG4TZX;VEKR\>4@'WOS#\LL1I
MQG/A7@*:S-*U#TVJ:F?SRY^<A(B3[KNCLP5\".'CZ.TXQ/%DO!SCXN79?$XO
MU"A&E="S!(%G 8H7#I%I(KC5@2E$S"Y=%VA=ZX(6VU&BA$7L>''QB!=5TB]P
MLEQ<?J>3?2?WNU&<BWG[=>VE-#N;+A?OP]<0)WBY-BN2=?2BTYM-]%3))_ Y
M!)!>%A&R1Y5MX[6M1W)]?2M$VING9[-YQCEM@L^??<:Z85WLA^>PPCS=8MCU
M=_'B$R\69Z>GW>\$HL_IY<^7^>RT*0>6L^:B/]<RK:,!#>9GF->LT(?HA-$*
MDBD2E(\)G/8*. N<ER"3=+X]$]:#V80,XH<E0P,%-./#R]ET.0]I^4]R%EZ>
M+9:S4YQ?8OMZB8P)Z0-&#MGI2(Z BA M&E JE20Y<EM,8VIL@FL3EL@?DR7-
MU=*,, <?<4X"F7YXB^38W,*$"06SK(#PBGS&R#D$I1$R.8Q9)\UBP,94N1_1
M)B11/R9)&JJB'3THX)BOV]Q8L;D(!=YQ#2KS0IM;]&!$Y"X'K5R1K7FQ'LHF
MA- _*"$:"+^=I[%8X/(*@N,^.EX00B)&*JDT1%4RB$SD3$P8:9O[F:L =K:3
M87&R-\WU/_O_/J,P>4*_=+&W?!GF\Z_T"OXC3,YPQ UISY4 5BA+J\P6O"5!
MLQQ*L*((;DIK0[D)L"$YU]OSXI:1;*Z39N0_.IG-E\<X/WTS_82+9<W++$;&
M&RZTXV!3H%>;O'QR_94"ZPI7.DF;3&O;N ['D)SK=F386>(M0ZPNW#LD TRD
MI(CO'2ZOMF*?DV"TJ1=ID8(^;FDK1@NB:,M+\:)PW5.\O0[/D%SH=EQHIH%F
MG*BDG-)'OA*0D<HI&9,8[4B&$!CKR3&+$4HI6D@74@F\,0=6GS\DC[B=SK>6
M<#,=OY_CQS#.^U\^XG2!9)@Z=^S&"C'Z8&E)RB&C0$U$<$$:((2E,!N9;VX"
M-H U))>X'2-:ZZ,940[)/LW':8F=ZW()1403A2X,?%8<E'<,'.U5D+@L7&1!
MFU-K:JP%L@D9S ]'AMUEWDS]*P$:D?)H.4O_.IE-2*Z+ZL4NOXY(4B8FSB#&
M1!YK$@(<[6B0B)I)$3 57'_G#6LQ-5SS*,?,D)8(3%N*1C$P"/70,!=2J]><
MH>SQ.&5(H5!3)MQD_+8B;Q<#K5F/5IE)52,P,LG*10,^,@7"*)N8C-EA:!T!
M?8?+@SE<:,^ '170\(SA]'1\'I'5<'TVK3E+G*;*3,NBY,9H$%+50P\GP<OB
M@%NN$D;TKK2.A^Z!,Z1PJ%=JM%))XVSAB*-*7G!)BTC$S^PY^" \&)V*8H85
M["E-V#;;J;.WV4D)Z!+MMUXD<BLC XS&AH#.Z\!Z6<8 #].WT.RM>'YKX38,
M[F8?<;[\^GX2IDMZ9>H[^+&^/S7<#$QP@58!2B?(O"99\^L()=J"AMXBS57S
MJ.YN/$,R< VTWTST/9V!'E8Q'I0_*<:LBQVA8#Y0\ C<F;HO.P].:@*GA:AQ
M!M>L]2' O8"&9-0:T*&=\'L*Z&\?2;R;3=/%YL53BME3^.J(N;1R%B%J3W"5
M93)9$HQJ'?QLCFYXF<&=F-*36MJ>E9^O<Q5*]K2#904E6'*_ CEB,1E:NV7&
M"Z:<PM;&9"V0X24%=]LV=A9VP\. 99A^&,<)7N#!Y?Z7-#FKI=W_-9OES^/)
M9&2B]<%F#X%1M$[NO(?(<@27K*+ORZQC:T]X$US#RP[NQ(KFJFA&DJNG9R'1
M2Z2X#A-6#P?!(T5]2H9L3!8V-S\M>HBR[8^C[*U$VF<Z+!=GE/,"$%4&I8R
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M^/8L:7A"=)]4[Q+DJ&0,I2M^K-?-J]H(Z[)PP$O,BFMO2[2/:@CO0CJDQ,>
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M8B/:B(OW18&N8PB44QZB]Q3=^H(B!2ZBZJ/-[2X\0TI%]$2+'130C!(KU.S
M+19GM=ONVQQ@+1.A@"*%(DR)0628*R:FDN#!Y-:DN!_1 ],#_1Z>-N-%0RT,
MQ&NY;)N\6$*//LL=3WI<CV63Y3:KT;_Q*.*>TMGXJ"+DFI14A@*J0*XL$/.4
MT\AX<:V;[M? :'MO$#GX] [0]EA[A!<C@Y@%.@WH$[U>)M#K53*'Q(S/P;E:
M'=!XB??A&9+7LBLC[K\;: <]-"R&O+7";WW:JP4D5G*=:'' '"U6H68UOJ,O
ME4<GK(C9M#YIV13;D!R:UHSI13\;6K*+[]<_8EC@W_[R_P%02P,$%     @
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M],7G^NWK$8WQ8D2>T(H_>3,,<7@VG'WC Q2!F"T4,,,2V6C&@D]&0[:,U1-
MY;UIO-#L:&C/G:S[S(3[A-?-_:H!)E;#,PK0TZJKHG80''I(NEBAM$Q6MLZI
MN ?B4$BTG73OJ]LT4_?K41J?8PW1#8ISREI.JVVQJL9K"%)) I +;XSTRL<E
MF>5M%'X-XW!<YPU%V\-N1KLK3G!ZY;"]'8_&5R 'ICA/&VT ST0=*M/DMTD&
M/%JN!-GH4>?&6G\ SK/7?BM1]['$U[R@FX N"7KEES'CH^:TJD7!4UW?,MG;
M(<^=^F(9CU&W3LUY&-&SYT)#@?>P!5PO3U<)(L/1!8%<K%]DIOR"93S!R_=]
M#'_A]-5?M!72\\D.FGR;RX=&5U/U2<AG\_%=DG]@F U:D.$NR% 'E3*2CV]H
MD-:AR*;PZ%MSJ<?A/'LB[HNJ[[/8MF$Q05[,JE]PA/68PA<12O0&I$UDK:F@
MP(D0P:/3RFKN;&A]G+<"RH&P9SL1W]>\VU;S;W%VP\*R0BL9BH)2@B8SR] N
MZW4UUKE%89E6HK6^;P%X]EK>7)SW=>N;F"KD<7^9X.=ZY>$K7F,CH*>%V/BN
MQI%(P+/99!@O9O4RT\?QNS AB7SWV8K@S@?RLC*Y5:"X2Q D"20:[H0M+BG>
M.FNG$?1GSZ>G4.&2PZ6MLYM7C>/D:QB>5<2T<4[#&7[ =#$A%>'T)/_7Q72>
MX=)AG ,G7"'74 --*YIICM93YWV HET4N=2Q[HJBC8;T!$&;I^!:1[X_!4]Z
M29.\-[(KU .62D86"X0DR? CBP\<X0$N<HH>)0^V=1#[ 3C/?N5L)>HE+-B8
M!O.CF^M)]0XG'SX3+[_/'#3":\X"!%$8V?[DT(;D.*!F,4DO.(FCTTG8ZF<\
M6[VVE-T2G6Y](OXJ3$;DT7T']DN8#A.MA2EI(VB]F=\8-4Y#*&3BZURLH)6'
MB]@ZE68ID-VIO:F>QJUEW,.:?A?4R^'9Q0SS0"D=,%D!-B;::FRTX%UQ4 ++
MD;P %5AK7VH%E,-4_B9R[B$39BDGYV;,R^&T5N6XF-PX_C(L9^E<)!>P9O.B
M8N"4+V!*R#Y[H05K?4ZP%L!GNSWTKXXE2\?6>9C_P%H,#_/)5YR$3_CVHLKJ
MM,R13T\O9K527+T"=+G0":US-$Q!O;,(*G,)P10.JNBDM8S,Y]9GR6L!W#UY
M>M3V>%>:ZF%+6@%VL6+>PSR00IAD50#GF"&O*$;PC%947SAJSYPU/.V&6*L@
M_H#4:J*ME1O>?_OYCB1I^?WG#FK5??AX^N)__.?IFY>OWG]X]3__>/WQ?_=;
MG^ZAY^VV)EWGD?=7ARZ3+:23#R"EI8VUD,L;E2NUK(4J3F;/3>L-I/<Z=+)D
M$[PQM-2*0C./>_ B"$@T,.]#%-*VMJCVI@[=.OI\I [=.F)\ZCIT]X;PZO]<
M#&??:L1G/*IY@_-B3:RD@IXS2(:)NO/Z>J:FP%A>G".O,.O6(>$' >U)I;JU
M%+V*,UL+O \__#:F126@+J#6*5NWCN.U#-!NR]?UH+B[_E8SJ>^,$IAY0<ZJ
M-<X\V4]DL 49$DCA4V2FN,1;7V':(156U+1[*B:L(^Q^#ES.QZ,/LW'ZYU4M
M+X9&.UKPZ/\=*!_K$&FPG$F>R4DS7MG&VK\'X@F\F>V5<_]\90O)]E! ZR3G
MN1##V;LPS*]'+\*7X2R<+< %)KR.S (7;!YY-%#OSH,WC)OL+1.Q4XG:-=3^
M(*!#H$ [B?<P\T]2NCB_.*M]*58=*B^ 2L%CDI%#(A<>E""+*$J"[!.7V?I<
M=&P=_>@,[B!HTHLF>@CEO\<9C17S5>AG@<HZU-P@H5)>@THU'.T1P>7 7(G&
MAN9UTY8C.00R-)!Q#_40B(43#%-\B9?_OK[<V#Z/S^CSIY=2>#\^._MU//DS
M3/) T!"38@IBJG"+YX2TYOD%KKBT2JCFQSAK0MR+@YQMXA-]JJ0'Z^.&.70_
M8BN<(T,H9+"1'&\53 2?B>Q!:JEJ$JBTK>-N#^'9/3=Z5>9JPW0[3?119./>
MJ ="IVHV2V"2U0OZA>8(&@=8'"(RY;AHG?9U'\5A,V)+J?=@:=Q)$V=8ZX-[
ML+8VC[""0\Q)0XJ.U\NQ+K/6OLD39]WO4ON;R[H'0V/+'-N!S<)$4:O)U0-
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M:D].S6H+S<P@)/0V:E98:'Z9OCN\ [4>^E)0#R':!Z!> WT;SJ_F3Q>X?14
M60_JDR7H]J/Z[A1KIK<^RC:L"=OQ&$*H57<8H\TW\@21VP!&)Q0^T.936E]E
MV0N:/9Y=NY<L6T==?61]8_H\&I^-/WW[)4R70+[<O7/$A$H9***F%$@1@6R\
M#$&X%*1'*4WK+;$3L">XO]NG>N\F;S?730^6U9MAHAEX5?\_&!>3-0H,2_5(
MOV;K29%!>&<S]\I;T_H<\A: PR;$YK)NW.+BW62<+]+L='*9/'S9MJ-DG7EA
M#G3VU?R;)W8$!MPX:YA(48E.B\0CG2Z6/?O C.(F(F[<5FB!YSIC'*_RO[N
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MT1XDPW:DO"6\V_HR284Z(:_M'\/9YQ<7T]GX'"?7W9Y%"E8J299YR#0KM,U
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M?BBJ;*"&W0;Y3E*Z.+\XNU=NU<7:)Y7%VCLU5^<N@[,D&,8K6'1,6[D[XJQ
M^6-1J86J>D@I>@#Q6YP-1!;)J,"AI%!K4ED+P<@ TI20?.&!Z=87S!]&]&.1
M9ET5K.QKU%.NRHO3MW]_]?[CZU_>O/KPZNWKT_=O3S^^^O"V7FV>T7BVR#OI
M^,E-<T@V&4VC?)"7&&>O1[6L]KP7Y7=>>3*$BW8%5!&A5C=-4*L*@HH\^^R<
MRW>;LS0(L2^%LOUAPLV/O8QW:4X[:Y0<$E:OFU9"("M>5L_+)".S<LV/HY;
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MMQ].WK[\\)\G[U_]<O+AU<L7I[^_>T6O?7Q]^K9%'<F-GM,TR63[D39*+?E
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M(OJ/OC14TJ2EA#LH\_B,,Z0/_'XRSJ_Q)YY/?E2.EY[6DD1EI-!<*BCH:N=
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M']R_RQ_7O^IT]?_ZC_\'4$L#!!0    ( (6 9EOU9*.V?1L  $,<   4
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M\3/0!@$P #"P,/Q'@/\I#(QT&UG9V#DXN>@*K7P (P,3$R,ST[]6TU?CZ>L
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MNL[SOMF)V MZC:]FHF]QQYP^#(JBFO)YA%Q3$'W;P[1G1UO\'U!+ P04
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MZ+U.CVS]4,.M?DQ.JLVA&81M+K4%G+K^&'9M7<W_Q-.7,O/? %!+ P04
M" "%@&9;A*F]0/E&  !Q50  %    '!A8V(M,C R-3 Y,S!?9S,N:G!G[+Q[
M/%3__C^ZY%;$Y%Z4J8AR28549"HAE2:ID,M40I*F0I0Q2X3<HU!\,JY)Q>2>
MZ[A+DEQRC;D@E=N,RUC,S)JS['W.][O/WNUS]CF/W_GG/+ZKQYMZSWJO]7Z]
M7L_G\_5ZK9F)W\^G 1M.FEF8 0)K!(#+R!^ /P-('KV&O^H"N #((< ? DR
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M#PA]Y*64D&-PLB73DO.7BHMD_/"U24X[R[H745(?=T0K:YH^T?UX_N ]C>C
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M;@F1:^D\ C;I87Z_160!#7,-Q31C,Q!$1%P'O]D@=,/PH'NR-FA3!%"R7_G
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M#R.JL'KK7^#*N02>N,U_D8SKMI",9--803[@1((3ZQ%,1&->(+^07C$'%D.
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M$C)%N4$2@)+.07?R<3=N):[<O+28T"CU_<8V0JGI%?<#+ZW;]KYH'GYH;,7
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M-5Y_(#KU5_+%=%]VPF 2^P&:32@M[UCI]I%ZI#ZR^\*15EF!IPQ\!(EYE@]
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MC;= B1V7ONKS]DN8'._5^]58NM3[=&O\+L:=ALQ,34W)M5LC@-Z,FEO(+2O
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MNXM>B&S>ZW$6=%7:D!W=6CX\_C@HZ%1B;5WK1OT68CNFC#1UA7,-=V,0-U7
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MF]Z3TOEX3G@[0,AC-=!04[-76!1X71YG U>DBM1(0:6S1,BC.-3OE86,.4:
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M?R=6QL3W/IVUG79%OK>34>D5G6'HTK&F@K(1;H77\%(Q-\F0.IXK8T+/-7B
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MF[D62QJ9!2-6T;%P$G;9@@+.]R #/X"P?UKNBK:%H3 '$QGNNA/HR358"43
MEP?.FO4_ZB>"?]ZW&*"RI@N.81/1O9GB;"#1EYL-.+Y%C"6 V+ 2<^L?(5*1
M[@IO$]G$]YO-WA 49G]+ACJP)6CJ"2)BJ=.(I=@ 2[:4F#;>N2Y,HJGT,M5F
M^9$3%ME _Q#(N$W_(6R!?8JJJ_OS[$;-,#$*3:DA(?X)LA+HJ US?\?7IFQ
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M/@MGCCZ=\\N];_ACV'<64M.MIRZ)7%W1/^<TVY7VY(FEC_M=\QS0.J'AYK\
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M6)=T4"90Y.ZC*R^_O^!$*L<06Z8"%,JX#]9)U6B#=4<,CL!?,P]W#X_Y-['
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M%H/+<:.1;&"-APWT-"4'Z6&/@75.;&!*@H34T;_X$7/&'%YJ90.3KJ>9M]E
M]^/5:DXV(//M$ANXIH[^O8"ICY;/(CFC>WQ_S\,[F]E 6@L;\%F#)^>12C+T
M!7J*%RL"+JB,>;-,U8?&T)3OWNOO"&LJX*_SGY9@OCK&$=Q=5@E(227M1KMZ
M#Q)K1ZF) 6WVO7>VW_F$8IS_UOG%S-.K>?K&] \S8;/R/4[@L^:[%*='_%/[
MS-B 5"6)O@0G)JSTD%76=>TB6/6($L+Q6'HMBXCV_DFBO,4+(QDO "9;,;5[
M;N$LJ ;S396I44S?[!\.Y5%*EXF#:=/:5]/09<ST&_8^77$KV_>:%SVYU3F8
M /.*,:X&[%JC?X X&5<@WX91 7V0<01R:6N\=SZ?NF2:?AXK/N X*Z8;5T8:
M=)@^ZN RT#B\W=+Y0MZP/_IEP"OZ-6CJ#1+L?/05&=<&(2FP(4.+[M:KKW!_
M7&51[]K4W/+\[1\R%8/MF8'MA['M D^;C]I**B92O1>>,=PA,YB7A^$!?R7M
M4"HE\6DUJ7 &'.FGC,;ZM100;Q7Z.>B95H9C#;[I[ T8C_>/LV^/\U<43< K
MUJ-E]4ET658%FI*/+DT-PXOA^P@[826XD[!/7VXBAJ4#R^ .0??WNJ=5-"QJ
M+G@E.GVJ[+7O_%#RV:Y@.LYAT$Z*Z]%$.B1.(0SGH2 =L7$5^@RY,Z(DTF"G
M6^H]-C#(Y/!%#3'5_:*8&0;[1E&R-##ZYY+1(F^_WH3W )G^E?7&X!CS .U\
M I+V4KZB78FQF8(T..D=SHB5O3FQ(\IGUF;F_^7%@0CSI,7+CSY=J#WI*[E;
MVU1"_.8&M@G<BO90"<52KZ A#S0'W-%OH -YT-3&)),H'?Z-][!1MY2EJ<E]
MY;E*W5>NV'__7'SE].2':Y/AUWU>N(H#TVS@*FJ("/,F,+SA'JRPGSU)B"E/
MG:DCAK*!4FQT-7^@IV2POV;5N)[]]G+#W3>.10^WQ9OLZ0CIKM(>B'ZEARKF
M06I6^D,(J9.X]M"0+TG-Y8[[,9'W7!M&]\];?QV8+3;.E<B0G+D4_U5=UOIZ
MV*V7(UI34;=$/I,1W^"*8SW%Z^#;==&+(AZTMCK4@$_ $OT]C1A;+4\:NMN/
M]NI2F:KP,"/]#D2UKG!Y,SYJ?OZP_MA'<8(0_K>EHR+Y].L(7EUP9Y%77=QQ
MY-7_Y/CO5!-:9M08?\PB[;1I2=?2[PQ'C]EN_XK$DW=2;:L3-<(>VP2<^A7U
ML98G'^J$>0TW[T31RM86Y*@]]+L18SE$A$_<5 FU@:5IX;GCBY*_S/8?6=[)
M;]Y[>7S;BXPK61+I<>]%USN?O#[#D?86TJ,3D,OV..!_.!Y&/ERZ21"$MSL$
MI)#K1#/UWD.3([R?3!;5Q5T]C,MU#_]83*,5EC^4';MA\NIQ>KO+B2K2=M(U
ME2%B WH?2$F'CWZ#10/W^M=B'FQT1N"5OB.$WK:"+IJ##E<?WO-BJ"2E\H>O
MM]+]Q<8WFEY*PN$&56.$P8B)%$0"[C8:9C$JD!)$V*6!&B1@J#FID:32Q81G
M^>1"TSOT45?!]8G=[\&CS5(ZM=<#7O#+0&CDI#^@3BH?/9"5OX34Q8M2#??6
M8D$GEJ.$QZ)];7GQ@!U4R#=L,M-S3+CC8%F:G;0)@?NQ5@C'D.^,/YIZ:738
MBN[5@[")[M%2PN))AD; 3+VD-LWZ<4[ RIA*PS--#X/M%;W9MJ\^E%<Q<.0+
M'JZ)QW2K#^]"7>.<<:P@CU)-.^,(I2.;A(<7LJ<IFB74CZ!8+U=1.SJH;8TK
MH\/?#?TT,UX;EKL?##%.D^^F;TO^=L;8^?N%HW7O" ]&2_J;&?.CG+C#M$ZF
M!('*UV @V^.GN*TZD&9O@>4S11)%<<.AH-=L !/]1:PF,?#Q_I=A$YC#QMAC
MGZT>[>I&#R$QZR4#H7]U)T%WS, PW8$V4P]R0/:4+Z_&FHIIN='Z<G[Y-[GF
M=$\YQ%PJ,WOZ*NE.C;O[CXB48)$;/DVITYCA%7H)JQ3MY0UI34QHQ>E[%@;P
M-=P;;<"(S&?R0#]RW4=0'S^&-@K-5N9D'VM[;=+/>RM8*;[9\*E6.W R-FB4
M(8AO1^^KV8V(<!9]"YLPNILIP"*,H:+3ED)^Z7/G@^[#9JRW^\,C/;V&6Z.-
M4G8F[7_Z;'?%I>\ZQ/1%A"X_)90M16T^=(U":%+R6QRZO!OG0<-.>,<RS2E\
M?)]\.B;ZE+R\%[T6GK<)%SX2;]SQTMG)24F_-E3V@<$J*T8=$P^C6&G5RKGX
MKAHT=2D*=U9](&,5PP?A'51[AU450M"'[&8\YYY:>T+7MW/X1C._]I%N=D)R
MA 4D5W$OL(C>).\._P9-S4IR6 V*&"[1F"F8?FD7S6VR<RJR8'KY,[^HZ?#S
M^ \3OROHBC12L[<DW#&RMP\VP'_92*U?$K(?E$E>>UCFX--ID:(B8WU,/JUC
M1)586AP;SBGQ0&,<+.Y?**$-C_4S11CT/-:;:@\*I@CB'\>$,_D]*)_^F+M;
M#+JUY<YV-P34G#K;<WKJ<YWOX0.WILQVN7%.J4!R_61,"&$K$LT'"51K]"!I
M[.XKQ%\TF.*Y-PTD0H9/!AWJ:=[[[9DG>ICXNTI!0#_;'^6J*GQ2FIBTHOC0
MBX2H&,DJ-^!B;J56,(7U)OP740P-CQ'>OB7U&.)>N!/>_;PB$J>1=5.H2;#%
M.X@^XS',\,N4RY2ML(5-RQ?Y/MP#-Y^%E^DDHW@A;SJ"\Q#'A%UEA(4^FH=1
M33]^)]0Z:E'F1[V;^Y:3WB$\^"R,G"329?_F+GGJEJ!"4GL29PC$SU# ?S40
MIXJ%DEPZ46!=%;ID<29._?2U;"AU0K* #6QK@+ 72AZ0]VT4D_?M?%/=<R:V
MGA-P?KQ,=COP(,B.ZD]?I)$C2)[>0Z?IUUAYWG?,M<Y"KF.+6N1,X-N[ DG.
M( HCW1W?HUZ5\3#.W<];"7. 5\*'AM738HJBZ,0N]%7B@U%!G$T64_=KC0J^
M-_/H)VQ$S/A:$@8AEV'Z.I5FD67[3\8.%^ZXBW)YDE?M8E-YXEB%AQ^!:D^$
M9&<6-1@.$'F,'$^Z87KH?9]&F\0H4J#N(0K2^5PQP-SR:9DI\E*&?M<M^N0[
MBU^/XWH\C>K(YHCE-Y_3\X(2)KS#:[AQ5JRT&JX .7)EZL)B8>N&:]VHA'+E
MK('<5R^E[B_SYVPJC4/$OVF_<)-^NJ<KBVM9],%1-N#,#\F3R)V[\,.SC.UP
MUVBI<3U_K/MX9T1E1!23DX8:,RP>?%KXS@[?GS,GZN[O$XFK$&PZ_%GU36T(
MIF4,S8<06D0',!9%-?V IA1>]H\QX'(;4@EGJKWQZ"?P.U'#6(VP;-'[CYEZ
M'YVJQ&XJ[7DG&'BAN3BH25E>I<P@A15=(Q!08@/U!TW<]X8.@?5+@Z03/3B%
M0&^/<06KAL7Q^ZSS5R,/E>W5U3WI)K7RS3CE:K=8PLVPG9D2=&]6",F#GP.L
M*ZU,8 HQF@B\^!;:73 4/MQUB)I*7WR83EPZHL%3'K%HJE,F\2T@?DGKYJ_U
MR+I:GCQ;L.X,+ WUT]=8:7C> #VC'F7<=EH)Y>[;B;CS$FTNB?"(&Z4L;4C]
MJ?:%EZX'@T]_B-_V5L,;DN^,AB600'0*[:82BA*Q.1<Q%E&7\. >V,CSL>2]
M]R)@\C%QR?>99F7DB_6+AY^ORFE,@,(D9Y7A4/H]&F'!@W$#)\)Z-CQN74+U
MH#36;(4RJ-WDIKNB>V,/S9B5)'26??CPR/[<M0\AAGZ"^QN\VL.//&+N9<6B
M/3%#*_0F5FZ-,CR$+9$&MS%%:,/TP#*J:)2WQ\1Q].7JXE,5ULL%Y,'LVH^7
MGG8L*SSD.2-8I;@76-F<*E%DW FPHMN]1]"2X<$&)$DN;81MWXW="T;Q[96>
M%%!P&/(9=^(KL=3Z&&1QX+%SP.7!&URZBSLT;>:]P_6-LP,:&NZ!,7?XB 8-
M%XNBEUMOW6@/O[@K+K3G<&W_9&>MRD _/0F2H5HU;*XR(%%&51X8:--FPI65
M2_?@=6[&C3T>R[C>O;-(MB0@;GO?C@[!\!2![2FFG$<529RK)28]MTH]9?N-
M>^[,W]>[;W8G?*3[RX%'M=$O+PF<X+CXM_^*(\QQ_9^N =XL;Q!^T*J%EV(#
MWU%(,A.]:.&PCF7&_@3CT1N6!A4/P,G*5M*"; 2<$04A!,IF(7?#"Y\!UGT8
M7;%#_T+\Z'L&/L/"$&_12%K60X*0%QN8E6<#Q_5]V$!2SE/PNPKKF(E\5C0U
MH>6?/3G[WVO\[,'_!U!+ P04    " "%@&9;$G4K+,,]  !B2P  %    '!A
M8V(M,C R-3 Y,S!?9S4N:G!G[;MW5!-OUS8Z2 <QTD&4*%4IHA1!0&*CJP@(
M" CY"0("0D2E2<A8* )"E"J@Y$<3$1&E2HUT%1$I2I5 0!!I"6 82#+YQN?]
MSCGO>A^?L[[WK.];Z_SQC.M.8#)SWWOO>^]K7]<$.4.<"6"[E9FE&<"UA0OX
M"_D'<): ;<<NX3R\ "\ .;@XH\ )8 O7[^/WZY;?!P_W[U=>'AYN'CY>/KY_
M#'Y! 63P\_$)" L("OT^D)^V"@MM_?W+[TG^X]8MO-S<O$+\?/Q"_^V#\Q80
M%> RXSK/S:4 ;!'EXA;EXK0!:,1&WG^8QP7\SX-K"S</+Q\_8H8P<D'5=L1\
M;F[$:%[$8N332.1S@$>45VS/P6-\XK87^16")+1O/\P54#S^NEG2KI>FI.-Q
M[8Z@D)2TC.P.9175O?O4=/4.Z1L<-CQQTM3,W,+2ROZ<@Z/3>6<7STM>WCZ7
M??VNWP@."0T+OWDW*CHF]EY<?')*:EIZQJ/,K+S\@L*G1<^*GY=75%95U[RI
MK6MI;6OOZ'SW_D-?_\"7KX-#PR.3U*GI[S.S/^9^TE=6UWXQUJ&-S=]^<0'<
M7/_7\4>_1!&_MOS> _[??G%M"?U]@2@/[YZ#?&+';/DO!HDK:-\6D#C^,/=U
MLZ"BCAU-TN-:KY"4DNZD,OVW:__P['_-L3O_GSS[OQW[?_P: ;9R<R&;QRT*
M8  V*R]^+_#O\7]T<-/)C+<<X$X)89PB#/J!][#;C 7I4PN&^V.I3*;F_BY8
M-'(_5D%@UNLD1;G$Z"] NRUE+&N5".$S6!()<)(^!] 407. A^JWD%EN@>^7
M6><YP&L.<(X#]&64[2D;?)7I[:JA>>A'<XTDPPEW@KU[<HEO(FN#3ZSP5 5J
MGU7:H='\T]5CX@$UNUQ_]A2!DRM8FIW6I@&%5:D+PB?S8;0R!^!5X #YB1R@
MZX0Y!YBVVHBO,=G!.D0G=Z!VSE%$"'(_Q/RR9DH/)ISIISX4?7JU\![O.]N6
ME/>[U'V]:L\I?%<[8 F&8*9OIKU!WSJP5NCXTCGZOD=V0&]!LK7C:%"YI=^H
MR6T.$/L>;+8@_Y@"5S[W<H -L3_X..-?[YH@5WSEY=0^#6UMJRCV5WX>0O N
MS$)#!8P_P0&XB!M2;X1O[ZC[\(H"*61P (5((PZ 2D9"\Q#L[>  WW/S.<"*
M,IJVH07MDV;OQ,$N.S#(94X?S]G#75V8V38,388#/.   _*\'"#748X#\-@A
M/MO\KT8F'E.^TK-!1['X,-/HGZ@M'.!SB0BR_CYP1;6?_%_7M?V3=?AV4_1P
MN \+BH6YT2NH7_RWP1\.,1R@68*\(3Y'^:>P[/WGV#5YY!'_4U#X-^^^):^I
MM8(3\5A6W-HRR\0:%C+E .:(>^DQ1 [P+A5LG29/%&#7@L@;ER]S %8<]J"M
M.</=F0.8[.$ MSI9=]G')K";DA?)-%,M^.1FZ)_<9VLCOIPD]))E03_4L,<J
M%=-I@X0ST-\VK&GI@Q%E83[BRM$'H^5/N\*FSFQ-NGY_=? V-D:2J8-$68@#
MI.P>P"R 9"1S_:TVEE3>3KS:\#FB9IM0]\54%5*DDW:]<8K13N()N\_'E[@C
MYZMPED2NH//X3WI\2"2Q^D=>/.L'K"FT-^_6?V=@<DC07GY6#@=H)S+1OVS8
M^VZN[/BU_,_GV&6\\*P-2WW%?#.E%;-RYB_R_!<,6V$/MI!2GDZD,1EJB.^^
ME\&:T%;B\*H-='=JT<8Q8W&S<%K%/N_H_OV[]T<[9 GT>@BUAR3W?\\.!%B]
M98U-6WPI-90%8:8.9,U(9Y.,+WI-E7%#XQ8O]5"\+G/ZTKW.UDH^UZV><Q]O
M?ICK$W=K_W,YS-XRC!&Q,E<(_][=VFS$OG=<WQ6[9J+3KH$9+'^Q7]3Q_H5Y
M\_7KCXL[MZ=>^B9MI_YMQJ7DQYB=CSX32P&;#Y,ODZ18*E 1K:LMR^G6$OYT
M. [=WHBR>)7IV:<0M#/YX_-7]S[>P__H,BNPL#KH7L DM1)'< PANNHB=K)L
MB,@@L!-8@M0R+K\2R:@<S0PSY\#9M-*/9?K+DZMNGAV[I@,X@.*KW;P])+#Y
M NB#X_;+X89,F<<@U,1K6BC11.G%5?\<@?[2D/=Z Z],=V/W.-@\3K;\_EI(
M]F/"F\"7RY.HA?472+;OQ?BTTD,P=S=KDF!CJ*5Y<>T)QK+7IZF*-J#!=5&Q
MY067K-OT]DL7O^<.R9^@GDN7>NEVIB\[9>:^PO?*LGJ_0=L?HU4-/1\/!I=O
M!?G^VE"GJKKX5>T\(OBU1M,]Y(GEN5@MW;TNO<7[#)[[JE_7F>FY3ZF87<#2
M<+#0B2F;NZ!T@_^+'^#62G/F*?[C(D'7RM_[B[2<+PF_]E@CN=+UT26>[[??
ME[DB>WZ?)<HF-B!%PC,-A=-C&8Z0699R41S+YTKOSZS'9J?/4+E](M/2G<)E
MU'4O5O.-/BCB!E"Q)IJC+$?T=CU-SRGWM!<C4(IC;>0).T-V:OJZSGMU*5_G
M2PX&WCT&G456S&S&$ =(568A6/(ZOI\#6.JIK07I_NPMC0HL"?RIA0T>V;_T
MS36RI[+G0'B,6^;5[Y93S\^E%)])[2,M/3?HRTX=<VK?9^F^@GNOB=N8QWJS
MMK-?82Z"PZ&,@,\WE@'"1Y?0-IOXFU'/\+:14P&[Y 7T S72%UI.5!$LOIQ5
M67*+,T:GKVG=P4BS3M/ZST'O)Y=C1KJ7HV]8W^8K+1L]7S\R\BZ$]7+B+]%&
MG;G&ZXFM&&NXARR"P9&&%-^.8!8S:4;-(^;W=,F[?MB.F&U&%M25N(Y^]'PL
MF'=O7W1-V_;'#V0D/UF\9'7]_%*\U\J%8K%Z[>EBA3_6".W4T:/\\=7V5L<7
MA<IVO86+[/M^YVS)%<4&1<KY,]_G+RV^'D#RQ WF8:%HE%9T%*4RMK4LVI&$
M"EY&S[D3&B?J#=(E[F6'>8_M<;"5,^M[-!;M-IJ:ME7D*IEFAN:"T%3]Q5K/
MR;)[[B)]58MZ#8>?68P0*HI,@[F"34<Z#CMD*+[NE%S T)RQ NU3N.'9"0ZP
MZ$K7:KT.X:A.<1K4\D'6$>6V9BE,A6SV%;'7!\*O>:H=:%V4P;_J#B]B;:^'
M;2@VR)YAD0;R6:KAN8,WY)T_$VKEW]?]@W2N^A2TM7Y77/&$NW9^R;YST<8G
M Z='$^[/I'H:U>QMM>@(_:*T-GP%\>\*V0<5RP&VPOL@^RF?9E!X+@L;C?<L
M.%(Q\J-:$(?;EGN9J21_X2\-KX?YO%<%+Q>H/A[\P@'*P05_&GJRAR7^Z8@Z
M5;_%1OAGTV$R%!%)=3N^[/A9<TE+T_2C7>.;5:7C](6C]P!CXT#SPR]#)W&M
M/0+P^ A_.W%HL/-FJG\PK8*1T/"E\FN&45+*_K*K_2<;5][A4C[K/O2Y[9;1
M3$DZ@ >A;J;;_(A#W_M\"-OR55[V<[K.BL:AZLU7J2\-U ;Y''E 0<DI:I!!
MYE^*,3.A!?VXND U],V,"0(NQR?S6Z!8?K)AA?U;*YT2H\I9P8'"G=JX,EWU
MZB_K3PD';4TE-P79\7_L$2SOLF$2M-N)E<F7RP$\V1P 3G%QZ@[R8<5CH8R?
M!-DU)&XI(1Q@?A'#?L,,C-];]A$U,9$7#Z7 PO,<0.58$0= :NLB!R@8#/YR
MIS7RNK20=(U.U?H16.H=!_CJKM#RG= _S/1]MNJ:G<X." :M\Q?KU#<2\II:
MV58< +E]0XL#7 $M.4!;&3A 05HR!V"^9AO:8C^Z28#%V#4.P &01KEX%U:.
M@)\BU^,XP#?B7%\\[/$C_S_/@::K4WXA/;T+A!? ,ZE.J]*FZ)].;(0EO >9
M?W& .'<.4$R&$<19]]R\D4=^5(?T?3OR'.*T-0<8Y6=9K;-/(_0!L:$>W5\H
MR6KO-=],XP!(!JY@X2$,U8G\$UD[G0.PA^ G>\MF]L=C!LHV00Z $!!&,P<0
M:^0 ]B"KA@,L=:[-F8(';]C"A2""-RR$2%6CH+3ES6R$HR"A#\$46:EO("O?
M0>Y&&*?J/Q@G8D5?:MD/EZ:(PQ_ <G6SG:RQ#TS77SY3)BI0, ?8/GLP-WIS
ML(;QZAI95?G%HO_U3W#-,5,)I_L$;PE;4P \@J&=16T<X0 ): ;F)VG3[M>T
MWCSEG\\QW879GTB0TS3QEVH,./VX&1Q\#FZ>/-Z4Q+Y#GL@'I<F>6K+G??NA
M#,<!&"T<-_.%A18_V:5CO%\RU_?<(U26[>A%M]$SU[,V.N)?F.V(V9]0Z*B?
M #=Q !W\K/('Z.[^XML?]ZFE/LWR+5FK&O15GU/VSBE^>A-LTQK59V1")?38
MD] JG9O:.%-(!47&3P3_[=X3P)]6U"61H"93VB)PCM_!X]#%5_K<[D_^!;WS
M,>;C*[!+VUM9Z13?WW]ZFX:- "U'.\TP>&53/%&OBU?MW$C\>.\9K32LJ[IB
M!41G'L=CV4\;0@@J>!P]E#%>?66J2I\\S&!0:HE&TEX-EQ\'&B^^[U$I@T89
M)= Z77HB_3;S,-352;I"PT4OV44*F\%=5<2%/C6+^'&_D^5-4KY\NX;PXZWR
M$:977JU)>*1*YE<GV)RA*'Y.LDUM2=L1U-ILEM"H]U[.WM?90-U%4V6P/F 7
M\1@M8]&>OOZ6S%W5,TQN(8GNUV#)4HU(E?X[M$>/M_CLX?8P.Z' )_JWEQE7
M]<JV,S?!X5E82)+I#G<1Y'!\>#F(?-TSKS)1P5>Z^JR[:]O"-1>])^@/[Y4>
M1!]32A8LD\[+"SNE:?'F4Y9O?7UAR1*+]?'@A2,//"\/Y-]KL7^L9IWC=S;!
M[DEIM]+7\G+KS/G HB#Z%.,A-,D\#;TV#J#W4Y77[^D)>!QTU7MG0:T^?LUQ
M;[Y#TFX;);7[.6?\4+=!=),FW.UN0J2"S392H,?\:Y<NW*[U(<VE((E;_&XI
M'7/ON)_4[BI)RBL;LF6X=Z5=6_17=ZVJ-G1T2-<@_Q2*.A)=&TG2"#\,9B2/
M5:]4$6V@ *8WW,<!! C[PU*F:EI)<2MS.6KTZV[Z]X(-UD:=>4<OG%%-?500
MEW?<2^[V2;>&Z+=*#N =2A5Y49AI_"-'E;;<@KH74# 2]H$WMNUU4Z;_#9RM
MHP-0U7;F79!Q0ZY=Z/3CVT2#O,+)JWVG#30#(J6J1^ G1C)?WETS_/Q8[:+O
M^]/'+ U,B]5N]MOU._"_$(=NGM^;%S_VZSC9&YRXC5VYM".635SG )NG?;'W
MO_R1:+_40#0$4KQB;)M6$T3YK 12V)$(*M6@ WI-)3=NLW9*TE59TH/PJ;N_
MNQG<BC"0E_.+=7\$T9^72"N'\F&ER/5H\DJ0=L\F4YR>A>#N$&KMT8T#W4':
MKJ-M?9:*O"=-WWN$ 5P#@S6LL^S;)D?P>]G9#?I,T[",9I,],;N\?]+U E2F
M6O5%+?-.".^.CXB]N*+4'&?W(3^I2"\"%@R=0D>;<+/K\+Q4\'Z-8\B(KG3%
M<_>?RB>E:@)P:J-6W]^<K9"AS48%O+ 8?;C>TTE*0OPI6PAB'H56J<OMB&#*
M($LT\?M7ISS-*)K3.1J@VQ5ZZ:#LK;CQW:]Q2<?GO[^[](D:1!0^^#'H//[2
M7EOKP "WVJH:#=<^=N@"P;8#[TORVGDZ]L/*SQNCTXSJ8CT4;MEJ6_0^RVO%
MI:HO4B"'%]\XP)[-M5(;\3!T1XZPJQ2=&!5\1,DOQ&/Y#-SW.AE5==0YU5J>
MII_K=?'-)2^+'LEETNO.Q<*)Y6&PPW I?Q(]G-]J.%-6!MWAHWTMI>+68FGL
MFD=3'^[S;/MXXJF;&^9+TK8P!A$R<(+/U"/HS;!!&&C?_(>?Z8:5UV4N%I[I
M30XP*KV283H?8!-2)N5](ZQ?)/E+\XI=Z8[D1'/=L<;''B-G$S>N3*=]U[RR
M4.H-'X%<F7KP9U#N1:">312:%V]#=;5V&KX>FG^YPF8K[E:(M(.:',^NVD]&
M3CI4DB!4]':$W1-M[#]9ST:?*T_QFLE^[MS80#ND4S5U5?8,ZKCZ+]S;?K@/
M*\T!)K) _BODB4QWE>J^X%W;SE]I",!)T%P^[,]/8._)+)*SRH[Q/;\UPUGB
MUE@\#0UI.=UOX"TC?#81I55G*Y=V)JRAA06,?<)]!,]I&VD\:$\^K+:5F'15
MQ79P=]"D3OS08_!5D&-#6@J^]_N\<J]);/?5Y3C9I&!DEX?U#M!LKY7)G_]P
MIDK+H\^N5*I49H!<ZU/O4C') ;:%76^3/S"XT* ^>5IJWF[@EUQJS:O^A;]\
MO=]DOG-(%#VFT?8 V)GLC]3WY%UR '%3M^<>&3(?!^EU/\&)-!A=0]=B2: F
MDT@W?A1OJU$>GY/AJA/V+7*WB>R]=>1=V6>M$?.W%)H#60)_FCX8!WKC1B@M
M=G-U(;D:63ZW=+\='SEM]7783.R0LZ9506GED[+=L@;?<M0JMO:]E)9Y9MH>
M4=.0;>WD?YE$O1%$0D^] >/V?3^G'/NTT/+<];)]'8;=S:8&9HXCZVG)RZ\W
MN",]PY^Z=S_]>:C\6!!.W=18+-<I<6 R[?;T]F,\3A?U%RC,HZ.L0VB964B5
MFDK+K':]377\7"1E8G_@F.J3&N^^MJVSLGI=83&SSHV#RV7&9LIP;_J*$WEU
M:@@.NH:]-A%@5/'P]EUL%<(L;]/T$\"))VA!L@_EGAHOL6V9?SR,(!OVX6-
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M=U LLMOY3JOQR1P<E7O<5A#2(HF.CD1"SX_TZO>#81CX_31FTRT<R]WK5G4
M#]4Y;#3Q*@>NUV ?K@TU[3C_4O&M]_/2IA*A5]_]EMQ[C[E]^/GU^\(R(79>
M*P&685U@(SEQ$7LG"\<2SY_2),8N-F@6G>"/7PO M&G[]K6'3A^OS<R5N]NI
M?69:?[_W*M^2X"H:TN#+1O3N?<H.$WY"]X@JL7*7#?7"H;@\J+7MM&&!;9?1
M2#MJQ.W8/F9OT/X6?87W3\@&/;/!.;E@D47?W'K_T85"Y]Q4A)C<,?>++7-9
M?;6A08/N#3CH$G6(]:7?69_@7XVB]$Q,C,S]_,.%]Y/T#,ZFA=NYO]^WZM3(
M+CWC_\6VL:\2YQ6:9Y**&\J>K&G&C.8-,FS8+P@ZHW,CQKV[L]L).]^8)HTX
MYZ[N7KW_X^3NZH& 5N&&0R&L+PR;!4^D]I?IH0LHIGU8 N,)%$<GM=+PFOVZ
MKI-%\_WSZ,8!S:=JO>%3?L_4_M;9;N$K&<+WR?R[7/V[&<N=%0??>URS++Y$
M)F?U:B@W9OZ=F& N;&&UYXC%+JY2>CA!2])ZN&[38*7KF\NZOYO<1OX 55Z$
M:LP!MKQ*Z3Y\T2ZYT#E"I@HS4WSZNI;/8;^:QW95:5\H-G1FQXAJ&SD)UH.(
MDR6.=\_0^1."-:UM;@_Z)@DN%:1))+6IWXYG"T+S=%57Z"#B0#H[T^0 =.GA
M,\BG<^0(^]FW6[!;=<&,#MS%.V)^]33A4J^K1SGDX: <L==H9+"NPI%E8V\R
M,78H?&=3=G&7C;#>?L?:VJF%[S8/ZTO<K)W*GA;]I+ D8ZE%+=A8='D@05@R
M?I[Q@,Z;7E_<(P?T#YGZ^GV:VOG,([W6?<:72!=U]T)2$/6\K!,5^SP?"#LS
M 6#FIP=G$R4[[[Y7O%MLY1=Z=6:.K&T9W/=>^2MLWDT;C*X,P\G>:CLA\=-8
MYR5%-[AX,5_ W-VG:V&N/RHD0Z_I4S."976$ES?76>((JMB DQ@V<1,+IQ:"
MQ[^P$+'<C.C=Z758_!^4LI #S%DYK6EB<^@9S&]:-+B(3NKSAZV,4>R;X*:K
MT-Z\)EW8YW_+4US$+,O%: G;H[Q_&G\ /K)L"<,'%I#\38"?@8BQ"-(7?$U;
MO>#, 10R8.5-4DPDPLBFOY$WF0B(!YJ,(C"VR@T9J%-M(*TR!%I)OZ$U%DYQ
M&QP-_@/!'GB/F0XP9UDPEX7!::H7Z1=#=4I/PA;["CUWP-94 O@7@PN1S,@L
MOS5SU&]<G0,W[=+8PDZ_&P</YS]:A,WO%H&(^L)]V,]5A(@.[/(-<NLFJ0.T
M+-O82\/\0CK&W!6D04#]&X^1-P"^"4[\C5Y!^JD4(AN^8-8*Y]_Y#Y+_^1RC
M09KY!$,K>X_^:;,5@:[#=Y 6=@Z)USTDM&ZJU;]U_I_&_\ZG.V5QF(DF,B)\
M0#:1@=X\'8H-&&PCT;#8#6T1#-S)1+%5ZLOLD>;SL I-5UQNT$0FB4L'!X=(
M]P>0CO46+$!R]"S7OQC\9>"?4[3'Y@\9O;$L"S8B]!'U$Y1EJY"G\]]R@$&D
M_18BC5=]RF;FZN]O /_Q(.4/W]RY__GT" V[= -A#F0EL-@8"9O2C##<:(]\
MJ(!$\D;.T+_*#:>%'M9V=23'SO[.L=^98%FJ3L_Z@T[4:R>M[ .IV&+(IP\-
MGQY%]K 22:6IQ;J]>>0#F+MW_M2Z(VNP8F!S)#C]3I<#,-$+F+6LI<93*;#9
M -A&;*+5P&=4D,K >A!T;$TEF5QPRA\+[7\.^<9_D:R_'Q+]*;MG&[S@=6L6
MIICELY;% 9*)W!S G02GMR!)D8C)1-[^1LT6P4)<'$"53/>$.]E(Q*S<&V(:
M(_YPDNS?#-8B]2+$>@@7T'I8*8^T-G\ARUK<0VSOB[CXK_(#6X&A'2U#\NP$
MDF<<@*U26=;AQ\Y$@L4+OG_@AV9@*$BZZ!7B!Z7 =TCFQ!&*)DD6X(8^#FY"
MEAO]CR^QWL+;A/ZHK1G?_DBE?FG;;,C9(OK=A-E"V3#(]&%'QD'="* M\&^>
M^E<5]WO\&X3_#<+_!N&9ZVU5-D.*$U_+BL=^#IJHT>O>!QMU*[13F6EG/[;?
M ^3Y;+BKCG& ;>N_1=L)7!('H)77<H =ZU9[N5LXP.3X/_;T1P"= DLY8:;,
M64:4"1);I,D( >D/LRS_;PCV"'. V(C?MN76=(*0\P4.D(BF+8-WP+5#$)+*
MPNHD>MF-O%O&6O"N99H-'$/9A4SL=1W6!5L;84$.\'ETBLS2> EV-/;% S0R
M%$INQFS*X4,1:9?6 _7^V[I_6_?_;^M,(PK_$Q7YB*Y194E>GU!=,*>+MU*
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MG!@4T9RS<\#X(G7Q6O^IOAO9LCB]TU9P<+RP==B#AA2+A>-Y:NHZ!W<#@H@
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MF<CC+V&WL-SIRPMS$V$LUTD.((;?DY9RBMZ4<:2@K_V1H^M=7V/M%L\W#J'
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M!##*E"H#>DQ$0;Q8DKL$<,LZ4=T)5N#*E&>+FY5PN/NA%AU*K8$*XTKJ?N^
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M;N[Y\3OYLC,/M&O.?\OA\N5?/GV8:7_--DO="?S[R5U0PPE41&/G4!U5X&:
M$]D2.GR1F^#<M0@)\#/M;'PKZF\)\@"<Q$F D\FP'?@;%=)H*&:>8>!4ZI->
ML1PT.;98 GQ:WZR1C%:8EW@7](.(E&%Y=Z'.&,12 HP=P?+U05O:_#(),-RC
M* $R[>,-L8AJ^_Q%"?".+KX LHTD0#Y&E" !>AZ!G(.4-.+T&G2/7J$V&?\7
MYNZ%FNZ(U]-_[9< &2XXQ&?GAE?0/QKXCY:'2X"XC?/VT)<8";#E-5'4X>?@
M@@K.?[/1X1],ET*YK.-TI@1XC$'<3M/GGO31>JGPFAC1_70)($YV9LX3?(F)
MS+^?[,PEB)8%H:++6K"Q:XM% 97O3E0*:!=5,YP_7?(2Q1/AC-$P2"9,I\:;
M5VV!#'#(M%'X^(K]U 'VB]".BDW#>2<O][2[NVYY)3P<OX'V$=,746N,4@E4
MC+^_[P+US7B@FSY[7.!&MD6)Q4*^KNZ4 %SHM03H\*V:V4Z8TT'M5S7.JR?R
M55YL62% &L>H58('-:('3-^TS)4]XY^PCI,GXX=^T?HP=LC&QQ+@.!%!_9]E
M]SF<"E.7%3GN1U[012B@3C2^SGDSOP$#/XT1'X?FT(69,6<L+TVC>VB/F7\A
M 2;1A* O;4#G0K<J$SMS'-U4=-\IJZ(T6K_NA9J-P5&4_;1A$9&Y@F%R#AKW
M>&^HVUD"W 7%<)"Z,]82#:_Z%PGP@B8!C" A;QXK4$<]^@2C&.W1DR4!\N2)
M;\M$TRAC!R7 CUE$30*@B)J'TI.#SM.;B=G\#.%W' _)US7\)4:]GM-'=\4G
M+'@,?/M3@&^].SBQ^6V!ZWCH]Z#7#I8:_/P-#I;J4G^;;B^(SF8$H9.]@'[;
M]=[NI4'_^;UQ$F[6#.U)J6!7]@H)D'H%S6WWY^CB*@H;<JH(?AMRXH%_-@P%
M7HB<A@18O^_9PFPHYWG2DPY_(I: O+VTN>W*^Y%6%'/$ZTMIF9SV.74Z']<E
MVO$;5>SKQR5 +P,27A)\5W<@WL/6UQ-5H7JTD[Y#4T"(Y8+3F7]J!VAQ(*N6
M/NFI#8F3!=AY^V#WIV@NZ%T .=9,DBL*'6IH#=&*P!7/<N+%:-!M(^(W/%KT
M+P8&U3$1J(7O)T0&$@#==11Q.N[0?IVD9U-A]!T1JNX:("%VFB[>>!")>CDU
MN%T"A.8AV"YD!UI#[ZUOH&NADLKN#(I@+=2/[ 4(FT)3<C& [B031F?T0-"8
MY>'<][N__:=O$\M8]&^_T:Y,L4&[.,D+L?VH);Z>CT;M !K-WWM>_ZMO\&C]
M5'BUL^C^$C2)/=#]1])..@^94%!8KE]$__'.!"/$3J PGME1ZYL _CB*LDFZ
M(Z_]"2C*0GL"$26?XZT#5QTL*:<AV<7_M)R$ ;4+E[_FT?#<1C\N /N@WR;?
MK]\W$"6BB!*'#6,'BAX<*D%JFT3G4:XAD!:O1S,C_%^-/:&(O 3UWX#.HR*M
M8A2+#AZE/[Z 7(=85+2:0E'<65B[ [4YSW!>D]9.:A/_R8 A1[C]-ZIO]75E
MD;>@>',4FAO:T [TK[W8=H)(71HA0)Q6<?)\/G+G;8CR]=G_]!:E%T7P*_F(
MQIR>V)9-G3/82IP9I2(IRU"CGP@:_E5ZT,]#K!M$--%BQ,FS$F#>WH=XJUNX
M Q4G"@N!Z@*Y$'TA3@?G"M&,2T$S1U5,:,3?1GT)8(K#T!VLP/I_M=28NR%:
MJ<$W$&GU(H<BT5PI0E!8MBT<&Z^"TQ#%L85"R?];89]!][SWVJ@G=7)G+K(N
M;#:*/GEI>_N\4(V?B6)A'V;ZWK\JN84Q,_'/$G;N][]*\#U#N-DJ(EM,& *?
M](KND+#S*#),EZL[6))]1)\7+JM#>T#>$<S<'@F0@!6 H]3YHS,_3,:8__D]
MH;NB^/-"VTV>,8B&?CRHAWI?0/,'_HK?4)@V\"]30HP*VHC%T/O;%]"9F"BN
MF.11=CASVT7+#-% '5D(U$*ZV!88_GQ3@ECB1'8SH-(\VN+>5T,S BKR+:P"
M+;J?LKR+SDU4'I&(0@N(0@M&O+Z:5C[&(< X&EH<U(7BB$'2W'J?IT+O&,EP
MRNP@RF3>-[6!8UQ"RX4-.?338,?I_^*K<NE>^C]/T)'\?YK0HME;],'?4,P,
M> M)(TXZL* QM*@Z^OZ&P5.[_AN$_]\&X9&X"]37UO4%1,?*[D+R\:%KJ:/!
MF98)S;.;'M]/6 98*&7+7HA$5DWP"$@T$V6Y['-7$),_=X[(1DF QK<+>_IE
M8(@N,BJ$6I+A8'H].*]##D8!.KT=[JURV*N+,JZELPN&[0],0IE3<:4$T ;9
M@R@P2(!?_GPFHND,#KG_M@1(1)$YDT45*]>BS+SAPXC(6P+$A"Y\I_>XHA6"
M3YR2 (FA>>I2;(@W 45 TSMA%+ 5#:G\W/^V[K^M^_^N=?&S!_\]2KZ:T!H+
M1K1YV<\Y>PP;3:NZ>ZCYA"O^N3Y/MUV"UETJ,5)9<6*9S0\9-^[+NRM.;_>U
MB@?X.-B .3[&<T440*%I/Z4#DC&:"<.WN#E-V777@!QS;U97J:_0YZ"=[S7U
M@+&5X7ZW@=8?Z9@5=9.??!%%%=[$$3B=7\*FUD']CIS9Y@3J#>V[#_/@XC'V
M8)1/R*H_^=?6YO;U&W[7^V1"GS@T=]Q%%/-CV)2,<NO%B^$L?ALB9R[T(=O
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MZR;E])[14)T9<8-LP)-MQ?9=X3 ;Z/':EF5_8EZ*++IS:Y)&M[:IN-KJ[LX
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MW-P:!9T/7';A^H]+E_W]"W'9C/7DL.\=RY:$61=<1=N9 X$A 89B6@-O!:(
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MBU.KMAKE:RDT*]P^N'%T<:B)NA2O)07-W_4\,&8ZRTUVW\)C-12&P&FGT^_
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MEBN/)]9SMO]J2;=Y/Y7OV?E[RT<+9?;@Z@^[RM_Z!:D6;#!3/>B8OVN].,_
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M<R9SSON\Z^MU,O"&>11@N[6YE3G MXD/N 3_ ;R?P+;C5P.N> *> 'SP\<:
MD\ FOK_'W]=-?P\!_K^O@@("_ *;!3=O_E<3$MX"-Z'-F[>(;A$6^7O G[:*
MBFS]>_)WD/_]UDV"_/R"(D*;A43^7Q^\#\".+7RZ?.?Y^?8!FW;P\>_@X[4#
M"%A&P7^)QP?\EX-O$[^ X&8A6 Q1^ O5VV'Q^?EAH05AB>&KX?!U0&"'H,1>
MG>.;)>TO"^T+E-*]G_)BB]*)\A9IAWZZLMZ56Q'"(C*R.^7D5535]JMKZ!L<
M,C0Z;'SRE)FYA:65M>/9<T[.YR]<]+CJ><W+V\<W*#@D- Q[^T[D@ZCHF(>Q
M<:EIC],S,I\\S<K++RA\6?3J]9N*RJKJFMKW=?6M;>T=G5T?NS\-# Y]^TX:
M'AFETJ:F9V;G?LPO,'ZMKOUFKD,;?_ZNBP_@Y_L_CG]<UPYX79O^VD#H[[KX
M-H7]_<(. <&].ILECML+70Z4W*=[?XO4B907Y2W"2GH.=.DKM_I%9)3UJ2J,
MOTO[U\K^QQ86\3^ULO^ZL/^VKE%@*S\?;#S^'0 *X+#SXO8#_]G^L_W/M+)8
M%*69^.NJ/,A)9B+^V(9A_$GM!#H&LZ$KAN)VL<0YJ@UECLH\(*4:P5!::=3F
M 6FQ&2!IF) P9&^&_P 6M)@9[[SV_JGV,LU'.24B;]]TN0D +/B-<??C/Q!V
M-TOA>R<5.'F--A3"]K9ME2'8K)JT0&KVPX+^O5&/S(ZVO=N0N-3^VM.^RS'K
M4^$=?<^=7YQNA;I?7V74U;AD.N7;2)X[<:ZP1X#<H6GH^0OM5N;98 6%2 _A
M=" E1O+4N6\3R:WB4?4\($[U7>+5YOCC YX-?B%73E0^'%H6B-A\A_*=E 1>
M)8[&4).C2AL#& K,VXS<J/P+UUG7BHNQ-V8G)Q5_EK^<5]Q4ZI9NCE:YMW*R
MS%QO^I;S<@CX/D3/M31)_?(;YXA7HZZE]@X-([<FU\,&;=%'\QK04<3*Y*Z5
M1&:M(0\0XFZ%LMMKF $5"W-F_=?>QZE]."+7;QW=\F5\3K'X*4,M&F=%F0A=
M;.4BZ1QF^NL1:X_&P6I-BPCL+E"TDZ)+N"+H\-K.\::MVXWZ;,=.R@)-)2;*
MLCX%RLNZY?YF':.;*!W6EKN+(91@P$**0(YF]4/51\UGM)?T63OE+Y2JWI+V
M.'7&1D<9$%+.6B-"EU;&/+B)>C0D=\<Z@7WC):S6G"+EIHOFYQL'M3Y864BZ
M2XU]4[?6(1:.FN3&9?SI7#W=E&T[Y'\U@C;I%(=5.5&F\+I-D__CGH@MI:T!
M(T3F_5KHNJE.'QW=H4[5NU[+WU[RPDX+]_)2!/K(C=["AW)?='T+'9YI?QYH
M[OQ6CCV-0E:_WKFJGQ^:/C:B^9-\*DDCCD@%1;&9G9-[*^F9D56BO8YGA]3.
M:^DOFXZ\S*69_W@8)WPE'"@!8XF"W -LF2'M*D(\>6OURE8W]]9K5;6DJM?^
M[MXMHQ=.Q8D"V(\KME]$?,6*FW,LM)QD=C[\FGZJ2"5$H?1:YME:[UGOO+C\
M(!*10N !O^[R &$>L 0.\("U0LT_,F5S15RX@P>H$>D$;A<'R0.L'8@O?-GK
M"<3)>3#F-RJ!FX;Y94\!%P=YP,"PO9DTHVC5R-Y,"K#')/* &B&VM N3";FP
M'-DGH$ *.AEQN3\8)4L>\0G%T./G;VULMSBBH;JA?6$,X,M0SITF/0/;IHF4
M LQ:(''#VYL'L&,Q]C8/*C6JI@R,+A2LAX/+@^N-XOVDQ,JMTEKG3,P5S0L\
M5&X/-16D.5>KE=8O]$W<T:3G<Q$J/$!P'P_(AX7H.6G! Z:M4=1?&+H#\H\1
MF5VE#W)/E:"&EOHVJ.L]<*@:\P#:Q?>+W(B;9$@1PW7 +_9CHA#T#22D+LO9
M%<"]*(_B ?OL>8!X*@^(2 '[.WG S(M\6&,JB(50+S:=-<,#/L:P;9P5P:]V
M"CR OY@'?$+_#\N2S['[S -R$3CBQG8>$.L[5?9'N VDA( ;5JPR,[S4ORG%
M@FUJPQ4QXP$6\&09T<GP[(_!UR.$U;:53%A2!$/;-80''#<*8&\KXP'JJ) ?
M9:W)$"Z3+17/38(#4%L, 2][/P^(Z09;+(D_IL!?7_MYP(9$\N\C>EQL^"]8
MRI-<E>(DX@\U,1YP_QN\7K6?3=+0/^O@WS3%+;H&]HDW8]@/P?;J0!)'@$JD
M&Q/9!1Q2'E'DWU;_CRKZ;]81AS)*80L]?V;(%7+F 8\)]6O.U'_00/H?3QX@
M\)"3C]?E#B$J.N;:P:1<'>[X]SQ&^,3C,.+(=^;P_;VUGK89C,YG<KOFY.;*
M-KW7V[:[<^8]Z.]D[\OL;UA<2/F%\Z*0).FFIU=-PGUUBS[G>UO?<$Y?+GC=
MX6(W-U1E;X:UF'Z!D0!;PL'IC_H\@(580JUE_6P>^[?*X/[2B@<H^:)H%F2L
M"QQ#DEH\H*P<)?<J+XYSCP=8)8.P(MV@+BH:/KM!X,,2IK2_Y=0D"BXM9-;'
MV@N6C+E\JAFHNR&EU6ERF*K@)W%H.GR5,3=%7%YD[<)_-36!&A@@=6:E WE_
M=+E@OG#^S^FO"K:Z$R-;S2_M"WNHY3+UJ'[CEIS>^V<>JUU,?KKX4A\#S4QX
M!X6QSBW67L3$A-Q5?UXQI/U;NNI\P*\2\:>:FZ1W"MG=-#2>CN.H<N)XP+7D
M47&F!*,H*: 9A;O3/PT)^Q6,)\J0G$D7:7L5K$NV1AQVOKXS\K.SF5'HS4W$
MK:8GCV*]KXS//B9HN%:@)YU9$A=?NW)O,GPOJ"(>%L:V=QKXWMW2-GPN(;5$
MR)[(]"W'?2TMS*^XXS+$ "$EF9Q7:'H\,XG1UZIHWM:65?K"1[KV0=&WE?0K
M ZXG[]"[M1**IA-?/JB4WK,1?L19CA4.(;DB\53$2'-XV)3:LF8>VP+R?-L;
M(%-RFWIA3]:DVH7^%[HI_I("J_U L/(-/A?!>R9"2\FL7=POY)J)LO9$R1:4
M[ T3Y-0/ YO7C?S4AL4G+RJ&]->//#<7E#?7..Z\Q>I,?\W@E_#U3L*V&T1*
M#I%N!>["]Y&KG!.J[B;+0JLNJ6AQZ$8K#^CSSCCIF_UX^[8AF14](P4^3]>?
M-\YY62?Y]<D4'K;;/?UB1>5J:>&,WX1/^,?/"Y=T5[:[JSYXX2+MO",&+>XL
M?J<\1EFISZ[8?U3$A,VPUK!:]8WBO&\VPIWC1/" *X2106K?4C>MEO[^^YHL
M\3ORNO:4KAM:L>E9J<N=1Z=2)SXN':'P?^@(!.DN30K6##"B61 _,# ?RORS
MGFBRJ\TM8TMK;$V+E\GM+K>7LY>$YQ0LCFD2H0XZTAUVP7?X#E @A#S2UC$J
MD,4#[@4/%F*++(9^BZLLJV"U7Z0_$;SR_.CS$ %<]Q[-U(-8 J31NQYEJLX^
M#4FR-K%U&;,IM]]@S3L5)<]]FZD7]?$/NZ6M[6'E%O3N5>WD@NZQQUN]XGJ0
MP=3XO)K7<N="CHRY!-WV#_BP^MX4JX7:[NFCLLM?_OV&AV*)P>8%H_I24F!8
M4??=DCIT#@^@I',1M0PD6TJ<FD0(_O%Z6ZW*Y/Q./GB2(G=T>/^]HQ_+OB)'
M+3Z0Z>>(4CA;!BD6O!8P2FYUF*\/?:&5Y75/?^+$J*WU]Q%SB4,7M*T+2JIR
MRO;(&4WD:E(W<V*;%7"2G'IM\"H/&.V:.MJ<D]\K(=SH3.UY<'ZY, NA*V[T
MY<$)47_S\8,-;5X!O9BKW$X4W8X'R.(_\(!JPX=$'_)#@AP;)=0ZH6?6+(]O
M,BUGP?-=*9'-/?0FX@V_CD!TBO.EZ]/^V=_:K"O:.WV:S7KD3CZU<?E!=JY.
MK3^*DM#94+P^(#>A97:XEWKEAT-Q-/-=V9TD*\?'6>LS(;([NW(U^J[U?5K9
M/KYH6,_Y/?>PG3BJ.VF]SL7=17PY8//35:PH]-;!@WY,(O.,Z69& %LRGVJX
MQ&(('BN'<BBL/O$VI-R%Q)+/PW(K,QUZZ@MRLHI^C*ZI]<0J="RHR/9C(-J<
M2C;GT,1E%BYF$/A+!W=)3EAIJ"L^=.:7_B/)(-'L:ND>7&%MEB[N,KU;R9[>
MEUQUEV7?P,=N\+?Z[,7)$*U*HF3-][WJD[81%_S9W8-6^[2\KC?!"#K0[E6'
MMWT0P3SGZ^1*''^]Y&L$4O1JQV][L27B*9;0298MS@J:8KQL^_@.$L[W1;[)
MV'4@3^#KLBMG:L8LV")\3&?(&<Z>0D*NO7?A)%<RT[[OL K]:BDC\E'!N(39
MG2*V= RMJ!43@ZBX@1>5CEMD/F((9C2\[E, !H?-?'R_3.UZ=26CSGW6)YFQ
MPQVN"T+B;\JZQ&/>Y -8.PJ 6IPFR6RK/GTM\*2LP0U/_4S/G7#%GOYB\8G^
MW2.1%B!QJW1OQ_$64M*^9U>XG[T=(C+)%T/P5HA<?7NS\*<<XSOK;$D>P$6#
M5!0G^0^&^[@0//&-O<8#6N#R-[W.A2\.\X!"'C!O[;RFC<EE9+(FD'1N$8,P
MX,>U-A'GW '_N(CLSVO6YWK!;_=0N01HOQ [EP=T)+,0O]$<]3N_Y'^O_'L?
MITR0.X=F:_ZR^)/6AOIE=XFX^ W%V;?7A2"&5\"2IX22@E>BB6)KP@:V04Y/
M.HI\&)8/!XT<VC=-[Z=:32>EQV *R149R7064P..?!]OL#:L+7ED%0U%3BVC
MG3*7_Q1.JSKF'3MP8,^!J'-96_JOB'2$I@[.9-\ NG0Z&Z6EIA0^H3,T"R>6
MPUYF[<;(,8[:[>SQ^1*%]'%O_*9A[[^_/M4A<"XMT-ITL;GVKK8;:;9DHJ0C
M<:C&.?!QAIR<R@G\(G\$RCBIN9M3W6@+5^L9J+^$K05-T ?\P*VN?IE./(!>
M:Z)$]3_Z;>G*Y5VIC=8>E@F?<#]ZU+99Z\@)F9+I-LPJ3JRI#G[ 5(Z3PN4#
M6TQQVL584>=3E77?JU'B[:.IDG+(6ZS\T+'=F^=NBSXJK.6_[SK8JWERVQL-
MB9$Z]YZ,L87U7S4_&(&NX4^HO[ >'NE._N8%"Z]O#9Y-/S14IEY5,)$=D;B1
M7]*_D6P67HA@2R9_0$D1*<7NJIQ4O(*?HPL6<>*]?&YQH#\J6SLQ.46@8DRI
MYM:B_N)UN5KIA;&X1W?%QR91V[#.%,.'IM+X+PCZ:19!')+XCKV"B2>-\G-*
M@R.H.\>URG8\/KXWV3O#ZN:\ZLV&>V^XI'R-H?E!YR"KA8&*#%+#MPW-RC#:
M@0LN.BV7WCT>GWD899ST*\K +@<3U9-KO>J[[!BCGT.P,=Q@F4G_\6!M@PSA
M0B0*9\TG-2B%JI7A2C.HB=8;T$G2\?GCUA?MT5B?*J[7K8Q*T7SKK3U]W<-;
M>:TWV(-1S&^M-S/K_ZHPN!H?8!=3UL%VW";9,W]%$>FGD:YDK3.;<'1>]??C
M$JG4^ 9_I-ZJ<=P?#ZZ(,.MX%P/)4J(VE[&$O(F"(3GR,S]+/2H'!'-ZIQU4
MOVTC7(N*VR0L].AVAQ\<%CMQ0A3P(;EF)CFZ>2_6T)I4]9T^^T+)Y\^7'.DA
MP6^R?CMGG%R3NG8Y9!PZ2Y=H'XIZFUT].-;K\UH:RJL1?:#I]>2S7DSE@Y?S
MKUO#[!N<GBG$SUXL/GH ]\(LO G&CA6<9Z8(MAY41$4G$@39R)<^>&E&TB-F
MGU_>L$I3HW%4_M*CVX'WRC/,$Z0_J.0]R@W".'.[>4!YV0<P!D5'&ZV5/20+
MFR#?0+,\@+J\'ALBVN1RK/9]8[6LCC5SZG.*:%?YICT G5&W:_:]G]?PG?/R
MV%RGC8F2;V'$_*\;U[LZWA+X6I_LFK=_W%Q]P,Q6OU FVW$V_(7*)_;H3_QA
MF!?])!1'X6&0W[*)./W10)R%6($Y5M8 4:Z8Z<7=(LT#5(^_ N&< 6/"@N_I
MJZX78!B=R57Y0X@.WPNGE GB'Q8:1HFF8WEQFJO\D)$F#0TAR]A/-\.\S8,3
MPTUS(XV%,-38LB3NZ4CXF^7<-AABEBX.=:.F_2W8EJP547":YDGXS52;,I"R
MQ[Q#S!]TOCR%2')',4BMH!!.AB$X+?X"DJ[>_'5?DEC%WJ:GGMEWO>8V'OGW
M3<A)=_4[[C]A>ZCFVVV?@.Y*D??7C]YY/.>@7A^0I5T6[5IJZ$;0*FA2<#.S
MP(X;ZS@Y/CK>LKF@H:EQ2,W0>?U6GR9?O56!5M?NV;R\5Z.?UE6JFIO>/>JY
M?%MKZ\=S67(BJ46O/BZ%:VCL?ZY5%N@V::%K.?,TR48RU=9&A</^'GM9>ZE7
MX/I%HXLG[(47COT0.VG&=[4U;O_SRV929_C@)E0&_G/:[4/_0Y;>6)$#FV""
M*[X RG%4B=/Y<#$G%<%WO8,U.X6>O9D7MY]_8Q[.CO? [A7V>5B5/. LS&XS
MR_:6N?]S]R@=\S.8![02E<'7)GH\0'E6E-OD"%_<)[U>^\'V")/%N0]> X7Q
M ^3*N02MQA *J- MW?F"4NRF2ONCJ7XUX:?/N6/>YW7UM1@'!;^=])J1IMN&
M*[($P19S+A+?Z:[[;K"(<:#D-=M45K*W&#)5C<VXAG75/#'P^B!"/[^FM:'F
MV9Q!;]:9,HR8;Z!#3:GNJ$U%..(:%G<W_5I=J4UW1+Y=??QLCOSK6]_CT.,)
M;\?5[AK9V(;Y^(;+P=%CR$G%R3%.]%&2.Y QX-:UOAAPNZGV^$G/M]"5F8Z"
M?3^]]SVZ_49*($4%U"9<NJ9[@")?@[K2!SMMBQGQ2D#2Y';. YP-_2+9D1[U
MI:KDE:^3O&U[>6'AH%#N3\UIC2<Q09(I+>;N!?*0YE39\E'&'#.=\6PW"B(Q
MX"+D,K0TZ/F@5&+GLNR1\JWV&@6N]ZS."3P2[I9>J,>PI4E<$>D"[&&<M!_K
MQ(3)CM:]2<PYBXHLNJI.Y$WZ4SGBV!4,Y\VJ6OK4Y"8CGUNV%R9LLLTG$X^Z
MS-B-C@U!U]%\@>%V.UZD?L?B3DOYJIL7%[/JK!V8MXH<!IZE[^])5]]?DY%X
MO7F,DV0B1X]DAL'V[<:=AXY3<ES?&A,?"'9F"TXLHO>Y67[/#).9]$C]TA:<
MBFNO^798^;5J *3:U0Z.57:1J[PZ @3P(_1%0W>QZOZ?@XX8B?DK"@IWB57[
MM,[(F*%5EGM;-.I.Q)7\0,_8Y3".T ZD,81-M>8GC;Y=89C<B26ZA0<0ED$?
MK?.?/+_0VM-2T8</+[JW,3!<D4C6+;8O=-NP=06!"Z[/MFBXU_;JI,?+BR/=
MM^5VJFL].I7TR?SD@6.7+"_Y:=F9Q;X.?G9U9F?')^=9NZ,>^>1O?D/4+VRU
M+XSQKU'6!H7N42+G-,\Y,*MF+"R<TO,UZTHNWHJ?M:K3^Q* WXPS8XA'LVUA
MM$5J:_([0U>-*N[V1SU\7AY64^LPU2.N>G ;*8%@N_CLAMR?@ \!L-^<@="L
MS5BO+B*_J;H-JLTE>]WX1C:E)YC@,/AT[MDG3_6 V0(\]B8/:+PD-Q1LL!KP
M@.A+2&X6A!1+\;U<*2@VT(O2MV.<DW^^/V-41O+P%@4)7;GM!Q/Y-0Z*U3ZZ
M%53-,N).H*I12P2OP +<-J@LI'"^-NAVK;%MQUM#IQ)5X,"^'$7[AX",;<$]
M/K5-3=>=$'+N.767-:WGK9<-;M3[:/^V(KSPVK#8,?M>#3U,?<,R[G^L=,$Z
M,,= X6YO!\NX]E95OIQRU4)?.5S>!Z#,#I!N!]XG; >]M8_Z<]71X;O""'[5
MV]VJ*T>M!S./\9VXH#5"XO=K/FCLG ([ORAQF@-C/I;T;R2'SV\.G4RL(G8A
M1R,[RJ&QJ;+V([UX[I8$I]Q;RF?&S.VL.[9:EW<*MQPY*WG/SM8)DF6P:.2E
M;U,_N&IL*887\T"#]-L:!CD\8G)NAR40,F)RX]F]PV,IHW7S,^DOTOI$0WH/
MW& 7/YWL*<E\,46!9/7:L/[Q'P]3BIW.O<W4+;3]]KC@A>+A.J6[.,.)88XQ
MY$)?;475UMQG># -&).%\A,X+4[>BH&_0>&7J8*>XG']?B2N0F%Z34SY L79
MDQXVE8! </7PI#O,]. *;ZXLO3HF.E@E@1TO5M+\5D4S2:2Z)?T^HM4,?YY]
MB%,)^H /4+(F5HPQ:E_[1G"?-+:N-+O=^-D=_[<1RZ5JDI]..YSJWZN;^"'O
MP.0)BH0&L07F9<PH3FXP6A(*HPJU'QKP-_'<U$8[3SY=76_XJECCWD6:VE6C
M7/<SKX_\LCO6)>@:N<.H5UW3U/U<:1(CZ&[(S"#IQ:^=/&"+WC,S+5=U4E&/
MBE5__*TJU07[7%7;5T>"ZM5;N\E/BWH:5N-@8/V6&RG">0J'LR#8_<@7P421
MX:I@4(C7<U[J8V_7A(ODF;]%\N_FIE6)YNS[2JX9DFWS&[7USTD>T-T _F82
MN./AM692SK-"])O._[;%7[/X[P7X=2KX<3092EF?E('':.]!+2ZA.WWWYQ$O
MH08N_=_\J,#_OWS[E>]?7.08"JZ)6G]1Q1MPWH;TB 07RG_K6\8BUXU!*B85
M-90+%X/4($$>X/X:5M8.F)C4HZ_OSXL#_JEI_A-N@7HQE2CZL3)84R=A3?$
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M+#TNM)5/\4.9$0^(=H2^\8!C34(PWG>#Y4\M_KVDZI71)6IK_-46YBQC0SS
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MPY-JX3L).T!*U'>PJB@!M^E/3!=*FBT%U\ZG:IUW2QQF&D\B'O[4GRH^?NL
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M>;4>56O)6GFX1I08OFA%U2SVM[M0\/Y];5W*U?<QW3?;NK>VSQS[HLO7R_V
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M#M9DLAR.B&T?G:A-ETK44E ]HJ.[]T;Q^R",X1CL*3HH/[(D_*Z,NDX8T72
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M/_BZ/JC&?+1%\Y&7UY[MF\./$YY8'N_-ETU^[_MR/%_\EY8"K8GX53NCPM)
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M/&_3SWS:?T7;_*O&5$<W>J3?Y]>[;JT/-^Y;V1K^O4[S!5&4,2]0HZ$#Q5U
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M^+69"NP-,#)J#:LT'R38]M/GZZ?+L<UAB4ON?F>/][94\608=XW/NN3R?Q@
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M>^<V]-W(IAQM%J*5D8/2%NS*NW/_NK1$O6PC/(P4@6M,( ;-IRL#B>UP.(P
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MS&U>CYJQ"[2TW9&/,Y4^JQ.SA.;82]D.8^>&WN*\^AVO-OS52S/^?BYP&HF
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MR@-6347A:JL$J#@M'XN&=9QMN%I&VT]P59]8RQV664AQS;O1"S9F0MS, ^W
MEFJU00?8*J:2P[>J-96<^Z2D1KL]O:J[,,4!1HX"F&LTF36T<0#9<=#C8LAK
MJ](N=_]^+W5YM^9/]3)#B1]2CB&.10)10%2O7>[)8$EXF>K"1T++>C0-Z5/?
MAO;JI0Y[+M12GUY+!O"'4@DT.AFF/IBAK>?E)L/0S*]I]*W0 ^Z*"C,# )S7
MENG(_DY590:P7*XG,QED9FZKCL6C%S9^V#P17BWC*$R\)/9AF 4RA,L$A7(7
MET 9UBG2:8_%&"^?V_J1-:[6FD[+M9XFD_)86^WY^8H_YD71XZV^HM+,^8M*
MB1]Y?L!AZ*G^ 7X:0)RF$4R(2+U OJV8B>Y%O2G8?YO7M-758'O*?M WI+D6
M?4_,S=8K!TQ=.RZNGMH+T"K^ ]!LC6'ZO>FR+NKWWX/V:@Q>9_15HX(L$J\^
M%X_OBK>*SNJFOA._U^OB\;7<@-Q7U7]6;_YK_7+SM6*U_&>Y!;G]4K'_K'[E
MC1O0S<2R''_JU*QV:RV]ZIX/#^#F?D11@#65/EVG^GOIOZLV2: CY&O>1=WC
MW;LMOW#5'49]R""1RQ;Z80\\%^IF3G8ZP,$?K>ZNDL*NA,XN2\Q6Z'QI8U?"
M<I!'=NU8ED? +9F<(H\YU_1F5^.G#E[D_]@#_K;T"?6"5)5K1'$&D6 9Q#C"
M4 2(",;C+#$[YK#086)/V#:CL"+:LP$TY*$( YS +$:\;72#0Y'!)$19BEGD
MQSA9RLE-RA\$TKXN^D>[<\&I>?P]+42&Q]ZM,FVY\J7V8?N"VZU.0"KE\+#;
M'A%7A]P6&LQ[N&T/T<FA]A5#6281;QE:WQ7/,EI^+Q58!5WX1'G,4I02F-"8
M0!3X%)+(0S *TR0EQ(L#WXA.=4#6Q+Z[$04"PXS@ 6CTW(DC@\W<QCYL5-Y!
MR5V SGZ'$:"!B:ZR= <DS9N*.V[R2;ZMQB.VL5J]KG*5K*WJ\F^*YC]J-_ %
MKU1.T)(D@8S,_ 1Z7BP@BGT,TU!P*(.SD(5ABB(_-0O,A@5.??&^$P^HHJ;
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M#K&U.E)S(7^VPSB'8/6/\5P.>RTACMPML U=_PVK$MWURXYQYZ@U>,9#$M
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M=.<H-(UTY!K&I,WJ##1-/Y[^NH_93?@/?'V+Z\_WJF$UX^S5RV\R%GI7M.T
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M5/%KIJ& J6 A]-.(,9KZ)/.9]N9\4-34E]G;F*W>"0=423?8/0Y#I;&[=@:
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M OHDE-Y0%?!E6:KX T-&4,!2+(SZ. Q*F^<R8"_3ZK1B&"\]1^8,!:NC?7T
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M$064AI0( 9F6":,^;31M;S0XJEE"]ZH[(OR/ABW8X$<@X!87$V/">%&8[N=
M$#0Z<SPD74=GPA#U-CS3#8B!X9G 1:<<GNDF[\'P3,=%O&>[U',79VF41%10
MTS>4YYCDIH58G$<XBQ470O*(%\I36DM-<&3S7-- -W2UJC.Y(./[K"&S\\M\
M @$SL+TI*OX';MH*.G["24/N9\DLV1,>D$*R_YYK2] E_^?S<J'?J)K@T3;+
M649"1:R0.(_S#!-:Q)BF<8Z#-.19E/%<2MCXBK.DQLX)Z1#^O_^O/ JS_Q?)
MF@%H7]"S6%E> GA! *;C#9TK=+U>K^;L;6U&J*#U$CW057/UZ3]K?%A,;XU"
MSQ*:N$OHD,#'+4('WX!GF?^U6I=/']8?3?3V7MW^MU[T7RNAS42Y%M>ET'^M
M3<C-]Y7X^ZJ= V^9> Y>>&2%_JNLZJ%0!]<\)HC87B+5P?"JN0TRU<FE0.8E
M_:]S4Z^D'2?]KR;?SCY?'8YNOU$8'5B8G?"(*?JC8=93PQEGD)R2X>'4)LN/
M=P:BFS+OOHAKK\-K(58FV-3\CPDTA3-6I()%D<1%:M(G%)&8)232_X@*&@LF
M);/NT7:6RLA6J.T*V%*\VOP+JF.;]Z5E*4P_3OTFQ)OT0)?"57"'SH@]@EW0
M'_'4JA-W2>P1[+A78M_#;G[_5UEI2\V?M<I_D-_E8OEJH@QM(OJ,J#113.28
M,W,/HZC"E 4<9XQ&) Y4HG*KOB96U$96TPWM>L,2.^HPW[\?+SOWWQL*,'7=
M Z!#>-/0VY_C;R6@)]^_G]:D[K^5V(<G +N7',NU.7][>:L;:]3Y'R:)9"6?
M]<KS[_*NY,L7V;JH2N5I0K)8'^H+O0]'G&+&S<P/D26<2AE)2D"5W+:41U;Z
M#A]M$MD>)ZAAI4U' -:"6X-K9Q5&@0QF(:[O;^[.!@B\^?+. ONJ-[>F.VTI
M.A2.HRIU\ (.5[O7&L[@0?]J[DKQQNL<-/-?VGH]/LO[EW*NJ9@_:'_ZA1(J
M(]JD)#+.,$G3#.<R#7 >12*(DS!6*K2^V(71'MFR&%Z0H7:%=NRT?Z Y0IHE
MU/)4_RG@+A*(<;]Y&1DYF(&!@C9L=2Y&#W"/.QZ*;K>XWGZ"L%M<-QAZ[W"!
M2TYW@^LFZ][]K>,2/LK1[DIMV&2U-@-IZV%4HFU%09_D+ HESXHLQ6D6%IAP
MPC$K5(Y-O\HBS(.D4*#V!/:DITBXF7>2&ZJ:OOZCAB5D6LM=4LW6"ZN=LS<.
M6#!C?)0$LF&CG<3=<()VK(Q5&&<C_B@%<[V$?V AG0T@_05V5BLXWA1O*VN;
MF-3?YD)[EVJY>JEWKZ_-Z-6/6L3;/S43IC-O.\6R^O7]8;741G!=:>OW3:Z^
MS[FL=MWU\YP4>:H4CB6+,2E8BO,B3'' )*5!PF-&05F_HW$Z]CUUIZ:\9=*4
M3,%&ZHS_N>PLW4_Q$:"!L@9SHZ9HP]5V?&YEOL6&L3J6MF$-_?%(FP2Z$69P
MCXZCK[OXT?B<]BI_;+B/,@%&)^AIT,3?EJM_RM6U^(<F7]>;F>:]ZQ6=E_J9
M+\OU7,UYS?+?KK]^N>;KS;3 VY?7Q?)=RE]E*=5\7<V44%$4I@6F,B>8")5@
MRDE@?E)Y)@+):&B52#@ZIR.;>T,=F2G=NQ&ELN4 L9:%"\<T>/MF%K&&G^5+
M@"]'3@U^:!A'.\[;)N,;WE&7>?2+8?\OZ+K]EDW >2,#^O4G^Y87SNCX$=_4
MZU"/2;_MY?- ?.,-'B#BC8$?.W'$-XZ#(TJ\$W0[M]V_FI[ZFN0G,]OWTYRR
M^4+[&5^6S<B4<CTS$1_&98YED(:8!$F(<QDE)MM7L(B22!+0^6N0XL@;ZY8^
M6M3CK!<M!W.C_>6RQ"T;L /5,(YV!R.OZ, VNQTP->TKM*5^A7;T_9U=K$7U
M= 89IC?I6<):_,,S@?V+;B;AKM2'"OWIWHV),M.^E_K@H!V#*$ES)B7F211A
MDM,<4_-O<2ZSC*6,Y"*'V('39,;VJC4MDY#ZVE"#Z?@98.P4^W)Q8=J\I=>X
M-$;HEJ;WRIU^T3QI[QDBDZILOZ"'>CKP-$PYJ]5Z=JV/]=HIJ-H[2LEC03*9
MXECE#).01+@@3.&0"C.N1N_+-+-1R..EQTZ_:8G9:=\)R?LU[C)Y8%JVH>,Q
M$>8\^WV:I-_J:)'^KYT&G5AP$JTY+\A&4WJ>< A+/<Y?FI9'=?E,T]%HHRHR
M9X*2'!,9ZG^HO.XI$&!!J. L+ (2VD_B.T]G9+TQA#&KFZ-5AC1:O@)GP?5
M9!'#\2,X3,$,3=0TA*NIMIW>7%) >H0'!#W\@. 6LH#^ &#AA6')>H,#/:]/
M=[0?EF'O8&[QN(,A^K0LGTP9?GWLGYLV_C>T>MXV3MN-?9X51<JHI(GI$YIB
MDF4*%TFD,$D9#PJN/>K OLFZ-=F1S93A ^OW7M!JRPG2%OX9H*OV$%K8K5&
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MS.(,4TD$#EB21WD<)E* )I;OK3ZR^K:T@.>M/?$MSSRN0@'/'0V9$6:$GQ3
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MF-L"Q-+.!QD/(9CQV/#1=/+9<'*%MKQ<H0U^7X?Q SL%;C!XVN&!Q"?=KMV
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M=]AMJ[!9JEB8$EY@&:6AJ7.0F-$HQ%12KO^.$AE$H(0 ;ZR-;!$^O$E4CYA
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M84(+?<1***9%7&!5*)GG(LSU7FX]O>]P]9%UT5!#W<D6WV1IKFYK#@"#XXY
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M(F7CSHY(PG@B#^AA3E( &>.@"*7-'&8T%#PM,*5&!PL#VO[U04<U8#VR9OK
M!$L]]> )(3-ML<-$?7_]C<]KJ-35XD70!^^S#GC&BL("!D=ZPX3RI&K$ I)]
MK6(SA*7[OW?/L',!L2E4<B>:2F!WQ\J#7?]<JU_E2]>+EZ>V"_U,T! 5C(>
MX[10X8!071<H7P?.XB(211Q2H^L"#TSZOG'>N9;;O;.["#9\JXB@MA[?\D2=
MOC^V[ <]_@V#A+S,L^8%QSO/GN&%R/M-G/E%BD=D75V\^&!QVHL:CR ?7.SX
MI&6V03!>SMIV&6]13![*]9S/<)QG$!69:GS*537K!!0YQ(#$E!0\"RGG6O?
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ME:_\0=TWV)NBAZ#H'J)'"&IZ5-Z0<A@!>E809T?>_?$G/MB>$._P^'KJ0<L
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M$,X'40Z\.[;H_([/['+!OO&Y6G57R]5Z51>IGL4XBN.$I8!D, 60DA2@-,D
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MC.3C+(> "Z02."D%10YC@.-"""9$2#.C!H4GZ'@/Z=E^I(MZ^3XW= W=!"=
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MT-"XTY;-OL2*ES9\NX._3]F4X69ZQY^R6TZ7[%\OJW5]#GY8?N.*T7+.-RV
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MZX58RF^LWJC'78F?&/*=;L-;;NHTSRT_;J[!3X$WK#X\XF:F/!Q#-OK6^PP
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M! (<(7F"8Q$'*$$,%)B2C),\XT4T6_!'=<>KIQ$&J&E]X*CYP/LTM;_SCG;
M&^*FK?-.XZ2WP,?*;IEAT@K=4JT[)VSHNFRK=U8X9_WU3E.:N-'>69$/.^Z=
M?\4\MOVAPBJ9[+*JZFH&FN'KNV]YWHM;8GVWZ'_JQY_O"3B\W,;)9K:ZCHCE
MK$S#:3FL@L'WAIHLWONX"/V0[A-/6*P#55F[MOI^+.?RE6_KA4$ZQ_&W?:^+
MNAAXCVKPC:]?JH5QBL8)V366RFBQ#9>,I<1FZV90*+OU<WS(Z=;1H$@[ZVGX
M23LS<=-<HBZ2HKHF?BTQ*>>M(8I5^5)VM_BFC-,VC4ON;E7WJ^HGMN^?BI,D
M"1-4@)A#:5V&* 9%"@D(280REA8,,V%RVG3/XH0.QH;G.HNQQW70L1W@]8X/
M<A'@8"-(W:_/\,SJ83[UK.#WG24S7=5#O.5,[?"KBQ[T:L+Z_'GU'_K#SI%M
M[H'!24UZ?P#OGP0\4C(WG&X6JU(^N37$OFJF1 V_[/-46],,CMC?*\<93'HB
M6ID4 \-.9E:<%ZUO6F@\;5YKM'5HO5W_I#_4+-[B)SY+"RKR2"*62%, P(2I
M$"Z>@3RE41BCF.-<*W7R% '?6WM+,NAH!HJH?CW1HY@,KT47DAK>PID):50S
M=$@2JU*A1P><K$+HD#C]PJ"#SWD*L%R="13ZLJP$+^49C6^BA09+FB$4B9@*
M!E(H5RV$%(*"< HH2S&6O_%$&.7J32V 9]5PI6K4S=O83.]EZEQ/KIZ1_Y&G
MS%#':01XKG0C/'M2]<,\/TX-.T_3,E5TJ&OV/U;HJ*?),8XK]<7'Q/D#\CC5
M,*S:4:_?MBE+_0)]WZ1^EO*HYV=R2R,)3T(0<\X 9 D#1% ,1$)%RA,8,JA5
M]7YRSCUO:$W5<N7$:C(-)DHT,)Z_A+!8Q 4#61CG .(P 07$7&6"10+!+,^E
M72(_4++\2\]@7P*GV]R974[*!!JA@D:J7F;G;M76X \E6M#*-E69%^/OQ9&I
M\Q[?@'L;9_+)GRZ[Q78BWCOGQ9COCV7.N)X.9_DQU@S8&3"_+I?LSW(^OURP
MFX4<_5$%>M5>X9NG9UQ6BO(LC;.(Y:D 49AB #D4 *4L 7(_BSB,>01#HZA\
M':*>S88MH8#*>7@T-1RT<-/3X:[1,%._'?7Z+FE+O[D2#+8<N%.5)O(ZTG):
M)"=54"8@[.L6HW=MXS)?Y2#+ZNT;_O,W+-=7B>>K689X$68%!D4"4P 1C0'*
M& *,B2)'3*1A9!2A?92*YX7?A;RSX*FC:!J*>0P:O:4^6F#3BZJ6W$4@"08;
MBLYS>P?E<A9Y>8S&Q#&7 V(>1EL./6RW+'NWM#.A6NM$2  89@F M"@ XJD\
M6L8I*HB((%5-M50TCMYB[(UMM 0W% R#L.9;>F8+L ^"WK*S%,ULL7W5D,=X
M81WAW-%RZH\\Z2(Z(M+^TCGVB&4[NL6Z9.7\95V^\FWJ@KK7^KQ\PN5BQK-<
M,(XS@$14 )C''!1R08$T2C"2ZTDDN5&QCG,$/>]N??*]3)J+^FXT^*/AP;1I
MW3D,]1:A2V3,5N9(4,Q;VVE*ZJK-W3ERT[:\TQ3^H/V=[GOV!NUJK2SCFP5=
M/O%;OIYE"8OR,*$ Q6H;38L,X"R) $&$)2&#14ZIJ3F[1\/W*79#,2AKDA?!
M@FO&;0\AHV_-CI#7W)9M1;UI1;T=$-7*A#TAC$,#=I_"Y.;K"1&/&:^G'C6/
M\+M?K!:7[%^K^ZKZ_DJO5EW'(,W<B!.O^SXH\D6=J"LIOS10K-2-N"H"S*O7
MLNTZKI\C<0J$X;7F2'ZSM:8GNL/T7 TIK6(<3XTY68#C&:'ZT8WG'K7T[\JM
M<_55'O;Y2L7S]EK=W F5SSLK$"=0Q#E(8M4E D<Y(#F- 0ZEJ$1=69K5-C]'
MT/.J5>15@@)KRA'WR!OZ=\_AING;=8B&H5]740Y^:6C_34&RV[%J*>IT>X=N
M74U17;ETSY&;UIVK*?R!*U?W/5NKEW%1+LHU_RK-ZGUO\>HW_*]E=37'JYT3
M<<@12XL$8$XP@%F< (+S'. $TR1,J6!Q9&85&_/@W6KN. (U2P?7'O)H6+,5
MU'R-.3O;3("N\>T55E/CW >B%C:\-2;.;'QS#B8^ UA#='A&L!_*3IW==>4*
MV@H&V[:1$60X8IP!RO(0P)P+:<#0%.0,"@SS!*9Q8:*T3E+RK)HV=+N*&9IU
M"LXCI*=5G,AMICL.1/;3-O.L9(XTP&DZDZ[SL^+NK^;S+YB?^W];5_,'7CVM
M[L1#Q2ZK:INNJWGT/SV"YX78W=@%-75E+1_)]M,__ \@<?[\[P8$LU6I)7_P
MA]-$8SU9K1P! \-.Y@LX+UK?':#QM.4FNO[!J]X-V]5+5:E@I;B(HY"'1.Z9
M10%@&%. <KF9$AQRN;.F, Z-@CM.T/&]@2JJ_;OEBX VA TWTA,H:6ZCXV4W
MW$1KL;_VQ;XZ([;Y#CHLE*O]\P25:7?/85$/]LXSCSLI>G(D+;_.P_]]L20K
M7KVJ=/R;Q?/+6G6G75#)2AUR^NFM?KTVQ-L#)E*YD&G*@8A5H4T"!2"97/@8
MTS"GK! 9S4:4/G'&J.^[\CK"L3F0VIWNO<V0GI;Y"+B;J2DCR,<6*'&.AY\R
M)>[8?,]B)<[!/E.RQ#T]RP1 U6)2V<)?-T5+!(L(1$4$1"88@'$2 4QY J(\
M08A1DF<T-LK4.R#A63%N"([IAWV(BYY2&R>MF3HR%-0\*>BD+*ZR=PX)3)MF
M<U+ @WR8TT]:MGM9X*=EM2[_S5G=\T_5V98\M]Z+69KFE&,2@CA.*8 1ES8.
MC!"(TBRB!:&(D;@K'OQ@T 5FD*K6E[I;1/C!?'GV>&BN.<N6BX N5VO37C'#
M,.JM60>HV/62Z2'1=//LD+@^4V39O(&,EHBN&LH,$YNVP8R6X <-9_3>&MN
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M=9S4DW,3L+GPWT\3BJ_$YQU+-Y8P&!UT\HXDQI"1A"=B<"D0XQW$K'QV)E<
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M1QVV"]-_]Y,K6,,A>AR! IXE*91N_URKTK]2$,X-<UJ(0*MWX]B>RF%[O30
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MK/ZK&S<DEB;1C O"(K?H-SN/;H@IK6:"<<K(+&SMALDUZ1_8.:P!J%DCVFT
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MQZ,L*L^(B<7N2 C$EMP/,&7+%TY7?__0.U.-V/W# W;=UFD"/0ULIUWNK7U
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M$14)4E@?G4Z:AY^)?N?5:QBM3J:?_)]XZL-\[">+4="<F9(8IC*BIX&A%[&
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M0[CM3,A8"JG4V8 NK95*/P 7T%BRG)QE&O_<+ .U&5J>$S#,D55'I\\!LJ>
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MU=\7KZ!CR!*YW@^AO07?('AN-E7);05J&8D!#(K%X6;P0A"JN:1<@.>N=HG
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M9;F?3)#77U>..%"O@LQ$,8^;.'I*G,R68*R!QP*SW#VU:]6*,@_ 7L,%6'4
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MM5M([T[M9NA\C5</!]9D YB]'5KYM_'RR_'58CF[A/D=6R,>O1%28-3C$VY
M91+!36A)UBGX+ **L7:'EQ<)V@QYK_'NH;X^6@?7[0CH8)PVTB [6NGBU&;B
M041BK(*$41 3IG:9X"9T;0:UUWC7T)MV6D?<0RM-%403'0E!)F0K4N*90]?6
M9 ],6LT@'!)TVQZNK_&>H4\=#9X+V8RGFR+%HDT,ZL>S-#*@P$MN2%2ELTTP
M9>(X*,*-]%Q+HYW;K"/SKA1LAK=7>[-P$,6T;OCN&@?<ELB.LD8^0H@$RAL5
MZ9@D/E%D-D0OLS/<N(/:OV<4;E;"_!KO( Z@L0;PN%&OBA%%-X)9QPG&\[C)
MDJ DQ*[/*P6?9:;U$W\;$;89^E[CQ41_^GDMH,,?QJ+-SS 2-.1,G2>1YNY%
MJ2=>!D],=E)HE0(\O=8_#/SN2=P,B*_QIN,0.GLMD'RI9\^U.\)&B6>,Q=#^
MX\[S&(TY1TKS0^(P0 LVAQQL[1.[%NV;@?@UWZ$,HN6A8Y[SI9\F/T\W;=G^
M5D;>3)<_;OSG7)JT2Z7+1'@4IT97Q5OA"(M4::ZBR,IN%-B\N,QFT'J-%R65
M1?SW,%7Z\?NG7H=+KU[JX#.F-^!XSUE2MQ;L;/[93V^J4,H=QVPR3M?[:(KH
MN^?U++\;3Q'L8S]!<"[A\=QTZA286.J0618$_4,,FKG#(,4&8:@7G@51^9"J
M0OC>'3KO3,%/7I/>M!"P74-W29@VLE2466*3 *)Y2LD$"UK6;K.X'87#]O(X
M/!:?]03M3Y\-^*0_X>GY; (0QFCU_[?W;LUMY$K^X/M^%^SB?GG9"+4M>QSA
MMKR63D^<)P6N,N=0+ ])N=O_3[\)BKJ35%41Q0)MSYEP^UK(RP^)S$0BTR..
M0^ZNBBDR3&B40(0V$$5<+#\QNQ.)X^)U2+2\& PYG.KJ1^;&+O,IUWN+ .+$
M&L3)I4:&1H%L3"*H%*VAI>\/>Y Y+D('A4TWB.ZMPRI@NAY@G\?[ B5?X6!:
M-XS*9]"Z(Y1/A$;'!")!T-N,K;&8(ZPH3C'"?V3YL? M"*L:BOO#XP4<2^NJ
M"@"VWL^/HE 3"37>(L.I1MR+A(S#&@4K@U$YN4!+-[KM0^>X,T[J/,O[*;$"
MH.X8&?.EF4[?-?._[3Q<RJ0MCC[!?E-Y^I4F>2@M1LXJ::F7EE-:&)KM**O:
M5A9 2/M)8GW550$(G[/R*2Y?=LOQ1FB-@T4D/[KA)$H0H/9P# AOJ#$1/Q^S
M6< ZODY7M>/#>N/AA14LK)S>@/NVRJJN9B0,WHGK)8O,8$HB=TA()Q"W'%CT
MX'<S\''@?QY+5?QT[D)@M:/'B@%Q,'5U1Z2Y1>0L7N47@A<#-(=[QN%]_BSS
M[IOK>#;/%QGS^#7.%B#UV]\\S;GF1?Y'I[.;ZW41_*6U2C.N!1+!\2QT\)U-
M'EVI@^6&6\5<Z5OT(?@8^:@?#GU;<3X2!H['(X#31FJ'&"8Y)C0169_@!Z<$
MA(N825=ZM$PQCZ#X97I]'D%[Y>SI$9S.0@WWGSLD_P[4M&&H^I!7I'M0<^!;
MU%)RV_.B]?8^_^8;R#[;6#O=7#20F^M,F\7-/-Y?9(EDI62*H,!R-[O<43&7
M0"%*&?C$Q&/V?-C[MDJ*'JN7NQG=).@_?CSZU6U&16N#@\AM7'1^=:*)0(XK
MBB"JY4%SKVPLW>&S*XUC]A,?&D#;;T('T%\%GD"7&>V2!<8DIR@%0[+7Q9 )
M\ ,W@4FIHH28]'!9JEKO0(? 2?LTU5Y*JQN/FV=L:\)E" 0)K10X6A;G<>H>
MN"56R!2H8Z4[=G<DL=H,UGY0:0_)O?56 2PWC,/Y,KGZ"LS=WI^I!#Y]2AJ1
MX"7BA"5D%07WGTJFG51,F](E(J^05"WL]H=#,YQN*H#:W5NH5;>L?'A\G7R[
M8T5ZG2+6!@40%^+<6F0<RR-KB=;2.XZ+CY3904ZU*='B$"NEDQ'AE0>(?\E]
MM6X+7!A5*2BP[=%3Q)D,R&@?413,Y#]S(;;*[<!7'X$(?O4 H"<+UG*I/:!S
MUE_ -:!B#6:L?6 IY3RFRL->.,^7IPP%)YSG5MH@6[E3;7 QYCFUA[*>J[N'
MY$96^)]@.:]OKN]*?XAA1@>*1,H/:X432%.&P9(9RQ06OJ7K\HK*GRPZLM+[
MJ*PI(;^Q%6__>42X@\^KR 4B40"Y.GJ4TR'(PD%&:)(F/&]3V4_QCQ<=YQPH
MIOC>\JO K]SA+WV\+YZAW.3N(A91)@#,A,1<9)B0UQA+95Q2J?3+C#9TC7OG
M4TMNIY^:JH;>HV:'QA)*LKQ"H 9Q"C\S)N?QP9!&R;WPSQ],5M2*<H0@IR<:
M^O2A[**:JN&V>#_/@T&5DE8FQ9%C<B4PG%L(6Y2,%-$9V+#L@(GL%4W5QM)#
MPZR'2NJ&V(GW-]<WTQ>MS;7+DY&QR].20\X.!*05"!*3S%S46*C2;T.[4UEM
M<<7@,"RAMGT+W8:&YJ>XO*2!>LDM0<G;W-50*60ELXC)9+U)Q&)1NH_&;HK&
MF1U9 ^2ZJJ._W6N6=EI##<_I8CFYSDA_=[/,-_2/-EKN#C);P-]YY$VO!T8\
ME]O?D^77MX\>!@Q9YS,PQ0>N!3JD_$>K%PJ"6ZZM1-CGQYO68*2]3<ABHF"7
M*:QXNX$N8]0+[3JA7FKKMN$.6,C<"F#A[?3?T<XOP6/"!F)-)#QU.:>9$!Q3
M!$ECL!0<Y"-*EQ 5(/O8JHJZP*R+'S*$EBOWF%^R_ FLQ\7?<?H]_MG,EE\7
MEXF)%%52*,7<CI3#.6PD#HA(X1S3(;)XP,14"XK'">B. <Y[Z?;HD)SWZL7?
M3:X(%S:ZB&@RX$-2"=L5 EZD#,&.6B)3\9XWO0@=)P(\!MSVT>1QPA7P%R\#
M2<+S %%.;G_!)?8@6)-SVM8DSQ,CX7"C@7:2.DX$>320[:S-HP3MN^9F?DE\
MHLQ2@X+/M_D)?M"*<$1C4MCBI)4O_8BY'Z6M(#O0!*'Z(=M9EV.W MW.XEW3
MT\><GB18]IY/$!VA0A+$/#'@_42']&KXI=!"4DV%3Z%5N+H'$:W@.-!8H4/!
M\:"*JMN$YL2C\!+BQR00UICE44H".1$"PB(XHB4A41VPY4C;//! \X8J,HE=
M=7/\2>';<:^+R2QWJ)I_CZF9/^WW.QDTP]ME^0.G:WM+9K3<*[:<&9:+X8@'
M&ZD-0\Y"/"^-$8(%9AEN-_IXC-SKG\WW>-L7X*[O],DLG*Y%^:P%]8>9GT>[
MB&_C[7\?/_YV,5=]2X:P8A8"1*>1M2PBQHE)*H^1U:7+"PJ1?FPYV"YP>VZ#
MQ]!V!6[!,\Y.O)_?V.EE3.!3FSRQ,P]YX@Q^<,1PE+3C7(JDK2M]9["9DG'K
MK48!15-<0]7T@-K,R\/I]6&QN(D@KJ0$;.7<X%)HB/6X0H8YEQ_2D! 45Z+X
MNZ9VE(U;EE4O&O?28+56\+/]L>JA?FF#HH0IA90R^<D@I4C;D%!D)E(2J-6D
M=#.RW12-6Y=5+PY[::R>?F1;3+V17BD*FTE1D<>.D8BTHPPE. -B;B DBE?A
M[W$8#U:;52_L.FGH.-HOO3G[]-?IEXL/?WP\/3_]].'LRZ>SB]/S3YGOY>1[
MW", ;_GEPK%U'WX*S9)Y&]UR4QL:QJ@0P:" -4'< 1:MH0XY(X."^"6RXF4Y
MFRG9OQF"@ST)W[K)N_/VR8L@@'HXZY&/.5OO"$&.KI)73GK) M?%^W!L(&/<
MX*& WE_V-MA/U!6X6D]96+VWY=1&S#U!FL=LD*U&AE@02S T$I;G&98NA7])
MQ?A8V4NQ.X'26<K5X>11XX9@?32.:^2]%KG!0D(ZJ("(PEI9&IR4I2O6M]%2
M$V:ZZW@G9'H*?.R;UQ/0G7[3S+['^3)?HIS'V:29?VJ6\:X_AQ!&6+"_2"B9
M0$0X(9-R/\X8>7"*1LOY:RY,NZ5J0D=?=3:#R;8&I)C'Q)L <6'$ 6'G%?CP
MN86J9 *(-S@2B84+IC4P3%<<#)8T&@8'O24WMMI/__&K6[0+B-\6M\-F[\!+
MF95:&R1Y"HCGKD#.$( Q\SP)K:W1K)7^MRXQ;M:F/!#*R')L1 "<&=YIUB(+
M4EGKD;,.\.V!+Y-L;B^NO788?I>VZSC[ZE+C)E@&,14%95N!5_JQF5W!UZZS
MJ"[@WZR\+NH9E20&1)U0&>T<:689HC$/J=:&<DH*>Z2;Z*CIG-D_@ME;TA6B
M9;V=K#.1)\E1=!'#>0E'I36KSC-4&).HQL63(YLI&==#W5_#KT"FA[@K ,TC
M<YD96=M)*R*FUE DO,T]R9Q!6BN!DO-)Q:A-*#X2;",A=4&FCX:?]W+<6]QC
M.S!/+>\C?BY 4HNS=/L[BZRBO,-"I(F"Z44X\)B[VSGDO&9(!6VQU9';Y_F3
M+=Y,MW5K<G[[GTY#"_QXL+3>>DP)00T$^D$($!W!$CD%DB3"FZ1@MSC2[G5U
MUY5'K$T;4O_]<-9#&34@[8&!6XYF=QWY5+26T,21(CF1Q!U#(*J(F'<&1^\I
M%J0UJK:M<A0(ZJ/9YQ@J(N8*\7+Q=[-FA!-&B?,@#\(YXBI8I$G4B'$K>)0Q
M6=DN=[-KE1&?<(^*EWYBKJ&+\?I.Q!AE\GVK#CI72TIP#B-!.C$(+$*B@I?H
M:]JMM_6!<CC]'9W^,JQ!\7>]>&.@CH2<K<IS*_(K5T=)0HY989REGII6;Y:/
MJWUU)V5M:5_=17)C=S%^TGXY.B>X4AYAIB%P(_D%EF 1F1"UH#(G*TMT+*^P
M?74GE6UM7]U%?F,K_DG[98(),8HH)"/-H^<E!=1;AW"*7E(<K?2MDK#'U[ZZ
MM^)[RZ^"+-G3<^[C?6\^8QQ.0H,WFZA%W'B/K,KC-T!")FBM RX]I70+*>.\
MZ3],05$_>5<'FS=V/O\QF5V=7#<WL^6E)S%G#"WRN44WMQ0C'0E&S,:HJ-0X
MM',7>F/G*3TUU8_T5/A.$.TA_>J0]&$&7XZ+Y1>[C*O!T>%SG/NLKZMXR:VS
M.,^:U,&NY@MHI*D TRJ]@$ **S&P3=I%74VWAD.@K)AFJL/<.^OC>N\P:@DA
M3,+IG^LMD@>.$C7(KQJR:Q-"\1OH;;34E.<? D\]I5X)>AY2.^LD4NXX<<?:
M^5>0\?H%'[GD,K-'P?5W>6]0$9 6D2.L8\226>(2'P!3[2FL*=%2#FD#:6CL
M].W=R[P/F:W_N9FMJL7^>[+\NBH&NJLDNS0^,!$L14ZE_*I9X[RE0(0Z_UP8
MP^.SCEU;$KGMUJO)1]\/0D,)>6S<_%<S#> C?EZ]?7O7S%>UAD#&R6(QN9IE
M;L_FYS8/XWD'-AGT=;M%+CUG$,TFC@SPE-OA&F2#9,@[;YPP6KKG;R:W *DG
M >.TT!H,68=00R5'Y.9[%L#(XBL(X<%Y/$OGR\;_Y_-\XN/%?')U%>>7(1GC
M+?>(<Y+?=GF)K'009GNC%<7@4(8ASLP]2!ZGS=8!@\Q!=5@S9!\<B2]9G^32
M$*=\GDQ+:<H=%+6#72D)$D8YH1W7VI3NAMF:N%8PU#\%#/?2RW$ ;K6?P#\E
M(F*B&7)!9:'AB)SA>?@=)I);'72[NYBR@+LEKA7@S$\&N!YZJ1EP]P8=O)'L
MG;RU/Q:705J- X1"4EB5)^AX<'-SBP>Z*NAD>;+GP8_@1P2VR^KBGP)Y>ROH
M*- 'O[>(_B:WD7C$)[E4VG,;'$91R=P6-BK@,2A$O!<>7 GJR1 -'GH1VPZ5
MQWS9,)#BJD/HEQCB];?EG;5_G.P.S&&K@ ^]FD<= W*4.Y2<96#WL>5FV(?S
M6TEKA[XCOH0HHY2Q<S%/>5JU-XG)WDR7;R#RSPV95O9=$:J=Q!))S$%T(0\B
MLI@CI;5@,G NS3.SUZHB?,MR[:!S%/<- \FX+M3<7<=]F%U\C:??<^(HK3F\
MQ-@&1E5"@NE<E4 -!-T,HB$LL=..T1?Q0BOD[%BR'7J.X@YA0%G7A:"3$%;3
M".WT@;]GS!FFM7?6()S?67!L+')6>R2I54(KKIELU^.CZ\KM\'0\%PJ#2KX"
MU^F]G<P6'YO%(B[.<E=U8-0O;^;@"6:6W/(R$!]DOMA5*7?9=1AVB(D)1:$]
M"T%)C$NW7GR-IG88.XJKA4'4,+:UVD#_G=.WNA2Y%)0*""\"LB'F/2(5,L #
MH@J"#(N]P[3=8Y775FJ'E*-([I>7; 76Y^UZV7>36>YO_Z99+!?OY[ -+K&.
M(<L"\5R1RWT$$5'!D5#,*FV9%+%\J+:%F'8H.K+<? G!CVUH5I)9+&[N6/B8
MFY7.W\6XN$S&PUX@%D6=A\%2GCLRY40;II'':(4)[6Z_MZ_1#A9'D4$O*<TJ
MS,ICT=Q>V4_\NC;DSG.[5"S/3:,:2:\BR@%C+H(D"'Q_JX+AP-JP5]5;"&M7
MCWK$^?$2"JD 9;D5Q\6Z%<<EX\:YW%^=*4[!;#J/P) F9$1D$<YD8IZ[-$4Z
MVMRMWPXS1Y6][BW>"J#Q*->^*CP#I*_>GW#%8@H*(Y4YX"D!PIV.*'G"N0V4
MV>+C.+>0T@XP1Y5P+B'TNK!SMP6>L"/!3$;+,2+&Y6=J-$ DZ%*NSHG1,YZP
M*7ULO4)2.RP=109Z""54@*G5E 98=6+=9#K)4VK>W,RS;"^IYHQ%H9%73.7-
M(9&SUJ 4)?/6*2-=+(RFK<2TP]%1Y*++"KX"!#UK$O;.3N9_V>E-?&COO[B4
MD@@2P++")H!#6EB+M"01N<@$A \T<3]PA[9-9+5#U5%DI(=21A5Q_.M7Q8^[
MO*S^Z)+$X)2+L'5XLKEW*LW\280Q-1H'0CAK-UVS+P7MP'44J>C#::)JN#TN
MU,+$:9^L0C3E1^(0A" G@3-AHQ'.,*&2WA]>74OCZ/'DJP>1=-7PV5Q1=1F9
MH1Y[X$]JC#AV B3H)&).24^=Q>IY)5P?)&U>O!VHCB)]?1#Y5^!M/;D.//UG
M"6S<3!9?K]<WS0[<1]@2D8>(&,OMS21XCL80CZ(.PDHC4B2E\TVO$M4.:$>1
M$!]&$?7,6=S>(> TI>CS]GE4HJ>Q2%Q+#:=Y[I)HP4[;E"?M2L<I%E%&-FP=
M[RL$MGMQ?\09\Y(*JL"\G5PW$+W\GY6&SM+M'23LK-4MY"63G.A<;"QM(+GQ
M-/"BJ42:6,PQL(E3:;#MHJ<=MHXJLUY,_,6@=. AGN?^:PPWT]BD-ZOWX(ME
ML_P:[X?Z%!_MV7*]@PS\[,/[L&- E0-\!4J02OER.6&"K%,)84.)<O!#8$/<
MPQYF#&BD(5C8JDCHF/OK1(:T)@X%QK"4CB@[0!W+<8P![:+W-F- NXBZ@D/P
M665I[ENJ="!8Y]E"5@8XQB5$P5I*))VWC#MC@AL6+'6. >VDV-?'@':1<G4X
M>323BEB:@K$$R83SH!C828Y%B53@AD67.+9A4+14/ :TDX[;C@'M(O"QDU0O
M1A1*8%JP/!/5^Y 3M+F?0TQ(&FWR; 8-/VF5@>HUW/'P0SX[*6OG<,<NDJO.
M7CQ$#$ESCH-F2.)D$,<"(@:!(X+@D$C#@F5BV,/EGI2:&BZ6/F'ZR;L"V&RK
MGI'2 [F8(D*,A$ S6;"D1.=$JL&":Q="Z7!\GY*E@P?BG=3<LF*IB\Q[0^?;
MJ@KS?&GGRR( NLM1G?[S+<X6JXOITW_\]";<-KB]SSA<IA"%QT0@+!QLMA@Y
M<B2_WTP!ZV2DD\_'S.Z-J+:TU629RD!L$*W4D\?>MH.4QKG&(2)F@D=<$H9L
M+B4VQ.4TF1$QE3[L]K%:!Z^-&\)J=9'YGE;K=!9JR!Y^BL]:> ^8.=RZUH&S
MANUX'C9C2+UR%EN*J ',<N$2LKFB-WIEL7.$$3Q$'[?#9 QUU%($3B&^H,!<
M<@H9+X&Y2+6,7C"BAWV64F_&L(O>VV0,NXBZ A=]0YXC8(@_?:#($K"T/'<S
M ^,K(7 A3H: )8W#-M:O,V/82;&O9PR[2+DZG#S*B4B>A/:2(. @(,X2B,4*
MB@3/ WT]J'K@=H059PP[Z;AMQK"+P"O(&#+\R+<[C[-),W^<",.8,"^I1;!_
M..+$Y4Y-X#X29:)V*8+CV*Z([=6E:D)'7W4V@\FV.A/S$%=(*4DTV")O,08V
MHD9&AH@D4Q!=2N\I+_V<Y&B2C.4.I7[RK@XVS\8? <PUX1+L;EK-XC7 2[ !
M"?B#H*)DU(I!L7,,PZ<Z*;S+\*DNTN^-)+!_KAD$2_^:V=ML5@R?Y_%Z<G,-
MHK+61T,15C;?V_"$=&2Y*$Y#M$!=C'C8"X^7--5DE(; U)Y:J,!"/>+@<3^,
M=?KT4D6=C 'RH\ZOJHA1R$G&$(M21B8%MZK5*.4.F-I-49WIQ7T055 #]>2I
MGS0S,)3(Q%5N86!%'DUND8U!Y"9-+#AG8OEWDIU[11S\E>T^D.DMW?X&IUG:
M:0TIZ!?W.X,EH+>L=.#T<QM^ATT^.P^G%B$DCTB$2(VGA)R GVE-HV.41OB_
MHTT^ QX299@@2AAL'B7R#&0%FR<%$YW'\+_2Y]NQ))^[Z+U-\KF+J"MPC#:D
MS'2RAB@O$#.Y51QG-+\ZR:.M"#-<)&'8L 6(=2:?.RGV]>1S%RE7AY-'R3/G
M%0TL,9!#!#Z(3LAX(Q'65&@AO0O/!QO^.LGG3CINFWSN(O#ZD\_>8P;L:- R
M;"T>@T8.YV(#YZ40S#+L_6LNSE$GGSNILUORN8ML*T *U3NYL2I?W-B$_*J-
MJ4L>&2T9"@E[JEU2(;9K_?GJ4C6E<PHAI:!LJSN,'H)-;1/$E &(C\[D8),#
M&V!^,6,$"^$)B\..R*KXFJ*<^])/WA7 IG71I$K11J%4'G@..RTX 7P1C[1R
M)E'+I0ZE8\&BI:P'O[[H!(2^I:Q=M%(!VG8^QZ;>6&I50!@+B;AE$MD0'&*1
MD. M9UJ5SA7N_1K^X!<8^Z"JF/0K0-*&'7*9,!<V*(9$DAAQ0P2RA%-DG"%$
M<2U4\8S.!C+JO*8H;(TZR;K^U/.7T_.++_]Z<P'_YM/[APSLYWF\L/\\F43Q
MYJN=7^W5-Z'W6H73SV5X+I2 ?K+>R2Q\B=-\*W62N[^L>HG>YR8#4<XQ@&\(
MQB$N'<T#E#FRTH20-#C\L?0IT9JX?8W:G1;.TI8E5Z;ZUG<-#!LN'(9XQ/#<
MC$F#'"+L0@%RH9[E_B6%Y="!O'%=LF'0]-PL#J6M"D[7I]L?V%@QM8CS[W&5
MQ'-:69R,@=@8C@#.F4(.2X$25O!?R1T$5D-NPI<DC0NXP:#0#*>7"F!V 7_O
MF<C6>1T<$[.60C3#O$9<^X2<Y@(%;4% P7OQ?*;-W@#;2DQ%MFQ?E3=#R'_L
M-.DI>%W-CQC/(TATI9?5;ENG\0SX743E22L<@X4W*B+P>QD*,6GO-?4NM!L/
MN7.9<3%22(_-($*MP,Z<+;_&^1/QK/E@20C&8,L(O!K(S"P$O8XC;(AE$. P
MITO7X6ZC9=QT0UD$%95[!?CY,(.H*9Z#.N(JJL[_("LFV]](-=.<YR%R$GY@
MDB)MC$81V*-:8@L6N7C282LYXZ+H4&Y0*7W4"ZWUYK,)HA,>&2*)6\1M3N]B
M$5!^&2II[H_A2Y>=["1HW&.NF-K;P:F'#BH U'F<PA]=O8^S.+=3V'HGX7HR
MF^1X-W?27>?P[@YRE3@QR7NDF 5#[#Q&3F*&(MAUD)G@//C" .M$8)6 ZP.,
MY[F#P;14 01S> ($? 6VWL;O<=I\R]);\[1FB3MBF#0!81; @\31Y &(X$$J
M*Q/&00"GY3,(KY$U[O$Y'-Q*:Z0"D&57XBR=V^E#P4;,(Y]=1$SDP1IY*K0Q
MB2#-I?9,!,^*/ZI[0<2XES_# 6@_:5< ER<.Z>>IO?4:E"+@((#7D$63RX?
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MA.$$!LG$@#35%F4;EE3@X#=6TU:P,W='^F2[X':J#T2_R/:R_ZPD0Z5S)/"
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M-2YH=&U02P$"% ,4    " "%@&9;<UX(0RL(  !5)@  &0
M@ %D"   <&%C8BTQ,'%X97AX,S$R>'$S>#(U+FAT;5!+ 0(4 Q0    ( (6
M9ELF(.RPQ 0  #,2   9              "  <80  !P86-B+3$P<7AE>'@S
M,C%X<3-X,C4N:'1M4$L! A0#%     @ A8!F6PF!+("R!   \!(  !D
M         ( !P14  '!A8V(M,3!Q>&5X>#,R,GAQ,W@R-2YH=&U02P$"% ,4
M    " "%@&9;57F2=EU, @!V^1D $0              @ &J&@  <&%C8BTR
M,#(U,#DS,"YH=&U02P$"% ,4    " "%@&9;\BVZ>^41  #YN   $0
M        @ $V9P( <&%C8BTR,#(U,#DS,"YX<V102P$"% ,4    " "%@&9;
M?L==,L >  " * $ %0              @ %*>0( <&%C8BTR,#(U,#DS,%]C
M86PN>&UL4$L! A0#%     @ A8!F6^(Z%-*P8@  %,<$ !4
M ( !/9@" '!A8V(M,C R-3 Y,S!?9&5F+GAM;%!+ 0(4 Q0    ( (6 9EOU
M9*.V?1L  $,<   4              "  2#[ @!P86-B+3(P,C4P.3,P7V<Q
M+FIP9U!+ 0(4 Q0    ( (6 9EL/$G<6TAD  * :   4              "
M <\6 P!P86-B+3(P,C4P.3,P7V<R+FIP9U!+ 0(4 Q0    ( (6 9EN$J;U
M^48  '%5   4              "  =,P P!P86-B+3(P,C4P.3,P7V<S+FIP
M9U!+ 0(4 Q0    ( (6 9EM_.WO7VCL  )))   4              "  ?YW
M P!P86-B+3(P,C4P.3,P7V<T+FIP9U!+ 0(4 Q0    ( (6 9EL2=2LLPST
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E,#(U,#DS,%]P<F4N>&UL4$L%!@     2 !( M@0  *QE!@    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>pacb-20250930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:pacb="http://www.pacificbiosciences.com/20250930"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="pacb-20250930.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ServiceAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ServiceAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ServiceAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ServiceAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">pacb:AchievementOfMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-02</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-02</startDate>
            <endDate>2023-08-02</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-02</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-02</startDate>
            <endDate>2023-08-02</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pacb:AptonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2025RestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2025RestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">pacb:DevelopedTechnologyAndIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-07</startDate>
            <endDate>2025-03-07</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">pacb:DevelopedTechnologyAndIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2025-10-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2026-10-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-21</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-21</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-21</startDate>
            <endDate>2024-11-21</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-21</startDate>
            <endDate>2024-11-21</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <startDate>2024-11-21</startDate>
            <endDate>2024-11-21</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pacb:DebtInstrumentConvertibleTermsOfConversionAxis">pacb:DebtConversionTermsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-21</startDate>
            <endDate>2024-11-21</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pacb:DebtInstrumentConvertibleTermsOfConversionAxis">pacb:DebtConversionTermsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-21</startDate>
            <endDate>2024-11-21</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pacb:DebtInstrumentConvertibleTermsOfConversionAxis">pacb:DebtConversionTermsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-21</startDate>
            <endDate>2024-11-21</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pacb:DebtInstrumentConvertibleTermsOfConversionAxis">pacb:DebtConversionTermsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-21</startDate>
            <endDate>2024-11-21</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-21</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ExchangeTransactionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-21</startDate>
            <endDate>2024-11-21</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-30</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pacb:DebtInstrumentConvertibleTermsOfConversionAxis">pacb:DebtConversionTermsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-30</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-30</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-30</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pacb:DebtInstrumentConvertibleTermsOfConversionAxis">pacb:DebtConversionTermsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-30</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ExchangeTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:ExchangeTransactionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-30</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2030ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-16</instant>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-07</instant>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2029NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-07</instant>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-16</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pacb:A2028ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pacb:EmployeeSeparationCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2025RestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2025RestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2025RestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pacb:EmployeeSeparationCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2025RestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pacb:EmployeeSeparationCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2025RestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pacb:InProcessResearchAndDevelopmentIndefiniteLivedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2025RestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pacb:EmployeeSeparationCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2025RestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2025RestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pacb:EmployeeSeparationCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2025RestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2025RestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2025RestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pacb:EmployeeSeparationCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2024RestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2024RestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2024RestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2024RestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2024RestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2024RestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2024RestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:SanDiegoOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:SanDiegoOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2024RestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2024RestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2024RestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2024RestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:A2024RestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pacb:SanDiegoOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pacb:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-04</instant>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pacb:A2020PlanInducementPlanAndTheOmniomePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsPSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:TimeBasedRestrictedStockUnitsRsusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:StockBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pacb:StockBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pacb:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pacb:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pacb:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pacb:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pacb:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pacb:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AmericasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AmericasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AmericasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AmericasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:InstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:InstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:InstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:InstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ConsumableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ConsumableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ConsumableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001299130</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pacb:ConsumableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="d">
        <measure>utr:D</measure>
    </unit>
    <unit id="customer">
        <measure>pacb:customer</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-25">0001299130</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-26">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-27">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-28">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-29">false</dei:AmendmentFlag>
    <pacb:StockIssuedDuringPeriodAverageTradingPeriodAcquisition contextRef="c-91" id="f-465">P20D</pacb:StockIssuedDuringPeriodAverageTradingPeriodAcquisition>
    <us-gaap:ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-107" id="f-559">http://fasb.org/us-gaap/2025#GoodwillAndIntangibleAssetImpairment</us-gaap:ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1 contextRef="c-128" decimals="8" id="f-739" unitRef="number">0.20451570</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1 contextRef="c-143" decimals="7" id="f-740" unitRef="number">0.0465116</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-171" id="f-747">http://fasb.org/us-gaap/2025#CostOfRevenue</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-182" id="f-777">http://fasb.org/us-gaap/2025#CostOfRevenue</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2025-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-34899</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">Pacific Biosciences of California, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">16-1590339</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">1305 O&#x2019;Brien Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-10">Menlo Park</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-11">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-12">94025</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-13">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-14">521-8000</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-15">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-16">PACB</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-17">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-18">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-19">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-20">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-21">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-22">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-23">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-24" unitRef="shares">301907431</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-30" unitRef="usd">56467000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-31" unitRef="usd">55370000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments contextRef="c-3" decimals="-3" id="f-32" unitRef="usd">242187000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="c-4" decimals="-3" id="f-33" unitRef="usd">334561000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-3" decimals="-3" id="f-34" unitRef="usd">30616000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-4" decimals="-3" id="f-35" unitRef="usd">27524000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c-3" decimals="-3" id="f-36" unitRef="usd">53153000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-4" decimals="-3" id="f-37" unitRef="usd">58755000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-38" unitRef="usd">11513000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-39" unitRef="usd">18781000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c-3" decimals="-3" id="f-40" unitRef="usd">300000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c-4" decimals="-3" id="f-41" unitRef="usd">690000</us-gaap:RestrictedCashCurrent>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="-3" id="f-42" unitRef="usd">394236000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-43" unitRef="usd">495681000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-44" unitRef="usd">22127000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-45" unitRef="usd">30505000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-46" unitRef="usd">42583000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-47" unitRef="usd">16091000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-3" decimals="-3" id="f-48" unitRef="usd">1532000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-4" decimals="-3" id="f-49" unitRef="usd">1532000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-3" decimals="-3" id="f-50" unitRef="usd">16143000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-4" decimals="-3" id="f-51" unitRef="usd">389572000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill contextRef="c-3" decimals="-3" id="f-52" unitRef="usd">317761000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-4" decimals="-3" id="f-53" unitRef="usd">317761000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-3" decimals="-3" id="f-54" unitRef="usd">8776000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-55" unitRef="usd">9305000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-3" decimals="-3" id="f-56" unitRef="usd">803158000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-57" unitRef="usd">1260447000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-3" decimals="-3" id="f-58" unitRef="usd">16362000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-59" unitRef="usd">16590000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-60" unitRef="usd">29172000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-61" unitRef="usd">22595000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-3" decimals="-3" id="f-62" unitRef="usd">16049000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-4" decimals="-3" id="f-63" unitRef="usd">13864000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-64" unitRef="usd">621000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-65" unitRef="usd">10026000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-66" unitRef="usd">1005000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-67" unitRef="usd">3224000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-68" unitRef="usd">63209000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-69" unitRef="usd">66299000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-70" unitRef="usd">4400000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-71" unitRef="usd">5900000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-72" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-73" unitRef="usd">18700000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-74" unitRef="usd">54300000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-75" unitRef="usd">14914000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ConvertibleLongTermNotesPayable contextRef="c-3" decimals="-3" id="f-76" unitRef="usd">645159000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:ConvertibleLongTermNotesPayable contextRef="c-4" decimals="-3" id="f-77" unitRef="usd">647494000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-3" decimals="-3" id="f-78" unitRef="usd">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-79" unitRef="usd">546000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-3" decimals="-3" id="f-80" unitRef="usd">767068000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-81" unitRef="usd">753853000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-3" id="f-82" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-83" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-84"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-85"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-86" unitRef="shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-87" unitRef="shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c-4" decimals="INF" id="f-88" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-89" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-3" decimals="INF" id="f-90" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-91" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="c-3" decimals="-3" id="f-92" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-4" decimals="-3" id="f-93" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-94"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-95"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-96" unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-97" unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="-3" id="f-98" unitRef="shares">301853000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="-3" id="f-99" unitRef="shares">301853000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="-3" id="f-100" unitRef="shares">294418000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="-3" id="f-101" unitRef="shares">294418000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue contextRef="c-3" decimals="-3" id="f-102" unitRef="usd">302000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-103" unitRef="usd">294000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-3" decimals="-3" id="f-104" unitRef="usd">2690304000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-4" decimals="-3" id="f-105" unitRef="usd">2654804000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-3" decimals="-3" id="f-106" unitRef="usd">415000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-107" unitRef="usd">422000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-3" id="f-108" unitRef="usd">-2654931000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-109" unitRef="usd">-2148926000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-110" unitRef="usd">36090000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-111" unitRef="usd">506594000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="-3" id="f-112" unitRef="usd">803158000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-113" unitRef="usd">1260447000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-5" decimals="-3" id="f-114" unitRef="usd">32597000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-3" id="f-115" unitRef="usd">35296000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="-3" id="f-116" unitRef="usd">96793000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-8" decimals="-3" id="f-117" unitRef="usd">102051000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-9" decimals="-3" id="f-118" unitRef="usd">5844000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-10" decimals="-3" id="f-119" unitRef="usd">4671000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-11" decimals="-3" id="f-120" unitRef="usd">18567000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-12" decimals="-3" id="f-121" unitRef="usd">12739000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-13" decimals="-3" id="f-122" unitRef="usd">38441000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-14" decimals="-3" id="f-123" unitRef="usd">39967000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-124" unitRef="usd">115360000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-15" decimals="-3" id="f-125" unitRef="usd">114790000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-5" decimals="-3" id="f-126" unitRef="usd">19204000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-6" decimals="-3" id="f-127" unitRef="usd">23278000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-7" decimals="-3" id="f-128" unitRef="usd">65559000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-8" decimals="-3" id="f-129" unitRef="usd">68808000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-9" decimals="-3" id="f-130" unitRef="usd">3078000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-10" decimals="-3" id="f-131" unitRef="usd">3484000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-11" decimals="-3" id="f-132" unitRef="usd">11709000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-12" decimals="-3" id="f-133" unitRef="usd">10588000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization contextRef="c-13" decimals="-3" id="f-134" unitRef="usd">183000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization contextRef="c-14" decimals="-3" id="f-135" unitRef="usd">3201000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization contextRef="c-1" decimals="-3" id="f-136" unitRef="usd">4711000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization contextRef="c-15" decimals="-3" id="f-137" unitRef="usd">7172000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <pacb:LossOnPurchaseCommitment contextRef="c-13" decimals="-3" id="f-138" unitRef="usd">75000</pacb:LossOnPurchaseCommitment>
    <pacb:LossOnPurchaseCommitment contextRef="c-14" decimals="-3" id="f-139" unitRef="usd">0</pacb:LossOnPurchaseCommitment>
    <pacb:LossOnPurchaseCommitment contextRef="c-1" decimals="-3" id="f-140" unitRef="usd">4167000</pacb:LossOnPurchaseCommitment>
    <pacb:LossOnPurchaseCommitment contextRef="c-15" decimals="-3" id="f-141" unitRef="usd">998000</pacb:LossOnPurchaseCommitment>
    <us-gaap:CostOfRevenue contextRef="c-13" decimals="-3" id="f-142" unitRef="usd">22540000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c-14" decimals="-3" id="f-143" unitRef="usd">29963000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c-1" decimals="-3" id="f-144" unitRef="usd">86146000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c-15" decimals="-3" id="f-145" unitRef="usd">87566000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit contextRef="c-13" decimals="-3" id="f-146" unitRef="usd">15901000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-14" decimals="-3" id="f-147" unitRef="usd">10004000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-1" decimals="-3" id="f-148" unitRef="usd">29214000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-15" decimals="-3" id="f-149" unitRef="usd">27224000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-13" decimals="-3" id="f-150" unitRef="usd">22846000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-14" decimals="-3" id="f-151" unitRef="usd">25516000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-152" unitRef="usd">74428000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-15" decimals="-3" id="f-153" unitRef="usd">107456000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-13" decimals="-3" id="f-154" unitRef="usd">31099000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-14" decimals="-3" id="f-155" unitRef="usd">43746000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-156" unitRef="usd">107442000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-15" decimals="-3" id="f-157" unitRef="usd">133376000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="c-13" decimals="-3" id="f-158" unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="c-14" decimals="-3" id="f-159" unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="c-1" decimals="-3" id="f-160" unitRef="usd">15000000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="c-15" decimals="-3" id="f-161" unitRef="usd">93200000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <pacb:AmortizationOfAcquiredIntangibleAssets contextRef="c-13" decimals="-3" id="f-162" unitRef="usd">833000</pacb:AmortizationOfAcquiredIntangibleAssets>
    <pacb:AmortizationOfAcquiredIntangibleAssets contextRef="c-14" decimals="-3" id="f-163" unitRef="usd">3649000</pacb:AmortizationOfAcquiredIntangibleAssets>
    <pacb:AmortizationOfAcquiredIntangibleAssets contextRef="c-1" decimals="-3" id="f-164" unitRef="usd">363708000</pacb:AmortizationOfAcquiredIntangibleAssets>
    <pacb:AmortizationOfAcquiredIntangibleAssets contextRef="c-15" decimals="-3" id="f-165" unitRef="usd">13377000</pacb:AmortizationOfAcquiredIntangibleAssets>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-13" decimals="-3" id="f-166" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-14" decimals="-3" id="f-167" unitRef="usd">1170000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-1" decimals="-3" id="f-168" unitRef="usd">-18700000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-15" decimals="-3" id="f-169" unitRef="usd">1100000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:OperatingExpenses contextRef="c-13" decimals="-3" id="f-170" unitRef="usd">54778000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-14" decimals="-3" id="f-171" unitRef="usd">74081000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-172" unitRef="usd">541878000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-15" decimals="-3" id="f-173" unitRef="usd">348509000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-13" decimals="-3" id="f-174" unitRef="usd">-38877000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-14" decimals="-3" id="f-175" unitRef="usd">-64077000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-176" unitRef="usd">-512664000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-15" decimals="-3" id="f-177" unitRef="usd">-321285000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpenseNonoperating contextRef="c-13" decimals="-3" id="f-178" unitRef="usd">1739000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-14" decimals="-3" id="f-179" unitRef="usd">3538000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-1" decimals="-3" id="f-180" unitRef="usd">5214000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-15" decimals="-3" id="f-181" unitRef="usd">10655000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-13" decimals="-3" id="f-182" unitRef="usd">2999000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-14" decimals="-3" id="f-183" unitRef="usd">6890000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-184" unitRef="usd">11989000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-15" decimals="-3" id="f-185" unitRef="usd">19718000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-13" decimals="-3" id="f-186" unitRef="usd">-37617000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-14" decimals="-3" id="f-187" unitRef="usd">-60725000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-188" unitRef="usd">-505889000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-15" decimals="-3" id="f-189" unitRef="usd">-312222000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-190" unitRef="usd">383000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-14" decimals="-3" id="f-191" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-192" unitRef="usd">116000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-15" decimals="-3" id="f-193" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-194" unitRef="usd">-38000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-14" decimals="-3" id="f-195" unitRef="usd">-60725000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-196" unitRef="usd">-506005000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-3" id="f-197" unitRef="usd">-312222000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-13" decimals="-3" id="f-198" unitRef="usd">148000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-14" decimals="-3" id="f-199" unitRef="usd">2076000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-200" unitRef="usd">-7000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-15" decimals="-3" id="f-201" unitRef="usd">1334000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-13" decimals="-3" id="f-202" unitRef="usd">-37852000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-14" decimals="-3" id="f-203" unitRef="usd">-58649000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-204" unitRef="usd">-506012000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-15" decimals="-3" id="f-205" unitRef="usd">-310888000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-13"
      decimals="2"
      id="f-206"
      unitRef="usdPerShare">-0.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-14"
      decimals="2"
      id="f-207"
      unitRef="usdPerShare">-0.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-208"
      unitRef="usdPerShare">-1.69</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-15"
      decimals="2"
      id="f-209"
      unitRef="usdPerShare">-1.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-13"
      decimals="2"
      id="f-210"
      unitRef="usdPerShare">-0.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-14"
      decimals="2"
      id="f-211"
      unitRef="usdPerShare">-0.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-212"
      unitRef="usdPerShare">-1.69</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-15"
      decimals="2"
      id="f-213"
      unitRef="usdPerShare">-1.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-13" decimals="-3" id="f-214" unitRef="shares">300844000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-14" decimals="-3" id="f-215" unitRef="shares">272915000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-216" unitRef="shares">299303000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-15" decimals="-3" id="f-217" unitRef="shares">271631000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-13" decimals="-3" id="f-218" unitRef="shares">300844000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-14" decimals="-3" id="f-219" unitRef="shares">272915000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-220" unitRef="shares">299303000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-15" decimals="-3" id="f-221" unitRef="shares">271631000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-16" decimals="-3" id="f-222" unitRef="shares">300350000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-16" decimals="-3" id="f-223" unitRef="usd">300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-3" id="f-224" unitRef="usd">2677853000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-225" unitRef="usd">267000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-226" unitRef="usd">-2616931000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="-3" id="f-227" unitRef="usd">61489000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-21" decimals="-3" id="f-228" unitRef="usd">-38000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-229" unitRef="usd">-38000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-22" decimals="-3" id="f-230" unitRef="usd">148000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-13" decimals="-3" id="f-231" unitRef="usd">148000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-23" decimals="-3" id="f-232" unitRef="shares">1503000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-23" decimals="-3" id="f-233" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-24" decimals="-3" id="f-234" unitRef="usd">1467000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-13" decimals="-3" id="f-235" unitRef="usd">1469000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-24" decimals="-3" id="f-236" unitRef="usd">10984000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-13" decimals="-3" id="f-237" unitRef="usd">10984000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-25" decimals="-3" id="f-238" unitRef="shares">301853000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-3" id="f-239" unitRef="usd">302000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-3" id="f-240" unitRef="usd">2690304000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-3" id="f-241" unitRef="usd">415000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="-3" id="f-242" unitRef="usd">-2654931000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-243" unitRef="usd">36090000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-29" decimals="-3" id="f-244" unitRef="shares">294418000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-29" decimals="-3" id="f-245" unitRef="usd">294000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-30" decimals="-3" id="f-246" unitRef="usd">2654804000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-3" id="f-247" unitRef="usd">422000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="-3" id="f-248" unitRef="usd">-2148926000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-249" unitRef="usd">506594000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-33" decimals="-3" id="f-250" unitRef="usd">-506005000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-251" unitRef="usd">-506005000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-34" decimals="-3" id="f-252" unitRef="usd">-7000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-253" unitRef="usd">-7000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-35" decimals="-3" id="f-254" unitRef="shares">7435000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-35" decimals="-3" id="f-255" unitRef="usd">8000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-36" decimals="-3" id="f-256" unitRef="usd">3420000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-1" decimals="-3" id="f-257" unitRef="usd">3428000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-36" decimals="-3" id="f-258" unitRef="usd">32080000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-259" unitRef="usd">32080000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-25" decimals="-3" id="f-260" unitRef="shares">301853000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-3" id="f-261" unitRef="usd">302000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-3" id="f-262" unitRef="usd">2690304000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-3" id="f-263" unitRef="usd">415000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="-3" id="f-264" unitRef="usd">-2654931000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-265" unitRef="usd">36090000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-37" decimals="-3" id="f-266" unitRef="shares">272491000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-37" decimals="-3" id="f-267" unitRef="usd">272000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-38" decimals="-3" id="f-268" unitRef="usd">2583523000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-39" decimals="-3" id="f-269" unitRef="usd">-523000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-40" decimals="-3" id="f-270" unitRef="usd">-2090572000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-41" decimals="-3" id="f-271" unitRef="usd">492700000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-42" decimals="-3" id="f-272" unitRef="usd">-60725000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-14" decimals="-3" id="f-273" unitRef="usd">-60725000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-43" decimals="-3" id="f-274" unitRef="usd">2076000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-14" decimals="-3" id="f-275" unitRef="usd">2076000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-44" decimals="-3" id="f-276" unitRef="shares">1321000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-44" decimals="-3" id="f-277" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-45" decimals="-3" id="f-278" unitRef="usd">810000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-14" decimals="-3" id="f-279" unitRef="usd">812000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-45" decimals="-3" id="f-280" unitRef="usd">18259000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-14" decimals="-3" id="f-281" unitRef="usd">18259000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-46" decimals="-3" id="f-282" unitRef="shares">273812000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-46" decimals="-3" id="f-283" unitRef="usd">274000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-47" decimals="-3" id="f-284" unitRef="usd">2602592000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-48" decimals="-3" id="f-285" unitRef="usd">1553000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-49" decimals="-3" id="f-286" unitRef="usd">-2151297000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-50" decimals="-3" id="f-287" unitRef="usd">453122000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-51" decimals="-3" id="f-288" unitRef="shares">267744000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-51" decimals="-3" id="f-289" unitRef="usd">268000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-52" decimals="-3" id="f-290" unitRef="usd">2539892000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-53" decimals="-3" id="f-291" unitRef="usd">219000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-54" decimals="-3" id="f-292" unitRef="usd">-1839075000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-55" decimals="-3" id="f-293" unitRef="usd">701304000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-56" decimals="-3" id="f-294" unitRef="usd">-312222000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-3" id="f-295" unitRef="usd">-312222000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-57" decimals="-3" id="f-296" unitRef="usd">1334000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-15" decimals="-3" id="f-297" unitRef="usd">1334000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-58" decimals="-3" id="f-298" unitRef="shares">6068000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-58" decimals="-3" id="f-299" unitRef="usd">6000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-59" decimals="-3" id="f-300" unitRef="usd">7697000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-15" decimals="-3" id="f-301" unitRef="usd">7703000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-59" decimals="-3" id="f-302" unitRef="usd">55003000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-15" decimals="-3" id="f-303" unitRef="usd">55003000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-46" decimals="-3" id="f-304" unitRef="shares">273812000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-46" decimals="-3" id="f-305" unitRef="usd">274000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-47" decimals="-3" id="f-306" unitRef="usd">2602592000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-48" decimals="-3" id="f-307" unitRef="usd">1553000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-49" decimals="-3" id="f-308" unitRef="usd">-2151297000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-50" decimals="-3" id="f-309" unitRef="usd">453122000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-310" unitRef="usd">-506005000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-3" id="f-311" unitRef="usd">-312222000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation contextRef="c-1" decimals="-3" id="f-312" unitRef="usd">10251000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-15" decimals="-3" id="f-313" unitRef="usd">10932000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-3" id="f-314" unitRef="usd">368429000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-15" decimals="-3" id="f-315" unitRef="usd">20558000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-1" decimals="-3" id="f-316" unitRef="usd">3083000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-15" decimals="-3" id="f-317" unitRef="usd">10912000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-318" unitRef="usd">32080000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-15" decimals="-3" id="f-319" unitRef="usd">55003000</us-gaap:ShareBasedCompensation>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="c-1" decimals="-3" id="f-320" unitRef="usd">15000000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="c-15" decimals="-3" id="f-321" unitRef="usd">93200000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium contextRef="c-1" decimals="-3" id="f-322" unitRef="usd">3905000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium contextRef="c-15" decimals="-3" id="f-323" unitRef="usd">10663000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-1" decimals="-3" id="f-324" unitRef="usd">-18700000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-15" decimals="-3" id="f-325" unitRef="usd">1100000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:InventoryWriteDown contextRef="c-1" decimals="-3" id="f-326" unitRef="usd">9768000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown contextRef="c-15" decimals="-3" id="f-327" unitRef="usd">3715000</us-gaap:InventoryWriteDown>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c-1" decimals="-3" id="f-328" unitRef="usd">-546000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c-15" decimals="-3" id="f-329" unitRef="usd">0</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-1" decimals="-3" id="f-330" unitRef="usd">-1456000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-15" decimals="-3" id="f-331" unitRef="usd">-1002000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-332" unitRef="usd">3092000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-15" decimals="-3" id="f-333" unitRef="usd">-7232000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-3" id="f-334" unitRef="usd">4926000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-15" decimals="-3" id="f-335" unitRef="usd">15394000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-336" unitRef="usd">-7797000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-15" decimals="-3" id="f-337" unitRef="usd">-3534000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-338" unitRef="usd">761000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-15" decimals="-3" id="f-339" unitRef="usd">-2222000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-1" decimals="-3" id="f-340" unitRef="usd">-1396000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-15" decimals="-3" id="f-341" unitRef="usd">-26665000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-1" decimals="-3" id="f-342" unitRef="usd">685000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-15" decimals="-3" id="f-343" unitRef="usd">875000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-344" unitRef="usd">-661000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-15" decimals="-3" id="f-345" unitRef="usd">-9252000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-1" decimals="-3" id="f-346" unitRef="usd">-2219000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-15" decimals="-3" id="f-347" unitRef="usd">-7053000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-348" unitRef="usd">-92140000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-15" decimals="-3" id="f-349" unitRef="usd">-175408000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-350" unitRef="usd">1853000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-15" decimals="-3" id="f-351" unitRef="usd">4571000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-1" decimals="-3" id="f-352" unitRef="usd">5000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-15" decimals="-3" id="f-353" unitRef="usd">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireInvestments contextRef="c-1" decimals="-3" id="f-354" unitRef="usd">183817000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments contextRef="c-15" decimals="-3" id="f-355" unitRef="usd">418164000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt contextRef="c-1" decimals="-3" id="f-356" unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt contextRef="c-15" decimals="-3" id="f-357" unitRef="usd">8061000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="c-1" decimals="-3" id="f-358" unitRef="usd">280089000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="c-15" decimals="-3" id="f-359" unitRef="usd">480440000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-360" unitRef="usd">89419000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-15" decimals="-3" id="f-361" unitRef="usd">65766000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-1" decimals="-3" id="f-362" unitRef="usd">3428000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-15" decimals="-3" id="f-363" unitRef="usd">7703000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:RepaymentsOfNotesPayable contextRef="c-1" decimals="-3" id="f-364" unitRef="usd">0</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="c-15" decimals="-3" id="f-365" unitRef="usd">490000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-366" unitRef="usd">3428000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-15" decimals="-3" id="f-367" unitRef="usd">7213000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-368" unitRef="usd">707000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-15" decimals="-3" id="f-369" unitRef="usd">-102429000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-370" unitRef="usd">57592000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-55" decimals="-3" id="f-371" unitRef="usd">182633000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-372" unitRef="usd">58299000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-50" decimals="-3" id="f-373" unitRef="usd">80204000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-374" unitRef="usd">56467000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-50" decimals="-3" id="f-375" unitRef="usd">77982000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="c-3" decimals="-3" id="f-376" unitRef="usd">1832000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="c-50" decimals="-3" id="f-377" unitRef="usd">2222000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-378" unitRef="usd">58299000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-50" decimals="-3" id="f-379" unitRef="usd">80204000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-380" unitRef="usd">29575000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-15" decimals="-3" id="f-381" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c-1" id="f-382">&lt;div style="margin-top:15pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"&gt;&lt;span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;NOTE 1.  ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Business Overview&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a life science technology company that designs, develops, and manufactures advanced sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our products and technology, which include our HiFi long-read sequencing technology, address solutions across a broad set of applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our focus is on creating some of the world's most advanced sequencing systems to provide our customers with the most complete and accurate view of genomes, transcriptomes, and epigenomes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations ("CROs"), pharmaceutical companies, and agricultural companies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;References in this report to &#x201c;PacBio,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; the &#x201c;Company,&#x201d; and &#x201c;our&#x201d; refer to Pacific Biosciences of California, Inc. and its consolidated subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Basis of Presentation and Consolidation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States, or U.S. GAAP, as set forth in the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC. The unaudited condensed consolidated financial statements include the accounts of Pacific Biosciences and our wholly owned subsidiaries. Certain information and footnote disclosures typically included in our audited financial statements have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements have been prepared on a consistent basis with the December&#160;31, 2024 audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state our financial position, results of operations, comprehensive loss, and cash flows for the period, but are not necessarily indicative of the results to be expected for the entire year or any future periods. All intercompany transactions and balances have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2024 (the "2024 Annual Report").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes to the financial statements. On an ongoing basis, we evaluate our significant estimates, including those relating to the valuation of inventory, fair value of contingent consideration, valuation of acquired intangible assets, useful lives assigned to finite-lived assets, asset impairment assessments, computation of provisions for income taxes, and valuations related to our convertible senior notes. While the extent of the potential impact of current macroeconomic conditions on our business is highly uncertain, we considered information available related to assumptions and estimates used to determine the results reported and asset valuations as of September&#160;30, 2025. Actual results could differ materially from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, Restricted Cash, and Investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all highly liquid investments purchased with an original maturity of 90 days or less to be cash equivalents. Cash equivalents may be comprised of money market funds, certificates of deposit, commercial paper, corporate bonds and notes, and government agencies&#x2019; securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We classify our investments in debt securities as available-for-sale and report the investments at fair value in current assets. We evaluate our available-for-sale investments in unrealized loss positions and assess whether the unrealized loss is credit-related. Unrealized gains and losses that are not credit-related are recognized in accumulated other comprehensive income (loss) in stockholders&#x2019; equity. Realized gains and losses, expected credit losses, as well as interest income, on available-for-sale securities are reported in other income, net. The cost used in the determination of gains and losses of securities sold is based on the specific identification method. The cost of marketable securities is adjusted for the amortization of premiums and discounts to expected maturity. Premium and discount amortization is recorded in other income, net. We have the ability to hold, and do not intend to sell investments in unrealized loss positions before the recovery of their amortized cost bases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our investment portfolio at any point in time contains investments in cash deposits, money market funds, commercial paper, corporate debt securities and U.S. government and agency securities with high credit ratings. We have established guidelines regarding diversification and maturities of investments with the objectives of maintaining safety and liquidity, while maximizing yield. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash includes cash that is not readily available for use in the Company&#x2019;s operating activities. Restricted cash is primarily comprised of cash pledged under letters of credit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Pronouncements Pending Adoption&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This new standard requires a company to expand its existing income tax disclosures, specifically related to the rate reconciliation and income taxes paid. The standard is effective for annual periods beginning in 2025 and is expected to be applied retrospectively. We expect that the adoption of this new standard will result in incremental income tax related disclosures to the notes to the consolidated financial statements but will not have a material impact on the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&#x2014;Debt With Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This new standard clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion or extinguishment of convertible debt. The standard will be effective for us beginning in the first quarter of 2026, with early adoption permitted. The new standard is expected to be applied prospectively, but retrospective application is permitted. We do not expect the adoption of this new standard to have a material impact on the consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This new standard requires a company to provide disaggregated disclosures, within the notes to the financial statements, of specified categories of expenses that are included in line items on the face of the income statement. The standard will be effective for us beginning in 2027, and interim periods within 2028, with early adoption permitted. The new standard is expected to be applied prospectively, but retrospective application is permitted. We are currently evaluating the impact of ASU 2024-03 on the consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2025, the FASB issued ASU 2025-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles&#x2014;Goodwill and Other&#x2014;Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; This new standard clarifies and modernizes the recognition and disclosure framework for capitalized internal-use software costs by removing all references to project stages and introduces a more judgment-based approach. The standard also clarifies the threshold to be applied to begin capitalizing. The standard will be effective for us beginning in the first quarter of 2028, with early adoption permitted, and can be applied using a prospective, retrospective, or modified transition approach. We are currently evaluating the impact of ASU 2025-06 on the consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no changes to our significant accounting policies as disclosed in our 2024 Annual Report.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-383">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Basis of Presentation and Consolidation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States, or U.S. GAAP, as set forth in the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC. The unaudited condensed consolidated financial statements include the accounts of Pacific Biosciences and our wholly owned subsidiaries. Certain information and footnote disclosures typically included in our audited financial statements have been condensed or omitted. The accompanying unaudited condensed consolidated financial statements have been prepared on a consistent basis with the December&#160;31, 2024 audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state our financial position, results of operations, comprehensive loss, and cash flows for the period, but are not necessarily indicative of the results to be expected for the entire year or any future periods. All intercompany transactions and balances have been eliminated.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-384">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes to the financial statements. On an ongoing basis, we evaluate our significant estimates, including those relating to the valuation of inventory, fair value of contingent consideration, valuation of acquired intangible assets, useful lives assigned to finite-lived assets, asset impairment assessments, computation of provisions for income taxes, and valuations related to our convertible senior notes. While the extent of the potential impact of current macroeconomic conditions on our business is highly uncertain, we considered information available related to assumptions and estimates used to determine the results reported and asset valuations as of September&#160;30, 2025. Actual results could differ materially from these estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-385">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, Restricted Cash, and Investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all highly liquid investments purchased with an original maturity of 90 days or less to be cash equivalents. Cash equivalents may be comprised of money market funds, certificates of deposit, commercial paper, corporate bonds and notes, and government agencies&#x2019; securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We classify our investments in debt securities as available-for-sale and report the investments at fair value in current assets. We evaluate our available-for-sale investments in unrealized loss positions and assess whether the unrealized loss is credit-related. Unrealized gains and losses that are not credit-related are recognized in accumulated other comprehensive income (loss) in stockholders&#x2019; equity. Realized gains and losses, expected credit losses, as well as interest income, on available-for-sale securities are reported in other income, net. The cost used in the determination of gains and losses of securities sold is based on the specific identification method. The cost of marketable securities is adjusted for the amortization of premiums and discounts to expected maturity. Premium and discount amortization is recorded in other income, net. We have the ability to hold, and do not intend to sell investments in unrealized loss positions before the recovery of their amortized cost bases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our investment portfolio at any point in time contains investments in cash deposits, money market funds, commercial paper, corporate debt securities and U.S. government and agency securities with high credit ratings. We have established guidelines regarding diversification and maturities of investments with the objectives of maintaining safety and liquidity, while maximizing yield. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash includes cash that is not readily available for use in the Company&#x2019;s operating activities. Restricted cash is primarily comprised of cash pledged under letters of credit.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-386">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Pronouncements Pending Adoption&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This new standard requires a company to expand its existing income tax disclosures, specifically related to the rate reconciliation and income taxes paid. The standard is effective for annual periods beginning in 2025 and is expected to be applied retrospectively. We expect that the adoption of this new standard will result in incremental income tax related disclosures to the notes to the consolidated financial statements but will not have a material impact on the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&#x2014;Debt With Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This new standard clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion or extinguishment of convertible debt. The standard will be effective for us beginning in the first quarter of 2026, with early adoption permitted. The new standard is expected to be applied prospectively, but retrospective application is permitted. We do not expect the adoption of this new standard to have a material impact on the consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This new standard requires a company to provide disaggregated disclosures, within the notes to the financial statements, of specified categories of expenses that are included in line items on the face of the income statement. The standard will be effective for us beginning in 2027, and interim periods within 2028, with early adoption permitted. The new standard is expected to be applied prospectively, but retrospective application is permitted. We are currently evaluating the impact of ASU 2024-03 on the consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2025, the FASB issued ASU 2025-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles&#x2014;Goodwill and Other&#x2014;Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; This new standard clarifies and modernizes the recognition and disclosure framework for capitalized internal-use software costs by removing all references to project stages and introduces a more judgment-based approach. The standard also clarifies the threshold to be applied to begin capitalizing. The standard will be effective for us beginning in the first quarter of 2028, with early adoption permitted, and can be applied using a prospective, retrospective, or modified transition approach. We are currently evaluating the impact of ASU 2025-06 on the consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock contextRef="c-1" id="f-387">&lt;div style="margin-top:15pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"&gt;&lt;span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;NOTE 2.  FINANCIAL INSTRUMENTS&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value hierarchy established under U.S. GAAP requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs that may be used to measure fair value are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt"&gt;Level 1: quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt"&gt;Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt"&gt;Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider an active market as one in which transactions for the asset or liability occurs with sufficient frequency and volume to provide pricing information on an ongoing basis. Conversely, we view an inactive market as one in which there are few transactions for the asset or liability, the prices are not current, or price quotations vary substantially either over time or among market makers. Where appropriate, our non-performance risk, or that of our counterparty, is considered in determining the fair values of liabilities and assets, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We classify our cash deposits and money market funds within Level 1 of the fair value hierarchy because they are valued using bank balances or quoted market prices. We classify our investments as Level 2 instruments based on market pricing and other observable inputs. We did not classify any of our investments within Level 3 of the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities measured at fair value are classified in their entirety based on the lowest level input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the entire fair value measurement requires management to make judgments and consider factors specific to the asset or liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of our accounts receivable, prepaid expenses, other current assets, accounts payable, accrued expenses and other liabilities, current, approximate fair value due to their short maturities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the fair value of our financial assets and liabilities that were measured on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.203%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.618%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.933%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;52,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;56,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;55,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;55,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Corporate debt securities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;23,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;23,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;46,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;46,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;U.S. government &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;218,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;218,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;287,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;287,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Total investments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;242,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;242,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;334,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;334,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Short-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Long-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Total assets measured at fair value &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;54,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;246,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;300,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;57,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;334,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;392,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Total liabilities measured at fair value &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September&#160;30, 2025, there were no transfers between Level 1, Level 2, or Level 3 assets or liabilities reported at fair value on a recurring basis, and our valuation techniques did not change compared to the prior year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Contingent Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the August 2023 &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Apton Biosystems, Inc. (&#x201c;Apton&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; acquisition, contingent consideration of $25.0&#160;million, which we may elect to pay in cash, shares of our common stock or a combination of cash and shares of our common stock, is due upon the achievement of a milestone, defined as the achievement of $50.0&#160;million in revenue associated with Apton's technology, provided that the milestone event occurs prior to the five-year anniversary of the closing date of the acquisition. The number of shares, if any, to be issued in connection with the achievement of the specified milestone is not known and will be calculated based on the daily volume-weighted average price of our common stock for the &lt;span style="-sec-ix-hidden:f-465"&gt;twenty&lt;/span&gt; trading days ending on and including the fifth trading day immediately prior to the occurrence of the specified milestone. Upon achievement of the milestone, we may pay cash in lieu of our common stock to ensure that the issuance of our common stock does not exceed 19.9% of our outstanding shares of common stock then outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contingent consideration is accounted for as a liability at fair value, with changes during each reporting period recognized in our condensed consolidated statements of operations and comprehensive loss. The fair value of the contingent consideration liability was calculated using a Monte Carlo Simulation to estimate the volatility and systematic relative risk of revenues subject to sales milestone payments and discounting the associated cash payment amounts to their present values using a credit-risk-adjusted interest rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We classify contingent consideration within Level 3, as factors used to develop the estimate of fair value include unobservable inputs that are not supported by market activity and are significant to the fair value. Estimates and assumptions used in the Monte Carlo simulation include risk-adjusted forecasted revenues for products and services leveraging Apton's technology and an estimated credit spread.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the fair value of the contingent consideration liability based on the simulated revenue of the Company through the five-year anniversary of the closing date of the acquisition. The key input used in the determination of the fair value included projected revenues of the high-throughput short-read products and services leveraging Apton's technology. Primarily due to management's decision to cease development of the high-throughput short-read system, and the resulting changes in the expected future revenues, among other factors, and as the milestone event must occur prior to the five-year anniversary of the closing date of the acquisition, the estimated fair value of the contingent consideration liability is $0. An increase in the fair value of the liability may result from an acceleration in the timing of or increase in projected revenues and from a &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;decrease in discount rates, including the risk-free rate and estimated subordinated credit spread for a CCC credit rating.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the estimated fair value of the contingent consideration liability during the nine months ended September&#160;30, 2025 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Beginning balance as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Change in estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(18,700)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Ending balance as of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes to the fair value are recorded as change in fair value of contingent consideration in the condensed consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, Restricted Cash, and Investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize our cash, cash equivalents, restricted cash, and investments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortized&lt;br/&gt;Cost &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;56,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;56,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Corporate debt securities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;23,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;23,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. government &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;218,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;218,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total investments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;241,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;242,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total cash, cash equivalents and investments &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;298,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;298,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Short-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Long-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;55,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;55,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;46,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;46,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. government &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;287,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(155)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;287,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;334,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;334,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total cash, cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;389,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;389,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Short-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Long-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the contractual maturities of our cash equivalents and available-for-sale investments, excluding money market funds, as of September&#160;30, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Due in one year or less &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;181,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Due after one year through five years &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;64,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;246,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Actual maturities may differ from contractual maturities because issuers may have the right to call or prepay obligations without call or prepayment penalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investment income included in other income, net &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on the condensed consolidated statements of operations and comprehensive loss &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;was $3.1 million and $10.4 million for the three and nine months ended September&#160;30, 2025, respectively, and $6.0 million and $19.8 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for the three and nine months ended September&#160;30, 2024, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="c-1" id="f-388">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider an active market as one in which transactions for the asset or liability occurs with sufficient frequency and volume to provide pricing information on an ongoing basis. Conversely, we view an inactive market as one in which there are few transactions for the asset or liability, the prices are not current, or price quotations vary substantially either over time or among market makers. Where appropriate, our non-performance risk, or that of our counterparty, is considered in determining the fair values of liabilities and assets, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We classify our cash deposits and money market funds within Level 1 of the fair value hierarchy because they are valued using bank balances or quoted market prices. We classify our investments as Level 2 instruments based on market pricing and other observable inputs. We did not classify any of our investments within Level 3 of the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities measured at fair value are classified in their entirety based on the lowest level input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the entire fair value measurement requires management to make judgments and consider factors specific to the asset or liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of our accounts receivable, prepaid expenses, other current assets, accounts payable, accrued expenses and other liabilities, current, approximate fair value due to their short maturities.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="c-1" id="f-389">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the fair value of our financial assets and liabilities that were measured on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.203%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.618%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.933%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;52,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;56,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;55,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;55,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Corporate debt securities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;23,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;23,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;46,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;46,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;U.S. government &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;218,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;218,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;287,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;287,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Total investments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;242,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;242,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;334,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;334,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Short-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Long-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Total assets measured at fair value &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;54,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;246,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;300,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;57,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;334,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;392,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Total liabilities measured at fair value &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;18,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-60" decimals="-3" id="f-390" unitRef="usd">52483000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-61" decimals="-3" id="f-391" unitRef="usd">3984000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-62" decimals="-3" id="f-392" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-3" decimals="-3" id="f-393" unitRef="usd">56467000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-63" decimals="-3" id="f-394" unitRef="usd">55370000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-64" decimals="-3" id="f-395" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-65" decimals="-3" id="f-396" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-4" decimals="-3" id="f-397" unitRef="usd">55370000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-66" decimals="-3" id="f-398" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-67" decimals="-3" id="f-399" unitRef="usd">23420000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-68" decimals="-3" id="f-400" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-69" decimals="-3" id="f-401" unitRef="usd">23420000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-70" decimals="-3" id="f-402" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-71" decimals="-3" id="f-403" unitRef="usd">46905000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-72" decimals="-3" id="f-404" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-73" decimals="-3" id="f-405" unitRef="usd">46905000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-74" decimals="-3" id="f-406" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-75" decimals="-3" id="f-407" unitRef="usd">218767000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-76" decimals="-3" id="f-408" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-77" decimals="-3" id="f-409" unitRef="usd">218767000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-78" decimals="-3" id="f-410" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-79" decimals="-3" id="f-411" unitRef="usd">287656000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-80" decimals="-3" id="f-412" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-81" decimals="-3" id="f-413" unitRef="usd">287656000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-82" decimals="-3" id="f-414" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-83" decimals="-3" id="f-415" unitRef="usd">242187000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-84" decimals="-3" id="f-416" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-85" decimals="-3" id="f-417" unitRef="usd">242187000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-86" decimals="-3" id="f-418" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-87" decimals="-3" id="f-419" unitRef="usd">334561000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-88" decimals="-3" id="f-420" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-89" decimals="-3" id="f-421" unitRef="usd">334561000</us-gaap:InvestmentsFairValueDisclosure>
    <pacb:ShortTermRestrictedCashFairValueDisclosure contextRef="c-60" decimals="-3" id="f-422" unitRef="usd">300000</pacb:ShortTermRestrictedCashFairValueDisclosure>
    <pacb:ShortTermRestrictedCashFairValueDisclosure contextRef="c-61" decimals="-3" id="f-423" unitRef="usd">0</pacb:ShortTermRestrictedCashFairValueDisclosure>
    <pacb:ShortTermRestrictedCashFairValueDisclosure contextRef="c-62" decimals="-3" id="f-424" unitRef="usd">0</pacb:ShortTermRestrictedCashFairValueDisclosure>
    <pacb:ShortTermRestrictedCashFairValueDisclosure contextRef="c-3" decimals="-3" id="f-425" unitRef="usd">300000</pacb:ShortTermRestrictedCashFairValueDisclosure>
    <pacb:ShortTermRestrictedCashFairValueDisclosure contextRef="c-63" decimals="-3" id="f-426" unitRef="usd">690000</pacb:ShortTermRestrictedCashFairValueDisclosure>
    <pacb:ShortTermRestrictedCashFairValueDisclosure contextRef="c-64" decimals="-3" id="f-427" unitRef="usd">0</pacb:ShortTermRestrictedCashFairValueDisclosure>
    <pacb:ShortTermRestrictedCashFairValueDisclosure contextRef="c-65" decimals="-3" id="f-428" unitRef="usd">0</pacb:ShortTermRestrictedCashFairValueDisclosure>
    <pacb:ShortTermRestrictedCashFairValueDisclosure contextRef="c-4" decimals="-3" id="f-429" unitRef="usd">690000</pacb:ShortTermRestrictedCashFairValueDisclosure>
    <pacb:LongTermRestrictedCashFairValueDisclosure contextRef="c-60" decimals="-3" id="f-430" unitRef="usd">1532000</pacb:LongTermRestrictedCashFairValueDisclosure>
    <pacb:LongTermRestrictedCashFairValueDisclosure contextRef="c-61" decimals="-3" id="f-431" unitRef="usd">0</pacb:LongTermRestrictedCashFairValueDisclosure>
    <pacb:LongTermRestrictedCashFairValueDisclosure contextRef="c-62" decimals="-3" id="f-432" unitRef="usd">0</pacb:LongTermRestrictedCashFairValueDisclosure>
    <pacb:LongTermRestrictedCashFairValueDisclosure contextRef="c-3" decimals="-3" id="f-433" unitRef="usd">1532000</pacb:LongTermRestrictedCashFairValueDisclosure>
    <pacb:LongTermRestrictedCashFairValueDisclosure contextRef="c-63" decimals="-3" id="f-434" unitRef="usd">1532000</pacb:LongTermRestrictedCashFairValueDisclosure>
    <pacb:LongTermRestrictedCashFairValueDisclosure contextRef="c-64" decimals="-3" id="f-435" unitRef="usd">0</pacb:LongTermRestrictedCashFairValueDisclosure>
    <pacb:LongTermRestrictedCashFairValueDisclosure contextRef="c-65" decimals="-3" id="f-436" unitRef="usd">0</pacb:LongTermRestrictedCashFairValueDisclosure>
    <pacb:LongTermRestrictedCashFairValueDisclosure contextRef="c-4" decimals="-3" id="f-437" unitRef="usd">1532000</pacb:LongTermRestrictedCashFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-60" decimals="-3" id="f-438" unitRef="usd">54315000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-61" decimals="-3" id="f-439" unitRef="usd">246171000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-62" decimals="-3" id="f-440" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-3" decimals="-3" id="f-441" unitRef="usd">300486000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-63" decimals="-3" id="f-442" unitRef="usd">57592000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-64" decimals="-3" id="f-443" unitRef="usd">334561000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-65" decimals="-3" id="f-444" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-4" decimals="-3" id="f-445" unitRef="usd">392153000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-60" decimals="-3" id="f-446" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-61" decimals="-3" id="f-447" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-62" decimals="-3" id="f-448" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-3" decimals="-3" id="f-449" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-63" decimals="-3" id="f-450" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-64" decimals="-3" id="f-451" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-65" decimals="-3" id="f-452" unitRef="usd">18700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-4" decimals="-3" id="f-453" unitRef="usd">18700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-60" decimals="-3" id="f-454" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-61" decimals="-3" id="f-455" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-62" decimals="-3" id="f-456" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-3" decimals="-3" id="f-457" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-63" decimals="-3" id="f-458" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-64" decimals="-3" id="f-459" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-65" decimals="-3" id="f-460" unitRef="usd">18700000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-4" decimals="-3" id="f-461" unitRef="usd">18700000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-90" decimals="-5" id="f-462" unitRef="usd">25000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <pacb:BusinessCombinationConsiderationTransferredRevenueAchievementMilestone contextRef="c-91" decimals="-5" id="f-463" unitRef="usd">50000000</pacb:BusinessCombinationConsiderationTransferredRevenueAchievementMilestone>
    <pacb:BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod contextRef="c-92" id="f-464">P5Y</pacb:BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod>
    <pacb:PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger contextRef="c-93" decimals="3" id="f-466" unitRef="number">0.199</pacb:PercentageOfOutstandingSharesOfCommonToBeIssuedInMerger>
    <pacb:BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod contextRef="c-94" id="f-467">P5Y</pacb:BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod>
    <pacb:BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod contextRef="c-94" id="f-468">P5Y</pacb:BusinessCombinationContingentConsiderationLiabilityMeasurementPeriod>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-94" decimals="-6" id="f-469" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c-1" id="f-470">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the estimated fair value of the contingent consideration liability during the nine months ended September&#160;30, 2025 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Beginning balance as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Change in estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(18,700)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Ending balance as of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-65" decimals="-3" id="f-471" unitRef="usd">18700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-95" decimals="-3" id="f-472" unitRef="usd">-18700000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-62" decimals="-3" id="f-473" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock contextRef="c-1" id="f-474">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize our cash, cash equivalents, restricted cash, and investments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortized&lt;br/&gt;Cost &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;56,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;56,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Corporate debt securities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;23,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;23,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. government &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;218,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;218,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total investments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;241,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;242,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total cash, cash equivalents and investments &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;298,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;298,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Short-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Long-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;55,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;55,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;46,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;46,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. government &amp;amp; agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;287,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(155)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;287,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;334,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;334,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total cash, cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;389,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;389,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Short-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Long-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the contractual maturities of our cash equivalents and available-for-sale investments, excluding money market funds, as of September&#160;30, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Due in one year or less &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;181,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Due after one year through five years &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;64,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;246,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-96" decimals="-3" id="f-475" unitRef="usd">56467000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-96" decimals="-3" id="f-476" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-96" decimals="-3" id="f-477" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-96" decimals="-3" id="f-478" unitRef="usd">56467000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-97" decimals="-3" id="f-479" unitRef="usd">23298000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-97" decimals="-3" id="f-480" unitRef="usd">123000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-97" decimals="-3" id="f-481" unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-97" decimals="-3" id="f-482" unitRef="usd">23420000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-98" decimals="-3" id="f-483" unitRef="usd">218475000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-98" decimals="-3" id="f-484" unitRef="usd">309000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-98" decimals="-3" id="f-485" unitRef="usd">17000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-98" decimals="-3" id="f-486" unitRef="usd">218767000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-85" decimals="-3" id="f-487" unitRef="usd">241773000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-85" decimals="-3" id="f-488" unitRef="usd">432000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-85" decimals="-3" id="f-489" unitRef="usd">18000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-85" decimals="-3" id="f-490" unitRef="usd">242187000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-3" decimals="-3" id="f-491" unitRef="usd">298240000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-3" decimals="-3" id="f-492" unitRef="usd">432000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-3" decimals="-3" id="f-493" unitRef="usd">18000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-3" decimals="-3" id="f-494" unitRef="usd">298654000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:RestrictedCashCurrent contextRef="c-3" decimals="-3" id="f-495" unitRef="usd">300000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c-3" decimals="-3" id="f-496" unitRef="usd">300000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-3" decimals="-3" id="f-497" unitRef="usd">1532000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-3" decimals="-3" id="f-498" unitRef="usd">1532000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-99" decimals="-3" id="f-499" unitRef="usd">55370000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-99" decimals="-3" id="f-500" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-99" decimals="-3" id="f-501" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-99" decimals="-3" id="f-502" unitRef="usd">55370000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-100" decimals="-3" id="f-503" unitRef="usd">46746000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-100" decimals="-3" id="f-504" unitRef="usd">184000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-100" decimals="-3" id="f-505" unitRef="usd">25000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-100" decimals="-3" id="f-506" unitRef="usd">46905000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-101" decimals="-3" id="f-507" unitRef="usd">287393000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-101" decimals="-3" id="f-508" unitRef="usd">418000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-101" decimals="-3" id="f-509" unitRef="usd">155000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-101" decimals="-3" id="f-510" unitRef="usd">287656000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-89" decimals="-3" id="f-511" unitRef="usd">334139000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-89" decimals="-3" id="f-512" unitRef="usd">602000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-89" decimals="-3" id="f-513" unitRef="usd">180000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-89" decimals="-3" id="f-514" unitRef="usd">334561000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss contextRef="c-4" decimals="-3" id="f-515" unitRef="usd">389509000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-4" decimals="-3" id="f-516" unitRef="usd">602000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-4" decimals="-3" id="f-517" unitRef="usd">180000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest contextRef="c-4" decimals="-3" id="f-518" unitRef="usd">389931000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:RestrictedCashCurrent contextRef="c-4" decimals="-3" id="f-519" unitRef="usd">690000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c-4" decimals="-3" id="f-520" unitRef="usd">690000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-4" decimals="-3" id="f-521" unitRef="usd">1532000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-4" decimals="-3" id="f-522" unitRef="usd">1532000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue contextRef="c-3" decimals="-3" id="f-523" unitRef="usd">181705000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue contextRef="c-3" decimals="-3" id="f-524" unitRef="usd">64466000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate contextRef="c-3" decimals="-3" id="f-525" unitRef="usd">246171000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate>
    <us-gaap:InvestmentIncomeNet contextRef="c-13" decimals="-5" id="f-526" unitRef="usd">3100000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c-1" decimals="-5" id="f-527" unitRef="usd">10400000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c-14" decimals="-5" id="f-528" unitRef="usd">6000000.0</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c-15" decimals="-5" id="f-529" unitRef="usd">19800000</us-gaap:InvestmentIncomeNet>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="c-1" id="f-530">&lt;div style="margin-top:15pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#1383c6;border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;NOTE 3.  BALANCE SHEET COMPONENTS &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Inventory, Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our inventory, net, consisted of the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Purchased materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;41,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;45,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;25,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;22,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 8.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Inventory, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;83,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;81,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 2.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Inventory reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(30,259)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(22,768)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 8.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Inventory, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;53,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;58,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Goodwill and Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is reviewed for impairment at least annually during the second quarter, or more frequently if an event occurs indicating the potential for impairment. Based on quantitative interim impairment tests performed in 2024, we recorded impairment charges of $93.2&#160;million in the second quarter of 2024 and $51.3&#160;million in the fourth quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We conducted a quantitative interim impairment test as of March 31, 2025, based on a decline in stock price and market capitalization during the first quarter of 2025, macroeconomic uncertainties, and revised strategic plans emphasizing HiFi sequencing and discontinuing short-read platform development, and concluded there was no impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We completed our annual goodwill impairment assessment on April 1, 2025 and noted no impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in our future operating results, cash flows, share price, market capitalization or discount rates used when conducting future goodwill impairment tests could affect the implied fair value of goodwill and may result in additional impairment charges in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets include developed technology, customer relationships, and acquired in-process research and development ("IPR&amp;amp;D"). In connection with the Apton acquisition in August 2023, we allocated $55.0 million of the purchase price to IPR&amp;amp;D. This asset is considered indefinite-lived until the associated research and development activities are either completed or abandoned, and it is tested for impairment annually and more &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized a $40.0&#160;million impairment charge in the fourth quarter of 2024 as a result of a quantitative interim impairment test.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on our decision to cease development of the high-throughput short-read sequencing platform, which would utilize the IPR&amp;amp;D, and the resulting changes to the expected future cash flows, among other factors, we concluded that it was more likely than not that the fair value of the IPR&amp;amp;D was less than its carrying amount, requiring an interim impairment assessment. Using a discounted cash flow model under the income approach, we determined the fair value was below carrying value and recorded a $15.0&#160;million impairment charge. The decline in the fair value of the IPR&amp;amp;D below its carrying amount as of March 31, 2025 resulted primarily from changes in the timing of expected future cash flows as compared to the fair value as of December 31, 2024, driven by the restructuring initiatives that prioritize the adoption of HiFi sequencing. The impairment charge is included in our consolidated statements of operations and comprehensive loss for the nine months ended September 30, 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant estimates and assumptions used in the income approach include timing of future cash flows, revenue growth assumptions, a selected discount rate of 14.0%, and a selected obsolescence factor of 11 years. The discount rate was based primarily on the weighted average cost of capital, determined using market, peer company, industry data, and related risk factors. The assessment is a level 3 measurement due to its reliance on certain unobservable inputs and significant management judgment. The assumptions used were inherently subject to uncertainty and small changes in these assumptions could have had a significant impact on the concluded value. A decrease of 200 basis points to the discount rate used in our analysis would have resulted in an increase in the estimated fair value of the IPR&amp;amp;D of approximately $3&#160;million, and an increase of one year to the obsolescence factor used in our analysis would have resulted in an increase in the estimated fair value of the IPR&amp;amp;D of approximately $3&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes to IPR&amp;amp;D during the nine months ended September&#160;30, 2025 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Balance as of December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:f-559"&gt;Impairment charge&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(15,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Balance as of September&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_46" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 5. Restructuring&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for additional information on costs incurred in connection with our current year restructuring activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to IPR&amp;amp;D, we had the following acquired finite-lived intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.596%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.163%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.056%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands, except years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;br/&gt;Useful Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Developed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3 &#x2014; 15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;421,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(405,036)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;411,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(36,607)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;374,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(360)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(360)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;421,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(405,396)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;411,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(36,967)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;374,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated future amortization expense of intangible assets with finite lives is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Remainder of 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2030 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of acquired intangible assets is included within our cost of revenue if the costs and expenses related to the intangible assets are attributable to revenue generating activities. Amortization expense for intangible assets that are not directly related to sales generating activities are amortized to operating expenses. For developed technology intangible assets that are utilized in both revenue generating activities and in research and development activities, we allocate the amortization expense between cost of revenue and operating expenses. The finite-lived intangible assets are amortized using the straight-line method over their estimated useful lives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2025, we revised the estimated useful life of the developed technology acquired in the 2021 Omniome, Inc. ("Omniome") acquisition. This change reflects updated strategic plans and restructuring initiatives focused on accelerating HiFi sequencing adoption, leading to ceased development of our high-throughput short-read platform and revised expectations for the timing and amount of future cash flows from short-read sequencing products and services. As a result of the change in estimate, during the three months ended March 31, 2025, we recognized accelerated amortization of $359.3&#160;million within amortization of acquired intangible assets in operating expenses, reflecting our revised estimate that the asset will no longer generate economic benefit beyond March 31, 2025. This expense had a negative impact on basic and diluted net loss per share of $1.20 for the nine months ended September 30, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We review finite-lived intangible assets for impairment when indication of potential impairment exists, such as a significant reduction in cash flows associated with the assets. In the first quarter of 2025, as part of our interim goodwill impairment test, we also performed a recoverability test for the definite-lived asset group and noted no impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March&#160;7, 2025, the Company entered into an agreement to acquire certain developed technology and related intellectual property from The Chinese University of Hong Kong for total consideration of $9.7&#160;million. In addition, the Company entered into a license agreement for complementary developed technology during the three months ended March 31, 2025. Both the acquired technology and license are classified as intangible assets and are being amortized over an estimated useful life of three years. As of September&#160;30, 2025, $5.0&#160;million of these intangible assets remained unpaid. This amount is included in accrued liabilities on the condensed consolidated balance sheets and is expected to be paid in 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_46" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 5. Restructuring&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for additional information on costs incurred in connection with our current year restructuring activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Deferred Revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2025, we had a total of $20.4&#160;million of deferred revenue, $16.0&#160;million of which was recorded as deferred revenue, current, and $4.4&#160;million of which was recorded as deferred revenue, non-current, which primarily relates to deferred service contract revenues and is scheduled to be recognized in the next four years. Revenue recorded in the three and nine months ended September&#160;30, 2025 includes $2.4&#160;million and $10.5&#160;million, respectively, that was included in deferred revenue as of December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Performance Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We regularly enter into contracts with multiple performance obligations. These contracts are believed to be firm as of the balance sheet date. However, we may allow customers to make product substitutions or certain modifications at our discretion. The timing of shipments depends on several factors, including agreed upon shipping schedules, which may span multiple quarters. Most performance obligations are generally satisfied within a year of the contract execution date. As of September&#160;30, 2025, the aggregate amount of the transaction price allocated to remaining performance obligations was $48.7&#160;million, of which approximately 72% is expected to be converted to revenue over the next twelve months, approximately 23% in the following twelve months, and the remainder thereafter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Product Warranties&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generally provide a one-year warranty on instruments. In addition, we provide a limited warranty on consumables. At the time revenue is recognized, an accrual is established for estimated warranty costs based on historical experience as well as anticipated product performance. We periodically review the warranty reserve for adequacy and adjust the warranty accrual, if necessary, based on actual experience and estimated costs to be incurred. Warranties are recorded as part of accrued expenses on the condensed consolidated balance sheets and warranty expense is recorded as a component of cost of product revenue in the condensed consolidated statements of operations and comprehensive loss. There were no material changes in estimates for the periods presented below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the reserve for product warranties were as follows for the periods indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.778%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.782%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Balance at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Additions charged to cost of product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Repairs and replacements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,384)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,610)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4,353)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(6,202)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Balance at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c-1" id="f-531">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our inventory, net, consisted of the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Purchased materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;41,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;45,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;25,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;22,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 8.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Inventory, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;83,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;81,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 2.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Inventory reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(30,259)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(22,768)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 8.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Inventory, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;53,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;58,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials contextRef="c-3" decimals="-3" id="f-532" unitRef="usd">41788000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials contextRef="c-4" decimals="-3" id="f-533" unitRef="usd">45270000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess contextRef="c-3" decimals="-3" id="f-534" unitRef="usd">25189000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess contextRef="c-4" decimals="-3" id="f-535" unitRef="usd">22172000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods contextRef="c-3" decimals="-3" id="f-536" unitRef="usd">16435000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="c-4" decimals="-3" id="f-537" unitRef="usd">14081000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross contextRef="c-3" decimals="-3" id="f-538" unitRef="usd">83412000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross contextRef="c-4" decimals="-3" id="f-539" unitRef="usd">81523000</us-gaap:InventoryGross>
    <us-gaap:InventoryValuationReserves contextRef="c-3" decimals="-3" id="f-540" unitRef="usd">30259000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves contextRef="c-4" decimals="-3" id="f-541" unitRef="usd">22768000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryNet contextRef="c-3" decimals="-3" id="f-542" unitRef="usd">53153000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-4" decimals="-3" id="f-543" unitRef="usd">58755000</us-gaap:InventoryNet>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-102" decimals="-5" id="f-544" unitRef="usd">93200000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-103" decimals="-5" id="f-545" unitRef="usd">51300000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-104" decimals="-5" id="f-546" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-105" decimals="-5" id="f-547" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="c-92" decimals="-5" id="f-548" unitRef="usd">55000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c-103" decimals="-5" id="f-549" unitRef="usd">40000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="c-1" decimals="-5" id="f-550" unitRef="usd">15000000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <pacb:IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate contextRef="c-3" decimals="3" id="f-551" unitRef="number">0.140</pacb:IntangibleAssetImpairmentDiscountedCashFlowModelDiscountRate>
    <pacb:IntangibleAssetImpairmentDiscountedCashFlowModelTerm contextRef="c-3" id="f-552">P11Y</pacb:IntangibleAssetImpairmentDiscountedCashFlowModelTerm>
    <pacb:IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate contextRef="c-3" decimals="4" id="f-553" unitRef="number">200</pacb:IntangibleAssetImpairmentIncreaseInBasisPointDiscountRate>
    <pacb:AdditionalIntangibleAssetImpairmentChangeInDiscountRate contextRef="c-1" decimals="-6" id="f-554" unitRef="usd">3000000</pacb:AdditionalIntangibleAssetImpairmentChangeInDiscountRate>
    <pacb:IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm contextRef="c-3" id="f-555">P1Y</pacb:IntangibleAssetImpairmentIncreaseInObsolescenceFactorTerm>
    <pacb:AdditionalIntangibleAssetImpairmentChangeInTerm contextRef="c-1" decimals="-6" id="f-556" unitRef="usd">3000000</pacb:AdditionalIntangibleAssetImpairmentChangeInTerm>
    <us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock contextRef="c-1" id="f-557">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes to IPR&amp;amp;D during the nine months ended September&#160;30, 2025 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Balance as of December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:f-559"&gt;Impairment charge&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(15,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Balance as of September&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-106" decimals="-3" id="f-558" unitRef="usd">15000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-107" decimals="-3" id="f-560" unitRef="usd">15000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-108" decimals="-3" id="f-561" unitRef="usd">0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="c-1" id="f-562">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to IPR&amp;amp;D, we had the following acquired finite-lived intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.596%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.163%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.056%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands, except years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Estimated&lt;br/&gt;Useful Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Developed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3 &#x2014; 15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;421,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(405,036)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;411,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(36,607)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;374,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(360)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(360)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;421,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(405,396)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;411,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(36,967)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;374,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-109" id="f-563">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-110" id="f-564">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-111" decimals="-3" id="f-565" unitRef="usd">421179000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-111" decimals="-3" id="f-566" unitRef="usd">405036000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-111" decimals="-3" id="f-567" unitRef="usd">16143000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-112" decimals="-3" id="f-568" unitRef="usd">411179000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-112" decimals="-3" id="f-569" unitRef="usd">36607000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-112" decimals="-3" id="f-570" unitRef="usd">374572000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-113" id="f-571">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-113" decimals="-3" id="f-572" unitRef="usd">360000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-113" decimals="-3" id="f-573" unitRef="usd">360000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-113" decimals="-3" id="f-574" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-114" decimals="-3" id="f-575" unitRef="usd">360000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-114" decimals="-3" id="f-576" unitRef="usd">360000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-114" decimals="-3" id="f-577" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-3" decimals="-3" id="f-578" unitRef="usd">421539000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-3" decimals="-3" id="f-579" unitRef="usd">405396000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-3" decimals="-3" id="f-580" unitRef="usd">16143000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-4" decimals="-3" id="f-581" unitRef="usd">411539000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-4" decimals="-3" id="f-582" unitRef="usd">36967000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-4" decimals="-3" id="f-583" unitRef="usd">374572000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="c-1" id="f-584">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated future amortization expense of intangible assets with finite lives is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Remainder of 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2030 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear contextRef="c-3" decimals="-3" id="f-585" unitRef="usd">1020000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-3" decimals="-3" id="f-586" unitRef="usd">4078000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-3" decimals="-3" id="f-587" unitRef="usd">4078000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-3" decimals="-3" id="f-588" unitRef="usd">1301000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-3" decimals="-3" id="f-589" unitRef="usd">745000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <pacb:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour contextRef="c-3" decimals="-3" id="f-590" unitRef="usd">4921000</pacb:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-3" decimals="-3" id="f-591" unitRef="usd">16143000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <pacb:RestructuringAndRelatedCostAcceleratedAmortization contextRef="c-115" decimals="-5" id="f-592" unitRef="usd">359300000</pacb:RestructuringAndRelatedCostAcceleratedAmortization>
    <pacb:ChangeInEarningsPerShare
      contextRef="c-116"
      decimals="2"
      id="f-593"
      unitRef="usdPerShare">1.20</pacb:ChangeInEarningsPerShare>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-104" decimals="-5" id="f-594" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:AssetAcquisitionConsiderationTransferred contextRef="c-117" decimals="-5" id="f-595" unitRef="usd">9700000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-118" id="f-596">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-119" id="f-597">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent contextRef="c-120" decimals="-5" id="f-598" unitRef="usd">5000000</us-gaap:AssetAcquisitionContingentConsiderationLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiability contextRef="c-121" decimals="-5" id="f-599" unitRef="usd">20400000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-121" decimals="-5" id="f-600" unitRef="usd">16000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-121" decimals="-5" id="f-601" unitRef="usd">4400000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <pacb:ContractWithCustomerLiabilityNoncurrentRecognitionPeriod contextRef="c-122" id="f-602">P4Y</pacb:ContractWithCustomerLiabilityNoncurrentRecognitionPeriod>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-123" decimals="-5" id="f-603" unitRef="usd">2400000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-122" decimals="-5" id="f-604" unitRef="usd">10500000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-3" decimals="-5" id="f-605" unitRef="usd">48700000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage contextRef="c-124" decimals="2" id="f-606" unitRef="number">0.72</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 contextRef="c-124" id="f-607">P12M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage contextRef="c-125" decimals="2" id="f-608" unitRef="number">0.23</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 contextRef="c-125" id="f-609">P12M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <pacb:StandardProductWarrantyPeriod contextRef="c-1" id="f-610">P1Y</pacb:StandardProductWarrantyPeriod>
    <us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock contextRef="c-1" id="f-611">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the reserve for product warranties were as follows for the periods indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.778%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.782%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Balance at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Additions charged to cost of product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Repairs and replacements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,384)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,610)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4,353)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(6,202)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Balance at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock>
    <us-gaap:ProductWarrantyAccrual contextRef="c-20" decimals="-3" id="f-612" unitRef="usd">2688000</us-gaap:ProductWarrantyAccrual>
    <us-gaap:ProductWarrantyAccrual contextRef="c-41" decimals="-3" id="f-613" unitRef="usd">3462000</us-gaap:ProductWarrantyAccrual>
    <us-gaap:ProductWarrantyAccrual contextRef="c-4" decimals="-3" id="f-614" unitRef="usd">3100000</us-gaap:ProductWarrantyAccrual>
    <us-gaap:ProductWarrantyAccrual contextRef="c-55" decimals="-3" id="f-615" unitRef="usd">4681000</us-gaap:ProductWarrantyAccrual>
    <us-gaap:ProductWarrantyAccrualWarrantiesIssued contextRef="c-13" decimals="-3" id="f-616" unitRef="usd">1252000</us-gaap:ProductWarrantyAccrualWarrantiesIssued>
    <us-gaap:ProductWarrantyAccrualWarrantiesIssued contextRef="c-14" decimals="-3" id="f-617" unitRef="usd">1414000</us-gaap:ProductWarrantyAccrualWarrantiesIssued>
    <us-gaap:ProductWarrantyAccrualWarrantiesIssued contextRef="c-1" decimals="-3" id="f-618" unitRef="usd">3809000</us-gaap:ProductWarrantyAccrualWarrantiesIssued>
    <us-gaap:ProductWarrantyAccrualWarrantiesIssued contextRef="c-15" decimals="-3" id="f-619" unitRef="usd">4787000</us-gaap:ProductWarrantyAccrualWarrantiesIssued>
    <us-gaap:ProductWarrantyAccrualPayments contextRef="c-13" decimals="-3" id="f-620" unitRef="usd">1384000</us-gaap:ProductWarrantyAccrualPayments>
    <us-gaap:ProductWarrantyAccrualPayments contextRef="c-14" decimals="-3" id="f-621" unitRef="usd">1610000</us-gaap:ProductWarrantyAccrualPayments>
    <us-gaap:ProductWarrantyAccrualPayments contextRef="c-1" decimals="-3" id="f-622" unitRef="usd">4353000</us-gaap:ProductWarrantyAccrualPayments>
    <us-gaap:ProductWarrantyAccrualPayments contextRef="c-15" decimals="-3" id="f-623" unitRef="usd">6202000</us-gaap:ProductWarrantyAccrualPayments>
    <us-gaap:ProductWarrantyAccrual contextRef="c-3" decimals="-3" id="f-624" unitRef="usd">2556000</us-gaap:ProductWarrantyAccrual>
    <us-gaap:ProductWarrantyAccrual contextRef="c-50" decimals="-3" id="f-625" unitRef="usd">3266000</us-gaap:ProductWarrantyAccrual>
    <us-gaap:ProductWarrantyAccrual contextRef="c-3" decimals="-3" id="f-626" unitRef="usd">2556000</us-gaap:ProductWarrantyAccrual>
    <us-gaap:ProductWarrantyAccrual contextRef="c-50" decimals="-3" id="f-627" unitRef="usd">3266000</us-gaap:ProductWarrantyAccrual>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-628">&lt;div style="margin-top:15pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"&gt;&lt;span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;NOTE 4.  CONVERTIBLE SENIOR NOTES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;2029 Convertible Senior Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 7, 2024, we entered into an exchange agreement with SB Northstar LP (&#x201c;SBN&#x201d;), a subsidiary of SoftBank Group Corp., pursuant to which we agreed to exchange the remaining approximately $459.0&#160;million in aggregate principal amount of our previously held 1.50% Convertible Senior Notes due 2028 (the &#x201c;2028 Notes&#x201d;) outstanding for (i) $200.0&#160;million aggregate principal amount of 1.50% Convertible Senior Notes due 2029 (the &#x201c;2029 Notes&#x201d;), (ii) 20,451,570 shares of common stock (the &#x201c;Exchange Shares&#x201d;) and (iii) $50.0&#160;million of cash (the &#x201c;2024 Exchange Transaction&#x201d;). The Exchange Shares were issued on November 21, 2024 (the &#x201c;Closing Date&#x201d;). The 2029 Notes, the Exchange Shares, and shares of common stock issuable upon conversion of the 2029 Notes were subject to certain lock-up restrictions for a six-month period (the &#x201c;Lock-Up Period&#x201d;) beginning on the Closing Date of the 2024 Exchange Transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon any conversion of the 2029 Notes, SBN will not be entitled to be issued a number of shares of the Company&#x2019;s common stock which would cause SBN's beneficial ownership of common stock to exceed either 9.9% of the total number of issued and outstanding shares of common stock or 9.9% of the combined voting power of all of the securities of the Company, in each case, following such conversion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2029 Notes are governed by an indenture (the &#x201c;2029 Indenture&#x201d;) between the Company and U.S. Bank Trust Company, National Association, as trustee. The 2029 Notes bear interest at a rate of 1.50% per annum. Interest on the 2029 Notes is payable semi-annually in arrears on February 15 and August 15, commencing on February 15, 2025. The 2029 Notes will mature on August 15, 2029, subject to earlier conversion, redemption or repurchase.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2029 Notes are convertible at the option of the holder at any time from the expiration of the Lock-Up Period until the second scheduled trading day prior to the maturity date, including in connection with a redemption by the Company. The 2029 Notes are convertible into shares of our common stock based on an initial conversion rate of 204.5157 shares of common stock per $1,000 principal amount of the 2029 Notes (which is equal to an initial conversion price of approximately $4.89 per share of common stock), in each case subject to customary anti-dilution and other adjustments as a result of certain extraordinary transactions. Upon conversion of the 2029 Notes, we may elect to settle such conversion obligation in cash, shares of our common stock, or a combination of cash and shares of our common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On or after August 20, 2027, and prior to the 31st scheduled trading day immediately preceding the maturity date, the 2029 Notes will be redeemable by the Company in the event that the closing sale price of our common stock has been at least 150% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide the redemption notice at a redemption price of 100% of the principal amount of such 2029 Notes, plus accrued and unpaid interest up to, but excluding, the redemption date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the occurrence of a Fundamental Change (as defined in the 2029 Indenture), the holders of the 2029 Notes may require that we repurchase all or part of the principal amount of the 2029 Notes at a purchase price of par plus unpaid interest up to, but excluding, the maturity date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2029 Notes are subject to certain debt and lien covenants as well as springing guarantees, in each case, the terms of which are set forth in a second letter agreement between the Company and SBN entered into in connection with the Indenture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2029 Indenture includes customary &#x201c;events of default,&#x201d; which may result in the acceleration of the maturity of the 2029 Notes under the 2029 Indenture. The 2029 Indenture also includes customary covenants for convertible notes of this type.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To the extent we elect, the sole remedy for an event of default relating to our failure to comply with certain of our reporting obligations shall, for the first 360 calendar days after the occurrence of such an event of default, consist exclusively of the right to receive additional interest on the 2029 Notes at a rate equal to (i) 0.25% per annum of the principal amount of the 2029 Notes outstanding for each day during the first 180 calendar days of the 360-day period after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived) and (ii) 0.50% per annum of the principal amount of the 2029 Notes outstanding for each day from, and including, the 181&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;st&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; calendar day to, and including, the 360&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;th&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; calendar day after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived as provided for in the 2029 Indenture). On the 361&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;st&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; day after such event of default (if the event of default relating to our failure to comply with its obligations is not cured or waived prior to such 361&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;st&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; day), the 2029 Notes shall be subject to acceleration as provided for in the 2029 Indenture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2029 Notes are accounted for in accordance with the authoritative guidance for convertible debt instruments that may be settled in cash upon conversion. Under ASU 2020-06, the guidance requires that debt with an embedded conversion feature is accounted for in its entirety as a liability and no portion of the proceeds from the issuance of the convertible debt instrument is accounted for as attributable to the conversion feature unless the conversion feature is required to be accounted for separately as an embedded derivative or the conversion feature results in a substantial premium. The conversion feature of the 2029 Notes is not accounted for as an embedded derivative because it is considered to be indexed to our common stock, and the 2029 Notes were not issued at a substantial premium; therefore, the 2029 Notes are accounted for in their entirety as a liability. Because we may elect to settle any conversions entirely in shares, and because settlement in shares is the default settlement method, the liability is classified as non-current.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The requirement to repurchase the 2029 Notes, including unpaid interest to the maturity date in the event of a Fundamental Change, is considered a put option for certain periods requiring bifurcation under ASC 815 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; However, given the low probability of such a Fundamental Change occurring during the applicable periods, the value of the embedded derivative is immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The additional interest feature in the event of our failure to comply with certain reporting obligations is also considered an embedded derivative requiring bifurcation under ASC 815. However, due to the nature and terms of the reporting obligations, the value of the embedded derivative is immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The exchange qualified as a troubled debt restructuring under ASC 470-60 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Troubled Debt Restructurings by Debtors&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Since the undiscounted cash flows of the 2029 Notes were less than the carrying amount of the exchanged 2028 Notes, the carrying value of the 2029 Notes was determined based on the total undiscounted cash flows. As a result, no interest expense will be recognized for the 2029 Notes. The Company recorded a gain on debt restructuring of $154.4&#160;million, which resulted in a decrease of basic net loss per share of $0.56, during the year ended December 31, 2024 in our consolidated statements of operations and comprehensive loss. The gain was calculated as the difference between the carrying amount of the old debt and the carrying amount of the new debt, adjusted for debt issuance costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We incurred issuance costs related to the 2029 Notes of approximately $3.1&#160;million, including $0.2&#160;million of lender fees, which were recorded as a reduction to the gain on debt restructuring in our consolidated statements of operations and comprehensive loss. We also paid accrued but unpaid interest of $1.8&#160;million on the 2028 Notes in connection with the 2024 Exchange Transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We did not receive any cash proceeds from the 2024 Exchange Transaction. In exchange for issuing the 2029 Notes, Exchange Shares and paying $50.0&#160;million of cash pursuant to the 2024 Exchange Transaction, we received and cancelled the exchanged 2028 Notes. Following the closing of the 2024 Exchange Transaction, no amounts were outstanding on the 2028 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of the liability for the 2029 Notes as of September&#160;30, 2025 is $212.0&#160;million, of which $209.0 million is included as convertible senior notes, net, non-current, and $3.0 million is included as accrued expenses on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes to the 2029 Notes during the nine months ended September 30, 2025 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Carrying amount as of December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;214,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Contractual interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Carrying amount as of September&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;212,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2025, the estimated fair value (Level 2) of the 2029 Notes was $169.4&#160;million. The fair value of the 2029 Notes is estimated using a binomial lattice model that is primarily affected by the trading price of our common stock, market interest rates and volatility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;2030 Convertible Senior Notes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2023, we entered into a privately negotiated exchange agreement with a holder of our outstanding 2028 Notes, pursuant to which we issued $441.0&#160;million in aggregate principal amount of our 1.375% Convertible Senior Notes due 2030 (the &#x201c;2030 Notes&#x201d; and together with the 2029 Notes, the &#x201c;Notes&#x201d;) in exchange for $441.0&#160;million principal amount of the 2028 Notes (the &#x201c;2023 Exchange Transaction&#x201d;), pursuant to exemptions from registration under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), and the rules and regulations thereunder. The 2030 Notes were issued on June 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2030 Notes are governed by an indenture (the &#x201c;2030 Indenture&#x201d;) between the Company and U.S. Bank Trust Company, National Association, as trustee. The 2030 Notes bear interest at a rate of 1.375% per annum. Interest on the 2030 Notes is payable semi-annually in arrears on June 15 and December 15, commencing on December 15, 2023. The 2030 Notes will mature on December 15, 2030, subject to earlier conversion, redemption or repurchase.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2030 Notes are convertible at the option of the holder at any time until the second scheduled trading day prior to the maturity date, including in connection with a redemption by the Company. The 2030 Notes are convertible into shares of our common stock based on an initial conversion rate of 46.5116 shares of common stock per $1,000 principal amount of the 2030 Notes (which is equal to an initial conversion price of approximately $21.50 per share of common stock), in each case subject to customary anti-dilution and other adjustments as a result of certain extraordinary transactions. Upon conversion of the 2030 Notes, we may elect to settle such conversion obligation in cash, shares of our common stock, or a combination of cash and shares of our common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On or after June 20, 2028, and prior to the 31st scheduled trading day immediately preceding the maturity date, the 2030 Notes will be redeemable by the Company in the event that the closing sale price of our common stock has been at least 150% of the conversion price then in effect for at least 20 trading days (whether or not &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide the redemption notice at a redemption price of 100% of the principal amount of such 2030 Notes, plus accrued and unpaid interest up to, but excluding, the redemption date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the occurrence of a Fundamental Change (as defined in the 2030 Indenture), the holders of the 2030 Notes may require that we repurchase all or part of the principal amount of the 2030 Notes at a purchase price equal to 100% of the principal amount of the notes to be repurchased, plus any accrued and unpaid interest up to, but excluding, the fundamental change repurchase date, and all unpaid interest from the fundamental change repurchase date thereon, but excluding, the maturity date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2030 Indenture includes customary &#x201c;events of default,&#x201d; which may result in the acceleration of the maturity of the 2030 Notes under the 2030 Indenture. The 2030 Indenture also includes customary covenants for convertible notes of this type.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To the extent we elect, the sole remedy for an event of default relating to our failure to comply with certain of our reporting obligations shall, for the first 360 calendar days after the occurrence of such an event of default, consist exclusively of the right to receive additional interest on the 2030 Notes at a rate equal to (i) 0.25% per annum of the principal amount of the 2030 Notes outstanding for each day during the first 180 calendar days of the 360-day period after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived) and (ii) 0.50% per annum of the principal amount of the 2030 Notes outstanding for each day from, and including, the 181&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;st&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; calendar day to, and including, the 360&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;th&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; calendar day after the occurrence of such an event of default during which such event of default is continuing (or, if earlier, the date on which such event of default is cured or waived as provided for in the 2030 Indenture). On the 361&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;st&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; day after such event of default (if the event of default relating to our failure to comply with its obligations is not cured or waived prior to such 361&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;st&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; day), the 2030 Notes shall be subject to acceleration as provided for in the 2030 Indenture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2030 Notes are accounted for in accordance with the authoritative guidance for convertible debt instruments that may be settled in cash upon conversion. Under ASU 2020-06, the guidance requires that debt with an embedded conversion feature is accounted for in its entirety as a liability and no portion of the proceeds from the issuance of the convertible debt instrument is accounted for as attributable to the conversion feature unless the conversion feature is required to be accounted for separately as an embedded derivative or the conversion feature results in a substantial premium. The conversion feature of the 2030 Notes is not accounted for as an embedded derivative because it is considered to be indexed to our common stock, and the 2030 Notes were not issued at a substantial premium; therefore, the 2030 Notes are accounted for in their entirety as a liability. Because we may elect to settle any conversions entirely in shares, and because settlement in shares is the default settlement method, the liability is classified as non-current.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The requirement to repurchase the 2030 Notes, including unpaid interest to the maturity date in the event of a Fundamental Change, is considered a put option for certain periods requiring bifurcation under ASC 815 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; However, given the low probability of such a Fundamental Change occurring during the applicable periods, the value of the embedded derivative is immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The additional interest feature in the event of our failure to comply with certain reporting obligations is also considered an embedded derivative requiring bifurcation under ASC 815. However, due to the nature and terms of the reporting obligations, the value of the embedded derivative is immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2023 Exchange Transaction was accounted for as an extinguishment driven by the change in fair value of the embedded conversion option. We recorded a loss on extinguishment of debt of approximately $2.0&#160;million in connection with the 2023 Exchange Transaction during the year ended December 31, 2023, which represents the difference between the fair value and the principal amount of the 2030 Notes of the debt at the modification date, plus unamortized debt issuance costs of $1.5&#160;million related to the respective portion of the 2028 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We incurred issuance costs related to the 2030 Notes of approximately $7.3&#160;million, which were recorded as debt issuance costs and are presented as a reduction to the 2030 Notes on our condensed consolidated balance sheets. The debt issuance costs are amortized to interest expense using the effective interest method over the term of the 2030 Notes, resulting in an effective interest rate of 1.6%. We also paid accrued but unpaid interest of $2.5&#160;million on the 2028 Notes in connection with the 2023 Exchange Transaction on June 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We did not receive any cash proceeds from the 2023 Exchange Transaction. In exchange for issuing the 2030 Notes pursuant to the 2023 Exchange Transaction, we received and cancelled the exchanged 2028 Notes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following the closing of the 2023 Exchange Transaction, $459.0&#160;million in aggregate principal amount of 2028 Notes remained outstanding with terms unchanged.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net carrying amount of the liability for the 2030 Notes is included as convertible senior notes, net, non-current in the condensed consolidated balance sheets as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;441,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;441,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Unamortized debt premium&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5,239)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5,959)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;436,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;435,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense for the 2030 Notes was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.778%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.782%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Contractual interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2025, the estimated fair value (Level 2) of the 2030 Notes was $314.5 million. The fair value of the 2030 Notes is estimated using a binomial lattice model that is primarily affected by the trading price of our common stock, market interest rates and volatility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;2028 Convertible Senior Notes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 9, 2021, we entered into an investment agreement with SBN relating to the issuance and sale to SBN of $900.0&#160;million in aggregate principal amount of the 2028 Notes. The 2028 Notes were issued on February 16, 2021 and bore interest at a rate of 1.50% per annum. As discussed above, in June 2023 we completed an exchange of $441.0&#160;million in aggregate principal amount of our 2028 Notes for $441.0&#160;million aggregate principal amount of the 2030 Notes, leaving approximately $459.0&#160;million in aggregate principal amount of 2028 Notes outstanding. Also as discussed above, in November 2024 we completed an exchange of the remaining $459.0&#160;million in aggregate principal amount of the 2028 Notes outstanding for (i) $200.0&#160;million aggregate principal amount of the 2029 Notes, (ii) the Exchange Shares and (iii) $50.0&#160;million of cash. As of December 31, 2024 no amounts were outstanding on the 2028 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We incurred issuance costs related to the 2028 Notes of approximately $4.5&#160;million, which were recorded as debt issuance costs and are presented as a reduction to the 2028 Notes on our consolidated balance sheets. The debt issuance costs were amortized to interest expense using the effective interest method over the term of the 2028 Notes, resulting in an effective interest rate of 1.6%. In connection with the 2024 Exchange Transaction, the remaining unamortized debt issuance costs related to the 2028 Notes of $1.1&#160;million were extinguished by offsetting the carrying amount of the convertible senior notes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense for the 2028 Notes was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.778%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.778%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.778%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.782%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Contractual interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-126" decimals="-5" id="f-629" unitRef="usd">459000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-126" decimals="4" id="f-630" unitRef="number">0.0150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-127" decimals="-5" id="f-631" unitRef="usd">200000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-127" decimals="4" id="f-632" unitRef="number">0.0150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="c-128" decimals="0" id="f-633" unitRef="shares">20451570</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <pacb:PaymentsInConjunctionWithNotesExchange contextRef="c-129" decimals="-5" id="f-634" unitRef="usd">50000000</pacb:PaymentsInConjunctionWithNotesExchange>
    <pacb:HoldingPeriodForTransferAssignmentOrSaleOfFounderShares contextRef="c-130" id="f-635">P6M</pacb:HoldingPeriodForTransferAssignmentOrSaleOfFounderShares>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger contextRef="c-129" decimals="4" id="f-636" unitRef="number">0.099</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger contextRef="c-129" decimals="4" id="f-637" unitRef="number">0.099</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-127" decimals="4" id="f-638" unitRef="number">0.0150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-127"
      decimals="2"
      id="f-639"
      unitRef="usdPerShare">4.89</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger contextRef="c-128" decimals="2" id="f-640" unitRef="number">1.50</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays contextRef="c-128" decimals="INF" id="f-641" unitRef="d">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1 contextRef="c-128" decimals="INF" id="f-642" unitRef="d">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="c-128" decimals="2" id="f-643" unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-128" id="f-644">P360D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentInterestInTheEventOfDefault contextRef="c-131" decimals="4" id="f-645" unitRef="number">0.0025</pacb:DebtInstrumentInterestInTheEventOfDefault>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-131" id="f-646">P180D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-128" id="f-647">P360D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentAdditionalInterestInEventOfDefault contextRef="c-132" decimals="4" id="f-648" unitRef="number">0.0050</pacb:DebtInstrumentAdditionalInterestInEventOfDefault>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-133" id="f-649">P181D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-134" id="f-650">P360D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-132" id="f-651">P361D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-132" id="f-652">P361D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <us-gaap:GainsLossesOnRestructuringOfDebt contextRef="c-135" decimals="-5" id="f-653" unitRef="usd">154400000</us-gaap:GainsLossesOnRestructuringOfDebt>
    <pacb:RestructuringOfDebtPricePerShare
      contextRef="c-135"
      decimals="2"
      id="f-654"
      unitRef="usdPerShare">0.56</pacb:RestructuringOfDebtPricePerShare>
    <us-gaap:DeferredFinanceCostsGross contextRef="c-136" decimals="-5" id="f-655" unitRef="usd">3100000</us-gaap:DeferredFinanceCostsGross>
    <pacb:DebtIssuanceCostLenderFees contextRef="c-136" decimals="-5" id="f-656" unitRef="usd">200000</pacb:DebtIssuanceCostLenderFees>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest contextRef="c-137" decimals="-5" id="f-657" unitRef="usd">1800000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <pacb:PaymentsInConjunctionWithNotesExchange contextRef="c-129" decimals="-5" id="f-658" unitRef="usd">50000000</pacb:PaymentsInConjunctionWithNotesExchange>
    <us-gaap:LongTermDebt contextRef="c-126" decimals="0" id="f-659" unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:ConvertibleNotesPayable contextRef="c-138" decimals="-5" id="f-660" unitRef="usd">212000000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleLongTermNotesPayable contextRef="c-138" decimals="-5" id="f-661" unitRef="usd">209000000.0</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-138" decimals="-5" id="f-662" unitRef="usd">3000000.0</us-gaap:AccruedLiabilitiesCurrent>
    <pacb:ScheduleOfInterestExpenseTableTextBlock contextRef="c-1" id="f-663">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes to the 2029 Notes during the nine months ended September 30, 2025 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.082%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Carrying amount as of December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;214,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Contractual interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Carrying amount as of September&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;212,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense for the 2030 Notes was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.778%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.782%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Contractual interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense for the 2028 Notes was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.778%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.778%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.778%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.782%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Contractual interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</pacb:ScheduleOfInterestExpenseTableTextBlock>
    <us-gaap:ConvertibleNotesPayable contextRef="c-139" decimals="-3" id="f-664" unitRef="usd">214200000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-140" decimals="-3" id="f-665" unitRef="usd">2200000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:ConvertibleNotesPayable contextRef="c-138" decimals="-3" id="f-666" unitRef="usd">212000000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleDebtFairValueDisclosures contextRef="c-141" decimals="-5" id="f-667" unitRef="usd">169400000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-142" decimals="-5" id="f-668" unitRef="usd">441000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-142" decimals="5" id="f-669" unitRef="number">0.01375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-142" decimals="-5" id="f-670" unitRef="usd">441000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-142" decimals="5" id="f-671" unitRef="number">0.01375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-142"
      decimals="2"
      id="f-672"
      unitRef="usdPerShare">21.50</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <pacb:DebtInstrumentRedemptionPricePercentageOfConversionPrice contextRef="c-143" decimals="2" id="f-673" unitRef="number">1.50</pacb:DebtInstrumentRedemptionPricePercentageOfConversionPrice>
    <pacb:DebtInstrumentRedemptionPriceTradingDays contextRef="c-143" id="f-674">P20D</pacb:DebtInstrumentRedemptionPriceTradingDays>
    <pacb:DebtInstrumentRedemptionPriceConsecutiveTradingDays contextRef="c-143" id="f-675">P30D</pacb:DebtInstrumentRedemptionPriceConsecutiveTradingDays>
    <us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="c-143" decimals="2" id="f-676" unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="c-143" decimals="2" id="f-677" unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-143" id="f-678">P360D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentInterestInTheEventOfDefault contextRef="c-143" decimals="4" id="f-679" unitRef="number">0.0025</pacb:DebtInstrumentInterestInTheEventOfDefault>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-144" id="f-680">P180D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-143" id="f-681">P360D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentAdditionalInterestInEventOfDefault contextRef="c-143" decimals="4" id="f-682" unitRef="number">0.0050</pacb:DebtInstrumentAdditionalInterestInEventOfDefault>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-145" id="f-683">P181D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-146" id="f-684">P360D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-147" id="f-685">P361D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <pacb:DebtInstrumentDebtDefaultCalendarDays contextRef="c-147" id="f-686">P361D</pacb:DebtInstrumentDebtDefaultCalendarDays>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-148" decimals="-5" id="f-687" unitRef="usd">-2000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DeferredFinanceCostsGross contextRef="c-149" decimals="-5" id="f-688" unitRef="usd">1500000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DeferredFinanceCostsGross contextRef="c-150" decimals="-5" id="f-689" unitRef="usd">7300000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-142" decimals="3" id="f-690" unitRef="number">0.016</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest contextRef="c-151" decimals="-5" id="f-691" unitRef="usd">2500000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:LongTermDebt contextRef="c-152" decimals="-5" id="f-692" unitRef="usd">459000000</us-gaap:LongTermDebt>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="c-1" id="f-693">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net carrying amount of the liability for the 2030 Notes is included as convertible senior notes, net, non-current in the condensed consolidated balance sheets as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30,&lt;br/&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;441,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;441,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Unamortized debt premium&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5,239)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5,959)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;436,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;435,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-153" decimals="-3" id="f-694" unitRef="usd">441000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-154" decimals="-3" id="f-695" unitRef="usd">441000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedPremium contextRef="c-153" decimals="-3" id="f-696" unitRef="usd">398000</us-gaap:DebtInstrumentUnamortizedPremium>
    <us-gaap:DebtInstrumentUnamortizedPremium contextRef="c-154" decimals="-3" id="f-697" unitRef="usd">453000</us-gaap:DebtInstrumentUnamortizedPremium>
    <us-gaap:UnamortizedDebtIssuanceExpense contextRef="c-153" decimals="-3" id="f-698" unitRef="usd">5239000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:UnamortizedDebtIssuanceExpense contextRef="c-154" decimals="-3" id="f-699" unitRef="usd">5959000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:LongTermDebt contextRef="c-153" decimals="-3" id="f-700" unitRef="usd">436159000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-154" decimals="-3" id="f-701" unitRef="usd">435494000</us-gaap:LongTermDebt>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-155" decimals="-3" id="f-702" unitRef="usd">1516000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-156" decimals="-3" id="f-703" unitRef="usd">1516000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-157" decimals="-3" id="f-704" unitRef="usd">4548000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-158" decimals="-3" id="f-705" unitRef="usd">4565000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-155" decimals="-3" id="f-706" unitRef="usd">241000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-156" decimals="-3" id="f-707" unitRef="usd">237000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-157" decimals="-3" id="f-708" unitRef="usd">720000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-158" decimals="-3" id="f-709" unitRef="usd">712000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InterestExpenseDebt contextRef="c-155" decimals="-3" id="f-710" unitRef="usd">1757000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-156" decimals="-3" id="f-711" unitRef="usd">1753000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-157" decimals="-3" id="f-712" unitRef="usd">5268000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-158" decimals="-3" id="f-713" unitRef="usd">5277000</us-gaap:InterestExpenseDebt>
    <us-gaap:ConvertibleDebtFairValueDisclosures contextRef="c-159" decimals="-5" id="f-714" unitRef="usd">314500000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-160" decimals="-5" id="f-715" unitRef="usd">900000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-160" decimals="4" id="f-716" unitRef="number">0.0150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-152" decimals="-5" id="f-717" unitRef="usd">441000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-142" decimals="-5" id="f-718" unitRef="usd">441000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebt contextRef="c-152" decimals="-5" id="f-719" unitRef="usd">459000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-161" decimals="-5" id="f-720" unitRef="usd">459000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-162" decimals="-5" id="f-721" unitRef="usd">200000000</us-gaap:DebtInstrumentFaceAmount>
    <pacb:PaymentsInConjunctionWithNotesExchange contextRef="c-129" decimals="-5" id="f-722" unitRef="usd">50000000</pacb:PaymentsInConjunctionWithNotesExchange>
    <us-gaap:LongTermDebt contextRef="c-163" decimals="-3" id="f-723" unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DeferredFinanceCostsGross contextRef="c-160" decimals="-5" id="f-724" unitRef="usd">4500000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-160" decimals="3" id="f-725" unitRef="number">0.016</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-164" decimals="-5" id="f-726" unitRef="usd">1100000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-165" decimals="-3" id="f-727" unitRef="usd">0</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-166" decimals="-3" id="f-728" unitRef="usd">1721000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-167" decimals="-3" id="f-729" unitRef="usd">0</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-168" decimals="-3" id="f-730" unitRef="usd">5163000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-165" decimals="-3" id="f-731" unitRef="usd">0</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-166" decimals="-3" id="f-732" unitRef="usd">81000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-167" decimals="-3" id="f-733" unitRef="usd">0</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-168" decimals="-3" id="f-734" unitRef="usd">243000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InterestExpenseDebt contextRef="c-165" decimals="-3" id="f-735" unitRef="usd">0</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-166" decimals="-3" id="f-736" unitRef="usd">1802000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-167" decimals="-3" id="f-737" unitRef="usd">0</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-168" decimals="-3" id="f-738" unitRef="usd">5406000</us-gaap:InterestExpenseDebt>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="c-1" id="f-741">&lt;div style="margin-top:15pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"&gt;&lt;span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;NOTE 5.  RESTRUCTURING&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;2025 Restructuring&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter of 2025, we implemented an expense reduction initiative aimed at lowering our annualized run-rate operating expenses. These actions, which included workforce reductions and other cost-saving measures, were part of a broader strategic shift to prioritize the adoption of HiFi sequencing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the pre-tax restructuring charges are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.687%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.172%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.175%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Cumulative amount incurred to date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Employee separation costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="-sec-ix-hidden:f-747"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total restructuring charges &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Cumulative charges incurred to date include $3.3&#160;million in sales, general and administrative expense and $2.1&#160;million in research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Charges included employee separation costs comprised of approximately $2.5&#160;million related to salaries, wages and other employee benefits paid to terminated employees pursuant to the Worker Adjustment and Retraining Notification (WARN) Act and approximately $2.3&#160;million of severance costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Charges included in other costs are primarily related to legal expenses incurred in connection with employee separation matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the restructuring and strategic shift, we incurred an additional $388.6&#160;million in costs. These include $359.3&#160;million of accelerated amortization of certain intangible assets, $15.0&#160;million of IPR&amp;amp;D impairment charges, $8.0&#160;million related to excess inventory due to decreased external demand and $3.9&#160;million for estimated losses on purchase commitments tied to anticipated future excess inventory included in cost of revenue, and $2.4&#160;million of accelerated depreciation of fixed assets. See &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_37" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 3. Balance Sheet Components&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for additional information on the IPR&amp;amp;D impairment assessment and the change in estimated useful life of the intangible asset and accelerated amortization.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the liabilities related to the restructuring is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.115%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands, excluding non-cash activities)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Employee Separation Costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expense recorded in YTD 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash paid during YTD 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4,787)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,315)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amount recorded in current liabilities&lt;br/&gt;as of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Estimated total restructuring costs to still be incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;2024 Restructuring&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the second quarter of 2024, we implemented an expense reduction initiative that included workforce reductions, the closing of our San Diego office, and other actions to reduce annualized run-rate operating expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the pre-tax restructuring charges are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.687%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.172%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.175%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Cumulative amount incurred to date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Employee separation costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="-sec-ix-hidden:f-777"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total restructuring charges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;26,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:40.5pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Cumulative charges incurred to date include $15.8 million in sales, general and administrative expense; $5.9 million in research and development expense; and $4.4 million in cost of revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumulative charges incurred to date include employee separation costs comprised of approximately $5.5&#160;million related to salaries, wages and other employee benefits paid to terminated employees pursuant to the Worker Adjustment and Retraining Notification (WARN) Act and approximately $4.5&#160;million of severance costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other costs in cumulative charges incurred to date are primarily related to accelerated amortization and depreciation of $8.1&#160;million for the right-of-use asset, leasehold improvements, and furniture and fixtures relating to the abandonment of the San Diego office. We also incurred cumulative charges to date for excess inventory of $3.6&#160;million primarily relating to a decrease in internal demand resulting from the expense reduction initiatives which were recognized in cost of product revenues. The accelerated amortization and depreciation, which was recognized in sales, general and administrative expense, was determined as a result of the Company's change in estimate pertaining to its remaining useful life of the San Diego office utilizing the estimated date on which it planned to abandon the San Diego office. The lease liability pertaining to the San Diego office was also remeasured during the three months ended June 30, 2024 resulting in a reduction in the operating lease liability balance of $4.4&#160;million, which was offset against the right-of-use asset on the condensed consolidated balance sheets. We fully exited our San Diego office in September 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the liabilities related to the restructuring is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.114%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amount recorded in current liabilities as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additional expense recorded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,058)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,058)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amount recorded in current liabilities as of September&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated total restructuring costs to still be incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table above excludes noncash activities and amounts incurred relating to the San Diego office lease liability. The ending balance of the San Diego office lease liability was $0 at the end of the second quarter of 2025.&lt;/span&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock contextRef="c-1" id="f-742">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the pre-tax restructuring charges are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.687%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.172%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.175%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Cumulative amount incurred to date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Employee separation costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="-sec-ix-hidden:f-747"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total restructuring charges &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:31.5pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Cumulative charges incurred to date include $3.3&#160;million in sales, general and administrative expense and $2.1&#160;million in research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the pre-tax restructuring charges are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.687%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.172%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.175%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Cumulative amount incurred to date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Employee separation costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="-sec-ix-hidden:f-777"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total restructuring charges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;26,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:40.5pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Cumulative charges incurred to date include $15.8 million in sales, general and administrative expense; $5.9 million in research and development expense; and $4.4 million in cost of revenue.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:RestructuringCharges contextRef="c-169" decimals="-3" id="f-743" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostIncurredCost contextRef="c-169" decimals="-3" id="f-744" unitRef="usd">4787000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringCharges contextRef="c-170" decimals="-3" id="f-745" unitRef="usd">66000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostIncurredCost contextRef="c-170" decimals="-3" id="f-746" unitRef="usd">629000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringCharges contextRef="c-171" decimals="-3" id="f-748" unitRef="usd">66000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostIncurredCost contextRef="c-171" decimals="-3" id="f-749" unitRef="usd">5416000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost contextRef="c-172" decimals="-5" id="f-750" unitRef="usd">3300000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost contextRef="c-173" decimals="-5" id="f-751" unitRef="usd">2100000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <pacb:RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits contextRef="c-116" decimals="-5" id="f-752" unitRef="usd">2500000</pacb:RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits>
    <us-gaap:SeveranceCosts1 contextRef="c-116" decimals="-5" id="f-753" unitRef="usd">2300000</us-gaap:SeveranceCosts1>
    <pacb:RestructuringChargesAdditionalCostsIncurred contextRef="c-116" decimals="-5" id="f-754" unitRef="usd">388600000</pacb:RestructuringChargesAdditionalCostsIncurred>
    <pacb:RestructuringAndRelatedCostAcceleratedAmortization contextRef="c-116" decimals="-5" id="f-755" unitRef="usd">359300000</pacb:RestructuringAndRelatedCostAcceleratedAmortization>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c-174" decimals="-5" id="f-756" unitRef="usd">15000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:InventoryWriteDown contextRef="c-116" decimals="-5" id="f-757" unitRef="usd">8000000</us-gaap:InventoryWriteDown>
    <pacb:GainLossOnPurchaseCommitments contextRef="c-116" decimals="-5" id="f-758" unitRef="usd">3900000</pacb:GainLossOnPurchaseCommitments>
    <us-gaap:RestructuringReserveAcceleratedDepreciation contextRef="c-116" decimals="-5" id="f-759" unitRef="usd">2400000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock contextRef="c-1" id="f-760">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the liabilities related to the restructuring is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.115%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands, excluding non-cash activities)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Employee Separation Costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expense recorded in YTD 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash paid during YTD 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4,787)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(528)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,315)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amount recorded in current liabilities&lt;br/&gt;as of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Estimated total restructuring costs to still be incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the liabilities related to the restructuring is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.114%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amount recorded in current liabilities as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additional expense recorded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,058)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,058)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amount recorded in current liabilities as of September&#160;30, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated total restructuring costs to still be incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringCharges contextRef="c-175" decimals="-3" id="f-761" unitRef="usd">4787000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-176" decimals="-3" id="f-762" unitRef="usd">629000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-116" decimals="-3" id="f-763" unitRef="usd">5416000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring contextRef="c-175" decimals="-3" id="f-764" unitRef="usd">4787000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-176" decimals="-3" id="f-765" unitRef="usd">528000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-116" decimals="-3" id="f-766" unitRef="usd">5315000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve contextRef="c-177" decimals="-3" id="f-767" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-178" decimals="-3" id="f-768" unitRef="usd">101000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-179" decimals="-3" id="f-769" unitRef="usd">101000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1 contextRef="c-177" decimals="-3" id="f-770" unitRef="usd">0</us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1>
    <us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1 contextRef="c-178" decimals="-3" id="f-771" unitRef="usd">0</us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1>
    <us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1 contextRef="c-179" decimals="-3" id="f-772" unitRef="usd">0</us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1>
    <us-gaap:RestructuringCharges contextRef="c-180" decimals="-3" id="f-773" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostIncurredCost contextRef="c-180" decimals="-3" id="f-774" unitRef="usd">10008000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringCharges contextRef="c-181" decimals="-3" id="f-775" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostIncurredCost contextRef="c-181" decimals="-3" id="f-776" unitRef="usd">16102000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringCharges contextRef="c-182" decimals="-3" id="f-778" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostIncurredCost contextRef="c-182" decimals="-3" id="f-779" unitRef="usd">26110000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost contextRef="c-183" decimals="-5" id="f-780" unitRef="usd">15800000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost contextRef="c-184" decimals="-5" id="f-781" unitRef="usd">5900000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost contextRef="c-185" decimals="-5" id="f-782" unitRef="usd">4400000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <pacb:RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits contextRef="c-186" decimals="-5" id="f-783" unitRef="usd">5500000</pacb:RestructuringChargesWorkerAdjustmentAndRetrainingNotificationWARNActAndOtherEmployeeBenefits>
    <us-gaap:SeveranceCosts1 contextRef="c-186" decimals="-5" id="f-784" unitRef="usd">4500000</us-gaap:SeveranceCosts1>
    <us-gaap:RestructuringReserveAcceleratedDepreciation contextRef="c-187" decimals="-5" id="f-785" unitRef="usd">8100000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:InventoryWriteDown contextRef="c-187" decimals="-5" id="f-786" unitRef="usd">3600000</us-gaap:InventoryWriteDown>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-188" decimals="-5" id="f-787" unitRef="usd">-4400000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:RestructuringReserve contextRef="c-189" decimals="-3" id="f-788" unitRef="usd">170000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-190" decimals="-3" id="f-789" unitRef="usd">170000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges contextRef="c-191" decimals="-3" id="f-790" unitRef="usd">888000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-186" decimals="-3" id="f-791" unitRef="usd">888000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring contextRef="c-191" decimals="-3" id="f-792" unitRef="usd">1058000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-186" decimals="-3" id="f-793" unitRef="usd">1058000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve contextRef="c-192" decimals="-3" id="f-794" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-193" decimals="-3" id="f-795" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1 contextRef="c-192" decimals="-3" id="f-796" unitRef="usd">0</us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1>
    <us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1 contextRef="c-193" decimals="-3" id="f-797" unitRef="usd">0</us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1>
    <us-gaap:OperatingLeaseLiability contextRef="c-194" decimals="-5" id="f-798" unitRef="usd">0</us-gaap:OperatingLeaseLiability>
    <us-gaap:LossContingencyDisclosures contextRef="c-1" id="f-799">&lt;div style="margin-top:15pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"&gt;&lt;span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;NOTE 6.  COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into various operating lease agreements, primarily relating to our corporate offices. On March 7, 2025, we amended our existing lease covering our corporate headquarters, as well as our research and development, manufacturing, and distribution facilities in Menlo Park, California. The lease amendment extends the term to April 30, 2034. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 6 &#x2013; Commitments and Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, subsection titled &#x201c;Leases&#x201d;, in Part I, Item 1 of the Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 for information regarding the Company&#x2019;s maturity of lease liabilities under its lease agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may become involved in legal proceedings, claims and assessments from time to time in the ordinary course of business. We accrue liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not believe that the ultimate outcome of any such pending matters is probable or reasonably estimable, or that these matters will have a material adverse effect on our business; however, the results of litigation and claims are inherently unpredictable. Regardless of the outcome, litigation can have an adverse impact on us because of litigation and settlement costs, diversion of management resources, and other factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Please see subsection titled &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_91" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Legal Proceedings, in Part II, Item 1&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of this Quarterly Report on Form 10-Q.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Indemnification&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to Delaware law and agreements entered into with each of our directors and officers, we may have obligations, under certain circumstances, to hold harmless and indemnify each of our directors and officers against losses suffered or incurred by the indemnified party in connection with their service to us, and judgements, fines, settlements and expenses related to claims arising against such directors and officers to the fullest extent permitted under Delaware law, our bylaws and our certificate of incorporation. We also enter and have entered into indemnification agreements with our directors and officers that may require us to indemnify them against liabilities that arise by reason of their status or service as directors or officers, except as prohibited by applicable law. In addition, we may have obligations to hold harmless and indemnify third parties involved with our fundraising efforts and their respective affiliates, directors, officers, employees, agents or other representatives against any and all losses, claims, damages and liabilities related to claims arising against such parties pursuant to the terms of agreements entered into between such third parties and us in connection with such fundraising efforts. To the extent that any such indemnification obligations apply to the lawsuits described above, any associated expenses incurred are included within the related accrued litigation expense amounts. No additional liability associated with such indemnification obligations has been recorded as of September&#160;30, 2025 and December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:LossContingencyDisclosures>
    <pacb:AdditionalLiabilityAssociatedWithIndemnificationObligations contextRef="c-4" decimals="0" id="f-800" unitRef="usd">0</pacb:AdditionalLiabilityAssociatedWithIndemnificationObligations>
    <pacb:AdditionalLiabilityAssociatedWithIndemnificationObligations contextRef="c-3" decimals="0" id="f-801" unitRef="usd">0</pacb:AdditionalLiabilityAssociatedWithIndemnificationObligations>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-802">&lt;div style="margin-top:15pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"&gt;&lt;span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;NOTE 7.  EQUITY PLANS AND SHARE-BASED COMPENSATION&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Equity Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2025, the Company had share-based compensation awards outstanding under the 2020 Equity Incentive Plan (the &#x201c;2020 Plan&#x201d;), the 2020 Inducement Equity Incentive Plan (the &#x201c;Inducement Plan&#x201d;), the 2021 adopted Omniome Equity Incentive Plan of Pacific Biosciences of California, Inc. (the &#x201c;Omniome Plan&#x201d;) and the 2010 Employee Stock Purchase Plan, from which we issued equity awards and employee stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 4, 2025, our stockholders approved an amendment to the 2020 Plan to reserve an additional 23&#160;million shares of our common stock for issuance pursuant to equity awards granted under the 2020 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2025, we had 37.8&#160;million shares remaining and available for future issuance under the 2020 Plan, Inducement Plan, and the Omniome Plan. Shares remaining and available for future issuance reflect shares that may become eligible to vest upon the achievement of maximum targets for certain equity awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 9 &#x2013; Stockholders' Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in Part II, Item 8 of our 2024 Annual Report for more information on the Company's equity plans&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for time-based awards:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(shares in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Number&lt;br/&gt;of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,509&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Granted &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,290&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,501)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(376)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Outstanding at September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15,922&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Restricted Stock Units ("RSU") and Performance Stock Units ("PSU")&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We grant RSUs for which the respective shares vest when the requisite service period is achieved.&#160;We granted PSUs during the first quarter of 2023 for which the number of shares issuable is based on performance relative to specified revenue targets and continued employment through the vesting period. The PSUs are issuable following the third year of the performance period. Maximum achievement of the revenue goal under the PSUs will result in up to 200% of the target number of shares subject to the PSUs to become eligible to vest, while not meeting the minimum achievement of the revenue goal under the PSUs will result in no shares subject to the PSUs becoming eligible to vest. The following table summarizes the time-based RSUs and PSUs activity: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:26pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Restricted Stock Units (RSU)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Performance Stock Units (PSU)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Weighted average grant date&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(shares in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;RSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;PSU&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4,331)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,652)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Outstanding at September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan ("ESPP")&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares issued under our ESPP wer&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;e 3,102,930 and 1,906,529&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; durin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;g the nine months ended September&#160;30, 2025 and 2024, respectively. In the first quarter of 2025, an additional 4.0&#160;million shares were reserved under the ESPP. As of September&#160;30, 2025, 15.2&#160;million shares of our common stock remain avai&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;lable for issuance under our ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Share-based Compensation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.627%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research and development &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Sales, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;35,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;32,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;55,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt dotted #df1995;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Determining Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the fair value of stock options granted using the Black-Scholes valuation method and a single option award approach. When determining the current share prices underlying the stock options for calculating the grant-date fair value, we reference the observable market prices of our stock. This fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. The fair market value of RSUs and PSUs granted is the closing price of our shares on the date of grant and is generally recognized as compensation expense on a straight-line basis over the respective vesting period. For shares purchased under our ESPP, we estimate the grant-date fair value, and the resulting share-based compensation expense, using the Black-Scholes option-pricing model. We estimate forfeitures of stock options, RSUs and shares purchased under our ESPP which is utilized to determine the compensation expense to be recorded over the requisite service period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt"&gt;Expected Term - The expected term used in the Black-Scholes valuation method represents the period that the stock options are expected to be outstanding and is determined based on historical experience of similar awards, considering the contractual terms of the stock options and vesting schedules.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt"&gt;Expected Volatility - The expected volatility used in the Black-Scholes valuation method is derived from the implied volatility related to our share price over the expected term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt"&gt;Expected Dividend - We have never paid dividends on our shares and, accordingly, the dividend yield percentage is zero for all periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt"&gt;Risk-Free Interest Rate - The risk-free interest rate used in the Black-Scholes valuation method is the implied yield currently available on U.S. Treasury constant maturities issued with a term equivalent to the expected terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of employee stock options was estimated using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected volatility &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;95% &#x2014; 96%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;81% &#x2014; 93%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;3.89% &#x2014; 4.29%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.48% &#x2014; 4.32%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Dividend yield &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted average grant date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$0.90&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$1.40&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:15pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of shares to be issued under the ESPP was estimated using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.5 &#x2014; 2.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.5 &#x2014; 2.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected volatility &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;101% &#x2014; 113%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;81% &#x2014; 118%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.66% &#x2014; 4.31%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.88% &#x2014; 5.27%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Dividend yield &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted average grant date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$0.89&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$1.53&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-195"
      decimals="-6"
      id="f-803"
      unitRef="shares">23000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-196"
      decimals="-5"
      id="f-804"
      unitRef="shares">37800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-805">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for time-based awards:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(shares in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Number&lt;br/&gt;of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,509&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Granted &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,290&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,501)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(376)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Outstanding at September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15,922&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-197"
      decimals="-3"
      id="f-806"
      unitRef="shares">10509000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-197"
      decimals="2"
      id="f-807"
      unitRef="usdPerShare">11.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-198"
      decimals="-3"
      id="f-808"
      unitRef="shares">8290000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-198"
      decimals="2"
      id="f-809"
      unitRef="usdPerShare">1.22</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c-198"
      decimals="-3"
      id="f-810"
      unitRef="shares">2501000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-198"
      decimals="2"
      id="f-811"
      unitRef="usdPerShare">7.89</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="c-198"
      decimals="-3"
      id="f-812"
      unitRef="shares">376000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-198"
      decimals="2"
      id="f-813"
      unitRef="usdPerShare">6.44</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-199"
      decimals="-3"
      id="f-814"
      unitRef="shares">15922000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-199"
      decimals="2"
      id="f-815"
      unitRef="usdPerShare">6.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <pacb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal contextRef="c-200" decimals="2" id="f-816" unitRef="number">2</pacb:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountEligibleToVestUponAchievementOfGoal>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="c-1" id="f-817">The following table summarizes the time-based RSUs and PSUs activity: &lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:26pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Restricted Stock Units (RSU)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Performance Stock Units (PSU)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Weighted average grant date&lt;br/&gt;fair value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(shares in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;RSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;PSU&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4,331)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,652)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Outstanding at September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-201"
      decimals="-3"
      id="f-818"
      unitRef="shares">14211000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-202"
      decimals="-3"
      id="f-819"
      unitRef="shares">392000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-201"
      decimals="2"
      id="f-820"
      unitRef="usdPerShare">7.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-202"
      decimals="2"
      id="f-821"
      unitRef="usdPerShare">9.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-203"
      decimals="-3"
      id="f-822"
      unitRef="shares">11895000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-204"
      decimals="-3"
      id="f-823"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-203"
      decimals="2"
      id="f-824"
      unitRef="usdPerShare">1.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-204"
      decimals="2"
      id="f-825"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-203"
      decimals="-3"
      id="f-826"
      unitRef="shares">4331000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-204"
      decimals="-3"
      id="f-827"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-203"
      decimals="2"
      id="f-828"
      unitRef="usdPerShare">9.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-204"
      decimals="2"
      id="f-829"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-203"
      decimals="-3"
      id="f-830"
      unitRef="shares">3652000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-204"
      decimals="-3"
      id="f-831"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-203"
      decimals="2"
      id="f-832"
      unitRef="usdPerShare">4.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-204"
      decimals="2"
      id="f-833"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-205"
      decimals="-3"
      id="f-834"
      unitRef="shares">18123000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-206"
      decimals="-3"
      id="f-835"
      unitRef="shares">392000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-205"
      decimals="2"
      id="f-836"
      unitRef="usdPerShare">3.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-206"
      decimals="2"
      id="f-837"
      unitRef="usdPerShare">9.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan contextRef="c-1" decimals="0" id="f-838" unitRef="shares">3102930</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan contextRef="c-15" decimals="0" id="f-839" unitRef="shares">1906529</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-207"
      decimals="-5"
      id="f-840"
      unitRef="shares">4000000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-208"
      decimals="-5"
      id="f-841"
      unitRef="shares">15200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-842">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.627%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research and development &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Sales, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;35,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;32,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;55,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-209" decimals="-3" id="f-843" unitRef="usd">892000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-210" decimals="-3" id="f-844" unitRef="usd">1229000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-211" decimals="-3" id="f-845" unitRef="usd">2982000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-212" decimals="-3" id="f-846" unitRef="usd">4466000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-213" decimals="-3" id="f-847" unitRef="usd">3050000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-214" decimals="-3" id="f-848" unitRef="usd">4740000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-215" decimals="-3" id="f-849" unitRef="usd">8964000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-216" decimals="-3" id="f-850" unitRef="usd">15119000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-217" decimals="-3" id="f-851" unitRef="usd">7042000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-218" decimals="-3" id="f-852" unitRef="usd">12290000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-219" decimals="-3" id="f-853" unitRef="usd">20134000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-220" decimals="-3" id="f-854" unitRef="usd">35418000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-221" decimals="-3" id="f-855" unitRef="usd">10984000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-222" decimals="-3" id="f-856" unitRef="usd">18259000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-857" unitRef="usd">32080000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-15" decimals="-3" id="f-858" unitRef="usd">55003000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-1" decimals="INF" id="f-859" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-15"
      decimals="INF"
      id="f-860"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-861">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of employee stock options was estimated using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected volatility &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;95% &#x2014; 96%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;81% &#x2014; 93%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;3.89% &#x2014; 4.29%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.48% &#x2014; 4.32%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Dividend yield &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted average grant date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$0.90&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$1.40&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-223" id="f-862">P4Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-224" id="f-863">P4Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="c-223" decimals="2" id="f-864" unitRef="number">0.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="c-223" decimals="2" id="f-865" unitRef="number">0.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="c-224" decimals="2" id="f-866" unitRef="number">0.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="c-224" decimals="2" id="f-867" unitRef="number">0.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c-223" decimals="4" id="f-868" unitRef="number">0.0389</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="c-223" decimals="4" id="f-869" unitRef="number">0.0429</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c-224" decimals="4" id="f-870" unitRef="number">0.0348</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="c-224" decimals="4" id="f-871" unitRef="number">0.0432</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-223" decimals="0" id="f-872" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-224" decimals="0" id="f-873" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-223"
      decimals="2"
      id="f-874"
      unitRef="usdPerShare">0.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-224"
      decimals="2"
      id="f-875"
      unitRef="usdPerShare">1.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock contextRef="c-1" id="f-876">&lt;div style="margin-top:15pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of shares to be issued under the ESPP was estimated using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.5 &#x2014; 2.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.5 &#x2014; 2.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected volatility &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;101% &#x2014; 113%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;81% &#x2014; 118%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.66% &#x2014; 4.31%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.88% &#x2014; 5.27%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Dividend yield &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted average grant date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$0.89&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$1.53&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-225" id="f-877">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-226" id="f-878">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-227" id="f-879">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-228" id="f-880">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="c-229" decimals="2" id="f-881" unitRef="number">1.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="c-229" decimals="2" id="f-882" unitRef="number">1.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="c-230" decimals="2" id="f-883" unitRef="number">0.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="c-230" decimals="2" id="f-884" unitRef="number">1.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c-229" decimals="4" id="f-885" unitRef="number">0.0366</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="c-229" decimals="4" id="f-886" unitRef="number">0.0431</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c-230" decimals="4" id="f-887" unitRef="number">0.0388</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="c-230" decimals="4" id="f-888" unitRef="number">0.0527</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-229" decimals="0" id="f-889" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-230" decimals="0" id="f-890" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-229"
      decimals="2"
      id="f-891"
      unitRef="usdPerShare">0.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-230"
      decimals="2"
      id="f-892"
      unitRef="usdPerShare">1.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-893">&lt;div style="margin-top:15pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"&gt;&lt;span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;NOTE 8.  NET LOSS PER SHARE&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding and potential shares assuming the dilutive effect of the Notes, using the if-converted method, and outstanding equity awards using the treasury stock method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the calculation of the basic and diluted net loss per share amounts presented in the condensed consolidated statements of operations and comprehensive loss:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.748%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.235%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(38,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(60,725)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(506,005)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(312,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted average shares used in computing&lt;br/&gt;basic net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;300,844&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;272,915&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;299,303&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;271,631&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Basic net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0.13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1.69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1.15)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted average shares used in computing&lt;br/&gt;diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;300,844&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;272,915&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;299,303&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;271,631&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0.13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1.69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1.15)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:15pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following shares issuable upon conversion of the Notes and outstanding equity awards were excluded from the computation of diluted net loss per share for the periods presented because the effect of including such shares would have been antidilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.748%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.235%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Shares issuable upon conversion of&lt;br/&gt;convertible senior notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;61,415&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;31,063&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;61,415&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;31,063&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Equity awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;42,599&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;36,496&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;42,599&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;36,496&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ieb0962265ffb4e35ba6bd2d2c7eff64b_52" style="color:#0000ff;font-family:'Roboto',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 7. Equity Plans and Share-Based Compensation&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for detailed information on equity awards.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-894">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the calculation of the basic and diluted net loss per share amounts presented in the condensed consolidated statements of operations and comprehensive loss:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.748%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.235%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(38,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(60,725)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(506,005)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(312,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted average shares used in computing&lt;br/&gt;basic net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;300,844&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;272,915&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;299,303&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;271,631&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Basic net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0.13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1.69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1.15)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted average shares used in computing&lt;br/&gt;diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;300,844&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;272,915&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;299,303&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;271,631&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0.13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1.69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1.15)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-13" decimals="-3" id="f-895" unitRef="usd">-38000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-14" decimals="-3" id="f-896" unitRef="usd">-60725000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-1" decimals="-3" id="f-897" unitRef="usd">-506005000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-15" decimals="-3" id="f-898" unitRef="usd">-312222000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-13" decimals="-3" id="f-899" unitRef="shares">300844000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-14" decimals="-3" id="f-900" unitRef="shares">272915000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-901" unitRef="shares">299303000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-15" decimals="-3" id="f-902" unitRef="shares">271631000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-13"
      decimals="2"
      id="f-903"
      unitRef="usdPerShare">-0.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-14"
      decimals="2"
      id="f-904"
      unitRef="usdPerShare">-0.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-905"
      unitRef="usdPerShare">-1.69</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-15"
      decimals="2"
      id="f-906"
      unitRef="usdPerShare">-1.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-13" decimals="-3" id="f-907" unitRef="shares">300844000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-14" decimals="-3" id="f-908" unitRef="shares">272915000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-909" unitRef="shares">299303000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-15" decimals="-3" id="f-910" unitRef="shares">271631000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-13"
      decimals="2"
      id="f-911"
      unitRef="usdPerShare">-0.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-14"
      decimals="2"
      id="f-912"
      unitRef="usdPerShare">-0.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-913"
      unitRef="usdPerShare">-1.69</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-15"
      decimals="2"
      id="f-914"
      unitRef="usdPerShare">-1.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-915">&lt;div style="margin-top:15pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following shares issuable upon conversion of the Notes and outstanding equity awards were excluded from the computation of diluted net loss per share for the periods presented because the effect of including such shares would have been antidilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.748%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.235%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Shares issuable upon conversion of&lt;br/&gt;convertible senior notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;61,415&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;31,063&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;61,415&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;31,063&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Equity awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;42,599&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;36,496&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;42,599&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;36,496&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-231"
      decimals="-3"
      id="f-916"
      unitRef="shares">61415000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-232"
      decimals="-3"
      id="f-917"
      unitRef="shares">31063000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-233"
      decimals="-3"
      id="f-918"
      unitRef="shares">61415000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-234"
      decimals="-3"
      id="f-919"
      unitRef="shares">31063000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-235"
      decimals="-3"
      id="f-920"
      unitRef="shares">42599000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-236"
      decimals="-3"
      id="f-921"
      unitRef="shares">36496000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-237"
      decimals="-3"
      id="f-922"
      unitRef="shares">42599000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-238"
      decimals="-3"
      id="f-923"
      unitRef="shares">36496000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-924">&lt;div style="margin-top:15pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#1383c6;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;padding-left:49.5pt;text-align:justify;text-indent:-49.5pt"&gt;&lt;span style="color:#ffffff;font-family:'Roboto',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;NOTE 9.  SEGMENT AND GEOGRAPHIC INFORMATION&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are organized as, and operate in, one reportable segment: the development, manufacturing, and marketing of integrated platforms for genetic analysis. Our chief operating decision-maker ("CODM") is our Chief Executive Officer. Our CODM reviews financial information presented on a consolidated basis for the purposes of evaluating financial performance and allocating resources.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On a regular basis, our CODM reviews:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt"&gt;total revenues by category&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt"&gt;total expenses and expenses by function, including sales and marketing and general and administrative, which include depreciation and share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#df1995;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.41pt"&gt;net loss per share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our assets are primarily located in the United States of America and not allocated to any specific region, and we do not measure the performance of geographic regions based upon asset-based metrics. Therefore, geographic information is presented only for revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the segment profit or loss, including significant segment expenses is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.748%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.235%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;38,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;39,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;115,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;114,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;22,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;29,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;86,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;87,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;22,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;25,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;74,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;107,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Sales and marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;55,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;64,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;25,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;52,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;68,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Impairment charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;93,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Change in fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(18,700)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortization of acquired intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;363,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other income, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Income tax provision&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Consolidated net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(38,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(60,725)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(506,005)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(312,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:15pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our revenue by geographic location is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.748%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.235%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Americas&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;52,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;58,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Europe, Middle East and Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;29,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;24,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Asia-Pacific&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;33,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;31,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;38,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;39,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;115,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;114,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:15pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our revenue by category is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.748%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.235%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Instrument revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;36,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;50,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Consumable revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;60,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;51,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;32,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;35,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;96,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;102,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Service and other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;38,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;39,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;115,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;114,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-925"
      unitRef="customer">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c-1" id="f-926">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the segment profit or loss, including significant segment expenses is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.748%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.235%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;38,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;39,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;115,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;114,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;22,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;29,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;86,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;87,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;22,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;25,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;74,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;107,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Sales and marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;55,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;64,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;25,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;52,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;68,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Impairment charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;93,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Change in fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(18,700)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortization of acquired intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;363,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other income, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Income tax provision&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Consolidated net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(38,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(60,725)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(506,005)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(312,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-239" decimals="-3" id="f-927" unitRef="usd">38441000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-240" decimals="-3" id="f-928" unitRef="usd">39967000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-241" decimals="-3" id="f-929" unitRef="usd">115360000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-242" decimals="-3" id="f-930" unitRef="usd">114790000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CostOfRevenue contextRef="c-239" decimals="-3" id="f-931" unitRef="usd">22540000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c-240" decimals="-3" id="f-932" unitRef="usd">29963000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c-241" decimals="-3" id="f-933" unitRef="usd">86146000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c-242" decimals="-3" id="f-934" unitRef="usd">87566000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-239" decimals="-3" id="f-935" unitRef="usd">22846000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-240" decimals="-3" id="f-936" unitRef="usd">25516000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-241" decimals="-3" id="f-937" unitRef="usd">74428000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-242" decimals="-3" id="f-938" unitRef="usd">107456000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c-239" decimals="-3" id="f-939" unitRef="usd">15465000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c-240" decimals="-3" id="f-940" unitRef="usd">18435000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c-241" decimals="-3" id="f-941" unitRef="usd">55057000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c-242" decimals="-3" id="f-942" unitRef="usd">64779000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-239" decimals="-3" id="f-943" unitRef="usd">15634000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-240" decimals="-3" id="f-944" unitRef="usd">25311000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-241" decimals="-3" id="f-945" unitRef="usd">52385000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-242" decimals="-3" id="f-946" unitRef="usd">68597000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="c-239" decimals="-3" id="f-947" unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="c-240" decimals="-3" id="f-948" unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="c-241" decimals="-3" id="f-949" unitRef="usd">15000000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="c-242" decimals="-3" id="f-950" unitRef="usd">93200000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-239" decimals="-3" id="f-951" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-240" decimals="-3" id="f-952" unitRef="usd">1170000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-241" decimals="-3" id="f-953" unitRef="usd">-18700000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-242" decimals="-3" id="f-954" unitRef="usd">1100000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-239" decimals="-3" id="f-955" unitRef="usd">833000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-240" decimals="-3" id="f-956" unitRef="usd">3649000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-241" decimals="-3" id="f-957" unitRef="usd">363708000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-242" decimals="-3" id="f-958" unitRef="usd">13377000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-239" decimals="-3" id="f-959" unitRef="usd">1260000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-240" decimals="-3" id="f-960" unitRef="usd">3352000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-241" decimals="-3" id="f-961" unitRef="usd">6775000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-242" decimals="-3" id="f-962" unitRef="usd">9063000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-239" decimals="-3" id="f-963" unitRef="usd">383000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-240" decimals="-3" id="f-964" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-241" decimals="-3" id="f-965" unitRef="usd">116000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-242" decimals="-3" id="f-966" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-239" decimals="-3" id="f-967" unitRef="usd">-38000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-240" decimals="-3" id="f-968" unitRef="usd">-60725000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-241" decimals="-3" id="f-969" unitRef="usd">-506005000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-242" decimals="-3" id="f-970" unitRef="usd">-312222000</us-gaap:NetIncomeLoss>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock contextRef="c-1" id="f-971">&lt;div style="margin-top:15pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our revenue by geographic location is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.748%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.235%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Americas&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;52,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;58,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Europe, Middle East and Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;29,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;24,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Asia-Pacific&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;33,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;31,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;38,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;39,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;115,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;114,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-243" decimals="-3" id="f-972" unitRef="usd">18097000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-244" decimals="-3" id="f-973" unitRef="usd">20107000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-245" decimals="-3" id="f-974" unitRef="usd">52087000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-246" decimals="-3" id="f-975" unitRef="usd">58542000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-247" decimals="-3" id="f-976" unitRef="usd">10752000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-248" decimals="-3" id="f-977" unitRef="usd">9119000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-249" decimals="-3" id="f-978" unitRef="usd">29459000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-250" decimals="-3" id="f-979" unitRef="usd">24497000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-251" decimals="-3" id="f-980" unitRef="usd">9592000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-252" decimals="-3" id="f-981" unitRef="usd">10741000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-253" decimals="-3" id="f-982" unitRef="usd">33814000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-254" decimals="-3" id="f-983" unitRef="usd">31751000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-13" decimals="-3" id="f-984" unitRef="usd">38441000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-14" decimals="-3" id="f-985" unitRef="usd">39967000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-1" decimals="-3" id="f-986" unitRef="usd">115360000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-15" decimals="-3" id="f-987" unitRef="usd">114790000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock contextRef="c-1" id="f-988">&lt;div style="margin-top:15pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our revenue by category is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:1pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.748%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.235%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Instrument revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;36,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;50,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Consumable revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;60,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;51,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;32,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;35,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;96,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;102,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Service and other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e7f2f9;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;38,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;39,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1383c6;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;115,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e7f2f9;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Roboto',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;114,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-255" decimals="-3" id="f-989" unitRef="usd">11318000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-256" decimals="-3" id="f-990" unitRef="usd">16788000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-257" decimals="-3" id="f-991" unitRef="usd">36484000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-258" decimals="-3" id="f-992" unitRef="usd">50491000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-259" decimals="-3" id="f-993" unitRef="usd">21279000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-260" decimals="-3" id="f-994" unitRef="usd">18508000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-261" decimals="-3" id="f-995" unitRef="usd">60309000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-262" decimals="-3" id="f-996" unitRef="usd">51560000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-5" decimals="-3" id="f-997" unitRef="usd">32597000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-6" decimals="-3" id="f-998" unitRef="usd">35296000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-7" decimals="-3" id="f-999" unitRef="usd">96793000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-8" decimals="-3" id="f-1000" unitRef="usd">102051000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-9" decimals="-3" id="f-1001" unitRef="usd">5844000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-10" decimals="-3" id="f-1002" unitRef="usd">4671000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-11" decimals="-3" id="f-1003" unitRef="usd">18567000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-12" decimals="-3" id="f-1004" unitRef="usd">12739000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-13" decimals="-3" id="f-1005" unitRef="usd">38441000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-14" decimals="-3" id="f-1006" unitRef="usd">39967000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-1" decimals="-3" id="f-1007" unitRef="usd">115360000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-15" decimals="-3" id="f-1008" unitRef="usd">114790000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-13" id="f-1009">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-13" id="f-1010">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-13" id="f-1011">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-13" id="f-1012">false</ecd:Rule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
